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“To get back to my youth I would do anything in the world except take exercise, 




Both physical activity and exercise greatly benefit overall health. They determine 
energy balance and weight control, improve bone health, and something as little as 30 
minutes of brisk walking, 15 minutes of running, or 45 minutes of playing volleyball is  
associated with a decreased risk of coronary heart disease, hypertension, diabetes, cancer, 
and even death (U.S. Department of Health and Human Services, 2007). They elevate 
mood (Dunn et al., 2005; Lawlor and Hopker, 2001), improve sleep (Driver and Taylor, 
2000) and cognition (Colcombe and Kramer, 2003), and are associated with a decreased 
risk for Alzheimer’s disease  (Yaffe et al., 2001; Larson et al., 2006), Parkinson’s disease 
(Thacker et al., 2008), and a decreased infarct from ischemic stroke (Hu et al., 2000; Lee 
and Paffenbarger, 1998).  
High amounts of physical activity are generally better associated with decreased 
risks for neurological disorders. In a multivariate analysis controlling for age, BMI, 
hypertension history, and other covariates physical activity reduced the risk of total and 
ischemic stroke in a dose responsive manner in a study of 72,488 female nurses over 8 
years (Hu et al., 2000).  This effect is also seen in men. An 11 year study with over 
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11,000 men found a decreased risk of stroke at mild energy expenditures (1999 
kcal/week) and a further risk decrement at moderate energy expenditures (2000-2999 
kcal/week) (Lee and Paffenbarger, 1998). 
Additionally, mild physical activity, as little as walking, is associated with 
decreases in the risk of cognitive decline. In a six year study of 5,925 women (Yaffe et 
al., 2001) the risk of cognitive decline decreased with the number of blocks walked, and 
particularly, the greatest risk reduction of dementia associated with voluntary physical 
activity was in the lower performance levels in a six year smaller study of 1,740 men and 
women with the limiting factor of a large number of physically active people at baseline 
(Larson et al., 2006). In a larger study of 143,325 men and women, the lowest risk of 
Parkinson’s disease was in the highest baseline categories of moderate to vigorous 
activity (bicycling, aerobics, and tennis) (Thacker et al., 2008). This evidence suggests 
that physical activity is neuroprotective in a dose response manner in men and women 
across multiple neurological diseases.  
To achieve many of the health benefits from physical activity the Center for 
Disease Control (CDC) recommends 30 minutes per day, 5 days per week of moderate 
intensity activity (brisk walking, biking, vacuuming, and gardening) or 20 minutes per 
day, 3 days per week of vigorous intensity activity (running, aerobics, and heavy yard 
work). A reported questionnaire conducted by the CDC in the United States in 2007  
showed that only 48.8% of people got the recommended amount of physical activity, 
37.7% of people got insufficient physical activity, and 13% of people were inactive (U.S. 
Department of Health and Human Services, 2007), but people commonly over-report 
their physical activity levels (Troiano et al., 2008).  
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Automated systems using Actigraph accelerometers, however, provide more 
accurate physical activity levels (Troiano et al., 2008). In fact lower levels of objective 
physical activity using waist mounted uniaxial accelerometers correspond to higher levels 
of self-reported physical activity (Troiano et al., 2008). Even with objective 
measurements, physical activity declines across age groups with 42% of children and 8% 
of adolescents getting the recommended 60 minutes of physical activity and 5% of adults 
obtaining the recommended 30 minutes of physical activity (Troiano et al., 2008). 
Statistics subjectively or objectively tell the same story – a majority of people do not get 
the recommended amount of physical activity. Even with the knowledge that exercise 
greatly improves overall health, as society becomes more digital and is given enhanced, 
convenient, stimulating, and often sedentary opportunities and activities, many people do 
not exercise, but this dissertation will show how simply increasing overall activity level 
can provide the same and even better benefits for brain health. 
 
 
EXPERIENCE INDUCED BRAIN REMODELING 
The studies previously mentioned are association studies, and have helped define 
the relationship between physical activity and a number of illnesses, but they have not 
precisely defined causation. To understand if and how physical activity decreases the risk 
of neurodegenerative disorders, such as Parkinson’s disease, many have turned to 
designed studies in animals to elucidate the molecular mechanism by which physical 
activity influences the central nervous system to combat neurodegenerative and other 
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diseases (Poulton and Muir, 2005; Howells et al., 2005; Caudle et al., 2007; Mabandla et 
al., 2004; Petzinger et al., 2007; Mandel et al., 2003; O'Dell et al., 2007). 
These studies began in the 1970s when researchers saw plasticity in the brains of 
animals in response to changes in the environment. Cortical maps dynamically remodel 
in detail in response to behaviorally important experiences throughout life (Buonomano 
and Merzenich, 1998). The cortex reorganizes its effective local connections following 
peripheral or central alterations of input and in response to behavior, which partially 
accounts for certain forms of perceptual and motor learning (Buonomano and Merzenich, 
1998). This occurs after lesions in the somatosensory cortex in monkeys (Merzenich et 
al., 1983; Merzenich et al., 1984; Merzenich and Jenkins, 1993; Buonomano and 
Merzenich, 1998), in the barrel cortex in rodents (Diamond et al., 1993), in the visual 
cortex in cats (Kaas, 1995; Wiesel, 1999) and in the auditory cortex in owls, rats, and 
humans (Plascencia et al., 2003; Untergasser et al., 2003; Hurlstone et al., 2003). 
Furthermore, cortical representation changes with training. Examples include increases in 
cortical representation of (a) the left hand in string players (Elbert et al., 1995), (b) nipple 
bearing skin in rat mothers nursing their young (Xerri et al., 1994), and (c) the fingers 
after training in monkeys (Jenkins et al., 1990; Recanzone et al., 1993). Cortical maps 
reorganize in response to experience.  
Animals in various environments can, even as adults, remodel features of their 
cortex, including the number and distribution of synapses (Greenough, 1975). Adult rats 
in enriched environments for 80 days have higher cortical weight than their counterparts 
in standard housing; changing the environment increases both dendritic size and 
complexity (Bennett et al., 1964). Enriched environments in adult animals can increase 
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dendrite length and branching, spine density and numbers, synaptogenesis, neurogenesis, 
and angiogenesis, and furthermore wheel running seems to increase this most (Greenough 
and Volkmar, 1973; Diamond and Connor, 1982; Turner and Greenough, 1985; Rampon 
et al., 2000; Brown et al., 2003; Lazarov et al., 2005). Furthermore, physical activity 
accompanied with calorie restriction also increases the density of dendritic spines in the 
entorhinal cortex and hippocampus (Stranahan et al., 2007; Stranahan et al., 2009). These 
studies suggest that an individual’s experience can help the brain gain new neural 




What causes these changes in the brain? In search of a soluble factor Neeper et al 
looked at the expression of brain derived neurotrophic factor (BDNF) and nerve growth 
factor (NGF) in all regions of the brain (Neeper et al., 1996) after voluntary wheel 
running in rodents. BDNF and NGF promote the survival and function of forebrain 
cholinergic and mesencephalic dopaminergic neurons, which are vulnerable to aging and 
degenerative conditions. Neeper et al found that neurotrophic factors were indeed 
significantly increased across brain regions in animals that ran on wheels versus animals 
without running wheels with the greatest increases in the hippocampus and caudal cortex 
(Neeper et al., 1996). Another group looked at the expression of fibroblast growth factor 
2 (FGF2) in the hippocampus and found that it was also increased with physical activity 
(Gomez-Pinilla et al., 1997). These studies led to a belief that neurotrophic factors were 
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partly responsible for the changes observed in the brain after physical activity and in 
enriched environmental settings.  
Even more precisely the molecular mechanism is thought to involve the 
methylation of DNA. Stimulation of the dentate gyrus in the hippocampus with 
electroconvulsive therapy, which induces neuronal activity by direct electrical current, 
decreases the methylation level of specific regulatory regions of both BDNF and FGF, 
which result in increases of mRNA and protein (Yu et al., 2011). Even early life stress 
also has been shown to change the methylation pattern of BDNF (Roth and Sweatt, 
2011). This places more attention to how epigenetics affects plasticity. 
Other studies using microarrays looked more globally for gene expression 
changes associated with voluntary wheel running in the hippocampus (Tong et al., 2001a; 
Molteni et al., 2002), which has given a better picture of the molecular mechanisms of 
physical activity. Four groups of genes increased with wheel running: neurotrophic 
factors (NGF, BDNF, and basic fibroblast growth factor, FGF-2), synaptic trafficking  
proteins (syntaxin, synapsin I, and synaptotagmin), neutrotransmitter systems (ionotropic 
glutamate receptor subunits NR2A and NR2B, excitatory amino-acid carrier 1 (EAAC1), 
γ-aminobutyric-acid receptor β3 (GABAA β3), and glutaminic acid decarboxylase 
(GAD65)), and signal transduction pathways (CaMKIIδ, ERK1/2, and protein kinase C 
(PKC))
 
(Molteni et al., 2002). CAMKIIδ was more highly expressed during acute 
physical activity (3 days) and ERK1/2 was more highly expressed during chronic 
physical activity (28 days)
 
(Molteni et al., 2002).  
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It is now understand that physical activity modulates the BDNF system through 
intracellular signaling systems such as AKT and the extracellular signal-regulated kinases 
1 and 2 (ERK1/2) with endpoint effects on the phosphorylation and function of CREB 
(Vaynman et al., 2004) (Figure 1). AKT also phosphorylates forkhead box O3 (FOXO3), 
a transcription factor, causing its retention in the cytoplasm. When in the nucleus, 
FOXO3 likely triggers apoptosis by inducing the expression of genes critical for cell 
death (Brunet et al., 1999). Keeping FOXO3 in the cytoplasm, therefore, promotes cell 
survival. This provides an even more detailed mechanism of how physical activity alters 
and changes neurons that results in plasticity. 
Figure 1. BDNF Signaling Pathways. BDNF activates the AKT and ERK1/2 pathways. PI3K indirectly 
causes the phosphorylation of AKT, which phosphorylates and inhibits death proteins (FOXO3 and BAD). 
ERK1/2 is phosphorylated by a kinase cascade (RAF to MEK to ERK1/2) that is activated by RAS, which 
is activated by RAS-GEF binding to Grb2 bound to phosphorylated TrkB dimers. These pathways also can 
modulated by other kinases. CaMKII, which is increased with wheel running in rodents, can phosphorylate 
components of the ERK1/2 pathway (Chen and Russo-Neustadt, 2005; Brunet et al., 1999; Tong et al., 





ANGIOGENESIS AND VASCULAR VOLUME 
Plasticity extends to changes in the brain vasculature, which also changes in 
response to physical activity, exercise, and enriched environments. With exercise the 
motor cortex, visual cortex, frontal cortex, striatum, and cerebellum increase their 
capacity to supply blood (Black et al., 1990; Ding et al., 2004; Ding et al., 2006; Swain et 
al., 2003). In enriched environments capillaries in the visual cortex become larger, and 
more elaborately branched (Whishaw et al., 1984; Mohammed et al., 1990; Galani et al., 
1998). Both exercise and enrichment environment settings must be sustained, however, 
because increases in vascular volume in the motor cortex of exercised cynomolgus 
monkeys reverse following a sedentary period (Cameron et al., 2010).  
Peripheral factors, such as insulin-like growth factor 1 (IGF-1) and c-reactive 
protein (CRP), may be responsible for vascular changes in the brain. IGF-1, which has 
effects similar to other growth factors, increases neuronal survival, angiogenesis, and is 
increased with physical activity (Llorens-Martin et al., 2009). Other factors, like CRP, 
have more detrimental effects. Increased levels of CRP can increase tissue damage after 
stroke (Stewart et al., 2010). CRP of the pentraxin family is involved in host defense 
related functions, recognizes foreign pathogens and damaged cells, and initiates their 
elimination by interacting with humoral and cell effector systems in the blood 
(Stenvinkel, 2006). It is increased in the blood plasma in response to tissue injury, 
infection, and other inflammatory stimuli and is associated with increased risk for type II 
diabetes (Lakka et al., 2005), hypertension, cardiovascular disease, and ischemic stroke 
(Stewart et al., 2010).  Exercise can lower CRP levels (Lakka et al., 2005; Gill et al., 
2004), and in healthy individuals the concentration of CRP in serum is low (Yeh, 2004). 
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While some factors positively associated with exercise enrich brain vasculature, others 
that are negatively associated with exercise are harmful. 
 
 
BEHAVIORAL AND BIOCHEMICAL SPARING IN PARKINSON’S DISEASE 
MODELS 
Physical activity can also result in neuroplasticity in animal models of 
Parkinson’s disease, but specific and detailed gene expression analyses to determine the 
mechanisms of neuroprotection are still being researched. Parkinson’s disease is 
characterized by tremor at rest, muscle rigidity, postural instability, and a slowing of 
physical movement (bradykinesia) that can progress to a complete loss of movement 
(akinesia) (Betarbet et al., 2002). As disabling motor symptoms are managed with 
medications (such as L-3, 4-dihydroxyphenylalanine, L-DOPA), other symptoms become 
more apparent. These include depression, high level cognitive dysfunction, and subtle 
language problems (Brown et al., 2006; Dagher, 2001). It is thought that symptoms 
emerge from the progressive loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc). At the onset of motor symptoms dopaminergic neuron loss is already 
60-80%. These neurons normally project to the striatum (caudate nucleus and putamen) 
forming the nigrostriatal dopaminergic pathway (Betarbet et al., 2002). Insufficient action 
of dopamine (DA) on the striatum is believed to lead to decreased stimulation of the 
motor cortex and Parkinson’s disease symptoms (Brown et al., 2006).  
Neuroprotective strategies, such as physical activity, aim to slow dopaminergic 
neuron loss and lead to improved functioning of the remaining neurons (Mohammed et 
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al., 1990) that will result in improved motor function. In Parkinson’s disease patients 
exercise induces lasting improvements in motor scores, cognitive function, mood, and 
performance in daily activities (Palmer et al., 1986; Huang et al., 2003; Escudero et al., 
2003; Reuter et al., 1999; Reuter et al., 1999; Plaschke et al., 2003). Furthermore, 
voluntary wheel running, forced limb use, and treadmill running in rodent Parkinson’s 
disease models, unilateral 6-hydroxydopamine (6-OHDA) lesions in rats and bilateral 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesions in mice, improve behavioral 
functioning and provide biochemical sparing in the striatum. 
Using a forced limb use paradigm, Tillerson et al demonstrated that early forced 
use after a unilateral 6-OHDA injection into the medial forebrain bundle improves limb 
asymmetry and provides biochemical sparing in the striatum. They unilaterally injected 
6-OHDA and desipramine (a norepinephrine reuptake inhibitor) into the medial forebrain 
bundle to selectively kill dopaminergic neurons in the SNpc, cast the unimpaired limb on 
days 1-7, 3-9, or 7-13 after lesioning, and forced use of the impaired limb. They 
prevented limb use asymmetry only by casting on days 1-7 and they significantly 
improved DA and dopamine metabolite (DOPAC and HVA) levels with early forced use 
(days 1-7 and 3-9 of casting) (Tillerson et al., 2001). 
Tillerson switched to a forced treadmill running paradigm, as unilateral forced use 
is an exercise modality not commonly practiced in humans. They believed that treadmill 
running, like forced use, would attenuate DA loss and behavior. Rats were given either 6-
OHDA and mice were given MPTP and forced to run until day 12 or 30 for behavioral 
tests and sacrificed for biochemical analysis. Moderate forced treadmill running reversed 
6-OHDA movement impairments in rats after one day with 450 m/day of treadmill 
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running, reversed MPTP movement impairments in mice after three days with 50 m/day, 
and attenuated striatal DA loss and DA terminal marker loss (DAT, VMAT, tyrosine 
hydroxylase (TH)) in both models (Tillerson et al., 2003). Treadmill running, like forced 
use, attenuated both movement impairments and dopamine loss. 
 Numerous other studies demonstrate that voluntary and forced exercise can 
ameliorate the behavioral and biochemical consequences of 6-OHDA and MPTP lesions 
(Poulton and Muir, 2005; Howells et al., 2005; Caudle et al., 2007; Mabandla et al., 2004; 
Petzinger et al., 2007; Mandel et al., 2003) though the time, amount, method of exercise, 
and type of lesion do affect the behavioral and biochemical outcome. Early physical 
activity intervention, (Tillerson et al., 2001), before and after the lesion (Mabandla et al., 
2004; Poulton and Muir, 2005; O'Dell et al., 2007), and in nonstressful situations 
(Howells et al., 2005) have proven to be the most beneficial – while limb disuse has been 
shown to exacerbate both behavioral and biochemical recovery (Caudle et al., 2007).  
In all of the studies the number of SNpc cells did not change with exercise and 
physical activity (Poulton and Muir, 2005; Howells et al., 2005; Caudle et al., 2007; 
Mabandla et al., 2004; Petzinger et al., 2007; Mandel et al., 2003); rather, we believe 
behavioral and biochemical sparing comes from neuroplasticity and the sparing of SNpc 
terminals projecting to the striatum (Petzinger et al., 2007). It has been hypothesized that 
forced use ameliorates the behavioral and biochemical effects of 6-OHDA and MPTP 
through a cascade of events that involves glial derived neurotrophic factor, GDNF 
(Zigmond et al., 2009), a potent survival factor for DA neurons (Cohen et al., 2003). 
There is a significant increase of striatal GDNF 24 and 72 hours after using a non-
impaired limb (Lin et al., 2008). Furthermore, ERK1/2 activation by GDNF in the 
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striatum remains elevated up to 1 month after limb use (Lin et al., 2008; Lindgren et al., 
2008).  
Dopamine neurons from the SNpc project to the caudate nucleus and putamen of 
the striatum where they modulate glutamatergic input from the cortex. When SNpc 
dopaminergic neurons are lost, glutamatergic input to the striatum is no longer properly 
modulated resulting in overexcitation and the destruction of spine heads of the medium 
spiny neurons. Physical activity, which induces neuroplasticity and globally increases 
neurotrophic factors (BDNF, NGF, insulin growth factor-like 1 (IGF-1), FGF-2) (Neeper 
et al., 1996; Tong et al., 2001a; Molteni et al., 2002; Carro et al., 2001), could ameliorate 
the behavioral and biochemical effects of this loss, by increasing survival of these spine 
heads through BDNF, GDNF, and other neurotrophic factors, or by directly causing the 
protection of dopaminergic projections reaching the striatum. The ultimate goal is to 
elucidate the mechanism of how physical activity and exercise enhance neuroplasticity in 
the motor cortex and striatum to protect the brain against neurodegenerative diseases. 
  
 
HYPOTHESIS AND SPECIFIC AIMS 
Mild, moderate, and vigorous physical activity are associated with decreased risks 
of Alzheimer’s disease, Parkinson’s disease, and a decreased infarct from stroke. Physical 
activity increases neurogenesis in the hippocampus and upregulates neurotrophic factors 
throughout the brain, but it largely has been understudied in motor brain regions related 
to Parkinson’s disease. To understand the mechanisms of physical activity, exercise, and 
neuroprotection in motor regions of the brain we used three cohorts of monkeys: (1) 
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spontaneously physically active rhesus monkeys, (2) exercised rhesus monkeys, and (3) 
spontaneously physically active and exercised rhesus monkeys before and after receiving 
a MPTP lesion. We hypothesized that aerobic exercise would be protective against a 
MPTP lesion in Rhesus monkeys and be associated with a distinct gene expression 
signature in Parkinson’s disease related brain areas, which would allow us to elucidate 
the mechanisms of physical activity dependent neuroplasticity and neuroprotection. 
Specific Aim 1: We believed that spontaneous physical activity and BMI 
would be associated with distinct gene expression signatures in the brain and sought 
to establish the gene expression signatures associated with each in the motor cortex 
and caudate.  Using DNA microarrays we investigated gene expression correlates of 
spontaneous physical activity and body mass index in the motor cortex and caudate 
nucleus of 14 Rhesus monkeys. Microarray data were verified by qPCR. In addition, we 
examined the activation of the AKT and ERK1/2 signaling pathways using Western 
Blots. The activity-associated and BMI-associated gene expression signatures did not 
overlap – suggesting that different mechanisms are associated with each. These gene 
expression signatures are discussed in detail in Chapters II and III.  
Using the same Rhesus monkey cohort, we cross correlated the level of 
spontaneous physical activity, blood c-reactive protein (CRP) levels, and the expression 
of BDNF, and ARC, an immediate early gene, in the brain with CRP.  CRP induces 
vascular changes in the brain and we saw an inverse correlation of CRP with physical 
activity level and ARC/BDNF expression in the brain, while ARC/BDNF expression are 
positively correlated with the level of spontaneous activity. These correlations are 
discussed in Chapter IV. 
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Specific Aim 2: We believed that in response to exercise different brain areas 
would share a common mechanism and investigated the gene expression signature 
associated with exercise in the motor cortex, putamen, and hippocampus. Using 
DNA microarrays we investigated differentially gene expression associated with exercise 
in the motor cortex, putamen, and hippocampus of 12 Rhesus monkeys. Rhesus monkeys 
were pair matched based on initial physical activity levels and placed into two groups: 
sedentary and 60% maximal heart capacity runners. Runners ran for 5 days a week, 1 
hour a day on a human sized treadmill for 3 months while sedentary animals sat on the 
treadmill. Shared gene expression across the brain regions was minimal suggesting 
different mechanisms of action in the motor cortex, putamen, and hippocampus. We did, 
however, find components of the electron transport chain increased in expression across 
brain regions. These gene expression signatures and proposed mechanisms are discussed 
in detail in Chapter V. 
Specific Aim 3: We believed that exercise would provide behavioral and 
biochemical sparing in a monkey model of Parkinson’s disease using MPTP, and 
sought to explore the mechanism of exercise and physical activity dependent 
neuroprotection. Physical activity, not exercise per se, protected against the MPTP 
lesion in a nonhuman primate model. We first demonstrated biochemical sparing and 
restored functional imaging parameters with physical activity level in nine monkeys 
treated with MPTP. We next established a gene expression signature associated with 
physical activity neuroprotection using DNA microarrays in the caudate and putamen. 
This gene expression signature and proposed mechanism of neuroplasticity and 
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Physical activity plays a critical role in energy balance and weight loss. Looking 
in our cohort of adult rhesus monkeys (M. mulatta) with a wide range of physical activity 
levels, we previously established that physical activity influences both weight gain and 
weight loss. The most active monkeys gained the least amount of weight as a part of a 
weight gain study (Sullivan et al., 2006), and as part of a weight loss study, the animals 
who did not lose weight compensated for their reduced food intake with a decrease in 
their activity level (Sullivan and Cameron, 2010). These studies suggest that physical 
activity levels must be increased to lose significant weight in adulthood. 
In addition to its role in the regulation of body weight, physical activity also is 
associated with a decreased lifetime risk of neurological disorders, such as Parkinson’s 
disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS) (Yaffe et al., 2001; 
Thacker and Ascherio, 2008; Lee and Paffenbarger, 1998; Tsermentseli et al., 2011). In 
the brain, physical activity most dramatically affects the hippocampus (Neeper et al., 
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1996) with increases in neurogenesis (Brown et al., 2003) and growth factors,  nerve 
growth factor (NGF) and brain derived neurotrophic factor (BDNF) (Neeper et al., 1996). 
In contrast, little attention has been paid to other brain regions that undoubtedly play a 
role in the interaction between physical activity and neurological disease. The motor 
cortex is one such area. Motor neurons in this region are devastated in ALS (Tsermentseli 
et al., 2011). Moreover, the motor cortex is affected with synuclein and tau pathology at 
the end stages of Parkinson’s and Alzheimer’s disease (Braak et al., 2006), and physical 
activity is known to slow the progress of both disorders. 
Based on these studies, we hypothesized that spontaneous physical activity is 
associated with a unique gene expression signature in the motor cortex that may be 
important in body weight regulation as well as protection against neurodegenerative 
disease. To test this hypothesis, we performed whole genome expression profiling of the 
motor cortex of 14 female rhesus monkeys with a wide range of stable physical activity 
levels using both Affymetrix Rhesus Macaque Genome (RhG) and Human Genome (HG) 
microarrays (Figure 2). Physical activity levels ranged from 46,376 counts per day to 
897,948 counts per day with a skew of 1.93, indicating that our activity measurements 
were skewed right with more animals having low activity values. The rhesus and human 
genomes share 93% sequence identity (Gibbs et al., 2007) and we have successfully used 
human microarrays to query rhesus monkey gene expression changes in the past (Sabatini 
et al., 2007). Whereas the Affymetrix RhG microarrays provided us with the most 
specific hybridization information for rhesus monkeys, the Affymetrix HG microarrays 
contained more extensive and higher quality annotations.  
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Figure 2. Spontaneous Activity Gene Expression Analysis Experimental Design. Motor cortex and 
caudate nucleus tissue were harvested respectively from 14 female macaques with vastly different 
spontaneous activity levels. Their transcriptome was profiled using both Affymetrix Rhesus Macaque 
Genome microarrays (RhG) and Affymetrix Human Genome U133 2.0 Plus microarrays (HG). We used a 
linear model to define gene expression associated with physical activity (gene value = α + β (activity)) for 
both microarrays separately. RhG and HG probes were cross matched based on sequence similarity and a 
transcript was considered associated with activity if both microarray models (a) were significant with p < 
0.05, and (b) had an interquartile range (IQR) > 0.263 corresponding to a 20% gene expression change. 
Significant gene expression changes are reported in Supplementary Tables 1 and 2, and clustered in Figures 
3 and 4.  
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Microarray data were log2 transformed, RMA-normalized (Arion et al., 2007a; 
Arion et al., 2007b), and linearly modeled with physical activity level. We focused on 
convergent findings between the RhG and HG microarrays, which enabled us to identify 
a strong and distinct physical activity associated gene expression signature of ninety-
eight significantly altered transcripts (Supplementary Table 1), and twenty-eight 
significantly altered transcripts in the caudate nucleus (Supplementary Table 2).  
Ninety-six of the ninety-eight significantly altered transcripts changed in the same 
direction on both microarrays, suggesting a high degree of concordance between the two 
data sets and a low false discovery rate. Furthermore, our Pearson Hierarchal Clustering 
(Subramanian et al., 2005) revealed a progression of gene expression levels from 
monkeys with low activity to monkeys with high activity (Figures 3 and 4). 
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Figure 3. Hierarchal Clustering of Physical Activity Associated Gene Expression in the Motor Cortex. 
One-way hierarchical clustering was performed on log2-transformed expression levels of 98 differentially 
expressed genes using GenePattern. Monkeys are arranged by activity level in vertical columns. Monkey 
identities correspond to level of activity (eg. Monkey ACT046378 had an average daily activity count of 
46,378). Genes, denoted by Affymetrix Rhesus and Human Probes and NCBI gene symbols, were clustered 
horizontally. Each colored square represents a normalized gene expression value with color intensity 
proportional to magnitude of change (blue indicates lower expression and red indicated increased mRNA 
levels). (A) Clustering of Rhesus Genome Microarray Data. (B) Clustering of Human Genome Microarray 




Figure 4. Hierarchal Clustering of Physical Activity Associated Gene Expression in the Caudate 
Nucleus. One-way hierarchical clustering was performed on log2-transformed expression levels of 28 
differentially expressed genes using GenePattern. Monkeys are arranged by activity level in vertical 
columns. Monkey identities correspond to level of activity (eg. Monkey ACT046378 had an average daily 
activity count of 46,378). Genes, denoted by Affymetrix Rhesus and Human Probes and NCBI gene 
symbols, were clustered horizontally. Each colored square represents a normalized gene expression value 
with color intensity proportional to magnitude of change (blue indicates lower expression and red indicated 
increased mRNA levels). (a) Clustering of Rhesus Genome Microarray Data. (b) Clustering of Human 
Genome Microarray Data. Note the progression of gene expression levels from monkeys with low activity 
to monkeys with high activity. 
 
Several genes with altered transcript levels were part of signaling cascades and 
nutrient sensing pathways. Namely, AKT3, which showed more than a 2-fold change in 
expression over the quartile in our dataset, is at the apex of both growth factor signaling 
and nutrient sensing (Bhaskar and Hay, 2007; Sarbassov et al., 2005). AKT pathway 
activation is associated with physical activity in the hippocampus (Brunet et al., 1999; 
Chen and Russo-Neustadt, 2005). When activated, it phosphorylates downstream 
effectors, such as glycogen synthase kinase (GSK3) (which when inhibited 
phosphorylation promotes glycogen synthesis) (Wilson et al., 2007), tuberous sclerosis 
protein 2 (TSC2) (which activates mammalian target of rapamycin complex 1, mTORC1, 
and is involved in ribosome biogenesis and protein synthesis) (Bhaskar and Hay, 2007), 
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and forkhead box O3 (FOXO3) (which when phosphorylated is no longer recruited to the 
nucleus where it would bind as a transcription factor to activate transcription of apoptotic 
related genes (Brunet et al., 1999).  
 
Figure 5. Validation of activity associated microarray-reported changes by qPCR. (a) Monkey activity 
levels were measured in counts/day, while AKT3, CRBN, ORC4L, and PDK4 relative expression levels are 
reported in threshold cycle difference relative to myelin basic protein (ΔCT). AKT3, CRBN, ORC4L, and 
PDK4 expressions were significantly positively correlated (R) with activity.  (b) Scatter plot showing qPCR 
expression (1/dCT) versus activity levels (counts/day) for AKT3 (blue diamond), CRBN (red circle), 
ORC4L (black triangle), and PDK4 (green square).   
 
To validate the correlation of AKT3 gene expression level with physical activity 
we performed qPCR on 12 of the monkeys studied by microarrays. In addition, we also 
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assessed the expression-activity correlation (R) for two other nutrient genes, cereblon 
(CRBN) and pyruvate dehydrogenase 4 (PDK4), and origin recognition complex subunit 
4-like (ORC4L) (Figure 5). CRBN and PDK4 converge on AMP activated protein kinase 
(AMPK), the master energy sensor. During exercise AMPK activity is known to increase 
and promote catabolic processes and inhibit anabolic processes thereby increasing 
cellular energy. CRBN decreases phosphorylation of the α1 subunit of AMPK to inhibit 
its activity (Lee et al., 2011), while PDK4 is induced by AMPK activity (Kwon et al., 
2010). The qPCR validation revealed that AKT3, CRBN, PDK4, and ORC4L showed a 
positive correlation (R) with increasing physical activity.  
Furthermore, we examined AKT protein expression, its phosphorylation state at 
serine 473, which is required for its full activation (Bhaskar and Hay, 2007), and the 
protein expression of its downstream effector, FOXO3. While total AKT (tAKT) levels 
were not changed, we found a significant and positive correlation of active pAKT (R = 
0.624, p = 0.017 for pAKT/tAKT, and R = 0.542, p = 0.045 for pAKT/actin) with 
physical activity level (Figure 6a). We also found a significant and positive correlation 
of FOXO3 protein level with spontaneous activity levels (R = 0.649, p = 0.012) (Figure 
6b). Given the striking changes in mRNA levels of AKT3, it seems likely that the 
immunoblotting data were also assessing changes in this protein. However, we used pan-
AKT antibodies that could not distinguish between the different AKT isoforms per se.  
Nonetheless, our data suggest AKT phosphorylation might be a critical molecular 




Figure 6. PhosphoAKT and FOXO3 Protein Levels are positively correlated with activity levels. (a) 
Scatter plot showing activity level (counts/day) versus protein ratios for pAKT/actin (blue diamond) and 
for pAKT/tAKT (red square) with an insert of the original Western blot data for four monkeys. We 
observed a significant correlation between activity levels and pAKT expression (p = 0.017 vs. ACT and p = 
0.045 vs. tAKT). (b) Scatter plot denotes activity level (counts/day) versus protein ratios for FOXO3/actin 
(blue diamond) with an insert of the original Western blot data for four monkeys. The analysis revealed a 
significant correlation between activity level in the monkeys and FOXO3 expression of (p = 0.012). Note 
that physical activity level is correlated with both pAKT and FOXO3 protein levels.  
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We ran gene set enrichment analysis (GSEA) (Subramanian et al., 2005) on the 
human microarray data (HG) for both the motor cortex and the caudate nucleus using the 
curated C2 pathway gene sets from the Molecular Signatures Database (MSigDB) 
(Liberzon et al., 2011). We did not find any significantly altered pathways in the motor 
cortex, but we did find two altered pathways in the caudate nucleus (Table 1). These 
pathways included mTORC1 mediated signaling and the generation of second messenger 
molecule pathways – both of which are involved in nutrient sensing. 











EIF4E, RHEB, EEF2K, EIF4EBP1, EIF4B, 
RPS6KB1 
Generation of Second 
Messenger Molecules 
0.000 0.151 
HLA-DQB1, HLA-DQA, PAK1, WAS, CD4, 
ITK, PLCG1, LCK, HLA-DMA, CD3G, HLA-
DMB, HLA-DRA, VASP, GRAP2, HLA-DOB, 
HLA-DRB1, LCP2 
Table 1. Caudate Nucleus Gene Set Enrichment Analysis (GSEA) for Physical Activity. Two gene sets 
from the curated gene lists C2 module of GSEA (Liberzon et al., 2011) were found significantly altered in 
the caudate nucleus by GSEA. Gene sets are identified by their pathway name, nominal p-value (NOM p-
val), and false discovery rate q-value (FDR q-val). Gene sets are enriched with increasing physical activity 
levels. 
 
In summary, our study reveals that (1) spontaneous physical activity in Rhesus 
monkeys is associated with a strong and reproducible gene expression signature in the 
motor cortex, (2) the observed gene expression signature is related to activation of 
transcriptional machinery, and (3) spontaneous activity is associated with activation of 
the AKT-FOXO3 signaling pathway and several nutrient sensing transcripts. Given 
previous findings in the hippocampus, it is noteworthy that we did not observe changes in 
growth factor or growth factor receptors in the motor cortex, suggesting that spontaneous 
activity levels and planned exercise might have distinct gene expression profiles across 
the different brain regions. Whereas planned exercise might be growth factor dependent 
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(and activate the AKT pathway), it is conceivable that growth factor systems still could 
be activated by non-transcriptional cellular machinery or that spontaneous activity 
induces AKT/FOXO3 through a different, non-growth factor dependent pathway, but this 
deserves further investigation. However, our studies did not examine the causality of 
these changes, but the strong correlational relationship suggests that this is an important 
avenue for further investigations. 
Studies in knockout mice suggest that the three isoforms of AKT play vastly 
differing roles: mice without AKT1 have decreased body weight, whereas mice without 
AKT2 have increased fasting plasma glucose levels and diabetes symptoms while mice 
without AKT3 have decreased brain weight (Dummler et al., 2006; Choi and Sung, 
2000). These data also suggest that that AKT3 might be critical for neuronal health, and 
raise the possibility that activation of the AKT3 signaling pathway may play a crucial 
role in activity-induced weight loss and the delayed onset of neurological disorders 
associated with physical activity. Indeed, we have previously found that both physical 
activity and the neurotrophic factor GDNF increase the phosphorylation state of AKT in 
the rodent striatum (Smith AD, Castro, SL, Lindgren, N, and Zigmond MJ, unpublished 
observations). Thus, future studies are warranted to address whether varying levels of 
spontaneous motor activity are associated with differences in vulnerability to disease 







The Animal Care and Use Committee of the Oregon National Primate Research 
Center reviewed and approved all experiments. Fourteen adult female ovariectomized 
Rhesus monkeys (Macaca mulatta) with various levels of spontaneous activity were used 
in this study with care methods previously published (Sullivan et al., 2006; Sullivan and 
Cameron, 2010; Mitchell et al., 2010). Their activity levels were measured in counts/day 
with an accelerometer throughout the study and ranged from 46,378 to 897,948 activity 
counts per day. These monkeys also participated in a previous weight loss study (Sullivan 
et al., 2006). Monkeys were deeply anesthetized with ketamine/pentobarbital, quickly 
decapitated, and the entire brain was removed from the skull. The brain was then 
hemisected by a midline sagittal cut. The right hemisphere was cut into 5-mm thick 
coronal blocks, flash-frozen in isopentane over dry ice, and stored at -80 °C until use 
(Volk et al., 2000).  
 
Sample preparation, hybridization, and DNA microarray processing 
Motor cortex was dissected from frozen coronal blocks using anatomical 
landmarks, homogenized and total RNA isolated using TRIzol® reagent (Invitrogen, 
Carlsbad, CA) with RNA quality assessed via analysis on an Agilent 2100 Bioanalyzer. 
Only samples with an RIN > 7.0 were considered for further analysis. The samples were 
prepared with 2 μg of total RNA using the Enzo BioArray™ Single-Round RNA 
Amplification and Biotin Labeling System. Fifteen micrograms of the purified and 
fragmented aRNA were hybridized to 14 GeneChip
®
 Rhesus Macaque Genome (RhG) 
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Arrays and 14 GeneChip
®
 Human Genome (HG) U133 Plus 2.0 Arrays. Image 
segmentation analysis and generation of DAT files was performed using Microarray 
Suite 5.0 (MAS5). Segmented images were normalized and log2 transformed using 
robust multi-array analysis (RMA) separately for Rhesus and Human arrays (Sabatini et 




Microarray data analysis 
Microarrays were assessed for activity gene expression changes for each 
probe/gene (Figure 2). We tested for skew of the data using the following equation   (n / 
((n-1)(n-2))) * ∑ ((xi – ) / s)
3
. Data from RhG and HG arrays were fit using the model: 
log transformed gene expression value = α + β(activity). RhG and HG probe sets were 
matched on the basis of sequence identity using the Affymetrix HG-U133 Plus 2.0 to 
Rhesus Best Match Spreadsheet. Gene expression was considered correlated with 
spontaneous activity if (a) p < .05 for testing H0: β = 0, using data for RhG and HG 
microarrays; and if (b) the interquartile range, IQR > 0.263 (measuring the difference 
between the third and first quartiles was less than 0.263) on the RhG and HG microarrays, 
which represented a 20% change in gene expression values. One-way hierarchical 
clustering of the replicating data was performed using GenePattern software 
(Subramanian 2005) using log2 transformed RMA normalized expression levels utilizing 
row (gene) centering and Pearson correlation. 
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Quantitative real-time PCR Validation 
We used High Capacity cDNA Archive Kit® (Applied Biosystems, Foster City, 
CA) to synthesize cDNA from 500 ng of the same total RNA used for microarray 
analysis. Priming was performed with random hexamers. For each sample, amplified 
product differences were measured with three independent replicates using SYBR Green 
chemistry-based detection (Arion et al., 2007a). Myelin basic protein was used as the 
endogenous reference gene. Primer sequences for myelin basic protein (MBP) were 5’ 
GGG TCT TCC TGG AGA TTT GG 3’ and 5’ GTG GTT TGG AAA CGA GGT TG 3’, 
for AKT3 were 5’ GCA AGG ATT GTA CAC GCT GA 3’ and 5’ GCA GCA TCT CTT 
CTC CCA AA 3’, for cereblon (CRBN) were 5’ CAA GCA TGA ACG GCA GTC TA 3’ 
and 5’ CTT CAT GTC CCA TCA ATG ACA 3’, for origin recognition complex subunit 
4-like (ORC4L) were 5’ CAT GCT TTG AAA GAA CTC ATG CT 3’ and 5’ TGA TCT 
GCA GCA GTC CAT TT 3’, and for pyruvate dehydrogenase kinase 4 (PDK4) were 5’ 
ATT GTC AGC TGC CTG GTC TT 3’ and 5’ GCC GTT ACT TTG GCA ATT CT 3’. 
The efficiency for each primer set was assessed prior to qPCR measurements, and a 
primer set was considered valid if its efficiency was > 90%. The qPCR reactions were 
carried out on an ABI Prism 7300 thermal cycler (Applied Biosystems Inc.), quantified 
using ABI Prism 7300 SDS software (with the auto baseline and auto threshold detection 










Infrared imaging of immunoblots was used for assessing phosphorylation and 
total protein state of AKT (Li-Cor Biosciences, Lincoln, NE), and the total protein state 
of FOXO3. Samples were sonicated in a Triton-based lysis buffer (Cell Signaling, 
Danvers, MA) and subjected to standard SDS-page immunoblotting procedures. Blots 
were then blocked in 5% bovine serum albumin in Tris-buffered saline (TBS) with 0.1% 
Tween for 1 hr prior to incubation overnight at 4
o
C in primary antibody made in the same 
blocking solution. We used mouse anti-total AKT (Cell Signaling), rabbit anti-phospho 
AKT (Ser473, Cell Signaling), mouse anti-FOXO3 (gift of Anne Brunet’s laboratory), 
and mouse anti--actin (Sigma-Aldrich) to control for differences in protein loading. 
After overnight incubation with primary antibody, blots were washed in TBS-tween and 
incubated with goat secondary antibodies raised against the appropriate IgG fluorescing 
in the infrared range (700 and 800 nm, Li-Cor Biosciences). After three washes in TBS-
tween, immunostained protein bands on the blots were visualized on an Odyssey Infrared 
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INTRODUCTION 
Since 1980 the number of people worldwide considered obese has doubled with 
over 1.5 billion people now considered overweight (body mass index, BMI, 25 or higher) 
and 500 million people considered obese (BMI 30 or higher) (WHO, 2006). The negative 
effects of obesity on health are far reaching. As weight increases to levels defined as 
overweight and obese, the risks for the following conditions also increases: coronary 
heart disease, type 2 diabetes, cancers, hypertension, dyslipidemia, stroke, liver and 
gallbladder disease, sleep apnea, osteoarthritis, and gynecological problems (NIH, 1998; 
Baba et al., 2002;
 
Yatsuya et al., 2010;
 
Falkstedt et al., 2007). According to the American 
Medical Association the best ways to decrease the risk of obesity are to eat a diet low in 
fat and to increase physical activity levels (Kushner, 2003; Gaab et al., 2005). Indeed, 
modern sedentary life is associated with increased risks for obesity, as well as 
cardiovascular disease, type II diabetes (Marwick et al., 2009), and depression (Lawlor 
and Hopker, 2001;
 
Vance et al., 2005).  
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These co-morbidities strongly suggest that obesity may be associated with 
alterations in the molecular content of the brain. Decreased brain volume has been seen in 
the frontal lobe, the temporal lobe, the anterior cingulate, the hippocampus, and the basal 
ganglia with high BMI (Ho et al., 2010). Using correlations of BMI with brain volumes 
the same group showed that overweight and obese individual’s brains age prematurely 
(Raji et al., 2010). Other studies also link higher BMI with smaller regional brain 
volumes (Gustafson et al., 2004; Pannacciulli et al., 2007; Raji et al., 2010; Taki et al., 
2008).  
Given that high BMI is associated with brain alterations and that physical activity 
can decrease obesity, we hypothesized that BMI was associated with a unique gene 
expression signature in motor regions of the brain. Using BMI as a continuous variable 
we investigated transcriptome changes in motor brains regions (motor cortex and caudate 
nucleus) of 14 Rhesus monkeys with DNA microarrays. We found a distinct BMI 
associated gene expression signature in both the motor cortex and the caudate nucleus, 
and decreased protein phosphorylation of a survival kinase, pERK1/2, in the motor 
cortex. Our studies indicate that obesity is associated with molecular changes in motor 
regions of the brain that these changes include alterations in metabolic and apoptotic 
related genes and that increases in BMI are associated with decreases in the 






Fourteen adult female ovariectomized rhesus monkeys (Macaca mulatta) were 
allowed to eat a high fat diet freely for three years (Sullivan et al., 2006; 
 
Sullivan and 
Cameron, 2010) with care methods previously published (Sullivan et al., 2006; 
 
Sullivan 
and Cameron, 2010; 
 
Mitchell et al., 2010). Their activity and percent body fat were 
measured throughout the diet and were found to be extremely stable. As part of a 
different study they were then placed on a two month calorie reduction diet. Food 
composition was the same, but their calorie intake was reduced by 30% the first month 
and 60% the second month from their normal intake. Their BMI was measured in 
kilograms / crown of rump length squared (kg/CRL
2
) at the end of the study. Monkeys 
were deeply anesthetized with ketamine/pentobarbital, quickly decapitated, and the entire 
brain was removed from the skull. The brain was then hemisected by a midline sagittal 
cut. The right hemisphere was cut into 5-mm thick coronal blocks, flash-frozen in 
isopentane over dry ice, and stored at -80 °C until use (Volk et al., 2000). 
 
 
Sample preparation and hybridization 
Motor cortex and caudate nucleus brain tissue was homogenized and total RNA 
isolated using TRIzol® reagent (Invitrogen, Carlsbad, CA) with RNA quality assessed 
via analysis on an Agilent 2100 Bioanalyzer. Only samples with an RIN > 7.0 were 
considered for further analysis. The samples were prepared using the Enzo BioArray™ 
Single-Round RNA Amplification and Biotin Labeling System. The samples were 
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primed with a standard T7-oligo(dT) primer and cDNA synthesis was performed using 
2 μg of total RNA according to the Affymetrix® manufacturer's protocol. Amplified 
antisense RNA (aRNA) was produced using in vitro transcription directed by T7 
polymerase. Fifteen micrograms of the purified and fragmented aRNA were hybridized to 
GeneChip
®
 Rhesus Macaque Genome (RhG) Arrays and GeneChip
®
 Human Genome 
(HG) U133 Plus 2.0 Arrays. Image segmentation analysis and generation of DAT files 
was performed using Microarray Suite 5.0 (MAS5). 
 
Microarray data analysis 
Fourteen RhG arrays for the motor cortex and 14 RhG arrays for the caudate 
nucleus were scanned and analyzed. Scaling factors ranged from 1.58-3.11 with 
backgrounds from 29.8-85 and percent present calls from 45-52%. Fourteen HG arrays 
for the motor cortex and 14 HG arrays for the caudate nucleus were scanned and 
analyzed. Scaling factors ranged from 6.26-15.28, noise was between 1.2-1.8, and percent 
present calls were from 31.3% to 35.0%. Segmented images were normalized and log2 
transformed using robust multi-array analysis (RMA) separately for Rhesus and Human 
arrays (Wu and Irizarry, 2004) with RMA normalized expression levels utilized for all of 
our subsequent analyses.  
We analyzed the microarrays for transcripts associated with BMI. We fit data 
from HG and RhG arrays using the model: log transformed gene expression value = α + 
β(BMI) (Zabawski and Cockerell, 1998). RhG and HG probe sets were matched on the 
basis of sequence similarity using the Affymetrix HG-U133 Plus 2.0 to Rhesus Best 
Match Spreadsheet. Genes were considered correlated BMI if (a) p < 0.05, where H0: β = 
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0 for RhG arrays; (b) p < 0.05, where H0: β = 0 for HG arrays; (c) if the interquartile 
range, IQR > 0.263 on the RhG arrays, measuring the difference between the third and 
first quartiles was less than 0.263 (representing a 20% change in gene expression values); 
and (d) if the interquartile range, IQR > 0.263 on the HG arrays, measuring the difference 
between the third and first quartiles was less than 0.263 (representing a 20% change in 
gene expression values). The strength of our model was tested for false discovery using a 
binomial probability test for the direction of change, where the H0: p = 0.50. We tested 
our model using a binomial probability test with a null hypothesis that p = 0.50, which 
was rejected. Hierarchical clustering of the replicating data was performed using 
GenePattern software (Subramanian et al., 2005). Clustering was performed on log2 





Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) 
We assessed our data for the enrichment of functional gene pathways using Gene 
Ontology (GO) terms (Ashburner et al., 2000) and Gene Set Enrichment Analysis 
(GSEA) (Subramanian et al., 2007). First, we analyzed the GO terms for all of our 
transcripts significantly associated with BMI in the motor cortex and caudate nucleus. 
Second, we performed GSEA (Subramanian et al., 2007) using all of the gene sets in the 
Molecular Signatures Database (MSigDBv.3.0) for the human (HG) arrays. We report 





Infrared imaging of immunoblots was used for assessing phosphorylation and 
total protein state of ERK1/2 and AKT (Li-Cor Biosciences, Lincoln, NE). Samples were 
sonicated in a Triton-based lysis buffer (Cell Signaling, Danvers, MA) and subjected to 
standard SDS-page immunoblotting procedures. Blots were then blocked in 5% bovine 
serum albumin in Tris-buffered saline (TBS) for 1 hr prior to incubation overnight at 4
o
C 
in primary antibody made in the same blocking solution with 0.1% Tween. Antibodies 
used were: rabbit anti-phospho-ERK1/2 (Cell Signaling, Cat. no. 9101), mouse anti-total 
ERK1/2 (Millipore, Cat. no. 05-1152), rabbit anti-phospho-AKT (Cell Signaling, Cat. no. 
9271), mouse anti-total AKT (Cell Signaling, Cat. no. 2920) . Mouse -tubulin (Sigma-
Aldrich, Cat. no. T5168) was used concurrently to control for differences in protein 
loading. After overnight incubation with primary antibody, blots were washed in TBS-
tween and incubated with goat secondary antibodies raised against the appropriate IgG 
fluorescing in the infrared range (700 and 800 nm, Li-Cor Biosciences). After further 
washing, immunostained protein bands on the blots were visualized on an Odyssey 




Microarray Data Analysis Reveals a BMI-associated Gene Expression Pattern 
We hypothesized that BMI is associated with a unique gene expression signature 
in the motor cortex and caudate nucleus that may be of importance given observed 
decreases in brain volume associated with obesity. To test this hypothesis, we performed 
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whole genome expression profiling of the motor cortex of 14 female rhesus monkeys 
with a wide range of BMIs using both Affymetrix Rhesus Macaque Genome (RhG) and 
Human Genome (HG) microarrays (Figure 7). The rhesus and human genomes share 
93% sequence identity (Gibbs et al., 2007) and human microarrays successfully have 
been used to query rhesus monkey gene expression changes in the past (Sabatini et al., 
2007). Whereas the Affymetrix RhG microarrays provided us with the most specific 
hybridization information for rhesus monkeys, the Affymetrix HG microarrays contained 
more extensive and higher quality annotations.  
Microarray data were log2 transformed, RMA-normalized (Arion et al., 2007a; 
Arion et al., 2007b) and linearly modeled with BMI. We focused on convergent findings 
between the RhG and HG microarrays, which enabled us to identify a strong and distinct 
BMI-associated gene expression signature in the motor cortex and caudate nucleus. Two 
types of data-mining approaches were employed. First, we identified the transcripts that 
were associated with BMI, followed by a molecular pathway analysis that revealed the 




Figure 7. BMI Gene Expression Analysis Experimental Design. Motor cortex and caudate nucleus tissue 
was harvested from 14 female rhesus macaques with wide ranges of BMI. The motor cortex and caudate 
nucleus transcriptomes were profiled separately using both Affymetrix Rhesus Macaque Genome 
microarrays (RhG) and Affymetrix Human Genome U133 2.0 Plus microarrays (HG). We used a linear 
model to define gene expression associated with BMI (gene value = α + β (BMI)) for both microarrays 
separately. Probes were cross matched based on sequence similarity and significance was defined if both 
microarray models (i) were significant with p < 0.05, and (ii) had an interquartile range (IQR) > 0.263 
corresponding to a 20% gene expression change. Significant genes are contained in Supplementary Tables 
5 and 6, and clustered in Figure 2. Pathway analysis was performed using both Gene Ontology (GO) 
contained in Supplementary Tables 3 and 4, and Gene Set Enrichment Analysis (GSEA) contained in 
Tables 2 and 3. Note that the human and monkey data are highly concordant between the RhG and HG 
arrays for both  the motor cortex and caudate nucleus.  
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We identified 27 transcripts that were associated with BMI in the motor cortex 
(17 positively correlated and 10 negatively correlated) and 51 transcripts that were 
associated with BMI in the caudate nucleus (41 positively correlated and 10 negatively 
correlated)  (Supplementary Table 3 and 4). All altered transcripts in the motor cortex 
and in the caudate nucleus were changed in the same direction on both human and 
monkey microarrays, suggesting a high degree of concordance between the two data sets, 
and a very low false discovery rate in our experiment. Furthermore, our Pearson 
Hierarchal Clustering (Subramanian et al., 2005) revealed a progression of gene 
expression levels from monkeys with high BMI to monkeys with to low BMI (Figure 8).  
Next, we performed a pathway analysis using Gene Ontology (GO) terms 
(Supplementary Table 5 and 6) (Ashburner et al., 2000) and GSEA assessment 
(Subramanian et al., 2007) (Table 2 and 3) to decipher which biological processes were 
involved with the BMI associated gene expression signature.  The GO analysis revealed 
that in the motor cortex (Supplementary Table 5) there was an enrichment of apoptosis-
related genes, and changes in gene expression in gene involved in metabolism. Similarly, 
in the caudate nucleus (Supplementary Table 6) we also found increased expression of 
apoptotic related genes, as well as increased expression of signal transduction genes, and 




Figure 8. Hierarchal Clustering of BMI Associated Gene Expression in the Motor Cortex and 
Caudate Nucleus. Hierarchical clustering was performed on log2-transformed expression level of genes 
associated with BMI. Vertical column labels indicate BMI in decreasing order. Genes, denoted by 
Affymetrix Human Probes and NCBI gene symbols, were clustered horizontally. Each colored square 
represents a normalized gene expression value with color intensity proportional to magnitude of change 
(blue indicates a decrease in expression and red an increase). (a) Motor Cortex Gene Expression Signature 
for Rhesus Genome Microarrays. (b) Motor Cortex Gene Expression Signature for Human Genome 
Microarrays. (c) Caudate Nucleus Gene Expression Signature for Rhesus Genome Microarrays. (d) 
Caudate Nucleus Gene Expression Signature for Human Genome Microarrays. Note that in both structures 
there is a progression of gene expression values from monkeys with low BMI to monkeys with high BMI, 

















Kuninger IGF1 vs. 
PDGFB targets up 
41 0.000 0.104 + 
TPM2, CKM, MYBPH, MYOG, 
RYR1, USP2, MYL1, TNNT2, 
TNNI1, ENAH, PYGM, C1QTNF3, 
PPFIA4, NCAM1, NPNT, SGCA, 




26 0.000 0.128 + 
NSUN2, DMAP1, PRMT5, NSD1, 
CARM1, DNMT3A, DNMT3B, 
EHMT1, PRM17, FOS, PRMT2 
Module 440 18 0.000 0.173 + 
CKM, OAT, ASL, GLUD1, 
BBOX1, CKB, ODC1, ACY1 
ABE VEGFA 
targets 30 min 
19 0.000 0.179 + 
HDC, DBC1, C2, EGR2, EGR3, 
CYR61, NR4A1, TRIB1 
Schuring STAT5A 
targets up 
7 0.000 0.184 + LIF, TRAF4, PIM1 
Module 199 57 0.000 0.197 + 
EPHB6, TEK, IL4R, KIT, KDR, 
PTK7, EPHB1, TIE1, IL2RB, 
MERTK, EPHA4, CCL2, MYLK, 
AXL, CDK5R1, ERBB2, EPHA7, 
MAP2K7, PDK4, FGFR3, 




Targets in the 
cytosol 






22 0.000 0.198 + 
METTL1, NSUN2, NSD1, 




34 0.000 0.216 + 
ATIC, METTL1, NSUN2, PRMT5, 
NSD1, CARM1, DNMT3A, 
DNMT3B, EHMT1, PBMT, 
PRMT7, SUV39H1, GART 
 
Table 2.  Motor Cortex Gene Set Enrichment Analysis (GSEA) for BMI. Gene Set Enrichment 
Analysis (GSEA) was performed on the motor cortex data set. The gene set name, size, nominal p-value 
(NOM p-val), false discovery rate q-value (FDR q-val), correlation with BMI, and core enriched genes are 
included. Nine gene sets were positively correlated with BMI, had a NOM p-val < 0.001, and a FDR < 0.25. 
Module 199 and 440 are from the C4 computational gene sets cancer model where they used 1,975 
published microarrays to span 22 tumor types. Module 199 is most strongly associated with leukemia and 
Module 440 is most strongly with associated liver cancer (Segal et al., 2004) . 
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We also assessed our data for the enrichment of functional gene pathways using Gene Set 
Enrichment Analysis (GSEA) (Subramanian et al., 2007) using the gene sets in the Molecular 
Signatures Database (MSigDBv.3.0) for the human (HG) arrays. We found 9 gene sets 
significantly associated with BMI in the motor cortex (Table 2), and 3 gene sets in the caudate 
nucleus (Table 3). Prominently, in the motor cortex the BMI-associated changes included 
VEGFA targets (genes upregulated in HUVEC endothelium cells at 30 minutes after VEGFA 
stimulation (Abe and Sato, 2001)) and AKT phosphorylation targets in the cytosol, while in the 
caudate nucleus significant gene sets included HDAC targets (genes whose transcription is altered 
by histone deacetylase inhibitors (Marks, 2007)). 








Enriched Genes  
Cell Maturation 15 0.000 0.137 - TP53, GADD45B, FAS, GSN, CASP3, 
GLRX, BAD, CCNE1, TXN, MCM3 
Developmental 
Maturation 
17 0.000 0.202 - KCNIP2, MYH11, ACTA1, KRT19, 
EREG, IL21, PICK1, MYOZ1 
MARKS HDAC 
targets up 
18 0.000 0.238 - MYH11, ACTA1, KRT19, EREG, 
IL21, PICK1, MYOZ1 
 
Table 3.  Caudate Nucleus Gene Set Enrichment Analysis (GSEA) for BMI. Gene Set Enrichment 
Analysis (GSEA) was performed on the caudate nucleus data set. Three gene sets were positively 
correlated with BMI, had a nominal p-value (NOM p-val) < 0.001, and a false discovery rate (FDR) < 0.25. 
 
 
The observed gene expression changes are putatively a result of altered ERK1/2 
signaling 
One particular BMI-dependent gene expression attracted further attention.  Our 
data identified inversely correlated mRNA levels of forkhead box O3 (FOXO3) with 
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BMI. FOXO3 is activated via the growth factor pathway, and involved in apoptosis and 
neuronal survival (Brunet et al., 1999). Furthermore, as a number of pro-apoptotic genes 
were positively correlated with BMI, and as both AKT and ERK1/2 are effector signaling 
pathways of neurotrophic factors (Park and Cho, 2006; Brunet et al., 1999;
 
Lindgren et al., 
2008),  we next investigated the association of the AKT and ERK protein 
phosphorylation state with BMI (Figure 9) through Western analysis. While AKT levels 
and its phosphorylation state was unchanged, we identified a strong negative correlation 
of both ERK1/2 and pERK1/2 levels with BMI (pERK1/2 / tubulin r = -0.663 with p  
0.010 and pERK1/2 / ERK1/2 of -0.595 with p = 0.025) (Figure 9). As pERK1/2 
phosphorylates CREB, a transcription factor in the nucleus to reduce apoptosis (Park and 
Cho, 2006) and activate transcription of neuronal survival genes (Brunet et al., 1999), the 
decreased phosphorylation of ERK1/2 with increasing BMIs suggests that this might be a 
critical signaling pathway mediating some of the detrimental effect of BMI on the gene 





Figure 9. PhosphoERK1/2 levels are negatively correlated with BMI. Figure 9 is a scatterplot showing 
BMI (kg/CRL
2
) versus protein ratios for pERK1/2 / tubulin (blue diamond) and for pERK1/2 / ERK1/2 
(red square). There is a significant negative correlation between BMI and pERK1/2 / tubulin protein ratio 
(r= -0.663; p = 0.010) and a significant negative correlation of BMI and protein ratio for phospho ERK1/2 / 
total ERK1/2 (r=-0.595; p = 0.025). Inset provides examples of ERK1/2 protein levels in four monkeys 





In summary, we discovered a distinct gene expression signature associated with 
BMI in the motor cortex and caudate nucleus. Our linear model allowed us to model BMI 
and gene expression continuously, and to find a gene expression signature with 100% 
concordance in directionality between significant probes on RhG and HG microarrays. 
We saw increases in apoptotic related genes and changes in metabolic related genes 
across both brain regions, suggesting that motor regions of the brain are affected at the 
transcriptional level by obesity. Decreased ERK1/2 phosphorylation was associated with 
increasing BMI. Activation of this prototypical survival kinase provides a potential 
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explanation for the enrichment of pro-apoptotic genes in animals with high BMI and 
putatively explains how obesity raises the risk for reduced brain volume (Gustafson et al., 
2004; Raji et al., 2010; Pannacciulli et al., 2007; Taki et al., 2008).  
Although we did not find evidence of BMI-dependent changes to the AKT 
signaling pathway, we cannot rule out the possibility of cross talk between the AKT and 
ERK1/2 pathways (Tang et al., 2010; Shelton et al., 2004; Dai et al., 2009;
 
Levinthal and 
DeFranco, 2004) in the nonhuman primate brain.  Furthermore, our previous data suggest 
that physical activity is positively correlated with pAKT protein levels in nonhuman 
primates (Mitchell et al., 2011b), potentially leading to a double-risk to the brain: the 
sedentary lifestyle might decrease pAKT signaling and increased BMI can repress the 
activation of the neuronal survival kinase ERK1/2. These two events, in concert might 
significantly increase brain susceptibility to various insults. Although it is tempting to 
hypothesize that both of these events are the result of a change in a growth factor 
signaling pathway, we found relatively meager evidence to support this theory at the level 
of the transcriptome. However, it is known that growth factor signaling is profoundly 
regulated at the post-transcriptional level (Lindgren et al., 2008; Chen and Russo-
Neustadt, 2007) and this should be a topic of further follow-up experiments. 
The positive correlation between the expression of apoptosis-related genes and 
BMI is also noteworthy. Increased pro-apoptotic gene expression can lead to increased 
vulnerability of neurons to various environmental insults, and the decreased brain volume 
observed in persons with high BMI (Gustafson et al., 2004; Pannacciulli et al., 2007; Taki 
et al., 2008; Raji et al., 2010) might be closed linked to the gene expression changes we 
uncovered. 
 45 
Since our monkeys were placed on a calorie restriction diet immediately prior to 
transcriptome analyses some of the deleterious effects associated with high BMI may 
have been masked. A number of previous studies have demonstrated many beneficial 
effects of calorie restriction on health, the rate of aging, and longevity (Kemnitz, 2011). 
These findings suggest important roles for the plasma membrane redox system in 
protecting brain cells against age-related increases in oxidative and metabolic stress, and 
these findings might be directly related to the BMI-correlated increases in pro-apoptotic 
gene expression (Hyun et al., 2006). Furthermore, our results are also in concordance 
with previous transcriptome profiling studies performed on monkeys that underwent 
dietary restriction (Prolla and Mattson, 2001). The neuroprotective effect of dietary 
restriction reported increased production of neurotrophic factors and protein chaperones, 
resulting in protection against oxyradical production, stabilization of cellular calcium 
homeostasis, and inhibition of apoptosis. 
 Finally, based on our studies and previous literature we conclude that active 
lifestyles with low BMI create a brain homeostasis more conducive to brain resiliency 
and neuronal survival. Brain health is clearly linked to body health, and, we now show 
the converse, that maintaining a health BMI is also essential for maintaining a healthy 
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INTRODUCTION  
A growing body of evidence suggests that mild (Yaffe et al., 2001), moderate, and 
vigorous physical activity (Thacker et al., 2008) are neuroprotective, decreasing the risk 
of many brain disorders including ischemic stroke (Hu et al., 2000; Lee and Paffenbarger, 
1998), Alzheimer’s disease (Yaffe et al., 2001; Larson et al., 2006), and Parkinson’s 
disease (PD) (Thacker et al., 2008). Numerous studies also associate the modern 
sedentary lifestyle with increased risks for obesity, cardiovascular diseases, type 2 
diabetes (Marwick et al., 2009), and depression (Lawlor and Hopker, 2001; Vance et al., 
2005).  
At the molecular level, exercise is correlated with increased levels of neurotrophic 
factors (nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), and 
fibroblast growth factor-2 (FGF-2)), synaptic trafficking genes (syntaxin, synapsin I, and 
synaptotagmin), and activation of signal transduction pathways (CaMKIIδ, ERK1/2, and 
PKC) (Neeper et al., 1996; Molteni et al., 2002; Tong et al., 2001b). In a previous study 
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we found that both BDNF and activity regulated cytoskeletal associated protein (ARC) 
are elevated in mice exposed to enriched environments (Lazarov et al., 2005), suggesting 
that activation of the ARC-BDNF pathway might be a critical mediator of 
neuroprotective events. ARC is an immediate early gene induced by neuronal excitation 
with a role in activity dependent synaptic modification (Steward and Worley, 2002), and 
active behavior in the hippocampus, neocortex, and striatum (Vazdarjanova et al., 2006).  
In contrast, high c-reactive protein (CRP) is associated with increased risks for 
type II diabetes (Lakka et al., 2005), hypertension, cardiovascular disease, and ischemic 
stroke (Stewart et al., 2010). It is involved in host defense related functions, recognizes 
foreign pathogens and damaged cells, and initiates their elimination by interacting with 
humoral and cell effector systems in the blood (Stenvinkel, 2006). In healthy individuals 
the concentration of CRP in serum is low (Yeh, 2004). As a result of ischemic infraction 
CRP binds to phosphocholine expressed on the surface of dead or dying cells in order to 
activate complement during the acute phase response (Volanakis and Kaplan, 1971) 
(Stenvinkel, 2006), and is increased in the bloodstream in response to tissue injury, 
infection, and other inflammatory stimuli (Futterman and Lemberg, 2002). Furthermore, 
high CRP enhances ischemic tissue damage in rats (Gill et al., 2004), indicating that it 
may be an active contributor to pathophysiological events.  
Recently, it has been shown that exercise can also lower CRP in the blood plasma 
(Maglott et al., 2011). This finding, combined with well-established activity-dependent 
elevation of ARC/BDNF expression the brain, leads us to the hypothesis that there is a 
relationship between spontaneous physical activity, CRP plasma levels, and ARC/BDNF 
expression in the brain. To test this hypothesis, we measured and correlated CRP serum 
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levels and brain expression of ARC and BDNF in 11 Rhesus monkeys with various levels 





All experiments were reviewed and approved by the Animal Care and Use 
Committee of the Oregon National Primate Research Center. Eleven adult female 
ovarectomized rhesus monkeys (Macaca mulatta) were housed in individual cages (32 x 
24 x 27 or 32 x 34 x 27 in.) in a temperature-controlled room (24  2 C), with lights on 
between 0700 and 1900 h. Two and a half years prior to the initiation of this study, these 
monkeys were ovariectomized and placed on a diet higher in fat than standard monkey 
chow (35% of calories from fat) to approximate the conditions experienced by many 
post-menopausal women in the Western world (Williams et al., 2003).  This diet was 
formulated at the Oregon National Primate Research Center (ONPRC) (Sullivan et al., 
2006; Sullivan and Cameron, 2010), following a modification of the recipe developed by 
Clarkson and colleagues to study diet-induced atherosclerosis (Shadoan et al., 2003; 
Williams et al., 2003). Monkeys were subsequently placed on a diet of Purina high 
protein monkey chow (no. 5045; Ralston Purina, St. Louis MO), supplemented with fresh 
fruits and vegetables for two months. During the first month available calories were 
reduced to 30% as compared to baseline on the higher fat diet, and in the second month 
calorie intake was reduced to 60% as compared to baseline. 
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In vivo Experimental Measures 
Throughout the study, food intake was measured at every meal, body weight was 
measured weekly, and activity was measured continuously using omnidirectional Actical 
accelerometers (Respironics, Phoenix, AZ), attached to a loose-fitting metal collar, via 
previously published methods (Sullivan et al., 2006; Sullivan and Cameron, 2010). 
Percent body fat was determined using dual energy X-ray absorptiometry scans (Sullivan 
et al., 2006; Sullivan and Cameron, 2010). 
 
 
Collection of Brain Tissue 
Monkeys were deeply anesthetized with ketamine/pentobarbitol, quickly 
decapitated, and the entire brain was removed from the skull. The brain was then hemi-
sected by a midline saggital cut. The right hemisphere was cut into ~5 mm-thick coronal 





RNA sample preparation 
The motor cortex was identified using anatomical landmarks, and a 2mm x 2mm 
tissue cube of transcortical gray matter was dissected from the frozen block using 
surgical tools under RNAse-free conditions.  The motor cortex brain material was 
homogenized and total RNA isolated using TRIzol® reagent (Invitrogen, Carlsbad, CA) 
with RNA quality assessed via analysis on an Agilent 2100 Bioanalyzer. Only samples 
with an RIN > 7.0 were considered for further analysis.  
 
 
Quantitative real-time PCR 
cDNA synthesis was performed using two independent reverse transcription 
reactions for each sample with High Capacity cDNA Archive Kit® (Applied Biosystems). 
For each 100 μl reaction, we used 700 ng of the same total RNA used for microarray 
analysis. Priming was performed with random hexamers. For each sample, amplified 
product differences were measured with 4 independent replicates using SYBR Green 
chemistry-based detection (Mimmack et al., 2004). β-actin was used as the endogenous 
reference gene since it has been established as a stable reference gene in the literature 
(Chen et al., 2001; Arion et al., 2007a; Arion et al., 2007b). Primer sequences for β-actin 
were 5’ GAT GTG GAT CAG CAA GCA 3’ and 5’ AGA AAG GCT GTA ACG CAA 
CTA 3’; for BDNF were 5’ GAC TGG ACG ACC ACA CTC AAG 3’ AND 5’ CAA 
CCT GCT CCA GGC TAA TC 3’; and for ARC 5’ CGC CTG GAG AAG AAT CAG 
AG 3’ AND 5’ CTC AGC CGG ATT TGA GGA C 3’. The efficiency for each primer set 
was assessed prior to qPCR measurements, and a primer set was considered valid if its 
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efficiency was > 90%. The qPCR reactions were carried out on an ABI Prism 7300 
thermal cycler (Applied Biosystems Inc.), quantified using ABI Prism 7300 SDS 
software (with the auto baseline and auto threshold detection options selected) and 




C-reactive protein (CRP) was analyzed using serum drawn immediately prior to 
termination of the study, after animals had been on a low fat diet for two months 
following a three-year period on a 35% fat diet. Serum was stored frozen, warmed to 
make aliquots and then refrozen before use. A quantitative ELISA kit specific for 
monkey CRP (Alpha Diagnostic international, 96 well) was used to measure serum levels 
of CRP according to the manufacturers instructions. Serum aliquots were diluted with the 
Elisa kit diluent between 1:200 and 1:800 in order to cover the range of CRP levels in 
these animals, and run on a single ELISA plate in triplicate. Results shown were based on 
a 1:400 dilution, as this range best centered the observed levels within the standard curve, 
but other dilutions did not alter the conclusions drawn. Optical density of the colored 
reactant was quantified using an Emax Precision Microplate Reader (Molecular Devices) 
set to 450nm, measured twice and averaged. A standard curve was generated using 
known sample concentrations, run on the same ELISA plate in duplicate. Sigma Plot 




BDNF, ARC, CRP and spontaneous activity measurements were correlated using 
Pearson product-moment correlation coefficient in Microsoft Excel 2007. The 
significance of the Pearson product-moment correlation coefficient was calculated using t 
= r / [(√(1 – r2) / (N - 2)]. P-values were obtained from the t-statistic (Lowry, 2010). As 
higher values mean lower absolute transcript expression, to denote meaningful 




Spontaneous activity levels activity levels, measured continuously with 
accelerometers, showed individual variation of more than an order of magnitude, and 
encompassed a range of 46,717 – 760,838 counts/day (mean = 398,152 counts/day, SD = 
273,011 counts/day) at the beginning of the calorie restriction diet and 46,478 - 515,105 
counts/day (mean = 244,855 counts/day, SD = 161,681 counts/day) at the end of the 
calorie restriction diet. Activity measurements at the beginning and end of the calorie 
restriction diet were highly correlated (r=0.85, p=0.000379), suggesting that diet was not 
a crucial factor in defining the relative level of spontaneous activity, and that relative 
activity level was a stable intrinsic characteristic of monkeys over the investigated time 
window. The monkeys displayed serum concentrations of CRP in the range of 4.82 –
26.28 mg/L (mean concentration = 12.47, SD = 7.30) (Table 1 in Figure 10a), while 
brain expression measurement of BDNF and ARC suggested that both genes were 
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abundantly expressed in the motor cortex, albeit with less individual variability than the 
CRP levels and spontaneous activity levels. 
As we obtained measurements for continuous variables (spontaneous activity, 
serum CRP, cortical ARC and cortical BDNF), to test our hypotheses we cross-correlated 
the overall data using Pearson product-moment correlation coefficient. As expected from 
our previously reported findings (Lazarov et al., 2005), the expression of ARC and 
BDNF were correlated in the motor cortex (r=0.51, p=0.05) (Figure 10b). Furthermore, 
ARC and BDNF activity were also significantly correlated with spontaneous activity 
(r=0.60, p=0.02 and r=0.54, p=0.04, respectively) (Figure 10c). In contrast, CRP plasma 
levels were inversely and significantly correlated with spontaneous activity (r=-0.64, 
p=0.01) (Figure 10d). Finally, the CRP levels were also strongly and inversely correlated 
with the motor cortical expression of ARC and BDNF (r=-0.81, p<0.001 and r=-0.80, 
p<0.001, respectively) (Figure 10e), raising the possibility of a causal co-regulation 
between these measurements. 
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Figure 10. Correlation of spontaneous activity, serum CRP levels, and BDNF and ARC expression in 
motor cortex of 11 Rhesus monkeys. (a) Monkey activity levels were measured in counts/day, CRP in 
milligrams per liter (mg/L), BDNF and ARC in threshold cycle difference relative to β-actin (ΔCT). (b) 
Scatter plot of ARC expression (X axis) and BDNF expression (Y axis) for the motor cortex of the 11 
monkeys included in the study. Solid line represents trend line. Note the correlation between the expression 
of these two genes. (c) X axis denotes gene expression level measured by qPCR for ARC (blue diamonds) 
and BDNF (red squares) for the 11 monkeys, while Y-axis represent end of experiment spontaneous 
activity counts. Solid lines denote trend lines. Note that both ARC and BDNF expression are significantly 
correlated with spontaneous activity in the studied monkeys.  (d) Scatter plot of serum CRP levels (X axis) 
vs. spontaneous activity (Y axis). Each symbol represents a single experimental animal. Note the inverse 
correlation between spontaneous activity and serum CRP levels. (e) Correlation of serum CRP level and 
ARC and BDNF expression in the motor cortex. The figure layout is similar to that of 1c. Note the high 
inverse correlation between the ARC-CRP and BDNF-CRP measurements. 
 
DISCUSSION 
This study gave rise to three major findings. First, spontaneous activity in the 
primate is stable over time and although a monkey’s activity level decreases with calorie 
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restriction (Sullivan and Cameron, 2010) their activity level relative to that of other 
monkeys remains stable. Second, spontaneous activity is positively correlated with ARC 
and BDNF expression in the motor cortex of nonhuman primates, and negatively 
correlated with serum CRP levels. Third, serum CRP levels are strongly and negatively 
correlated with ARC and BDNF expression in the motor cortex of nonhuman primates.  
Previous studies in mice, rats, and monkeys show the same general localization of 
BDNF and ARC to layers II, III, IV, and VI in the cortex (Link et al., 1995; Grinevich et 
al., 2009; Hofer et al., 1990; Phillips et al., 1990; Zhang et al., 2007), and both are 
predominantly expressed in the principal (projection) neurons in the cortex. Thus, we 
believe that the CRP-correlated cortical expression changes occur in the same population 
of the projection neurons. Nevertheless, this hypothesis will have to be confirmed in 
follow up co-localization studies in a different experimental cohort, as our fresh-frozen 
material is less then ideally suited for such experiments. 
Activity, CRP, BDNF and ARC co-regulation raises an important and interesting 
question: how are peripheral changes in CRP levels in the blood related to the gene 
expression changes in the motor cortex? Based on previous literature findings, we believe 
that this relationship could be causal and related to dynamic changes in brain 
vascularization: 1) CRP can significantly influence gene expression in the vascular 
endothelium after 24 hours (Wang et al., 2005), 2) increased levels of CRP can increase 
infarct in rats and enhance ischemic tissue damage (Gill et al., 2004), 3)  CRP is also 
increased in the blood plasma in response to tissue injury, infection, and other 
inflammatory stimuli (Yeh, 2004), 4) CRP causes blood–brain barrier disruption 
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involving the formation of ROS by the NAD(P)H-oxidase (Kuhlmann et al., 2009),  5) 
brain endothelial cells express higher levels of CRP receptors and have increased 
vulnerability of brain endothelial cells to CRP following stroke (Kuhlmann et al., 2009), 
6) MPTP administration increases CRP levels in nonhuman primates (De Pablos et al., 
2009) and 7) high CRP is associated with increased risk for type II diabetes (Lakka et al., 
2005), hypertension, cardiovascular disease, and ischemic stroke (Stewart et al., 2010). 
Furthermore, exercise results in the reduction of weight and is associated with 
improvements in CRP (Church et al., 2010). 
However, we must also acknowledge the possibility that the correlation between 
peripheral CRP levels and BDNF/ARC is a result of a more complex, coordinated set of 
pathophysiological events. This cascade might also involve an insulin-like growth factor 
(IGF) dependent mechanism: peripheral administration of IGF has also been shown to 
induce BDNF mRNA expression in the hippocampus and cortex (Carro et al., 2000). 
Furthermore, exercise increases IGF1 levels in the brain, and IGF1 blocking antibodies 
administered before a neural injury results in decreased neuroprotection (Carro et al., 
2001). Thus, one could hypothesize that the activity-induced increase in IGF1 levels 
leads to upregulation of BDNF/ARC in the hippocampus and cortex. 
Finally, our findings and the literature data raise a critical question: do increased 
peripheral CRP levels increase the chance of an individual to develop neurodegenerative 
brain diseases? If so, lowering CRP levels in the periphery might be neuroprotective, and 
this could be assessed in various in vitro and in vivo model systems. Further studies of the 
activity-CRP-ARC-BDNF relationships and the health of the brain are warranted by our 
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findings, and could lead to important new strategies for early detection of, as well as 
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Mild (Yaffe et al., 2001), moderate, and vigorous physical activity (Thacker et al., 
2008) are associated with a decreased risk of neurodegenerative brain disorders such as 
Alzheimer’s disease (Yaffe et al., 2001; Aaron et al., 2006), Parkinson’s disease (Thacker 
and Ascherio, 2008), and the size of the infarct from stroke. Many clinicians routinely 
recommend physical activity for those suffering from the effects of these diseases. In 
Parkinson’s disease patients physical activity has been shown to improve gait, tremor, 
grip strength, balance, and motor coordination (Hirsch et al., 2003; Palmer et al., 1986) 
while physical activity alone has been shown to improve sleep (Driver and Taylor, 2000), 
cognition (Colcombe and Kramer, 2003; Weuve et al., 2004), and decrease depression 
(Dunn et al., 2005; Lawlor and Hopker, 2001; Reuter et al., 1999). It has been 
hypothesized that exercise is neuroprotective against Parkinson’s disease and other 
neurodegenerative diseases.  
Many people have explored the mechanism of exercise in the brain. Animal 
studies show that exercise and environmental enrichment
 
increase the production of 
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neurotrophic factors (nerve growth factor, NGF, brain derived growth factor, BDNF, and 
basic fibroblast growth factor, FGF-2), immediate early genes, synaptic trafficking genes 
(syntaxin, synapsin I, and synaptotagmin), and signaling transduction molecules (AKT, 
CaMKIIδ, ERK1/2, and protein kinase C, PKC) throughout the brain with the most 
dramatic effects in the hippocampus (Neeper et al., 1996; Molteni et al., 2002; Gomez-
Pinilla et al., 2002). Physical activity and enriched environments also enhance learning 
and memory, increase neuronal survival, increase resistance to brain insults, trigger 
synaptogenesis, promote brain angiogenesis, and promote neurogenesis in the 
hippocampus (Brown et al., 2003).   
Little has been done to evaluate exercise alone in brain regions other than the 
hippocampus, which is a unique brain region, one of only two sites that undergo adult 
neurogenesis (Neeper et al., 1996; Molteni et al., 2002; Brown et al., 2003; Tong et al., 
2001a), and some studies suggest regional differences in the brain in response to exercise.  
The hippocampus does show a high frequency of neural activity during exercise, like the 
motor cortex and striatum (Vissing et al., 1996), but the hippocampus does not show an 
increase in bioenergetic capacity (McCloskey et al., 2001). This suggests that additional 
responses to, or mechanisms of, exercise may be seen in regions outside of the 
hippocampus. 
Other models have confirmed the principal that physical activity can provide 
protection against brain lesions. Animal neurodegeneration models for Alzheimer’s 
disease and Parkinson’s disease show that physical activity and exercise can decrease the 
size of the lesion as evidenced in the caudate nucleus and putamen (Tillerson et al., 2001; 
Tillerson et al., 2003; Howells et al., 2005; Caudle et al., 2007; Mabandla et al., 2004; 
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Petzinger et al., 2007; Lazarov et al., 2005; Mitchell et al., 2011a). Indeed in our monkey 
MPTP model of Parkinson’s disease we found that overall physical activity level, not 
exercise alone, protected the brain against neurodegeneration of dopaminergic projections 
to the caudate and putamen (Mitchell et al., 2011a).  
The mechanism of neuroprotection has been explored in greater detail using 
disease models. Zigmond et al hypothesized that forced use ameliorates the behavioral 
and biochemical effects of Parkinson’s disease using the 6-OHDA model through 
cascade of events that involves glial derived neurotrophic factor (GDNF) (Zigmond et al., 
2009), a potent survival factor for DA neurons (Cohen et al., 2003). There is a significant 
increase of striatal GDNF 24 and 72 hours after using the non-impaired limb in the 
unilateral 6-OHDA model of Parkinson’s disease (Lin et al., 2008). Furthermore, ERK1/2 
activation by GDNF in the striatum remains elevated up to 1 month after limb use (Lin et 
al., 2008; Lindgren et al., 2008). We have also found that physical activity gene 
expression in the motor cortex is associated with phosphorylated AKT – a signaling 
kinase important in cellular survival – and in the caudate nucleus with the mTORC1 
nutrient sensing and generation of second messengers pathways (Mitchell et al., 2011b), 
which indicates that there are some common responses and mechanisms of physical 
activity across different brain regions.  
Thus, we hypothesized that the motor cortex and putamen would share an 
exercise-associated gene expression signature with the hippocampus, but also would 
contain unique gene expression changes. We used sedentary and exercising Rhesus 
monkeys (Macaca mulatta) to explore the mechanism of exercise by DNA microarray in 
the motor cortex, putamen, and hippocampus. We found exercise associated gene 
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expression included solute carrier family (SLC) members, members of the electron 
transport chain, and translation initiation genes, suggesting that the mechanism of aerobic 





Twelve female Rhesus monkeys (Macaca mulatta) (15-20 years of age, 5-8 kg) 
were matched based on initial activity levels and placed into two groups: sedentary and 
animals that ran 5 days/week on a treadmill at 80% of their maximal heart capacity, 




Sample preparation and hybridization 
Hippocampus tissue, motor cortex tissue, and putamen tissue, respectively, were 
homogenized and total RNA was isolated using TRIzol® reagent (Invitrogen, Carlsbad, 
CA). RNA quality was assessed on an Agilent 2100 Bioanalyzer. A RNA integrity 
number (RIN) > 7 was considered acceptable for further analysis. Samples were 
amplified using the Enzo
TM
 BioArray Single Round RNA Amplification and Biotin 
Labeling System. They were primed with a standard T7-oligo(dT) primer and cDNA 
synthesis was performed using 3 µg of total RNA. Amplified antisense RNA (aRNA) 
was produced using in vitro transcription directed by a T7 polymerase. Six µg of each 
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purified and fragmented aRNA was hybridized to GeneChip
®
 HT Human Genome (HG) 
U133 Plus PM Arrays Plates. Image segmentation analysis and generation of DAT files 
was performed using Microarray Suite 5.0 (MAS5). 
 
 
Microarray data analysis 
One 24 Affymetrix Human Gene Titan array plate containing hippocampal and 
motor cortex samples, and one 16 Affymetrix Human Gene Titan array plate containing 
putamen samples were scanned and analyzed. Segmented images were normalized and 
log2 transformed using robust multi-array analysis (RMA) separately for hippocampus, 
motor cortex, and putamen with RMA normalized expression levels utilized for all 
subsequent analyses. All microarray data will be available at 
http://mirnicslab.vanderbilt.edu. 
Probes with a p-value < 0.05 for both paired and groupwise t-tests, and an average 
log ratio (ALR) > 0.263 (representing a 20% change) were considered associated with 
exercise. Gene lists for hippocampus, motor cortex, and putamen exercise-associated 
were created. Exercise-associated probes from each region were tested for concordance in 
directionality of gene expression change between the other 2 regions.  
 We performed gene set enrichments analysis (GSEA) on the motor cortex, 
putamen, and hippocampus using Broad Institute GenePattern Software (Subramanian et 
al., 2005) on all gene sets in the Molecular Signatures Database (MSigDB 3.0) (Liberzon 






We hypothesized that the motor cortex, putamen, and hippocampus would be 
associated with unique gene expression changes, but also share common gene expression 
changes relating to neuronal survival. We used two groups of monkeys: 6 sedentary 
monkeys who sat on treadmills and 6 exercising monkeys who ran on treadmills at 80% 
of their maximum heart capacity. We isolated RNA from the motor cortex, putamen, and 
hippocampus, and profiled the transcriptome using Human Genome DNA microarrays 
(HG) (Figure 11).  
 We identified 434 transcripts that were associated with exercise in the motor 
cortex (336 increasing with exercise and 98 decreasing with exercise), 265 transcripts 
that were associated with exercise in the putamen (127 increasing with exercise and 138 
decreasing with exercise), and 5508 transcripts that were associated with exercise in the 
putamen (1673 increasing with exercise and 3835 decreasing with exercise) 




Figure 11. Exercise Gene Expression Analysis Experimental Design.  Twelve female rhesus monkeys 
were placed into either a sedentary group or a group of 80% maximum heart capacity runners to look for 
transcripts by Human Genome (HG) DNA microarray in the brain associated with exercise. We looked at 3 
regions of the brain: motor cortex (blue), putamen (red), and the hippocampus (green). We defined 
transcripts significantly associated by a groupwise and paired t-test with a p-value<0.05, and an average log 
ratio (ALR) > 0.263, representing a 20% change. Additionally, we looked for functional pathways 
associated with each brain region by gene set enrichment analysis (GSEA) (Liberzon et al., 2011).  
 
 Our data suggests that the motor cortex and the hippocampus respond differently 
to exercise. There was no overlap between all three brain regions. Furthermore, we saw 
only 3 of 55 overlapping gene transcripts between the motor cortex and hippocampus 
changing in the same direction (Figure 12). Between the motor cortex and putamen we 
saw 4 of 5 overlapping gene transcripts changing in the same direction, and 89 of 91 
overlapping gene transcripts changing in the same direction between the hippocampus 
and putamen.  
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Figure 12. Exercise Related Gene Expression Motor Cortex, Putamen, and Hippocampus Venn 
Diagram. We used a Venn diagram to compare gene expression associated with exercise in three regions 
of the brain: motor cortex (blue), putamen (red), and hippocampus (green). There are 434 transcripts in 
total associated with exercise in the motor cortex, 265 in total associated with exercise in the putamen, and 
5508 transcripts in total associated with exercise in the hippocampus. Ninety one transcripts overlap 
between the hippocampus and putamen, 89 of which are changing in the same direction. Five transcripts 
overlap between the motor cortex and putamen, 4 of which are changing in the same direction. Fifty five 
transcripts overlap between the hippocampus and motor cortex, 3 of which are changing in the same 
direction. This indicates that exercise associated gene expression is different between the hippocampus and 
motor cortex, and that the putamen shares exercise associated gene expression with the motor cortex and 
hippocampus.  
 
 In all three brain regions we found members of the solute carrier (SLC) family 
and genes involved in the mitochondria electron transport carrier, and by GSEA in the 
motor cortex using the Molecular Signatures Database (MSigDB) we found exercise 
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enriched genes in the NADH Dehydrogenase, mitochondrial respiratory chain complex, 
and respiratory chain complex I gene sets (Table 4, Figure 13).  
Table 4. Exercise Motor Cortex Gene Set Enrichment Analysis (GSEA) 







NDUFA13, NDUFB6, NDUFS3, 
NDUFS8, NDUFS7, NDUFV1, NDUFS1 
0.000 0.145 
Mitochondrial Respiratory 
Chain Complex I 
NDUFA13, NDUFB6, NDUFS3, 
NDUFS8, NDUFS7, NDUFV1, NDUFS1 
0.000 0.073 
Respiratory Chain Complex I 
NDUFA13, NDUFB6, NDUFS3, 
NDUFS8, NDUFS7, NDUFV1, NDUFS1 
0.000 0.048 
 
Table 4.  Motor Cortex Gene Set Enrichment Analysis (GSEA) for Exercise. Three gene sets using all 
of the gene sets from the Molecule Signatures Database (MSigDB) (Liberzon et al., 2011) were found 
significantly altered in the motor cortex by GSEA. Gene sets are identified by their pathway name, size, 
nominal p-value (NOM p-val), and false discovery rate q-value (FDR q-val). Nominal p-values of 0.000 
indicate that the value was below 1 / (number of permutations, or 1000). Complex I of the electron 
transport chain is enriched with exercise in the motor cortex.  
 
 In the motor cortex we saw increased in SLC25A27 and SLC25A37 and 
decreased SLC23A1 and SLC39A13 (Figure 13). SLC25A27 is mitochondrial 
uncoupling protein 4. It reduces the mitochondrial membrane potential and separates 
oxidative phosphorylation from ATP synthesis with energy dissipated as heat. 
SLC25A37 is a mitochondria inner membrane protein that imports iron for synthesis into 
mitochondria heme and iron-sulfur clusters. SLC23A1 is a vitamin C transporter. 
SLC39A13 is a zinc transporter (Maglott et al., 2011). These mRNA transcript changes 




Figure 13. The Electron Transport Chain. We found solute carrier family (SLC) members and electron 
transport chain family members associated with exercise in the motor cortex (light blue), putamen (red), 
hippocampus (green), and in the motor cortex by GSEA (dark blue). This figure was edited from 
Wikipathways (Pico et al., 2008).  
 
 In the putamen we saw increased SLC25A18, SLC15A2, and SLC37A4 and 
decreased SLC38A1 and SLC4A4 (Figure 13). SLC25A18 is a mitochondrial carrier 
protein. SLC15A2 is an H+/peptide transporter. SLC37A4 is a glucose 6 phosphate 
translocase. SLC38A1 is an amino acid transporter that transports glutamine, an 
intermediate in detoxification of ammonia and production of urea. SLC4A4 is an 
electrogenic sodium bicarbonate co-transporter (Maglott et al., 2011). These mRNA 
transcript changes suggest that there are changes in transport of many solutes with 
exercise in the brain.  
 In the hippocampus we saw numerous genes involved in the mitochondrial 
respiratory chain (Figure 13). These were involved with Complex 1 (NDUFA6, 
NDUFB2, NDUFB1, NDUFA1, NDUFA5, and NDUFA8), Complex II (SDHD), 
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Complex III (UQCRC2, UQCRB, and UQCRH), Complex IV (COX5A, COX5B, 
COX6B1, BOX6C, COX7A2, COXA2L, COX7B, COX7C, and COX17), Complex V 
(ATP5C1, ATP5J, ATP50, ATP5F1, ATP5I, ATP5J2, AND ATPIF1), and the 
uncoupling protein (SLC25A27 and SLC25A14) (Maglott et al., 2011). This suggests 





We believe that exercise contributes to physical activity level, but that physical 
activity level itself is neuroprotective. We have looked at spontaneous activity gene 
expression signatures in the motor cortex, caudate nucleus (Mitchell et al., 2011b), and 
the putamen (Mitchell et al., 2011a). We found that activity is associated with increases 
in the phosphorylation state of AKT, a neuronal survival signaling cascade (Mitchell et 
al., 2011b). This is distinct from weight and BMI gene expression signatures in the brain 
(Mitchell et al., 2011c) where increases in BMI are associated with decreases in the 
phosphorylation of ERK1/2, another neuronal survival signaling cascade, and increases in 
apoptotic factors. Finally, in the caudate nucleus and putamen we find chromatin 
remodeling and anti-apoptotic factors associated with physical activity-associated 
neuroprotection (Mitchell et al., 2011a). The physical activity associated gene expression 
signatures in all 3 regions that we have studied (the motor cortex, caudate, and putamen) 
promote neuronal survival.  
In exploring the exercise associated gene expression signature in the motor cortex, 
putamen, and hippocampus we found that the putamen shared the most similar gene 
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expression between the regions. After GSEA we found an enrichment of genes in the 
motor cortex associated with complex I of the electron transport chain (Table 4).  
 These results confirm other results of changes in the electron transport chain in 
the brain with exercise. In general exercise increases the metabolic rate, the rate of 
mitochondrial respiration, the rate of oxidative phosphorylation, and oxygen flux 
(Meydani et al., 1993; Ji et al., 1998). In a recent study the number of mitochondria was 
found increased, as assessed via mtDNA, with exercise in the brain (Steiner et al., 2011). 
In the hippocampus of mice uncoupling protein 2 and oxygen consumption were found 
increased with voluntary exercise (Dietrich et al., 2008). In addition defects in complex I, 
III, and IV proteins are associated with exercise intolerance (DiMauro, 1999). Some of 
the best evidence comes from a study using mice running on treadmills. Exercise 
prevented the decrease in antioxidant enzyme activities (Mn, Cu, and ZN superoxide 
dismutase and catalase), prevented the decrease in complex III and IV in the brain 
(Navarro et al., 2004).  
These results have implications for aging and disease. Generally there are higher 
levels of superoxides and progressive oxidative damage with aging (Maklashina et al., 
2003), longer lifespans correlate with low reactive oxygen species production by the 
mitochondria (Perez-Campo et al., 1998), and decreased complex I and IV activity is 
associated with aging (Bowling et al., 1993; Navarro et al., 2002). Complex I defects may 
have a role in the etiology of Parkinson’s disease. Though the exact etiology of 
Parkinson’s disease is unknown, there an increase in peroxides produced by the complex 
I and decreased proteasome activity may lead to Parkinson’s disease (Chou et al., 2010). 
In Parkinson’s disease patient cell lines there is increased proton leakage in complex I 
 70 
(Esteves et al., 2010), and complex I is inhibited by toxins used to create Parkinson’s 
disease lesions in animal models (Betarbet et al., 2002).  
Although we did not find neuroprotection by exercise (only by activity level) in 
our MPTP model of Parkinson’s disease in rhesus monkeys (Mitchell et al., 2011a), our 
data supports the idea that exercise is also important in upregulating transcripts that 
combat Parkinson’s disease in the putamen. This supports the idea that exercise 
contributes the physical activity in a way that is neuroprotective. This leads us to the 
belief that exercise is important in promoting brain resiliency to protect the brain against 
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INTRODUCTION 
 Studies in rodents have shown that several forms of exercise (wheel-running, 
treadmill running, and forced use by casting the opposite forelimb) can lead to plastic 
changes in the brain including angiogenesis, neurogenesis, synaptogenesis, and increased 
tissue concentrations of trophic factors (Neeper et al., 1996; Cotman and Berchtold, 
2002; Kleim et al., 2003; Klintsova et al., 2004). Moreover, in rodents exercise can 
prevent or significantly mitigate the destruction of nigrostriatal dopamine (DA) neurons 
and the development of PD symptoms that occurs after exposure to the DA neurotoxins 
6-hydroxydopamine (6-OHDA) or 1,2,3,6-methyl-phenyl-tetrahydropyridine (MPTP) 
(Tillerson et al., 2001; Fisher et al., 2004; Faherty et al., 2005). Interestingly, however, 
housing animals in an enriched environment with other animals and toys can also 
decrease damage after DA neurotoxin exposure (Faherty et al., 2005; Urakawa et al., 
2007). Since an enriched environment is well known to be associated with increase motor 
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activity, these findings suggest that increasing activity, rather than aerobic exercise per 
se, may lead to neuroprotection of DA neurons. 
 Increased overall physical activity that does not involve aerobic exercise has been 
associated with numerous health benefits in humans. An increased level of activity has 
been correlated with overall better health in older adults, including less risk of 
arteriosclerosis, hypertension, and hyperglycemia (Kuller et al., 2006; Aoyagi and 
Shephard, 2009). Physical activity is also positively correlated with a reduced level of 
metabolic risk factors (Riechman et al., 2002; (Healy et al., 2008; Sisson et al., 2010), a 
reduced fatty liver index, associated with increased insulin sensitivity and decreased 
coronary heart disease risk (Gastaldelli et al., 2009), and higher plasma levels of 
adenopectin (Jurimae et al., 2010), which protects against metabolic diseases in middle- 
and older-aged adults (Dekker et al., 2008; Fretts et al., 2009). In addition, higher levels 
of physical activity are associated with a lower risk of osteoporosis (Aoyagi and 
Shephard, 2009) and gall bladder disease (Kriska et al., 2007). 
 Given the numerous health benefits provided by increased levels of physical 
activity in humans, we sought to determine whether objectively measured activity is 
associated with neuroprotection of DA neurons in a primate model of PD, the MPTP-
treated rhesus monkey.  A broad range of physical activity levels was studied by taking 
advantage of stable individual differences in monkeys’ daily levels of physical activity 
(Sullivan et al., 2006; Hunnell et al., 2007; Papailiou et al., 2008), as well as by having 
some monkeys undertake planned exercise regimens five days a week, which we have 
previously shown increases an individual monkey’s daily activity by two- to four-fold 
(Sullivan and Cameron, 2010). Furthermore, as neuroprotection by activity and planned 
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exercise is known to be associated with strong transcriptome profile changes (Lazarov et 
al., 2005), we analyzed the mRNA expression of the caudate and putamen and correlated 





Nine female rhesus macaques (Macaca mulatta), aged 14-20 years (mean+SE: 
16.44+0.74 years) were housed in social living pens (4m x 4m x 4.7m) that had multiple 
perches, toys, and a thick layer of sawdust bedding. This housing facility has 20 pens in a 
wing, such that monkeys in each pen could see and hear other monkeys in a number of 
other pens. Six monkeys were of Chinese origin (sedentary: n=2; running: n=4) and three 
were of Indian origin (sedentary: n=1; running: n=2). All monkeys were housed with at 
least one other monkey. Monkeys were fed Purina Monkey Chow (#5038; Ralston Purina 
Co., St. Louis, MO) once daily and given fruit, vegetables, nuts and seeds to encourage 
foraging, as well as ad libitum access to drinking water.  All monkeys were observed 
daily for health and menstrual status.  All procedures were performed in accordance with 
the NIH Guide for the Care and Use of Laboratory Animals and were approved by the 







Monkeys were studied in groups of three: one sedentary monkey, one monkey 
running at 60% of maximal aerobic capacity, and one running at 80% of maximal aerobic 
capacity. Prior to MPTP administration, monkeys were studied for a 3-month period, 
during which the runners ran and sedentary animals sat on a treadmill 5 days/week. All 
monkeys then received a right intracarotid injection of MPTP-HCl (0.8 mg; Sigma 
Chemical Co., St. Louis MO), at a concentration of 0.2 mg/mL, delivered at 1mL/min) 
using previously published techniques (Ovadia et al., 1995; Gash et al., 1996; Grondin et 
al., 2002). After surgery animals were allowed to recover in quarantine for 4 days to 




Activity was measured in each animal using an omnidirectional Actical 
accelerometer (Respironics, Phoenix, AZ) mounted on a loose-fitting collar (Primate 
Products, Immokalee, FL), and using previously published methods (Sullivan et al., 2006; 
Sullivan and Cameron, 2010; Papailiou et al., 2008). Activity counts per minute were 
recorded. Each group of three animals studied together was chosen so that they were 
‘activity-matched’ prior to the initiation of exercise training. Baseline activity was 
measured for 7 days prior to the experimental period, and activity during the 
experimental period was measured for 8-12 weeks prior to MPTP administration. 




Monkeys were trained to run a on a human size treadmill (Model 910e, Precor, 
Inc., Bothell, WA) using procedures developed and previously published by this 
laboratory (Williams et al., 2007; Williams et al., 2001b; Williams et al., 2001a; Cameron 
et al., 2010; Rhyu et al., 2010).  Briefly, runners were adapted to the treadmill by first 
sitting on it, then learning to walk at a slow pace, and then increasing the speed and 
duration of running until they were running 1 hour/day, 5 days/week, at a target speed. 
Target speed was determined from a maximal exercise test performed after animals had 
learned to walk on the treadmill, and was set at a speed equivalent to either 60% or 80% 
of maximal aerobic power. A second maximal exercise test was performed at week 6 of 
the study and running speed adjusted, so that animals continued to train at 60% or 80% of 
maximal aerobic power as they became more fit. Monkeys ran for 3 months prior to 
receiving MPTP and 7 weeks post-MPTP. Sedentary monkeys sat on a treadmill and 
watched the runners each day. 
 
 
Monkey Motor Assessment Panel (mMAP) testing 
The mMAP is a reward-based test panel that reliably detects subtle improvements 
or declines in fine motor function by measuring performance time in milliseconds for a 
monkey to use its hands to retrieve a small food treat from a receptacle chamber attached 
to a testing cage (Gash et al., 1999; Zhang et al., 2000; Grondin et al., 2000; Grondin et 
al., 2003).  Beginning 4 weeks prior to MPTP exposure, monkeys were placed in a testing 
cage in a behavioral testing room and adapted to the test apparatus for 10-15 minute 
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periods for 5-6 days. When the animals were routinely retrieving food from the food 
receptacle with each hand, active testing began. Each monkey was then tested 5 
days/week for four weeks pre-MPTP to obtain baseline data. Each testing session 
consisted of 12 trials, 6 on each side, alternating between the right and left hand. Three 
tests of increasing difficulty were evaluated: the platform test (Level I), the straight rod 
test (Level II), and the straight rod placed at a distance test (Level III).  Both fine motor 
performance (i.e., the time the hand was in the receptacle picking up the food reward) and 
coarse motor performance (i.e., the time for the upper limb to move from the armhole 
portal to the food receptacle portal and then back from the receptacle portal into the cage, 
or total time) were recorded.  Fine motor performance and total time to complete the task 




At 6 weeks post-MPTP, all monkeys received positron emission tomography 
(PET) scans using [
11
C]dihydrotetrabenazine (DTBZ), which binds to vesicular 
monoamine transporter (VMAT2) receptors, as a ligand. This radioligand was selected 
for its high specificity for VMAT2 receptors, and because it is not sensitive to 
pharmaceutical treatments for PD such as L-DOPA; thus findings in the monkey could be 
more easily translated to clinical studies. Monkeys were transported to the University of 
Pittsburgh PET imaging facility, anaesthetized with 10mg/kg IM ketamine hydrochloride 
(Ketaject, Phoenix Pharmaceuticals Inc., St. Louis, MO), and placed under isofluorane 
anaesthesia (0.5 - 2.0% minimum alveolar concentration) for the duration of the 90-
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minute PET scan.  Each animal’s body temperature was maintained at a constant 37°C 
using a recirculating hot water blanket (Gaymar Industries, Inc., Orchard Park, NY) 
controlled by a rectal temperature probe. A catheter was placed in a saphenous vein for 
the injection of the radiotracer and administration of isotonic saline for hydration. Vital 
signs were monitored continuously throughout the experiment.  PET imaging was 
performed on a microPET P4 scanner (Siemens Molecular Imaging, Knoxville TN), 
according to previously published procedures (Lopresti et al., 2008).  The outcome 
measure was binding potential, which is a unitless measure of radiotracer specific binding 
that is directly proportional to the ratio of Bmax, of the free receptor pool, to KD, the ligand 
dissociation constant. Binding potential values (Bmax/KD) were computed on a voxel-by-
voxel basis to generate maps [
11




Tissue Collection  
At 7 weeks post-MPTP, subjects were sedated with 10 mg/kg IM ketamine HCl 
and deeply anesthetized with sodium pentobarbital (30 mg/kg, i.v.; Nembutal, Abbott 
Laboratories, North Chicago, IL). The carotid arteries were severed, and animals were 
exsanguinated. The brains were rapidly removed from the skull, immediately placed in 
ice-cold RNAse-free saline, and then quickly transferred into a custom-made macaque 
brain mold (Bioanalytical Systems Inc., West Lafayette, IN). The brain was sectioned 
rostral to caudal every 4 mm using the guides in the mold for placement of blades. Fresh 
sections were laid flat on glass slides, brain regions of interest were harvested (i.e., 
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punches of caudate and putamen), and the punches and remaining tissue were snap frozen 




Tyrosine hydroxylase protein levels in the caudate and putamen were measured 
by Western Blot analysis, using minor modifications of previous techniques (Leak et al., 
2008).  Modifications include sonicating monkey tissue in 0.1% sodium dodecyl sulfate 
(BioRad, Philadelphia PA) in 1x lysis buffer (Cell Signaling Technologies, Danvers, 
MA) with a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) in 20 volumes of 
liquid per mg wet tissue weight. After immunoblotting, membranes were visualized on an 
Odyssey Imager with infrared secondary antibodies (Li-Cor, Lincoln, NE), which were 
used to bind mouse anti-TH (Millipore, Billerica, MA) and anti-β-actin primary 
antibodies (mouse monoclonal; Sigma Aldrich). TH is expressed over actin, to control for 




Expression profiling was performed on four (two for caudate nucleus and two for 
putamen) independently harvested and analyzed samples from each monkey. Tissue 
samples were dissected from each animal from frozen coronal blocks using anatomical 
landmarks, homogenized, and total RNA was isolated using TRIzol® reagent 
(Invitrogen, Carlsbad, CA) with RNA quality assessed via analysis on an Agilent 2100 
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Bioanalyzer. Only samples with an RIN > 7.0 were considered for further analysis. The 
samples were prepared with 2 μg of total RNA using the Enzo BioArray™ Single-Round 
RNA Amplification and Biotin Labeling System. Purified and fragmented aRNA samples 
were hybridized to 2 Affymetrix HU133 GeneTitan 24-array plates. Image segmentation 
analysis and generation of DAT files was performed using Microarray Suite 5.0 (MAS5). 
Segmented images were normalized and log2 transformed using robust multi-array 
analysis (RMA) (Sabatini et al., 2007). We obtained RMA normalized data from two 
pieces of caudate for each animal. The averaged RMA normalized log2 expression levels 




Linear regression models were used to determine whether mean daily activity 
counts during exercise training predicted 1) [
11
C]DTBZ binding to VMAT2 receptors in 
the caudate and putamen, as well as in the striatum (caudate + putamen), and 2) the 
TH/-actin ratio in each of these regions.  For each of these measures, the sides of the 
brain ipsilateral (i.e. the right side) and contralateral (i.e. the left side) the side of the 
MPTP injection, were examined separately.  Activity data during the experimental period 
was not available for one monkey, and preliminary analysis revealed that a second 
monkey’s mean daily pre-MPTP activity was 2.6 standard deviations greater than the 
group mean, and significantly higher than any other monkey we have ever recorded 
activity for, so both were excluded from analyses. The rhesus monkeys used in this study 
were of both Indian origin (n=3) and Chinese origin (n=6). To determine whether 
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differences in origin influenced each outcome, independent-samples t-tests were 
employed. Independent-samples t-tests were also used to analyze the mMAP data, with 
the total duration to complete the task for each hand as the outcome (left vs. right, as 
MPTP administration to the right side of the brain would be expected to affect left-side 
motor function).  An alpha level of 0.05 was considered statistically significant, and 
SPSS software (PASW Version 18, Chicago, IL) was used for all analyses. 
To examine correlations with the gene expression profile, first, we performed a 
data reduction step by correlating the replicate harvests R1c and R1c for the caudate 
nucleus, and R1p and R2p for the putamen across the 8 monkeys used in analyses 
(Figure 18). Only probe sets with a correlation r > 0.70 were considered for further data 
analysis. Next, we correlated RMA normalized log2 gene expression values from each 
replicate separately with activity, percent loss [
11
C]DTBZ binding potential (PET) from 
the affected hemisphere versus the nonaffected hemisphere, and percent loss tyrosine 
hydroxylase (TH) levels from the affected hemisphere versus the nonaffected 
hemisphere. In this step, a gene was significantly changed if it showed a correlation in 
both replicates greater that 0.60 or less than -0.60 (r>0.6 or r<-0.6). This analysis was 
separately performed for activity, percent loss [
11
C]DTBZ binding potential, and percent 
loss of tyrosine hydroxylase levels. In the final step we queried the data for overlap 
between the activity, percent loss of [
11
C]DTBZ binding compared to the nonaffected 
hemisphere, and percent loss of TH compared to the unlesioned side, identifying the gene 
expressions changes that best explained DA terminal sparing by the three functional 
measurements.  
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Additionally, we profiled the putamen of the nonlesioned hemisphere for three 
monkeys (one from each group) using DNA microarrays, and compared it to the lesioned 
hemisphere for each monkey. We used a paired t-test to find differentially expressed 
genes associated with the lesion with a p<0.05 and an average log ratio (ALR) greater 
than 0.3785, representing a 30% change in expression. Hierarchical clustering was 
performed using GenePattern software (Subramanian et al., 2005) using log2 transformed 




Mean daily activity counts significantly predicted the amount of [
11
C]DTBZ 
binding to VMAT2 receptors in the striatum ipsilateral to MPTP injection, such that 
monkeys that were more active prior to MPTP exhibited greater binding potentials 
(striatum: r
2
=0.636, p=0.032; Figures 14, 15a). Greater activity also predicted 
[
11
C]DTBZ binding in the ipsilateral putamen (r
2
=0.698, p=0.019), with a trend toward 
predicting [
11
C]DTBZ binding in the ipsilateral caudate (r
2
=0.511, p=0.07).  Mean daily 
activity also predicted the percent loss of [
11
C]DTBZ binding in the putamen with 
reference to the side contralateral to the MPTP injection (r
2
=0.713, p=0.017).   
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Figure 14. Parametric PET image of [
11
C] DTBZ binding in a monkey with high (left), intermediate 
(middle), and low daily activity (right). Distribution Volume Ratio (DVR) is shown rather than binding 
potential for anatomical reference. Given the same unilateral intracarotid dose of MPTP there was less 
damage to the ipsilateral striatum in more active animals. 
 
Mean daily activity also significantly predicted TH in the ipsilateral striatum, 
putamen and caudate (striatum: r
2
=0.760, p=0.011; putamen: r
2
=0.833, p=0.004; caudate: 
r
2
=0.625, p=0.034; Figure 15b).  Further, mean daily activity predicted the percent loss of 
TH in the striatum and putamen with reference to the side contralateral to the MPTP 
injection (striatum: r
2





Figure 15. Regression analysis of PET scan data showing (a) average daily level of physical activity vs.  
[
11
C] DTBZ binding potential in the striatum and (b) average daily level of physical activity vs. tyrosine 
hydroxylase/β-actin levels in the striatum. Black circles represent sedentary monkeys, blue squares 
represent monkeys that ran at 60% maximal heart rate 5 days/week and the red triangle represents a 
monkey that ran at 80% maximal heart rate 5 days/week. The numbers 1 and 2 indicate monkeys whose 24-
hour actigrams are depicted in Figure 17. 
 
Interestingly, we found the rhesus monkeys of Indian origin showed a 
significantly higher percent loss of TH compared rhesus monkeys of Chinese origin 
(t(7)=2.67; p=0.03; 71.74+1.73% vs. 38.04+8.58%; Figure 16a). As shown in Figure 
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16b, the sedentary Indian monkey did not use her left hand (the hand affected by MPTP) 
at anytime after MPTP administration to complete any stage of testing, while she relied 
on her right hand for both the platform and straight rod near tasks and, as would be 
expected, performed slightly better with her right hand as testing progressed.  In contrast, 
the 60% runner used both hands similarly for the platform task (t(10)=0.68, p=0.51) and 
while she used both hands for the straight rod near task, she was significantly faster with 
her right hand (control) than her left hand (MPTP) throughout testing on this task (t(10)=-
2.27, p=0.03).  Most strikingly, the 80% runner used both hands equally well on both the 
platform and straight rod near task, and was the only monkey to perform the straight rod 
far task where again she used both hands equally well (p>0.10 for all tasks).  Thus it 
appears that the 60% runner was able to use the hand affected by MPTP moderately well 
in tests of fine motor skills, while the 80% runner showed no loss of fine motor function. 
Physiological parameters that we measured did not differ significantly between Chinese 
and Indian rhesus monkeys, including weight (Chinese: 6.43±0.47, Indian: 7.05±0.37, 




Figure 16. Monkey Origin and mMAP testing. (a) Percent loss of tyrosine hydroxylase/β-actin levels in 
the ipsilateral putamen, with reference to the contralateral putamen, seven weeks after a unilateral 
intracarotid injection of MPTP. Asterisk indicates a significant difference, p<0.05, between monkeys of 
Indian origin (n=3) compared to monkeys of Chinese origin (n=6). (b) Time to retrieve a lifesaver on a 
platform (open bars), on a straight-rod place close (grey bars) or on a straight-rod placed at a distance 
(black bar), with the left hand (closed circles) and right hand (open circles) for the three Indian origin 
monkeys. Asterisks represent a significant difference in time to retrieve the lifesaver with the right vs. left 
hand. 
 
 Examination of patterns of activity of individual monkeys revealed that there 
were two patterns of activity that were evident in these monkeys. Monkeys that were 
exercising an hour a day showed an increased level of activity during the hour of exercise 
(see Figure 17, left panel). In contrast, some monkeys have relatively high levels of 
mean daily activity and these monkeys tended to show consistent patterns of higher 
activity throughout the 12-hour light period (see Figure 17, right panel). Thus, it was 
possible for two monkeys with very similar daily mean activity levels (Monkeys 1 and 2; 
Figures 15A and 15B) to have very different patterns of daily activity (Figure 17, left 




Figure 17. Twenty-four hour actigrams of activity across a 24-hour day for two monkeys identified in 
Fig. 14a and 14b, which had similar mean daily levels of activity and neuroprotection as indicated by both 
[
11
C] DTBZ binding and TH levels. Monkey 1 was a runner who was extremely inactive most of the day, 
except when exercising. Monkey 2 was a sedentary monkey who showed naturally occurring bouts of 
substantial activity over the course of a normal day. Black bars at the top of the actigrams indicate periods 
of lights off; light bars indicate periods of lights on. 
 
A comparable gene expression profile (r>0.70) was seen in 5359 transcripts 
between the two caudate samples (R1c and R2c), and in 2831 transcripts between the two 
putamen samples (R1p and R2p) (Figure 18). These transcripts were correlated 
subsequently with monkey activity values, independently for both structures. Seventy-
nine transcripts were correlated (r>0.60) with activity in both R1c and R2c caudate 
samples (34 positively correlated and 45 negative correlated) (Supplementary Table 10) 
and two-hundred fifty seven transcripts were correlated (r>0.60) with activity in both R1p 
and R2p putamen samples (166 positively correlated and 91 negatively correlated) 
(Supplementary Table 11). When subjected to a two-way hierarchical clustering, both 
the caudate and putamen samples showed a nice progression of gene expression levels 
from monkeys with low activity to monkeys to high activity (Figures 19 and 20).   
Interestingly, the activity associated gene expression profiles of the caudate and putamen 
were quite distinct, with only two genes (vomeronasal 1 receptor 4 and transducin (beta)-
like 1 X-linked receptor) overlapping across the two structures.  
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Figure 18. Identifying neuroprotection-associated transcripts in the caudate nucleus and putamen.  
Gene expression was assessed by two independent, adjacent dissections of caudate nucleus (R1c and R2c) 
and putamen (R1p and R2p) on the Affymetrix GeneTitan 24-array plate platform. In the caudate 5359 
transcripts showed a dataset correlation of r>0.7 between R1c and R2c, while in the putamen 2831 
transcripts showed a dataset correlation of r>0.7 between R1p and R2p. These data were subjected to 
subsequent analysis, where we identified transcripts that were correlated (r>0.6 or r<-0.6) with percent loss 
of [
11
C]DTBZ binding, tyrosine hydroxylase levels, and with mean total activity counts (counts/day) in 
both caudate (R1c and R2c) and both putamen (R1p and R2p) samples. There were 17 overlapping 
transcripts associated with all 3 measurements in the caudate, and 91 overlapping transcripts associated 
with all 3 measurements in the putamen.   
 
In both brain regions we identified several genes that target chromatin (DPF3, 
MDB3L1, SRCAP, TBLR1) (Lange et al., 2008; Zeng et al., 2010; Wong et al., 2007; 
Jiang et al., 2004; Slupianek et al., 2010; Zhang et al., 2006; Yoon et al., 2005), a few 
genes previously associated with neuronal survival and apoptosis (CAPN6, NEUROG3, 
and NTRK3) (Rho et al., 2008; Huang and Wang, 2001; Lee et al., 2003; Nikoletopoulou 
et al., 2010), two genes with critical functions at the synapse (STX3 and UHRF1BP1L) 
(Martin-Martin et al., 1999; Binda et al., 2008; Beckman et al., 1998; Haase et al., 2001; 
Lee et al., 2004; Sung et al., 2003; Dipace et al., 2007; Otto et al., 2010), and two 
members of the leucine rich repeat family (LRRC27 and LRRC40) (Matsushima et al., 
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2009; Smith et al., 2005; Lee et al., 2010). All of these genes, in concert, could be 
considered as potential mediators of activity associated neuroprotection, and deserve a 
more detailed follow-up in future studies.  
 
Figure 19. Hierarchal clustering of transcripts associated with mean total activity in the caudate 
nucleus. One-way hierarchical clustering was performed on the log2-transformed expression levels of 
caudate (R1c and R2c) replicate transcripts associated with mean total activity. Genes, denoted by their 
Affymetrix Human Probe Set ID and NCBI gene symbol, were clustered horizontally. Monkeys are 
identified by their mean total activity. Each colored square represents a normalized gene expression value 
with color intensity proportional to the level of expression (blue indicates lower expression and red 
indicates increased mRNA levels). Note the progression of gene expression levels from monkeys with low 
mean total activity to monkeys with high mean total activity in both caudate replicates. 
 
In the next step we hypothesized that expression of the most critical 
neuroprotection genes would be correlated with all three of our functional measurements: 
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activity levels, in vivo [
11
C]DTBZ binding, and TH levels. To test this hypothesis we 
performed a correlational analysis between all three measurements (Figure 18) and gene 
expression in the caudate and putamen samples. In the caudate we identified 79 activity, 
242 [
11
C]DTBZ binding, and 185 TH correlated transcripts that were present in both R1c 




Figure 20. Hierarchal clustering of transcripts associated with mean total activity in the putamen. 
One-way hierarchical clustering was performed on the log2-transformed expression levels of putamen (R1p 
and R2p) replicate transcripts associated with mean total activity. Genes, denoted by their Affymetrix 
Human Probe Set ID and NCBI gene symbol, were clustered horizontally. Monkeys are identified by their 
mean total activity. Each colored square represents a normalized gene expression value with color intensity 
proportional to the level of expression (blue indicates lower expression and red indicates increased mRNA 
levels). Note the progression of gene expression levels from monkeys with low mean total activity to 
monkeys with high mean total activity in both putamen replicates. 
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Figure 21. Hierarchal clustering of transcripts associated with mean total activity, percent loss 
[
11
C]DTBZ binding, and percent loss TH in the caudate nucleus and putamen. Two-way hierarchical 
clustering was performed on log2-transformed expression levels on the caudate (R1c and R2c) and 
putamen (R1p and R2p) replicate samples. Genes, denoted by their Affymetrix Human Probe Set ID and 
NCBI gene symbol, were clustered horizontally, and monkey samples were clustered vertically. Monkey 
identifiers denote mean total activity, percent loss [
11
C]DTBZ binding, and percent TH loss. Each colored 
square represents a normalized gene expression value with color intensity proportional to the level of 
expression (blue indicates lower expression and red indicated higher mRNA levels). Note the progression 
of gene expression levels correlate with mean total activity, percent loss [
11
C]DTBZ binding, and percent 
loss TH  in both the caudate and putamen replicates. 
 
Of these 17 genes we identified as correlated with all three functional readouts 
(activity, [
11
C]DTBZ binding, and TH levels), with 9 showing positive and 8 showing 
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negative correlation (Supplementary Table 12). In the putamen, we identified 257 
activity, 219 [
11
C]DTBZ binding, and 239 TH correlated transcripts that were present in 
both R1p and R2p samples. Of these we identified 91 transcripts as correlated with all 
three functional readouts (activity levels, [
11
C]DTBZ binding, and TH levels) with 66 
showing a positive correlation and 25 transcripts showing a negative correlation 
(Supplementary Table 13). When these common expression changes were subjected to 
a two-way hierarchical clustering, both the caudate and putamen samples showed a nice 
progression of expression levels with all three functional measurements (Figure 21). The 
putamen-correlated expression changes were more numerous than those in the caudate, 
and this is probably a result of a differential connectivity and distinct effects of MPTP on 
these two structures. Transcripts associated with all three measurements included 
LRRC40 and TBL1XR1 in the caudate, and DPF3, MBD3L1, NEUROG3, STX3, 
UHRF1BP1L, and VN1R4 in the putamen. It is highly unlikely, however, that any single 
gene alone was responsible for the observed neuroprotection; rather, this pattern is 




Figure 22. Identifying Differentially Expressed Between the Lesioned and Nonlesioned Putamen. We 
dissected both the right and left putamen from one monkey from each group (sedentary, 60% runners, and 
80% runners) and analyzed gene expression via DNA microarray. Significant differentially expressed 
transcripts had a p < 0.05 and an ALR > 0.3785 (a 30% change).  
 
In addition, we also looked at genes associated with the lesioned hemisphere by 
assessing significantly differentially expressed transcripts between the lesioned right 
putamen and the nonlesioned left putamen (Figure 22). We found 384 differentially 
express transcripts (199 decreasing with the lesion and 185 increasing with the lesion) 
between the lesioned and nonlesioned hemispheres. We found a gene involved in repair 
decreased, ataxia telangiectasia and Rad3 related (ATR), a gene involved in apoptosis 
increased (CASP9), increases in some neurotrophic factor signaling genes (FGF2 and 
eukaryotic translation initiation factor 4E (EIF4E)), and specifically an increase in 
syntaxin 3 (Figure 23 and Supplementary Table 14). This supports the idea that some 
compensatory mechanisms (axon sprouting) promote survival of neurons after a lesion 
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(Greenough and Volkmar, 1973). These mechanisms include an increase in dopamine 
release and a decrease in dopamine uptake (Connor and Diamond, 1982; Zigmond et al., 
1992; Abercrombie et al., 1990; Snyder et al., 1990). They also confirm the MPTP lesion 
(decreased in ATR and an increase in CASP9). 
 
Figure 23. Putamen Transcripts Differentially Expressed Between the Lesioned and Nonlesioned 
Hemispheres. We found 384 differentially express transcripts (199 decreasing with the 




 By several different measures of function (i.e., [
11
C]DTBZ binding as measured 
by PET scan, TH levels measured by Western blot), monkeys with higher daily levels of 
physical activity showed greater protection of nigrostriatal dopaminergic neurons when 
exposed to the dopaminergic neurotoxin, MPTP. This greater level of neuroprotection 
translated to greater functional protection after MPTP exposure in monkeys with higher 
activity levels. Although monkeys with higher levels of physical activity were those that 
were participating in a planned exercise program of 1 hour of running/day, 5 days/week, 
both naturally-occurring daily activity and planned exercise contributed to mean daily 
activity level (as shown in Figure 17), such that the monkeys that had the greatest mean 
daily activity levels were not those that exercised at the greatest intensity. These findings 
offer strong support for the concept that increased daily activity, at any intensity, is 
neuroprotective in primates. This is encouraging in that it suggests that maintaining an 
active lifestyle may protect the brain against neurodegenerative diseases (e.g., 
Parkinson’s disease), yet be accessible to many people regardless of their baseline fitness. 
Functional imaging methods, such as PET scans, have been widely applied to 
non-invasively assess the degree of striatal DA terminal loss in PD patients by 










(Leenders et al., 1986; Brooks et al., 1990; Morrish et al., 1998; Innis et al., 1991; Frost 
et al., 1993; Guttman et al., 1997; Rinne et al., 1999a; Rinne et al., 1999b). PET 
assessment of DA terminal degeneration has been shown to correlate with disease stage 
as well as the severity of bradykinesia and rigidity (Seibyl et al., 1995; Brucke et al., 
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1997). VMAT-2 is a membrane bound protein found in monoaminergic neurons that 
translocates monoamines that are either newly synthesized or taken back up via DAT (or 
other monoaminergic transporters) from the cytosol into synaptic storage vesicles 
(Schuldiner, 1994). While VMAT-2 transporters are not selective for any one 
monoamine, more than 95% of VMAT-2 sites in the striatum are associated with the 
dopaminergic nigrostriatal projection (Vander Borght et al., 1995; Wilson and Kish, 
1996). PET and SPECT radioligands developed for imaging VMAT-2 non-invasively are 
all structural analogs of the potent and selective inhibitor of VMAT-2, tetrabenazine 
(TBZ) (Efange, 2000). In this study we used a-[
11
C]dihydrotetrabenazine (DTBZ), a 
metabolite of TBZ, as a PET imaging agent for VMAT-2. In vitro investigations of 
[
3
H]DTBZ demonstrated specific binding to VMAT-2 and low non-specific binding. In 
postmortem human brain tissue, [
3
H]DTBZ demonstrated binding to a single high-
affinity site (Kd = 7 nM), and the distribution of binding sites was consistent with the 
distribution of TH immunoreactivity (Thibaut et al., 1995). Likewise, we have found in 
monkeys that striatal binding of [
11
C]DTBZ correlates strongly with TH quantified by 
Western blot (Lopresti et al., 2008). VMAT-2 immunochemistry has shown significant 
reductions (70-88%) in the caudate and putamen of PD subjects (Miller et al., 1999). 
Similar reductions in the striatal binding of [
11
C]DTBZ have been demonstrated in vivo 
using PET in PD patients (Bohnen et al., 1999; Bohnen et al., 2006; Frey et al., 1996) and 
in primate models of PD (Doudet et al., 2006). Thus, our finding in this study that 
monkeys with higher levels of physical activity showed increased [
11
C]DTBZ binding in 
the striatum after MPTP lesions is a strong indication that there was less damage to 
striatal DA neurons in these monkeys. 
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Experimentally induced striatal DA depletion in animals has proven to be a useful 
approach for studying many motor aspects of parkinsonism (Blum et al., 2001; Oiwa et 
al., 2003). In most models, one of two selective toxins is used: 6-OHDA, which acts 
through oxidative stress by increasing hydrogen peroxide and quinone breakdown 
products or 1,2,3,6-methyl-phenyl-tetrahydropyridine (MPTP), which causes oxidative 
stress by inhibition of Complex I of the mitochondrial electron transport chain  (Chassain 
et al., 2001; Jenner, 2003; Barcia et al., 2004). The capacity of MPTP to induce stable 
parkinsonism in nonhuman primates (Davis et al., 1979; Burns et al., 1983) provides the 
opportunity to create a primate model of PD. Moreover, the introduction by Bankiewicz 
and colleagues of an intra-carotid approach to the administration of MPTP in nonhuman 
primates (Bankiewicz et al., 1986) and its continued development by investigators of the 
University of Kentucky Udall Center (Ovadia et al., 1995; Gash et al., 1996; Gash et al., 
2005; Grondin et al., 2002; Ai et al., 2003; Ding et al., 2008) provides a model with a 
highly reproducible, unilateral lesion with a quantifiable phenotype. Administration of a 
moderate dose of MPTP (0.8 mg) leads to a loss of TH+ cells in the substantia nigra and 
TH+ fiber density in the striatum (Ding et al., 2008). Using these same procedures, here 
we found that more active monkeys had significantly less loss of TH in the striatum, 
strongly supporting the conclusion that there was less damage to DA neurons in more 
active animals. These results support findings in the rodent that exercise or housing in an 
enriched environment can protect DA terminals from the effects of 6-OHDA or MPTP, as 
shown by measures of DA content, TH in the striatum, and counts of TH+ cells in the 
substantia nigra (Tillerson et al., 2002; Tillerson et al., 2001; Tillerson et al., 2003; 
Bezard et al., 2003; Cohen et al., 2003; Faherty et al., 2005; Anstrom et al., 2007). 
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Interestingly, we found that genetic origin of the rhesus monkeys in our study 
(Indian origin vs. Chinese origin) also influenced the degree of response to MPTP, with 
monkeys of Indian origin having a greater loss of DA terminals after MPTP exposure. 
Strain differences in nigrostriatal DA neuron response to MPTP have been previously 
reported in C57BL/6 mice (i.e., MPTP-sensitive) vs. Swiss-Webster (SW) MPTP-
resistant mice (Hamre et al., 1999; Smeyne et al., 2007). In these two mice strains 
differential expression of glutathione-S-transferase (GST) π appears to play a key role in 
the level of MPTP sensitivity. GST π is expressed in nigrostriatal dopaminergic neurons, 
and is a detoxifying enzyme that inhibits JNK-activated signaling, blocking the 
phosphorylation of cJUN and apoptosis of the cell (Wang et al., 2001). C57BL/6 MPTP-
sensitive mice show a decrease in GST π levels in nigrostriatal DA neurons after MPTP 
exposure, whereas SW MPTP-resilient mice show stable levels of GST π post-MPTP 
(Smeyne et al., 2007). In people, polymorphisms in GST π have been loosely correlated 
with increased risk of idiopathic PD after exposure to pesticides (Menegon et al., 1998; 
Kelada et al., 2003). Whether Indian origin rhesus monkeys have lower levels of GST π 
in nigrostriatal DA neurons is unknown at this time, but this or a similar genetic 
difference between Indian and Chinese origin rhesus monkeys could account for 
differences in MPTP toxicity. There are substantial genetic differences in rhesus monkeys 
of Indian vs. Chinese origin in mitochondrial DNA (Kanthaswamy and Smith, 2004; 
Satkoski et al., 2008), and in the nuclear genomes as demonstrated by differences in 
microsatellites (Smith et al., 2006), Major Histocompatability Complex (MHC) loci 
(Penedo et al., 2005), and SNPs (Ferguson et al., 2007; Hernandez et al., 2007). We did 
not find a significant difference in mean daily activity between Chinese and Indian 
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monkeys, however, this may be because sample size was low. So it is possible that Indian 
rhesus monkeys may have lower activity than Chinese rhesus, and if so, that this may 
contribute to differences in sensitivity to MPTP.  
In both humans (Hornykiewicz, 1962; Fearnley and Lees, 1991) and animals 
(Zigmond and Stricker, 1972) motor impairment does not occur until there is 
approximately a 70-80% loss of striatal dopamine, we only expected to find motor 
impairment in the monkeys of Indian origin in this study. And, we did find that the 
sedentary Indian origin animal essentially would not use her left hand for mMAP testing 
(as shown in Figure 17). However, we found that both exercising monkeys of Indian 
origin showed much less motor impairment compared to the sedentary animal, with the 
monkey running at 80% capacity showing no detectable slowness of movement of the left 
hand compared to the right hand. These findings strongly support a wealth of data in rats 
(Mabandla et al., 2004; Howells et al., 2005; Poulton and Muir, 2005; Jadavji et al., 2006; 
Steiner et al., 2006; O'Dell et al., 2007) and mice (Tillerson et al., 2003; Fisher et al., 
2004; Petzinger et al., 2007) showing that giving animals access to exercise equipment 
(i.e., running wheels, treadmills), or housing them in an enriched environment that 
encourages an increase in physical activity (Bezard et al., 2003; Faherty et al., 2005; 
Petzinger et al., 2007) leads to a clear reduction in the behavioral consequences of 6-
OHDA and MPTP. This also supports evidence that has been mounting over the past 
decade suggesting benefits of exercise in people in early and mid-stages of PD 
(Schenkman et al., 2008; Ellis et al., 2005) on general motor function. Our findings 
would in fact suggest that participation in planned exercise is not necessary but that just 
being more active in daily activities may slow the progression of PD.  
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The gene expression profiling studies also led us to several interesting 
conclusions. After MPTP exposure in a non-human primate model (1) there is a strong 
association between non-human primate activity and functional measurements of 
dopamine system sparing ([
11
C]DTBZ binding and TH levels), and gene expression in the 
caudate and putamen; (2) caudate and putamen gene expression patterns are distinct, 
which may be explained by distinct functional connectivity between these two brain 
regions or differential effect of MPTP on striatal structures., and (3) the neuroprotection-
associated gene expression pattern in the caudate and putamen included multiple genes 
previously associated with chromatin remodeling and anti-apoptotic processes.  
We found a number of increased chromatin-remodeling gene transcripts 
associated with planned physical activity after MPTP exposure. These genes have a 
unique, but putatively converging function. D4, zinc and double PHD fingers, family 3 
(DPF3) is a histone acetylation and methylation reader of the BAF chromatin remodeling 
complex (Lange et al., 2008). It initiates gene transcription during development by 
binding histones H3 and H4 in an acetylation sensitive manner (Zeng et al., 2010). In 
contrast, methyl-CpH binding domain protein 3-like 1 (MBD3L) is a transcriptional 
repressor that interacts with methyl-CpG-binding protein 2 (MeCP2/MBD2) (Jiang et al., 
2004), a protein that plays a critical role in both CNS development and response to cell 
death (Russell et al., 2007). Snf2-related CREBBP activator protein (SRCAP) is also a 
chromatin remodeling protein (Wong et al., 2007), and has been shown to enhance the 
ability of CREB binding protein to activate transcription (Slupianek et al., 2010). Finally,  
transduction (beta)-like 1 X-linked receptor 1 (TBL1XR1) is a multifunctional co-
repressor of transcription (Zhang et al., 2006) that binds preferentially to hypoacetylated 
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histones H2B and H4, and has a critical role in targeting the co-repressor complexes to 
chromatin in vivo (Yoon et al., 2005).  Additional chromatin remodeling genes that were 
also correlated with activity included chromodomain helicase DNA binding domain 2 
(CHD2), microcephalin (MCPH1), and runt-related transcription factor 2 (RUNX2) 
(Nagarajan et al., 2009; Marfella et al., 2006; Yang et al., 2008; Westendorf et al., 2002). 
These combined findings suggest that neuroprotection by activity after MPTP exposure 
is, at least in part, achieved though epigenomic mechanisms that deserve further 
investigation.  
We propose that a second, anti-apoptotic molecular mechanism also might play an 
important activity-dependent role in sparing the DA terminals after MPTP exposure. 
Calpain 6 (CAPN6), an atypical protease lacking the active site (Huang and Wang, 2001) 
has been shown to inhibit apoptosis and facilitate neurogenesis (Rho et al., 2008), 
potentially counteracting MPTP effect in the stratum. Neurotrophic factor receptor 3 
(NTRK3/TrkC) is the high affinity catalytic receptor for the neurotrophin NT-3 
mediating neuronal differentiation and survival. TrkC activation instructs developing 
neurons to die both in vitro and in vivo (Nikoletopoulou et al., 2010), and this is 
consistent with the repressed TrkC expression level we observed in the monkeys with 
higher activity. Similarly, the Huntington interacting protein 1 (HIP1) was negatively 
correlated with our measurements, and this gene is known to induce cell death through 
the caspases 3, 8, 9 system (Hackam et al., 2000; Wanker, 2002; Choi et al., 2006). 
Additional anti-apoptotic genes that were also correlated with mean total activity 
included v-rel reticulotheliosis viral oncogene homolog B (RELB) (El Gazzar et al., 
2007) and dual specificity phosphatase 26 (DUSP26) (Shang et al., 2010).  
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In particular our attention was focused on STX3, as we also found it associated 
with activity-associated neuroprotection in the putamen and associated with the lesioned 
hemisphere, albeit a different probe. Syntaxin 3 was decreased with activity, [
11
C]DTBZ 
binding, and TH levels, and increased in the lesioned hemisphere. Syntaxins function in 
vesicle mediated exocytosis of neurotransmitters (Sudhof and Rothman, 2009), and bind 
synaptotagmin in a calcium dependent way (Sudhof et al., 1993; Lin and Scheller, 1997).  
There is a coordinated change in the expression of several syntaxin isoforms after long 
term potentiation (LTP) and learning in the hippocampus. Expression of syntaxin 3A 
(STX3A) increases 6 hours after LTP while syntaxin 3A (STX3B) decreases 30 minutes 
after LTP (Rodger et al., 1998). Healthy neurons may prefer STX3A over STX3B, but 
the role of STX3 in causing damaging and preventing neuroprotection is difficult to 
determine from current research and the literature, and requires further investigation.   
 In summary, our findings do suggest that participating in a planned exercise 
program increases the probability of having high levels of mean daily activity, as 
indicated by our finding that monkeys in our study with the highest mean daily activity 
levels were those who ran on treadmills five days a week. However, as can be seen in 
Figures 15a and 15b, mean daily activity level was not solely dependent on the level of 
planned exercise that was undertaken. One of the sedentary monkeys with a relatively 
high level of baseline activity had slightly higher mean daily activity levels than one of 
the monkeys which ran at 60% maximal capacity 5 days a week. Likewise, one monkey 
running at 80% maximal capacity had lower mean daily activity levels than two other 
monkeys that ran at 60% maximal capacity. Mean daily activity strong predicted the level 
of neuroprotection after neurotoxin exposure, whether daily activity came from planned 
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exercise, high levels of naturally-occurring activity or a combination of both. This finding 
is particularly encouraging for the aging population, or those in the early stages of 
diseases that target motor function, in that it suggests that a variety of forms of activity 
are neuroprotective, not just aerobic exercise that many may have difficulty undertaking. 
Finally, the identification of the molecular underpinnings of activity-associated 
expression profile in the striatal structures gives us a glance into the neuroprotective 
mechanisms at work, and might enable development of targeted therapeutic interventions 
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It has been over a decade since the publication of the first high-throughput gene 
expression profiling studies of the brain (Mirnics et al., 2000; Hakak et al., 2001; 
Lockhart and Barlow, 2001; Pasinetti and Ho, 2001; Mimmack et al., 2002). During the 
last decade the opinion and attitude of the scientific community has changed toward these 
technologies multiple times. The first phase, lasting about 3-4 years, was characterized by 
enthusiasm, excitement, and often unjustified optimism. Many viewed DNA microarray 
technology as a “magic bullet” that would fundamentally change our understanding of 
various brain disorders, and during this golden era of microarrays funding agencies were 
generous in supporting data-driven exploratory efforts. As a result, several important 
studies were generated, along with a large number of mediocre studies that resulted in 
long lists of gene dumpouts without meaningful interpretation of the findings. The 
backlash was predictable, and over a relatively short time period the dominant scientific 
opinion transformed itself to one of skepticism toward anything that was DNA 
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microarray-generated. In the meanwhile, proteomics became “hot”, followed by other 
novel “omics” technologies, and microarray expression studies fell in disgrace: 
microarray manuscripts started to be considered “descriptive studies”, and as such they 
routinely started to receive editorial rejections by the top journals in the field of 
neuroscience. The attitude of many journals and editors was best summarized by the 
boilerplate rejection letter of the Journal of Neuroscience from 2005, stating that “We 
tend to be circumspect when we receive an expression array paper.” (Journal-of-
Neuroscience, 2005) - not caring about the quality of the presented science, but 
condemning the technology.  Many microarray enthusiasts jumped on a bandwagon of 
new, hotter and better-funded “omic” technologies – while the real puritans of microarray 
technology went to work: they teamed up with expert teams of biostatisticians and 
bioinformaticians and started to generate standards of performing, reporting (Brazma et 
al., 2001), analyzing (Tusher et al., 2001; Irizarry et al., 2003; Subramanian et al., 2005) 
and sharing (Barrett et al., 2005) the experiments. To the classical “most changed gene” 
analyses novel pathway assessments were added (Mirnics et al., 2000; Mirnics et al., 
2001; Dennis et al., 2003; Curtis et al., 2005; Subramanian et al., 2005; Langfelder and 
Horvath, 2008), and the best microarray experiments started to include both data 
verification and functional follow-up assays. The gene expression profiling field grew up, 
entered its current phase of “accepted method” and took its place as a powerful, yet not 
omnipotent, scientific tool in the exploratory research portfolio.  
Being part of this evolution process was both fascinating and frustrating. Over the 
years we received many criticisms from our peers, editors and reviewers. Some were 
fully justified and pointed out our own ignorance, while others were clearly malicious 
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and had no foundation in reality. However, a number of observations and statements 
made in this process constituted great starting points for interesting discussions. The 
latter ones are the topic of this manuscript, in a hope that public pondering of some of 
these issues will help achieve better experimental design, higher quality data, enhanced 
recognition of a good microarray experiment, and improved interpretation of findings. 
 
 
“Without a testable hypothesis, there is no good science.” 
 We strongly disagree with this notion. “I believe in ignorance-based methods 
because humans have a lot of ignorance and we should play to our strong suit …you take 
raw ignorance and turn it into processed ignorance, and processed ignorance, well-
defined ignorance, well-asked questions that we don't know the answer to, that's the root 
of experiment.” - Dr. Eric Lander, founding director of the Broad Institute, eloquently 
pointed out the prevailing philosophy of data-driven researchers (Lander, 2002). It should 
be noted that initial and unproven hypotheses per se carry little value, and are limited by 
our current perception of how a biological system might work (Mirnics and Pevsner, 
2004; Horvath et al., 2010). Data-driven, hypothesis-free approaches allow simultaneous 
testing of thousands of unformulated hypotheses: comparing the whole genome 
transcription machinery allows us to find the truly unknown, the unexpected, and the 
counterintuitive. It allows us to generate novel hypotheses, which can, and should be 
followed up in detail, in a hypothesis-driven fashion. Thus, in our experiments the precise 
initial hypothesis becomes secondary to a stellar experimental design that maximizes the 
chance of finding meaningful and fundamentally novel data (Mirnics et al., 2006). What 
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to analyze (e.g. which cell types or brain regions), which subjects to include (e.g. co-
morbidity, endophenotypes, technical exclusion), how to analyze the dataset are critical, 
and often very challenging considerations, and the poorly performed expression profiling 
studies almost invariably fail at this.   
 
 
“Sample size should be increased…” 
In theory, this is true. I have never met a biostatistician who did not advocate an 
increased sample size. Yet, the reality is that in expression profiling studies sample size 
will always be limited, especially in postmortem brain studies. We simply cannot even 
approach the sample size of  genome-wide association studies (GWAS) studies (Sullivan, 
2010), where thousands of samples are required to perform a meaningful study – we can 
be considered fortunate if we have several dozens of high-quality postmortem samples to 
work with (Mirnics et al., 2006). So, due to the limited sample size, should we abandon 
this line of research? Absolutely not! There is a huge difference between the gene 
expression profiling and genome wide association studies, which is strongly in favor of 
transcriptome assessment: invariably the disease associated gene expression signature is 
much stronger than the genetic association signal! For example, genetics studies of 
schizophrenia (and also bipolar disorder, ADHD, major depression, and a host of other 
disorders) could only identify miniscule genetic signals for any putative susceptibility 
genes (Harrison and Weinberger, 2005), yet, gene expression studies, despite the small 
sample sizes, have successfully identified expression changes that are characteristic of 
>50% of the diseased cohort (Mirnics et al., 2000; Hakak et al., 2001; Middleton et al., 
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2002; Arion et al., 2007a; Garbett et al., 2008). The explanation for this is functional 
convergence and the fundamental nature of the brain transcriptome itself – gene 
expression networks are interdependent (Mirnics, 2008; Horvath and Mirnics, 2009; 
Winden et al., 2009), and the various genetic and environmental insults converge at 
critical molecular pathways, resulting in common alteration of transcript levels of 
different origin (Mirnics et al., 2006). As a result, one might argue that while genetic 
predispositions speak of the origins of the disturbance seen in psychiatric disorders, gene 
expression changes give us clues about the mechanisms by which the pathophysiology 
progresses and the disease symptoms arise.  
 
 
“Transcript changes do not matter if the protein levels are not altered.” 
 This is an interesting reasoning, and at the first glance it makes a lot of sense – or 
does it? Let us follow this line of reasoning for a second. If the transcript alteration does 
not matter in the absence of an obvious protein change, than the protein level is also 
unimportant if the protein is not activated or transported to its place of action. Obviously, 
this trafficking also becomes irrelevant unless it affects the electrical conductivity and the 
responsiveness of the neuron. Similarly, any change in excitability of the single cell also 
becomes meaningless unless the activity of a whole neural network is altered and neural 
network activity fluctuations mean virtually nothing if the behavior of an individual is not 
altered… This logic could be applied in such a manner to make any important discovery 
seem meaningless.  We believe that such a line of reasoning is deeply flawed, and put 
serious limits on future discoveries.  
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Furthermore, the argument that the transcript changes are trivial in the absence of 
changing protein levels also demonstrates disrespect for the most fundamental principles 
of brain anatomy. The majority of neurons project out from the brain regions where the 
cell bodies reside, and they traffic proteins from the somata to thousands of synaptic 
terminals in remote brain regions. So, a proteomic profile of any brain region at any 
given moment is a sum of proteins that are produced by the cell somata which reside in 
the harvested area (intrinsic proteins) and proteins that are contained within the synaptic 
terminals that project into the area from other brain regions (extrinsic proteins). 
Importantly, many proteins (such as synaptic release machinery) have both an intrinsic 
and an extrinsic source, and bulk tissue proteomics cannot differentiate between them.  In 
contrast, the mRNA expression profile is primarily made up by the somatodendritic 
transcripts of cells that reside in the harvested brain region (intrinsic transcripts), with a 
minimal contribution from extrinsic mRNA species. Thus, transcriptomics and 
proteomics measure different anatomical substrates, and this is very important for the 
interpretation of both “omics” findings: a change in mRNA, without a corresponding 
protein change might mean that the intrinsic cell population is affected at both the mRNA 
and protein level, but the substantial extrinsic source of the same protein (which is 






“The magnitude of gene expression change is too small to be physiologically 
relevant” 
This is clearly an assumption, yet it is surprising how little discussion it has 
attracted over the years. The “bigger is better” mentality, while characteristic of our 
society, is not clearly applicable to biological systems. Homeostatic systems are 
differently tuned, with various degrees of tolerances. For example, changing the blood 
pH by 20% is lethal, yet dynamic blood glucose concentration doubling after meals or 
significant hormonal oscillations are part of normal physiology. The same principle 
applies to gene expression changes – many knockout animals do not show any readily 
discernable phenotypes (McMahon et al., 1996; Schluter et al., 1999) and copy-number 
variations (CNVs) normally occur at a high rate in the disease-free human population 
(Vogler et al., 2010). Yet, modest decreases in mRNA expression of the 67-kilodalton 
isoform of glutamic acid decarboxylase (GAD67) appear to be a critical, functional 
component of schizophrenia pathophysiology (Hashimoto et al., 2008). Thus, it appears 
that the individual function of the gene, its place in the transcriptome network, other 
genes performing a similar function, associated regulatory and compensatory 
mechanisms, simultaneously occurring gene expression changes in the same molecular 
pathway and many other factors decide the functional consequence of a gene expression 
change. While the magnitude of the gene expression change is also certainly one part of 





“The most significant expression changes are the most important” 
This is clearly another assumption. While statistical assessment is essential, 
probability values in a transcriptome profiling experiments represent a continuum, and 
there is no way to predict if a gene expression change associated with a p=0.0001 is more 
functionally relevant than an expression alteration reporting a p=0.01.  
Furthermore, if statistical assessments are not selected carefully, the results can be 
quite misleading. In the following example, the prefrontal cortex of a genetically altered 
mouse was compared to the prefrontal cortex of its wild-type littermates using whole-
genome expression profiling. The analysis of 5 transgenic and 5 control mice, after RMA 
normalization, revealed the following log2 expression values for Gene X: 6.0, 6.8, 7.0, 
6.2, 6.5 for WT, and 7.2, 10.0, 15.0, 8.0, 7.8 for TG samples. Performing a standard, two-
tailed groupwise, equal-variance Student t-test in Microsoft Excel will report a 
significance of p=0.0637. If not careful, such a result will not be even noticed, and 
discarded as “non-significant”. In contrast, Gene Y in the same experiment might report 
the following values across the studies samples: 2.2, 2.2, 2.2, 2.3, 2.3 for WT, and 2.4, 
2.4, 2.3, 2.3, 2.3 for the TG samples. A similar t-test analysis for Gene Y in Microsoft 
Excel will yield a “significant” p=0.0203, yet Gene Y is certainly less promising for 
follow up than Gene X. How did this happen? The variance for Gene X was big and for 
Gene Y was small (possibly a normalization artifact), and the t-test alone was quite 
inappropriate to analyze the transcriptome changes. 
Involving a knowledgeable biostatistician in your experimental design and 
discussing the data mining strategies before performing the experiment is always a good 
idea. Determining “true expression changes” and subsequently identifying the “most 
 112 
promising expression changes” requires pulling resources from both biological and 
statistical knowledge, requiring (an often painful) cross-field education for both the 
molecular biologist and biostatistician. 
 
 
 “The authors did not apply a Bonferroni correction…” 
… because they did not want to throw out the baby with the bath water. False 
discovery assessment is very important in all transcriptome profiling experiments, but in 
most cases Bonferroni correction is ill-suited for this purpose. First, in a typical 
transcriptome profiling experiment the number of genes tested is greater than the number 
of samples by 3 orders of magnitude. Second, human brain samples show a molecular 
diversity similar to the genetic and symptom diversity of the disease, postulating that not 
all the affected brains will have an identical gene expression signature, and this weakens 
statistical significance measures. Third, in complex brain disorders typical gene 
expression differences are relatively modest, often in the range of 20-50%, and precise 
expression measurement can be challenging.  As a result, gene expression changes almost 
never reach significance that that can withstand a whole-genome Bonferroni p-value 
correction. Should we have applied a Bonferroni correction to the schizophrenia 
microarray datasets over the last ten years, we would have not obtained any novel leads – 
and the immune (Arion et al., 2007a), mitochondrial (Middleton et al., 2002), synaptic 
(Mirnics et al., 2000), oligodendroglial (Hakak et al., 2001) and GABAergic (Hashimoto 
et al., 2008) changes could have not been identified and consequently replicated. 
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So, how can we ensure that the gene expression changes we uncovered are “real”, 
and not a result of experimental noise or cohort bias? There are multiple alternatives to 
extremely stringent statistical corrections that still ensure that true biological findings, 
and not experimental artifacts, are uncovered. First, one can use less stringent statistical 
corrections for multiple comparisons, such as the Benjamini-Hochberg procedure (Sibille 
et al., 2004). This method is very effective, especially if the gene expression dataset is a 
priori trimmed for non-expressed genes and genes with very low variance: proper 
“trimming” procedures can reduce the number of performed comparisons by up to 75%, 
thus reducing the stringency of statistical correction that is required for false discovery 
assessment. Second, assessment of false discovery by various kinds of permutation 
analyses has gained great popularity over the years (Gao, 2006; Sohn et al., 2009). At 
core of all these assessments is mixing the experimental and control samples randomly 
into two balanced groups, and performing the same analyses repeatedly – for both 
pathways and individual genes. If the disease effect is bigger than the random noise, the 
random assignment of microarrays into variously permutated groups will report less 
differentially expressed genes than the “pure” comparison of control and experimental 
samples (Unger et al., 2005). In the past such analyses have been challenging for 
laboratories without strong bioinformatics support, however, recently developed public 
domain software packages make these assessments (both at the individual gene and 
pathway level) straightforward (Gentleman et al., 2004; Kuehn et al., 2008). Third, a very 
elegant, biology-based assessment of false discovery includes defining the differentially 
expressed transcripts in the initial cohort, and then testing this pattern in a second, 
independent replication cohort (Lazarov et al., 2005). Although false discovery 
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assessments should always be incorporated in the experimental design, the exact choice 
of the false discovery analysis method should depend on availability of samples, cohort 
size, experimental design and many other factors. 
 
 
“The authors should have employed the analysis strategy by Doe et al, published in 
Nature” 
 There is no such a thing as a “universally good” microarray study design. Each 
experimental design and analysis strategy should be tailored to your own experiment. 
Applying an experimental design or analysis strategy only because it was published in a 
high-impact journal is a common mistake made most often by trainees who try to emulate 
successful studies. Rather, considerations should include sample size, type and diversity, 
employed technology, number of replicates, and many other factors. Establishing clear 
and carefully crafted experimental parameters before the start of the study goes a long 
way toward obtaining meaningful experimental data – “patching up” microarray 
experiments with changing inclusion-exclusion criteria and adding additional samples at 
a later time usually results in noisy (and often uninterpretable) experimental outcomes.   
 
 
“In this transcriptome profiling study, genes X and Y and pathway Z were not 
changed” 
 This is true, but is potentially misleading: not finding gene expression changed 
and not being changed are fundamentally different statements. DNA microarrays studies 
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notoriously carry a high percentage of type II errors – a true biological difference is often 
not detected in these experiments. The explanation to this is a technical limitation, and 
has three major sources. First, universal hybridization conditions are never ideal for all of 
the hundreds of thousands of probes on a single microarray. Second, some DNA 
microarray probes perform less then ideally, and cross-hybridize to other genes than their 
own target, and the specificity of the signal is lost. Third, genes that are expressed in only 
a small subpopulation of cells in the tissue, or are expressed at very low levels, are at the 
cusp of detection limit even on the highest quality microarrays. Thus, failing to find a 
gene expression change in a microarray experiment is not a definitive proof that a gene 
expression is absent between the compared samples (Hollingshead et al., 2005), and 
negative data must be interpreted with great care.   
 
 
“Finding hundreds of diverse gene expression changes is uninterpretable” 
 Not so. Unfortunately, the human brain appears to like simple solutions, and we 
scientists are not immune to this. A list of several hundred gene expression changes 
between two conditions is overwhelming, and we would prefer to explain the main 
pathophysiological process by very few changes in mRNA level. More is less: a big panel 
of changed genes somehow became less informative than the alteration of only one 
mRNA. However, the vast majority of complex brain disorders cannot be explained by 
individual gene dysfunction and the transcriptome profiling results merely reflect this 
complexity of the pathophysiological process. Unfortunately, many microarray studies 
fall short of proper interpretation of data by simply discussing the role of several, usually, 
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“most changed” genes.  The ability to decipher and interpret the data, and subsequently 
build a falsifiable model related to the studied pathophysiological process is the trait that 
sets apart a great expression profiling manuscript from a mediocre one.  
So, how can we avoid writing a mediocre manuscript? First, we must reduce the 
emphasis on single gene changes, and shift our attention to analysis of co-regulated 
transcript networks (Korade and Mirnics, 2011; Voineagu et al., 2011). This can be 
achieved by using a number of freely available tools such as weighted gene co-expression 
network analysis (WGCNA) (Langfelder and Horvath, 2008), WholePathwayScope (Yi 
et al., 2006), Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(Dennis et al., 2003), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Aoki and 
Kanehisa, 2005; Arakawa et al., 2005), Gene Set Enrichment Analysis (GSEA) (Kuehn et 
al., 2008). Second, we must start more actively comparing our datasets to those generated 
by other investigators, especially the ones that are deposited in the main microarray data 
repositories (Barrett et al., 2005; Parkinson et al., 2005). Third, beyond data verification, 
we should attempt to follow-up our findings with additional experiments, obtaining 
supporting readouts about the consequences of the observed gene expression changes 
(Horvath and Mirnics, 2009; Huffaker et al., 2009). 
 
 
“Transcriptome profiling studies are descriptive” 
 Actually, gene expression profiling studies are not any more descriptive than 
anatomical, brain imaging, genetic association or any other “omic” studies. None of these 
studies can prove causality beyond doubt, yet they all offer critical information about the 
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disease state. On the other hand, transgenic animal models, tissue culture experiments 
and certain electrophysiology studies test causal relationships, yet they all have serious 
limitations of a different kind: they will never be able to fully recapitulate complex brain 
disorders in their model systems: they study biological processes in isolation, and not the 
disease itself. Furthermore, “mechanistic” studies invariably obtain their leads from 
“descriptive” scientific discoveries.  Is a genetic study reporting a higher proportion of 
CNVs in schizophrenia (Stefansson et al., 2008) or autism (Sebat et al., 2007) descriptive 
or causal? Neither of these two findings gave direct insight into the mechanism by which 
the CNVs might produce a disease, so, they must be considered “descriptive”. Yet, they 
discovered a critical process by which these two devastating diseases might arise, and 
they suggest causality, so they must be considered “mechanistic” at the same time. Thus, 
separating studies into “descriptive” and “mechanistic” is highly artificial – the 
information value of the study is critical, and not the classification of the technology that 
was employed in the studies.  
In summary, nowadays we are fully aware of the interpretational challenges 
associated with high-throughput expression profiling. We hope that we were able to 
convince you that a carefully designed, executed, and thoughtfully interpreted expression 
profiling experiment is a valuable source of scientific data, that our field has high 
standards, and that we are able to generate valuable leads for brain researchers. We 
expect that the “circumspect” attitude (Journal-of-Neuroscience, 2005) toward our 
experiments will fade into the sunset, and we deeply believe that transcriptome profiling 
studies will continue to be essential for deciphering the pathophysiological mechanisms 








 In our model spontaneous activity, not exercise per se, predicted the size of the 
MPTP lesion in Rhesus monkeys. Neuroplasticity and neuroprotective mechanisms 
associated with spontaneous activity in the brain have been explored via gene expression 
analyses in depth (Figure 24). Exercise does increase the likelihood of having a high 
activity level, but daily activity can be gained in other ways, as one of the monkeys, who 
was sedentary, did have a high activity level. This suggests that spontaneous activity gene 
expression is of more importance to neuronal sparing and plasticity than exercise 
differentially expressed transcripts, which makes sense given that enriched environments 
also influence changes in the brain.  Furthermore, spontaneous activity gene expression in 
the motor cortex is inversely correlated with a peripheral protein, c-reactive protein 
(CRP), a marker of inflammation that has been associated with neuronal death 
(Stenvinkel, 2006; Futterman and Lemberg, 2002). Increasing physical activity as 








Figure 24. Activity, BMI, and exercise signaling pathways converge.  
Proteins highlighted in red are associated with activity, those in green are associated with BMI, and those in 
blue are associated with exercise. At the transcriptome level activity is associated with increases in AKT in 
the motor cortex and the mTORC1 signaling pathway by GSEA in the caudate nucleus, BMI is associated 
with decreases in MNK1 in the motor cortex and increases of FOXO3 in the caudate nucleus, and exercise 
is associated with increases in eIF4E and eIF4A and decreases in eIF4G. At the protein level activity is 
associated with phosphorylation of AKT, and BMI is associated with decreased phosphorylation of 
ERK1/2. In sum, translation initiation is promoted by physical activity and exercise, while apoptosis is 
promoted by exercise and BMI.  
 
 
SPONTANEOUSLY ACTIVE RHESUS MONKEY STUDIES 
 
These studies began by looking for gene expression associated with activity and 
BMI in spontaneously activity Rhesus monkeys. Spontaneous activity and BMI were 
independent measurements though multiple measurements were taken. The monkeys 
were fed a high fat diet 3 years prior to the end of the study at which time they received 
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one month of a 30% calorie reduction followed by one month of a 60% calorie reduction. 
Measurements were taken of CRP (mg/L), body mass index (kg/CRL
2
) at the beginning 
and the end of the calorie reduction, change in BMI over the calorie reduction, weight 
(kg) at the beginning and the end of the calorie reduction, weight loss after 1 month of a 
30% calorie reduction, weight loss after 1 month of a 60% calorie reduction, total weight 
lost (kg), and activity at the beginning of the diet (counts/day), activity at the end of the 
diet (counts/day), and change in activity (Table 5). 
BMI @ start 
(kg/CRL2)









∆ wt @ 
30%










29.25 29.37 0.12 6.72 6.75 0.03 -2.00 1.64 710317 515105 195212
26.27 25.92 -0.35 7.30 7.20 -0.10 -0.68 2.04 506925 240431 266494
44.96 37.20 -7.76 11.60 9.60 -2.00 5.57 14.48 200427 191266 9161
37.16 35.53 -1.63 9.83 9.40 -0.43 0.25 4.33 188606 183932 4675
29.59 31.72 2.13 8.02 8.60 0.58 -7.89 1.29 95848 75677 20172
37.21 36.71 -0.50 8.67 8.55 -0.12 -1.84 3.25 160564 143509 17054
22.49 26.80 4.31 5.66 6.75 1.09 -12.19 -4.45 1007746 897948 109798
26.69 27.82 1.13 6.72 7.00 0.28 -7.40 3.61 174187 123780 50407
20.99 23.06 2.07 4.82 5.30 0.48 -7.88 -1.19 46717 46478 239
21.11 21.76 0.65 5.72 5.90 0.18 -3.98 1.05 135683 73961 61722
43.78 37.09 -6.68 10.74 9.10 -1.64 4.42 13.02 173182 134284 38898
26.20 21.97 -4.23 6.68 5.60 -1.08 4.00 14.67 760838 271736 489102
33.44 30.98 -2.46 8.20 7.60 -0.60 2.65 5.15 191991 129822 62169
45.72 37.78 -7.94 10.65 8.80 -1.85 4.42 15.89 556938 485187 71751
Table 5 . Spontaneously Active Rhesus Monkeys
 
 
Table 5. Measurements for Spontaneously Active Rhesus Monkeys. BMI measurements (kilograms per 
crown of rump length squared) are in green. Weight loss (kg) measurements are in blue. Activity 
measurements (counts per day) are in red. Measurements taken at the beginning of the calorie reduction 
diet are indicated by @start, those taken at the end of the diet are indicated by @end, those taken at 30% 
calorie reduction are indicated by @30%, and those taken at 60% calorie reduction are indicated by @60%.  
 
CRP was not measured in all of the monkeys, but using the monkeys with CRP 
measurements we also found that CRP was inversely correlated with activity. CRP, 
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which is located in blood plasma, is associated with increased neuronal death from injury 
(Stenvinkel, 2006; Futterman and Lemberg, 2002), and worse health outcomes such as 
hypertension and heart attack. Even more interesting CRP was correlated with both 
BDNF and ARC mRNA levels in the motor cortex, suggesting that CRP could be a 
peripheral marker of brain health. From the literature it is known that BDNF can cause 
the activation of ARC, an immediate early gene, in neurons (Zheng et al., 2009), and 
there was a positive correlation of BDNF and ARC, supporting the idea that high activity 
levels provide brain resiliency.  
To select independent measurements for microarray analyses all of the 
measurements were correlated with each other (Table 6). Since BMI and weight 
measurements intercorrelated, activity and BMI were used for subsequent microarrays 
analyses. The continuous gene expression data were modeled a few ways with Pearson 
correlations and linear models. Linear models proved superior, because genes interacting 
between activity and BMI could be found. The following formulas were used: gene 
expression = α + β(activity), gene expression = α + β(BMI), and gene expression = α + 
β1(activity) + β2(BMI) + β3(activity x BMI). We tested the hypothesis that the slope (β) 
was not equal to 0 for activity, BMI, and activity x BMI. If the slope (β) of the probeset 
was significantly different from 0 with a p < 0.05, then the probeset (gene) was 
considered significantly associated with either activity, BMI, or interacting between 
activity and BMI.  
Individually, different gene transcripts, and thus mechanisms, associated with 
activity and BMI were found. Physical activity was associated with nutrient sensing and 
neuronal survival genes in both the motor cortex and the caudate nucleus. BMI was 
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associated with apoptosis, insulin signaling, and metabolism in the motor cortex and 
caudate nucleus. Two kinases downstream of neurotrophic factors involved in neuronal 
survival were associated individually with each: pAKT was increased with activity levels, 










∆ wt @ 
30%








BMI @ start 
BMI @ end 0.933
∆ BMI -0.834 -0.580
wt @ start 0.974 0.906 -0.817
wt @ end 0.877 0.946 -0.534 0.923
∆ wt @ 30% 0.734 0.475 -0.934 0.732 0.449
∆ wt @ 60% 0.738 0.466 -0.958 0.726 0.429 0.876
∆ wt -0.826 -0.569 0.999 -0.813 -0.527 -0.938 -0.956
Activity 
@start 
-0.192 -0.238 0.069 -0.232 -0.289 -0.066 -0.007 0.077
Activity 
@end 
-0.063 -0.008 0.131 -0.124 -0.086 -0.213 -0.137 0.143 0.901
∆ activity -0.316 -0.513 -0.072 -0.301 -0.492 0.222 0.222 -0.078 0.661 0.270
Table 6. Spontaneously Active Rhesus Monkeys Correlation Matrix
 
 
Table 6. Spontaneously Active Rhesus Monkey Correlation Matrix. Significant correlations (p<0.05) 
are in bold green, blue, or red. All BMI measurements significantly intercorrelated (green bold font), as did 
weight loss measurements (blue bold font), and activity measurements (red bold font), but BMI also 
correlated with weight loss measurements. BMI and activity were independent measures.  
 
A host of genes interacting between activity and BMI were found in the 
interaction model (gene expression = α + β1(activity) + β2(BMI) + β3(activity x BMI)), 
suggesting shared mechanisms for activity and BMI, which were difficult to interpret. 
These results do suggest that activity and BMI interact in complicated ways in the motor 
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cortex and caudate nucleus. To ease the analyses genes associated with either activity or 
BMI in the simpler models (gene expression = α + β (activity) or gene expression = α + β 
(BMI)) were found and interactions in signaling cascades were investigated.   
One potential site of crosstalk between AKT, ERK1/2, and even AMPK was 
FOXO3, as it can be modified by all three kinases. Protein modifications of FOXO3 
determine its nuclear/cytoplasmic localization. AKT phosphorylation of FOXO3 results 
in its retention in the cytoplasm while AKT inhibition leads to its nuclear translocation 
and activation of its target genes, which induce apoptosis (Brunet et al., 1999; Matsuzaki 
et al., 2005; Plas and Thompson, 2003; Aoki et al., 2004; Huang and Porter, 2005). 
AMPK phosphorylation of FOXO3 has been shown to activate FOXO3 transcriptional 
activity without affecting its subcellular location (Greer et al., 2007).  
ERK directly phosphorylates FOXO3, and the phosphorylated FOXO3 can be 
degraded via an MDM2-mediated ubiquitin-proteasome pathway (Yang et al., 2008). The 
simultaneous blockade of ERK1/2 and MDM2 signaling upregulates levels of the BH3-
only proteins Puma and Bim, in part through the transcriptional up-regulation of FOXO3, 
which promotes apoptosis (Zhang et al., 2010). Direct evidence of this was seen in our 
BMI dataset. Low pERK1/2 levels were associated with high BMI’s in the motor cortex, 
along with increases in caspase 9 mRNA, and increases in FOXO3 mRNA with increased 
BMI. The exact mechanism by which FOXO3 remains in the cytoplasm is not fully 
understood though AKT, ERK1/2, and AMPK do regulate its location, and this results in 
changes in neuronal survival and apoptosis.  
Exhaustive lists of growth factors associated with activity or BMI were not found, 
though increases in the insulin receptor (which signals through similar cascades as 
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growth factors) were seen with increased BMI. It is conceivable that growth factor 
systems still could be activated by non-transcriptional cellular machinery or that 
spontaneous activity and BMI induce AKT/FOXO3 and ERK1/2 respectively through 
different, non-growth factor dependent pathway, and this deserves further investigation. 
However, our studies did not examine the causality of these changes, but the strong 
correlational relationship suggests that this is an important avenue for further 
investigations. 
In addition, there was upregulation of MAP kinase interacting kinase 1 (MNK1) 
at low BMIs. MNK1 has been found to be recruited to the eukaryotic initiation factor 4F 
(eIF4F) complex through association with eIF4G (Pyronnet et al., 1999) (Figure 24). 
This complex has been implicated in preventing the large ribosomal subunit from binding 
the small subunit before it is ready to start elongation and it helps to position mRNA near 
the exit site of the 40S ribosome subunit and promote the assembly of the pre-initiation 
complex. Protein synthesis regulation by the eIF4F complex plays an important role in 
controlling cell growth and proliferation (Sonenberg and Dever, 2003). It consists of 
three subunits: eIF4A, eIF4E, and eIF4G. eIF4E binds the 5’ cap of mRNAs and recruits 
them to the complex. It interacts with eIF4G, which recruits the eIF4A RNA helicase to 
the complex, unwinds the secondary structure in the mRNA, and facilitates translation 
initiation by the 40S ribosomal complex. eIF4E activity is partially regulated by 
phosphorylation through ERK1/2 (Flynn et al., 1997), but also is activated by mammalian 
target of rapamycin complex 1 (mTORC1) (Bhaskar and Hay, 2007), which is 
downstream of AKT. Translation initiation can be regulated by AKT, ERK, and MNK1 
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(Figure 24), and could be important in mediating neuroprotection, plasticity, and 
neuronal survival in motor areas of the brain.  
There was significant overlap between both the Rhesus Macaque Genome (RhG) 
and the Human Genome (HG) microarrays for both activity and BMI – suggesting that 
both arrays can be used to query rhesus macaque gene expression and providing a strong 
dataset for analyses. While the RhG arrays are more specific, the HG arrays provide 
higher quality genome annotations and are more useful in deciphering function from 
differentially expressed gene transcripts. There were no overlapping transcripts 
associated with activity and BMI again suggesting that activity and BMI have different 
mechanisms.
 
While activity provides brain resiliency via AKT, low BMIs provide brain 
resiliency via ERK1/2, and both activity and BMI provide resiliency by influencing 




EXERCISED RHESUS MONKEYS 
 Next, gene expression in three brain regions of exercised Rhesus monkeys were 
analyzed: the motor cortex, the hippocampus, and the putamen. In addition the datasets 
were analyzed using gene set enrichment analysis (GSEA) for enrichment using all of the 
gene sets in the Molecular Signatures Database (MSigDB) and gene sets made from the 
significant gene transcripts from the spontaneous activity, BMI, and MPTP datasets. 
Differentially expressed gene transcripts varied in number, strength, type, and associated 
pathways across all three brain regions. The hippocampus contained the highest number 
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of differentially expressed transcripts (5508), which were strong in their magnitude of 
change (on average an ALR of + or - 0.650, which represents about a 50% change in 
expression), but not significantly associated with a pathway as assessed by GSEA. The 
motor cortex, conversely, contained 435 differentially expressed transcripts with exercise, 
which were intermediate in magnitude (on average an ALR of + or - 0.463, which 
represents about a 35% change in expression), but significantly associated by GSEA with 
three pathways associated with complex I of the electron transport chain. These pathways 
included three genes set: the NADH dehydrogenase complex gene set, the mitochondrial 
respiratory chain complex I gene set, and the respiratory chain complex I gene set. The 
putamen contained the smallest number of differentially expressed transcripts (265), 
which were small in the magnitude of change (on average an ALR of + or – 0.367, which 
represents about a 30% change in expression).  
Overall increases in complex I of the electron transport chain were found in all 
three brain regions. In the hippocampus a number of transcripts involved in translation 
initiation, a pathway increased by spontaneous physical activity, were increased (Figure 
24). These genes operate downstream of AKT and the mTOR. Additionally, in the motor 
cortex and putamen there were decreases in AKT3, something that was increased in the 
motor cortex of spontaneously active rhesus monkeys. Some genes in the motor cortex 
known to be protective including APOE, AChE, and IGF-1 (Carro et al., 2001) also were 
increased. CASP9 was also increased in the motor cortex suggesting that apoptotic 
processes may also be increased with exercise. This is not surprising, considering that 
exercise results in mitochondrial stress (Mattson et al., 2000; Mattson et al., 2008). 
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Although, exercise did not significantly predict the size of the MPTP lesion, but 
alterations in pathways associated with Parkinson’s disease also associated with exercise. 
This suggests that exercise, since it decreases the production of genes involved in 
Parkinson’s disease, likely contributes to total activity levels, and helps to decrease the 
onset of Parkinson’s disease, though it was not significantly associated with the MPTP 
lesion. 
After doing a probe by probe comparison there were no gene transcripts 
overlapping between all three regions. There was overlap (a) between the putamen and 
motor cortex of 91 transcripts, 89 which were changing in the same direction, (b) 
between the putamen and hippocampus of 5 transcripts, 4 of which were changing in the 
same direction, and (c) between the motor cortex and hippocampus of 55, with only 3 
changing in the same direction. This suggests again that different processes are occurring 
in the motor cortex and the hippocampus – the hippocampus being specifically involved 
in neurogenesis while the motor cortex seemed to also have hints of apoptosis. Together 
with transcripts associated with physical activity and BMI we have diagramed exercise 
related transcripts indicated in blue on an activity, BMI, and exercise pathway diagram 
(Figure 24). In sum apoptosis is promoted by increases in BMI and exercise and 
prevented by increases in physical activity levels, while translation initiation is promoted 






MPTP TREATED RHESUS MONKEYS 
Participating in a planned exercise program increases the probability of having 
high levels of mean daily activity, as indicated by the finding that monkeys with the 
highest mean daily activity levels were those who ran on treadmills five days a week. In 
fact the pvalue for a t-test comparing the activity levels of all monkeys who ran versus 
those who did not is 0.06, nearing significance (Table 7). Furthermore, there was not a 
significant difference between the monkey strains based on their activity levels (the 
pvalue between Indian rhesus monkeys animals and Chinese rhesus monkeys was 0.22 
for activity level). Activity levels were significantly correlated with PET and TH in both 
the caudate nucleus and putamen, indicating that spontaneous activity also predicted the 
















Indian 60% runner 167476 -76.13 -69.31 -70.46 -72.76 -68.48 -70.32
Chinese 60% runner 312065 -31.83 -18.78 -24.62 -23.22 -5.19 -13.65
Chinese 60% runner 260492 -46.24 -37.09 -39.89 -45.02 -40.83 -42.90
Chinese 80% runner 237041 -22.19 -30.94 -27.96 -23.55 -24.41 -24.07
Indian Sedentary 142717 -85.34 -83.75 -84.59 -81.12 -72.35 -76.48
Chinese Sedentary 138870 -44.66 -51.18 -48.99 -33.75 -43.77 -39.56
Chinese Sedentary 182218 -66.02 -75.72 -72.29 -69.24 -66.59 -67.80
0.222 0.028 0.100 0.066 0.047 0.103 0.069
0.062 0.268 0.095 0.125 0.318 0.194 0.234
1 0.683 0.844 0.800 0.642 0.826 0.756
ttest for Origin (pvalue)
ttest for Exercise (pvalue)
Correlation (R) with Activity
Table 7. MPTP Treated Rhesus Monkeys
 
Table 7. MPTP Treated Rhesus Monkeys. Monkey origins, exercise group during the study, activity 
measures (counts/day), and percent loss of PET or TH compared to the nonlesioned hemisphere for the 
caudate nucleus and putamen. We performed t-tests for the origin of the monkeys and exercise group on all 
measures and correlated each measure with activity levels.  
 
 However, as can be see in Figures 15a and 15b, mean daily activity levels were 
not solely dependent on the level of planned exercise that was undertaken. One of the 
sedentary monkeys with a relatively high level of baseline activity had slightly higher 
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mean daily activity levels than one of the monkeys which ran at 60% maximal capacity 5 
days a week. Likewise, one monkey running at 80% maximal capacity had lower mean 
daily activity levels than two other monkeys that ran at 60% maximal capacity. Mean 
daily activity strongly predicted the level of neuroprotection after neurotoxin exposure, 
whether daily activity came from planned exercise, high levels of naturally-occurring 
activity or a combination of both. This finding is particularly encouraging for the aging 
population, or those in the early stages of diseases that target motor function, in that it 
suggests that a variety of forms of activity are neuroprotective, not just aerobic exercise 
that many may have difficulty undertaking.  
Studies also show that neuronal plasticity can be achieved by a specific diet, 
calorie restriction, and physical and cognitive activities (i.e. the individual’s experience) 
(which also increase levels of  GDNF and BDNF and activate signal transduction 
pathways that involve ERK1/2 and PI3K) (Mattson et al., 2003; Duan et al., 2001; Lee et 
al., 2000; Lee et al., 2002; Bramham and Messaoudi, 2005), and the brain gains resilience 
to neurodegeneration by means of creating new neuronal resources (Llorens-Martin et al., 
2009). Though we see that physical activity and exercise provide behavioral and 
biochemical sparing, other activities could also provide neuroprotection. 
These results warrant future investigations into exactly how genetics and the 
environment interact. Monkeys of Indian origin in the study have a more severe MPTP 
lesion than the monkeys of Chinese origin (Table 7) with pvalues reaching < 0.05 for % 
loss for PET and TH caudate nucleus measures. In mice glutathione-S-transferase (GST) 
pi plays a key role in the level of MPTP sensitivity. C57BL/6 MPTP-sensitive mice show 
a decrease in GST π levels in nigrostriatal DA neurons after MPTP exposure, whereas 
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SW MPTP-resilient mice show stable levels of GST π post-MPTP (Smeyne et al., 2007). 
GST π is expressed in nigrostriatal dopaminergic neurons, and is a detoxifying enzyme 
that inhibits JNK-activated signaling, blocking the phosphorylation of cJUN and 
apoptosis of the cell (Wang et al., 2001). In people, polymorphisms in GST π have been 
loosely correlated with increased risk of idiopathic PD after exposure to pesticides 
(Menegon et al., 1998; Kelada et al., 2003).  
Indian monkeys were used in the other two studies investigating spontaneous 
activity and exercise. Whether Indian origin rhesus monkeys have lower levels of GST π 
in nigrostriatal DA neurons is unknown at this time, but this or a similar genetic 
difference between Indian and Chinese origin rhesus monkeys could account for 
differences in MPTP toxicity. There are substantial genetic differences in rhesus monkeys 
of Indian vs. Chinese origin in mitochondrial DNA (Kanthaswamy and Smith, 2004), 
(Satkoski et al., 2008), and in the nuclear genomes as demonstrated by differences in 
microsatellites (Smith et al., 2006), Major Histocompatability Complex (MHC) loci 
(Penedo et al., 2005), and SNPs (Ferguson et al., 2007; Hernandez et al., 2007). 
However, there was not a significant difference in mean daily activity between Chinese 
and Indian monkeys (Table 7).  
To elucidate the mechanism of physical activity associated neuroprotection gene 
expression in the caudate nucleus and putamen was assessed. There was a strong gene 
expression association between non-human primate activity and functional measurements 
of dopamine system sparing ([
11
C]DTBZ binding and TH levels) in the caudate and 
putamen of the MPTP treated Rhesus monkeys. These gene expression signatures were 
different in each region which may reflect the different functional connectivity of each 
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region and included several transcripts previously associated with chromatin remodeling 
and anti-apoptotic processes. These combined findings suggest that neuroprotection by 
activity after MPTP exposure is, at least in part, achieved though epigenetic mechanisms 
that deserve further investigation.  
In addition, genes associated with the lesioned hemisphere were found by 
assessing significantly differentially expressed transcripts between the lesioned right 
putamen and the nonlesioned left putamen (Figure 22). These included decreases in a 
gene involved in repair, ataxia telangiectasia and Rad3 related (ATR),  increases in a 
gene involved in apoptosis increased (CASP9), increases in some neurotrophic factor 
signaling genes (FGF2 and eukaryotic translation initiation factor 4E (EIF4E)), and 
specifically an increase in syntaxin 3 (Figure 23 and Supplementary Table 12). This 
supports the idea that some compensatory mechanisms promote survival of neurons after 
MPTP exposure. These mechanisms include an increase in dopamine release and a 
decrease in dopamine uptake (Zigmond et al., 1989; Zigmond et al., 1992; Abercrombie 
et al., 1990; Snyder et al., 1990). They also confirm the MPTP lesion (decreased in ATR 
and an increase in CASP9). 
 In particular attention was focused on STX3, as it was associated with activity-
associated neuroprotection in the putamen, albeit with a different probeset. Syntaxin 3 
was decreased with activity, [
11
C]DTBZ binding, and TH levels, and increased in the 
lesioned hemisphere. Syntaxins function in vesicle mediated exocytosis of 
neurotransmitters (Sudhof and Rothman, 2009), and bind synaptotagmin in a calcium 
dependent way (Sudhof et al., 1993; Lin and Scheller, 1997).  Healthy neurons may 
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prefer STX1 over STX3, but the role of STX3 in causing damaging and preventing 
neuroprotection is difficult to determine from current research and the literature.  
In summary, physical activity levels were associated with increased protection in 
the MPTP model of Parkinson’s disease in rhesus monkeys.  The gene expression 
associations converge from two separate dissections of caudate nucleus and two separate 
dissections of putamen from each monkey. This is analogous to performing the same 
microarray on each brain regions twice for each animal giving us a good measure of true 
discovery from the experiments. In both the caudate nucleus and the putamen the 
activity-associated gene transcripts include those involved in chromatin remodeling and 
anti-apoptosis. In the putamen STX3 decreased with activity, [
11
C]DTBZ binding, and 
TH levels, and increased with the lesion. This specifically warrants further investigation 
into how physical activity is associated with chromatin remodeling, how STX3 operates 
at the synapse, and further suggests that other experiences which are associated with 





 We have proven that physical activity, as measured by accelerometers and 
pedometers, is associated with reduced CRP, protection from a MPTP lesion, and should 
be of more interest than exercise. Spontaneous activity is associated with activation of the 
AKT signaling pathway, low BMI is associated with the ERK1/2 signaling pathway, and 
exercise is associated with the electron transport chain and translation initiation pathway 
– all of which converges and interact in the cell and when in proper balance promote 
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neuroplasticity and brain resiliency (Figure 24).  Furthermore, physical activity is 
associated with a peripheral marker, CRP, is protective in the MPTP model of 
Parkinson’s disease, and results in changes to chromatin remodeling and anti-apoptotic 
gene transcripts in the caudate nucleus and putamen.  
We tested the hypothesis that exercise is neuroprotective in two ways. First, we 
looked at the mechanisms of exercise alone in rhesus monkeys in the motor cortex, 
putamen, and hippocampus. We found that components of complex I of the electron 
transport chain are increased, and these are associated with Parkinson’s disease (Chou et 
al., 2010; Betarbet et al., 2002). Upon directly testing the hypothesis using the MPTP 
model of Parkinson’s disease in exercised Rhesus monkeys, we did not find that exercise 
decreased the size of the lesion. Instead, we have found that physical activity levels 
strongly predicted the size of the MPTP lesion. 
 Further studies are warranted to explore how both genetics and experience 
interact to protect against neurodegenerative diseases. One way to explore the genetic 
component of physical activity is by looking for quantitative trait loci (QTL) in mice bred 
to be highly active or highly inactive. Mouse lines natural have different physical activity 
levels (Knab et al., 2009). C576J/BL mice have higher activity levels than C3H mice and 
this has been explained by examining quantitative trait loci (QTL), which have 
implicated the dopamine system in genetic predispositions to exercise (Bronikowski et 
al., 2004). Other studies in ADHD patients have linked dopamine markers with activity 
levels as well (Arnsten, 2006; Li et al., 2006). There is a dopamine model of the genetics 
of physical activity levels, which suggests that dopamine both affects and is affected by 
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activity levels, but other studies are needed to investigate the other QTL associated with 
physical activity.  
Another way to study if physical activity levels alone protect against 
neurodegenerative lesions is, in a very well controlled study, to manipulate physical 
activity levels in mice, who naturally have the same activity levels. A group of mice 
matched with the same levels of activity could be divided into three groups: (a) one group 
whose activity levels would be increased, (b) a second group whose activity levels would 
not be manipulated, and (c) a third group whose activity levels would be reduced. All 
three groups after three months of their condition would be exposed to MPTP, and seven 
weeks after the extent of the lesion could be assessed by measuring TH and DAT levels. 
Studies similar to this have been done and do suggest that physical activity levels protect 
against Parkinson disease like lesions (Caudle et al., 2007; Mabandla et al., 2004; O'Dell 
et al., 2007), but they haven’t been well controlled specifically for activity levels.  
In sum, we provide evidence that an individual’s experiences, specifically 
physical activity levels, are associated with a change in neural resources that change the 
ability to cope with a MPTP lesion, mimicking Parkinson’s disease. The mechanism of 
these changes includes chromatin remodeling, anti-apoptotic processes, and neuronal 
survival signaling cascades (Mitchell et al., 2010; Mitchell et al., 2011b; Mitchell et al., 
2011c). One’s experiences, may that be their physical activity levels, BMI, exercise, or 
even as suggested by other research the foods they eat and calorie intake (Stranahan et 
al., 2009), can change his or her neuronal resiliency. Taken together these things help 
shape the brain’s resources to take on highly complex interactions and deal with the 
onslaught of neurodegeneration.  
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Supplementary Table 1. Spontaneous Activity Associated Gene Expression Changes in the Motor Cortex. Genes are identified with their HG and RhG 
probes names, the human gene symbol, the human gene title, percent identity between RhG and HG probes (% ID), both HG and RhG interquartile ranges, and 
both HG and RhG Entrez Gene ID numbers. Genes decreasing in expression with physical activity level are indicated with (-), genes increasing in expression 
with physical activity level are indicated with (+), genes changing in different directions on both arrays are indicated with (≠). Note the high degree of 
concordance between the two datasets: of the ninety-eight probes reporting activity-dependent expression ninety-six reported expression change in the same 
direction.  
 
SUPPLEMENTARY TABLE 1. Spontaneous Activity-Associated Gene Expression Changes in the Motor Cortex.  





















237782_at MmugDNA.20858.1.S1_at 97.2 0.005 0.034 - 0.313 0.405 --- --- --- --- 
238714_at MmugDNA.21680.1.S1_at 89.51 0.009 0.043 - 0.494 0.467 --- --- --- --- 
239856_at MmugDNA.42244.1.S1_at 89.91 0.010 0.004 - 0.391 0.419 --- --- --- --- 
240216_at MmugDNA.15928.1.S1_at 98.06 0.039 0.042 - 0.433 0.325 --- --- --- --- 
239361_at MmugDNA.15335.1.S1_at 93.3 0.007 0.029 - 0.284 0.267 --- --- --- --- 
235713_at MmugDNA.2645.1.S1_at 93.15 0.016 0.028 - 0.580 1.352 
alkB, alkylation repair 
homolog 8 (E. coli) 
ALKBH8 91801 706917 
203264_s_at MmugDNA.8595.1.S1_at 95.47 0.025 0.039 - 0.601 1.248 
Cdc42 guanine 
nucleotide exchange 
factor (GEF) 9 
ARHGEF9 23229 707387 
201229_s_at MmugDNA.5444.1.S1_s_at 91.67 0.031 0.014 - 0.643 0.568 
ariadne homolog 2 
(Drosophila) 
ARIH2 10425 719993 
203796_s_at MmuSTS.3204.1.S1_at 93.71 0.027 0.015 - 0.368 0.357 
B-cell CLL/lymphoma 
7A 
BCL7A 605 705028 
1555773_at MmugDNA.34502.1.S1_at 89.04 0.002 0.007 - 0.484 0.462 
bactericidal/permeability-
increasing protein-like 2 
BPIL2 254240 717287 
1556072_at MmugDNA.4176.1.S1_at 63.51 0.039 0.012 - 0.270 0.307 
chromosome 22 open 
reading frame 37 
C22orf37 200298 --- 
219578_s_at MmugDNA.36706.1.S1_at 97.39 0.039 0.033 - 0.429 0.268 
cytoplasmic 
polyadenylation element 
binding protein 1 
CPEB1 64506 694357 
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201201_at MmugDNA.35450.1.S1_at 64.01 0.038 0.021 - 0.391 0.434 cystatin B (stefin B) CSTB 1476 713504 
201693_s_at MmugDNA.10815.1.S1_at 98.1 0.027 0.031 - 0.456 0.389 early growth response 1 EGR1 1958 716786 
208962_s_at MmugDNA.23574.1.S1_at 93.75 0.033 0.034 - 0.752 0.772 
fatty acid desaturase 1 /// 






237466_s_at MmugDNA.6750.1.S1_at 93.39 0.007 0.014 - 0.713 0.590 
hedgehog interacting 
protein 
HHIP 64399 701205 
200775_s_at MmugDNA.4119.1.S1_at 99.39 0.021 0.033 - 0.904 1.185 
heterogeneous nuclear 
ribonucleoprotein K 
HNRNPK 3190 709112 
242293_at MmugDNA.18588.1.S1_at 83.63 0.016 0.027 - 0.419 0.367 
inhibitor of growth 
family, member 3 
ING3 54556 694005 
216807_at MmugDNA.6876.1.S1_at 93.12 0.018 0.038 - 0.349 0.392 KIAA1751 KIAA1751 85452 709689 
207065_at MmuSTS.1586.1.S1_at 94.93 0.009 0.046 - 0.305 0.264 keratin 75 KRT75 9119 699682 
203836_s_at MmugDNA.12217.1.S1_at 97.1 0.027 0.007 - 0.303 0.275 
mitogen-activated protein 
kinase kinase kinase 5 
MAP3K5 4217 711382 
218211_s_at MmugDNA.20540.1.S1_at 92.73 0.001 0.029 - 0.543 1.237 melanophilin MLPH 79083 694820 




NDST1 3340 712425 
208612_at MmugDNA.2124.1.S1_at 97.67 0.026 0.015 - 0.466 0.498 
protein disulfide 
isomerase family A, 
member 3 
PDIA3 2923 711029 
222019_at MmugDNA.30493.1.S1_at 91.41 0.020 0.032 - 0.265 0.303 prefoldin subunit 6 PFDN6 10471 718253 
204048_s_at MmugDNA.19278.1.S1_at 92.17 0.014 0.006 - 0.466 0.631 
phosphatase and actin 
regulator 2 
PHACTR2 9749 700363 
229376_at MmugDNA.22007.1.S1_at 99.3 0.012 0.038 - 0.653 0.686 prospero homeobox 1 PROX1 5629 709465 
221277_s_at MmugDNA.19674.1.S1_at 96.85 0.005 0.002 - 0.340 0.364 
pseudouridylate synthase 
3 
PUS3 83480 713746 
204243_at MmuSTS.1735.1.S1_at 96.22 0.045 0.014 - 0.398 0.635 rearranged L-myc fusion RLF 6018 693503 
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213459_at MmugDNA.41298.1.S1_at 93.14 0.028 0.009 - 0.459 0.383 ribosomal protein L37a RPL37A 6168 
696415 /// 
707154 
224754_at MmuSTS.4487.1.S1_at 90.96 0.018 0.006 - 0.486 0.449 Sp1 transcription factor SP1 6667 702710 
219685_at MmugDNA.35136.1.S1_at 96.1 0.014 0.041 - 0.697 0.955 
transmembrane protein 
35 
TMEM35 59353 702205 
209226_s_at MmugDNA.5339.1.S1_at 31.15 0.004 0.020 - 0.298 0.551 transportin 1 TNPO1 3842 707195 
242499_at MmugDNA.32356.1.S1_at 86.12 0.029 0.049 - 0.354 0.286 
U2 small nuclear RNA 
auxiliary factor 1 
U2AF1 7307 --- 
204893_s_at MmuSTS.2611.1.S1_at 91.21 0.021 0.033 - 0.583 0.793 
zinc finger, FYVE 
domain containing 9 
ZFYVE9 9372 713155 
214942_at MmugDNA.7677.1.S1_at 93.68 0.011 0.010 ≠ 0.274 0.355 
RNA binding motif 
protein 34 
RBM34 23029 711962 
222831_at MmugDNA.11779.1.S1_at 0 0.033 0.043 ≠ 0.345 0.302 SAP30-like SAP30L 79685 714400 
1564381_s_at MmugDNA.41201.1.S1_at 92.28 0.015 0.047 + 0.278 0.338 --- --- --- --- 
239262_at MmugDNA.12727.1.S1_at 94 0.017 0.013 + 0.291 0.385 --- --- --- --- 
226280_at MmugDNA.31249.1.S1_at 82.68 0.018 0.026 + 0.427 0.275 --- --- --- --- 
237008_at MmugDNA.2202.1.S1_at 97.71 0.043 0.039 + 0.817 0.956 --- --- --- --- 
209027_s_at MmugDNA.3144.1.S1_at 96.83 0.023 0.022 + 0.300 0.329 abl-interactor 1 ABI1 10006 707698 
242876_at MmugDNA.2158.1.S1_at 91.92 0.018 0.043 + 0.328 1.206 
V-akt murine thymoma 
viral oncogene homolog 
3 (protein kinase B, 
gamma) 
AKT3 10000 --- 
222767_s_at MmugDNA.3366.1.S1_at 95.32 0.035 0.004 + 0.401 0.300 
chromosome 12 open 
reading frame 49 
C12orf49 79794 713916 
1553801_a_at MmugDNA.6301.1.S1_s_at 97.73 0.019 0.034 + 0.310 0.328 
chromosome 14 open 
reading frame 126 
C14orf126 112487 717267 
214816_x_at MmugDNA.21116.1.S1_at 78.62 0.002 0.007 + 0.315 0.469 
chromosome 19 open 
reading frame 40 
C19orf40 91442 --- 
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236634_at MmugDNA.15731.1.S1_at 95.2 0.010 0.025 + 0.452 0.382 
chromosome 8 open 
reading frame 48 
C8orf48 157773 700746 
219147_s_at MmugDNA.30781.1.S1_at 95.84 0.022 0.018 + 0.346 0.468 
chromosome 9 open 
reading frame 95 
C9orf95 54981 703868 
223300_s_at MmugDNA.27206.1.S1_at 93.14 0.047 0.015 + 0.469 0.324 
coiled-coil domain 
containing 82 
CCDC82 79780 700198 
219947_at MmuSTS.718.1.S1_at 96.24 0.036 0.019 + 0.298 0.417 
C-type lectin domain 
family 4, member A 
CLEC4A 50856 716122 
1554242_a_at MmugDNA.12890.1.S1_at 91.11 0.049 0.015 + 0.489 0.516 
coagulation factor C 
homolog, cochlin 
(Limulus polyphemus) 
COCH 1690 717114 
218142_s_at MmugDNA.28472.1.S1_at 86.33 0.028 0.021 + 0.361 0.271 cereblon CRBN 51185 704436 
207630_s_at MmugDNA.34749.1.S1_at 96.5 0.035 0.029 + 0.357 0.276 
cAMP responsive 
element modulator 
CREM 1390 698636 
238554_at MmugDNA.40221.1.S1_at 94.77 0.015 0.045 + 0.388 0.383 
cytochrome b5 type B 
(outer mitochondrial 
membrane) 
CYB5B 80777 705093 
223331_s_at MmugDNA.309.1.S1_at 96.13 0.022 0.037 + 0.340 0.340 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 20 
DDX20 11218 704731 




FAHD1 81889 722505 




FAHD2A 51011 706967 
217850_at MmugDNA.15299.1.S1_at 88.46 0.044 0.040 + 0.395 0.369 
guanine nucleotide 
binding protein-like 3 
(nucleolar) 
GNL3 26354 695877 
202605_at MmuSTS.4305.1.S1_at 77.02 0.037 0.003 + 0.402 0.352 glucuronidase, beta GUSB 2990 677692 
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228375_at MmugDNA.2210.1.S1_at 90.45 0.017 0.016 + 0.301 0.287 
immunoglobulin 
superfamily, member 11 
IGSF11 152404 713784 
209566_at MmugDNA.2140.1.S1_at 94.47 0.018 0.044 + 0.347 0.305 insulin induced gene 2 INSIG2 51141 693654 
226816_s_at MmugDNA.5413.1.S1_at 90.88 0.043 0.039 + 0.634 0.586 KIAA1143 KIAA1143 57456 --- 
229393_at MmuSTS.4452.1.S1_at 98.15 0.031 0.022 + 0.278 0.307 
l(3)mbt-like 3 
(Drosophila) 
L3MBTL3 84456 710947 
228338_at MmugDNA.27645.1.S1_at 94.04 0.024 0.009 + 0.291 0.369 
hypothetical protein 
LOC120376 
LOC120376 120376 710801 
223098_s_at MmugDNA.30130.1.S1_at 87.54 0.035 0.028 + 0.291 0.421 
lon peptidase 2, 
peroxisomal 
LONP2 83752 --- 
218027_at MmuSTS.954.1.S1_at 82.4 0.005 0.030 + 0.319 0.277 
mitochondrial ribosomal 
protein L15 
MRPL15 29088 694274 






222837_s_at MmugDNA.38789.1.S1_at 74.25 0.012 0.041 + 0.426 0.343 
NMDA receptor 
regulated 1 
NARG1 80155 697123 
209105_at MmugDNA.40567.1.S1_at 63.5 0.027 0.025 + 0.270 0.534 
nuclear receptor 
coactivator 1 
NCOA1 8648 693342 
202150_s_at MmugDNA.7464.1.S1_at 97.28 0.004 0.003 + 0.290 0.291 




NEDD9 4739 699359 
224436_s_at Mmu.13961.1.S1_at 82.88 0.008 0.021 + 0.342 0.476 
nipsnap homolog 3A (C. 
elegans) 
NIPSNAP3A 25934 716188 
239293_at MmuSTS.1691.1.S1_at 92.94 0.000 0.010 + 0.330 0.271 neurensin 1 NRSN1 140767 707362 
203351_s_at MmugDNA.29856.1.S1_at 98.72 0.007 0.011 + 0.333 0.265 
origin recognition 
complex, subunit 4-like 
(yeast) 
ORC4L 5000 721876 
222719_s_at MmugDNA.37743.1.S1_at 94.83 0.009 0.006 + 0.409 0.489 
platelet derived growth 
factor C 
PDGFC 56034 700236 
205226_at MmugDNA.20932.1.S1_at 96.3 0.031 0.048 + 0.322 0.588 
platelet-derived growth 
factor receptor-like 
PDGFRL 5157 703117 
 140 
205960_at MmugDNA.985.1.S1_at 87.27 0.014 0.004 + 0.393 0.475 
pyruvate dehydrogenase 
kinase, isozyme 4 
PDK4 5166 698726 
230434_at MmugDNA.25986.1.S1_at 98.74 0.024 0.019 + 0.676 0.695 phosphatase, orphan 2 PHOSPHO2 493911 --- 
222699_s_at MmugDNA.2610.1.S1_s_at 94.49 0.006 0.005 + 0.384 0.381 
pleckstrin homology 
domain containing, 
family F (with FYVE 
domain) member 2 
PLEKHF2 79666 701884 
227148_at MmugDNA.37529.1.S1_at 95.49 0.008 0.024 + 0.353 0.498 
pleckstrin homology 
domain containing, 
family H (with MyTH4 
domain) member 2 
PLEKHH2 130271 713488 
209317_at MmugDNA.1251.1.S1_at 95.74 0.024 0.027 + 0.321 0.451 
polymerase (RNA) I 
polypeptide C, 30kDa 
POLR1C 9533 700727 
1554365_a_at Mmu.15077.1.S1_at 0 0.025 0.013 + 0.270 0.273 
protein phosphatase 2, 
regulatory subunit B', 
gamma isoform 
PPP2R5C 5527 718894 
221547_at MmugDNA.10448.1.S1_at 90.57 0.016 0.042 + 0.318 0.295 
PRP18 pre-mRNA 
processing factor 18 
homolog (S. cerevisiae) 
PRPF18 8559 696401 
222077_s_at MmuSTS.2069.1.S1_at 61.9 0.034 0.038 + 0.437 0.350 
Rac GTPase activating 
protein 1 
RACGAP1 29127 711887 
212591_at MmugDNA.11046.1.S1_at 95.45 0.007 0.042 + 0.577 0.479 
RNA binding motif 
protein 34 
RBM34 23029 711962 
214943_s_at MmugDNA.7677.1.S1_at 93.6 0.049 0.010 + 0.418 0.355 
RNA binding motif 
protein 34 
RBM34 23029 711962 
210138_at MmuSTS.3132.1.S1_at 92.49 0.020 0.027 + 0.397 0.320 
regulator of G-protein 
signaling 20 
RGS20 8601 693454 
209091_s_at MmugDNA.13601.1.S1_at 0 0.025 0.028 + 0.299 0.399 
SH3-domain GRB2-like 
endophilin B1 
SH3GLB1 51100 712393 
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206613_s_at MmugDNA.7833.1.S1_at 96.64 0.021 0.012 + 0.274 0.334 
TATA box binding 
protein (TBP)-associated 
factor, RNA polymerase 
I, A, 48kDa 
TAF1A 9015 704624 
224560_at MmugDNA.21307.1.S1_at 82.74 0.019 0.016 + 0.295 0.299 
TIMP metallopeptidase 
inhibitor 2 
TIMP2 7077 --- 
210379_s_at MmugDNA.33852.1.S1_at 91.57 0.050 0.020 + 0.287 0.300 tousled-like kinase 1 TLK1 9874 701221 
219253_at MmugDNA.20643.1.S1_at 59.09 0.024 0.025 + 0.299 0.363 
transmembrane protein 
185B (pseudogene) 
TMEM185B 79134 695744 
229126_at MmugDNA.15766.1.S1_at 92.94 0.037 0.028 + 0.427 0.401 
transmembrane protein 
19 
TMEM19 55266 --- 
225375_at MmugDNA.11921.1.S1_at 67.81 0.040 0.020 + 0.414 0.346 
transmembrane protein 
199 
TMEM199 147007 708298 
209412_at MmugDNA.31122.1.S1_at 96.2 0.045 0.047 + 0.359 0.370 
trafficking protein 
particle complex 10 
TRAPPC10 7109 --- 
203599_s_at MmuSTS.2586.1.S1_at 94.83 0.046 0.037 + 0.293 0.264 
WW domain binding 
protein 4 (formin binding 
protein 21) 
WBP4 11193 698220 
224898_at MmugDNA.20064.1.S1_at 96.15 0.013 0.001 + 0.489 0.505 WD repeat domain 26 WDR26 80232 704911 
226668_at MmugDNA.16148.1.S1_at 89.23 0.016 0.004 + 0.451 0.268 
WD repeat, sterile alpha 
motif and U-box domain 
containing 1 
WDSUB1 151525 699456 
1552608_at MmugDNA.12587.1.S1_at 77.4 0.005 0.040 + 0.287 0.273 
WAP four-disulfide core 
domain 11 
WFDC11 259239 709928 




Supplementary Table 2. Spontaneous Activity Associated Gene Expression Changes in the Caudate Nucleus. Genes are identified with their HG and RhG 
probes names, the human gene symbol, the human gene title, percent identity between RhG and HG probes (% ID), both HG and RhG interquartile ranges, and 
both HG and RhG Entrez Gene ID numbers. Genes decreasing in expression with physical activity level are indicated with (-), genes increasing in expression 
with physical activity level are indicated with (+), genes changing in different directions on both arrays are indicated with (≠). Note the high degree of 
concordance between the two datasets: of the twenty-eight probes reporting activity-dependent expression twenty-eight reported expression change in the same 
direction.  
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229781_at MmugDNA.24219.1.S1_at 92.67 0.001 0.024 - 0.484 1.175 --- --- --- --- 
243904_at MmugDNA.32292.1.S1_at 92.51 0.006 0.003 - 1.156 1.816 --- --- --- --- 
243915_at MmugDNA.4635.1.S1_at 91.04 0.017 0.031 - 0.610 1.053 --- --- --- --- 
238714_at MmugDNA.21680.1.S1_at 89.51 0.019 0.018 - 0.312 0.607 --- --- --- --- 
239278_at MmugDNA.3222.1.S1_at 94.99 0.033 0.011 - 0.280 0.401 --- --- --- --- 
235713_at MmugDNA.2645.1.S1_at 93.15 0.014 0.013 - 0.381 0.645 
alkB, alkylation repair 
homolog 8 (E. coli) 
ALKBH8 91801 706917 
231918_s_at MmugDNA.13970.1.S1_at 91.69 0.030 0.016 - 0.717 0.471 
G elongation factor, 
mitochondrial 2 
GFM2 84340 704247 
225392_at MmugDNA.33130.1.S1_at 94.39 0.033 0.003 - 0.289 0.355 
G elongation factor, 
mitochondrial 2 
GFM2 84340 704247 
201721_s_at MmuSTS.2956.1.S1_at 86.83 0.020 0.013 - 0.316 0.270 
lysosomal multispanning 
membrane protein 5 
LAPTM5 7805 --- 
221277_s_at MmugDNA.19674.1.S1_at 96.85 0.004 0.008 - 0.312 0.495 pseudouridylate synthase 3 PUS3 83480 713746 
218354_at MmugDNA.16031.1.S1_at 96.89 0.020 0.022 - 0.365 0.416 
trafficking protein particle 
complex 2-like 
TRAPPC2L 51693 697970 
215330_at MmugDNA.31871.1.S1_at 86.75 0.003 0.022 + 0.322 0.688 --- --- --- --- 
237008_at MmugDNA.2202.1.S1_at 97.71 0.021 0.016 + 0.441 0.422 --- --- --- --- 
229648_at MmugDNA.29513.1.S1_at 87.61 0.033 0.019 + 0.608 0.634 --- --- --- --- 
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214953_s_at MmuSTS.2836.1.S1_at 97.77 0.019 0.023 + 0.986 0.915 
amyloid beta (A4) precursor 
protein 
APP 351 708212 
217818_s_at MmugDNA.4234.1.S1_s_at 0 0.002 0.026 + 0.477 1.132 
actin related protein 2/3 
complex, subunit 4, 20kDa /// 
tubulin tyrosine ligase-like 






211672_s_at MmugDNA.4234.1.S1_s_at 97.38 0.013 0.026 + 0.730 1.132 
actin related protein 2/3 
complex, subunit 4, 20kDa /// 
tubulin tyrosine ligase-like 






241836_x_at MmugDNA.3354.1.S1_at 85.14 0.019 0.047 + 0.275 0.581 centrosomal protein 97kDa CEP97 79598 --- 
212539_at MmuSTS.2204.1.S1_at 0 0.018 0.030 + 0.327 0.373 
chromodomain helicase DNA 
binding protein 1-like 
CHD1L 9557 700179 
1556988_s_at MmuSTS.2204.1.S1_s_at 78.32 0.006 0.001 + 0.265 0.322 
chromodomain helicase DNA 
binding protein 1-like 
CHD1L 9557 700179 
223875_s_at MmugDNA.25989.1.S1_at 94.24 0.003 0.022 + 0.375 0.608 
enhancer of polycomb 
homolog 1 (Drosophila) 
EPC1 80314 721332 
237392_at MmugDNA.41027.1.S1_at 94.5 0.010 0.007 + 0.528 0.630 
hypothetical protein 
LOC283480 
LOC283480 283480 --- 






PAICS 10606 694743 
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230434_at MmugDNA.25986.1.S1_at 98.74 0.039 0.018 + 0.332 0.341 phosphatase, orphan 2 PHOSPHO2 493911 --- 
235711_at MmugDNA.5589.1.S1_at 96.43 0.008 0.037 + 0.628 0.965 
purine-rich element binding 
protein B 
PURB 5814 705519 
226762_at MmugDNA.1658.1.S1_at 97.88 0.027 0.039 + 1.354 1.151 
purine-rich element binding 
protein B 
PURB 5814 705519 
205529_s_at MmugDNA.6345.1.S1_at 98.81 0.026 0.033 + 0.806 0.660 
runt-related transcription factor 
1; translocated to, 1 (cyclin D-
related) 
RUNX1T1 862 696934 
221096_s_at MmugDNA.8060.1.S1_at 73.61 0.001 0.000 + 0.293 0.331 
transmembrane and coiled-coil 
domains 6 




Supplementary Table 3. BMI Associated Gene Expression Changes in the Motor Cortex. All genes in the table were significant on both RhG and HG 
microarrays with a p < 0.05. Genes are identified with their HG and RhG probes names, the human gene symbol, the human gene title, percent identity between 
RhG and HG probes (% ID), both HG and RhG p values (pval), both HG and RhG interquartile ranges (IQR), and both HG and RhG Entrez Gene ID numbers. 
Genes with negatively correlated expression with BMI are blue and indicated with (-), and genes with positively correlated expression with BMI are red and 
indicated with (+). There is 100% concordance between the human and monkey microarray datasets. 
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ID 












233940_at MmugDNA.24373.1.S1_at 95.28 0.042 0.045 - 0.277 0.310 --- --- --- --- 




AGR3 155465 714517 
201525_at Mmu.8637.1.S1_at 63.93 0.044 0.044 - 0.489 0.793 apolipoprotein D APOD 347 709223 
218936_s_at MmuSTS.1498.1.S1_at 90.26 0.024 0.028 - 0.657 0.782 
coiled-coil domain 
containing 59 
CCDC59 29080 698443 




DECR1 1666 696035 
214240_at MmugDNA.42549.1.S1_at 94.88 0.041 0.049 - 0.876 1.052 
galanin 
prepropeptide 
GAL 51083 721572 
227466_at MmugDNA.38075.1.S1_at 89.9 0.014 0.046 - 0.364 0.612 
hypothetical protein 
LOC285550 
LOC285550 285550 714235 





MAP4K4 9448 --- 
57540_at MmugDNA.35682.1.S1_at 87.14 0.026 0.023 - 0.291 0.344 ribokinase RBKS 64080 702464 
1568627_at MmugDNA.35505.1.S1_at 96.06 0.022 0.042 - 0.493 0.477 
SMEK homolog 2, 
suppressor of mek1 
(Dictyostelium) 
SMEK2 57223 --- 
1568932_at MmugDNA.5906.1.S1_at 93.15 0.001 0.010 + 0.509 0.561 --- --- --- --- 
1560422_at MmugDNA.40378.1.S1_at 92.31 0.015 0.021 + 0.719 1.079 --- --- --- --- 
204608_at MmugDNA.11311.1.S1_at 85.13 0.032 0.033 + 0.391 0.448 
argininosuccinate 
lyase 
ASL 435 697109 
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218447_at MmugDNA.14860.1.S1_at 83.64 0.018 0.034 + 0.530 0.368 
chromosome 16 
open reading frame 
61 
C16orf61 56942 --- 




CASP9 842 694544 




CLIP2 7461 --- 




CTNNA2 1496 712135 
204718_at MmugDNA.26316.1.S1_at 96.85 0.033 0.008 + 0.422 0.410 EPH receptor B6 EPHB6 2051 704886 
215313_x_at Mmu.2935.4.S1_x_at 60.42 0.020 0.008 + 0.338 0.484 
major 
histocompatibility 
complex, class I, A 
HLA-A 3105 --- 




IGSF1 3547 704264 
221659_s_at MmugDNA.24287.1.S1_at 56.5 0.030 0.047 + 0.437 0.604 




MYLC2PL 93408 --- 
211778_s_at MmugDNA.9681.1.S1_at 96.72 0.026 0.008 + 0.413 0.422 
ovo-like 2 
(Drosophila) 
OVOL2 58495 699284 
206691_s_at MmugDNA.14080.1.S1_at 87.6 0.044 0.011 + 0.301 0.337 
protein disulfide 
isomerase family A, 
member 2 
PDIA2 64714 694964 




RNPS1 10921 695816 
231650_s_at MmugDNA.43618.1.S1_at 95.1 0.019 0.022 + 0.515 0.540 
Seizure related 6 
homolog (mouse)-
like 
SEZ6L 23544 --- 
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220135_s_at MmugDNA.19382.1.S1_at 77.32 0.007 0.003 + 0.458 0.456 
solute carrier family 
7 (cationic amino 
acid transporter, y+ 
system), member 9 
SLC7A9 11136 703081 
200990_at MmugDNA.7917.1.S1_at 98.79 0.033 0.041 + 0.354 0.461 
tripartite motif-
containing 28 




Supplementary Table 4. BMI Associated Gene Expression Changes in the Caudate Nucleus. All genes in the table were significant on both RhG and HG 
microarrays with a p < 0.05. Genes are identified with their HG and RhG probes names, the human gene symbol, the human gene title, percent identity between 
RhG and HG probes (% ID), both HG and RhG p values (pval), both HG and RhG interquartile ranges (IQR), and both HG and RhG Entrez Gene ID numbers. 
Genes with negatively correlated expression with BMI are blue and indicated with (-), and genes with positively correlated expression with BMI are red and 
indicated with (+). There is 100% concordance between the human and monkey microarray datasets. 
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240234_at MmugDNA.13915.1.S1_at 84.53 0.005 0.033 - 0.269 0.845 --- --- --- --- 
204142_at MmugDNA.32608.1.S1_at 92.45 0.003 0.042 - 0.381 0.547 
enolase superfamily 
member 1 
ENOSF1 55556 697333 
204143_s_at MmugDNA.32608.1.S1_at 89.42 0.013 0.042 - 0.415 0.547 
enolase superfamily 
member 1 
ENOSF1 55556 697333 
223933_at MmugDNA.12670.1.S1_at 95.24 0.043 0.045 - 0.669 1.226 
kinesin family 
member 5A 
KIF5A 3798 --- 
1558448_a_at MmugDNA.35655.1.S1_at 84.26 0.001 0.034 - 0.397 0.571 
hypothetical protein 
LOC100128439 
LOC100128439 100128439 --- 
227556_at MmugDNA.24357.1.S1_at 97.56 0.023 0.015 - 0.941 1.085 
non-metastatic cells 
7, protein expressed 
in (nucleoside-
diphosphate kinase) 
NME7 29922 --- 
213887_s_at MmugDNA.37439.1.S1_at 95.43 0.008 0.036 - 0.423 0.393 
polymerase (RNA) 
II (DNA directed) 
polypeptide E, 
25kDa 
POLR2E 5434 721178 
226923_at MmugDNA.34854.1.S1_at 95.9 0.038 0.036 - 0.305 0.297 
sec1 family domain 
containing 2 
SCFD2 152579 698111 
200986_at MmuSTS.2736.1.S1_at 89.43 0.035 0.006 - 0.536 0.689 
serpin peptidase 
inhibitor, clade G 
(C1 inhibitor), 
member 1 
SERPING1 710 703928 
228711_at MmuSTS.49.1.S1_at 94.83 0.040 0.027 - 0.325 0.418 
zinc finger protein 
37A 
ZNF37A 7587 701714 
222365_at MmugDNA.2151.1.S1_at 86.82 0.025 0.002 + 0.275 0.654 --- --- --- --- 
 149 
1561341_at MmugDNA.25585.1.S1_at 92.8 0.021 0.008 + 0.335 0.430 --- --- --- --- 
1560422_at MmugDNA.40378.1.S1_at 92.31 0.006 0.009 + 0.818 2.226 --- --- --- --- 
241391_at MmugDNA.9839.1.S1_at 79.9 0.018 0.009 + 0.287 0.737 --- --- --- --- 
214949_at MmugDNA.8635.1.S1_s_at 0 0.042 0.014 + 0.330 0.437 --- --- --- 706318 
238044_at MmugDNA.4781.1.S1_at 96.22 0.019 0.016 + 0.302 0.267 --- --- --- --- 
229733_s_at MmugDNA.9332.1.S1_at 93.95 0.029 0.034 + 0.602 0.919 --- --- --- --- 
225937_at MmugDNA.21190.1.S1_at 96 0.032 0.042 + 0.913 1.064 --- --- --- --- 
218447_at MmugDNA.14860.1.S1_at 83.64 0.018 0.020 + 0.513 0.330 
chromosome 16 
open reading frame 
61 
C16orf61 56942 --- 
206967_at MmuSTS.1418.1.S1_at 97.44 0.026 0.002 + 0.513 1.152 cyclin T1 CCNT1 904 707754 





CNOT6L 246175 697981 





DNAJB14 79982 711298 




EFHC1 114327 708517 
231523_at MmugDNA.27702.1.S1_at 95.02 0.009 0.026 + 0.462 0.423 
fibroblast growth 
factor 14 
FGF14 2259 701077 
204131_s_at MmuSTS.62.1.S1_at 96.66 0.005 0.003 + 0.348 0.387 forkhead box O3 FOXO3 2309 700731 
210655_s_at MmugDNA.14229.1.S1_at 77.34 0.035 0.018 + 0.370 0.408 forkhead box O3 FOXO3 2309 700731 
204132_s_at MmugDNA.39885.1.S1_at 95.73 0.008 0.028 + 0.531 0.556 forkhead box O3 FOXO3 2309 700731 
227475_at MmugDNA.15888.1.S1_at 94.88 0.045 0.034 + 0.362 0.286 forkhead box Q1 FOXQ1 94234 722908 
221312_at MmuSTS.1464.1.S1_at 90.19 0.001 0.020 + 0.305 0.354 
glucagon-like 
peptide 2 receptor 
GLP2R 9340 717783 
217232_x_at MmugDNA.5184.1.S1_s_at 97.37 0.037 0.023 + 0.709 0.823 hemoglobin, beta HBB 3043 --- 
211696_x_at MmugDNA.5184.1.S1_s_at 97.37 0.040 0.023 + 0.717 0.823 hemoglobin, beta HBB 3043 --- 
212966_at MmugDNA.37606.1.S1_at 95.4 0.047 0.029 + 0.333 0.613 
hypermethylated in 
cancer 2 
HIC2 23119 698399 
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HIP1 3092 --- 
215313_x_at Mmu.2935.4.S1_x_at 60.42 0.017 0.007 + 0.343 0.444 
major 
histocompatibility 
complex, class I, A 
HLA-A 3105 --- 
213792_s_at MmugDNA.39585.1.S1_at 88.01 0.011 0.003 + 0.633 0.700 insulin receptor INSR 3643 --- 
235672_at MmugDNA.14538.1.S1_at 96.34 0.004 0.002 + 0.299 0.353 
microtubule-
associated protein 6 
MAP6 4135 696223 
204601_at MmugDNA.9396.1.S1_at 94.36 0.014 0.014 + 0.320 0.429 
NEDD4 binding 
protein 1 
N4BP1 9683 717876 
213032_at MmugDNA.22443.1.S1_at 96.71 0.013 0.019 + 0.363 0.300 nuclear factor I/B NFIB 4781 714098 
231361_at MmugDNA.9065.1.S1_at 97.21 0.033 0.020 + 0.320 0.265 Neuroligin 1 NLGN1 22871 --- 




NRIP1 8204 693428 
200637_s_at MmugDNA.16229.1.S1_at 97.87 0.043 0.021 + 0.294 0.378 
protein tyrosine 
phosphatase, 
receptor type, F 
PTPRF 5792 701160 
205037_at MmugDNA.9524.1.S1_at 95.47 0.002 0.007 + 0.509 0.544 
RAB, member of 
RAS oncogene 
family-like 4 
RABL4 11020 697032 
215138_s_at MmugDNA.19723.1.S1_at 98.69 0.018 0.011 + 0.370 0.320 kazrin RP1-21O18.1 23254 --- 
213478_at MmugDNA.38661.1.S1_at 90.81 0.008 0.030 + 0.842 0.765 kazrin RP1-21O18.1 23254 --- 








SRD5A1 6715 695103 




SS18 6760 709897 




SS18 6760 709897 
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200976_s_at MmugDNA.14263.1.S1_at 85.92 0.049 0.031 + 0.476 0.436 
Tax1 (human T-cell 
leukemia virus type 
I) binding protein 1 
TAX1BP1 8887 698103 
222634_s_at MmugDNA.41253.1.S1_at 98.44 0.038 0.025 + 0.263 0.494 
151eparin151ing 
(beta)-like 1 X-
linked receptor 1 
TBL1XR1 79718 712740 
214948_s_at MmugDNA.8635.1.S1_s_at 93.77 0.039 0.014 + 0.421 0.437 
TATA element 
modulatory factor 1 
TMF1 7110 706318 
213922_at MmugDNA.9234.1.S1_at 95.07 0.011 0.031 + 0.748 0.662 tau tubulin kinase 2 TTBK2 146057 712249 
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Supplementary Table 5. Gene Ontology Classification of BMI-associated Expression Changes in the Motor Cortex. GO Biological Process terms were 
used to determine the function of BMI associated genes in the motor cortex. Genes highlighted in blue denote decreased expression, while genes in red denote 
increased expression with increased BMI. Note that the most altered BMI-dependent GO terms were associated with apoptosis. 
 
SUPPLEMENTARY TABLE 5. Gene Ontology Classification of BMI-associated Expression Changes in the Motor Cortex 
Analysis GO TERM # OF GENES GENE NAMES 
GO Biological 
Process 
metabolism 6 ASL, APOD, DECR1, RBK5, RNPS1, SLC6A9 
protein amino acid 
phosphorylation 
2 EPHB6, MAP4K4 




Supplementary Table 6. Gene Ontology Classification of BMI-associated Expression Changes in the Caudate Nucleus. GO Biological Process terms were 
used to determine the function of BMI associated genes in the caudate nucleus. Genes highlighted in blue denote decreased expression, while genes in red denote 
increased expression with increased BMI. Note that the most altered BMI-dependent GO terms were associated with transcription and apoptosis. 
 
SUPPLEMENTARY TABLE 6. Gene Ontology Classification of BMI-associated Expression Changes in the Caudate Nucleus 




CCNT1, CNOT6L, FOXO3B, FOXQ1, HIC2, HIP1, NFIB, 
NRIP1, POL2E, SS18, SMF, TBLIXR1, ZNF37A 
apoptosis 4 HIP1, PTFRF, TAX1BP1, TTBK2 
metabolism 3 SRD5A1, NME7, ENOSF1 
signal transduction 3 FGF14, GLP2R, INSR 




Supplementary Table 7. Exercise Associated Gene Expression in the Motor Cortex. All transcripts in the table are significant with p<0.05 for both paired 
and groupwise t-tests. All transcripts are identified by their Probe Set ID, Gene title, Entrez Gene ID, and Gene symbol. Transcript data is listed for the motor 
cortex (M), putamen (P), and hippocampus (H). For each transcript we calculated their average log ratio (ALR, the average expression change of the exercising 
monkeys minus the sedentary monkeys), the direction of the change, the p-value for the groupwise and paired t-tests, and if the transcript met the significance 
cutoff in each brain region. There are 434 transcripts differentially expressed by exercise in the motor cortex.  
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235201_PM_at --- --- --- -0.488 - 0.000 0.007 
1561212_PM_at --- --- --- -0.361 - 0.001 0.009 
234674_PM_at --- --- --- -0.266 - 0.003 0.007 
237421_PM_at --- --- --- -0.383 - 0.006 0.029 
1566032_PM_at --- --- --- -0.269 - 0.009 0.033 
234502_PM_at --- --- --- -0.298 - 0.009 0.018 
237583_PM_at --- --- --- -0.418 - 0.009 0.009 
229580_PM_at --- --- --- -0.378 - 0.013 0.008 
233646_PM_at --- --- --- -0.311 - 0.016 0.034 
238191_PM_at --- --- --- -0.329 - 0.020 0.033 
241814_PM_at --- --- --- -0.269 - 0.020 0.026 
1559063_PM_at --- --- --- -0.287 - 0.022 0.047 
238521_PM_at --- --- --- -0.290 - 0.022 0.032 
229531_PM_at --- --- --- -0.301 - 0.025 0.038 
230714_PM_s_at --- --- --- -0.278 - 0.029 0.015 
230913_PM_at --- --- --- -0.295 - 0.032 0.009 
229108_PM_at --- --- --- -0.399 - 0.037 0.038 
241636_PM_x_at --- --- --- -0.316 - 0.043 0.012 
209000_PM_s_at septin 8 23176 8-Sep -0.421 - 0.035 0.012 
226925_PM_at acid phosphatase-like 2 92370 ACPL2 -0.394 - 0.035 0.027 
204332_PM_s_at aspartylglucosaminidase 175 AGA -0.340 - 0.016 0.007 
1566989_PM_at AT rich interactive domain 1B (SWI1-like) 57492 ARID1B -0.434 - 0.022 0.025 
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209824_PM_s_at aryl hydrocarbon receptor nuclear translocator-like 406 ARNTL -0.348 - 0.021 0.048 
234584_PM_s_at arginyltransferase 1 11101 ATE1 -0.265 - 0.023 0.018 
228190_PM_at 
ATG4 autophagy related 4 homolog C (S. cerevisiae) /// Ctr9, 
Paf1/RNA polymerase II complex component, homolog (S. 
cerevisiae) 
84938 /// 9646 
ATG4C /// 
CTR9 
-0.431 - 0.014 0.023 
242230_PM_at ataxin 1 6310 ATXN1 -0.316 - 0.015 0.021 
227373_PM_at ataxin 1-like 342371 ATXN1L -0.313 - 0.046 0.024 
209964_PM_s_at ataxin 7 6314 ATXN7 -0.274 - 0.036 0.024 
210157_PM_at chromosome 19 open reading frame 2 8725 C19orf2 -0.428 - 0.003 0.003 
218721_PM_s_at chromosome 1 open reading frame 27 54953 C1orf27 -0.285 - 0.004 0.010 
228195_PM_at chromosome 2 open reading frame 88 84281 C2orf88 -0.279 - 0.001 0.004 
200757_PM_s_at calumenin 813 CALU -0.292 - 0.021 0.043 
236320_PM_at coiled-coil domain containing 17 149483 CCDC17 -0.284 - 0.045 0.045 
213110_PM_s_at collagen, type IV, alpha 5 1287 COL4A5 -0.643 - 0.025 0.028 
52255_PM_s_at collagen, type V, alpha 3 50509 COL5A3 -0.289 - 0.002 0.009 
216204_PM_at Catechol-O-methyltransferase 1312 COMT -0.275 - 0.020 0.027 
204172_PM_at coproporphyrinogen oxidase 1371 CPOX -0.315 - 0.007 0.001 
219139_PM_s_at ciliary rootlet coiled-coil, rootletin-like 2 114819 CROCCL2 -0.283 - 0.002 0.003 
213319_PM_s_at Cold shock domain protein A 8531 CSDA -0.326 - 0.011 0.009 
216680_PM_s_at EPH receptor B4 2050 EPHB4 -0.567 - 0.022 0.049 
227551_PM_at family with sequence similarity 108, member B1 51104 FAM108B1 -0.283 - 0.012 0.037 
224030_PM_s_at family with sequence similarity 115, member A 9747 FAM115A -0.297 - 0.039 0.014 
235043_PM_at family with sequence similarity 122A 116224 FAM122A -0.310 - 0.023 0.047 
218510_PM_x_at family with sequence similarity 134, member B 54463 FAM134B -0.305 - 0.013 0.013 
231001_PM_at fin bud initiation factor homolog (zebrafish) 387758 FIBIN -0.419 - 0.013 0.026 
230946_PM_at Formin 2 56776 FMN2 -0.274 - 0.003 0.002 
1558199_PM_at fibronectin 1 2335 FN1 -0.263 - 0.012 0.007 
206377_PM_at forkhead box F2 2295 FOXF2 -0.283 - 0.024 0.012 
204145_PM_at FSHD region gene 1 2483 FRG1 -0.386 - 0.027 0.023 
209702_PM_at fat mass and obesity associated 79068 FTO -0.326 - 0.038 0.047 
201723_PM_s_at 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 1 (GalNAc-T1) 
2589 GALNT1 -0.338 - 0.004 0.005 
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227525_PM_at glucocorticoid induced transcript 1 113263 GLCCI1 -0.283 - 0.017 0.040 
219269_PM_at homeobox containing 1 79618 HMBOX1 -2.305 - 0.013 0.042 
241650_PM_x_at hemicentin 2 256158 HMCN2 -0.284 - 0.040 0.012 
212115_PM_at hematological and neurological expressed 1-like 90861 HN1L -0.303 - 0.030 0.030 
216517_PM_at immunoglobulin kappa constant  100291464 IGKC -0.278 - 0.000 0.001 
204302_PM_s_at KIAA0427 9811 KIAA0427 -0.294 - 0.016 0.041 
205631_PM_at KIAA0586 9786 KIAA0586 -0.358 - 0.027 0.045 
223161_PM_at KIAA1147 57189 KIAA1147 -0.267 - 0.004 0.024 
220911_PM_s_at KIAA1305 57523 KIAA1305 -0.294 - 0.036 0.049 
229349_PM_at lin-28 homolog B (C. elegans) 389421 LIN28B -0.265 - 0.012 0.012 
225793_PM_at Lix1 homolog (mouse)-like 128077 LIX1L -0.284 - 0.038 0.036 
229179_PM_at similar to hCG2045012 100288901 LOC100288901 -0.265 - 0.006 0.015 
1566449_PM_at Leucine rich repeat containing 40 55631 LRRC40 -0.288 - 0.011 0.024 
218364_PM_at leucine rich repeat (in FLII) interacting protein 2 9209 LRRFIP2 -0.367 - 0.029 0.018 
227839_PM_at methyl-CpG binding domain protein 5 55777 MBD5 -0.352 - 0.018 0.043 
219673_PM_at minichromosome maintenance complex component 9 254394 MCM9 -0.307 - 0.011 0.012 
212872_PM_s_at mediator complex subunit 20 9477 MED20 -0.304 - 0.043 0.050 
242765_PM_at myelin-associated oligodendrocyte basic protein 4336 MOBP -0.590 - 0.018 0.040 
206001_PM_at neuropeptide Y 4852 NPY -0.310 - 0.027 0.043 
203814_PM_s_at NAD(P)H dehydrogenase, quinone 2 4835 NQO2 -0.266 - 0.007 0.034 
204622_PM_x_at nuclear receptor subfamily 4, group A, member 2 4929 NR4A2 -0.445 - 0.014 0.041 
216248_PM_s_at nuclear receptor subfamily 4, group A, member 2 4929 NR4A2 -0.435 - 0.017 0.006 
221684_PM_s_at nyctalopin 60506 NYX -0.367 - 0.015 0.016 
210415_PM_s_at outer dense fiber of sperm tails 2 4957 ODF2 0.471 - 0.044 0.006 
230246_PM_at placenta-specific 9 219348 PLAC9 -0.468 - 0.007 0.023 
77508_PM_r_at rabaptin, RAB GTPase binding effector protein 2 79874 RABEP2 -0.292 - 0.027 0.017 
241433_PM_at REST corepressor 3 55758 RCOR3 -0.277 - 0.003 0.004 
217776_PM_at retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 51109 RDH11 -0.325 - 0.011 0.029 
205923_PM_at reelin 5649 RELN -0.441 - 0.013 0.026 
213459_PM_at ribosomal protein L37a 6168 RPL37A -0.287 - 0.016 0.028 
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204923_PM_at SAM and SH3 domain containing 3 54440 SASH3 -0.286 - 0.034 0.020 
227369_PM_at SERPINE1 mRNA binding protein 1 26135 SERBP1 -0.297 - 0.049 0.036 
223732_PM_at solute carrier family 23 (nucleobase transporters), member 1 9963 SLC23A1 -0.284 - 0.024 0.013 
207827_PM_x_at synuclein, alpha (non A4 component of amyloid precursor) 6622 SNCA -0.342 - 0.042 0.040 
1563906_PM_at sine oculis binding protein homolog (Drosophila) 55084 SOBP -0.376 - 0.009 0.017 
203373_PM_at suppressor of cytokine signaling 2 8835 SOCS2 -0.402 - 0.004 0.012 
227426_PM_at son of sevenless homolog 1 (Drosophila) 6654 SOS1 -0.363 - 0.007 0.048 
226822_PM_at storkhead box 2 56977 STOX2 -0.295 - 0.008 0.016 
243766_PM_s_at TEA domain family member 2 8463 TEAD2 -0.278 - 0.005 0.023 
205016_PM_at transforming growth factor, alpha 7039 TGFA -0.395 - 0.047 0.036 
227804_PM_at TLC domain containing 1 116238 TLCD1 -0.377 - 0.015 0.011 
239265_PM_at transmembrane protein 20 159371 TMEM20 -0.279 - 0.035 0.012 
203049_PM_s_at tetratricopeptide repeat domain 37 9652 TTC37 -0.426 - 0.006 0.014 
228956_PM_at UDP glycosyltransferase 8 7368 UGT8 -0.525 - 0.030 0.049 
221513_PM_s_at 
UTP14, U3 small nucleolar ribonucleoprotein, homolog A 
(yeast)  
10813 /// 9724 
UTP14A /// 
UTP14C 
0.306 - 0.025 0.008 
239757_PM_at Zinc finger, AN1-type domain 6 54469 ZFAND6 -0.295 - 0.012 0.031 
204937_PM_s_at zinc finger protein 274 10782 ZNF274 -0.309 - 0.017 0.019 
233511_PM_at --- --- --- 0.337 + 0.001 0.002 
236961_PM_at --- --- --- 0.407 + 0.003 0.014 
1560327_PM_at --- --- --- 0.339 + 0.005 0.019 
238774_PM_at --- --- --- 0.308 + 0.005 0.038 
243881_PM_at --- --- --- 0.319 + 0.012 0.013 
239684_PM_at --- --- --- 0.414 + 0.018 0.050 
237441_PM_at --- --- --- 0.294 + 0.027 0.022 
1556904_PM_at --- --- --- 0.480 + 0.028 0.012 
1563469_PM_at --- --- --- 0.390 + 0.043 0.046 
226454_PM_at membrane-associated ring finger (C3HC4) 9 92979 9-Mar 0.264 + 0.037 0.009 
204343_PM_at ATP-binding cassette, sub-family A (ABC1), member 3 21 ABCA3 0.326 + 0.004 0.017 
225529_PM_at ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 116983 ACAP3 0.514 + 0.025 0.039 
205377_PM_s_at acetylcholinesterase (Yt blood group) 43 ACHE 0.327 + 0.025 0.032 
205378_PM_s_at acetylcholinesterase (Yt blood group) 43 ACHE 0.471 + 0.047 0.046 
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222707_PM_s_at ARP8 actin-related protein 8 homolog (yeast) 93973 ACTR8 0.461 + 0.010 0.011 
202740_PM_at aminoacylase 1 95 ACY1 0.365 + 0.025 0.003 
232133_PM_at ADAM metallopeptidase with thrombospondin type 1 motif, 10 81794 ADAMTS10 0.368 + 0.011 0.030 
90265_PM_at ArfGAP with dual PH domains 1 11033 ADAP1 0.375 + 0.037 0.020 
201401_PM_s_at adrenergic, beta, receptor kinase 1 156 ADRBK1 1.211 + 0.029 0.042 
206152_PM_at 
ArfGAP with GTPase domain, ankyrin repeat and PH domain 
2 
116986 AGAP2 0.366 + 0.036 0.042 
218480_PM_at ATP/GTP binding protein-like 5 60509 AGBL5 0.336 + 0.008 0.011 
231857_PM_s_at ATP/GTP binding protein-like 5 60509 AGBL5 0.371 + 0.020 0.010 
219723_PM_x_at 1-acylglycerol-3-phosphate O-acyltransferase 3 56894 AGPAT3 0.379 + 0.009 0.036 
224282_PM_s_at 1-acylglycerol-3-phosphate O-acyltransferase 3 56894 AGPAT3 0.840 + 0.027 0.043 
202139_PM_at 
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde 
reductase) 
8574 AKR7A2 1.170 + 0.016 0.014 
206469_PM_x_at 
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde 
reductase) 
22977 AKR7A3 0.327 + 0.030 0.022 
218555_PM_at anaphase promoting complex subunit 2 29882 ANAPC2 0.644 + 0.034 0.030 
213001_PM_at angiopoietin-like 2 23452 ANGPTL2 0.310 + 0.048 0.007 
219081_PM_at ankyrin repeat and KH domain containing 1 54882 ANKHD1 0.329 + 0.016 0.009 
231423_PM_s_at ankyrin repeat domain 16 54522 ANKRD16 0.353 + 0.019 0.038 
201043_PM_s_at 
acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member A 
8125 ANP32A 1.097 + 0.027 0.014 
225754_PM_at adaptor-related protein complex 1, gamma 1 subunit 164 AP1G1 0.292 + 0.003 0.006 
201613_PM_s_at adaptor-related protein complex 1, gamma 2 subunit 8906 AP1G2 0.513 + 0.003 0.021 
212161_PM_at adaptor-related protein complex 2, alpha 2 subunit 161 AP2A2 0.315 + 0.022 0.001 
203382_PM_s_at apolipoprotein E 348 APOE 0.570 + 0.023 0.040 
203219_PM_s_at adenine phosphoribosyltransferase 353 APRT 1.034 + 0.021 0.027 
202547_PM_s_at Rho guanine nucleotide exchange factor (GEF) 7 8874 ARHGEF7 0.536 + 0.010 0.025 
225184_PM_at AT rich interactive domain 1B (SWI1-like) 57492 ARID1B 0.858 + 0.001 0.007 
1552722_PM_at cyclic AMP-regulated phosphoprotein, 21 kD 10777 ARPP-21 0.519 + 0.014 0.034 
1570523_PM_s_at ATG10 autophagy related 10 homolog (S. cerevisiae) 83734 ATG10 0.373 + 0.001 0.007 
228984_PM_at ATP-grasp domain containing 1 57571 ATPGD1 -0.349 + 0.037 0.038 
203452_PM_at beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) 26229 B3GAT3 0.444 + 0.011 0.029 
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210534_PM_s_at B9 protein domain 1 27077 B9D1 1.079 + 0.012 0.023 
1555735_PM_a_at 
BRCA1 associated protein-1 (ubiquitin carboxy-terminal 
hydrolase) 
8314 BAP1 0.733 + 0.044 0.033 
225674_PM_at B-cell receptor-associated protein 29 55973 BCAP29 0.372 + 0.011 0.023 
200837_PM_at B-cell receptor-associated protein 31 10134 BCAP31 0.610 + 0.046 0.012 
202030_PM_at branched chain ketoacid dehydrogenase kinase 10295 BCKDK 0.294 + 0.031 0.006 
238692_PM_at BTB (POZ) domain containing 11 121551 BTBD11 0.426 + 0.018 0.008 
218220_PM_at chromosome 12 open reading frame 10 60314 C12orf10 0.393 + 0.033 0.042 
225313_PM_at chromosome 20 open reading frame 177 63939 C20orf177 -0.412 + 0.026 0.041 
50314_PM_i_at chromosome 20 open reading frame 27 54976 C20orf27 0.410 + 0.025 0.026 
218081_PM_at chromosome 20 open reading frame 27 54976 C20orf27 0.401 + 0.037 0.032 
223360_PM_at chromosome 21 open reading frame 56 84221 C21orf56 1.073 + 0.009 0.007 
235935_PM_at chromosome 6 open reading frame 154 221424 C6orf154 0.953 + 0.018 0.024 
227000_PM_at chromosome 7 open reading frame 41 222166 C7orf41 0.412 + 0.014 0.017 
211802_PM_x_at calcium channel, voltage-dependent, T type, alpha 1G subunit 8913 CACNA1G 0.470 + 0.025 0.016 
224291_PM_at calcium channel, voltage-dependent, gamma subunit 6 59285 CACNG6 0.528 + 0.000 0.001 
201615_PM_x_at caldesmon 1 800 CALD1 0.358 + 0.003 0.012 
1555608_PM_at caprin family member 2 65981 CAPRIN2 0.273 + 0.003 0.002 
210775_PM_x_at caspase 9, apoptosis-related cysteine peptidase 842 CASP9 0.377 + 0.006 0.001 
1559409_PM_a_at coiled-coil and C2 domain containing 2A 57545 CC2D2A 0.325 + 0.008 0.015 
206037_PM_at cysteine conjugate-beta lyase, cytoplasmic 883 CCBL1 0.289 + 0.010 0.004 
223316_PM_at coiled-coil domain containing 3 83643 CCDC3 0.338 + 0.004 0.001 
226539_PM_s_at coiled-coil domain containing 42B 387885 CCDC42B 0.278 + 0.019 0.029 
204610_PM_s_at coiled-coil domain containing 85B 11007 CCDC85B 0.624 + 0.032 0.044 
217849_PM_s_at CDC42 binding protein kinase beta (DMPK-like) 9578 CDC42BPB 0.710 + 0.009 0.012 
203198_PM_at cyclin-dependent kinase 9 1025 CDK9 0.426 + 0.026 0.013 
208052_PM_x_at carcinoembryonic antigen-related cell adhesion molecule 3 1084 CEACAM3 0.268 + 0.013 0.009 
1554489_PM_a_at centrosomal protein 70kDa 80321 CEP70 0.365 + 0.007 0.008 
224932_PM_at coiled-coil-helix-coiled-coil-helix domain containing 10 400916 CHCHD10 0.315 + 0.025 0.037 
222755_PM_s_at chromodomain helicase DNA binding protein 7 55636 CHD7 0.655 + 0.004 0.031 
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1553442_PM_a_at contactin associated protein-like 4 85445 CNTNAP4 0.747 + 0.008 0.009 
203653_PM_s_at coilin 8161 COIL 0.504 + 0.031 0.023 
209132_PM_s_at COMM domain containing 4 54939 COMMD4 0.268 + 0.026 0.010 
218057_PM_x_at COX4 neighbor 10328 COX4NB 0.269 + 0.028 0.002 
225815_PM_at complexin 2 10814 CPLX2 0.326 + 0.030 0.007 
202224_PM_at v-crk sarcoma virus CT10 oncogene homolog (avian) 1398 CRK 0.303 + 0.020 0.001 
206777_PM_s_at 
160eparin160ing, beta B2 /// 160eparin160ing, beta B2 
pseudogene 1 
1415 /// 1416 
CRYBB2 /// 
CRYBB2P1 
0.483 + 0.007 0.008 
214355_PM_x_at CTAGE family, member 4  
100128553 /// 
100142659 /// 
119437 /// 220429 
/// 340307 /// 4253 
/// 441294 /// 
643854 /// 647288 
CTAGE4  0.292 + 0.029 0.030 
201905_PM_s_at 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase-like 
10217 CTDSPL 0.461 + 0.037 0.022 
227886_PM_at cathepsin D 1509 CTSD 0.460 + 0.005 0.032 
209158_PM_s_at cytohesin 2 9266 CYTH2 0.386 + 0.035 0.031 
1569648_PM_at 
dapper, antagonist of beta-catenin, homolog 2 (Xenopus 
laevis) 
168002 DACT2 0.506 + 0.001 0.006 
238340_PM_at DDB1 and CUL4 associated factor 8 50717 DCAF8 0.444 + 0.023 0.014 
218892_PM_at dachsous 1 (Drosophila) 8642 DCHS1 0.283 + 0.007 0.014 
231151_PM_at discs, large (Drosophila) homolog-associated protein 3 58512 DLGAP3 0.446 + 0.008 0.008 
230936_PM_at DnaJ (Hsp40) related, subfamily B, member 13 374407 DNAJB13 0.872 + 0.014 0.033 
224612_PM_s_at DnaJ (Hsp40) homolog, subfamily C, member 5 80331 DNAJC5 0.968 + 0.041 0.046 
207648_PM_at dystrophin related protein 2 1821 DRP2 0.295 + 0.029 0.048 
1553983_PM_at deoxythymidylate kinase (thymidylate kinase) 1841 DTYMK 0.282 + 0.004 0.007 
238594_PM_x_at dual specificity phosphatase 8 1850 DUSP8 0.296 + 0.025 0.038 
211079_PM_s_at 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1A 
1859 DYRK1A 0.268 + 0.007 0.029 
1555306_PM_a_at endothelin converting enzyme 2 9718 ECE2 0.335 + 0.007 0.012 
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202496_PM_at enhancer of mRNA decapping 4 23644 EDC4 0.420 + 0.038 0.044 
209356_PM_x_at EGF-containing fibulin-like extracellular matrix protein 2 30008 EFEMP2 0.633 + 0.015 0.029 
205249_PM_at early growth response 2 1959 EGR2 0.268 + 0.004 0.003 
1555996_PM_s_at eukaryotic translation initiation factor 4A, isoform 2 1974 EIF4A2 0.428 + 0.014 0.013 
210376_PM_x_at ELK1, member of ETS oncogene family 2002 ELK1 0.299 + 0.024 0.034 
203464_PM_s_at epsin 2 22905 EPN2 0.298 + 0.010 0.013 
202176_PM_at 
excision repair cross-complementing rodent repair deficiency, 
complementation group 3 (xeroderma pigmentosum group B 
complementing) 
2071 ERCC3 0.350 + 0.015 0.049 
226411_PM_at ecotropic viral integration site 5-like 115704 EVI5L 0.389 + 0.036 0.048 
210012_PM_s_at Ewing sarcoma breakpoint region 1 2130 EWSR1 1.002 + 0.009 0.016 
218695_PM_at exosome component 4 54512 EXOSC4 0.388 + 0.011 0.014 
225874_PM_at family with sequence similarity 100, member A 124402 FAM100A 0.604 + 0.012 0.031 
229655_PM_at 
family with sequence similarity 19 (chemokine (C-C motif)-
like), member A5 
25817 FAM19A5 0.284 + 0.039 0.030 
232048_PM_at family with sequence similarity 76, member B 143684 FAM76B 0.309 + 0.003 0.007 
32209_PM_at family with sequence similarity 89, member B 23625 FAM89B 0.404 + 0.018 0.025 
214114_PM_x_at Fas-activated serine/threonine kinase 10922 FASTK 0.878 + 0.015 0.031 
210975_PM_x_at Fas-activated serine/threonine kinase 10922 FASTK 0.656 + 0.020 0.019 
202676_PM_x_at Fas-activated serine/threonine kinase 10922 FASTK 0.916 + 0.039 0.050 
219189_PM_at F-box and leucine-rich repeat protein 6 26233 FBXL6 0.532 + 0.032 0.005 
219305_PM_x_at F-box protein 2 26232 FBXO2 0.584 + 0.037 0.017 
223050_PM_s_at F-box and WD repeat domain containing 5 54461 FBXW5 0.295 + 0.006 0.008 
205866_PM_at 
ficolin (collagen/fibrinogen domain containing) 3 (Hakata 
antigen) 
8547 FCN3 0.307 + 0.015 0.029 
226705_PM_at fibroblast growth factor receptor 1 2260 FGFR1 0.512 + 0.024 0.040 
208234_PM_x_at fibroblast growth factor receptor 2 2263 FGFR2 0.667 + 0.023 0.049 
244498_PM_x_at 
similar to ubiquitin-conjugating enzyme E2Q 2 /// chondroitin 
sulfate proteoglycan 4 pseudogene /// chondroitin sulfate 
proteoglycan 4 pseudogene 





0.338 + 0.030 0.001 
201350_PM_at flotillin 2 2319 FLOT2 0.376 + 0.007 0.016 
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229272_PM_at formin binding protein 4 23360 FNBP4 0.640 + 0.024 0.026 
218843_PM_at fibronectin type III domain containing 4 64838 FNDC4 0.377 + 0.004 0.003 
221187_PM_s_at fuzzy homolog (Drosophila) 80199 FUZ 0.530 + 0.032 0.048 
203172_PM_at fragile X mental retardation, autosomal homolog 2 9513 FXR2 0.419 + 0.029 0.047 
233437_PM_at gamma-aminobutyric acid (GABA) A receptor, alpha 4 2557 GABRA4 0.337 + 0.017 0.007 
207352_PM_s_at gamma-aminobutyric acid (GABA) A receptor, beta 2 2561 GABRB2 0.801 + 0.040 0.039 
207704_PM_s_at growth arrest-specific 7 8522 GAS7 0.318 + 0.043 0.043 
216860_PM_s_at growth differentiation factor 11 10220 GDF11 0.287 + 0.005 0.007 
35436_PM_at golgi autoantigen, golgin subfamily a, 2 2801 GOLGA2 0.379 + 0.025 0.029 
218193_PM_s_at golgi transport 1 homolog B (S. cerevisiae) 51026 GOLT1B 0.337 + 0.010 0.036 
227215_PM_at golgi associated PDZ and coiled-coil motif containing 57120 GOPC 0.348 + 0.041 0.031 
210009_PM_s_at golgi SNAP receptor complex member 2 9570 GOSR2 0.404 + 0.005 0.017 
206266_PM_at glycosylphosphatidylinositol specific phospholipase D1 2822 GPLD1 0.266 + 0.026 0.036 
225058_PM_at G protein-coupled receptor 108 56927 GPR108 0.320 + 0.009 0.022 
221306_PM_at G protein-coupled receptor 27 2850 GPR27 0.310 + 0.047 0.050 
200736_PM_s_at glutathione peroxidase 1 2876 GPX1 0.634 + 0.014 0.024 
208465_PM_at glutamate receptor, metabotropic 2 2912 GRM2 0.718 + 0.019 0.015 
215333_PM_x_at 
glutathione S-transferase mu 1 /// glutathione S-transferase 
mu 2 (muscle) 
2944 /// 2946 
GSTM1 /// 
GSTM2 
0.296 + 0.000 0.007 
210892_PM_s_at general transcription factor Iii 2969 GTF2I 0.330 + 0.011 0.020 
225245_PM_x_at H2A histone family, member J 55766 H2AFJ 0.310 + 0.011 0.029 
201035_PM_s_at hydroxyacyl-Coenzyme A dehydrogenase 3033 HADH 0.315 + 0.012 0.034 
229181_PM_s_at HAUS augmin-like complex, subunit 2 55142 HAUS2 0.353 + 0.035 0.027 
215193_PM_x_at major histocompatibility complex, class II, DR beta 1  100133661 HLA-DRB1 1.059 + 0.006 0.029 
209675_PM_s_at heterogeneous nuclear ribonucleoprotein U-like 1 11100 HNRNPUL1 0.516 + 0.025 0.041 
221663_PM_x_at histamine receptor H3 11255 HRH3 0.376 + 0.034 0.017 
1552842_PM_at 162eparin sulfate 6-O-sulfotransferase 3 266722 HS6ST3 0.263 + 0.017 0.040 
1569905_PM_at hydroxysteroid (11-beta) dehydrogenase 1-like 374875 HSD11B1L 0.661 + 0.017 0.027 
213540_PM_at hydroxysteroid (17-beta) dehydrogenase 8 7923 HSD17B8 0.418 + 0.023 0.012 
211616_PM_s_at 5-hydroxytryptamine (serotonin) receptor 2A 3356 HTR2A 1.013 + 0.015 0.032 
201609_PM_x_at isoprenylcysteine carboxyl methyltransferase 23463 ICMT 0.823 + 0.022 0.031 
212203_PM_x_at interferon induced transmembrane protein 3 (1-8U) 10410 IFITM3 0.362 + 0.019 0.034 
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226324_PM_s_at intraflagellar transport 172 homolog (Chlamydomonas) 26160 IFT172 0.265 + 0.005 0.000 
209542_PM_x_at insulin-like growth factor 1 (somatomedin C) 3479 IGF1 0.273 + 0.016 0.011 
222963_PM_s_at interleukin 1 receptor accessory protein-like 1 11141 IL1RAPL1 0.637 + 0.036 0.047 
218234_PM_at inhibitor of growth family, member 4 51147 ING4 0.372 + 0.021 0.040 
213651_PM_at inositol polyphosphate-5-phosphatase J 27124 INPP5J 0.304 + 0.014 0.017 
215130_PM_s_at IQ motif containing K 124152 IQCK 0.285 + 0.006 0.022 
223428_PM_s_at ISY1 splicing factor homolog (S. cerevisiae) 57461 ISY1 0.289 + 0.035 0.021 
201189_PM_s_at inositol 1,4,5-triphosphate receptor, type 3 3710 ITPR3 0.379 + 0.005 0.003 
235467_PM_s_at 
potassium voltage-gated channel, Shaw-related subfamily, 
member 4 
3749 KCNC4 0.372 + 0.012 0.001 
223726_PM_at 
potassium voltage-gated channel, subfamily H (eag-related), 
member 3 
23416 KCNH3 0.532 + 0.020 0.009 
207141_PM_s_at potassium inwardly-rectifying channel, subfamily J, member 3 3760 KCNJ3 0.874 + 0.038 0.042 
212492_PM_s_at lysine (K)-specific demethylase 4B 23030 KDM4B 1.233 + 0.033 0.028 
203363_PM_s_at KIAA0652 9776 KIAA0652 0.711 + 0.012 0.028 
231842_PM_at KIAA1462 57608 KIAA1462 0.298 + 0.023 0.037 
224746_PM_at KIAA1522 57648 KIAA1522 0.414 + 0.003 0.018 
225140_PM_at Kruppel-like factor 3 (basic) 51274 KLF3 0.275 + 0.013 0.028 
208960_PM_s_at Kruppel-like factor 6 1316 KLF6 0.362 + 0.034 0.011 
209008_PM_x_at keratin 8 3856 KRT8 0.302 + 0.012 0.002 
219061_PM_s_at L antigen family, member 3 8270 LAGE3 0.264 + 0.033 0.032 




3955 LFNG 0.455 + 0.045 0.020 
200805_PM_at lectin, mannose-binding 2 10960 LMAN2 0.516 + 0.029 0.048 
219135_PM_s_at lipase maturation factor 1 64788 LMF1 0.433 + 0.029 0.023 
212682_PM_s_at lipase maturation factor 2 91289 LMF2 0.296 + 0.045 0.020 
229636_PM_at Hypothetical protein LOC100131226 100131226 LOC100131226 0.293 + 0.037 0.046 
216967_PM_at hypothetical protein LOC100288551 100288551 LOC100288551 0.303 + 0.017 0.035 
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232211_PM_at 
similar to protein phosphatase 1, regulatory (inhibitor) subunit 





0.353 + 0.021 0.046 
229528_PM_at hypothetical protein LOC283378 283378 LOC283378 0.424 + 0.016 0.007 
1556042_PM_s_at hypothetical LOC338799 338799 LOC338799 0.354 + 0.015 0.024 
229826_PM_at similar to CG32736-PA 440957 LOC440957 0.394 + 0.010 0.010 
203570_PM_at lysyl oxidase-like 1 4016 LOXL1 0.310 + 0.028 0.039 
1553940_PM_a_at leucine rich repeat containing 28 123355 LRRC28 0.417 + 0.027 0.017 
219922_PM_s_at latent transforming growth factor beta binding protein 3 4054 LTBP3 0.651 + 0.027 0.010 
213176_PM_s_at latent transforming growth factor beta binding protein 4 8425 LTBP4 0.269 + 0.029 0.016 
223234_PM_at MAD2 mitotic arrest deficient-like 2 (yeast) 10459 MAD2L2 0.654 + 0.028 0.029 
203668_PM_at mannosidase, alpha, class 2C, member 1 4123 MAN2C1 0.371 + 0.028 0.038 
215384_PM_s_at microtubule-associated protein 1A 4130 MAP1A 0.357 + 0.030 0.002 
226190_PM_at mitogen-activated protein kinase kinase kinase 13 9175 MAP3K13 0.406 + 0.039 0.025 
41160_PM_at methyl-CpG binding domain protein 3 53615 MBD3 0.290 + 0.001 0.010 
218664_PM_at mitochondrial trans-2-enoyl-CoA reductase 51102 MECR 0.418 + 0.022 0.046 
43544_PM_at mediator complex subunit 16 10025 MED16 0.693 + 0.041 0.037 
221650_PM_s_at mediator complex subunit 18 54797 MED18 0.313 + 0.039 0.009 
211913_PM_s_at c-mer proto-oncogene tyrosine kinase 10461 MERTK 0.397 + 0.027 0.015 
214588_PM_s_at microfibrillar-associated protein 3 4238 MFAP3 0.358 + 0.021 0.013 
214972_PM_at Meningioma expressed antigen 5 (hyaluronidase) 10724 MGEA5 0.616 + 0.026 0.034 
228261_PM_at mindbomb homolog 2 (Drosophila) 142678 MIB2 0.672 + 0.041 0.045 
219332_PM_at MICAL-like 2 79778 MICALL2 0.328 + 0.003 0.016 
232167_PM_at 
macrophage migration inhibitory factor (glycosylation-
inhibiting factor) /// solute carrier family 2 (facilitated glucose 
transporter), member 11 
4282 /// 66035 
MIF /// 
SLC2A11 
0.277 + 0.045 0.001 
214625_PM_s_at misshapen-like kinase 1 (zebrafish) 50488 MINK1 0.496 + 0.026 0.012 
220587_PM_s_at MTOR associated protein, LST8 homolog (S. cerevisiae) 64223 MLST8 0.497 + 0.013 0.032 
224207_PM_x_at matrix metallopeptidase 28 79148 MMP28 0.276 + 0.012 0.006 
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1557455_PM_s_at motile sperm domain containing 1 56180 MOSPD1 0.693 + 0.038 0.040 
206538_PM_at muscle RAS oncogene homolog 22808 MRAS 0.407 + 0.037 0.004 
219162_PM_s_at mitochondrial ribosomal protein L11 65003 MRPL11 0.347 + 0.002 0.002 
213897_PM_s_at mitochondrial ribosomal protein L23 6150 MRPL23 0.403 + 0.002 0.012 
243579_PM_at musashi homolog 2 (Drosophila) 124540 MSI2 0.773 + 0.045 0.039 
238583_PM_at methionine sulfoxide reductase B3 253827 MSRB3 0.439 + 0.027 0.036 
216222_PM_s_at myosin X 4651 MYO10 0.287 + 0.029 0.014 
210480_PM_s_at myosin VI 4646 MYO6 0.855 + 0.011 0.025 
213607_PM_x_at NAD kinase 65220 NADK 0.672 + 0.025 0.027 
222598_PM_s_at neuron navigator 2 89797 NAV2 0.324 + 0.013 0.040 
40640_PM_at non-SMC 165eparin165in II complex, subunit H2 29781 NCAPH2 0.340 + 0.013 0.020 
242121_PM_at non-protein coding RNA 182 100302692 NCRNA00182 0.399 + 0.038 0.045 
204325_PM_s_at neurofibromin 1 4763 NF1 0.345 + 0.004 0.007 
211094_PM_s_at neurofibromin 1 4763 NF1 0.320 + 0.012 0.043 
213298_PM_at nuclear factor I/C (CCAAT-binding transcription factor) 4782 NFIC 0.530 + 0.020 0.012 
209973_PM_at 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor-like 1 
4795 NFKBIL1 0.301 + 0.028 0.017 
209261_PM_s_at nuclear receptor subfamily 2, group F, member 6 2063 NR2F6 0.360 + 0.020 0.006 
218359_PM_at neurensin 2 80023 NRSN2 0.427 + 0.016 0.037 
206291_PM_at neurotensin 4922 NTS 0.279 + 0.035 0.014 
222025_PM_s_at 5-oxoprolinase (ATP-hydrolysing) 26873 OPLAH 0.440 + 0.025 0.027 
1558426_PM_x_at ORAI calcium release-activated calcium modulator 2 80228 ORAI2 0.382 + 0.023 0.049 
221237_PM_s_at oxysterol binding protein 2 23762 OSBP2 0.583 + 0.037 0.015 
204088_PM_at purinergic receptor P2X, ligand-gated ion channel, 4 5025 P2RX4 0.314 + 0.030 0.006 
1555823_PM_at phosphofurin acidic cluster sorting protein 2 23241 PACS2 0.608 + 0.014 0.015 
227053_PM_at protein kinase C and casein kinase substrate in neurons 1 29993 PACSIN1 0.316 + 0.021 0.020 
1552944_PM_a_at pannexin 2 56666 PANX2 0.470 + 0.004 0.013 
239067_PM_s_at pannexin 2 56666 PANX2 0.337 + 0.009 0.036 
204629_PM_at parvin, beta 29780 PARVB 0.330 + 0.006 0.010 
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211392_PM_s_at POZ (BTB) and AT hook containing zinc finger 1 23598 PATZ1 0.389 + 0.037 0.018 
209361_PM_s_at poly(rC) binding protein 4 57060 PCBP4 0.286 + 0.014 0.024 
208823_PM_s_at PCTAIRE protein kinase 1 5127 PCTK1 0.359 + 0.029 0.040 
219165_PM_at PDZ and LIM domain 2 (mystique) 64236 PDLIM2 0.403 + 0.007 0.020 
211564_PM_s_at PDZ and LIM domain 4 8572 PDLIM4 0.385 + 0.034 0.025 
203242_PM_s_at PDZ and LIM domain 5 10611 PDLIM5 0.402 + 0.035 0.005 
223543_PM_at PDZ domain containing 4 57595 PDZD4 0.334 + 0.032 0.037 
320_PM_at peroxisomal biogenesis factor 6 5190 PEX6 0.408 + 0.012 0.005 
55616_PM_at post-GPI attachment to proteins 3 93210 PGAP3 0.326 + 0.006 0.003 
218387_PM_s_at 6-phosphogluconolactonase 25796 PGLS 0.337 + 0.035 0.025 
218388_PM_at 6-phosphogluconolactonase 25796 PGLS 0.610 + 0.037 0.034 
235149_PM_at phosphoglucomutase 2-like 1 283209 PGM2L1 0.458 + 0.022 0.034 
222622_PM_at phosphoglycolate phosphatase 283871 PGP 0.269 + 0.006 0.007 
200658_PM_s_at prohibitin 5245 PHB 0.609 + 0.012 0.026 
205450_PM_at phosphorylase kinase, alpha 1 (muscle) 5255 PHKA1 0.415 + 0.019 0.037 
210647_PM_x_at phospholipase A2, group VI (cytosolic, calcium-independent) 8398 PLA2G6 0.264 + 0.005 0.013 
202240_PM_at polo-like kinase 1 (Drosophila) 5347 PLK1 0.269 + 0.000 0.004 
212235_PM_at plexin D1 23129 PLXND1 0.265 + 0.034 0.036 
210139_PM_s_at peripheral myelin protein 22 5376 PMP22 -0.295 + 0.037 0.031 
211697_PM_x_at partner of NOB1 homolog (S. cerevisiae) 56902 PNO1 0.335 + 0.010 0.029 
1557700_PM_at Polymerase (DNA directed), eta 5429 POLH 0.323 + 0.005 0.005 
1557701_PM_s_at polymerase (DNA directed), eta 5429 POLH 0.370 + 0.028 0.036 
218997_PM_at polymerase (RNA) I polypeptide E, 53kDa 64425 POLR1E 0.307 + 0.030 0.009 
213368_PM_x_at 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 3 
8541 PPFIA3 0.495 + 0.033 0.032 
228795_PM_at protein kinase C, beta 5579 PRKCB 0.543 + 0.038 0.029 
216088_PM_s_at proteasome (prosome, macropain) subunit, alpha type, 7 5688 PSMA7 0.517 + 0.023 0.012 
232702_PM_at RAB GTPase activating protein 1-like 9910 RABGAP1L 0.266 + 0.006 0.033 
206103_PM_at 
ras-related C3 botulinum toxin substrate 3 (rho family, small 
GTP binding protein Rac3) 
5881 RAC3 0.456 + 0.001 0.005 
204916_PM_at receptor (G protein-coupled) activity modifying protein 1 10267 RAMP1 0.316 + 0.019 0.024 
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203749_PM_s_at retinoic acid receptor, alpha 5914 RARA 0.264 + 0.012 0.049 
223802_PM_s_at retinoblastoma binding protein 6 5930 RBBP6 0.268 + 0.047 0.009 
217622_PM_at rhomboid domain containing 3 25807 RHBDD3 0.268 + 0.026 0.009 
207383_PM_s_at rhomboid, veinlet-like 1 (Drosophila) 9028 RHBDL1 0.436 + 0.013 0.043 
1570253_PM_a_at Ras homolog enriched in brain like 1 121268 RHEBL1 0.567 + 0.014 0.036 
220483_PM_s_at ring finger protein 19A 25897 RNF19A 0.553 + 0.035 0.050 
210706_PM_s_at ring finger protein 24 11237 RNF24 0.360 + 0.037 0.049 
212191_PM_x_at ribosomal protein L13 6137 RPL13 0.383 + 0.026 0.025 
200022_PM_at ribosomal protein L18 6141 RPL18 0.387 + 0.035 0.035 
204632_PM_at ribosomal protein S6 kinase, 90kDa, polypeptide 4 8986 RPS6KA4 0.392 + 0.025 0.025 
203777_PM_s_at ribosomal protein S6 kinase, 70kDa, polypeptide 2 6199 RPS6KB2 0.338 + 0.011 0.022 
212647_PM_at related RAS viral (r-ras) oncogene homolog 6237 RRAS 0.323 + 0.029 0.009 
216831_PM_s_at 
runt-related transcription factor 1; translocated to, 1 (cyclin D-
related) 
862 RUNX1T1 0.348 + 0.002 0.001 
202426_PM_s_at retinoid X receptor, alpha 6256 RXRA 0.320 + 0.008 0.013 
201844_PM_s_at RING1 and YY1 binding protein 23429 RYBP 0.309 + 0.006 0.001 
230290_PM_at signal peptide, CUB domain, EGF-like 3 222663 SCUBE3 0.323 + 0.004 0.011 
221220_PM_s_at SCY1-like 2 (S. cerevisiae) 55681 SCYL2 0.544 + 0.029 0.028 
202062_PM_s_at sel-1 suppressor of lin-12-like (C. elegans) 6400 SEL1L 0.505 + 0.025 0.007 
202283_PM_at 
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, 
pigment epithelium derived factor), member 1 
5176 SERPINF1 0.357 + 0.007 0.016 
1569106_PM_s_at SET domain containing 5 55209 SETD5 0.495 + 0.033 0.020 
213742_PM_at splicing factor, arginine/serine-rich 11 9295 SFRS11 0.337 + 0.018 0.034 
205367_PM_at SH2B adaptor protein 2 10603 SH2B2 0.332 + 0.011 0.004 
231787_PM_at solute carrier family 25, member 27 9481 SLC25A27 0.751 + 0.001 0.021 
222529_PM_at solute carrier family 25, member 37 51312 SLC25A37 0.484 + 0.020 0.026 
1552295_PM_a_at solute carrier family 39 (zinc transporter), member 13 91252 SLC39A13 0.356 + 0.035 0.015 
216230_PM_x_at sphingomyelin phosphodiesterase 1, acid lysosomal 6609 SMPD1 0.423 + 0.036 0.042 
209877_PM_at synuclein, gamma (breast cancer-specific protein 1) 6623 SNCG 0.629 + 0.044 0.005 
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223865_PM_at SRY (sex determining region Y)-box 6 55553 SOX6 0.267 + 0.049 0.023 
222532_PM_at signal recognition particle receptor, B subunit 58477 SRPRB 0.680 + 0.022 0.015 
232322_PM_x_at StAR-related lipid transfer (START) domain containing 10 10809 STARD10 0.314 + 0.027 0.018 
230691_PM_at syntaxin 1B 112755 STX1B 0.983 + 0.048 0.042 
226037_PM_s_at 
TAF9B RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 31kDa 
51616 TAF9B 0.353 + 0.032 0.003 
1552541_PM_at T-cell activation RhoGTPase activating protein 117289 TAGAP 0.354 + 0.012 0.027 
204877_PM_s_at TAO kinase 2 9344 TAOK2 0.589 + 0.006 0.005 
1554701_PM_a_at TBC1 domain family, member 16 125058 TBC1D16 0.311 + 0.014 0.015 
229192_PM_s_at tubulin folding cofactor D 6904 TBCD 0.297 + 0.047 0.029 
201149_PM_s_at TIMP metallopeptidase inhibitor 3 7078 TIMP3 1.024 + 0.018 0.046 
1552293_PM_at transmembrane protein 196 256130 TMEM196 0.297 + 0.026 0.025 
224981_PM_at transmembrane protein 219 124446 TMEM219 0.305 + 0.032 0.008 
238831_PM_at transmembrane protein 33 55161 TMEM33 0.356 + 0.027 0.007 
1554077_PM_a_at transmembrane protein 53 79639 TMEM53 0.483 + 0.034 0.033 
227570_PM_at transmembrane protein 86A 144110 TMEM86A 0.265 + 0.008 0.031 
219423_PM_x_at tumor necrosis factor receptor superfamily, member 25 8718 TNFRSF25 0.295 + 0.001 0.000 
211841_PM_s_at tumor necrosis factor receptor superfamily, member 25 8718 TNFRSF25 0.409 + 0.011 0.004 
211282_PM_x_at tumor necrosis factor receptor superfamily, member 25 8718 TNFRSF25 0.788 + 0.035 0.023 
239288_PM_at TRAF2 and NCK interacting kinase 23043 TNIK 0.303 + 0.038 0.047 
210585_PM_s_at transportin 2 30000 TNPO2 0.510 + 0.038 0.042 
243834_PM_at trinucleotide repeat containing 6A 27327 TNRC6A 0.323 + 0.045 0.027 
228834_PM_at transducer of ERBB2, 1 10140 TOB1 0.793 + 0.030 0.031 
1554379_PM_a_at tumor protein p73 7161 TP73 0.277 + 0.010 0.006 
210372_PM_s_at tumor protein D52-like 1 7164 TPD52L1 0.541 + 0.009 0.022 
225870_PM_s_at trafficking protein particle complex 5 126003 TRAPPC5 0.302 + 0.012 0.007 
213884_PM_s_at tripartite motif-containing 3 10612 TRIM3 0.775 + 0.046 0.031 
222651_PM_s_at trichorhinophalangeal syndrome I 7227 TRPS1 0.353 + 0.001 0.001 
224852_PM_at tetratricopeptide repeat domain 17 55761 TTC17 0.340 + 0.006 0.008 
201009_PM_s_at thioredoxin interacting protein 10628 TXNIP 0.380 + 0.022 0.039 
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211177_PM_s_at thioredoxin reductase 2 10587 TXNRD2 0.443 + 0.020 0.034 
238587_PM_at ubiquitin associated and SH3 domain containing, B 84959 UBASH3B 0.310 + 0.010 0.016 
215544_PM_s_at U-box domain containing 5 22888 UBOX5 0.305 + 0.024 0.039 
224221_PM_s_at vav 3 guanine nucleotide exchange factor 10451 VAV3 0.285 + 0.002 0.000 
224608_PM_s_at vacuolar protein sorting 25 homolog (S. cerevisiae) 84313 VPS25 0.377 + 0.014 0.004 
223293_PM_at WD repeat domain 24 84219 WDR24 0.301 + 0.037 0.043 
224898_PM_at WD repeat domain 26 80232 WDR26 0.325 + 0.023 0.029 
1552811_PM_at 
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin 
domain containing 1 
117166 WFIKKN1 0.511 + 0.041 0.028 
203827_PM_at WD repeat domain, phosphoinositide interacting 1 55062 WIPI1 0.282 + 0.008 0.015 
1554821_PM_a_at zinc finger, BED-type containing 1 9189 ZBED1 0.395 + 0.003 0.013 
231908_PM_at zinc finger, DHHC-type containing 18 84243 ZDHHC18 0.288 + 0.008 0.008 
224858_PM_at zinc finger, DHHC-type containing 5 25921 ZDHHC5 0.423 + 0.014 0.028 
222407_PM_s_at zinc finger protein 106 homolog (mouse) 64397 ZFP106 0.775 + 0.010 0.039 
223388_PM_s_at zinc finger, FYVE domain containing 1 53349 ZFYVE1 0.311 + 0.016 0.041 
210291_PM_s_at zinc finger protein 174 7727 ZNF174 0.337 + 0.049 0.016 
219314_PM_s_at zinc finger protein 219 51222 ZNF219 0.373 + 0.004 0.005 
217185_PM_s_at zinc finger protein 259 /// zinc finger protein 259, pseudogene 442240 /// 8882 
ZNF259 /// 
ZNF259P 
0.410 + 0.023 0.013 
242684_PM_at zinc finger protein 425 155054 ZNF425 0.310 + 0.014 0.023 
242697_PM_at zinc finger protein 540 163255 ZNF540 0.267 + 0.033 0.032 
213367_PM_at zinc finger family member 783 155060 ZNF783 0.466 + 0.012 0.028 
235448_PM_at ZXD family zinc finger C 79364 ZXDC 0.306 + 0.001 0.002 
215706_PM_x_at zyxin 7791 ZYX 0.476 + 0.013 0.013 




Supplementary Table 8. Exercise Associated Gene Expression in the Putamen. All transcripts in the table are significant with p<0.05 for both paired and 
groupwise t-tests. All transcripts are identified by their Probe Set ID, Gene title, Entrez Gene ID, and Gene symbol. Transcript data is listed for the motor cortex 
(M), putamen (P), and hippocampus (H). For each transcript we calculated their average log ratio (ALR,the average expression change of the exercising monkeys 
minus the average expression change of the sedentary monkeys), the direction of the change, the p-value for the groupwise and paired t-tests, and if the transcript 
met the significance cutoff in each brain region. There are 265 transcripts differentially expressed by exercise in the putamen. 
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243067_PM_at --- --- --- -0.284 - 0.003 0.012 
1558444_PM_at --- --- --- -0.303 - 0.003 0.020 
233081_PM_at --- --- --- -0.264 - 0.004 0.020 
230868_PM_at --- --- --- -0.299 - 0.004 0.007 
244170_PM_at --- --- --- -0.359 - 0.005 0.017 
216172_PM_at --- --- --- -0.286 - 0.005 0.024 
1563295_PM_at --- --- --- -0.288 - 0.006 0.013 
235150_PM_at --- --- --- -0.374 - 0.007 0.028 
244270_PM_at --- --- --- -0.279 - 0.008 0.021 
231101_PM_at --- --- --- -0.308 - 0.010 0.040 
244711_PM_at --- --- --- -0.304 - 0.014 0.031 
236117_PM_at --- --- --- -0.311 - 0.017 0.003 
236388_PM_at --- --- --- -0.343 - 0.025 0.022 
1562106_PM_at --- --- --- -0.423 - 0.043 0.032 
234862_PM_at --- --- --- -0.274 - 0.048 0.017 
1554878_PM_a_at ATP-binding cassette, sub-family D (ALD), member 3 5825 ABCD3 -0.299 - 0.038 0.037 
217007_PM_s_at ADAM metallopeptidase domain 15 8751 ADAM15 -0.288 - 0.010 0.039 
219393_PM_s_at 
v-akt murine thymoma viral oncogene homolog 3 (protein 
kinase B, gamma) 
10000 AKT3 -0.263 - 0.009 0.045 
236034_PM_at angiopoietin 2 285 ANGPT2 -0.265 - 0.001 0.010 
201686_PM_x_at apoptosis inhibitor 5 8539 API5 -0.466 - 0.001 0.007 
214959_PM_s_at apoptosis inhibitor 5 8539 API5 -0.538 - 0.001 0.005 
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1566989_PM_at AT rich interactive domain 1B (SWI1-like) 57492 ARID1B -0.623 - 0.015 0.027 
1566990_PM_x_at AT rich interactive domain 1B (SWI1-like) 57492 ARID1B -0.352 - 0.030 0.009 
225709_PM_at ADP-ribosylation-like factor 6 interacting protein 6 151188 ARL6IP6 -0.263 - 0.030 0.015 
211076_PM_x_at Atrophin 1 1822 ATN1 -0.378 - 0.006 0.016 
219558_PM_at ATPase type 13A3 79572 ATP13A3 -0.445 - 0.030 0.023 
209186_PM_at ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 488 ATP2A2 -0.289 - 0.017 0.014 
1557759_PM_at ATP5S-like 55101 ATP5SL -0.306 - 0.012 0.033 
221484_PM_at 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 5 
9334 B4GALT5 -0.361 - 0.007 0.026 
225472_PM_at HLA-B associated transcript 4 7918 BAT4 -0.263 - 0.000 0.000 
213016_PM_at bobby sox homolog (Drosophila) 56987 BBX -0.288 - 0.020 0.043 
1553021_PM_s_at bicaudal D homolog 2 (Drosophila) 23299 BICD2 -0.356 - 0.021 0.030 
1555544_PM_a_at cell adhesion molecule 2 253559 CADM2 -0.326 - 0.000 0.003 
200935_PM_at calreticulin 811 CALR -0.394 - 0.018 0.047 
231729_PM_s_at calcyphosine 828 CAPS -0.330 - 0.014 0.048 
213055_PM_at CD47 molecule 961 CD47 -0.517 - 0.010 0.030 
204739_PM_at centromere protein C 1 1060 CENPC1 -0.292 - 0.009 0.014 
1557786_PM_s_at cysteine-rich hydrophobic domain 1 53344 CHIC1 -0.334 - 0.023 0.046 
207486_PM_x_at chimerin (chimaerin) 2 1124 CHN2 -0.264 - 0.015 0.010 
206736_PM_x_at cholinergic receptor, nicotinic, alpha 4 1137 CHRNA4 -0.273 - 0.006 0.010 
210866_PM_s_at CCR4-NOT transcription complex, subunit 4 4850 CNOT4 -0.417 - 0.015 0.032 
218975_PM_at collagen, type V, alpha 3 50509 COL5A3 -0.622 - 0.033 0.000 
222686_PM_s_at calcineurin-like phosphoesterase domain containing 1 55313 CPPED1 -0.376 - 0.038 0.050 
206994_PM_at cystatin S 1472 CST4 -0.341 - 0.004 0.035 
220611_PM_at disabled homolog 1 (Drosophila) 1600 DAB1 -0.612 - 0.001 0.004 
222678_PM_s_at 
DCN1, defective in cullin neddylation 1, domain containing 1 
(S. cerevisiae) 
54165 DCUN1D1 -0.419 - 0.003 0.007 
225442_PM_at discoidin domain receptor tyrosine kinase 2 4921 DDR2 -0.708 - 0.010 0.002 
202516_PM_s_at discs, large homolog 1 (Drosophila) 1739 DLG1 -0.344 - 0.004 0.007 
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235341_PM_at DnaJ (Hsp40) homolog, subfamily C, member 3 5611 DNAJC3 -0.276 - 0.033 0.046 
1560916_PM_a_at dpy-19-like 1 (C. elegans) 23333 DPY19L1 -0.414 - 0.008 0.015 
221835_PM_at deltex homolog 3 (Drosophila) 196403 DTX3 -0.393 - 0.017 0.035 
214793_PM_at dual specificity phosphatase 7 1849 DUSP7 -0.287 - 0.035 0.013 
204954_PM_s_at 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1B 
9149 DYRK1B -0.302 - 0.003 0.004 
226911_PM_at EGF-like, fibronectin type III and laminin G domains 133584 EGFLAM -0.270 - 0.003 0.014 
219436_PM_s_at endomucin 51705 EMCN -0.269 - 0.014 0.030 
226432_PM_at ethanolamine kinase 1 55500 ETNK1 -0.356 - 0.014 0.027 
205521_PM_at endo/exonuclease (5’-3’), endonuclease G-like 9941 EXOG -0.273 - 0.009 0.028 
208092_PM_s_at family with sequence similarity 49, member A 81553 FAM49A -0.393 - 0.033 0.032 
201787_PM_at fibulin 1 2192 FBLN1 -0.484 - 0.021 0.029 
1564383_PM_s_at FLJ35934 protein 400579 FLJ35934 -0.484 - 0.003 0.000 
215977_PM_x_at glycerol kinase 2710 GK -0.420 - 0.017 0.039 
216316_PM_x_at glycerol kinase /// glycerol kinase 3 pseudogene 2710 /// 2713 GK /// GK3P -0.357 - 0.006 0.022 
215966_PM_x_at glycerol kinase 3 pseudogene 2713 GK3P -0.738 - 0.007 0.030 
205184_PM_at guanine nucleotide binding protein (G protein), gamma 4 2786 GNG4 -0.298 - 0.010 0.042 
203631_PM_s_at G protein-coupled receptor, family C, group 5, member B 51704 GPRC5B -0.284 - 0.039 0.044 
220142_PM_at hyaluronan and proteoglycan link protein 2 60484 HAPLN2 -0.287 - 0.018 0.049 
231043_PM_at primary ciliary dyskinesia protein 1 200373 hCG_17324 -0.793 - 0.001 0.004 
225116_PM_at homeodomain interacting protein kinase 2 28996 HIPK2 -1.031 - 0.003 0.025 
224016_PM_at homeodomain interacting protein kinase 2 28996 HIPK2 -0.316 - 0.049 0.033 
207764_PM_s_at homeodomain interacting protein kinase 3 10114 HIPK3 -0.335 - 0.004 0.024 
205967_PM_at histone cluster 1, H4c 8364 HIST1H4C -0.361 - 0.018 0.010 
1563532_PM_at hemicentin 2 256158 HMCN2 -0.300 - 0.016 0.018 
209098_PM_s_at jagged 1 (Alagille syndrome) 182 JAG1 -0.470 - 0.031 0.044 
203849_PM_s_at kinesin family member 1A 547 KIF1A -0.336 - 0.035 0.037 
225140_PM_at Kruppel-like factor 3 (basic) 51274 KLF3 -0.289 - 0.015 0.013 
223888_PM_s_at leucyl-tRNA synthetase 51520 LARS -0.280 - 0.028 0.049 
235036_PM_at Lix1 homolog (mouse)-like 128077 LIX1L -0.273 - 0.027 0.040 
239598_PM_s_at lysophosphatidylcholine acyltransferase 2 54947 LPCAT2 -0.399 - 0.000 0.004 
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212272_PM_at lipin 1 23175 LPIN1 -0.354 - 0.005 0.034 
207702_PM_s_at 
membrane associated guanylate kinase, WW and PDZ 
domain containing 2 
9863 MAGI2 -0.314 - 0.016 0.011 
203841_PM_x_at microtubule-associated protein, RP/EB family, member 3 22924 MAPRE3 -0.316 - 0.005 0.026 
205018_PM_s_at muscleblind-like 2 (Drosophila) 10150 MBNL2 -0.292 - 0.029 0.017 
222590_PM_s_at nemo-like kinase 51701 NLK -0.319 - 0.014 0.017 
1552932_PM_at NLR family, pyrin domain containing 6 171389 NLRP6 -0.272 - 0.003 0.012 
203964_PM_at N-myc (and STAT) interactor 9111 NMI -0.321 - 0.012 0.007 
226061_PM_s_at Nudix (nucleoside diphosphate linked moiety X)-type motif 3 11165 NUDT3 -0.266 - 0.047 0.042 
201282_PM_at oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) 4967 OGDH -0.267 - 0.036 0.045 
200815_PM_s_at 
platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 
(45kDa) 
5048 PAFAH1B1 -0.307 - 0.023 0.020 
1559052_PM_s_at p21 protein (Cdc42/Rac)-activated kinase 2 5062 PAK2 -0.489 - 0.002 0.000 
208875_PM_s_at p21 protein (Cdc42/Rac)-activated kinase 2 5062 PAK2 -0.287 - 0.005 0.009 
211502_PM_s_at PFTAIRE protein kinase 1 5218 PFTK1 -0.473 - 0.008 0.001 
205702_PM_at putative homeodomain transcription factor 1 10745 PHTF1 -0.343 - 0.004 0.019 
1568949_PM_at phosphatidylinositol transfer protein, cytoplasmic 1 26207 PITPNC1 -0.331 - 0.001 0.011 
235958_PM_at phospholipase A2, group IVF 255189 PLA2G4F -0.297 - 0.006 0.018 
206174_PM_s_at protein phosphatase 6, catalytic subunit 5537 PPP6C -0.284 - 0.010 0.016 
214545_PM_s_at proline synthetase co-transcribed homolog (bacterial) 11212 PROSC -0.511 - 0.021 0.045 
209385_PM_s_at proline synthetase co-transcribed homolog (bacterial) 11212 PROSC -0.422 - 0.038 0.019 
209599_PM_s_at prune homolog (Drosophila) 58497 PRUNE -0.325 - 0.043 0.042 
211711_PM_s_at phosphatase and tensin homolog 5728 PTEN -0.273 - 0.005 0.014 
208466_PM_at RAB3D, member RAS oncogene family 9545 RAB3D -0.389 - 0.008 0.013 
201156_PM_s_at RAB5C, member RAS oncogene family 5878 RAB5C -0.354 - 0.001 0.013 
212332_PM_at retinoblastoma-like 2 (p130) 5934 RBL2 -0.288 - 0.017 0.028 
203169_PM_at RGP1 retrograde golgi transport homolog (S. cerevisiae) 9827 RGP1 -0.440 - 0.016 0.004 
213430_PM_at RUN and FYVE domain containing 3 22902 RUFY3 -0.266 - 0.017 0.005 
1555819_PM_s_at sterile alpha motif domain containing 14 201191 SAMD14 -0.270 - 0.011 0.050 
233242_PM_at SCAN domain containing 2 pseudogene 54581 SCAND2 -0.271 - 0.017 0.044 
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201093_PM_x_at 
succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) 
6389 SDHA 0.300 - 0.008 0.047 
37462_PM_i_at splicing factor 3a, subunit 2, 66kDa 8175 SF3A2 -0.268 - 0.018 0.028 
214096_PM_s_at serine hydroxymethyltransferase 2 (mitochondrial) 6472 SHMT2 -0.267 - 0.009 0.033 
239435_PM_x_at shroom family member 1 134549 SHROOM1 -0.310 - 0.008 0.037 
218237_PM_s_at solute carrier family 38, member 1 81539 SLC38A1 -0.279 - 0.007 0.004 
210739_PM_x_at 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 
8671 SLC4A4 -0.404 - 0.003 0.007 
211494_PM_s_at 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 
8671 SLC4A4 -0.608 - 0.024 0.023 
34868_PM_at 
Smg-5 homolog, nonsense mediated mRNA decay factor (C. 
elegans) 
23381 SMG5 -0.328 - 0.003 0.007 
212777_PM_at son of sevenless homolog 1 (Drosophila) 6654 SOS1 -0.299 - 0.008 0.007 
212466_PM_at 174epari-related, EVH1 domain containing 2 200734 SPRED2 -0.368 - 0.008 0.030 
217903_PM_at striatin, calmodulin binding protein 4 29888 STRN4 -0.275 - 0.030 0.008 
1555052_PM_a_at synaptotagmin IX 143425 SYT9 -0.496 - 0.009 0.013 
244615_PM_x_at threonyl-tRNA synthetase-like 2 123283 TARSL2 -0.274 - 0.011 0.035 
1555189_PM_a_at tyrosine aminotransferase 6898 TAT -0.272 - 0.009 0.018 
218466_PM_at TBC1 domain family, member 17 79735 TBC1D17 -0.307 - 0.005 0.024 
203167_PM_at TIMP metallopeptidase inhibitor 2 7077 TIMP2 -0.567 - 0.026 0.038 
201001_PM_s_at 
TMEM189-UBE2V1 readthrough transcript /// ubiquitin-
conjugating enzyme E2 variant 1 




-0.380 - 0.007 0.006 
222736_PM_s_at transmembrane protein 38B 55151 TMEM38B -0.283 - 0.036 0.046 
226083_PM_at transmembrane protein 70 54968 TMEM70 -0.271 - 0.007 0.001 
216695_PM_s_at 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 
8658 TNKS -0.359 - 0.018 0.027 
206817_PM_x_at trinucleotide repeat containing 4 11189 TNRC4 -0.375 - 0.005 0.013 
214332_PM_s_at Ts translation elongation factor, mitochondrial 10102 TSFM -0.326 - 0.015 0.045 
223283_PM_s_at teashirt zinc finger homeobox 1 10194 TSHZ1 -0.404 - 0.001 0.007 
1564386_PM_at thioredoxin domain containing 8 (spermatozoa) 255220 TXNDC8 -0.343 - 0.039 0.025 
 175 
218382_PM_s_at U2 small nuclear RNA auxiliary factor 2 11338 U2AF2 -0.316 - 0.004 0.040 
205137_PM_x_at Usher syndrome 1C (autosomal recessive, severe) 10083 USH1C -0.383 - 0.001 0.006 
220769_PM_s_at WD repeat domain 78 79819 WDR78 -0.312 - 0.002 0.011 
1564053_PM_a_at YTH domain family, member 3 253943 YTHDF3 -0.322 - 0.008 0.025 
1554239_PM_s_at zinc binding alcohol dehydrogenase domain containing 2 284273 ZADH2 -0.270 - 0.009 0.025 
208446_PM_s_at zinc finger, FYVE domain containing 9 9372 ZFYVE9 -0.310 - 0.009 0.003 
1554159_PM_a_at zinc finger, MYND domain containing 11 10771 ZMYND11 -0.263 - 0.024 0.023 
1554958_PM_at zinc finger protein 641 121274 ZNF641 -0.503 - 0.019 0.027 
239080_PM_at --- --- --- 0.264 + 0.000 0.000 
235875_PM_at --- --- --- 0.379 + 0.000 0.002 
226345_PM_at --- --- --- 0.265 + 0.003 0.006 
243992_PM_at --- --- --- 0.350 + 0.006 0.044 
244184_PM_at --- --- --- 0.358 + 0.008 0.001 
208306_PM_x_at --- 730415 --- 0.608 + 0.010 0.015 
244633_PM_at --- --- --- 0.317 + 0.013 0.032 
228528_PM_at --- --- --- 0.376 + 0.016 0.001 
231513_PM_at --- --- --- 0.976 + 0.018 0.004 
214353_PM_at --- --- --- 0.306 + 0.018 0.050 
1561155_PM_at --- --- --- 0.336 + 0.022 0.018 
233005_PM_at --- --- --- 0.333 + 0.028 0.015 
243006_PM_at --- --- --- 0.308 + 0.029 0.026 
232834_PM_at --- --- --- 0.354 + 0.032 0.030 
240655_PM_at --- --- --- 0.446 + 0.032 0.027 
243666_PM_at --- --- --- 0.267 + 0.034 0.001 
239277_PM_at --- --- --- 0.307 + 0.036 0.018 
235657_PM_at --- --- --- 0.392 + 0.044 0.011 
228297_PM_at --- --- --- 0.795 + 0.044 0.041 
242932_PM_at --- --- --- 0.304 + 0.047 0.028 
226394_PM_at membrane-associated ring finger (C3HC4) 5 54708 5-Mar 0.327 + 0.008 0.007 
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202144_PM_s_at adenylosuccinate lyase 158 ADSL 0.455 + 0.044 0.049 
210250_PM_x_at adenylosuccinate lyase 158 ADSL 0.357 + 0.049 0.049 
238135_PM_at Angiotensin II receptor-associated protein 57085 AGTRAP 0.378 + 0.008 0.017 
229526_PM_at aquaporin 11 282679 AQP11 0.397 + 0.012 0.033 
225552_PM_x_at aurora kinase A interacting protein 1 54998 AURKAIP1 0.273 + 0.045 0.046 
229720_PM_at BCL2-associated athanogene 573 BAG1 0.275 + 0.002 0.007 
202201_PM_at biliverdin reductase B (flavin reductase (NADPH)) 645 BLVRB 0.263 + 0.044 0.050 
1555773_PM_at bactericidal/permeability-increasing protein-like 2 254240 BPIL2 0.392 + 0.004 0.017 
231960_PM_at bromodomain and WD repeat domain containing 1 54014 BRWD1 0.287 + 0.007 0.041 
1555923_PM_a_at chromosome 10 open reading frame 114 399726 C10orf114 0.267 + 0.035 0.032 
230259_PM_at chromosome 10 open reading frame 125 282969 C10orf125 0.314 + 0.044 0.049 
221599_PM_at chromosome 11 open reading frame 67 28971 C11orf67 0.309 + 0.003 0.019 
228721_PM_at chromosome 3 open reading frame 41 26172 C3orf41 0.305 + 0.038 0.003 
219124_PM_at chromosome 8 open reading frame 41 80185 C8orf41 0.322 + 0.003 0.011 
209682_PM_at 
Cas-Br-M (murine) ecotropic retroviral transforming sequence 
b 
868 CBLB 0.306 + 0.034 0.043 
205899_PM_at cyclin A1 8900 CCNA1 0.276 + 0.019 0.011 
228081_PM_at cyclin G2 901 CCNG2 0.301 + 0.016 0.031 
203493_PM_s_at centrosomal protein 57kDa 9702 CEP57 0.278 + 0.008 0.046 
211862_PM_x_at CASP8 and FADD-like apoptosis regulator 8837 CFLAR 0.390 + 0.002 0.018 
226702_PM_at cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 129607 CMPK2 0.380 + 0.005 0.002 
1554377_PM_a_at contactin associated protein-like 4 85445 CNTNAP4 0.347 + 0.015 0.017 
1554241_PM_at coagulation factor C homolog, cochlin (Limulus polyphemus) 1690 COCH 0.393 + 0.005 0.020 
208146_PM_s_at carboxypeptidase, vitellogenic-like 54504 CPVL 0.265 + 0.024 0.002 
240228_PM_at CUB and Sushi multiple domains 3 114788 CSMD3 0.439 + 0.006 0.002 
1554796_PM_at dipeptidyl-peptidase 6 1804 DPP6 0.350 + 0.000 0.001 
211625_PM_s_at dopamine receptor D3 1814 DRD3 0.314 + 0.036 0.001 
206032_PM_at desmocollin 3 1825 DSC3 0.286 + 0.025 0.028 
236649_PM_at DTW domain containing 1 56986 DTWD1 0.273 + 0.027 0.039 
201303_PM_at eukaryotic translation initiation factor 4A, isoform 3 9775 EIF4A3 0.289 + 0.002 0.004 
204824_PM_at endonuclease G 2021 ENDOG 0.274 + 0.001 0.016 
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231472_PM_at F-box protein 15 201456 FBXO15 0.770 + 0.046 0.036 
1570183_PM_at F-box protein 34 55030 FBXO34 0.503 + 0.009 0.008 
227298_PM_at hypothetical gene supported by AK095117 401264 FLJ37798 0.312 + 0.030 0.047 
233919_PM_s_at hyaluronan binding protein 4 22927 HABP4 0.272 + 0.023 0.028 
212964_PM_at hypermethylated in cancer 2 23119 HIC2 0.309 + 0.044 0.019 
215193_PM_x_at 
major histocompatibility complex, class II, DR beta 1 /// major 
histocompatibility complex, class II, DR beta 3 /// major 
histocompatibility complex, class II, DR beta 4 /// major 
histocompatibility complex, class II, DR beta 5 /// similar to 
HLA class II histocompatibility antigen, DR-W53 beta chain /// 




3123 /// 3125 /// 





0.912 + 0.011 0.041 
209312_PM_x_at 
major histocompatibility complex, class II, DR beta 1 /// major 
histocompatibility complex, class II, DR beta 4 
3123 /// 3126 
HLA-DRB1 /// 
HLA-DRB4 
1.037 + 0.005 0.023 
204670_PM_x_at 
major histocompatibility complex, class II, DR beta 1 /// major 
histocompatibility complex, class II, DR beta 4 
3123 /// 3126 
HLA-DRB1 /// 
HLA-DRB4 
0.418 + 0.041 0.041 
217362_PM_x_at 
major histocompatibility complex, class II, DR beta 6 
(pseudogene) 
3128 HLA-DRB6 0.381 + 0.002 0.002 
203960_PM_s_at heat shock protein family B (small), member 11 51668 HSPB11 0.530 + 0.009 0.028 
215691_PM_x_at heat shock protein family B (small), member 11 51668 HSPB11 0.303 + 0.019 0.038 
231183_PM_s_at Jagged 1 (Alagille syndrome) 182 JAG1 1.363 + 0.024 0.039 
215527_PM_at 
KH domain containing, RNA binding, signal transduction 
associated 2 
202559 KHDRBS2 0.322 + 0.031 0.048 
214961_PM_at KIAA0774 23281 KIAA0774 0.334 + 0.019 0.048 
233916_PM_at KIAA1486 57624 KIAA1486 0.276 + 0.050 0.046 
221841_PM_s_at Kruppel-like factor 4 (gut) 9314 KLF4 0.278 + 0.026 0.041 
202057_PM_at karyopherin alpha 1 (importin alpha 5) 3836 KPNA1 0.294 + 0.007 0.004 
206309_PM_at leukocyte cell derived chemotaxin 1 11061 LECT1 0.304 + 0.005 0.010 
229930_PM_at similar to hCG1811002 100134361 LOC100134361 0.603 + 0.010 0.026 
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238473_PM_at hypothetical LOC100216545 100216545 LOC100216545 0.314 + 0.028 0.025 
1559310_PM_at hypothetical protein LOC100292408 100292408 LOC100292408 0.475 + 0.018 0.046 
238207_PM_at similar to CG32736-PA 440957 LOC440957 0.333 + 0.009 0.004 
1569872_PM_a_at Hypothetical protein LOC650392 650392 LOC650392 0.297 + 0.011 0.021 
238534_PM_at Leucine rich repeat (in FLII) interacting protein 1 9208 LRRFIP1 0.377 + 0.025 0.013 
209580_PM_s_at methyl-CpG binding domain protein 4 8930 MBD4 0.277 + 0.026 0.048 
215663_PM_at muscleblind-like (Drosophila) 4154 MBNL1 0.279 + 0.007 0.006 
209087_PM_x_at melanoma cell adhesion molecule 4162 MCAM 0.389 + 0.006 0.004 
207447_PM_s_at 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme C (putative) 
25834 MGAT4C 0.346 + 0.029 0.040 
224385_PM_s_at Mov10l1, Moloney leukemia virus 10-like 1, homolog (mouse) 54456 MOV10L1 0.612 + 0.009 0.013 
215731_PM_s_at M-phase phosphoprotein 9 10198 MPHOSPH9 0.291 + 0.003 0.000 
222555_PM_s_at mitochondrial ribosomal protein L44 65080 MRPL44 0.272 + 0.010 0.033 
224873_PM_s_at mitochondrial ribosomal protein S25 64432 MRPS25 0.273 + 0.041 0.012 
225240_PM_s_at musashi homolog 2 (Drosophila) 124540 MSI2 0.309 + 0.010 0.022 
1554126_PM_at methionine sulfoxide reductase B3 253827 MSRB3 -0.338 + 0.008 0.023 
222794_PM_x_at mitochondrial poly(A) polymerase 55149 MTPAP 0.278 + 0.008 0.009 
227992_PM_s_at non-protein coding RNA 85 147650 NCRNA00085 0.287 + 0.046 0.042 
214657_PM_s_at 
nuclear paraspeckle assembly transcript 1 (non-protein 
coding) 
283131 NEAT1 0.285 + 0.044 0.045 
201467_PM_s_at NAD(P)H dehydrogenase, quinone 1 1728 NQO1 0.318 + 0.037 0.007 
212775_PM_at obscurin-like 1 23363 OBSL1 0.378 + 0.029 0.036 
219245_PM_s_at 
2-oxoglutarate and iron-dependent oxygenase domain 
containing 2 
79676 OGFOD2 0.297 + 0.027 0.031 
218736_PM_s_at palmdelphin 54873 PALMD 0.512 + 0.002 0.006 
230109_PM_at phosphodiesterase 7B 27115 PDE7B 0.276 + 0.002 0.030 
225830_PM_at PDZ domain containing 8 118987 PDZD8 0.427 + 0.029 0.023 
238131_PM_at polyhomeotic homolog 2 (Drosophila) 1912 PHC2 0.371 + 0.023 0.016 
229385_PM_s_at placenta-specific 2 (non-protein coding) 257000 PLAC2 0.278 + 0.045 0.037 
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208928_PM_at P450 (cytochrome) oxidoreductase 5447 POR 0.285 + 0.017 0.026 
228217_PM_s_at proteasome (prosome, macropain) assembly chaperone 4 389362 PSMG4 0.594 + 0.001 0.011 
223471_PM_at RAB3A interacting protein (rabin3) 117177 RAB3IP 0.442 + 0.011 0.013 
218526_PM_s_at RAN guanine nucleotide release factor 29098 RANGRF 0.304 + 0.015 0.011 
203696_PM_s_at replication factor C (activator 1) 2, 40kDa 5982 RFC2 0.342 + 0.010 0.028 
213566_PM_at ribonuclease, Rnase A family, k6 6039 RNASE6 0.465 + 0.008 0.030 
226548_PM_at SH3-binding domain kinase 1 388228 SBK1 0.282 + 0.043 0.032 
232983_PM_s_at secretion regulating guanine nucleotide exchange factor 26297 SERGEF 0.268 + 0.003 0.016 
211429_PM_s_at 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
5265 SERPINA1 0.375 + 0.048 0.021 
230660_PM_at SERTA domain containing 4 56256 SERTAD4 0.343 + 0.001 0.002 
200685_PM_at splicing factor, arginine/serine-rich 11 9295 SFRS11 0.265 + 0.006 0.019 
204270_PM_at v-ski sarcoma viral oncogene homolog (avian) 6497 SKI 0.392 + 0.006 0.016 
205317_PM_s_at solute carrier family 15 (H+/peptide transporter), member 2 6565 SLC15A2 0.442 + 0.032 0.033 
223605_PM_at solute carrier family 25 (mitochondrial carrier), member 18 83733 SLC25A18 0.402 + 0.000 0.005 
217289_PM_s_at 
solute carrier family 37 (glucose-6-phosphate transporter), 
member 4 
2542 SLC37A4 0.410 + 0.002 0.000 
226264_PM_at sushi domain containing 1 64420 SUSD1 0.271 + 0.029 0.004 
214348_PM_at tachykinin receptor 2 6865 TACR2 0.272 + 0.007 0.011 
213209_PM_at 
TAF6-like RNA polymerase II, p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa 
10629 TAF6L 0.402 + 0.006 0.004 
230236_PM_at testis development related protein 1 732253 TDRG1 0.396 + 0.010 0.031 
228906_PM_at tet oncogene 1 80312 TET1 0.356 + 0.017 0.038 
1554379_PM_a_at tumor protein p73 7161 TP73 0.283 + 0.007 0.018 
213748_PM_at tripartite motif-containing 66 9866 TRIM66 0.308 + 0.023 0.011 
211701_PM_s_at trophinin 7216 TRO 0.277 + 0.032 0.001 
213679_PM_at tetratricopeptide repeat domain 30A 92104 TTC30A 0.662 + 0.012 0.020 
244293_PM_at ubiquinol-cytochrome c reductase binding protein 7381 UQCRB 0.297 + 0.022 0.028 
224608_PM_s_at vacuolar protein sorting 25 homolog (S. cerevisiae) 84313 VPS25 0.277 + 0.001 0.005 
236635_PM_at zinc finger protein 667 63934 ZNF667 0.418 + 0.002 0.009 
1553172_PM_at zinc finger protein 777 27153 ZNF777 0.378 + 0.003 0.012 
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244180_PM_at zinc finger protein 793 390927 ZNF793 0.320 + 0.019 0.027 
226764_PM_at zinc finger protein 827 152485 ZNF827 0.407 + 0.001 0.003 





Supplementary Table 9. Exercise Associated Gene Expression in the Hippocampus. All transcripts in the table are significant with p<0.05 for both paired 
and groupwise t-tests. All transcripts are identified by their Probe Set ID, Gene title, Entrez Gene ID, and Gene symbol. Transcript data is listed for the motor 
cortex (M), putamen (P), and hippocampus (H). For each transcript we calculated their average log ratio (ALR, the average expression change of the exercising 
monkeys minus the sedentary monkeys), the direction of the change, the p-value for the groupwise and paired t-tests, and if the transcript met the significance 
cutoff in each brain region. There are 5508 transcripts differentially expressed by exercise in the hippocampus 
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229803_PM_s_at --- 84289 --- -0.975 - 1.60E-04 9.63E-04 
217211_PM_at --- 55031 --- -0.311 - 4.37E-04 8.71E-03 
1566524_PM_a_at --- 6303 --- -0.299 - 4.85E-04 1.79E-03 
1560926_PM_at --- 140885 --- -0.283 - 1.04E-03 6.44E-03 
239155_PM_at --- --- --- -0.410 - 1.14E-03 1.44E-02 
240482_PM_at --- 5930 --- -0.276 - 1.24E-03 1.47E-03 
1553498_PM_at --- 10658 --- -0.270 - 2.24E-03 1.91E-03 
242846_PM_at --- 9295 --- -0.324 - 2.68E-03 1.06E-02 
238495_PM_at --- 2067 --- -0.594 - 3.29E-03 4.34E-03 
1556432_PM_at --- 120 --- -0.327 - 4.24E-03 1.22E-02 
242403_PM_at --- --- --- -0.378 - 4.31E-03 3.92E-03 
244306_PM_at --- --- --- -0.506 - 4.37E-03 3.14E-02 
1562473_PM_at --- 9656 --- -1.081 - 4.65E-03 2.30E-03 
240216_PM_at --- --- --- -1.146 - 4.83E-03 9.17E-03 
237413_PM_at --- 8897 --- -0.621 - 4.83E-03 2.45E-02 
239082_PM_at --- --- --- -0.323 - 5.11E-03 4.03E-02 
241216_PM_at --- --- --- -0.316 - 5.61E-03 2.98E-02 
229244_PM_at --- 4297 --- -0.765 - 5.64E-03 1.92E-02 
235381_PM_at --- 65258 --- -0.481 - 5.78E-03 1.07E-02 
241929_PM_at --- --- --- -0.279 - 6.09E-03 6.10E-03 
243101_PM_x_at --- --- --- -0.279 - 6.38E-03 5.77E-03 
237964_PM_at --- --- --- -0.273 - 6.89E-03 3.12E-02 
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233626_PM_at --- 100129250 --- -0.328 - 7.34E-03 8.03E-03 
229297_PM_at --- 10466 --- -1.624 - 7.35E-03 2.77E-02 
242850_PM_at --- --- --- -0.346 - 7.91E-03 1.19E-02 
244678_PM_at --- --- --- -0.286 - 8.37E-03 4.16E-02 
236412_PM_at --- 3092 --- -0.266 - 8.92E-03 2.07E-03 
215345_PM_x_at --- 79776 --- -0.269 - 8.97E-03 9.17E-04 
214807_PM_at --- 51188 --- -0.398 - 9.23E-03 3.24E-02 
239742_PM_at --- 100294358 --- -1.862 - 9.63E-03 1.32E-02 
239758_PM_at --- 8239 --- -0.269 - 9.73E-03 2.05E-02 
229434_PM_at --- 10672 --- -1.830 - 1.04E-02 2.24E-02 
1562409_PM_s_at --- 7799 --- -0.288 - 1.20E-02 1.93E-02 
211973_PM_at --- 7803 --- -1.404 - 1.21E-02 2.07E-02 
244170_PM_at --- --- --- -2.294 - 1.24E-02 3.48E-02 
244358_PM_at --- --- --- -0.470 - 1.28E-02 4.98E-02 
233800_PM_at --- 647589 --- -0.834 - 1.29E-02 3.73E-02 
232333_PM_at --- 7707 --- -0.448 - 1.36E-02 3.95E-03 
243249_PM_at --- --- --- -0.274 - 1.45E-02 4.81E-02 
234151_PM_at --- --- --- -0.632 - 1.56E-02 1.54E-02 
231259_PM_s_at --- --- --- -0.514 - 1.57E-02 4.09E-02 
215287_PM_at --- 29967 --- -1.132 - 1.65E-02 1.67E-02 
1561639_PM_at --- 2274 --- -0.400 - 1.72E-02 4.73E-02 
244194_PM_at --- --- --- -0.341 - 1.76E-02 2.10E-02 
242768_PM_at --- --- --- -0.273 - 1.77E-02 6.64E-03 
232058_PM_at --- --- --- -0.283 - 1.97E-02 4.79E-02 
239095_PM_at --- --- --- -0.843 - 2.00E-02 1.28E-02 
227121_PM_at --- 8629 --- -1.068 - 2.81E-02 3.55E-02 
243665_PM_s_at --- 91862 --- -0.779 - 3.00E-02 1.81E-02 
236636_PM_at --- --- --- -0.371 - 3.12E-02 4.66E-02 
215528_PM_at --- 79862 --- -0.294 - 3.24E-02 1.40E-02 
212608_PM_s_at --- 27238 --- -1.408 - 3.36E-02 4.14E-02 
243394_PM_at --- --- --- -0.291 - 3.41E-02 4.23E-02 
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1558019_PM_at --- 5692 --- -0.279 - 3.69E-02 3.71E-02 
229606_PM_at --- 90025 --- -1.012 - 3.88E-02 4.16E-02 
217637_PM_at --- 222068 --- -1.202 - 4.06E-02 4.65E-02 
213048_PM_s_at --- 2892 --- -2.641 - 4.29E-02 4.86E-02 
228218_PM_at --- 54495 --- -0.578 - 4.78E-02 2.08E-02 
240157_PM_at --- 730631 --- -0.285 - 4.78E-02 7.96E-03 
213655_PM_at --- 5934 --- -1.591 - 4.85E-02 4.26E-02 
1555526_PM_a_at septin 6 4154 3-Mar -1.129 - 1.68E-03 2.22E-02 
200778_PM_s_at septin 2 8573 3-Mar -0.676 - 1.12E-02 4.12E-02 
1553422_PM_s_at ataxin 2-binding protein 1 55197 A2BP1 -0.606 - 1.08E-03 9.17E-03 
221217_PM_s_at ataxin 2-binding protein 1 8851 A2BP1 -1.398 - 9.97E-03 1.03E-02 




26025 /// 5098 /// 
56097 /// 56098 
/// 56099 /// 
56100 /// 56101 
/// 56102 /// 
56103 /// 56104 
/// 56105 /// 
56106 /// 56107 
/// 56108 /// 
56109 /// 56110 
/// 56111 /// 
56112 /// 56113 
/// 56114 /// 8641 
/// 9708 
AASDHPPT -2.342 - 6.49E-03 2.63E-02 
210100_PM_s_at ATP-binding cassette, sub-family A (ABC1), member 2 84899 ABCA2 -2.617 - 7.09E-03 1.90E-02 
1554878_PM_a_at ATP-binding cassette, sub-family D (ALD), member 3 3895 ABCD3 -1.408 - 2.38E-04 3.90E-03 
228123_PM_s_at abhydrolase domain containing 12 5814 ABHD12 -1.934 - 2.91E-02 4.95E-02 
87100_PM_at abhydrolase domain containing 2 54455 ABHD2 -0.281 - 8.07E-03 6.89E-03 
221679_PM_s_at abhydrolase domain containing 6 5453 ABHD6 -1.504 - 2.17E-02 4.65E-02 
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211793_PM_s_at abl-interactor 2 284161 ABI2 -0.948 - 3.35E-03 5.27E-03 
209856_PM_x_at abl-interactor 2 84991 ABI2 -0.659 - 1.30E-02 2.24E-02 
214671_PM_s_at active BCR-related gene 55255 ABR -0.327 - 2.07E-02 1.23E-02 
226442_PM_at ankyrin repeat and BTB (POZ) domain containing 1 6431 ABTB1 -0.361 - 5.80E-03 8.01E-03 
1552472_PM_a_at ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 10044 ACAP2 -0.610 - 2.71E-02 2.98E-02 
225529_PM_at ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 157773 ACAP3 -0.618 - 2.36E-02 3.10E-02 
202323_PM_s_at acyl-Coenzyme A binding domain containing 3 54812 ACBD3 -0.632 - 1.41E-03 1.88E-02 
210337_PM_s_at ATP citrate lyase 54536 ACLY -1.503 - 3.60E-02 4.04E-02 
215728_PM_s_at acyl-CoA thioesterase 7 55006 ACOT7 -1.824 - 3.60E-02 3.90E-02 
200801_PM_x_at actin, beta 51754 ACTB -0.407 - 1.94E-02 4.34E-02 
208637_PM_x_at actinin, alpha 1 9927 ACTN1 -1.603 - 2.57E-02 4.30E-02 
200720_PM_s_at 
ARP1 actin-related protein 1 homolog A, centractin alpha 
(yeast) 
782 ACTR1A -1.435 - 6.96E-04 1.89E-03 
1558015_PM_s_at ARP2 actin-related protein 2 homolog (yeast) 7388 ACTR2 -3.485 - 2.47E-04 6.08E-03 
200727_PM_s_at ARP2 actin-related protein 2 homolog (yeast) 5788 ACTR2 -2.827 - 5.05E-04 8.79E-03 
1554390_PM_s_at ARP2 actin-related protein 2 homolog (yeast) 9948 ACTR2 -2.711 - 1.04E-03 1.62E-02 
208223_PM_s_at activin A receptor, type IB 4839 ACVR1B -1.261 - 4.40E-03 8.66E-03 
220028_PM_at activin A receptor, type IIB 11334 ACVR2B -0.536 - 2.53E-03 5.24E-03 
207880_PM_at ADAM metallopeptidase domain 11 4750 ADAM11 -0.617 - 1.68E-02 2.91E-02 
217007_PM_s_at ADAM metallopeptidase domain 15 51527 ADAM15 -0.419 - 2.39E-02 2.61E-02 
206046_PM_at ADAM metallopeptidase domain 23 51747 ADAM23 -0.812 - 1.06E-02 1.49E-02 
1554393_PM_a_at arginine decarboxylase 9528 ADC -1.186 - 1.09E-02 2.21E-02 
214726_PM_x_at 184eparin184 1 (alpha) 59342 ADD1 -0.636 - 8.02E-04 8.96E-03 
205882_PM_x_at 184eparin184 3 (gamma) 81552 ADD3 -1.759 - 2.58E-03 1.31E-02 
201752_PM_s_at 184eparin184 3 (gamma) 7171 ADD3 -1.561 - 4.29E-03 1.61E-02 
201753_PM_s_at 184eparin184 3 (gamma) 5151 ADD3 -1.028 - 1.42E-02 3.51E-02 
216220_PM_s_at adenosine A1 receptor 51028 ADORA1 -0.326 - 3.11E-02 1.76E-02 
201401_PM_s_at adrenergic, beta, receptor kinase 1 9104 ADRBK1 -1.429 - 1.39E-02 3.24E-02 
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228998_PM_at adenylosuccinate lyase /// trinucleotide repeat containing 6B 25925 
ADSL /// 
TNRC6B 
-0.358 - 1.30E-02 4.92E-02 
217729_PM_s_at amino-terminal enhancer of split 7046 AES -0.870 - 1.55E-02 2.48E-02 
1555436_PM_a_at AF4/FMR2 family, member 4 5211 AFF4 -0.359 - 1.24E-02 4.16E-02 
217939_PM_s_at aftiphilin 79813 AFTPH -1.519 - 1.97E-02 4.69E-02 
215080_PM_s_at 
ArfGAP with GTPase domain, ankyrin repeat and PH domain 
2 
79870 AGAP2 -0.517 - 3.46E-02 2.94E-02 
231299_PM_at 
ArfGAP with GTPase domain, ankyrin repeat and PH domain 
3 
10150 AGAP3 -3.028 - 3.17E-03 1.11E-02 
231857_PM_s_at ATP/GTP binding protein-like 5 84945 AGBL5 -0.489 - 3.78E-03 1.75E-03 
213926_PM_s_at ArfGAP with FG repeats 1 3858 AGFG1 -0.328 - 9.38E-03 9.77E-03 
32836_PM_at 
1-acylglycerol-3-phosphate O-acyltransferase 1 
(lysophosphatidic acid acyltransferase, alpha) 
758 AGPAT1 -1.424 - 2.68E-02 4.09E-02 
224282_PM_s_at 1-acylglycerol-3-phosphate O-acyltransferase 3 84306 AGPAT3 -0.771 - 7.52E-03 5.97E-03 
205401_PM_at alkylglycerone phosphate synthase 6584 AGPS -0.509 - 2.03E-02 4.87E-02 
200850_PM_s_at adenosylhomocysteinase-like 1 91 AHCYL1 -2.708 - 2.38E-02 4.40E-02 
205002_PM_at AT hook, DNA binding motif, containing 1 4331 AHDC1 -1.296 - 6.21E-03 1.62E-02 
215789_PM_s_at adherens junctions associated protein 1 10776 AJAP1 -0.687 - 2.24E-03 1.83E-03 
222862_PM_s_at adenylate kinase 5 2901 AK5 -1.010 - 1.57E-02 2.36E-02 
210625_PM_s_at A kinase (PRKA) anchor protein 1 7555 AKAP1 -1.255 - 2.05E-02 3.87E-02 
218064_PM_s_at A kinase (PRKA) anchor protein 8-like 353116 AKAP8L -2.245 - 3.84E-03 1.46E-02 
222458_PM_s_at akirin 1 25976 AKIRIN1 -2.077 - 5.47E-03 1.83E-02 
223143_PM_s_at akirin 2 79817 AKIRIN2 -1.153 - 3.96E-03 1.93E-02 
222880_PM_at 
v-akt murine thymoma viral oncogene homolog 3 (protein 
kinase B, gamma) 
339479 AKT3 -0.741 - 7.02E-03 1.62E-02 
219393_PM_s_at 
v-akt murine thymoma viral oncogene homolog 3 (protein 
kinase B, gamma) 
5903 AKT3 -0.386 - 8.83E-03 4.99E-02 
210544_PM_s_at aldehyde dehydrogenase 3 family, member A2 79993 ALDH3A2 -0.318 - 2.83E-02 2.48E-02 
204290_PM_s_at aldehyde dehydrogenase 6 family, member A1 9779 ALDH6A1 -1.242 - 1.19E-03 2.24E-03 
201196_PM_s_at adenosylmethionine decarboxylase 1 5058 AMD1 -0.589 - 9.01E-03 3.49E-02 
231973_PM_s_at anaphase promoting complex subunit 1 3988 ANAPC1 -0.583 - 5.47E-03 1.96E-02 
208721_PM_s_at anaphase promoting complex subunit 5 996 ANAPC5 -1.968 - 1.28E-02 2.50E-02 
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202921_PM_s_at ankyrin 2, neuronal 23648 ANK2 -2.013 - 1.96E-02 3.53E-02 
207950_PM_s_at ankyrin 3, node of Ranvier (ankyrin G) 6038 ANK3 -0.775 - 4.36E-04 5.41E-03 
209442_PM_x_at ankyrin 3, node of Ranvier (ankyrin G) 55284 ANK3 -0.855 - 1.67E-02 1.17E-02 
223094_PM_s_at ankylosis, progressive homolog (mouse) 26504 ANKH -2.268 - 2.38E-03 9.63E-03 
233292_PM_s_at 
ankyrin repeat and KH domain containing 1 /// ANKHD1-





-1.610 - 1.04E-02 2.86E-02 
224687_PM_at ankyrin repeat and IBR domain containing 1 57614 ANKIB1 -1.418 - 5.19E-03 6.19E-03 
238642_PM_at ankyrin repeat domain 13 family, member D --- ANKRD13D -0.451 - 2.12E-02 1.22E-02 
225852_PM_at ankyrin repeat domain 17 80124 ANKRD17 -1.912 - 2.43E-03 1.58E-03 
211717_PM_at ankyrin repeat domain 40 114769 ANKRD40 -0.910 - 7.65E-03 2.32E-02 
201051_PM_at 
acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member A 
1859 ANP32A -0.453 - 1.59E-02 3.07E-02 
206200_PM_s_at annexin A11 8202 ANXA11 -0.609 - 4.93E-02 4.95E-02 
200982_PM_s_at annexin A6 1831 ANXA6 -0.695 - 3.74E-02 4.93E-02 
223025_PM_s_at adaptor-related protein complex 1, mu 1 subunit 79956 AP1M1 -0.849 - 2.19E-02 3.41E-02 
205196_PM_s_at adaptor-related protein complex 1, sigma 1 subunit 1385 AP1S1 -2.263 - 3.35E-02 4.58E-02 
209635_PM_at adaptor-related protein complex 1, sigma 1 subunit 10910 AP1S1 -0.556 - 4.05E-02 1.75E-02 
234068_PM_s_at adaptor-related protein complex 2, alpha 1 subunit --- AP2A1 -1.758 - 2.52E-03 7.15E-03 
223237_PM_x_at adaptor-related protein complex 2, alpha 1 subunit 79745 AP2A1 -0.525 - 1.42E-02 1.00E-02 
208710_PM_s_at adaptor-related protein complex 3, delta 1 subunit 64759 AP3D1 -1.743 - 2.67E-03 4.51E-03 
202652_PM_at 
amyloid beta (A4) precursor protein-binding, family B, 
member 1 (Fe65) 
10955 APBB1 -0.457 - 3.25E-02 3.85E-02 
216933_PM_x_at adenomatous polyposis coli 65008 APC -0.365 - 3.24E-02 1.07E-02 
201686_PM_x_at apoptosis inhibitor 5 6598 API5 -2.015 - 1.21E-03 1.42E-02 
214959_PM_s_at apoptosis inhibitor 5 51019 API5 -1.880 - 1.78E-03 2.05E-02 
214960_PM_at apoptosis inhibitor 5 64784 API5 -0.269 - 1.57E-02 6.99E-03 
209462_PM_at amyloid beta (A4) precursor-like protein 1 79101 APLP1 -0.446 - 2.19E-02 1.76E-02 
214875_PM_x_at amyloid beta (A4) precursor-like protein 2 56984 APLP2 -1.545 - 8.69E-03 1.52E-02 
208702_PM_x_at amyloid beta (A4) precursor-like protein 2 55737 APLP2 -1.394 - 8.95E-03 1.41E-02 
211404_PM_s_at amyloid beta (A4) precursor-like protein 2 338692 APLP2 -1.730 - 2.02E-02 3.78E-02 
203381_PM_s_at apolipoprotein E 80031 APOE -0.676 - 1.38E-02 3.50E-02 
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210906_PM_x_at aquaporin 4 148418 AQP4 -0.931 - 1.03E-03 4.54E-03 
210068_PM_s_at aquaporin 4 84240 AQP4 -1.454 - 1.21E-03 6.24E-03 
210066_PM_s_at aquaporin 4 10431 AQP4 -0.882 - 1.40E-02 3.74E-02 
211622_PM_s_at ADP-ribosylation factor 3 196403 ARF3 -1.461 - 3.09E-02 4.57E-02 
234001_PM_s_at ADP-ribosylation factor GTPase activating protein 1 --- ARFGAP1 -0.306 - 1.60E-02 1.13E-02 
216689_PM_x_at Rho GTPase activating protein 1 26995 ARHGAP1 -0.918 - 3.57E-03 5.34E-03 
1555020_PM_a_at Rho GTPase activating protein 20 6386 ARHGAP20 -0.282 - 4.92E-03 6.94E-03 
241701_PM_at Rho GTPase activating protein 21 --- ARHGAP21 -0.748 - 4.75E-02 9.25E-03 
1552627_PM_a_at Rho GTPase activating protein 5 129285 ARHGAP5 -0.641 - 4.82E-02 3.68E-02 
201167_PM_x_at Rho GDP dissociation inhibitor (GDI) alpha 23154 ARHGDIA -1.697 - 9.11E-03 2.00E-02 
206888_PM_s_at Rho GDP dissociation inhibitor (GDI) gamma 8487 ARHGDIG -1.356 - 4.12E-02 4.48E-02 
1554783_PM_s_at Rho/Rac guanine nucleotide exchange factor (GEF) 2 5908 /// 643752 ARHGEF2 -0.677 - 2.30E-03 5.48E-03 
211891_PM_s_at Rho guanine nucleotide exchange factor (GEF) 4 57582 ARHGEF4 -2.337 - 1.05E-02 2.52E-02 
202547_PM_s_at Rho guanine nucleotide exchange factor (GEF) 7 51501 ARHGEF7 -0.611 - 1.64E-03 2.97E-03 
212152_PM_x_at AT rich interactive domain 1A (SWI-like) 7072 ARID1A -0.507 - 2.49E-02 1.10E-02 
223111_PM_x_at AT rich interactive domain 4B (RBP1-like) 54942 ARID4B -0.881 - 2.55E-04 1.65E-03 
218150_PM_at ADP-ribosylation factor-like 5A 4087 ARL5A -0.550 - 1.14E-02 6.81E-03 
223328_PM_at armadillo repeat containing 10 79003 ARMC10 -0.280 - 1.28E-02 1.89E-02 
217858_PM_s_at armadillo repeat containing, X-linked 3 55773 ARMCX3 -0.460 - 2.61E-03 2.75E-02 
1555902_PM_at armadillo repeat containing, X-linked 5 9184 ARMCX5 -0.558 - 3.07E-02 4.88E-03 
211672_PM_s_at 
actin related protein 2/3 complex, subunit 4, 20kDa /// tubulin 




-2.525 - 1.89E-02 1.89E-02 
218554_PM_s_at ash1 (absent, small, or homeotic)-like (Drosophila) 25851 ASH1L -0.337 - 3.22E-02 1.71E-02 
1553997_PM_a_at aspartate beta-hydroxylase domain containing 1 23263 ASPHD1 -1.504 - 2.58E-02 4.22E-02 
218857_PM_s_at asparaginase like 1 91775 ASRGL1 -1.005 - 2.79E-02 4.29E-02 
244519_PM_at additional sex combs like 1 (Drosophila) --- ASXL1 -0.265 - 1.38E-03 6.10E-03 
205446_PM_s_at activating transcription factor 2 8821 ATF2 -0.925 - 2.24E-03 2.56E-02 
216208_PM_s_at activating transcription factor 6 beta 51108 ATF6B -0.829 - 8.77E-03 1.99E-02 
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1554487_PM_a_at activating transcription factor 6 beta 3939 ATF6B -0.819 - 3.40E-02 2.76E-02 
212280_PM_x_at ATG4 autophagy related 4 homolog B (S. cerevisiae) 66008 ATG4B -0.572 - 1.36E-02 3.15E-02 
211076_PM_x_at Atrophin 1 11276 ATN1 -0.516 - 5.22E-03 1.40E-02 
219558_PM_at ATPase type 13A3 9646 ATP13A3 -1.120 - 1.98E-03 1.37E-02 
201242_PM_s_at ATPase, Na+/K+ transporting, beta 1 polypeptide 80864 /// 9374 ATP1B1 -1.031 - 1.23E-02 2.35E-02 
209186_PM_at ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 29761 ATP2A2 -1.053 - 7.98E-03 1.57E-02 
209281_PM_s_at ATPase, Ca++ transporting, plasma membrane 1 54469 ATP2B1 -2.071 - 1.11E-02 2.87E-02 
211586_PM_s_at ATPase, Ca++ transporting, plasma membrane 2 127544 ATP2B2 -1.585 - 1.62E-03 4.55E-03 
201444_PM_s_at ATPase, H+ transporting, lysosomal accessory protein 2 782 ATP6AP2 -1.363 - 2.62E-02 4.30E-02 
205095_PM_s_at ATPase, H+ transporting, lysosomal V0 subunit a1 11060 ATP6V0A1 -1.710 - 4.36E-03 7.19E-03 
201971_PM_s_at ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 50488 ATP6V1A -2.812 - 2.69E-03 1.69E-02 
210192_PM_at 
ATPase, aminophospholipid transporter (APLT), class I, type 
8A, member 1 
317649 ATP8A1 -1.630 - 3.65E-03 1.93E-02 
203231_PM_s_at ataxin 1 137872 ATXN1 -1.668 - 7.39E-04 1.78E-03 
202685_PM_s_at AXL receptor tyrosine kinase 51131 AXL -0.340 - 2.75E-02 2.75E-02 
221484_PM_at 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 5 
4693 B4GALT5 -1.093 - 5.42E-03 9.21E-03 
206232_PM_s_at 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 6 
7336 B4GALT6 -1.449 - 6.88E-03 4.00E-02 
224335_PM_s_at beta-site APP-cleaving enzyme 1 133619 BACE1 -1.392 - 2.30E-02 3.71E-02 
205293_PM_x_at BAI1-associated protein 2 3631 BAIAP2 -2.345 - 1.86E-03 2.31E-03 
208132_PM_x_at HLA-B associated transcript 2 23321 BAT2 -1.001 - 2.90E-02 3.90E-02 
211948_PM_x_at BAT2 domain containing 1 7184 BAT2D1 -1.785 - 1.06E-02 4.64E-03 
211944_PM_at BAT2 domain containing 1 4677 BAT2D1 -1.091 - 1.35E-02 2.70E-03 
214055_PM_x_at BAT2 domain containing 1 29799 BAT2D1 -1.219 - 3.65E-02 2.74E-02 
222643_PM_s_at Bardet-Biedl syndrome 1 /// dipeptidyl-peptidase 3 112479 BBS1 /// DPP3 -0.682 - 3.60E-03 2.33E-02 
223135_PM_s_at bobby sox homolog (Drosophila) 29928 BBX -1.382 - 7.89E-03 2.19E-02 
232008_PM_s_at bobby sox homolog (Drosophila) 285550 BBX -1.279 - 1.44E-02 1.79E-02 
223134_PM_at bobby sox homolog (Drosophila) 79568 BBX -1.531 - 1.99E-02 2.83E-02 
213015_PM_at bobby sox homolog (Drosophila) 2922 BBX -0.848 - 2.52E-02 4.23E-02 
91920_PM_at brevican 11276 BCAN -0.488 - 9.25E-03 3.19E-02 
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234979_PM_at BCDIN3 domain containing 549 BCDIN3D -0.393 - 6.22E-03 4.08E-03 
224310_PM_s_at B-cell CLL/lymphoma 11B (zinc finger protein) 56893 BCL11B -0.892 - 1.64E-02 1.07E-02 
222895_PM_s_at B-cell CLL/lymphoma 11B (zinc finger protein) 54765 BCL11B -0.697 - 3.40E-02 3.80E-02 
206665_PM_s_at BCL2-like 1 7965 BCL2L1 -0.426 - 7.95E-03 2.48E-02 
215037_PM_s_at BCL2-like 1 56180 BCL2L1 -0.965 - 2.88E-02 3.27E-02 
223664_PM_x_at BCL2-like 13 (apoptosis facilitator) 2744 BCL2L13 -1.005 - 3.84E-03 9.65E-03 
215990_PM_s_at B-cell CLL/lymphoma 6 79726 BCL6 -0.806 - 8.05E-03 2.10E-02 
201101_PM_s_at BCL2-associated transcription factor 1 25970 BCLAF1 -2.642 - 2.23E-02 3.54E-02 
201169_PM_s_at basic helix-loop-helix family, member e40 801 BHLHE40 -1.041 - 2.48E-03 1.87E-02 
231243_PM_s_at basic helix-loop-helix family, member e41 57414 BHLHE41 -1.612 - 1.83E-03 1.15E-02 
223185_PM_s_at basic helix-loop-helix family, member e41 79570 BHLHE41 -0.286 - 4.68E-02 2.73E-02 
1553021_PM_s_at bicaudal D homolog 2 (Drosophila) 51008 BICD2 -0.398 - 5.71E-05 3.48E-04 
209203_PM_s_at bicaudal D homolog 2 (Drosophila) 54477 BICD2 -1.013 - 1.09E-02 2.06E-02 
202931_PM_x_at bridging integrator 1 5992 BIN1 -0.761 - 2.20E-02 4.42E-02 
210202_PM_s_at bridging integrator 1 57542 BIN1 -2.238 - 2.32E-02 4.77E-02 
1555675_PM_at BH3-like motif containing, cell death inducer 1488 BLID -0.321 - 6.89E-03 1.54E-02 
207595_PM_s_at bone morphogenetic protein 1 5930 BMP1 -0.331 - 6.51E-03 3.62E-02 
210523_PM_at bone morphogenetic protein receptor, type IB 8654 BMPR1B -0.384 - 9.29E-03 6.09E-03 
209920_PM_at 
bone morphogenetic protein receptor, type II (serine/threonine 
kinase) 
282991 BMPR2 -0.555 - 1.93E-02 4.96E-02 
207186_PM_s_at bromodomain PHD finger transcription factor 9736 BPTF -1.289 - 7.55E-03 1.08E-02 
208685_PM_x_at bromodomain containing 2 8942 BRD2 -1.544 - 9.62E-04 1.92E-03 
214911_PM_s_at bromodomain containing 2 64748 BRD2 -0.755 - 2.82E-02 2.01E-02 
202102_PM_s_at bromodomain containing 4 5621 BRD4 -1.694 - 1.08E-03 1.01E-03 
226054_PM_at bromodomain containing 4 1601 BRD4 -1.935 - 1.43E-02 1.61E-02 
222737_PM_s_at bromodomain containing 7 2495 BRD7 -1.288 - 2.11E-02 3.12E-02 
215010_PM_s_at BR serine/threonine kinase 2 56034 BRSK2 -0.622 - 4.58E-03 2.14E-02 
223653_PM_x_at 189epar-like 4, RNA binding protein (Drosophila) 58515 BRUNOL4 -2.696 - 5.54E-03 8.31E-03 
231744_PM_at 189epar-like 5, RNA binding protein (Drosophila) 128077 BRUNOL5 -0.793 - 2.00E-03 1.23E-02 
200920_PM_s_at B-cell translocation gene 1, anti-proliferative 7267 BTG1 -2.718 - 1.97E-02 4.66E-02 
201457_PM_x_at budding uninhibited by benzimidazoles 3 homolog (yeast) 5162 BUB3 -1.374 - 1.33E-02 4.11E-02 
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200776_PM_s_at 
basic leucine zipper and W2 domains 1 /// basic leucine 




-0.383 - 2.52E-03 9.46E-03 
219844_PM_at chromosome 10 open reading frame 118 10497 C10orf118 -0.402 - 2.67E-03 8.58E-03 
227257_PM_s_at chromosome 10 open reading frame 46 50509 C10orf46 -0.581 - 1.31E-03 3.94E-04 
1553566_PM_at chromosome 12 open reading frame 53 54498 C12orf53 -0.894 - 2.36E-02 3.77E-02 
1556299_PM_s_at chromosome 12 open reading frame 76 8087 C12orf76 -0.345 - 7.54E-04 4.87E-03 
203289_PM_s_at chromosome 16 open reading frame 35 1479 C16orf35 -0.734 - 1.63E-02 3.28E-02 
230296_PM_at Chromosome 16 open reading frame 52 283174 C16orf52 -1.797 - 3.64E-03 2.85E-03 
213986_PM_s_at chromosome 19 open reading frame 6 23398 C19orf6 -1.249 - 4.87E-03 6.06E-03 
224727_PM_at chromosome 19 open reading frame 63 85457 C19orf63 -0.788 - 4.53E-02 3.33E-02 
212002_PM_at chromosome 1 open reading frame 144 6319 C1orf144 -0.544 - 1.15E-02 4.41E-02 
243753_PM_at chromosome 1 open reading frame 173 10783 C1orf173 -0.476 - 3.26E-02 2.89E-02 
223127_PM_s_at chromosome 1 open reading frame 21 54851 C1orf21 -0.988 - 2.48E-02 2.18E-02 
233750_PM_s_at chromosome 1 open reading frame 25 6616 C1orf25 -0.496 - 3.17E-03 8.57E-03 
223938_PM_at chromosome 1 open reading frame 49 84233 C1orf49 -0.269 - 2.90E-03 1.09E-02 
223708_PM_at C1q and tumor necrosis factor related protein 4 84259 C1QTNF4 -1.855 - 1.10E-02 3.28E-02 
1557470_PM_at 
C1q and tumor necrosis factor related protein 9 /// 




-0.275 - 1.26E-02 3.84E-02 
224693_PM_at chromosome 20 open reading frame 108 200916 C20orf108 -0.503 - 8.22E-03 1.69E-02 
50314_PM_i_at chromosome 20 open reading frame 27 152485 C20orf27 -0.470 - 1.77E-02 5.51E-03 
218123_PM_at chromosome 21 open reading frame 59 9949 C21orf59 -0.447 - 1.72E-02 4.87E-02 
204757_PM_s_at C2CD2-like 5279 C2CD2L -0.408 - 3.46E-02 2.63E-02 
1560035_PM_at chromosome 2 open reading frame 85 2958 C2orf85 -2.919 - 1.82E-02 2.44E-02 
241666_PM_at chromosome 3 open reading frame 23 55554 C3orf23 -0.896 - 2.83E-04 4.67E-03 
1553158_PM_at chromosome 3 open reading frame 34 23281 C3orf34 -0.505 - 4.73E-03 1.72E-02 
242753_PM_x_at chromosome 4 open reading frame 16 347744 C4orf16 -0.428 - 5.61E-03 1.87E-02 
233558_PM_s_at chromosome 4 open reading frame 41 50509 C4orf41 -0.755 - 2.00E-02 4.39E-02 
1552660_PM_a_at chromosome 5 open reading frame 22 55610 C5orf22 -1.506 - 7.64E-03 3.16E-02 
48030_PM_i_at chromosome 5 open reading frame 4 --- C5orf4 -0.794 - 2.59E-02 2.99E-02 
1554229_PM_at chromosome 5 open reading frame 41 6155 C5orf41 -0.383 - 2.89E-02 1.15E-02 
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217924_PM_at chromosome 6 open reading frame 106 92906 C6orf106 -0.700 - 2.29E-03 9.82E-03 
205457_PM_at chromosome 6 open reading frame 106 7454 C6orf106 -0.590 - 8.32E-03 1.90E-02 
213875_PM_x_at chromosome 6 open reading frame 62 23243 C6orf62 -2.601 - 1.30E-02 3.24E-02 
227000_PM_at chromosome 7 open reading frame 41 285282 C7orf41 -0.755 - 8.99E-04 7.45E-03 
221629_PM_x_at chromosome 8 open reading frame 30A 55715 C8orf30A -0.295 - 6.18E-03 3.85E-03 
228701_PM_at chromosome 8 open reading frame 46 55846 C8orf46 -3.348 - 9.25E-03 2.72E-02 
228695_PM_at chromosome 8 open reading frame 46 91057 C8orf46 -2.114 - 2.05E-02 4.80E-02 
220712_PM_at chromosome 8 open reading frame 60 4129 C8orf60 -0.275 - 1.23E-02 3.34E-02 
235209_PM_at chromosome 8 open reading frame 84 9125 C8orf84 -0.851 - 2.41E-02 3.39E-03 
224458_PM_at chromosome 9 open reading frame 125 54602 C9orf125 -0.639 - 4.74E-04 9.24E-04 
241781_PM_at chromosome 9 open reading frame 41 --- C9orf41 -0.290 - 6.07E-04 3.30E-03 
223006_PM_s_at chromosome 9 open reading frame 5 51312 C9orf5 -1.795 - 1.92E-02 1.66E-02 
225377_PM_at chromosome 9 open reading frame 86 64776 C9orf86 -0.577 - 4.53E-02 3.11E-02 
224311_PM_s_at calcium binding protein 39 359948 CAB39 -0.778 - 2.44E-04 5.99E-03 
221003_PM_s_at calcium binding protein 39-like 9308 CAB39L -0.347 - 4.02E-03 1.76E-02 
222542_PM_x_at 
chaperone, ABC1 activity of bc1 complex homolog (S. 
pombe) 
1386 CABC1 -0.329 - 9.36E-03 3.31E-02 
208320_PM_at calcium binding protein 1 10369 CABP1 -0.563 - 5.00E-03 3.30E-02 
208321_PM_s_at calcium binding protein 1 9135 CABP1 -1.888 - 1.94E-02 2.73E-02 
210181_PM_s_at calcium binding protein 1 121536 CABP1 -2.517 - 2.06E-02 3.80E-02 
207050_PM_at calcium channel, voltage-dependent, alpha 2/delta subunit 1 54780 CACNA2D1 -0.429 - 7.14E-03 8.82E-03 
206996_PM_x_at calcium channel, voltage-dependent, beta 1 subunit 10962 CACNB1 -0.482 - 5.13E-03 1.00E-02 
210967_PM_x_at calcium channel, voltage-dependent, beta 1 subunit 128229 CACNB1 -0.540 - 6.15E-03 1.44E-02 
1555098_PM_a_at calcium channel, voltage-dependent, beta 2 subunit 3983 CACNB2 -0.308 - 4.10E-02 4.56E-02 
207693_PM_at calcium channel, voltage-dependent, beta 4 subunit 26009 CACNB4 -2.121 - 5.55E-03 8.83E-03 
214495_PM_at calcium channel, voltage-dependent, gamma subunit 2 29074 CACNG2 -2.535 - 1.08E-03 4.48E-03 
231737_PM_at calcium channel, voltage-dependent, gamma subunit 4 --- CACNG4 -0.558 - 9.76E-03 7.46E-03 
62987_PM_r_at calcium channel, voltage-dependent, gamma subunit 4 --- CACNG4 -0.385 - 1.80E-02 4.62E-02 
209030_PM_s_at cell adhesion molecule 1 55129 CADM1 -0.536 - 1.68E-02 1.01E-02 
1555544_PM_a_at cell adhesion molecule 2 9698 CADM2 -0.906 - 2.12E-03 1.66E-02 
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213948_PM_x_at cell adhesion molecule 3 286148 CADM3 -0.982 - 2.61E-02 2.57E-02 
215258_PM_at cell adhesion molecule 4 64081 CADM4 -0.752 - 2.32E-02 2.42E-02 
233950_PM_at Ca++-dependent secretion activator 439911 CADPS -1.236 - 1.62E-02 2.90E-02 
234220_PM_at Ca++-dependent secretion activator --- CADPS -0.358 - 3.45E-02 4.89E-02 
209563_PM_x_at calmodulin 1 (phosphorylase kinase, delta) 51390 CALM1 -0.435 - 9.39E-04 9.78E-03 
200622_PM_x_at calmodulin 3 (phosphorylase kinase, delta) 4287 CALM3 -1.375 - 9.22E-03 2.17E-02 
200623_PM_s_at calmodulin 3 (phosphorylase kinase, delta) 10520 CALM3 -0.297 - 2.87E-02 2.79E-02 
214845_PM_s_at calumenin 54951 CALU -1.775 - 4.60E-03 1.45E-02 
200756_PM_x_at calumenin 8525 CALU -1.478 - 5.42E-03 9.62E-03 
219896_PM_at calcyon neuron-specific vesicular protein 22856 CALY -4.585 - 1.65E-03 5.40E-03 
204392_PM_at calcium/calmodulin-dependent protein kinase I 1514 CAMK1 -1.802 - 4.04E-02 4.48E-02 
220246_PM_at calcium/calmodulin-dependent protein kinase ID 10426 CAMK1D -0.327 - 6.06E-03 1.67E-02 
235626_PM_at calcium/calmodulin-dependent protein kinase ID 392 CAMK1D -0.928 - 2.00E-02 2.69E-03 
207613_PM_s_at calcium/calmodulin-dependent protein kinase II alpha 158471 CAMK2A -3.856 - 3.92E-04 1.65E-03 
34846_PM_at calcium/calmodulin-dependent protein kinase II beta 728819 CAMK2B -1.536 - 2.00E-03 2.10E-03 
1552893_PM_at calcium/calmodulin-dependent protein kinase II inhibitor 2 1388 CAMK2N2 -1.165 - 1.65E-03 7.15E-03 
210349_PM_at calcium/calmodulin-dependent protein kinase IV 1184 CAMK4 -0.885 - 1.72E-04 4.48E-03 
212763_PM_at calmodulin regulated spectrin-associated protein 1-like 1 27292 CAMSAP1L1 -0.800 - 1.69E-02 4.16E-02 
208853_PM_s_at calnexin 58486 CANX -0.769 - 4.28E-02 2.97E-02 
212551_PM_at CAP, adenylate cyclase-associated protein, 2 (yeast) 79053 CAP2 -2.698 - 2.13E-02 4.99E-02 
226289_PM_at cell cycle associated protein 1 65055 CAPRIN1 -0.993 - 1.10E-02 2.25E-02 
200722_PM_s_at cell cycle associated protein 1 9555 CAPRIN1 -2.298 - 1.87E-02 3.91E-02 
201950_PM_x_at capping protein (actin filament) muscle Z-line, beta 5911 /// 5912 CAPZB -1.118 - 1.17E-02 2.16E-02 
201949_PM_x_at capping protein (actin filament) muscle Z-line, beta 1936 CAPZB -0.289 - 4.61E-02 3.84E-02 
207620_PM_s_at 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
23142 CASK -1.999 - 1.75E-03 6.05E-04 
238698_PM_at 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
55573 CASK -0.269 - 7.26E-03 2.55E-03 
238699_PM_s_at 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
23528 CASK -0.785 - 1.49E-02 1.84E-02 
211208_PM_s_at 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
10243 CASK -0.569 - 3.24E-02 4.79E-02 
203065_PM_s_at caveolin 1, caveolae protein, 22kDa 54602 CAV1 -0.351 - 1.78E-02 4.47E-02 
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209145_PM_s_at 
core-binding factor, runt domain, alpha subunit 2; translocated 
to, 2 
51022 CBFA2T2 -0.365 - 1.65E-03 1.18E-02 
1554637_PM_a_at 
core-binding factor, runt domain, alpha subunit 2; translocated 
to, 2 
151579 /// 9689 CBFA2T2 -0.383 - 1.21E-02 4.32E-02 
206724_PM_at chromobox homolog 4 (Pc class homolog, Drosophila) 51592 CBX4 -0.575 - 4.63E-03 8.20E-03 
226085_PM_at chromobox homolog 5 (HP1 alpha homolog, Drosophila) 9520 CBX5 -0.318 - 3.05E-02 2.82E-02 
242487_PM_at coiled-coil and C2 domain containing 1B --- CC2D1B -0.349 - 3.37E-03 3.34E-03 
1559409_PM_a_at coiled-coil and C2 domain containing 2A 11269 /// 55308 CC2D2A -0.299 - 2.70E-02 2.85E-02 
224736_PM_at cell division cycle and apoptosis regulator 1 4194 CCAR1 -1.073 - 6.31E-03 7.53E-03 
1553732_PM_s_at coiled-coil domain containing 123 54331 CCDC123 -0.300 - 3.04E-03 1.41E-02 
225454_PM_at coiled-coil domain containing 124 144233 CCDC124 -0.658 - 3.34E-02 4.84E-02 
1554217_PM_a_at coiled-coil domain containing 132 4735 CCDC132 -0.611 - 8.18E-03 3.79E-02 
228693_PM_at coiled-coil domain containing 50 --- CCDC50 -0.441 - 3.24E-04 1.32E-03 
221078_PM_s_at coiled-coil domain containing 88A 5422 CCDC88A -0.574 - 4.33E-03 2.42E-02 
227299_PM_at Cyclin I 56834 CCNI -1.886 - 1.57E-02 2.66E-02 
224651_PM_at cyclin Y 399959 CCNY -1.028 - 4.31E-03 7.68E-03 
208653_PM_s_at CD164 molecule, sialomucin 84162 CD164 -0.429 - 2.68E-03 1.91E-02 
202257_PM_s_at CD2 (cytoplasmic tail) binding protein 2 51386 CD2BP2 -0.612 - 6.19E-04 9.94E-03 
205049_PM_s_at CD79a molecule, immunoglobulin-associated alpha 644 CD79A -0.270 - 2.67E-02 2.61E-02 
217881_PM_s_at cell division cycle 27 homolog (S. cerevisiae) 64983 CDC27 -0.914 - 1.54E-02 4.49E-02 
203377_PM_s_at cell division cycle 40 homolog (S. cerevisiae) 51542 CDC40 -0.556 - 1.07E-02 2.40E-02 
1552613_PM_s_at CDC42 small effector 2 129285 CDC42SE2 -0.846 - 3.23E-03 1.19E-02 
1552612_PM_at CDC42 small effector 2 150290 CDC42SE2 -1.626 - 8.76E-03 4.70E-02 
207172_PM_s_at cadherin 11, type 2, OB-cadherin (osteoblast) 58517 CDH11 -0.646 - 1.87E-02 1.00E-02 
203441_PM_s_at cadherin 2, type 1, N-cadherin (neuronal) 29989 /// 29991 CDH2 -1.345 - 1.51E-02 2.57E-02 
210518_PM_at cadherin 8, type 2 132864 CDH8 -0.885 - 2.94E-02 4.85E-02 
210622_PM_x_at cyclin-dependent kinase 10 23678 CDK10 -0.954 - 7.36E-03 3.61E-02 
204996_PM_s_at cyclin-dependent kinase 5, regulatory subunit 1 (p35) 324 CDK5R1 -1.523 - 1.95E-03 4.26E-03 
207143_PM_at cyclin-dependent kinase 6 689 CDK6 -0.688 - 4.54E-02 1.48E-02 
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210240_PM_s_at cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 7559 CDKN2D -0.438 - 4.19E-02 4.99E-02 
205709_PM_s_at 
CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
6326 CDS1 -0.353 - 4.98E-04 6.77E-03 
228746_PM_s_at CDV3 homolog (mouse) 120534 CDV3 -1.614 - 3.17E-02 2.85E-02 
204373_PM_s_at centrosomal protein 350kDa 5782 CEP350 -0.717 - 3.74E-03 2.29E-02 
203491_PM_s_at centrosomal protein 57kDa 282890 CEP57 -0.533 - 3.56E-03 1.82E-02 
207971_PM_s_at centrosomal protein 68kDa 23254 CEP68 -0.329 - 1.42E-02 4.60E-02 
206861_PM_s_at CGG triplet repeat binding protein 1 4149 CGGBP1 -0.610 - 3.36E-02 2.98E-02 
201183_PM_s_at chromodomain helicase DNA binding protein 4 6509 CHD4 -0.835 - 2.04E-02 2.38E-02 
229586_PM_at chromodomain helicase DNA binding protein 9 --- CHD9 -0.378 - 1.10E-02 4.24E-05 
225119_PM_at chromatin modifying protein 4B 51106 CHMP4B -1.643 - 2.06E-02 2.19E-02 
207993_PM_s_at calcium binding protein P22 9470 CHP -3.182 - 1.99E-03 7.81E-03 
231783_PM_at cholinergic receptor, muscarinic 1 --- CHRM1 -0.342 - 1.50E-02 3.98E-03 
1564339_PM_a_at cholinergic receptor, muscarinic 3 7077 CHRM3 -0.688 - 5.35E-03 1.81E-02 
1559633_PM_a_at cholinergic receptor, muscarinic 3 322 CHRM3 -1.142 - 2.13E-02 1.81E-02 
230142_PM_s_at cold inducible RNA binding protein 645460 CIRBP -2.470 - 1.78E-02 2.96E-02 
201735_PM_s_at chloride channel 3 23213 CLCN3 -1.071 - 5.24E-04 3.13E-03 
201732_PM_s_at chloride channel 3 2036 CLCN3 -1.857 - 6.35E-04 1.57E-03 
221881_PM_s_at chloride intracellular channel 4 545 CLIC4 -1.165 - 1.11E-03 4.34E-03 
201768_PM_s_at clathrin interactor 1 23301 CLINT1 -1.053 - 1.18E-02 4.24E-02 
235243_PM_at CAP-GLY domain containing linker protein 3 --- CLIP3 -2.352 - 1.08E-03 4.21E-03 
219944_PM_at CAP-GLY domain containing linker protein family, member 4 10300 CLIP4 -0.662 - 2.04E-02 1.70E-02 
204980_PM_at clock homolog (mouse) 51430 CLOCK -0.363 - 1.45E-02 1.43E-02 
201640_PM_x_at cleft lip and palate associated transmembrane protein 1 3516 CLPTM1 -0.281 - 7.04E-03 3.24E-02 
211136_PM_s_at cleft lip and palate associated transmembrane protein 1 51495 CLPTM1 -3.019 - 1.42E-02 2.60E-02 
230070_PM_at cornichon homolog 2 (Drosophila) 83482 CNIH2 -0.300 - 3.74E-02 2.83E-02 
1554607_PM_at connector enhancer of kinase suppressor of Ras 2 8655 CNKSR2 -1.772 - 6.62E-03 2.26E-02 
203239_PM_s_at CCR4-NOT transcription complex, subunit 3 91833 CNOT3 -0.687 - 1.91E-02 4.43E-02 
211141_PM_s_at CCR4-NOT transcription complex, subunit 3 80318 CNOT3 -0.374 - 3.71E-02 4.23E-02 
210866_PM_s_at CCR4-NOT transcription complex, subunit 4 4810 CNOT4 -1.204 - 1.20E-02 1.84E-02 
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218250_PM_s_at CCR4-NOT transcription complex, subunit 7 84343 CNOT7 -2.112 - 8.49E-03 2.89E-02 
202162_PM_s_at CCR4-NOT transcription complex, subunit 8 134 CNOT8 -1.075 - 1.29E-02 3.98E-02 
207940_PM_x_at cannabinoid receptor 1 (brain) 6191 CNR1 -0.672 - 6.18E-04 4.42E-03 
211203_PM_s_at contactin 1 57545 CNTN1 -1.828 - 6.78E-03 2.53E-02 
215145_PM_s_at contactin associated protein-like 2 26589 CNTNAP2 -1.656 - 4.59E-02 2.58E-02 
203653_PM_s_at coilin 22866 COIL -0.880 - 1.23E-03 3.26E-03 
218975_PM_at collagen, type V, alpha 3 84902 COL5A3 -0.880 - 1.42E-04 1.67E-03 
52255_PM_s_at collagen, type V, alpha 3 --- COL5A3 -0.332 - 5.55E-03 2.62E-03 
208817_PM_at catechol-O-methyltransferase 54187 COMT -0.934 - 3.91E-02 4.53E-02 
214336_PM_s_at coatomer protein complex, subunit alpha 11180 COPA -1.770 - 2.29E-03 8.99E-03 
201942_PM_s_at carboxypeptidase D 5689 CPD -0.936 - 4.17E-04 7.27E-03 
235479_PM_at cytoplasmic polyadenylation element binding protein 2 9727 CPEB2 -0.510 - 1.76E-02 4.35E-02 
224829_PM_at cytoplasmic polyadenylation element binding protein 4 388789 CPEB4 -1.993 - 5.70E-04 5.90E-04 
224828_PM_at cytoplasmic polyadenylation element binding protein 4 4163 CPEB4 -2.171 - 1.92E-02 1.51E-02 
1554321_PM_a_at copine I /// NFS1 nitrogen fixation 1 homolog (S. cerevisiae) 6136 
CPNE1 /// 
NFS1 
-0.437 - 2.00E-02 4.78E-02 
204263_PM_s_at carnitine palmitoyltransferase 2 9685 CPT2 -0.457 - 3.62E-02 4.20E-02 
204312_PM_x_at cAMP responsive element binding protein 1 23429 CREB1 -1.519 - 4.56E-03 1.46E-02 
214513_PM_s_at cAMP responsive element binding protein 1 51056 CREB1 -0.647 - 9.43E-03 3.51E-02 
202978_PM_s_at CREB/ATF bZIP transcription factor 64895 CREBZF -0.492 - 1.09E-02 4.10E-02 
202226_PM_s_at v-crk sarcoma virus CT10 oncogene homolog (avian) 1627 CRK -1.185 - 1.31E-02 2.56E-02 
206184_PM_at v-crk sarcoma virus CT10 oncogene homolog (avian)-like 23176 CRKL -0.430 - 1.47E-03 1.02E-02 
202517_PM_at 195eparin195in response mediator protein 1 64840 CRMP1 -0.814 - 3.33E-02 3.42E-02 
222975_PM_s_at cold shock domain containing E1, RNA-binding 55742 CSDE1 -1.019 - 8.36E-03 2.67E-02 
219939_PM_s_at cold shock domain containing E1, RNA-binding 5156 CSDE1 -0.360 - 8.88E-03 4.57E-02 
1553405_PM_a_at CUB and Sushi multiple domains 1 9444 CSMD1 -0.319 - 3.82E-02 4.91E-02 
206562_PM_s_at casein kinase 1, alpha 1 1628 CSNK1A1 -2.264 - 1.44E-02 3.20E-02 
207945_PM_s_at casein kinase 1, delta 6642 CSNK1D -0.652 - 2.67E-02 4.12E-02 
202332_PM_at casein kinase 1, epsilon 114883 CSNK1E -1.037 - 9.50E-04 5.17E-03 
231920_PM_s_at casein kinase 1, gamma 1 22834 CSNK1G1 -0.779 - 2.34E-03 4.27E-03 
202574_PM_s_at casein kinase 1, gamma 2 54542 CSNK1G2 -0.675 - 1.25E-02 2.02E-02 
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212075_PM_s_at casein kinase 2, alpha 1 polypeptide 10945 CSNK2A1 -1.881 - 6.24E-03 1.71E-02 
212073_PM_at 
casein kinase 2, alpha 1 polypeptide /// casein kinase 2, alpha 




-0.530 - 3.60E-02 3.63E-02 
205344_PM_at chondroitin sulfate proteoglycan 5 (neuroglycan C) 9854 CSPG5 -2.000 - 1.02E-02 2.02E-02 
225042_PM_s_at cysteine-serine-rich nuclear protein 2 23383 CSRNP2 -0.547 - 9.97E-03 2.33E-02 
206994_PM_at cystatin S 2137 CST4 -0.294 - 2.89E-03 2.98E-03 
217844_PM_at 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 1 
64778 CTDSP1 -0.263 - 3.31E-02 3.94E-02 
201905_PM_s_at 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase-like 
10521 CTDSPL -0.679 - 3.08E-02 3.77E-02 
1558214_PM_s_at catenin (cadherin-associated protein), alpha 1, 102kDa 8883 CTNNA1 -0.656 - 2.47E-04 1.56E-03 
1554411_PM_at catenin (cadherin-associated protein), beta 1, 88kDa 7534 CTNNB1 -2.351 - 8.43E-03 2.28E-02 
213274_PM_s_at cathepsin B 10492 CTSB -1.725 - 1.80E-02 4.47E-02 
214074_PM_s_at cortactin 9236 CTTN -0.854 - 6.47E-05 3.32E-04 
228126_PM_x_at cortexin 1 --- CTXN1 -1.682 - 1.72E-02 3.27E-02 
1555467_PM_a_at CUG triplet repeat, RNA binding protein 1 10456 CUGBP1 -0.927 - 2.75E-03 1.20E-02 
204113_PM_at CUG triplet repeat, RNA binding protein 1 23471 CUGBP1 -0.872 - 1.67E-02 4.20E-02 
1554569_PM_a_at CUG triplet repeat, RNA binding protein 2 7323 CUGBP2 -0.979 - 4.61E-04 2.73E-03 
202157_PM_s_at CUG triplet repeat, RNA binding protein 2 1388 CUGBP2 -0.585 - 7.57E-03 7.21E-03 
210257_PM_x_at cullin 4B 10335 CUL4B -0.626 - 1.03E-02 4.94E-02 
242781_PM_at chromosome X open reading frame 39 --- Cxorf39 -0.339 - 1.20E-03 1.10E-02 
222996_PM_s_at CXXC finger 5 29105 CXXC5 -1.050 - 6.51E-03 1.48E-02 
233955_PM_x_at CXXC finger 5 53335 CXXC5 -0.971 - 8.58E-03 1.47E-02 
1554574_PM_a_at cytochrome b5 reductase 3 6711 CYB5R3 -1.158 - 2.09E-02 2.23E-02 
216607_PM_s_at cytochrome P450, family 51, subfamily A, polypeptide 1 25897 CYP51A1 -0.878 - 2.71E-03 1.87E-02 
202879_PM_s_at cytohesin 1 81894 CYTH1 -0.524 - 1.61E-03 8.17E-04 
216060_PM_s_at 196eparin196in associated activator of morphogenesis 1 57665 DAAM1 -0.843 - 2.49E-03 3.42E-03 
220611_PM_at disabled homolog 1 (Drosophila) 7257 DAB1 -1.857 - 1.22E-04 8.06E-05 
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225828_PM_at diacylglycerol lipase, beta --- DAGLB -0.416 - 8.86E-03 2.04E-02 
225833_PM_at diacylglycerol lipase, beta --- DAGLB -0.541 - 1.78E-02 3.35E-02 
211214_PM_s_at death-associated protein kinase 1 79664 DAPK1 -0.447 - 1.35E-02 2.61E-02 
203890_PM_s_at death-associated protein kinase 3 5048 DAPK3 -0.931 - 2.55E-03 5.54E-03 
217025_PM_s_at drebrin 1 11091 DBN1 -1.363 - 1.32E-02 2.77E-02 
209782_PM_s_at D site of albumin promoter (albumin D-box) binding protein 84811 DBP -0.934 - 1.90E-02 2.05E-02 
224730_PM_at DDB1 and CUL4 associated factor 7 140901 DCAF7 -0.610 - 1.78E-03 1.18E-02 
218508_PM_at DCP1 decapping enzyme homolog A (S. cerevisiae) 130074 DCP1A -0.296 - 1.07E-03 4.23E-03 
209231_PM_s_at dynactin 5 (p25) 55140 DCTN5 -0.500 - 8.33E-03 2.64E-02 
1553565_PM_s_at dimethylarginine dimethylaminohydrolase 1 64393 DDAH1 -1.376 - 6.56E-04 8.23E-03 
213998_PM_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 23066 DDX17 -2.228 - 1.29E-02 3.19E-02 
202576_PM_s_at 
DEAD (Asp-Glu-Ala-As) box polypeptide 19A /// DEAD (Asp-




-0.381 - 3.00E-02 4.63E-02 
212514_PM_x_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 5711 DDX3X -1.120 - 9.63E-04 9.73E-03 
201211_PM_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 3801 DDX3X -1.608 - 3.91E-03 2.84E-02 
1559954_PM_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 8813 DDX42 -2.339 - 9.29E-03 2.46E-02 
53991_PM_at DENN/MADD domain containing 2A --- DENND2A -0.274 - 2.55E-02 4.29E-03 
234915_PM_s_at density-regulated protein 10274 DENR -0.314 - 7.99E-03 3.78E-03 
219402_PM_s_at Der1-like domain family, member 1 1994 DERL1 -0.705 - 1.56E-03 1.63E-02 
207556_PM_s_at diacylglycerol kinase, zeta 104kDa 55818 DGKZ -1.106 - 3.22E-02 4.11E-02 
223138_PM_s_at DEAH (Asp-Glu-Ala-His) box polypeptide 36 55273 DHX36 -0.417 - 1.59E-02 1.93E-02 
213229_PM_at dicer 1, ribonuclease type III 57798 DICER1 -0.464 - 1.48E-03 1.94E-02 
232854_PM_at DIRAS family, GTP-binding RAS-like 1 51101 DIRAS1 -0.369 - 2.40E-02 1.89E-02 
210762_PM_s_at deleted in liver cancer 1 1387 DLC1 -0.443 - 7.83E-03 2.86E-02 
206253_PM_at discs, large homolog 2 (Drosophila) 8648 DLG2 -1.477 - 6.65E-03 6.57E-03 
207732_PM_s_at discs, large homolog 3 (Drosophila) 11011 DLG3 -0.816 - 2.14E-04 2.62E-04 
212729_PM_at discs, large homolog 3 (Drosophila) 4242 DLG3 -0.665 - 1.23E-02 8.41E-03 
210750_PM_s_at discs, large (Drosophila) homolog-associated protein 1 148423 DLGAP1 -0.431 - 3.21E-02 2.88E-02 
231151_PM_at discs, large (Drosophila) homolog-associated protein 3 56886 DLGAP3 -0.740 - 2.76E-03 1.65E-03 
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1560300_PM_a_at DMRT-like family C1 /// DMRT-like family C1B 7726 
DMRTC1 /// 
DMRTC1B 
-0.264 - 3.42E-02 2.04E-02 
1554429_PM_a_at dystrophia myotonica, WD repeat containing 6647 DMWD -1.436 - 3.20E-02 4.81E-02 
200664_PM_s_at DnaJ (Hsp40) homolog, subfamily B, member 1 9877 DNAJB1 -1.218 - 6.23E-03 2.16E-02 
222850_PM_s_at DnaJ (Hsp40) homolog, subfamily B, member 14 8707 DNAJB14 -1.066 - 5.27E-03 1.78E-02 
1555360_PM_a_at DnaJ (Hsp40) homolog, subfamily C, member 11 23646 DNAJC11 -0.421 - 2.16E-02 6.91E-03 
1554451_PM_s_at DnaJ (Hsp40) homolog, subfamily C, member 14 2752 DNAJC14 -1.498 - 1.11E-02 4.15E-02 
227166_PM_at DnaJ (Hsp40) homolog, subfamily C, member 18 4848 DNAJC18 -0.789 - 1.09E-02 2.41E-02 
205744_PM_at double C2-like domains, alpha 56242 DOC2A -1.206 - 4.19E-02 4.95E-02 
215041_PM_s_at dedicator of cytokinesis 9 64757 DOCK9 -0.454 - 1.62E-02 1.35E-02 
207747_PM_s_at docking protein 4 253959 DOK4 -0.428 - 2.46E-02 4.52E-02 
231599_PM_x_at D4, zinc and double PHD fingers family 1 128854 DPF1 -1.434 - 2.77E-02 4.20E-02 
219590_PM_x_at DPH5 homolog (S. cerevisiae) 23219 DPH5 -0.302 - 4.45E-02 4.05E-02 
1560916_PM_a_at dpy-19-like 1 (C. elegans) 6672 DPY19L1 -0.408 - 5.13E-03 1.52E-02 
205492_PM_s_at dihydropyrimidinase-like 4 51375 DPYSL4 -0.615 - 2.50E-02 4.32E-02 
203267_PM_s_at developmentally regulated GTP binding protein 2 79971 DRG2 -1.670 - 2.35E-02 3.12E-02 
211515_PM_s_at dual serine/threonine and tyrosine protein kinase 163404 DSTYK -0.881 - 3.33E-02 4.57E-02 
208430_PM_s_at dystrobrevin, alpha 8295 DTNA -2.087 - 5.04E-03 3.19E-03 
211493_PM_x_at dystrobrevin, alpha 84332 DTNA -1.474 - 1.56E-02 2.18E-02 
210736_PM_x_at dystrobrevin, alpha 349565 DTNA -1.924 - 1.78E-02 2.66E-02 
49051_PM_g_at deltex homolog 3 (Drosophila) 100128644 DTX3 -1.507 - 6.52E-03 1.23E-02 
221835_PM_at deltex homolog 3 (Drosophila) 54453 DTX3 -0.804 - 1.41E-02 8.01E-03 
49049_PM_at deltex homolog 3 (Drosophila) --- DTX3 -1.171 - 2.19E-02 4.11E-02 
227098_PM_at dual specificity phosphatase 18 8539 DUSP18 -0.369 - 3.42E-03 2.68E-02 
1553701_PM_a_at dual specificity phosphatase 18 1033 DUSP18 -0.283 - 2.99E-02 5.44E-04 
201538_PM_s_at dual specificity phosphatase 3 3135 DUSP3 -0.980 - 1.35E-03 6.07E-03 
201537_PM_s_at dual specificity phosphatase 3 7422 DUSP3 -0.277 - 6.55E-03 1.22E-02 
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203590_PM_at dynein, cytoplasmic 1, light intermediate chain 2 117584 DYNC1LI2 -0.890 - 2.16E-02 1.70E-02 
217270_PM_s_at 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1B 
55540 DYRK1B -0.483 - 4.10E-02 4.82E-02 
202968_PM_s_at 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
2 
85021 DYRK2 -0.547 - 1.28E-02 2.99E-02 
38707_PM_r_at E2F transcription factor 4, p107/p130-binding --- E2F4 -0.646 - 8.68E-03 2.02E-02 
223243_PM_s_at ER degradation enhancer, mannosidase alpha-like 3 55336 EDEM3 -1.341 - 7.87E-04 9.14E-04 
207379_PM_at EGF-like repeats and discoidin I-like domains 3 23157 /// 84656 EDIL3 -2.460 - 4.91E-03 3.11E-02 
1558643_PM_s_at EGF-like repeats and discoidin I-like domains 3 7398 EDIL3 -1.296 - 6.77E-03 4.22E-02 
204540_PM_at eukaryotic translation elongation factor 1 alpha 2 3685 EEF1A2 -3.645 - 2.52E-08 1.02E-05 
210883_PM_x_at ephrin-B3 158 /// 23112 EFNB3 -0.564 - 3.13E-02 8.83E-03 
201983_PM_s_at 
epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avian) 
23007 EGFR -0.410 - 8.41E-03 4.55E-02 
221497_PM_x_at egl nine homolog 1 (C. elegans) 1842 EGLN1 -1.128 - 3.70E-03 1.57E-02 
223083_PM_s_at egl nine homolog 2 (C. elegans) 54969 EGLN2 -0.495 - 1.11E-02 2.42E-02 
212650_PM_at EH domain binding protein 1 7443 EHBP1 -0.788 - 5.73E-03 1.41E-02 
209037_PM_s_at EH-domain containing 1 4649 EHD1 -0.307 - 5.53E-03 3.53E-02 
201019_PM_s_at 
eukaryotic translation initiation factor 1A pseudogene 1 /// 




-0.760 - 7.06E-03 1.70E-03 
201017_PM_at eukaryotic translation initiation factor 1A, X-linked 509 EIF1AX -0.597 - 2.57E-02 3.47E-02 
225827_PM_at eukaryotic translation initiation factor 2C, 2 414899 EIF2C2 -0.925 - 2.98E-02 3.21E-02 
200596_PM_s_at eukaryotic translation initiation factor 3, subunit A 8487 EIF3A -0.479 - 8.58E-03 4.22E-03 
240513_PM_at Eukaryotic translation initiation factor 3, subunit M 55745 EIF3M -0.274 - 7.55E-03 2.60E-02 
211937_PM_at eukaryotic translation initiation factor 4B 8717 EIF4B -0.676 - 1.12E-03 5.05E-03 
238461_PM_at eukaryotic translation initiation factor 4E family member 3 202451 EIF4E3 -0.478 - 1.34E-03 1.74E-02 
208624_PM_s_at eukaryotic translation initiation factor 4 gamma, 1 23139 EIF4G1 -0.652 - 1.50E-02 1.17E-02 
1554310_PM_a_at eukaryotic translation initiation factor 4 gamma, 3 9045 EIF4G3 -0.622 - 1.55E-02 1.54E-02 
208705_PM_s_at eukaryotic translation initiation factor 5 51637 EIF5 -0.961 - 6.81E-03 2.06E-03 
208427_PM_s_at 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 
(Hu antigen B) 
9380 ELAVL2 -1.628 - 8.29E-03 3.80E-02 
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1555602_PM_a_at 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 
(Hu antigen C) 
262 ELAVL3 -0.508 - 1.48E-02 3.91E-02 
210376_PM_x_at ELK1, member of ETS oncogene family 10869 ELK1 -0.609 - 2.75E-03 1.25E-02 
217039_PM_x_at 
ELK1, member of ETS oncogene family /// similar to ETS 




-0.352 - 4.75E-02 1.18E-02 
220029_PM_at 
elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 2 
3720 ELOVL2 -0.570 - 7.82E-03 3.42E-02 
221094_PM_s_at elongation protein 3 homolog (S. cerevisiae) 2028 ELP3 -0.447 - 2.15E-02 2.85E-02 
204399_PM_s_at echinoderm microtubule associated protein like 2 10920 EML2 -0.508 - 9.84E-04 5.88E-04 
1570393_PM_at echinoderm microtubule associated protein like 5 10658 EML5 -0.272 - 4.39E-03 2.81E-02 
201340_PM_s_at ectodermal-neural cortex (with BTB-like domain) 7422 ENC1 -2.149 - 9.63E-04 7.23E-04 
212336_PM_at erythrocyte membrane protein band 4.1-like 1 1666 EPB41L1 -0.792 - 6.83E-03 5.99E-03 
206114_PM_at EPH receptor A4 546 EPHA4 -1.897 - 3.75E-04 3.93E-03 
228948_PM_at EPH receptor A4 9175 EPHA4 -0.991 - 8.20E-03 1.24E-02 
229374_PM_at EPH receptor A4 730094 EPHA4 -0.821 - 2.56E-02 3.62E-02 
215664_PM_s_at EPH receptor A5 63920 EPHA5 -0.702 - 2.45E-02 3.05E-02 
200842_PM_s_at glutamyl-prolyl-tRNA synthetase 83450 EPRS -1.262 - 8.28E-03 1.16E-02 
200841_PM_s_at glutamyl-prolyl-tRNA synthetase 7916 EPRS -1.159 - 1.53E-02 1.09E-02 
224576_PM_at 
endoplasmic reticulum-golgi intermediate compartment 
(ERGIC) 1 
90441 ERGIC1 -0.397 - 1.32E-02 1.31E-02 
202444_PM_s_at ER lipid raft associated 1 93974 ERLIN1 -0.524 - 5.98E-03 3.51E-02 
222646_PM_s_at ERO1-like (S. cerevisiae) 152559 ERO1L -0.632 - 4.56E-02 1.19E-02 
218859_PM_s_at 
ESF1, nucleolar pre-rRNA processing protein, homolog (S. 
cerevisiae) 
343450 ESF1 -0.781 - 2.96E-02 2.18E-02 
1555830_PM_s_at extended synaptotagmin-like protein 2 5500 ESYT2 -0.326 - 1.40E-02 2.04E-02 
226432_PM_at ethanolamine kinase 1 6731 ETNK1 -1.923 - 1.81E-02 3.53E-02 
216375_PM_s_at ets variant 5 79694 ETV5 -1.337 - 2.74E-04 6.31E-03 
210012_PM_s_at Ewing sarcoma breakpoint region 1 55684 EWSR1 -0.744 - 1.65E-02 4.17E-02 
1555808_PM_a_at exonuclease 3’-5’ domain containing 2 5339 EXD2 -0.462 - 1.34E-02 2.04E-02 
240528_PM_s_at exocyst complex component 4 4728 EXOC4 -1.828 - 1.43E-04 4.20E-04 
211051_PM_s_at exostoses (multiple)-like 3 84557 EXTL3 -0.296 - 8.51E-04 2.84E-03 
 201 
208621_PM_s_at ezrin 5322 EZR -1.321 - 2.68E-04 1.18E-03 
234963_PM_s_at fatty acid 2-hydroxylase 1024 FA2H -1.157 - 1.97E-02 3.41E-02 
216080_PM_s_at fatty acid desaturase 3 56926 FADS3 -1.703 - 3.56E-02 3.72E-02 
222511_PM_x_at Fas (TNFRSF6) associated factor 1 57215 FAF1 -0.325 - 5.04E-03 3.64E-02 
212106_PM_at Fas associated factor family member 2 55233 FAF2 -0.743 - 1.13E-02 4.41E-03 
224785_PM_at family with sequence similarity 100, member B 150684 FAM100B -0.784 - 2.19E-02 3.84E-02 
227869_PM_at 





-0.518 - 6.83E-04 1.07E-02 
209074_PM_s_at family with sequence similarity 107, member A 56945 FAM107A -1.023 - 1.46E-02 2.02E-02 
223059_PM_s_at family with sequence similarity 107, member B 54914 FAM107B -0.479 - 3.04E-02 3.20E-02 
221267_PM_s_at family with sequence similarity 108, member A1 8864 FAM108A1 -3.945 - 5.03E-03 1.74E-02 
220285_PM_at family with sequence similarity 108, member B1 2487 FAM108B1 -1.148 - 3.11E-03 2.13E-02 
210529_PM_s_at family with sequence similarity 115, member A 4215 FAM115A -2.785 - 9.15E-04 5.82E-03 
229739_PM_s_at family with sequence similarity 116, member B 84859 FAM116B -0.969 - 5.03E-03 1.88E-02 
228678_PM_at family with sequence similarity 116, member B 10220 FAM116B -0.384 - 7.95E-03 1.90E-03 
200767_PM_s_at family with sequence similarity 120A 649 FAM120A -0.651 - 1.09E-03 8.29E-03 
1555945_PM_s_at family with sequence similarity 120A 10856 FAM120A -0.948 - 7.67E-03 1.99E-02 
232806_PM_s_at family with sequence similarity 131, member A --- FAM131A -0.746 - 7.69E-03 2.77E-02 
229946_PM_at family with sequence similarity 168, member B 57380 FAM168B -0.308 - 1.12E-02 1.77E-02 
242762_PM_s_at family with sequence similarity 171, member B 63934 FAM171B -1.424 - 6.13E-04 6.64E-03 
1554132_PM_a_at family with sequence similarity 190, member B 7158 FAM190B -0.411 - 1.13E-02 5.34E-04 
208092_PM_s_at family with sequence similarity 49, member A 135138 FAM49A -0.740 - 8.90E-03 2.32E-02 
243011_PM_at family with sequence similarity 55, member C 440957 FAM55C -0.735 - 7.07E-03 3.81E-02 
228459_PM_at family with sequence similarity 84, member A 54542 FAM84A -0.895 - 1.42E-02 2.39E-02 
1556131_PM_s_at Fas (TNFRSF6) binding factor 1 56681 FBF1 -0.354 - 1.99E-02 2.26E-02 
201787_PM_at fibulin 1 6935 FBLN1 -0.693 - 1.66E-02 1.83E-02 
220080_PM_at F-box and leucine-rich repeat protein 8 51439 FBXL8 -0.265 - 1.07E-03 1.30E-02 
 202 
220233_PM_at F-box protein 17 /// seryl-tRNA synthetase 2, mitochondrial 2799 
FBXO17 /// 
SARS2 
-0.616 - 4.47E-02 4.32E-02 
219305_PM_x_at F-box protein 2 6659 FBXO2 -0.567 - 1.44E-02 9.72E-03 
212229_PM_s_at F-box protein 21 55186 FBXO21 -1.458 - 4.84E-03 7.07E-03 
219608_PM_s_at F-box protein 38 7320 FBXO38 -0.407 - 1.26E-03 3.68E-03 
225100_PM_at F-box protein 45 51277 FBXO45 -0.352 - 4.91E-04 2.53E-03 
1566509_PM_s_at F-box protein 9 348 FBXO9 -1.200 - 1.95E-02 3.82E-02 
209456_PM_s_at F-box and WD repeat domain containing 11 55364 FBXW11 -1.653 - 3.99E-05 3.63E-04 
214212_PM_x_at fermitin family homolog 2 (Drosophila) 8801 FERMT2 -1.277 - 2.06E-03 4.52E-04 
202305_PM_s_at fasciculation and elongation protein zeta 2 (zygin II) 26354 FEZ2 -0.655 - 2.33E-03 5.36E-03 
204819_PM_at FYVE, RhoGEF and PH domain containing 1 8880 FGD1 -0.326 - 3.86E-02 4.32E-02 
207501_PM_s_at fibroblast growth factor 12 7385 FGF12 -0.637 - 1.97E-02 4.03E-02 
207937_PM_x_at fibroblast growth factor receptor 1 93081 FGFR1 -0.877 - 7.01E-03 1.52E-02 
210973_PM_s_at fibroblast growth factor receptor 1 285313 FGFR1 -1.719 - 9.94E-03 1.65E-02 
211401_PM_s_at fibroblast growth factor receptor 2 6546 FGFR2 -0.620 - 2.72E-02 4.15E-02 
204380_PM_s_at fibroblast growth factor receptor 3 1942 FGFR3 -0.485 - 6.01E-03 1.95E-02 
201539_PM_s_at four and a half LIM domains 1 5799 FHL1 -2.777 - 2.71E-02 4.82E-02 
210298_PM_x_at four and a half LIM domains 1 9946 FHL1 -2.917 - 2.79E-02 4.94E-02 
40850_PM_at FK506 binding protein 8, 38kDa --- FKBP8 -1.414 - 3.64E-02 4.89E-02 
236329_PM_at hypothetical protein FLJ33996 23011 FLJ33996 -1.886 - 4.83E-03 2.06E-03 
208748_PM_s_at flotillin 1 2287 FLOT1 -1.202 - 3.20E-02 1.36E-02 
211299_PM_s_at flotillin 2 163081 FLOT2 -0.586 - 1.43E-03 1.26E-02 
234106_PM_s_at FLYWCH-type zinc finger 1 --- FLYWCH1 -0.324 - 1.54E-02 3.22E-02 
229272_PM_at formin binding protein 4 91404 FNBP4 -0.525 - 8.08E-03 1.30E-02 
228250_PM_at folliculin interacting protein 1 55802 FNIP1 -0.396 - 3.04E-03 2.56E-02 
223997_PM_at folliculin interacting protein 1 26503 FNIP1 -0.364 - 5.19E-03 7.26E-03 
204764_PM_at farnesyltransferase, CAAX box, beta 9267 FNTB -1.093 - 2.24E-02 3.98E-02 
204131_PM_s_at forkhead box O3 8451 FOXO3 -0.591 - 4.95E-02 3.85E-02 
230146_PM_s_at frequenin homolog (Drosophila) 283209 FREQ -0.490 - 1.25E-02 1.27E-02 
1554260_PM_a_at FRY-like 6156 FRYL -0.650 - 1.29E-02 4.30E-02 
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201564_PM_s_at 
fascin homolog 1, actin-bundling protein (Strongylocentrotus 
purpuratus) 
10093 /// 26140 FSCN1 -0.429 - 7.24E-03 4.59E-03 
210933_PM_s_at 
fascin homolog 1, actin-bundling protein (Strongylocentrotus 
purpuratus) 
9101 FSCN1 -0.312 - 4.17E-02 2.33E-02 
203091_PM_at far upstream element (FUSE) binding protein 1 4774 FUBP1 -0.655 - 2.14E-02 3.51E-02 
1565717_PM_s_at 
fusion (involved in t(12;16) in malignant liposarcoma) /// 
nuclear receptor subfamily 1, group H, member 3 
5932 FUS /// NR1H3 -2.732 - 1.25E-02 2.28E-02 
213594_PM_x_at FUS interacting protein (serine/arginine-rich) 1 23197 FUSIP1 -1.548 - 4.50E-04 7.89E-03 
210178_PM_x_at FUS interacting protein (serine/arginine-rich) 1 26057 FUSIP1 -1.446 - 1.85E-03 1.83E-02 
201635_PM_s_at fragile X mental retardation, autosomal homolog 1 3688 FXR1 -2.198 - 2.34E-02 4.50E-02 
220131_PM_at FXYD domain containing ion transport regulator 7 55719 FXYD7 -2.472 - 2.88E-02 4.72E-02 
211865_PM_s_at fizzy/cell division cycle 20 related 1 (Drosophila) 9147 FZR1 -0.486 - 7.71E-03 4.38E-02 
223254_PM_s_at G2/M-phase specific E3 ubiquitin ligase 53822 G2E3 -0.372 - 4.05E-02 3.89E-02 
201514_PM_s_at GTPase activating protein (SH3 domain) binding protein 1 2992 G3BP1 -0.284 - 1.88E-02 2.06E-02 
206383_PM_s_at GTPase activating protein (SH3 domain) binding protein 2 10057 G3BP2 -2.274 - 1.73E-03 1.45E-02 
208840_PM_s_at GTPase activating protein (SH3 domain) binding protein 2 29880 G3BP2 -0.985 - 1.57E-02 4.86E-02 
207112_PM_s_at GRB2-associated binding protein 1 9657 GAB1 -0.350 - 5.43E-03 1.05E-02 
225998_PM_at GRB2-associated binding protein 1 8992 GAB1 -0.725 - 8.32E-03 1.41E-02 
211679_PM_x_at gamma-aminobutyric acid (GABA) B receptor, 2 55337 GABBR2 -1.002 - 1.19E-02 1.29E-02 
209991_PM_x_at gamma-aminobutyric acid (GABA) B receptor, 2 80298 GABBR2 -3.259 - 1.36E-02 2.33E-02 
217077_PM_s_at gamma-aminobutyric acid (GABA) B receptor, 2 84937 GABBR2 -3.318 - 1.61E-02 2.85E-02 
206678_PM_at gamma-aminobutyric acid (GABA) A receptor, alpha 1 3305 GABRA1 -2.163 - 3.76E-03 2.25E-02 
207210_PM_at gamma-aminobutyric acid (GABA) A receptor, alpha 3 10137 GABRA3 -1.739 - 1.19E-02 2.29E-02 
217280_PM_x_at gamma-aminobutyric acid (GABA) A receptor, alpha 5 7227 GABRA5 -2.937 - 9.26E-03 2.53E-02 
215531_PM_s_at gamma-aminobutyric acid (GABA) A receptor, alpha 5 10842 GABRA5 -2.920 - 9.54E-03 3.07E-02 
229724_PM_at gamma-aminobutyric acid (GABA) A receptor, beta 3 6657 GABRB3 -1.653 - 1.43E-03 2.76E-03 
205850_PM_s_at gamma-aminobutyric acid (GABA) A receptor, beta 3 6166 GABRB3 -1.389 - 3.75E-03 1.58E-02 
208457_PM_at gamma-aminobutyric acid (GABA) A receptor, delta 2971 GABRD -1.253 - 1.30E-02 2.88E-02 
206670_PM_s_at glutamate decarboxylase 1 (brain, 67kDa) 23049 GAD1 -2.694 - 3.23E-03 1.13E-02 
211810_PM_s_at galactosylceramidase 83746 GALC -0.624 - 8.97E-03 5.62E-03 




acetylgalactosaminyltransferase 2 (GalNAc-T2) 
84061 GALNT2 -0.471 - 8.32E-04 1.60E-03 
1566271_PM_x_at GTPase activating Rap/RanGAP domain-like 1 11072 GARNL1 -0.269 - 6.75E-03 4.67E-03 
208258_PM_s_at growth arrest-specific 2 like 1 10228 GAS2L1 -0.783 - 6.67E-03 2.55E-02 
210872_PM_x_at growth arrest-specific 7 166968 GAS7 -0.678 - 1.25E-02 3.02E-03 
202191_PM_s_at growth arrest-specific 7 
22947 /// 653543 
/// 653544 /// 
653545 /// 
728410 
GAS7 -0.403 - 2.03E-02 4.53E-02 
208503_PM_s_at GATA zinc finger domain containing 1 10440 GATAD1 -1.163 - 1.13E-03 3.32E-03 
223921_PM_s_at glucosidase, beta (bile acid) 2 59277 GBA2 -1.346 - 2.77E-02 4.62E-02 
221279_PM_at ganglioside-induced differentiation-associated protein 1 6728 GDAP1 -1.954 - 2.71E-03 1.46E-02 
1555606_PM_a_at 
glycerophosphodiester phosphodiesterase domain containing 
1 
5707 GDPD1 -0.645 - 3.54E-03 1.44E-02 
217099_PM_s_at gem (nuclear organelle) associated protein 4 57409 GEMIN4 -0.348 - 2.64E-02 2.93E-02 
231917_PM_at G elongation factor, mitochondrial 2 284214 /// 9229 GFM2 -0.316 - 3.24E-04 1.29E-03 
205722_PM_s_at GDNF family receptor alpha 2 9522 GFRA2 -0.406 - 2.89E-02 2.74E-02 
214190_PM_x_at 
golgi associated, gamma adaptin ear containing, ARF binding 
protein 2 
284403 GGA2 -0.869 - 5.82E-03 1.00E-02 
208915_PM_s_at 
golgi associated, gamma adaptin ear containing, ARF binding 
protein 2 
582 GGA2 -1.578 - 1.22E-02 2.10E-02 
211815_PM_s_at 
golgi associated, gamma adaptin ear containing, ARF binding 
protein 3 
776 GGA3 -1.093 - 1.42E-02 1.01E-02 
226471_PM_at gamma-glutamyltransferase 7 2186 GGT7 -1.639 - 3.74E-03 1.31E-02 
215977_PM_x_at glycerol kinase 51218 GK -0.442 - 3.25E-04 1.83E-03 
229312_PM_s_at G kinase anchoring protein 1 112487 GKAP1 -0.806 - 6.07E-03 1.69E-03 
214730_PM_s_at golgi apparatus protein 1 80351 GLG1 -0.730 - 4.34E-02 1.52E-02 
203158_PM_s_at glutaminase 221955 GLS -1.205 - 2.63E-03 1.80E-02 
223079_PM_s_at glutaminase 9419 GLS -0.283 - 2.76E-02 1.99E-02 
217202_PM_s_at glutamate-ammonia ligase (glutamine synthetase) 5570 GLUL -2.428 - 1.59E-02 3.48E-02 
200648_PM_s_at glutamate-ammonia ligase (glutamine synthetase) 509 GLUL -1.986 - 1.93E-02 3.68E-02 
221628_PM_s_at glyoxylate reductase 1 homolog (Arabidopsis) 10787 GLYR1 -0.953 - 7.21E-03 1.25E-02 
 205 
204762_PM_s_at 
guanine nucleotide binding protein (G protein), alpha 
activating activity polypeptide O 
10775 GNAO1 -0.427 - 2.81E-02 3.11E-03 
200745_PM_s_at 
guanine nucleotide binding protein (G protein), beta 
polypeptide 1 
2257 GNB1 -1.665 - 6.19E-03 2.14E-02 
1555766_PM_a_at guanine nucleotide binding protein (G protein), gamma 2 1315 GNG2 -1.613 - 6.30E-03 1.54E-02 
224965_PM_at guanine nucleotide binding protein (G protein), gamma 2 441212 GNG2 -0.815 - 8.02E-03 3.94E-02 
203676_PM_at glucosamine (N-acetyl)-6-sulfatase 4668 GNS -1.113 - 2.25E-03 1.17E-02 
35436_PM_at golgi autoantigen, golgin subfamily a, 2 --- GOLGA2 -0.546 - 5.21E-03 1.04E-02 
204384_PM_at golgi autoantigen, golgin subfamily a, 2 3836 GOLGA2 -0.583 - 1.32E-02 3.14E-03 
227214_PM_at golgi associated PDZ and coiled-coil motif containing 55269 GOPC -0.752 - 1.03E-02 1.79E-02 
227215_PM_at golgi associated PDZ and coiled-coil motif containing 51542 GOPC -0.490 - 1.19E-02 7.90E-03 
225420_PM_at glycerol-3-phosphate acyltransferase, mitochondrial 54768 GPAM -0.795 - 1.15E-02 1.82E-02 
211613_PM_s_at glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 51271 GPD2 -0.589 - 4.86E-03 2.19E-02 
234941_PM_s_at gephyrin 9583 GPHN -1.045 - 3.03E-02 4.78E-02 
209167_PM_at glycoprotein M6B 64067 GPM6B -0.398 - 2.64E-02 2.14E-03 
225058_PM_at G protein-coupled receptor 108 57631 GPR108 -0.268 - 2.95E-02 1.04E-03 
43934_PM_at G protein-coupled receptor 137 --- GPR137 -1.159 - 4.27E-03 1.02E-02 
219430_PM_at G protein-coupled receptor 137 1345 GPR137 -0.668 - 1.74E-02 3.11E-02 
242592_PM_at G protein-coupled receptor 137C --- GPR137C -0.276 - 3.30E-03 1.70E-02 
228950_PM_s_at G protein-coupled receptor 177 6638 GPR177 -1.006 - 1.64E-02 4.97E-02 
221306_PM_at G protein-coupled receptor 27 10603 GPR27 -0.406 - 1.20E-02 1.35E-02 
207055_PM_at G protein-coupled receptor 37 like 1 7301 GPR37L1 -1.289 - 8.47E-03 1.55E-02 
203631_PM_s_at G protein-coupled receptor, family C, group 5, member B 23074 GPRC5B -2.836 - 3.74E-03 1.41E-02 
209410_PM_s_at growth factor receptor-bound protein 10 9448 GRB10 -1.025 - 1.44E-03 5.68E-03 
215075_PM_s_at growth factor receptor-bound protein 2 60487 GRB2 -0.625 - 7.98E-04 4.39E-03 
220794_PM_at 
gremlin 2, cysteine knot superfamily, homolog (Xenopus 
laevis) 
9649 GREM2 -0.349 - 8.09E-04 6.83E-03 
208032_PM_s_at glutamate receptor, ionotrophic, AMPA 3 57863 GRIA3 -1.937 - 2.37E-03 1.63E-02 
206730_PM_at glutamate receptor, ionotrophic, AMPA 3 90410 GRIA3 -2.472 - 2.95E-03 1.38E-02 
217565_PM_at glutamate receptor, ionotrophic, AMPA 3 65056 GRIA3 -1.747 - 3.65E-03 7.72E-03 
214966_PM_at glutamate receptor, ionotropic, 205eparin 5 51650 GRIK5 -1.204 - 4.36E-03 6.26E-03 
217509_PM_x_at glutamate receptor, ionotropic, 205eparin 5 9991 GRIK5 -0.300 - 4.00E-02 3.57E-02 
 206 
210781_PM_x_at glutamate receptor, ionotropic, N-methyl D-aspartate 1 
100302736 /// 
353376 
GRIN1 -1.986 - 1.10E-03 4.14E-03 
211125_PM_x_at glutamate receptor, ionotropic, N-methyl D-aspartate 1 57223 GRIN1 -1.258 - 5.09E-03 6.72E-03 
210782_PM_x_at glutamate receptor, ionotropic, N-methyl D-aspartate 1 65062 GRIN1 -0.918 - 5.91E-03 6.46E-03 
205915_PM_x_at glutamate receptor, ionotropic, N-methyl D-aspartate 1 23039 GRIN1 -1.401 - 7.92E-03 1.99E-02 
210412_PM_at glutamate receptor, ionotropic, N-methyl D-aspartate 2B 85315 GRIN2B -1.809 - 2.99E-02 1.62E-02 
207235_PM_s_at glutamate receptor, metabotropic 5 
100101267 /// 
9883 
GRM5 -0.465 - 3.56E-03 7.76E-03 
217008_PM_s_at glutamate receptor, metabotropic 7 55437 GRM7 -0.893 - 1.21E-02 3.56E-02 
201520_PM_s_at G-rich RNA sequence binding factor 1 2263 GRSF1 -0.657 - 9.90E-03 3.44E-02 
214040_PM_s_at gelsolin (amyloidosis, Finnish type) 8233 GSN -1.099 - 8.76E-03 2.23E-02 
238585_PM_at glycosyltransferase-like domain containing 1 --- GTDC1 -0.894 - 1.87E-02 3.68E-02 
202355_PM_s_at general transcription factor IIF, polypeptide 1, 74kDa 81539 GTF2F1 -0.619 - 1.92E-02 3.78E-03 
202453_PM_s_at general transcription factor IIH, polypeptide 1, 62kDa 27247 GTF2H1 -1.177 - 1.50E-02 4.02E-02 
210892_PM_s_at general transcription factor Iii 6326 GTF2I -0.397 - 2.77E-02 4.65E-02 
210620_PM_s_at general transcription factor IIIC, polypeptide 2, beta 110kDa 143384 GTF3C2 -0.619 - 4.05E-03 2.88E-02 
206927_PM_s_at guanylate cyclase 1, soluble, alpha 2 11235 GUCY1A2 -0.312 - 5.66E-03 2.35E-02 
208629_PM_s_at 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit 
23002 HADHA -0.929 - 7.33E-03 1.59E-02 
240975_PM_x_at hexaribonucleotide binding protein 3 92482 hCG_1776007 -0.688 - 1.34E-03 1.23E-02 
229406_PM_at hexaribonucleotide binding protein 3 9640 hCG_1776007 -1.442 - 3.43E-03 5.38E-03 
1556959_PM_at hCG2007354 3066 hCG_2007354 -0.347 - 6.68E-03 3.65E-02 
1557100_PM_s_at HECT domain containing 1 2908 HECTD1 -0.481 - 1.17E-03 3.53E-03 
241955_PM_at HECT domain containing 1 --- HECTD1 -0.465 - 4.78E-03 1.88E-02 
240703_PM_s_at 
hect (homologous to the E6-AP (UBE3A) carboxyl terminus) 
domain and RCC1 (CHC1)-like domain (RLD) 1 
254251 HERC1 -0.302 - 2.19E-03 1.11E-02 
233509_PM_at hect domain and RLD 4 8548 HERC4 -0.326 - 1.99E-02 2.93E-02 
210428_PM_s_at hepatocyte growth factor-regulated tyrosine kinase substrate 3267 HGS -0.354 - 1.62E-02 3.95E-02 
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1556037_PM_s_at hedgehog interacting protein 8878 HHIP -0.927 - 1.74E-02 4.60E-02 
224078_PM_at hippocampus abundant transcript-like 2 3038 HIATL2 -0.630 - 6.34E-03 4.65E-02 
213763_PM_at homeodomain interacting protein kinase 2 30849 HIPK2 -1.034 - 8.15E-04 2.12E-04 
225116_PM_at homeodomain interacting protein kinase 2 387923 HIPK2 -0.548 - 7.05E-03 4.22E-02 
204806_PM_x_at major histocompatibility complex, class I, F 7799 HLA-F -0.799 - 2.56E-02 2.93E-02 
221875_PM_x_at major histocompatibility complex, class I, F 5781 HLA-F -0.863 - 3.63E-02 4.23E-02 
211530_PM_x_at major histocompatibility complex, class I, G 5170 HLA-G -0.986 - 8.56E-03 2.25E-02 
205822_PM_s_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 7101 HMGCS1 -3.141 - 2.17E-02 3.39E-02 
212596_PM_s_at HMG box domain containing 4 10200 HMGXB4 -0.511 - 1.89E-02 1.69E-02 
208765_PM_s_at heterogeneous nuclear ribonucleoprotein R 23412 HNRNPR -1.055 - 1.16E-02 3.35E-02 
236244_PM_at 
Heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A) 
23476 HNRNPU -0.406 - 1.68E-02 4.47E-02 
209675_PM_s_at heterogeneous nuclear ribonucleoprotein U-like 1 23786 HNRNPUL1 -0.609 - 1.22E-02 2.97E-03 
206997_PM_s_at 207eparin sulfate 6-O-sulfotransferase 1 11183 HS6ST1 -0.337 - 5.81E-03 8.06E-03 
1569905_PM_at hydroxysteroid (11-beta) dehydrogenase 1-like 4216 HSD11B1L -0.576 - 1.38E-04 3.05E-04 
213756_PM_s_at heat shock transcription factor 1 157567 HSF1 -0.630 - 1.31E-02 4.21E-02 
211969_PM_at heat shock protein 90kDa alpha (cytosolic), class A member 1 4076 HSP90AA1 -0.811 - 3.91E-03 8.75E-03 
200064_PM_at heat shock protein 90kDa alpha (cytosolic), class B member 1 8910 HSP90AB1 -0.280 - 4.27E-02 4.90E-02 
200598_PM_s_at heat shock protein 90kDa beta (Grp94), member 1 8777 HSP90B1 -2.314 - 1.23E-02 3.25E-02 
216449_PM_x_at heat shock protein 90kDa beta (Grp94), member 1 23731 HSP90B1 -1.077 - 1.33E-02 1.77E-02 
211016_PM_x_at heat shock 70kDa protein 4 60509 HSPA4 -0.581 - 3.12E-03 2.46E-02 
211015_PM_s_at heat shock 70kDa protein 4 7391 HSPA4 -0.349 - 9.26E-03 9.50E-03 
208814_PM_at Heat shock 70kDa protein 4 28985 HSPA4 -0.560 - 2.28E-02 9.83E-03 
208744_PM_x_at heat shock 105kDa/110kDa protein 1 54948 HSPH1 -2.723 - 1.08E-02 3.32E-02 
202601_PM_s_at HIV-1 Tat specific factor 1 23590 HTATSF1 -0.499 - 2.65E-03 8.77E-03 
207949_PM_s_at islet cell autoantigen 1, 69kDa 90634 ICA1 -0.274 - 3.31E-02 1.20E-02 
206906_PM_at intercellular adhesion molecule 5, telencephalin 3597 ICAM5 -0.646 - 1.88E-02 1.69E-03 
202439_PM_s_at iduronate 2-sulfatase 152006 IDS -1.128 - 1.00E-03 9.53E-03 
206342_PM_x_at iduronate 2-sulfatase 2063 IDS -0.710 - 1.59E-03 8.21E-03 
217432_PM_s_at iduronate 2-sulfatase 84817 IDS -1.100 - 2.18E-03 5.08E-03 
202438_PM_x_at iduronate 2-sulfatase 29098 IDS -0.303 - 3.18E-02 3.88E-02 
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202081_PM_at immediate early response 2 27352 IER2 -0.269 - 3.62E-03 1.40E-02 
243358_PM_at insulin-like growth factor 1 receptor --- IGF1R -0.340 - 5.13E-03 1.70E-03 
203424_PM_s_at insulin-like growth factor binding protein 5 8618 IGFBP5 -0.271 - 8.15E-03 1.53E-02 
225025_PM_at immunoglobulin superfamily, member 8 11278 IGSF8 -0.567 - 6.48E-03 2.25E-02 
211027_PM_s_at 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta 
64682 IKBKB -0.341 - 1.80E-02 2.23E-02 
220086_PM_at IKAROS family zinc finger 5 (Pegasus) 3488 IKZF5 -0.536 - 1.60E-04 7.03E-03 
211612_PM_s_at interleukin 13 receptor, alpha 1 92579 IL13RA1 -0.597 - 1.17E-03 9.28E-03 
210904_PM_s_at interleukin 13 receptor, alpha 1 80318 IL13RA1 -0.345 - 4.72E-03 1.67E-02 
222698_PM_s_at Impact homolog (mouse) 26156 IMPACT -0.322 - 4.38E-03 2.17E-02 
222093_PM_s_at INO80 complex subunit B 125061 /// 3423 INO80B -0.925 - 7.50E-03 2.15E-03 
204553_PM_x_at inositol polyphosphate-4-phosphatase, type I, 107kDa 10613 INPP4A -0.540 - 1.40E-02 9.97E-03 
208363_PM_s_at inositol polyphosphate-4-phosphatase, type I, 107kDa 8828 INPP4A -0.700 - 1.96E-02 3.68E-02 
1554757_PM_a_at inositol polyphosphate-5-phosphatase, 40kDa 5048 INPP5A -1.428 - 1.60E-03 1.29E-02 
217124_PM_at IQ motif containing E 57461 IQCE -0.505 - 4.80E-02 2.10E-02 
223429_PM_x_at ISY1 splicing factor homolog (S. cerevisiae) 60685 ISY1 -0.795 - 1.03E-02 2.49E-02 
209743_PM_s_at itchy E3 ubiquitin protein ligase homolog (mouse) 51719 ITCH -1.083 - 1.58E-02 2.34E-02 
209744_PM_x_at itchy E3 ubiquitin protein ligase homolog (mouse) 1073 ITCH -0.812 - 2.50E-02 3.13E-02 
204989_PM_s_at integrin, beta 4 9702 ITGB4 -0.717 - 1.81E-04 7.67E-04 
214292_PM_at integrin, beta 4 6665 ITGB4 -0.400 - 2.55E-03 4.41E-03 
211360_PM_s_at inositol 1,4,5-triphosphate receptor, type 2 146664 ITPR2 -0.285 - 2.39E-02 3.60E-02 
1552611_PM_a_at Janus kinase 1 139324 JAK1 -0.548 - 1.11E-02 1.48E-02 
231720_PM_s_at junctional adhesion molecule 3 --- JAM3 -2.361 - 9.60E-05 2.96E-03 
231721_PM_at junctional adhesion molecule 3 729262 JAM3 -0.850 - 7.34E-03 2.81E-02 
225800_PM_at JAZF zinc finger 1 9125 JAZF1 -1.053 - 3.99E-03 3.86E-02 
224933_PM_s_at jumonji domain containing 1C 387758 JMJD1C -1.712 - 2.24E-03 2.63E-03 
60528_PM_at 
JMJD7-PLA2G4B readthrough transcript /// phospholipase 





-0.269 - 3.43E-02 4.65E-02 
220188_PM_at junctophilin 3 24138 JPH3 -1.435 - 9.10E-03 1.89E-02 
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216309_PM_x_at jerky homolog (mouse) 79693 JRK -0.360 - 6.17E-03 2.60E-02 
201465_PM_s_at jun oncogene 7341 JUN -1.264 - 2.25E-02 4.56E-02 
214326_PM_x_at jun D proto-oncogene 10917 JUND -0.731 - 3.01E-03 2.27E-02 
203751_PM_x_at jun D proto-oncogene 9665 JUND -1.442 - 4.94E-03 1.01E-02 
201015_PM_s_at junction plakoglobin 7295 JUP -0.286 - 4.89E-02 2.87E-02 
223585_PM_x_at kelch repeat and BTB (POZ) domain containing 2 79871 KBTBD2 -2.073 - 9.58E-03 3.88E-02 
207237_PM_at 
potassium voltage-gated channel, shaker-related subfamily, 
member 3 
11163 /// 440672 KCNA3 -1.317 - 1.25E-02 1.17E-02 
208213_PM_s_at 
potassium voltage-gated channel, shaker-related subfamily, 
beta member 1 
7170 KCNAB1 -0.972 - 8.67E-03 1.16E-02 
210079_PM_x_at 
potassium voltage-gated channel, shaker-related subfamily, 
beta member 1 
152007 KCNAB1 -0.717 - 1.51E-02 7.06E-03 
211791_PM_s_at 
potassium voltage-gated channel, shaker-related subfamily, 
beta member 2 
1995 KCNAB2 -1.741 - 1.13E-02 1.96E-02 
1552507_PM_at 
potassium voltage-gated channel, Isk-related family, member 
4 
54715 KCNE4 -0.700 - 1.63E-02 2.00E-02 
1555230_PM_a_at Kv channel interacting protein 2 3945 KCNIP2 -2.389 - 1.61E-03 7.04E-03 
221321_PM_s_at Kv channel interacting protein 2 38 KCNIP2 -1.584 - 3.46E-03 1.34E-02 
1555694_PM_a_at Kv channel interacting protein 3, calsenilin 4714 KCNIP3 -0.346 - 7.74E-03 2.27E-02 
224530_PM_s_at Kv channel interacting protein 4 29883 KCNIP4 -0.550 - 3.45E-03 3.12E-02 
231740_PM_at 
potassium inwardly-rectifying channel, subfamily J, member 
11 
63877 KCNJ11 -0.364 - 1.29E-03 1.40E-03 
207141_PM_s_at potassium inwardly-rectifying channel, subfamily J, member 3 56105 KCNJ3 -1.432 - 2.66E-03 1.08E-02 
207527_PM_at potassium inwardly-rectifying channel, subfamily J, member 9 80205 KCNJ9 -0.309 - 2.97E-02 1.52E-02 
220448_PM_at potassium channel, subfamily K, member 12 4548 KCNK12 -1.343 - 2.13E-02 4.26E-02 
224552_PM_s_at potassium channel, subfamily K, member 4 200933 KCNK4 -0.979 - 4.05E-03 1.21E-03 
221583_PM_s_at 
potassium large conductance calcium-activated channel, 
subfamily M, alpha member 1 
2556 KCNMA1 -1.116 - 3.42E-03 6.81E-03 
1563608_PM_a_at potassium channel, subfamily T, member 1 4087 KCNT1 -0.289 - 4.03E-03 7.78E-03 
214849_PM_at potassium channel tetramerisation domain containing 20 22861 /// 728392 KCTD20 -0.740 - 4.15E-02 2.95E-02 
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200922_PM_at 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 1 
7267 KDELR1 -1.935 - 1.57E-02 2.56E-02 
200700_PM_s_at 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 2 
3674 KDELR2 -1.247 - 7.38E-04 6.98E-03 
208987_PM_s_at lysine (K)-specific demethylase 2A 10169 /// 25764 KDM2A -1.550 - 1.01E-02 1.62E-02 
212492_PM_s_at lysine (K)-specific demethylase 4B 10559 KDM4B -1.130 - 1.36E-02 2.33E-02 
202040_PM_s_at lysine (K)-specific demethylase 5A 2885 KDM5A -0.576 - 1.08E-02 3.15E-03 
41386_PM_i_at lysine (K)-specific demethylase 6B --- KDM6B -1.275 - 2.94E-04 3.37E-04 
213146_PM_at lysine (K)-specific demethylase 6B 5627 KDM6B -0.305 - 4.73E-03 8.74E-04 
201488_PM_x_at 
KH domain containing, RNA binding, signal transduction 
associated 1 
22848 KHDRBS1 -1.576 - 1.22E-02 3.37E-02 
212396_PM_s_at KIAA0090 6632 KIAA0090 -0.385 - 9.04E-03 4.02E-02 
1558697_PM_a_at KIAA0430 5528 KIAA0430 -0.462 - 3.72E-04 2.13E-03 
201775_PM_s_at KIAA0494 6935 KIAA0494 -0.403 - 4.28E-02 4.85E-02 
203363_PM_s_at KIAA0652 55755 KIAA0652 -0.543 - 8.04E-03 1.90E-02 
1554755_PM_a_at KIAA0774 5720 KIAA0774 -0.352 - 3.60E-03 5.35E-05 
216294_PM_s_at KIAA1109 56254 KIAA1109 -1.524 - 1.18E-03 7.41E-03 
223799_PM_at KIAA1826 55632 KIAA1826 -0.638 - 1.54E-02 4.38E-02 
224706_PM_at KIAA2013 440145 KIAA2013 -0.289 - 4.09E-02 3.61E-02 
201992_PM_s_at kinesin family member 5B 334 KIF5B -0.523 - 5.32E-04 7.11E-03 
203129_PM_s_at kinesin family member 5C 151887 KIF5C -1.557 - 7.13E-03 1.02E-02 
219878_PM_s_at Kruppel-like factor 13 5993 KLF13 -2.192 - 3.00E-02 3.98E-02 
219657_PM_s_at Kruppel-like factor 3 (basic) 8932 KLF3 -0.275 - 2.10E-02 4.77E-02 
203542_PM_s_at Kruppel-like factor 9 10634 KLF9 -1.197 - 2.69E-04 4.85E-03 
225963_PM_at kelch domain containing 5 51256 KLHDC5 -2.104 - 1.78E-03 1.34E-02 
221837_PM_at kelch-like 22 (Drosophila) 10026 KLHL22 -1.605 - 6.00E-03 1.80E-02 
221986_PM_s_at kelch-like 24 (Drosophila) 10985 KLHL24 -0.532 - 2.25E-02 1.73E-02 
1554145_PM_a_at KLRAQ motif containing 1 55209 KLRAQ1 -1.466 - 4.26E-03 3.19E-02 
202058_PM_s_at karyopherin alpha 1 (importin alpha 5) 65220 KPNA1 -1.605 - 2.63E-04 6.36E-03 
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213741_PM_s_at karyopherin alpha 1 (importin alpha 5) 23001 KPNA1 -0.848 - 3.39E-03 3.19E-02 
221503_PM_s_at karyopherin alpha 3 (importin alpha 4) 23205 KPNA3 -1.632 - 6.18E-04 3.67E-03 
212102_PM_s_at karyopherin alpha 6 (importin alpha 7) 1108 KPNA6 -0.563 - 2.83E-02 4.99E-02 
213507_PM_s_at karyopherin (importin) beta 1 1949 KPNB1 -0.984 - 4.22E-02 2.52E-03 
214352_PM_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 51371 KRAS -2.330 - 8.02E-03 2.73E-02 
224534_PM_at kringle containing transmembrane protein 1 84918 KREMEN1 -0.480 - 1.27E-02 5.47E-03 
204738_PM_s_at KRIT1, ankyrin repeat containing 6845 KRIT1 -0.483 - 2.10E-02 4.60E-02 
230116_PM_at Keratin 8 pseudogene 12 145748 KRT8P12 -0.269 - 2.52E-03 1.98E-02 
200914_PM_x_at kinectin 1 (kinesin receptor) 5879 KTN1 -2.004 - 4.38E-03 1.72E-02 
1555815_PM_a_at l(3)mbt-like 2 (Drosophila) 9898 L3MBTL2 -0.341 - 1.13E-02 1.36E-02 
201551_PM_s_at lysosomal-associated membrane protein 1 84525 LAMP1 -2.294 - 1.04E-02 2.72E-02 
218219_PM_s_at LanC lantibiotic synthetase component C-like 2 (bacterial) 253558 LANCL2 -0.835 - 5.53E-03 2.74E-02 
1554679_PM_a_at lysosomal protein transmembrane 4 beta 4735 LAPTM4B -1.130 - 1.05E-02 1.84E-02 
223888_PM_s_at leucyl-tRNA synthetase 51259 LARS -0.552 - 2.05E-03 1.30E-02 
219813_PM_at LATS, large tumor suppressor, homolog 1 (Drosophila) 5519 LATS1 -0.359 - 9.49E-03 3.84E-02 
202595_PM_s_at leptin receptor overlapping transcript-like 1 27068 LEPROTL1 -0.819 - 1.73E-03 1.59E-02 
227821_PM_at leucine-rich repeat LGI family, member 4 378938 LGI4 -0.290 - 4.48E-02 3.58E-02 
212325_PM_at LIM and calponin homology domains 1 10915 LIMCH1 -0.664 - 2.82E-02 4.41E-02 
236156_PM_at lipase A, lysosomal acid, cholesterol esterase --- LIPA -0.345 - 3.25E-03 2.07E-02 
235036_PM_at Lix1 homolog (mouse)-like 3308 LIX1L -0.489 - 9.66E-05 3.26E-03 
31837_PM_at lipase maturation factor 2 --- LMF2 -0.302 - 4.27E-02 2.18E-02 
209204_PM_at LIM domain only 4 83440 LMO4 -1.322 - 4.36E-05 5.43E-04 
209205_PM_s_at LIM domain only 4 64850 LMO4 -1.257 - 5.64E-04 9.17E-03 
1557103_PM_a_at lemur tyrosine kinase 3 2908 LMTK3 -0.413 - 9.85E-03 3.22E-02 
1562022_PM_s_at similar to hCG1815675 /// RAD9 homolog A (S. pombe) 9551 
LOC100130987 
/// RAD9A 
-0.918 - 5.17E-03 2.44E-02 
1557783_PM_at similar to hCG1995169 158 LOC100133991 -0.287 - 5.14E-03 2.67E-02 
232309_PM_at hypothetical protein LOC202181 83852 LOC202181 -0.463 - 1.44E-02 2.79E-02 
241464_PM_s_at hypothetical LOC400931 84856 LOC400931 -0.731 - 2.96E-02 4.65E-02 
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1556771_PM_a_at hypothetical LOC415056 5431 LOC415056 -0.796 - 1.27E-03 1.46E-02 
215090_PM_x_at hypothetical protein FLJ11822 78991 LOC440434 -1.188 - 4.47E-03 4.61E-03 
214107_PM_x_at hypothetical protein FLJ11822 1506 LOC440434 -1.542 - 7.87E-03 1.86E-02 
1558688_PM_at hypothetical LOC441461 6744 LOC441461 -0.421 - 1.87E-02 1.20E-02 
212113_PM_at hypothetical protein LOC552889 10541 LOC552889 -1.873 - 8.13E-04 3.48E-03 
227223_PM_at 





-1.937 - 2.58E-03 2.59E-03 
215812_PM_s_at 
similar to solute carrier family 6 member 8 /// solute carrier 
family 6 (neurotransmitter transporter, creatine), member 10 
(pseudogene) /// solute carrier family 6 (neurotransmitter 





-1.643 - 4.75E-03 1.23E-02 
231808_PM_at hypothetical protein LOC729082 10691 LOC729082 -1.650 - 9.85E-03 2.62E-02 
216908_PM_x_at 
RRN3 RNA polymerase I transcription factor homolog (S. 
cerevisiae) pseudogene 
56987 LOC730092 -0.687 - 3.21E-03 1.33E-02 
40472_PM_at lysophosphatidylcholine acyltransferase 4 285147 LPCAT4 -1.204 - 7.81E-03 2.14E-02 
212272_PM_at lipin 1 1349 LPIN1 -0.616 - 1.04E-02 2.76E-02 
218509_PM_at lipid phosphate phosphatase-related protein type 2 5058 LPPR2 -1.954 - 2.12E-02 3.07E-02 
64899_PM_at lipid phosphate phosphatase-related protein type 2 --- LPPR2 -2.594 - 2.74E-02 4.22E-02 
200784_PM_s_at 
low density lipoprotein-related protein 1 (alpha-2-
macroglobulin receptor) 
785 LRP1 -0.910 - 1.01E-02 2.58E-03 
239320_PM_at leucine rich repeat containing 4B 92979 LRRC4B -1.035 - 5.05E-03 1.51E-02 
241585_PM_at leucine rich repeat containing 4C --- LRRC4C -0.466 - 9.82E-03 2.17E-02 
216164_PM_at leucine rich repeat neuronal 2 23409 LRRN2 -0.265 - 9.39E-03 9.08E-03 
212529_PM_at LSM12 homolog (S. cerevisiae) 669 LSM12 -2.283 - 6.11E-04 6.23E-03 
219653_PM_at LSM14B, SCD6 homolog B (S. cerevisiae) 11044 LSM14B -0.462 - 1.75E-02 2.18E-02 
1553304_PM_at LSM14B, SCD6 homolog B (S. cerevisiae) 7072 LSM14B -0.531 - 3.43E-02 4.71E-02 
213176_PM_s_at latent transforming growth factor beta binding protein 4 6731 LTBP4 -0.546 - 1.89E-02 2.31E-02 
208835_PM_s_at LUC7-like 3 (S. cerevisiae) 4708 LUC7L3 -1.647 - 1.92E-03 1.11E-02 
206773_PM_at lymphocyte antigen 6 complex, locus H 9747 LY6H -3.120 - 1.28E-02 1.97E-02 
210754_PM_s_at v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 84293 LYN -0.542 - 7.22E-04 6.92E-03 
200900_PM_s_at mannose-6-phosphate receptor (cation dependent) 23499 M6PR -0.919 - 1.69E-02 3.03E-02 
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209347_PM_s_at 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
81929 MAF -0.271 - 1.13E-02 8.98E-03 
222670_PM_s_at 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) 
220594 MAFB -0.472 - 9.65E-03 2.51E-02 
216617_PM_s_at myelin associated glycoprotein 51258 MAG -1.848 - 1.00E-02 4.70E-02 
220925_PM_at 
MAK10 homolog, amino-acid N-acetyltransferase subunit (S. 
cerevisiae) 
8269 MAK10 -1.098 - 3.64E-03 7.81E-03 
223940_PM_x_at 
metastasis associated lung adenocarcinoma transcript 1 (non-
protein coding) 
93974 MALAT1 -2.637 - 1.02E-03 1.42E-03 
224568_PM_x_at 
metastasis associated lung adenocarcinoma transcript 1 (non-
protein coding) 
28996 MALAT1 -2.587 - 3.51E-03 3.85E-03 
1558678_PM_s_at 
metastasis associated lung adenocarcinoma transcript 1 (non-
protein coding) 
2965 MALAT1 -0.658 - 2.41E-02 3.45E-02 
214577_PM_at microtubule-associated protein 1B 54529 MAP1B -3.423 - 8.88E-03 1.13E-02 
226084_PM_at microtubule-associated protein 1B 8452 MAP1B -0.708 - 4.14E-02 3.43E-02 
227219_PM_x_at microtubule-associated protein 1 light chain 3 alpha 51030 MAP1LC3A -0.969 - 2.12E-02 3.59E-02 
232011_PM_s_at microtubule-associated protein 1 light chain 3 alpha 440556 MAP1LC3A -3.074 - 2.26E-02 3.67E-02 
221697_PM_at microtubule-associated protein 1 light chain 3 gamma 10130 MAP1LC3C -0.322 - 6.37E-03 5.14E-03 
210015_PM_s_at microtubule-associated protein 2 85440 MAP2 -2.384 - 5.95E-04 7.90E-03 
203265_PM_s_at mitogen-activated protein kinase kinase 4 10600 MAP2K4 -2.058 - 4.61E-03 1.89E-02 
211081_PM_s_at mitogen-activated protein kinase kinase kinase kinase 5 148252 MAP4K5 -0.326 - 1.39E-02 3.70E-02 
208351_PM_s_at mitogen-activated protein kinase 1 2861 MAPK1 -2.629 - 7.81E-03 2.20E-02 
1552264_PM_a_at mitogen-activated protein kinase 1 5594 MAPK1 -2.508 - 8.19E-03 2.06E-02 
211087_PM_x_at mitogen-activated protein kinase 14 8437 MAPK14 -0.560 - 5.48E-03 7.80E-03 
211561_PM_x_at mitogen-activated protein kinase 14 8623 MAPK14 -0.855 - 6.04E-03 3.42E-02 
210449_PM_x_at mitogen-activated protein kinase 14 6095 MAPK14 -0.666 - 8.51E-03 2.32E-02 
213014_PM_at mitogen-activated protein kinase 8 interacting protein 1 2888 MAPK8IP1 -2.721 - 4.92E-04 3.88E-03 
208603_PM_s_at mitogen-activated protein kinase 8 interacting protein 2 51668 MAPK8IP2 -1.043 - 3.17E-03 7.09E-03 
229846_PM_s_at mitogen-activated protein kinase associated protein 1 29035 MAPKAP1 -1.650 - 5.03E-03 2.16E-02 
202501_PM_at microtubule-associated protein, RP/EB family, member 2 54946 MAPRE2 -0.287 - 2.19E-02 2.51E-02 
214270_PM_s_at microtubule-associated protein, RP/EB family, member 3 9639 MAPRE3 -3.238 - 4.73E-03 1.33E-02 
203841_PM_x_at microtubule-associated protein, RP/EB family, member 3 6418 MAPRE3 -3.191 - 4.76E-03 1.31E-02 
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206401_PM_s_at microtubule-associated protein tau 84263 MAPT -2.201 - 4.67E-03 4.89E-03 
201668_PM_x_at myristoylated alanine-rich protein kinase C substrate 800 MARCKS -2.391 - 2.56E-03 9.57E-03 
203942_PM_s_at MAP/microtubule affinity-regulating kinase 2 10724 MARK2 -1.126 - 2.45E-02 4.73E-02 
200769_PM_s_at methionine adenosyltransferase II, alpha 9497 MAT2A -2.621 - 8.19E-03 2.81E-02 
210734_PM_x_at MYC associated factor X 93589 MAX -1.556 - 1.80E-02 4.62E-02 
232138_PM_at Muscleblind-like 2 (Drosophila) --- MBNL2 -0.647 - 2.51E-03 8.99E-03 
205018_PM_s_at muscleblind-like 2 (Drosophila) 4925 MBNL2 -2.595 - 5.47E-03 2.18E-02 
205017_PM_s_at muscleblind-like 2 (Drosophila) 10150 MBNL2 -1.140 - 1.63E-02 4.86E-02 
1563809_PM_a_at MCF.2 cell line derived transforming sequence-like 4891 MCF2L -0.532 - 3.09E-03 2.34E-03 
212142_PM_at minichromosome maintenance complex component 4 55041 MCM4 -0.979 - 2.53E-03 9.97E-03 
204059_PM_s_at malic enzyme 1, NADP(+)-dependent, cytosolic 10054 ME1 -0.703 - 2.40E-02 3.85E-02 
221884_PM_at MDS1 and EVI1 complex locus 10181 MECOM -0.297 - 1.90E-03 2.06E-02 
212208_PM_at mediator complex subunit 13-like 8615 MED13L -0.737 - 1.44E-02 1.98E-02 
221517_PM_s_at mediator complex subunit 17 1472 MED17 -0.376 - 1.80E-02 3.38E-02 
226293_PM_at mediator complex subunit 19 9764 MED19 -0.801 - 3.46E-02 3.33E-02 
208328_PM_s_at myocyte enhancer factor 2A 5098 MEF2A -0.311 - 6.04E-03 1.00E-02 
235077_PM_at maternally expressed 3 (non-protein coding) 4791 MEG3 -1.997 - 1.30E-02 1.75E-02 
1569879_PM_a_at multiple EGF-like-domains 11 8412 MEGF11 -0.641 - 1.06E-02 1.15E-02 
211599_PM_x_at met proto-oncogene (hepatocyte growth factor receptor) 254531 MET -1.033 - 2.66E-04 5.38E-03 
213807_PM_x_at met proto-oncogene (hepatocyte growth factor receptor) 6272 MET -0.920 - 5.92E-03 6.54E-04 
206468_PM_s_at methyltransferase like 13 8930 METTL13 -0.436 - 1.11E-02 5.24E-03 
222567_PM_s_at mex-3 homolog C (C. elegans) 6874 MEX3C -1.077 - 4.27E-03 2.81E-02 
216205_PM_s_at mitofusin 2 80762 MFN2 -1.404 - 1.99E-03 1.09E-02 
219858_PM_s_at major facilitator superfamily domain containing 6 9917 MFSD6 -0.422 - 4.95E-03 2.97E-02 
220189_PM_s_at 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme B 
7915 MGAT4B -1.476 - 2.20E-02 3.80E-02 
200898_PM_s_at meningioma expressed antigen 5 (hyaluronidase) 23542 MGEA5 -0.709 - 8.95E-03 4.94E-02 
223494_PM_at meningioma expressed antigen 5 (hyaluronidase) 64864 MGEA5 -1.359 - 1.66E-02 2.02E-02 
214972_PM_at Meningioma expressed antigen 5 (hyaluronidase) 57826 MGEA5 -0.336 - 4.98E-02 1.33E-02 
228658_PM_at myocardial infarction associated transcript (non-protein 3696 MIAT -0.339 - 1.96E-02 2.35E-02 
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coding) 
214625_PM_s_at misshapen-like kinase 1 (zebrafish) 8303 MINK1 -1.132 - 3.28E-02 3.93E-02 
222510_PM_s_at makorin ring finger protein 2 23097 MKRN2 -1.475 - 1.27E-02 2.54E-02 
1565436_PM_s_at 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila) 
6635 MLL -0.498 - 9.33E-03 2.81E-02 
212078_PM_s_at 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila) 
23451 MLL -1.240 - 4.63E-02 1.26E-02 
222413_PM_s_at myeloid/lymphoid or mixed-lineage leukemia 3 124801 MLL3 -0.276 - 4.12E-02 3.37E-02 
223189_PM_x_at 
myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax 
homolog, Drosophila) 
51319 MLL5 -1.996 - 5.29E-03 3.68E-03 
223190_PM_s_at 
myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax 
homolog, Drosophila) 
55841 MLL5 -1.398 - 6.08E-03 7.91E-03 
216506_PM_x_at 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 10 
55017 MLLT10 -0.626 - 1.54E-02 1.25E-02 
216503_PM_s_at 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 10 
83641 MLLT10 -0.808 - 2.19E-02 2.52E-02 
202519_PM_at MLX interacting protein 5716 MLXIP -0.932 - 1.65E-02 4.79E-02 
221895_PM_at motile sperm domain containing 2 429 MOSPD2 -0.319 - 3.83E-03 6.79E-05 
205079_PM_s_at multiple PDZ domain protein 51668 MPDZ -0.458 - 1.18E-02 1.47E-02 
225041_PM_at M-phase phosphoprotein 8 286343 MPHOSPH8 -1.580 - 2.74E-03 1.06E-02 
221771_PM_s_at M-phase phosphoprotein 8 8543 MPHOSPH8 -0.836 - 1.54E-02 4.29E-02 
241398_PM_at Metallophosphoesterase domain containing 1 --- MPPED1 -0.368 - 3.82E-02 1.16E-02 
215692_PM_s_at metallophosphoesterase domain containing 2 81617 MPPED2 -1.162 - 2.22E-02 2.17E-02 
225233_PM_at musashi homolog 2 (Drosophila) 340554 MSI2 -1.033 - 2.54E-03 1.91E-02 
1554126_PM_at methionine sulfoxide reductase B3 57223 MSRB3 -0.931 - 1.11E-02 1.36E-02 
212251_PM_at metadherin 10314 MTDH -0.955 - 1.41E-02 1.47E-02 
205322_PM_s_at metal-regulatory transcription factor 1 9016 MTF1 -0.485 - 1.08E-02 9.28E-03 
214975_PM_s_at myotubularin related protein 1 57826 MTMR1 -0.351 - 9.97E-03 2.02E-02 
202198_PM_s_at myotubularin related protein 3 889 MTMR3 -0.426 - 4.52E-02 3.87E-02 
212095_PM_s_at mitochondrial tumor suppressor 1 8239 MTUS1 -0.378 - 1.54E-03 1.16E-02 
212347_PM_x_at MAX dimerization protein 4 1739 MXD4 -0.311 - 8.99E-03 3.12E-02 
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1557370_PM_s_at MYC binding protein 2 832 MYCBP2 -2.121 - 6.60E-03 9.63E-03 
201959_PM_s_at MYC binding protein 2 9444 MYCBP2 -1.444 - 9.34E-03 1.19E-02 
216222_PM_s_at myosin X 51773 MYO10 -0.287 - 2.10E-02 2.60E-02 
1560788_PM_at myosin IIIB 6921 MYO3B -0.343 - 1.30E-05 7.10E-04 
204527_PM_at myosin VA (heavy chain 12, myoxin) 9453 MYO5A -0.744 - 3.79E-02 2.25E-02 
203215_PM_s_at myosin VI 55578 MYO6 -0.421 - 2.80E-02 8.01E-03 
219027_PM_s_at myosin IXA 1762 MYO9A -0.285 - 2.03E-02 2.14E-02 
202423_PM_at MYST histone acetyltransferase (monocytic leukemia) 3 53343 MYST3 -0.642 - 1.58E-02 9.39E-03 
211874_PM_s_at MYST histone acetyltransferase (monocytic leukemia) 4 285093 MYST4 -1.571 - 3.90E-03 8.85E-03 
214496_PM_x_at MYST histone acetyltransferase (monocytic leukemia) 4 64771 MYST4 -1.491 - 4.64E-03 2.08E-02 
212452_PM_x_at MYST histone acetyltransferase (monocytic leukemia) 4 9197 MYST4 -1.394 - 5.24E-03 1.31E-02 
215822_PM_x_at myelin transcription factor 1 55620 MYT1 -0.497 - 3.01E-02 1.07E-03 
1554633_PM_a_at myelin transcription factor 1-like 5230 MYT1L -2.474 - 1.93E-03 1.13E-02 
216017_PM_s_at NGFI-A binding protein 2 (EGR1 binding protein 2) 7596 NAB2 -1.626 - 6.03E-03 5.05E-03 
215159_PM_s_at NAD kinase 64783 NADK -0.504 - 3.09E-03 1.18E-02 
213607_PM_x_at NAD kinase 23244 NADK -0.945 - 4.32E-03 1.16E-02 
208753_PM_s_at nucleosome assembly protein 1-like 1 51307 NAP1L1 -0.400 - 2.34E-02 2.79E-02 
206491_PM_s_at N-ethylmaleimide-sensitive factor attachment protein, alpha 3298 NAPA -2.181 - 2.04E-02 2.94E-02 
210048_PM_at N-ethylmaleimide-sensitive factor attachment protein, gamma 122786 NAPG -0.756 - 4.64E-03 2.65E-02 
219158_PM_s_at NMDA receptor regulated 1 10285 NARG1 -1.516 - 3.83E-04 2.79E-03 
235189_PM_at NMDA receptor regulated 2 --- NARG2 -0.327 - 7.89E-04 2.42E-03 
222599_PM_s_at neuron navigator 2 91 NAV2 -0.673 - 4.57E-02 4.01E-03 
201383_PM_s_at neighbor of BRCA1 gene 1 1837 NBR1 -0.779 - 7.79E-03 3.07E-02 
205669_PM_at neural cell adhesion molecule 2 6886 NCAM2 -0.540 - 2.51E-03 2.63E-02 
209557_PM_s_at neurochondrin 51538 NCDN -2.469 - 1.43E-03 4.76E-03 
209556_PM_at neurochondrin 11164 NCDN -0.429 - 1.20E-02 2.40E-02 
222206_PM_s_at nicalin homolog (zebrafish) 79572 NCLN -0.324 - 6.43E-03 7.04E-03 
205732_PM_s_at nuclear receptor coactivator 2 2322 NCOA2 -0.887 - 5.50E-03 3.51E-02 
211352_PM_s_at nuclear receptor coactivator 3 134218 NCOA3 -0.337 - 4.36E-03 4.02E-02 
222422_PM_s_at Nedd4 family interacting protein 1 23347 NDFIP1 -2.238 - 1.26E-02 3.70E-02 
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224799_PM_at Nedd4 family interacting protein 2 285282 NDFIP2 -1.098 - 2.11E-03 1.29E-02 
203039_PM_s_at 
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase) 
29058 NDUFS1 -0.631 - 9.30E-03 1.20E-02 
207279_PM_s_at nebulette 90411 NEBL -0.727 - 2.66E-03 5.75E-03 
223954_PM_x_at N-terminal EF-hand calcium binding protein 3 58527 NECAB3 -0.521 - 1.59E-03 4.57E-03 
212448_PM_at 
neural precursor cell expressed, developmentally down-
regulated 4-like 
10952 NEDD4L -0.589 - 1.26E-02 2.14E-02 
213328_PM_at NIMA (never in mitosis gene a)-related kinase 1 5612 NEK1 -0.650 - 3.71E-02 2.64E-02 
239267_PM_at NIMA (never in mitosis gene a)-related kinase 6 --- NEK6 -0.441 - 1.96E-03 1.08E-02 
214738_PM_s_at NIMA (never in mitosis gene a)- related kinase 9 29883 NEK9 -0.853 - 1.99E-02 4.71E-02 
222774_PM_s_at neuropilin (NRP) and tolloid (TLL)-like 2 9271 NETO2 -0.562 - 1.47E-02 3.21E-02 
204325_PM_s_at neurofibromin 1 1163 NF1 -0.324 - 1.39E-02 1.29E-02 
211092_PM_s_at neurofibromin 2 (merlin) 5136 NF2 -0.509 - 1.87E-03 1.60E-02 
211091_PM_s_at neurofibromin 2 (merlin) 26470 NF2 -0.367 - 3.21E-03 4.68E-03 
224976_PM_at nuclear factor I/A 150290 NFIA -2.043 - 4.78E-03 7.17E-03 
224975_PM_at nuclear factor I/A 7802 NFIA -1.247 - 7.14E-03 1.43E-02 
211524_PM_at 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2 (p49/p100) 
9749 NFKB2 -0.294 - 1.63E-03 2.75E-03 
243556_PM_at neuronal guanine nucleotide exchange factor --- NGEF -1.361 - 5.69E-04 9.90E-03 
1564746_PM_at Na+/H+ exchanger domain containing 2 79096 NHEDC2 -0.745 - 1.66E-03 3.10E-03 
242352_PM_at Nipped-B homolog (Drosophila) 439921 NIPBL -0.868 - 2.30E-02 2.51E-02 
211949_PM_s_at nucleolar and coiled-body phosphoprotein 1 3337 NOLC1 -0.339 - 1.74E-03 8.29E-03 
205895_PM_s_at nucleolar and coiled-body phosphoprotein 1 6506 NOLC1 -0.733 - 2.83E-03 5.11E-03 
221853_PM_s_at 






-0.303 - 1.97E-02 3.90E-02 
214427_PM_at NOP2 nucleolar protein homolog (yeast) 26073 NOP2 -0.282 - 1.81E-02 4.13E-02 
239132_PM_at Nitric oxide synthase 1 (neuronal) --- NOS1 -0.511 - 2.86E-05 1.66E-03 
205459_PM_s_at neuronal PAS domain protein 2 3290 NPAS2 -0.393 - 5.86E-04 4.92E-03 
220316_PM_at neuronal PAS domain protein 3 10127 NPAS3 -0.924 - 2.29E-02 4.62E-02 
218086_PM_at neural proliferation, differentiation and control, 1 153339 NPDC1 -0.817 - 1.26E-02 1.96E-02 
201454_PM_s_at aminopeptidase puromycin sensitive 3308 NPEPPS -0.529 - 3.35E-02 4.49E-02 
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210730_PM_s_at neuropeptide Y receptor Y2 90293 NPY2R -0.708 - 5.07E-03 1.22E-02 
217370_PM_x_at nuclear receptor subfamily 1, group H, member 3 64919 NR1H3 -2.465 - 1.44E-02 2.92E-02 
209261_PM_s_at nuclear receptor subfamily 2, group F, member 6 10776 NR2F6 -0.396 - 1.20E-02 2.81E-02 
201866_PM_s_at 
nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor) 
5786 NR3C1 -0.379 - 3.64E-03 3.28E-03 
201865_PM_x_at 
nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor) 
27332 NR3C1 -0.272 - 5.76E-03 2.01E-02 
216959_PM_x_at neuronal cell adhesion molecule 29761 NRCAM -2.755 - 1.85E-02 4.39E-02 
211279_PM_at nuclear respiratory factor 1 6546 NRF1 -0.396 - 2.57E-02 2.82E-02 
204081_PM_at neurogranin (protein kinase C substrate, RC3) 6856 NRGN -2.771 - 2.59E-02 4.86E-02 
202600_PM_s_at nuclear receptor interacting protein 1 55768 NRIP1 -0.950 - 2.06E-03 4.75E-03 
210510_PM_s_at neuropilin 1 256586 NRP1 -0.524 - 2.42E-02 4.09E-02 
214632_PM_at neuropilin 2 28998 NRP2 -0.337 - 1.17E-02 1.94E-03 
209914_PM_s_at neurexin 1 55704 NRXN1 -2.169 - 4.77E-04 4.27E-04 
216096_PM_s_at neurexin 1 63875 NRXN1 -2.737 - 1.38E-02 4.18E-02 
209982_PM_s_at neurexin 2 87178 NRXN2 -1.289 - 1.74E-02 5.40E-03 
215021_PM_s_at neurexin 3 65109 NRXN3 -1.583 - 3.99E-02 3.21E-02 
1569354_PM_at NOL1/NOP2/Sun domain family, member 6 1756 NSUN6 -0.306 - 9.19E-03 3.22E-02 
207152_PM_at neurotrophic tyrosine kinase, receptor, type 2 23215 NTRK2 -1.849 - 7.93E-03 3.97E-03 
214680_PM_at neurotrophic tyrosine kinase, receptor, type 2 55081 NTRK2 -1.316 - 2.88E-02 4.15E-02 
215025_PM_at neurotrophic tyrosine kinase, receptor, type 3 64763 NTRK3 -0.510 - 1.21E-02 3.12E-02 
1557795_PM_s_at neurotrophic tyrosine kinase, receptor, type 3 10381 NTRK3 -0.947 - 4.00E-02 3.57E-02 
200646_PM_s_at nucleobindin 1 486 NUCB1 -0.456 - 2.38E-02 4.72E-03 
229353_PM_s_at 
nuclear casein kinase and cyclin-dependent kinase substrate 
1 
285550 NUCKS1 -1.528 - 6.09E-03 5.86E-03 
226880_PM_at 
Nuclear casein kinase and cyclin-dependent kinase substrate 
1 
3837 NUCKS1 -1.053 - 2.19E-02 1.95E-03 
221579_PM_s_at nudix (nucleoside diphosphate linked moiety X)-type motif 3 2842 NUDT3 -0.751 - 6.78E-03 1.43E-02 
206303_PM_s_at nudix (nucleoside diphosphate linked moiety X)-type motif 4 8543 NUDT4 -0.398 - 6.51E-04 5.14E-03 
206302_PM_s_at 
nudix (nucleoside diphosphate linked moiety X)-type motif 4 /// 





-0.574 - 3.36E-03 3.75E-02 
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205134_PM_s_at 
nuclear fragile X mental retardation protein interacting protein 
1 
23387 NUFIP1 -0.414 - 1.36E-02 4.81E-02 
214251_PM_s_at nuclear mitotic apparatus protein 1 2119 NUMA1 -0.941 - 9.69E-03 5.99E-03 
214250_PM_at nuclear mitotic apparatus protein 1 182 NUMA1 -0.364 - 4.58E-02 1.41E-03 
211513_PM_s_at opioid growth factor receptor 9534 OGFR -0.413 - 4.16E-03 2.29E-02 
216408_PM_at olfactory receptor, family 2, subfamily B, member 2 64919 OR2B2 -0.299 - 2.69E-03 8.13E-03 
1555212_PM_at olfactory receptor, family 8, subfamily B, member 8 301 OR8B8 -0.293 - 9.86E-03 2.44E-02 
221237_PM_s_at oxysterol binding protein 2 8577 OSBP2 -0.518 - 3.67E-02 1.42E-02 
201245_PM_s_at OTU domain, ubiquitin aldehyde binding 1 
552900 /// 
654483 
OTUB1 -2.881 - 3.08E-02 3.67E-02 
201246_PM_s_at OTU domain, ubiquitin aldehyde binding 1 27040 /// 83985 OTUB1 -0.405 - 3.15E-02 2.79E-02 
1555426_PM_a_at OTU domain containing 5 9774 OTUD5 -1.110 - 1.26E-02 3.52E-02 
233933_PM_s_at OTU domain containing 5 --- OTUD5 -1.176 - 1.30E-02 1.73E-02 
1553351_PM_at OTU domain containing 7A 783 OTUD7A -0.816 - 2.01E-03 2.11E-03 
238409_PM_x_at oxidation resistance 1 --- OXR1 -0.351 - 9.44E-03 4.17E-02 
1564494_PM_s_at prolyl 4-hydroxylase, beta polypeptide 7088 P4HB -2.154 - 2.21E-03 1.55E-02 
215157_PM_x_at poly(A) binding protein, cytoplasmic 1 79589 PABPC1 -0.313 - 2.57E-02 3.10E-02 
1555823_PM_at phosphofurin acidic cluster sorting protein 2 4077 PACS2 -0.703 - 3.26E-02 2.46E-02 
1554385_PM_a_at peptidyl arginine deiminase, type II 5573 PADI2 -0.337 - 4.96E-02 3.74E-02 
200813_PM_s_at 
platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 
(45kDa) 
1453 PAFAH1B1 -0.805 - 1.10E-02 2.90E-02 
200815_PM_s_at 
platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 
(45kDa) 
288 PAFAH1B1 -0.563 - 2.33E-02 3.51E-02 
211547_PM_s_at 
platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 
(45kDa) 
2110 PAFAH1B1 -0.523 - 3.61E-02 1.12E-02 
225626_PM_at 
phosphoprotein associated with glycosphingolipid 
microdomains 1 
283554 PAG1 -0.406 - 2.45E-02 3.39E-02 
209615_PM_s_at p21 protein (Cdc42/Rac)-activated kinase 1 55075 PAK1 -0.894 - 2.50E-02 3.20E-02 
214607_PM_at p21 protein (Cdc42/Rac)-activated kinase 3 7570 PAK3 -1.553 - 5.71E-03 6.77E-03 
33814_PM_at p21 protein (Cdc42/Rac)-activated kinase 4 285343 PAK4 -0.342 - 1.64E-02 1.28E-02 
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202760_PM_s_at PALM2-AKAP2 readthrough transcript 9939 PALM2-AKAP2 -0.390 - 4.61E-04 5.01E-04 
242825_PM_at phosphatidic acid phosphatase type 2 161882 PAP2D -0.494 - 3.25E-02 1.60E-02 
224427_PM_s_at poly(A) polymerase gamma 90488 PAPOLG -0.734 - 1.41E-02 3.20E-02 
212858_PM_at progestin and adipoQ receptor family member IV 10485 PAQR4 -0.356 - 7.70E-03 1.61E-02 
226423_PM_at progestin and adipoQ receptor family member VIII 3084 PAQR8 -0.713 - 5.42E-03 2.69E-02 
221526_PM_x_at par-3 partitioning defective 3 homolog (C. elegans) 6334 PARD3 -0.966 - 2.57E-02 1.08E-02 
205245_PM_at par-6 partitioning defective 6 homolog alpha (C. elegans) 10978 PARD6A -0.328 - 2.59E-02 2.50E-02 
37965_PM_at parvin, beta --- PARVB -1.605 - 1.99E-02 3.20E-02 
212151_PM_at pre-B-cell leukemia homeobox 1 10159 PBX1 -1.244 - 2.10E-03 2.55E-03 
213517_PM_at poly(rC) binding protein 2 8487 PCBP2 -0.931 - 4.10E-02 1.51E-02 
219737_PM_s_at protocadherin 9 2308 PCDH9 -1.146 - 1.60E-02 2.44E-02 
224212_PM_s_at protocadherin alpha 1  7170 PCDHA1  -1.967 - 2.55E-03 2.55E-03 
216352_PM_x_at protocadherin gamma subfamily A, 1  51111 PCDHGA1  -0.392 - 1.56E-02 4.46E-02 
211876_PM_x_at protocadherin gamma subfamily A, 11 23333 PCDHGA11 -0.658 - 6.58E-03 1.18E-02 
211879_PM_x_at protocadherin gamma subfamily A, 3 
100130987 /// 
5883 
PCDHGA3 -0.460 - 1.58E-02 3.25E-02 
214564_PM_s_at protocadherin gamma subfamily C, 3 8649 PCDHGC3 -0.504 - 2.41E-02 4.25E-02 
235507_PM_at 
protein-L-isoaspartate (D-aspartate) O-methyltransferase 
domain containing 1 
--- PCMTD1 -0.418 - 8.76E-03 1.27E-02 
218952_PM_at proprotein convertase subtilisin/kexin type 1 inhibitor 23704 PCSK1N -1.988 - 2.40E-02 3.48E-02 
204870_PM_s_at proprotein convertase subtilisin/kexin type 2 4646 PCSK2 -0.457 - 2.67E-03 1.84E-02 
206474_PM_at PCTAIRE protein kinase 2 4345 PCTK2 -1.570 - 4.10E-03 2.78E-02 
1558680_PM_s_at phosphodiesterase 1A, calmodulin-dependent 8727 PDE1A -1.700 - 2.90E-03 1.87E-02 
233547_PM_x_at phosphodiesterase 1A, calmodulin-dependent 23033 PDE1A -0.467 - 3.52E-03 1.92E-02 
242789_PM_at phosphodiesterase 1A, calmodulin-dependent --- PDE1A -1.135 - 4.03E-02 4.84E-02 
214130_PM_s_at phosphodiesterase 4D interacting protein 4915 PDE4DIP -0.818 - 6.85E-04 3.28E-03 
213228_PM_at phosphodiesterase 8B 6751 PDE8B -1.077 - 2.46E-04 1.34E-03 
213724_PM_s_at pyruvate dehydrogenase kinase, isozyme 2 26036 PDK2 -1.621 - 7.38E-03 1.12E-02 
221957_PM_at pyruvate dehydrogenase kinase, isozyme 3 220988 PDK3 -0.620 - 1.29E-02 3.53E-04 
205960_PM_at pyruvate dehydrogenase kinase, isozyme 4 3030 PDK4 -0.465 - 2.28E-02 1.15E-02 
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218273_PM_s_at 
pyruvate 221eparin221ing221e phosphatase catalytic subunit 
1 
9185 PDP1 -1.534 - 6.42E-04 4.32E-03 
32029_PM_at 3-phosphoinositide dependent protein kinase-1 --- PDPK1 -0.407 - 3.34E-02 2.46E-02 
230068_PM_s_at Paternally expressed 3 57683 PEG3 -0.912 - 3.21E-02 3.04E-02 
222910_PM_s_at peroxisomal biogenesis factor 5-like 57003 PEX5L -1.047 - 2.49E-03 1.12E-02 
201102_PM_s_at phosphofructokinase, liver 1634 PFKL -0.485 - 3.70E-02 1.78E-02 
201118_PM_at phosphogluconate dehydrogenase 347733 /// 7280 PGD -0.398 - 3.48E-02 2.31E-02 
229553_PM_at phosphoglucomutase 2-like 1 7110 PGM2L1 -0.533 - 2.21E-02 2.00E-02 
213638_PM_at phosphatase and actin regulator 1 9444 PHACTR1 -1.010 - 2.16E-03 8.78E-03 
244774_PM_at phosphatase and actin regulator 2 10480 PHACTR2 -1.088 - 4.26E-02 2.11E-02 
202928_PM_s_at PHD finger protein 1 283234 PHF1 -1.192 - 3.90E-02 4.81E-02 
210417_PM_s_at phosphatidylinositol 4-kinase, catalytic, beta 29091 PI4KB -1.880 - 2.20E-02 4.08E-02 
215832_PM_x_at phosphatidylinositol binding clathrin assembly protein 79081 PICALM -1.525 - 1.63E-02 4.71E-02 
223470_PM_at phosphatidylinositol glycan anchor biosynthesis, class M 55236 PIGM -0.728 - 6.01E-03 3.23E-03 
1569022_PM_a_at phosphoinositide-3-kinase, class 2, alpha polypeptide 3909 PIK3C2A -0.408 - 1.56E-02 4.97E-02 
217620_PM_s_at phosphoinositide-3-kinase, catalytic, beta polypeptide 119504 PIK3CB -0.473 - 8.13E-04 5.07E-03 
209018_PM_s_at PTEN induced putative kinase 1 79677 PINK1 -1.148 - 1.33E-02 3.67E-02 
205570_PM_at phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 25780 PIP4K2A -1.380 - 5.37E-03 2.91E-02 
1568949_PM_at phosphatidylinositol transfer protein, cytoplasmic 1 4281 PITPNC1 -1.152 - 1.78E-03 4.23E-03 
238649_PM_at phosphatidylinositol transfer protein, cytoplasmic 1 8828 PITPNC1 -0.396 - 2.99E-02 2.20E-02 
1552923_PM_a_at phosphatidylinositol transfer protein, membrane-associated 2 1727 PITPNM2 -0.971 - 1.05E-02 3.78E-02 
201927_PM_s_at plakophilin 4 9659 PKP4 -1.762 - 2.03E-02 4.67E-02 
211925_PM_s_at phospholipase C, beta 1 (phosphoinositide-specific) 8629 PLCB1 -1.864 - 3.41E-04 5.66E-03 
215687_PM_x_at phospholipase C, beta 1 (phosphoinositide-specific) 57105 PLCB1 -1.699 - 2.64E-03 8.65E-03 
201050_PM_at phospholipase D family, member 3 10492 PLD3 -2.264 - 1.86E-02 2.97E-02 
201373_PM_at plectin 1, intermediate filament binding protein 500kDa 8165 PLEC1 -0.417 - 1.88E-02 2.11E-02 
219024_PM_at 
pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 1 
253827 PLEKHA1 -0.861 - 8.86E-05 1.13E-03 
217677_PM_at 
pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 2 
56990 PLEKHA2 -0.901 - 2.54E-03 1.23E-03 
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1558407_PM_at 
pleckstrin homology domain containing, family G (with 
RhoGef domain) member 2 
3093 PLEKHG2 -0.280 - 1.41E-02 1.53E-02 
215807_PM_s_at plexin B1 9236 PLXNB1 -2.211 - 1.65E-02 3.79E-02 
179_PM_at postmeiotic segregation increased 2-like 11 pseudogene 8732 PMS2L11 -0.310 - 1.80E-02 1.96E-02 
222406_PM_s_at proline-rich nuclear receptor coactivator 2 23131 PNRC2 -0.473 - 2.21E-03 3.63E-03 
215357_PM_s_at polymerase (DNA-directed), delta interacting protein 3 56935 POLDIP3 -1.176 - 4.74E-03 7.01E-03 
212178_PM_s_at 





-0.771 - 2.42E-02 1.86E-02 
233638_PM_s_at 
protein O-linked mannose beta1,2-N-
acetylglucosaminyltransferase 
1024 POMGNT1 -0.713 - 5.32E-03 2.80E-02 
208928_PM_at P450 (cytochrome) oxidoreductase 8409 POR -0.434 - 2.35E-02 2.06E-02 
219483_PM_s_at porcupine homolog (Drosophila) 3597 PORCN -0.898 - 1.92E-02 2.94E-02 
206789_PM_s_at POU class 2 homeobox 1 5921 POU2F1 -0.994 - 1.43E-03 6.60E-04 
208345_PM_s_at POU class 3 homeobox 1 6375 /// 6846 POU3F1 -0.786 - 3.09E-02 4.25E-02 
207084_PM_at POU class 3 homeobox 2 3597 POU3F2 -0.389 - 1.47E-02 2.43E-02 
208563_PM_x_at POU class 3 homeobox 3 2558 POU3F3 -0.457 - 9.77E-03 3.63E-02 
212226_PM_s_at phosphatidic acid phosphatase type 2B 11231 PPAP2B -1.563 - 1.91E-03 8.56E-04 
209355_PM_s_at phosphatidic acid phosphatase type 2B 54800 PPAP2B -2.898 - 3.02E-03 4.37E-03 
210235_PM_s_at 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 1 
51088 PPFIA1 -0.566 - 3.46E-02 4.97E-02 
208993_PM_s_at peptidylprolyl isomerase G (cyclophilin G) 51651 PPIG -1.261 - 7.44E-03 9.79E-03 
201703_PM_s_at protein phosphatase 1, regulatory (inhibitor) subunit 10 667 PPP1R10 -0.299 - 1.62E-02 3.31E-02 
201602_PM_s_at protein phosphatase 1, regulatory (inhibitor) subunit 12A 23163 PPP1R12A -0.783 - 4.38E-02 2.97E-02 
205478_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 1A 1428 PPP1R1A -0.493 - 2.32E-02 1.40E-02 
231966_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 9A 65986 PPP1R9A -0.359 - 1.42E-02 1.18E-02 
200695_PM_at 
protein phosphatase 2 (formerly 2A), regulatory subunit A, 
alpha isoform 
51603 PPP2R1A -3.202 - 3.45E-02 4.85E-02 
223574_PM_x_at 
protein phosphatase 2 (formerly 2A), regulatory subunit B, 
gamma isoform 
54665 PPP2R2C -1.111 - 1.51E-02 7.07E-03 
211159_PM_s_at protein phosphatase 2, regulatory subunit B’, delta isoform 54716 PPP2R5D -0.945 - 1.54E-03 9.00E-03 
202513_PM_s_at protein phosphatase 2, regulatory subunit B’, delta isoform 29789 PPP2R5D -0.352 - 3.13E-03 1.94E-02 
229322_PM_at protein phosphatase 2, regulatory subunit B’, epsilon isoform 57482 PPP2R5E -0.788 - 4.91E-03 9.74E-03 
220673_PM_s_at protein phosphatase 4, regulatory subunit 4 9781 PPP4R4 -1.682 - 4.15E-03 9.58E-03 
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201979_PM_s_at protein phosphatase 5, catalytic subunit 118 PPP5C -1.100 - 3.75E-02 4.03E-02 
212527_PM_at PPPDE peptidase domain containing 2 54726 PPPDE2 -0.390 - 7.79E-03 3.22E-02 
203056_PM_s_at PR domain containing 2, with ZNF domain 284361 PRDM2 -0.762 - 3.94E-03 2.51E-04 
212216_PM_at prolyl endopeptidase-like 567 PREPL -1.432 - 1.43E-02 3.57E-02 
224909_PM_s_at 
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac 
exchange factor 1 
3920 PREX1 -0.824 - 3.32E-03 6.70E-03 
218292_PM_s_at protein kinase, AMP-activated, gamma 2 non-catalytic subunit 85315 PRKAG2 -1.185 - 1.86E-02 3.66E-02 
200604_PM_s_at 
protein kinase, cAMP-dependent, regulatory, type I, alpha 
(tissue specific extinguisher 1) 
50855 PRKAR1A -1.706 - 2.14E-03 2.03E-02 
206270_PM_at protein kinase C, gamma 10548 PRKCG -1.060 - 8.84E-03 1.80E-02 
215707_PM_s_at prion protein 81609 PRNP -2.902 - 2.05E-02 4.19E-02 
228656_PM_at prospero homeobox 1 51312 PROX1 -0.521 - 1.56E-02 1.97E-02 
209162_PM_s_at PRP4 pre-mRNA processing factor 4 homolog (yeast) 51104 PRPF4 -0.348 - 7.07E-03 5.25E-03 
214941_PM_s_at 
PRP40 pre-mRNA processing factor 40 homolog A (S. 
cerevisiae) 
51696 PRPF40A -1.318 - 2.18E-03 1.21E-02 
213729_PM_at 
PRP40 pre-mRNA processing factor 40 homolog A (S. 
cerevisiae) 
114882 PRPF40A -1.341 - 1.12E-02 2.39E-02 
231739_PM_at proline-rich transmembrane protein 1 64866 PRRT1 -2.274 - 1.13E-02 3.18E-02 
209599_PM_s_at prune homolog (Drosophila) 29089 PRUNE -0.429 - 1.39E-02 4.56E-02 
212806_PM_at prune homolog 2 (Drosophila) 22881 PRUNE2 -0.271 - 3.20E-02 1.91E-02 
200871_PM_s_at prosaposin 4205 PSAP -0.291 - 2.87E-02 1.17E-02 
220892_PM_s_at phosphoserine aminotransferase 1 6018 PSAT1 -2.880 - 2.54E-02 4.69E-02 
228204_PM_at Proteasome (prosome, macropain) subunit, beta type, 4 5611 PSMB4 -1.399 - 3.36E-02 3.43E-02 
201198_PM_s_at 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
1 
6002 PSMD1 -1.498 - 2.12E-02 4.18E-02 
222611_PM_s_at paraspeckle component 1 9881 PSPC1 -1.037 - 6.19E-03 2.75E-02 
1554614_PM_a_at polypyrimidine tract binding protein 2 10956 PTBP2 -0.785 - 3.53E-03 2.21E-02 
204054_PM_at phosphatase and tensin homolog 5878 PTEN -0.703 - 1.26E-02 2.72E-02 
216988_PM_s_at protein tyrosine phosphatase type IVA, member 2 64801 PTP4A2 -0.987 - 1.23E-02 3.42E-02 
208616_PM_s_at protein tyrosine phosphatase type IVA, member 2 1528 PTP4A2 -0.294 - 2.72E-02 4.75E-02 
238841_PM_at protein tyrosine phosphatase domain containing 1 --- PTPDC1 -0.789 - 1.30E-02 1.25E-02 
222404_PM_x_at protein tyrosine phosphatase-like A domain containing 1 64795 PTPLAD1 -1.786 - 4.37E-03 5.76E-03 
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234000_PM_s_at protein tyrosine phosphatase-like A domain containing 1 --- PTPLAD1 -1.885 - 8.01E-03 1.23E-02 
227741_PM_at 
protein tyrosine phosphatase-like (proline instead of catalytic 
arginine), member b 
57616 PTPLB -0.404 - 4.78E-03 1.00E-02 
209895_PM_at protein tyrosine phosphatase, non-receptor type 11 54331 PTPN11 -0.764 - 2.38E-03 3.89E-03 
209896_PM_s_at protein tyrosine phosphatase, non-receptor type 11 93185 PTPN11 -0.854 - 4.95E-03 9.81E-03 
205868_PM_s_at protein tyrosine phosphatase, non-receptor type 11 3055 PTPN11 -0.558 - 1.48E-02 1.85E-02 
216915_PM_s_at protein tyrosine phosphatase, non-receptor type 12 170506 PTPN12 -0.343 - 3.03E-02 3.54E-02 
233471_PM_at 
protein tyrosine phosphatase, non-receptor type 5 (striatum-
enriched) 
2743 PTPN5 -1.440 - 6.96E-03 6.35E-03 
213799_PM_s_at protein tyrosine phosphatase, receptor type, A 23271 PTPRA -1.516 - 1.72E-03 1.07E-02 
205712_PM_at protein tyrosine phosphatase, receptor type, D 25988 PTPRD -0.552 - 1.49E-02 2.88E-02 
203030_PM_s_at protein tyrosine phosphatase, receptor type, N polypeptide 2 50801 PTPRN2 -1.257 - 8.19E-03 2.37E-02 
211534_PM_x_at protein tyrosine phosphatase, receptor type, N polypeptide 2 51663 PTPRN2 -0.597 - 3.08E-02 2.85E-02 
210823_PM_s_at protein tyrosine phosphatase, receptor type, S 284111 PTPRS -0.735 - 2.08E-03 9.40E-03 
1557938_PM_s_at polymerase I and transcript release factor 6880 PTRF -0.326 - 2.23E-02 8.86E-03 
227718_PM_at purine-rich element binding protein B --- PURB -1.586 - 3.95E-03 7.41E-04 
235711_PM_at purine-rich element binding protein B --- PURB -1.357 - 8.04E-03 1.15E-02 
201606_PM_s_at PWP1 homolog (S. cerevisiae) 51343 PWP1 -1.367 - 2.77E-02 4.70E-02 
1552274_PM_at PX domain containing serine/threonine kinase 54899 PXK -0.585 - 2.14E-03 6.51E-03 
205577_PM_at phosphorylase, glycogen, muscle 2562 PYGM -1.420 - 2.90E-02 4.50E-02 
225370_PM_at pygopus homolog 2 (Drosophila) 64147 PYGO2 -0.641 - 2.35E-02 1.88E-02 
1555154_PM_a_at quaking homolog, KH domain RNA binding (mouse) 309 QKI -2.105 - 2.64E-03 1.73E-02 
214543_PM_x_at quaking homolog, KH domain RNA binding (mouse) 394 QKI -2.044 - 5.81E-03 2.21E-02 
204157_PM_s_at serine/threonine-protein kinase QSK 10657 QSK -0.596 - 4.27E-03 5.02E-03 
34478_PM_at RAB11B, member RAS oncogene family --- RAB11B -1.368 - 1.45E-02 8.62E-03 
214999_PM_s_at RAB11 family interacting protein 3 (class II) 51098 RAB11FIP3 -0.280 - 2.41E-02 3.19E-02 
211503_PM_s_at RAB14, member RAS oncogene family 2917 RAB14 -1.753 - 3.38E-03 5.50E-03 
205461_PM_at RAB35, member RAS oncogene family 4862 RAB35 -0.437 - 1.58E-02 2.86E-02 
208466_PM_at RAB3D, member RAS oncogene family 26168 RAB3D -0.456 - 4.02E-03 8.84E-03 
203582_PM_s_at RAB4A, member RAS oncogene family 63827 RAB4A -1.133 - 2.71E-02 4.64E-02 
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201156_PM_s_at RAB5C, member RAS oncogene family 23291 RAB5C -1.126 - 4.78E-02 2.85E-02 
201048_PM_x_at RAB6A, member RAS oncogene family 10735 RAB6A -2.858 - 6.05E-03 2.12E-02 




RAB6B -1.141 - 7.61E-03 5.65E-03 
225259_PM_at RAB6B, member RAS oncogene family 219736 RAB6B -0.356 - 2.18E-02 6.56E-03 
214552_PM_s_at rabaptin, RAB GTPase binding effector protein 1 56993 RABEP1 -0.757 - 1.01E-02 3.89E-02 
1567458_PM_s_at 
ras-related C3 botulinum toxin substrate 1 (rho family, small 
GTP binding protein Rac1) 
9232 RAC1 -0.565 - 7.06E-03 4.30E-02 
208641_PM_s_at 
ras-related C3 botulinum toxin substrate 1 (rho family, small 
GTP binding protein Rac1) 
4651 RAC1 -1.036 - 1.85E-02 3.48E-02 
200607_PM_s_at RAD21 homolog (S. pombe) 23552 RAD21 -2.972 - 4.60E-03 1.84E-02 
201039_PM_s_at RAD23 homolog A (S. cerevisiae) 6774 RAD23A -0.823 - 3.74E-02 4.36E-02 
214435_PM_x_at v-ral simian leukemia viral oncogene homolog A (ras related) 58190 RALA -1.299 - 4.06E-04 3.13E-03 
202844_PM_s_at ralA binding protein 1 25912 RALBP1 -1.098 - 4.39E-03 8.45E-03 
201711_PM_x_at RAN binding protein 2 23063 RANBP2 -1.174 - 8.08E-04 8.03E-03 
1553535_PM_a_at Ran GTPase activating protein 1 23157 RANGAP1 -1.736 - 1.58E-02 2.59E-02 
212125_PM_at Ran GTPase activating protein 1 10625 RANGAP1 -0.534 - 5.00E-02 2.36E-02 
221830_PM_at RAP2A, member of RAS oncogene family 64087 RAP2A -2.074 - 9.36E-04 1.01E-02 
214487_PM_s_at 
RAP2A, member of RAS oncogene family /// RAP2B, member 




-0.925 - 4.79E-03 2.27E-02 
204680_PM_s_at Rap guanine nucleotide exchange factor (GEF) 5 6433 RAPGEF5 -1.335 - 4.23E-04 4.12E-04 
208530_PM_s_at retinoic acid receptor, beta 154661 RARB -0.531 - 1.69E-03 4.88E-03 
232902_PM_s_at arginyl-tRNA synthetase 2, mitochondrial 728485 RARS2 -0.389 - 1.50E-03 3.99E-03 
233144_PM_s_at RAS protein activator like 1 (GAP1 like) 3480 RASAL1 -0.882 - 2.14E-02 2.49E-02 
234343_PM_s_at RAS protein activator like 2 --- RASAL2 -1.403 - 6.96E-03 1.05E-02 
222810_PM_s_at RAS protein activator like 2 100272147 RASAL2 -1.110 - 2.24E-02 3.18E-02 
1554834_PM_a_at Ras association (RalGDS/AF-6) domain family member 5 10528 RASSF5 -0.419 - 9.44E-03 3.78E-02 
212332_PM_at retinoblastoma-like 2 (p130) 3423 RBL2 -0.727 - 5.39E-03 2.48E-02 
225751_PM_at RNA binding motif protein 17 124923 RBM17 -1.735 - 1.07E-03 2.70E-03 
1557081_PM_at RNA binding motif protein 25 5327 RBM25 -0.836 - 1.26E-02 1.41E-02 
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212028_PM_at RNA binding motif protein 25 8766 RBM25 -0.621 - 2.41E-02 4.32E-03 
212030_PM_at RNA binding motif protein 25 6745 RBM25 -0.285 - 3.42E-02 3.06E-02 
205740_PM_s_at RNA binding motif protein 42 8545 RBM42 -0.570 - 2.65E-02 1.93E-02 
209936_PM_at RNA binding motif protein 5 94056 RBM5 -1.319 - 1.68E-03 5.01E-03 
212104_PM_s_at RNA binding motif protein 9 1488 RBM9 -1.499 - 7.43E-03 1.71E-03 
213901_PM_x_at RNA binding motif protein 9 23299 RBM9 -3.091 - 1.09E-02 1.37E-02 
225265_PM_at RNA binding motif, single stranded interacting protein 1 728855 RBMS1 -0.737 - 1.88E-02 4.20E-02 
1556336_PM_at 
similar to RNA binding motif protein, X-linked /// hypothetical 
protein LOC100291994 /// RNA binding motif protein, X-linked 
/// RNA binding motif protein, X-linked-like 1 
8539 RBMXL1 -0.345 - 3.42E-02 7.81E-03 
230134_PM_s_at ring finger and CCCH-type zinc finger domains 2 56704 RC3H2 -0.489 - 1.41E-03 4.83E-03 
230133_PM_at ring finger and CCCH-type zinc finger domains 2 55266 RC3H2 -0.290 - 7.61E-03 6.62E-03 
220202_PM_s_at ring finger and CCCH-type zinc finger domains 2 9896 RC3H2 -1.426 - 8.86E-03 1.19E-02 
215253_PM_s_at regulator of calcineurin 1 79659 RCAN1 -2.280 - 1.15E-02 2.92E-02 
212398_PM_at radixin 2634 RDX -0.616 - 3.04E-02 2.21E-02 
208872_PM_s_at receptor accessory protein 5 27244 REEP5 -0.912 - 1.59E-02 3.55E-02 
1566472_PM_s_at retinol saturase (all-trans-retinol 13,14-reductase) 51362 RETSAT -1.137 - 4.04E-03 9.22E-03 
1552651_PM_a_at ring finger and FYVE-like domain containing 1 10771 RFFL -0.320 - 9.62E-03 6.78E-03 
226786_PM_at regulatory factor X, 1 (influences HLA class II expression) 23158 RFX1 -0.449 - 1.04E-02 2.26E-02 
208492_PM_at regulatory factor X-associated protein 23254 RFXAP -0.385 - 7.31E-04 1.07E-02 
209637_PM_s_at regulator of G-protein signaling 12 22931 RGS12 -0.630 - 1.46E-02 4.02E-02 
211021_PM_s_at regulator of G-protein signaling 14 54556 RGS14 -1.008 - 1.03E-02 1.08E-02 
232053_PM_x_at rhomboid domain containing 2 6117 RHBDD2 -3.103 - 3.21E-02 4.57E-02 
1553962_PM_s_at ras homolog gene family, member B 7559 RHOB -2.894 - 1.62E-03 1.05E-02 
240111_PM_at Rho-related BTB domain containing 3 645323 RHOBTB3 -0.450 - 7.80E-04 3.07E-03 
216048_PM_s_at Rho-related BTB domain containing 3 9236 RHOBTB3 -1.915 - 4.59E-03 1.46E-02 
202975_PM_s_at Rho-related BTB domain containing 3 83877 RHOBTB3 -2.064 - 1.28E-02 3.71E-02 
221789_PM_x_at ras homolog gene family, member T2 4664 RHOT2 -0.433 - 4.62E-03 1.16E-02 
210791_PM_s_at Rho GTPase-activating protein 57628 RICS -1.010 - 5.64E-03 1.46E-03 
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228248_PM_at RPTOR independent companion of MTOR, complex 2 2957 RICTOR -0.800 - 1.89E-02 4.00E-02 
216184_PM_s_at regulating synaptic membrane exocytosis 1 5519 RIMS1 -2.338 - 2.54E-03 1.18E-02 
212479_PM_s_at 
required for meiotic nuclear division 5 homolog A (S. 
cerevisiae) 
6310 RMND5A -0.596 - 4.43E-03 1.86E-03 
212478_PM_at 
required for meiotic nuclear division 5 homolog A (S. 
cerevisiae) 
6310 RMND5A -0.297 - 4.81E-02 1.16E-02 
205748_PM_s_at ring finger protein 126 2549 RNF126 -1.274 - 2.77E-02 3.82E-02 
219104_PM_at ring finger protein 141 374786 RNF141 -1.285 - 8.20E-03 2.20E-02 
1569080_PM_at ring finger protein 165 6925 RNF165 -0.432 - 3.42E-02 8.66E-03 
234461_PM_at ring finger protein 215 --- RNF215 -0.756 - 7.26E-03 2.10E-02 
210706_PM_s_at ring finger protein 24 10806 RNF24 -0.571 - 2.81E-02 8.64E-03 
224338_PM_s_at ring finger protein 26 84992 RNF26 -0.319 - 1.53E-02 2.80E-02 
222660_PM_s_at ring finger protein 38 8674 RNF38 -1.183 - 4.13E-03 2.01E-02 
201961_PM_s_at ring finger protein 41 5063 RNF41 -0.849 - 5.93E-03 5.48E-03 
204207_PM_s_at RNA guanylyltransferase and 5’-phosphatase 4659 RNGTT -0.500 - 7.98E-03 7.13E-03 
226975_PM_at RNA-binding region (RNP1, RRM) containing 3 23329 RNPC3 -1.528 - 4.17E-03 3.99E-03 
211504_PM_x_at Rho-associated, coiled-coil containing protein kinase 2 57584 ROCK2 -1.044 - 1.05E-03 5.70E-03 
215138_PM_s_at kazrin 51182 RP1-21O18.1 -0.544 - 5.46E-04 6.57E-03 
213478_PM_at kazrin 4116 RP1-21O18.1 -0.767 - 2.82E-03 2.50E-03 
204245_PM_s_at ribonuclease P/MRP 14kDa subunit 1182 RPP14 -2.049 - 3.28E-03 7.39E-03 
1555202_PM_a_at regulation of nuclear pre-mRNA domain containing 1A 10155 RPRD1A -1.528 - 1.49E-03 5.93E-03 
204906_PM_at ribosomal protein S6 kinase, 90kDa, polypeptide 2 6416 RPS6KA2 -0.453 - 2.00E-02 4.97E-02 
204633_PM_s_at ribosomal protein S6 kinase, 90kDa, polypeptide 5 8498 RPS6KA5 -0.706 - 3.33E-04 4.06E-04 
201476_PM_s_at ribonucleotide reductase M1 4771 RRM1 -1.350 - 1.30E-02 3.37E-02 
222540_PM_s_at remodeling and spacing factor 1 23507 RSF1 -1.368 - 1.09E-02 3.01E-02 
219507_PM_at arginine/serine-rich coiled-coil 1 1956 RSRC1 -1.335 - 2.88E-02 4.36E-02 
210251_PM_s_at RUN and FYVE domain containing 3 961 RUFY3 -1.072 - 7.02E-03 1.21E-02 
215321_PM_at RUN domain containing 3B 55070 RUNDC3B -0.524 - 1.53E-02 6.40E-03 
205528_PM_s_at 
runt-related transcription factor 1; translocated to, 1 (cyclin D-
related) 
51760 RUNX1T1 -0.498 - 4.63E-02 1.74E-02 
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215099_PM_s_at retinoid X receptor, beta 80206 RXRB -0.596 - 1.82E-04 2.54E-03 
201846_PM_s_at RING1 and YY1 binding protein 4141 RYBP -1.428 - 1.59E-03 1.60E-03 
233001_PM_at sterile alpha motif domain containing 10 4678 SAMD10 -0.276 - 2.02E-03 8.14E-04 
210790_PM_s_at SAR1 homolog A (S. cerevisiae) 64147 SAR1A -1.880 - 1.91E-03 1.03E-02 
201543_PM_s_at SAR1 homolog A (S. cerevisiae) 491 SAR1A -0.702 - 4.22E-03 2.34E-02 
209127_PM_s_at squamous cell carcinoma antigen recognized by T cells 3 81545 SART3 -0.887 - 2.21E-03 1.09E-02 
1552978_PM_a_at secretory carrier membrane protein 1 58155 SCAMP1 -1.563 - 2.44E-04 7.44E-03 
206667_PM_s_at secretory carrier membrane protein 1 8774 SCAMP1 -2.310 - 9.97E-04 1.45E-02 
206668_PM_s_at secretory carrier membrane protein 1 6877 SCAMP1 -0.346 - 2.14E-03 2.46E-03 
212417_PM_at secretory carrier membrane protein 1 11329 SCAMP1 -1.457 - 8.64E-03 2.87E-02 
235073_PM_at secretory carrier membrane protein 4 --- SCAMP4 -0.552 - 4.48E-03 3.29E-02 
223842_PM_s_at scavenger receptor class A, member 3 10194 SCARA3 -0.975 - 8.39E-04 6.82E-03 
201647_PM_s_at scavenger receptor class B, member 2 1457 /// 283106 SCARB2 -0.647 - 1.11E-02 1.26E-02 
211708_PM_s_at stearoyl-CoA desaturase (delta-9-desaturase) 55322 SCD -0.495 - 6.46E-03 2.47E-02 
200831_PM_s_at stearoyl-CoA desaturase (delta-9-desaturase) 10605 SCD -1.765 - 8.16E-03 2.02E-02 
224018_PM_s_at stearoyl-CoA desaturase 5 6860 SCD5 -3.371 - 5.24E-05 9.19E-04 
206381_PM_at sodium channel, voltage-gated, type II, alpha subunit 4094 SCN2A -1.573 - 3.88E-03 2.36E-02 
210363_PM_s_at sodium channel, voltage-gated, type II, beta 257415 SCN2B -1.836 - 5.84E-03 3.62E-03 
207049_PM_at sodium channel, voltage gated, type VIII, alpha subunit 2319 SCN8A -2.313 - 1.86E-02 3.87E-02 
228761_PM_at scratch homolog 1, zinc finger protein (Drosophila) --- SCRT1 -1.172 - 5.91E-03 2.49E-02 
221026_PM_s_at scratch homolog 1, zinc finger protein (Drosophila) 23047 SCRT1 -0.309 - 6.07E-03 3.20E-02 
221220_PM_s_at SCY1-like 2 (S. cerevisiae) 27245 SCYL2 -0.924 - 1.06E-02 4.52E-02 
228408_PM_s_at SDA1 domain containing 1 23261 SDAD1 -1.583 - 1.32E-02 1.15E-02 
212154_PM_at syndecan 2 7072 SDC2 -0.750 - 1.68E-02 2.78E-02 
1554864_PM_a_at syndecan 3 5710 SDC3 -0.340 - 3.37E-02 1.75E-02 
1557950_PM_at serologically defined colon cancer antigen 1 50999 SDCCAG1 -1.652 - 4.10E-04 2.05E-03 
1569594_PM_a_at serologically defined colon cancer antigen 1 2011 SDCCAG1 -1.198 - 1.16E-02 9.90E-03 
221972_PM_s_at stromal cell derived factor 4 147179 SDF4 -1.247 - 4.40E-03 1.76E-02 
202082_PM_s_at SEC14-like 1 (S. cerevisiae) 23256 SEC14L1 -0.832 - 6.70E-03 5.36E-03 
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224470_PM_at SEC22 vesicle trafficking protein homolog C (S. cerevisiae) 9644 SEC22C -0.344 - 2.18E-02 3.99E-02 
204344_PM_s_at Sec23 homolog A (S. cerevisiae) 2108 SEC23A -1.303 - 2.14E-02 4.85E-02 
244841_PM_at SEC24 family, member A (S. cerevisiae) 254251 SEC24A -0.409 - 3.72E-03 4.42E-04 
222385_PM_x_at Sec61 alpha 1 subunit (S. cerevisiae) 11017 SEC61A1 -0.746 - 3.24E-04 3.34E-03 
201914_PM_s_at SEC63 homolog (S. cerevisiae) 2677 SEC63 -1.199 - 6.73E-03 1.64E-02 
224250_PM_s_at SECIS binding protein 2 84302 SECISBP2 -1.528 - 1.90E-03 7.22E-04 
212451_PM_at SECIS binding protein 2-like 9025 SECISBP2L -0.659 - 4.97E-03 1.01E-02 
205405_PM_at 
sema domain, seven thrombospondin repeats (type 1 and 
type 1-like), transmembrane domain I and short cytoplasmic 
domain, (229eparin229ing) 5A 
535 SEMA5A -0.527 - 3.16E-02 1.05E-02 
233801_PM_s_at 
sema domain, transmembrane domain I, and cytoplasmic 
domain, (229eparin229ing) 6D 
58517 SEMA6D -0.564 - 2.59E-03 9.95E-03 
233882_PM_s_at 
sema domain, transmembrane domain I, and cytoplasmic 
domain, (229eparin229ing) 6D 
--- SEMA6D -1.421 - 1.90E-02 4.28E-02 
218122_PM_s_at SUMO1/sentrin/SMT3 specific peptidase 2 348180 SENP2 -1.978 - 1.48E-02 3.67E-02 
215113_PM_s_at SUMO1/sentrin/SMT3 specific peptidase 3 50862 SENP3 -0.877 - 2.20E-02 4.11E-02 
209669_PM_s_at SERPINE1 mRNA binding protein 1 84253 SERBP1 -0.741 - 6.04E-03 1.08E-02 
211769_PM_x_at serine incorporator 3 9690 SERINC3 -1.515 - 2.70E-02 2.54E-02 
221473_PM_x_at serine incorporator 3 8846 SERINC3 -1.147 - 3.16E-02 2.45E-02 
226763_PM_at SEC14 and spectrin domains 1 4128 SESTD1 -0.545 - 2.31E-02 2.86E-02 
200630_PM_x_at SET nuclear oncogene 862 SET -0.455 - 3.09E-02 8.04E-03 
1569106_PM_s_at SET domain containing 5 6636 SETD5 -0.823 - 6.67E-03 1.17E-02 
225094_PM_at SET domain containing (lysine methyltransferase) 8 9852 SETD8 -0.393 - 6.38E-03 2.59E-02 
220200_PM_s_at SET domain containing (lysine methyltransferase) 8 8161 SETD8 -0.398 - 8.00E-03 3.92E-02 
232229_PM_at senataxin 65998 SETX -0.382 - 2.80E-04 3.93E-03 
233337_PM_s_at seizure related 6 homolog (mouse)-like 2 171023 SEZ6L2 -2.576 - 2.80E-02 4.59E-02 
214305_PM_s_at splicing factor 3b, subunit 1, 155kDa 27292 SF3B1 -1.385 - 4.73E-04 7.59E-03 
201070_PM_x_at splicing factor 3b, subunit 1, 155kDa 23479 SF3B1 -0.969 - 1.77E-03 1.05E-02 
237746_PM_at Splicing factor, arginine/serine-rich 11 --- SFRS11 -0.331 - 2.05E-02 3.47E-02 
212177_PM_at splicing factor, arginine/serine-rich 18 55854 SFRS18 -1.342 - 7.38E-03 1.32E-02 
225507_PM_at splicing factor, arginine/serine-rich 18 1105 SFRS18 -1.177 - 9.42E-03 4.35E-03 
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209376_PM_x_at splicing factor, arginine/serine-rich 2, interacting protein 55737 SFRS2IP -0.767 - 4.20E-02 6.23E-03 
239512_PM_at splicing factor, arginine/serine-rich 4 --- SFRS4 -1.056 - 1.61E-02 1.89E-02 
210077_PM_s_at splicing factor, arginine/serine-rich 5 49854 SFRS5 -0.353 - 6.43E-03 4.32E-02 
202774_PM_s_at 
splicing factor, arginine/serine-rich 8 (suppressor-of-white-
apricot homolog, Drosophila) 
51111 SFRS8 -1.009 - 2.29E-03 2.02E-03 
205120_PM_s_at sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) 10210 SGCB -1.031 - 7.10E-03 3.63E-02 
215519_PM_x_at small G protein signaling modulator 3 58516 SGSM3 -0.394 - 1.31E-02 1.99E-02 
209322_PM_s_at SH2B adaptor protein 1 54934 SH2B1 -0.324 - 2.57E-02 4.42E-02 
205367_PM_at SH2B adaptor protein 2 6196 SH2B2 -0.368 - 4.80E-02 3.76E-02 
1552667_PM_a_at SH2 domain containing 3C 8672 SH2D3C -0.391 - 4.77E-03 1.27E-02 
1558647_PM_at SH3 domain containing 19 2965 SH3D19 -0.309 - 1.51E-03 1.31E-02 
218813_PM_s_at SH3-domain GRB2-like endophilin B2 55435 SH3GLB2 -1.892 - 2.59E-02 3.91E-02 
1554168_PM_a_at SH3-domain kinase binding protein 1 6152 SH3KBP1 -0.360 - 3.32E-02 4.23E-02 
225590_PM_at SH3 domain containing ring finger 1 129450 SH3RF1 -0.776 - 3.81E-02 2.58E-02 
223744_PM_s_at sialic acid acetylesterase 84247 SIAE -1.276 - 1.37E-02 4.06E-02 
221705_PM_s_at suppressor of IKBKE 1 4673 SIKE1 -0.308 - 5.61E-03 4.39E-02 
202255_PM_s_at signal-induced proliferation-associated 1 like 1 6595 SIPA1L1 -1.054 - 1.45E-02 1.89E-02 
217024_PM_x_at signal-regulatory protein alpha 83607 SIRPA -1.823 - 1.30E-04 2.10E-03 
202896_PM_s_at signal-regulatory protein alpha 51256 SIRPA -0.896 - 9.11E-03 2.32E-02 
200719_PM_at S-phase kinase-associated protein 1 23266 SKP1 -0.367 - 4.05E-02 3.11E-02 
224854_PM_s_at SLAIN motif family, member 2 114294 SLAIN2 -0.353 - 2.03E-03 4.52E-03 
224853_PM_at SLAIN motif family, member 2 133746 SLAIN2 -0.634 - 5.56E-03 3.43E-03 
203125_PM_x_at 
solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2 
124540 SLC11A2 -0.923 - 9.24E-03 3.19E-02 
223994_PM_s_at 
solute carrier family 12 (potassium/chloride transporters), 
member 9 
57002 SLC12A9 -0.417 - 5.46E-03 2.34E-02 
204230_PM_s_at 
solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 7 
9231 SLC17A7 -2.832 - 2.52E-02 3.59E-02 
206396_PM_at 
solute carrier family 1 (neuronal/epithelial high affinity 
glutamate transporter, system Xag), member 1 
9181 SLC1A1 -1.472 - 2.70E-02 4.18E-02 
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208389_PM_s_at 
solute carrier family 1 (glial high affinity glutamate 
transporter), member 2 
54470 /// 653354 SLC1A2 -2.050 - 4.19E-04 1.88E-03 
1558010_PM_s_at 
solute carrier family 1 (glial high affinity glutamate 
transporter), member 2 
10480 SLC1A2 -2.541 - 1.41E-02 3.61E-02 
1558009_PM_at 
solute carrier family 1 (glial high affinity glutamate 
transporter), member 2 
1398 SLC1A2 -3.328 - 1.70E-02 3.66E-02 
209611_PM_s_at 
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
83940 SLC1A4 -0.763 - 1.66E-02 2.97E-02 
201917_PM_s_at solute carrier family 25, member 36 5756 SLC25A36 -1.071 - 5.99E-03 6.90E-03 
218136_PM_s_at solute carrier family 25, member 37 2686 SLC25A37 -0.288 - 3.89E-03 8.82E-03 
205716_PM_at solute carrier family 25, member 40 10693 SLC25A40 -0.422 - 8.78E-03 2.45E-02 
225881_PM_at solute carrier family 35, member B4 147670 SLC35B4 -0.443 - 1.13E-02 3.05E-02 
209711_PM_at 
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), member D1 
63941 SLC35D1 -0.278 - 2.59E-02 4.63E-02 
218237_PM_s_at solute carrier family 38, member 1 145173 SLC38A1 -0.467 - 1.38E-03 1.57E-02 
202089_PM_s_at solute carrier family 39 (zinc transporter), member 6 2044 SLC39A6 -0.446 - 3.03E-03 2.09E-02 
219175_PM_s_at solute carrier family 41, member 3 3927 SLC41A3 -0.341 - 4.41E-03 2.57E-02 
211494_PM_s_at 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 
79582 SLC4A4 -0.813 - 5.74E-04 9.42E-03 
210739_PM_x_at 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 
285331 SLC4A4 -0.588 - 3.22E-02 4.98E-02 
207604_PM_s_at 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 7 
51574 SLC4A7 -0.813 - 3.57E-03 2.04E-02 
210854_PM_x_at 
solute carrier family 6 (neurotransmitter transporter, creatine), 
member 8 
1602 SLC6A8 -1.365 - 2.00E-03 3.73E-03 
213843_PM_x_at 
solute carrier family 6 (neurotransmitter transporter, creatine), 
member 8 
23276 SLC6A8 -1.277 - 4.83E-03 9.65E-03 
205864_PM_at 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 4 
4168 SLC7A4 -0.315 - 3.60E-03 2.42E-02 
211557_PM_x_at solute carrier organic anion transporter family, member 2B1 9230 SLCO2B1 -0.740 - 4.68E-03 1.54E-03 
209897_PM_s_at slit homolog 2 (Drosophila) 91272 SLIT2 -0.671 - 2.20E-02 1.14E-02 
232636_PM_at SLIT and NTRK-like family, member 4 22907 SLITRK4 -1.265 - 9.26E-04 3.68E-03 
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212257_PM_s_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 2 
5927 SMARCA2 -1.489 - 6.98E-03 2.76E-02 
212167_PM_s_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily b, member 1 
1845 SMARCB1 -0.873 - 1.88E-02 2.87E-02 
201073_PM_s_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1 
9733 SMARCC1 -0.437 - 1.51E-02 3.92E-03 
209257_PM_s_at structural maintenance of chromosomes 3 51742 SMC3 -1.534 - 1.81E-03 6.31E-03 
220368_PM_s_at SMEK homolog 1, suppressor of mek1 (Dictyostelium) 7764 SMEK1 -0.615 - 8.03E-03 4.34E-02 
210057_PM_at 
SMG1 homolog, phosphatidylinositol 3-kinase-related kinase 
(C. elegans) 
51704 SMG1 -0.269 - 2.37E-04 7.28E-03 
1555680_PM_a_at spermine oxidase 10250 SMOX -0.809 - 1.15E-02 3.53E-02 
1556629_PM_a_at Synaptosomal-associated protein, 25kDa 79022 SNAP25 -0.310 - 3.30E-02 3.38E-02 
207853_PM_s_at synuclein, beta 10592 SNCB -2.315 - 2.90E-02 4.81E-02 
218033_PM_s_at stannin 1911 SNN -0.958 - 7.34E-03 2.51E-02 
1554986_PM_a_at sorting nexin 19 7414 SNX19 -0.574 - 1.68E-03 1.61E-02 
1569481_PM_s_at sorting nexin 22 6880 SNX22 -0.279 - 1.14E-02 2.68E-02 
221006_PM_s_at sorting nexin family member 27 10610 SNX27 -1.343 - 1.70E-02 5.63E-03 
201085_PM_s_at SON DNA binding protein 9128 SON -0.558 - 2.51E-02 2.54E-02 
211819_PM_s_at sorbin and SH3 domain containing 1 9557 SORBS1 -0.550 - 2.69E-02 1.69E-02 
203509_PM_at sortilin-related receptor, L(DLR class) A repeats-containing 8573 SORL1 -1.160 - 6.25E-03 4.17E-03 
212797_PM_at sortilin 1 29902 SORT1 -0.448 - 5.92E-03 3.87E-02 
212807_PM_s_at sortilin 1 9829 SORT1 -0.577 - 9.80E-03 2.80E-02 
213721_PM_at SRY (sex determining region Y)-box 2 29072 SOX2 -1.575 - 1.65E-03 1.07E-03 
213722_PM_at SRY (sex determining region Y)-box 2 10486 SOX2 -0.868 - 7.94E-03 2.75E-02 
207336_PM_at SRY (sex determining region Y)-box 5 51603 SOX5 -0.419 - 3.24E-02 2.86E-02 
202935_PM_s_at SRY (sex determining region Y)-box 9 57704 SOX9 -0.901 - 1.34E-02 6.62E-03 
242668_PM_x_at sperm associated antigen 4-like --- SPAG4L -0.346 - 1.37E-02 2.68E-02 
222593_PM_s_at spermatogenesis associated, serine-rich 2 9857 SPATS2 -0.274 - 2.97E-02 7.92E-03 
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201996_PM_s_at spen homolog, transcriptional regulator (Drosophila) 23499 SPEN -1.633 - 1.92E-02 1.84E-02 
230884_PM_s_at 
spastic paraplegia 7 (pure and complicated autosomal 
recessive) 
286499 SPG7 -1.212 - 2.35E-03 7.00E-03 
217813_PM_s_at 233eparin233i 1 55727 SPIN1 -0.759 - 4.41E-04 5.07E-03 
202523_PM_s_at 
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 2 
29929 SPOCK2 -0.350 - 3.28E-03 1.61E-02 
209437_PM_s_at spondin 1, extracellular matrix protein 10072 /// 582 SPON1 -0.598 - 1.21E-02 8.96E-03 
215833_PM_s_at signal peptide peptidase-like 2B 57406 SPPL2B -0.271 - 1.09E-02 1.83E-02 
212466_PM_at 233epari-related, EVH1 domain containing 2 6302 SPRED2 -0.494 - 6.29E-05 3.37E-04 
200671_PM_s_at spectrin, beta, non-erythrocytic 1 311 SPTBN1 -1.079 - 9.27E-05 4.53E-03 
200672_PM_x_at spectrin, beta, non-erythrocytic 1 1740 SPTBN1 -2.869 - 2.71E-04 3.69E-03 
201471_PM_s_at sequestosome 1 9874 SQSTM1 -0.297 - 1.14E-02 2.08E-02 
208095_PM_s_at signal recognition particle 72kDa 5303 SRP72 -0.717 - 3.29E-02 4.26E-02 
203181_PM_x_at SFRS protein kinase 2 122704 SRPK2 -1.340 - 2.78E-03 2.35E-03 
214931_PM_s_at SFRS protein kinase 2 10827 SRPK2 -1.336 - 1.75E-02 4.80E-02 
200917_PM_s_at signal recognition particle receptor (docking protein) 7267 SRPR -1.741 - 1.50E-04 2.46E-03 
201224_PM_s_at serine/arginine repetitive matrix 1 1646 SRRM1 -1.193 - 1.90E-03 8.08E-04 
217051_PM_s_at synovial sarcoma translocation, chromosome 18 84937 SS18 -0.275 - 2.03E-03 1.19E-03 
209954_PM_x_at synovial sarcoma translocation, chromosome 18 54751 SS18 -0.502 - 4.60E-02 4.47E-02 
223635_PM_s_at single stranded DNA binding protein 3 30061 SSBP3 -2.223 - 3.13E-02 4.52E-02 
226712_PM_at signal sequence receptor, alpha 23198 SSR1 -0.307 - 9.56E-03 8.20E-03 
200889_PM_s_at signal sequence receptor, alpha 1837 SSR1 -0.714 - 2.67E-02 4.58E-02 
208482_PM_at somatostatin receptor 1 11340 SSTR1 -0.302 - 2.67E-02 3.38E-02 
1555702_PM_a_at ST3 beta-galactoside alpha-2,3-sialyltransferase 3 7296 ST3GAL3 -1.694 - 5.14E-03 2.60E-02 
207983_PM_s_at stromal antigen 2 898 STAG2 -1.552 - 3.18E-04 2.92E-03 
209023_PM_s_at stromal antigen 2 80025 STAG2 -0.831 - 3.95E-03 1.83E-02 
208194_PM_s_at 
signal transducing adaptor molecule (SH3 domain and ITAM 
motif) 2 
22924 STAM2 -0.433 - 6.56E-03 5.02E-03 
221610_PM_s_at signal transducing adaptor family member 2 6939 STAP2 -0.278 - 2.12E-02 1.96E-02 
208992_PM_s_at 
signal transducer and activator of transcription 3 (acute-phase 
response factor) 
55311 STAT3 -0.973 - 1.68E-02 2.42E-02 
1553117_PM_a_at serine/threonine kinase 38 6867 STK38 -0.432 - 2.63E-02 2.96E-02 
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218207_PM_s_at stathmin-like 3 29945 STMN3 -2.750 - 3.00E-03 1.21E-02 
234317_PM_s_at storkhead box 2 283933 STOX2 -0.884 - 3.51E-02 4.77E-02 
215505_PM_s_at striatin, calmodulin binding protein 3 51334 STRN3 -1.466 - 2.17E-02 4.39E-02 
221638_PM_s_at syntaxin 16 3567 STX16 -0.886 - 1.94E-03 9.42E-03 
1558249_PM_s_at syntaxin 16 10579 STX16 -1.192 - 2.18E-03 7.69E-03 
222708_PM_s_at syntaxin 17 286527 STX17 -0.408 - 2.53E-02 1.09E-02 
214441_PM_at syntaxin 6 55207 STX6 -0.271 - 2.32E-02 3.14E-02 
226462_PM_at syntaxin binding protein 6 (amisyn) 7204 STXBP6 -0.479 - 6.40E-03 2.57E-02 
233555_PM_s_at sulfatase 2 23135 SULF2 -1.779 - 1.92E-02 2.50E-02 
200739_PM_s_at SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae) 9536 SUMO3 -0.820 - 2.57E-02 4.82E-02 
233827_PM_s_at suppressor of Ty 16 homolog (S. cerevisiae) 1915 SUPT16H -1.567 - 1.18E-03 4.35E-03 
213971_PM_s_at 
suppressor of zeste 12 homolog (Drosophila) /// suppressor of 




-0.396 - 7.97E-04 8.22E-03 
225154_PM_at synapse associated protein 1, SAP47 homolog (Drosophila) 54813 SYAP1 -1.114 - 2.46E-02 4.11E-02 
1553264_PM_a_at synapsin I 83593 SYN1 -2.803 - 1.70E-02 2.78E-02 
210315_PM_at synapsin II 284252 SYN2 -2.624 - 1.71E-02 3.07E-02 
1553037_PM_a_at synapsin II 23040 SYN2 -2.193 - 1.78E-02 1.65E-02 
209024_PM_s_at synaptotagmin binding, cytoplasmic RNA interacting protein 23411 SYNCRIP -1.403 - 6.89E-03 1.66E-02 
207594_PM_s_at synaptojanin 1 9804 SYNJ1 -0.564 - 2.52E-03 3.73E-03 
232981_PM_s_at synergin, gamma 57563 SYNRG -0.313 - 4.22E-02 4.54E-02 
209198_PM_s_at synaptotagmin XI 57728 SYT11 -1.978 - 1.43E-03 2.98E-03 
205613_PM_at synaptotagmin XVII 5166 SYT17 -1.028 - 8.61E-03 7.89E-03 
206161_PM_s_at synaptotagmin V 8669 SYT5 -2.034 - 2.70E-02 3.37E-02 
206162_PM_x_at synaptotagmin V 3189 SYT5 -0.435 - 4.85E-02 4.94E-02 
1554690_PM_a_at transforming, acidic coiled-coil containing protein 1 60 TACC1 -1.256 - 2.11E-02 4.30E-03 
222728_PM_s_at 
TATA box binding protein (TBP)-associated factor, RNA 
polymerase I, D, 41kDa 
6227 TAF1D -0.420 - 4.38E-02 6.95E-03 
200916_PM_at transgelin 2 7267 TAGLN2 -0.458 - 2.08E-02 9.81E-04 
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210978_PM_s_at transgelin 2 79365 TAGLN2 -0.312 - 2.97E-02 1.47E-02 
218466_PM_at TBC1 domain family, member 17 285193 TBC1D17 -0.480 - 2.18E-02 7.80E-03 
226664_PM_at TBC1 domain family, member 20 3843 TBC1D20 -0.576 - 2.37E-03 4.37E-03 
201815_PM_s_at TBC1 domain family, member 5 5495 TBC1D5 -0.347 - 5.31E-03 1.03E-02 
1563839_PM_at TBC1 domain family, member 7 5925 TBC1D7 -0.283 - 2.74E-04 1.71E-03 
222633_PM_at 235eparin235ing (beta)-like 1 X-linked receptor 1 23637 TBL1XR1 -1.492 - 8.11E-03 2.00E-02 
230517_PM_at similar to GLI-Kruppel family member HKR1 51735 tcag7.1196 -0.304 - 3.32E-03 2.51E-02 
212931_PM_at transcription factor 20 (AR1) 10178 TCF20 -0.455 - 9.95E-03 2.87E-03 
213311_PM_s_at transcription factor 25 (basic helix-loop-helix) 27069 TCF25 -1.399 - 1.79E-05 8.66E-05 
212382_PM_at transcription factor 4 27336 TCF4 -2.047 - 2.17E-03 6.76E-03 
203753_PM_at transcription factor 4 57545 TCF4 -1.349 - 2.97E-03 5.39E-03 
222146_PM_s_at transcription factor 4 171023 TCF4 -0.970 - 1.42E-02 1.22E-02 
212762_PM_s_at transcription factor 7-like 2 (T-cell specific, HMG-box) 2801 TCF7L2 -0.848 - 1.57E-03 3.99E-04 
231912_PM_s_at tectonin beta-propeller repeat containing 1 151516 TECPR1 -0.339 - 1.24E-02 2.47E-02 
203176_PM_s_at transcription factor A, mitochondrial 57176 TFAM -0.323 - 1.57E-02 1.50E-03 
1565347_PM_s_at transcription factor binding to IGHM enhancer 3 8131 TFE3 -0.524 - 9.40E-03 2.58E-02 
203833_PM_s_at trans-golgi network protein 2 808 TGOLN2 -1.042 - 7.52E-03 1.26E-03 
213894_PM_at thrombospondin, type I, domain containing 7A 5771 THSD7A -0.982 - 1.10E-02 2.00E-02 
208850_PM_s_at Thy-1 cell surface antigen 1939 THY1 -1.207 - 3.13E-02 2.83E-02 
208851_PM_s_at Thy-1 cell surface antigen 51128 THY1 -0.536 - 3.34E-02 2.29E-02 
201446_PM_s_at TIA1 cytotoxic granule-associated RNA binding protein 2260 TIA1 -0.631 - 2.40E-02 1.66E-02 
1554890_PM_a_at TIA1 cytotoxic granule-associated RNA binding protein 694 TIA1 -0.311 - 2.65E-02 1.34E-02 
206409_PM_at T-cell lymphoma invasion and metastasis 1 8767 TIAM1 -0.824 - 2.14E-03 1.24E-02 
203167_PM_at TIMP metallopeptidase inhibitor 2 10059 TIMP2 -1.225 - 1.97E-03 3.55E-03 
201149_PM_s_at TIMP metallopeptidase inhibitor 3 288 TIMP3 -1.195 - 7.60E-04 1.50E-03 
208700_PM_s_at transketolase 3423 TKT -0.636 - 2.16E-02 2.53E-02 
203220_PM_s_at 
235eparin235ing-like enhancer of split 1 (E(sp1) homolog, 
Drosophila) 
80031 TLE1 -0.688 - 1.26E-02 2.11E-02 
216997_PM_x_at 
235eparin235ing-like enhancer of split 4 (E(sp1) homolog, 
Drosophila) 
160 TLE4 -0.318 - 5.00E-02 1.31E-02 
211077_PM_s_at tousled-like kinase 1 55754 TLK1 -0.750 - 8.33E-03 3.85E-02 
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209149_PM_s_at transmembrane 9 superfamily member 1 93 TM9SF1 -1.077 - 5.76E-03 1.63E-02 
212194_PM_s_at transmembrane 9 superfamily protein member 4 10289 TM9SF4 -1.605 - 1.71E-03 9.02E-03 
200803_PM_s_at transmembrane BAX inhibitor motif containing 6 7982 TMBIM6 -0.895 - 9.98E-04 8.44E-03 
220240_PM_s_at transmembrane and coiled-coil domains 3 596 TMCO3 -0.789 - 1.86E-02 4.69E-02 
204426_PM_at transmembrane emp24 domain trafficking protein 2 60496 TMED2 -2.619 - 1.73E-02 4.11E-02 
204427_PM_s_at transmembrane emp24 domain trafficking protein 2 5525 TMED2 -2.990 - 2.44E-02 4.69E-02 
224676_PM_at transmembrane emp24 protein transport domain containing 4 246184 TMED4 -1.649 - 2.31E-02 3.97E-02 
202195_PM_s_at transmembrane emp24 protein transport domain containing 5 1595 TMED5 -0.758 - 8.01E-03 3.90E-02 
242617_PM_at Transmembrane emp24 protein transport domain containing 8 --- TMED8 -0.294 - 2.42E-03 2.10E-02 
236667_PM_at transmembrane protein 120B --- TMEM120B -0.734 - 3.13E-02 3.77E-02 
222914_PM_s_at transmembrane protein 121 51465 TMEM121 -0.449 - 9.79E-03 4.45E-02 
1553479_PM_at transmembrane protein 145 55593 TMEM145 -0.700 - 1.10E-02 2.41E-02 
216315_PM_x_at 
TMEM189-UBE2V1 readthrough transcript /// ubiquitin-





-0.287 - 2.32E-02 6.47E-03 
226647_PM_at transmembrane protein 25 91369 TMEM25 -0.438 - 3.96E-02 3.25E-02 
232591_PM_s_at transmembrane protein 30A 6429 TMEM30A -1.970 - 1.91E-03 1.44E-02 
238831_PM_at transmembrane protein 33 --- TMEM33 -0.343 - 2.01E-02 2.85E-02 
222736_PM_s_at transmembrane protein 38B 2778 TMEM38B -0.408 - 1.69E-02 3.42E-02 
212202_PM_s_at transmembrane protein 87A 2192 TMEM87A -0.321 - 2.38E-02 2.39E-02 
207839_PM_s_at transmembrane protein 8B 10950 TMEM8B -0.344 - 7.11E-04 1.39E-03 
223827_PM_at tumor necrosis factor receptor superfamily, member 19 51496 TNFRSF19 -0.309 - 4.27E-02 4.21E-02 
213109_PM_at TRAF2 and NCK interacting kinase 27255 TNIK -1.140 - 8.43E-03 1.46E-02 
210585_PM_s_at transportin 2 57120 TNPO2 -0.715 - 1.54E-02 2.30E-02 
214550_PM_s_at transportin 3 58478 TNPO3 -0.581 - 1.89E-02 1.00E-02 
1553346_PM_a_at trinucleotide repeat containing 6A 57569 TNRC6A -1.937 - 6.45E-03 1.49E-02 
227149_PM_at trinucleotide repeat containing 6C 10062 TNRC6C -0.552 - 3.08E-03 2.84E-03 
216339_PM_s_at tenascin XA pseudogene /// tenascin XB 55151 TNXA /// TNXB -0.437 - 1.89E-02 4.15E-02 
217930_PM_s_at toll interacting protein 5537 TOLLIP -1.650 - 6.77E-03 1.85E-03 




translocase of outer mitochondrial membrane 22 homolog 
(yeast) 
255967 TOMM22 -1.936 - 3.44E-02 4.94E-02 
208900_PM_s_at topoisomerase (DNA) I 26273 TOP1 -1.435 - 1.53E-03 5.72E-03 
212409_PM_s_at torsin A interacting protein 1 51406 TOR1AIP1 -1.287 - 2.83E-03 1.07E-02 
201683_PM_x_at TOX high mobility group box family member 4 5905 TOX4 -1.498 - 9.19E-03 1.37E-02 
201684_PM_s_at TOX high mobility group box family member 4 4173 TOX4 -0.456 - 1.31E-02 2.35E-02 
1569098_PM_s_at tumor protein p53 binding protein 1 7164 TP53BP1 -0.423 - 1.55E-02 1.47E-02 
225605_PM_at tumor protein p53 inducible protein 13 154215 TP53I13 -0.296 - 1.44E-02 2.07E-02 
206116_PM_s_at tropomyosin 1 (alpha) 3422 TPM1 -0.721 - 4.58E-03 1.69E-02 
214365_PM_at tropomyosin 3 2590 TPM3 -0.618 - 3.95E-02 4.14E-02 
212481_PM_s_at tropomyosin 4 51020 TPM4 -0.686 - 1.86E-02 3.26E-02 
214196_PM_s_at tripeptidyl peptidase I 2332 TPP1 -2.460 - 9.73E-04 7.24E-03 
201730_PM_s_at translocated promoter region (to activated MET oncogene) 22998 TPR -1.572 - 1.78E-02 5.57E-03 
202079_PM_s_at trafficking protein, kinesin binding 1 23245 TRAK1 -0.338 - 1.75E-02 1.65E-02 
202124_PM_s_at trafficking protein, kinesin binding 2 8301 TRAK2 -0.755 - 1.23E-03 1.14E-04 
201399_PM_s_at translocation associated membrane protein 1 8671 TRAM1 -1.285 - 1.00E-02 4.19E-02 
56829_PM_at trafficking protein particle complex 9 3181 TRAPPC9 -0.618 - 3.33E-03 2.39E-03 
211788_PM_s_at three prime repair exonuclease 2 9672 TREX2 -0.273 - 2.31E-02 2.70E-02 
203147_PM_s_at tripartite motif-containing 14 9815 TRIM14 -0.422 - 1.01E-02 9.20E-03 
214248_PM_s_at tripartite motif-containing 2 22836 TRIM2 -2.268 - 1.01E-03 7.67E-03 
210995_PM_s_at tripartite motif-containing 23 60680 TRIM23 -2.338 - 1.55E-03 1.18E-02 
210994_PM_x_at tripartite motif-containing 23 8193 TRIM23 -2.464 - 6.02E-03 2.63E-02 
210541_PM_s_at tripartite motif-containing 27 8573 TRIM27 -1.734 - 1.11E-02 1.84E-02 
200990_PM_at tripartite motif-containing 28 10236 TRIM28 -1.016 - 2.87E-02 4.67E-02 
210266_PM_s_at tripartite motif-containing 33 55904 TRIM33 -0.454 - 9.22E-03 1.87E-02 
223131_PM_s_at tripartite motif-containing 8 51691 TRIM8 -1.117 - 2.50E-03 1.96E-02 
208178_PM_x_at triple functional domain (PTPRF interacting) 5432 TRIO -1.322 - 1.58E-02 3.19E-02 
209013_PM_x_at triple functional domain (PTPRF interacting) 57122 TRIO -0.774 - 4.09E-02 4.72E-02 
216452_PM_at 
transient receptor potential cation channel, subfamily M, 
member 3 
23731 TRPM3 -0.627 - 1.35E-02 4.74E-02 
234351_PM_x_at trichorhinophalangeal syndrome I --- TRPS1 -0.663 - 1.12E-02 2.87E-02 
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224218_PM_s_at trichorhinophalangeal syndrome I 8325 TRPS1 -1.003 - 1.18E-02 1.72E-02 
214908_PM_s_at transformation/transcription domain-associated protein 55802 TRRAP -0.694 - 2.75E-03 4.83E-03 
225484_PM_at testis specific, 14 390980 TSGA14 -0.658 - 2.84E-02 3.19E-02 
209890_PM_at tetraspanin 5 6470 TSPAN5 -1.995 - 2.40E-04 3.20E-03 
233617_PM_at TSPY-like 3 (pseudogene) 57599 TSPYL3 -0.420 - 6.94E-03 3.90E-03 
208663_PM_s_at tetratricopeptide repeat domain 3 10144 TTC3 -1.900 - 1.23E-03 3.11E-03 
208661_PM_s_at tetratricopeptide repeat domain 3 4099 TTC3 -2.734 - 3.75E-03 6.82E-03 
208664_PM_s_at tetratricopeptide repeat domain 3 23288 TTC3 -2.082 - 1.39E-02 2.83E-02 
208662_PM_s_at tetratricopeptide repeat domain 3 8073 TTC3 -0.992 - 1.59E-02 7.76E-03 
1554029_PM_a_at tetratricopeptide repeat domain 37 10062 /// 2521 TTC37 -0.524 - 3.10E-03 2.14E-02 
230872_PM_s_at tubulin tyrosine ligase-like family, member 3 64425 TTLL3 -1.187 - 1.73E-02 3.88E-02 
232042_PM_at tweety homolog 2 (Drosophila) 399959 TTYH2 -1.962 - 1.28E-03 1.14E-02 
209372_PM_x_at tubulin, beta 2A /// tubulin, beta 2B 29927 
TUBB2A /// 
TUBB2B 
-3.618 - 3.21E-02 4.91E-02 
208977_PM_x_at tubulin, beta 2C 55268 TUBB2C -0.432 - 2.85E-02 3.18E-02 
202154_PM_x_at tubulin, beta 3 4216 TUBB3 -0.357 - 2.73E-02 1.36E-02 
202476_PM_s_at tubulin, gamma complex associated protein 2 80155 TUBGCP2 -0.571 - 2.66E-03 2.76E-02 
230635_PM_at taurine upregulated 1 (non-protein coding) 134548 TUG1 -0.341 - 2.03E-03 1.15E-02 
203272_PM_s_at tumor suppressor candidate 2 118491 TUSC2 -1.401 - 3.32E-02 4.17E-02 
214007_PM_s_at twinfilin, actin-binding protein, homolog 1 (Drosophila) 221692 TWF1 -1.517 - 9.41E-03 4.72E-02 
201008_PM_s_at thioredoxin interacting protein 5687 TXNIP -1.286 - 1.51E-02 3.35E-02 
211431_PM_s_at TYRO3 protein tyrosine kinase 138639 TYRO3 -0.504 - 2.36E-02 4.72E-02 
200964_PM_at ubiquitin-like modifier activating enzyme 1 
100130966 /// 
387082 /// 6613 
/// 728825 
UBA1 -0.736 - 3.16E-02 4.99E-02 
201378_PM_s_at ubiquitin associated protein 2-like 4887 UBAP2L -1.001 - 1.57E-02 4.91E-02 
238587_PM_at ubiquitin associated and SH3 domain containing, B --- UBASH3B -0.346 - 2.54E-03 1.23E-02 
200669_PM_s_at ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 7168 UBE2D3 -1.327 - 1.04E-02 2.67E-02 
200668_PM_s_at ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 3157 UBE2D3 -0.519 - 1.25E-02 2.49E-02 
221962_PM_s_at ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 1282 UBE2H -1.112 - 4.73E-04 4.43E-03 
217799_PM_x_at ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 57580 UBE2H -2.119 - 1.60E-03 8.49E-03 
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217823_PM_s_at ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) 146223 UBE2J1 -0.267 - 6.49E-04 1.19E-03 
202347_PM_s_at ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 55830 UBE2K -0.826 - 1.97E-02 3.77E-02 
200682_PM_s_at ubiquitin-conjugating enzyme E2L 3 11163 UBE2L3 -0.501 - 2.81E-02 2.56E-02 
223014_PM_at ubiquitin-conjugating enzyme E2R 2 26060 UBE2R2 -0.542 - 4.73E-02 2.52E-02 
202779_PM_s_at ubiquitin-conjugating enzyme E2S 89797 UBE2S -2.792 - 2.08E-02 3.46E-02 
1554794_PM_a_at ubiquitin protein ligase E3C 
100291837 /// 
6227 
UBE3C -0.430 - 8.01E-03 2.88E-02 
212756_PM_s_at ubiquitin protein ligase E3 component n-recognin 2 10484 UBR2 -0.284 - 9.35E-03 3.54E-02 
212007_PM_at UBX domain protein 4 2058 UBXN4 -0.793 - 2.46E-03 5.69E-03 
223142_PM_s_at uridine-cytidine kinase 1 112399 UCK1 -0.600 - 1.11E-02 2.70E-02 
1552656_PM_s_at U2AF homology motif (UHM) kinase 1 30011 UHMK1 -1.760 - 2.88E-03 1.51E-03 
235003_PM_at U2AF homology motif (UHM) kinase 1 9478 UHMK1 -1.455 - 8.08E-03 3.54E-03 
227740_PM_at U2AF homology motif (UHM) kinase 1 55608 UHMK1 -1.306 - 1.01E-02 7.97E-03 
1554292_PM_a_at UHRF1 binding protein 1-like 3326 UHRF1BP1L -0.537 - 1.19E-04 6.22E-05 
231768_PM_at upstream transcription factor 1 5502 USF1 -0.267 - 2.17E-02 3.79E-02 
201831_PM_s_at USO1 homolog, vesicle docking protein (yeast) 1268 USO1 -1.993 - 4.88E-03 2.26E-02 
202412_PM_s_at ubiquitin specific peptidase 1 51053 USP1 -0.923 - 3.72E-03 3.65E-03 
209136_PM_s_at ubiquitin specific peptidase 10 55733 USP10 -0.499 - 2.86E-03 1.86E-02 
208723_PM_at ubiquitin specific peptidase 11 23588 USP11 -2.478 - 2.81E-02 4.67E-02 
201671_PM_x_at 
ubiquitin specific peptidase 14 (tRNA-guanine 
transglycosylase) 
4637 USP14 -0.438 - 8.60E-03 4.13E-02 
222616_PM_s_at ubiquitin specific peptidase 16 51663 USP16 -0.702 - 4.34E-03 1.19E-02 
1555559_PM_s_at ubiquitin specific peptidase 25 396 USP25 -0.322 - 1.98E-02 6.24E-03 
214843_PM_s_at ubiquitin specific peptidase 33 29093 USP33 -1.236 - 4.72E-03 1.39E-02 
226174_PM_at ubiquitin specific peptidase 42 25782 USP42 -0.303 - 1.56E-03 3.45E-03 
223701_PM_s_at ubiquitin specific peptidase 47 55122 USP47 -2.400 - 2.61E-02 4.37E-02 
230543_PM_at ubiquitin specific peptidase 9, X-linked 79364 USP9X -0.694 - 3.90E-02 2.48E-02 
201556_PM_s_at vesicle-associated membrane protein 2 (synaptobrevin 2) 2820 VAMP2 -0.673 - 1.67E-02 2.33E-02 
201796_PM_s_at valyl-tRNA synthetase 79882 VARS -0.331 - 1.77E-02 6.60E-03 
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208649_PM_s_at valosin-containing protein 9404 VCP -1.304 - 3.46E-02 4.66E-02 
217140_PM_s_at voltage-dependent anion channel 1 79576 VDAC1 -1.186 - 1.95E-02 4.85E-02 
210513_PM_s_at vascular endothelial growth factor A 441951 VEGFA -0.849 - 2.70E-03 3.90E-03 
211527_PM_x_at vascular endothelial growth factor A 91289 VEGFA -0.973 - 2.16E-02 2.63E-02 
212324_PM_s_at vacuolar protein sorting 13 homolog D (S. cerevisiae) 10007 VPS13D -0.316 - 1.75E-02 1.43E-02 
230306_PM_at vacuolar protein sorting 26 homolog B (S. pombe) 84948 VPS26B -0.463 - 9.39E-03 4.82E-02 
222387_PM_s_at vacuolar protein sorting 35 homolog (S. cerevisiae) 11017 VPS35 -1.990 - 4.22E-05 4.78E-04 
233864_PM_s_at vacuolar protein sorting 35 homolog (S. cerevisiae) --- VPS35 -1.751 - 1.96E-02 3.61E-02 
217727_PM_x_at vacuolar protein sorting 35 homolog (S. cerevisiae) 84191 VPS35 -1.692 - 3.57E-02 3.99E-02 
221707_PM_s_at vacuolar protein sorting 53 homolog (S. cerevisiae) 51366 VPS53 -0.300 - 1.87E-02 1.56E-02 
221998_PM_s_at vaccinia related kinase 3 23167 VRK3 -0.575 - 1.43E-02 7.83E-03 
219679_PM_s_at WW domain containing adaptor with coiled-coil 9806 WAC -2.361 - 3.06E-03 1.73E-02 
212264_PM_s_at wings apart-like homolog (Drosophila) 8500 WAPAL -0.776 - 2.00E-03 1.12E-02 
200628_PM_s_at tryptophanyl-tRNA synthetase 1386 WARS -0.831 - 6.54E-03 2.14E-02 
205810_PM_s_at Wiskott-Aldrich syndrome-like 7730 WASL -1.197 - 1.13E-04 1.01E-03 
205809_PM_s_at Wiskott-Aldrich syndrome-like 2911 WASL -1.714 - 2.82E-03 6.12E-03 
209117_PM_at WW domain binding protein 2 64146 /// 84342 WBP2 -0.878 - 3.35E-02 4.98E-02 
1554410_PM_a_at Williams-Beuren syndrome chromosome region 16 7534 WBSCR16 -0.322 - 1.34E-02 1.55E-02 
210935_PM_s_at WD repeat domain 1 130507 WDR1 -1.245 - 3.82E-03 1.91E-02 
200611_PM_s_at WD repeat domain 1 7804 WDR1 -0.725 - 1.23E-02 2.06E-02 
223308_PM_s_at WD repeat domain 5 665 WDR5 -0.530 - 3.65E-02 3.74E-02 
221981_PM_s_at WD repeat domain 59 57178 WDR59 -0.417 - 5.78E-03 1.04E-02 
221248_PM_s_at Wolf-Hirschhorn syndrome candidate 1-like 1 26747 WHSC1L1 -1.591 - 1.62E-02 4.43E-02 
222544_PM_s_at Wolf-Hirschhorn syndrome candidate 1-like 1 113146 WHSC1L1 -1.321 - 4.29E-02 2.46E-02 
202665_PM_s_at WAS/WASL interacting protein family, member 1 3778 WIPF1 -0.347 - 3.99E-02 3.79E-02 
212050_PM_at WAS/WASL interacting protein family, member 2 10724 WIPF2 -0.425 - 8.36E-04 4.05E-03 
221785_PM_at widely interspaced zinc finger motifs 84516 WIZ -0.563 - 1.78E-02 7.71E-03 
201295_PM_s_at WD repeat and SOCS box-containing 1 9478 WSB1 -0.478 - 8.01E-04 4.22E-03 
201294_PM_s_at WD repeat and SOCS box-containing 1 10772 WSB1 -1.851 - 2.93E-03 2.54E-03 
225273_PM_at WWC family member 3 120892 WWC3 -2.059 - 4.32E-04 6.21E-03 
237802_PM_at XK, Kell blood group complex subunit-related family, member --- XKR4 -1.183 - 4.44E-02 2.70E-02 
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208459_PM_s_at exportin 7 50814 XPO7 -1.172 - 3.97E-02 4.80E-02 
213342_PM_at Yes-associated protein 1, 65kDa 9169 YAP1 -0.533 - 5.42E-03 3.99E-03 
213996_PM_at yippee-like 1 (Drosophila) 92342 YPEL1 -0.483 - 3.30E-02 2.11E-02 
222703_PM_s_at yrdC domain containing (E. coli) 221981 YRDC -0.327 - 3.55E-02 2.46E-02 
1564053_PM_a_at YTH domain family, member 3 10244 YTHDF3 -0.907 - 6.03E-03 3.29E-02 
201020_PM_at 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide 
6938 YWHAH -0.297 - 2.41E-02 2.00E-02 
200638_PM_s_at 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
51601 YWHAZ -0.367 - 1.00E-03 8.96E-03 
200641_PM_s_at 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
5837 YWHAZ -2.026 - 1.49E-02 3.86E-02 
201901_PM_s_at YY1 transcription factor 3267 YY1 -1.415 - 7.59E-04 4.25E-03 
201902_PM_s_at YY1 transcription factor 6201 YY1 -0.349 - 5.44E-03 8.63E-03 
205883_PM_at zinc finger and BTB domain containing 16 10254 ZBTB16 -1.108 - 3.62E-02 3.06E-02 
235308_PM_at zinc finger and BTB domain containing 20 --- ZBTB20 -1.204 - 2.57E-02 2.32E-02 
204180_PM_s_at zinc finger and BTB domain containing 43 22916 ZBTB43 -1.013 - 3.63E-02 5.40E-03 
205787_PM_x_at zinc finger CCCH-type containing 11A 1009 ZC3H11A -1.285 - 8.36E-03 3.56E-02 
201593_PM_s_at zinc finger CCCH-type containing 15 11219 ZC3H15 -1.840 - 1.88E-02 2.96E-02 
219247_PM_s_at zinc finger, DHHC-type containing 14 3281 ZDHHC14 -0.328 - 1.99E-03 1.93E-02 
217486_PM_s_at zinc finger, DHHC-type containing 17 10923 ZDHHC17 -0.806 - 9.28E-03 7.55E-03 
218077_PM_s_at zinc finger, DHHC-type containing 3 10009 ZDHHC3 -0.374 - 2.96E-02 4.12E-02 
212758_PM_s_at zinc finger E-box binding homeobox 1 1307 ZEB1 -0.659 - 3.40E-02 4.59E-02 
202456_PM_s_at zer-1 homolog (C. elegans) 80227 ZER1 -0.309 - 5.39E-03 4.44E-02 
202448_PM_s_at zer-1 homolog (C. elegans) 56904 ZER1 -0.362 - 1.20E-02 2.67E-02 
222493_PM_s_at zinc finger, AN1-type domain 3 124222 ZFAND3 -0.722 - 3.15E-02 4.98E-02 
217741_PM_s_at zinc finger, AN1-type domain 5 2113 ZFAND5 -1.324 - 8.39E-03 3.22E-02 
219779_PM_at zinc finger homeobox 4 901 ZFHX4 -0.935 - 2.78E-02 2.10E-02 
224631_PM_at zinc finger protein 91 homolog (mouse) 586 ZFP91 -2.220 - 1.18E-02 2.41E-02 
213286_PM_at zinc finger RNA binding protein 7105 ZFR -2.223 - 8.90E-04 6.47E-03 
33148_PM_at zinc finger RNA binding protein 338811 ZFR -1.035 - 6.45E-03 6.59E-03 
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201856_PM_s_at zinc finger RNA binding protein 80823 ZFR -0.724 - 1.20E-02 1.36E-02 
223388_PM_s_at zinc finger, FYVE domain containing 1 199731 ZFYVE1 -0.349 - 2.22E-02 4.24E-02 
208446_PM_s_at zinc finger, FYVE domain containing 9 8776 ZFYVE9 -0.496 - 2.31E-02 4.60E-02 
1555609_PM_a_at zinc finger, matrin type 3 5111 ZMAT3 -1.850 - 6.67E-03 3.39E-02 
210281_PM_s_at zinc finger, MYM-type 2 128439 ZMYM2 -1.548 - 2.25E-03 1.90E-03 
1554159_PM_a_at zinc finger, MYND domain containing 11 84465 ZMYND11 -1.950 - 3.68E-03 1.73E-02 
1559881_PM_s_at zinc finger protein 12 86 ZNF12 -1.158 - 3.36E-03 9.30E-03 
207402_PM_at zinc finger protein 132 8801 ZNF132 -0.301 - 6.71E-03 3.98E-02 
207164_PM_s_at zinc finger protein 238 9221 ZNF238 -2.900 - 1.02E-02 3.39E-02 
203247_PM_s_at zinc finger protein 24 56945 ZNF24 -0.508 - 2.51E-02 4.05E-02 
206900_PM_x_at zinc finger protein 253 51635 ZNF253 -0.330 - 1.22E-02 6.42E-03 
242602_PM_x_at zinc finger protein 254 3192 ZNF254 -0.291 - 3.17E-02 1.72E-02 
226260_PM_x_at zinc finger protein 358 2983 ZNF358 -0.722 - 9.99E-03 4.33E-02 
1555015_PM_a_at zinc finger protein 398 22872 ZNF398 -0.282 - 8.46E-03 4.47E-02 
242684_PM_at zinc finger protein 425 8110 ZNF425 -0.317 - 1.51E-02 5.94E-03 
215359_PM_x_at zinc finger protein 44 54842 ZNF44 -0.432 - 1.61E-02 1.17E-02 
232247_PM_at zinc finger protein 502 84959 ZNF502 -0.498 - 2.37E-02 9.15E-03 
230542_PM_at zinc finger protein 597 11076 ZNF597 -0.437 - 1.40E-02 2.87E-02 
1553725_PM_s_at zinc finger protein 644 64783 ZNF644 -0.362 - 6.46E-03 3.71E-02 
235577_PM_at zinc finger protein 652 7184 ZNF652 -0.291 - 1.16E-02 1.92E-02 
220760_PM_x_at zinc finger protein 665 1036 ZNF665 -0.643 - 5.28E-04 3.19E-03 
220215_PM_at zinc finger protein 669 5116 ZNF669 -0.767 - 4.81E-02 4.87E-02 
217547_PM_x_at zinc finger protein 675 113201 ZNF675 -0.344 - 7.07E-03 8.36E-03 
215570_PM_s_at zinc finger protein 780A /// zinc finger protein 780B 55002 
ZNF780A /// 
ZNF780B 
-0.574 - 6.55E-03 3.36E-02 
1564362_PM_x_at zinc finger protein 843 6733 ZNF843 -0.354 - 4.96E-02 3.31E-04 
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215758_PM_x_at zinc finger protein 93 54904 ZNF93 -0.417 - 1.73E-02 9.04E-03 
223382_PM_s_at zinc and ring finger 1 2018 ZNRF1 -0.781 - 6.56E-03 2.62E-03 
223383_PM_at zinc and ring finger 1 7328 ZNRF1 -1.840 - 7.72E-03 2.20E-02 
225131_PM_at zinc finger, RAN-binding domain containing 1 5549 ZRANB1 -0.303 - 5.62E-03 3.63E-02 
223016_PM_x_at zinc finger, RAN-binding domain containing 2 55915 ZRANB2 -1.677 - 1.29E-02 2.35E-02 
218349_PM_s_at Zwilch, kinetochore associated, homolog (Drosophila) 144402 ZWILCH -0.417 - 4.55E-02 4.22E-02 
230106_PM_at ZXD family zinc finger C 339324 ZXDC -0.918 - 1.08E-02 1.86E-03 
229325_PM_at zinc finger, ZZ-type containing 3 84668 ZZZ3 -0.270 - 2.74E-02 1.58E-02 
1562408_PM_at --- 4719 --- 0.314 + 1.90E-05 2.04E-05 
241769_PM_at --- 54832 --- 0.592 + 4.69E-05 3.49E-05 
227499_PM_at --- 81566 --- 0.683 + 5.72E-05 2.07E-05 
227278_PM_at --- 51171 --- 0.416 + 7.09E-05 1.30E-05 
228548_PM_at --- 80018 --- 0.411 + 8.69E-05 3.97E-04 
238752_PM_at --- --- --- 0.355 + 1.04E-04 7.87E-05 
244349_PM_at --- --- --- 0.434 + 1.29E-04 3.61E-03 
1565810_PM_at --- 5000 --- 0.280 + 1.90E-04 2.34E-03 
225123_PM_at --- 128344 --- 0.592 + 1.92E-04 1.92E-05 
227306_PM_at --- 54834 --- 0.384 + 2.14E-04 1.46E-03 
228603_PM_at --- 57586 --- 0.404 + 5.07E-04 2.92E-03 
1557623_PM_at --- 23476 --- 0.272 + 5.76E-04 9.46E-03 
226231_PM_at --- 9653 --- 0.278 + 5.82E-04 6.11E-03 
229640_PM_x_at --- --- --- 0.871 + 6.00E-04 3.79E-04 
224769_PM_at --- 284184 --- 0.381 + 7.36E-04 2.79E-03 
236369_PM_at --- --- --- 0.278 + 7.40E-04 8.34E-03 
226282_PM_at --- 27252 --- 0.521 + 8.16E-04 1.75E-02 
1570301_PM_at --- 902 --- 0.916 + 8.74E-04 1.51E-02 
232788_PM_at --- 57689 --- 0.458 + 9.59E-04 7.37E-03 
224691_PM_at --- 116983 --- 0.549 + 9.71E-04 3.19E-03 
1559535_PM_s_at --- 102 --- 0.355 + 1.01E-03 5.54E-03 
230446_PM_at --- 258010 --- 0.312 + 1.06E-03 1.13E-02 
230139_PM_at --- 119504 --- 0.942 + 1.13E-03 4.97E-03 
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235663_PM_at --- --- --- 0.444 + 1.15E-03 8.05E-03 
228528_PM_at --- 64841 --- 0.646 + 1.15E-03 2.18E-03 
226621_PM_at --- 1822 --- 0.420 + 1.16E-03 4.02E-03 
226742_PM_at --- --- --- 0.497 + 1.20E-03 5.06E-03 
230154_PM_at --- 23360 --- 0.887 + 1.35E-03 4.08E-03 
220452_PM_x_at --- 8850 --- 0.366 + 1.35E-03 1.60E-02 
231165_PM_at --- 220164 --- 0.620 + 1.49E-03 4.54E-03 
226773_PM_at --- 6654 --- 0.490 + 1.49E-03 6.80E-03 
240415_PM_at --- --- --- 0.568 + 1.53E-03 3.12E-03 
232903_PM_at --- 5454 --- 0.852 + 1.62E-03 1.93E-03 
228560_PM_at --- 149041 --- 0.316 + 1.66E-03 3.85E-04 
1555617_PM_x_at --- 1654 --- 0.300 + 1.68E-03 6.99E-04 
1567913_PM_at --- 178 --- 0.390 + 1.77E-03 1.17E-02 
229248_PM_at --- 26524 --- 0.339 + 1.78E-03 1.45E-02 
217107_PM_at --- 51639 --- 0.371 + 1.80E-03 3.49E-03 
243023_PM_at --- --- --- 0.839 + 1.83E-03 7.25E-03 
1568799_PM_at --- 6502 --- 0.264 + 1.85E-03 8.70E-03 
240099_PM_at --- --- --- 0.291 + 1.95E-03 5.35E-03 
213705_PM_at --- 171546 --- 0.264 + 1.99E-03 9.42E-03 
1555848_PM_at --- 10159 --- 0.382 + 2.07E-03 6.68E-03 
1562979_PM_at --- 8050 --- 0.326 + 2.10E-03 1.31E-02 
228914_PM_at --- 6876 --- 0.752 + 2.18E-03 1.08E-02 
244008_PM_at --- --- --- 0.874 + 2.33E-03 1.17E-02 
230293_PM_at --- 5599 --- 0.396 + 2.34E-03 1.36E-02 
228692_PM_at --- 79832 --- 0.510 + 2.42E-03 4.85E-03 
227815_PM_at --- --- --- 0.499 + 2.53E-03 6.80E-03 
228070_PM_at --- 80854 --- 0.651 + 2.55E-03 8.48E-03 
227290_PM_at --- 55295 --- 0.632 + 2.63E-03 6.57E-03 
243887_PM_at --- --- --- 0.291 + 2.68E-03 2.46E-02 
243398_PM_at --- --- --- 0.794 + 2.70E-03 5.06E-03 
211976_PM_at --- 10550 --- 0.325 + 2.71E-03 8.55E-03 
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226873_PM_at --- 53844 --- 0.759 + 2.80E-03 1.88E-04 
229898_PM_at --- 79018 --- 0.341 + 2.87E-03 2.18E-03 
229885_PM_at --- 79884 --- 0.710 + 2.91E-03 3.01E-04 
232752_PM_at --- --- --- 0.289 + 2.93E-03 9.96E-03 
213549_PM_at --- 83941 --- 0.423 + 2.94E-03 1.67E-03 
242366_PM_at --- 54554 --- 0.629 + 2.97E-03 7.50E-03 
229111_PM_at --- --- --- 0.879 + 3.00E-03 1.50E-02 
240196_PM_at --- 100129122 --- 0.267 + 3.02E-03 8.61E-03 
243907_PM_at --- --- --- 0.559 + 3.03E-03 1.32E-02 
235227_PM_at --- 8467 --- 0.784 + 3.05E-03 3.85E-03 
213657_PM_s_at --- 23065 --- 0.546 + 3.06E-03 4.23E-03 
227682_PM_at --- 64328 --- 0.586 + 3.08E-03 5.21E-03 
239637_PM_at --- --- --- 0.514 + 3.17E-03 6.24E-03 
225880_PM_at --- 114783 --- 0.470 + 3.23E-03 5.87E-03 
1562194_PM_at --- 5799 --- 0.393 + 3.25E-03 1.39E-02 
238786_PM_at --- 221981 --- 0.558 + 3.28E-03 8.04E-03 
227630_PM_at --- 7328 --- 0.586 + 3.34E-03 8.60E-03 
240433_PM_x_at --- --- --- 0.470 + 3.44E-03 2.33E-02 
240095_PM_at --- --- --- 0.792 + 3.50E-03 1.21E-02 
239752_PM_at --- --- --- 0.883 + 3.50E-03 2.40E-02 
240502_PM_at --- --- --- 0.457 + 3.61E-03 2.94E-02 
226532_PM_at --- 22823 --- 0.474 + 3.74E-03 1.29E-02 
227749_PM_at --- 56985 --- 0.277 + 3.74E-03 8.41E-03 
235529_PM_x_at --- 388650 --- 0.744 + 3.83E-03 2.17E-03 
217329_PM_x_at --- 92259 --- 0.348 + 3.90E-03 8.00E-04 
238209_PM_at --- --- --- 0.294 + 4.20E-03 1.83E-02 
225950_PM_at --- 140469 --- 0.652 + 4.51E-03 4.99E-03 
237931_PM_at --- 1272 --- 0.285 + 4.51E-03 1.21E-02 
238919_PM_at --- --- --- 0.367 + 4.59E-03 2.84E-02 
230171_PM_at --- --- --- 0.398 + 4.60E-03 2.60E-03 
226480_PM_at --- 3400 --- 0.537 + 4.73E-03 1.71E-02 
235611_PM_at --- --- --- 0.623 + 4.79E-03 1.01E-03 
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235964_PM_x_at --- 79685 --- 0.617 + 4.84E-03 1.76E-03 
213573_PM_at --- 55573 --- 0.367 + 4.97E-03 6.09E-03 
235764_PM_at --- 60560 --- 0.312 + 5.06E-03 7.00E-03 
228240_PM_at --- 51132 --- 0.352 + 5.13E-03 1.59E-02 
229366_PM_at --- 140685 --- 0.501 + 5.21E-03 3.38E-02 
226719_PM_at --- 92140 --- 0.549 + 5.24E-03 1.51E-02 
226280_PM_at --- 6198 --- 0.538 + 5.26E-03 9.26E-03 
210030_PM_at --- 9117 --- 0.280 + 5.29E-03 3.50E-02 
238191_PM_at --- --- --- 0.600 + 5.36E-03 1.93E-02 
225318_PM_at --- 645323 --- 0.312 + 5.63E-03 1.49E-02 
228734_PM_at --- 84333 --- 0.277 + 5.70E-03 1.19E-02 
239923_PM_at --- 157503 --- 0.525 + 5.78E-03 2.49E-03 
242968_PM_at --- 57085 --- 0.528 + 5.81E-03 1.18E-02 
241687_PM_at --- --- --- 0.320 + 6.00E-03 1.43E-02 
230350_PM_at --- 9201 --- 0.661 + 6.11E-03 4.12E-03 
236089_PM_at --- --- --- 0.764 + 6.14E-03 2.61E-03 
213567_PM_at --- 26099 --- 0.873 + 6.29E-03 7.91E-03 
235984_PM_at --- --- --- 0.693 + 6.41E-03 1.12E-02 
233095_PM_at --- 54467 --- 0.454 + 6.45E-03 1.61E-02 
230589_PM_at --- --- --- 1.082 + 6.60E-03 2.30E-02 
231137_PM_at --- 54014 --- 0.368 + 6.64E-03 1.10E-02 
241721_PM_at --- --- --- 1.016 + 6.66E-03 3.11E-03 
1566221_PM_at --- 5428 --- 0.278 + 6.79E-03 1.80E-02 
228151_PM_at --- 22836 --- 0.605 + 7.26E-03 8.79E-03 
238297_PM_at --- --- --- 1.004 + 7.31E-03 2.64E-03 
230740_PM_at --- 728743 --- 0.355 + 7.33E-03 1.74E-02 
1560496_PM_at --- 8881 --- 0.270 + 7.44E-03 1.06E-02 
234907_PM_x_at --- 11137 --- 0.301 + 7.44E-03 1.69E-02 
215515_PM_at --- 56172 --- 0.294 + 7.45E-03 2.03E-02 
226821_PM_at --- 85453 --- 0.513 + 7.49E-03 5.80E-03 
242967_PM_at --- --- --- 0.298 + 7.54E-03 5.41E-03 
227167_PM_s_at --- 51186 --- 1.083 + 7.64E-03 1.05E-02 
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1556444_PM_a_at --- 120 --- 0.919 + 7.64E-03 9.86E-03 
229786_PM_at --- 60674 --- 0.869 + 7.70E-03 1.97E-02 
234807_PM_x_at --- 221078 --- 0.405 + 7.71E-03 6.84E-03 
229072_PM_at --- 5208 --- 0.706 + 7.71E-03 1.17E-02 
1556744_PM_a_at --- 7407 --- 0.832 + 7.78E-03 1.60E-03 
241629_PM_at --- --- --- 0.315 + 7.81E-03 3.43E-02 
239291_PM_at --- --- --- 0.975 + 8.11E-03 7.82E-04 
223366_PM_at --- 84900 --- 0.611 + 8.26E-03 1.56E-02 
227448_PM_at --- 57084 --- 0.553 + 8.29E-03 6.11E-03 
1568931_PM_at --- 4281 --- 0.300 + 8.36E-03 5.68E-03 
1562529_PM_s_at --- 857 --- 0.481 + 8.48E-03 2.27E-02 
237839_PM_at --- --- --- 0.268 + 8.53E-03 1.06E-02 
236031_PM_x_at --- --- --- 0.686 + 8.69E-03 4.32E-02 
230605_PM_at --- 127018 --- 0.679 + 8.72E-03 3.43E-02 
228611_PM_s_at --- 220213 --- 0.737 + 8.82E-03 9.39E-03 
230411_PM_at --- 11231 --- 0.366 + 8.82E-03 3.11E-03 
239678_PM_at --- --- --- 0.967 + 8.88E-03 2.15E-02 
239277_PM_at --- --- --- 1.069 + 8.92E-03 1.77E-02 
1560738_PM_at --- 8974 --- 0.291 + 8.92E-03 9.33E-03 
235355_PM_at --- 9939 --- 0.509 + 8.96E-03 2.75E-02 
229824_PM_at --- 29097 --- 0.510 + 9.07E-03 2.06E-02 
226883_PM_at --- 6868 --- 0.547 + 9.12E-03 2.70E-02 
226641_PM_at --- 1837 --- 0.492 + 9.20E-03 3.98E-03 
238879_PM_at --- 26009 --- 0.736 + 9.23E-03 1.10E-02 
230211_PM_at --- 149563 --- 0.301 + 9.25E-03 1.81E-02 
224107_PM_at --- 56776 --- 0.286 + 9.52E-03 1.79E-02 
235750_PM_at --- 79999 --- 0.524 + 9.60E-03 1.09E-02 
221788_PM_at --- 5178 --- 1.388 + 9.64E-03 9.82E-03 
1554597_PM_at --- 5518 --- 0.503 + 9.64E-03 3.56E-02 
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244621_PM_x_at --- --- --- 0.643 + 9.67E-03 2.47E-02 
236798_PM_at --- 56943 --- 0.772 + 9.80E-03 1.49E-02 
235065_PM_at --- 51366 --- 0.595 + 9.85E-03 6.02E-03 
226579_PM_at --- 2273 --- 0.461 + 1.00E-02 1.71E-02 
231925_PM_at --- 5814 --- 1.175 + 1.01E-02 1.30E-02 
242303_PM_at --- 5471 --- 0.562 + 1.02E-02 3.70E-02 
235659_PM_at --- --- --- 0.314 + 1.02E-02 3.10E-02 
239673_PM_at --- --- --- 0.422 + 1.03E-02 5.92E-03 
234998_PM_at --- 5121 --- 0.476 + 1.04E-02 3.13E-02 
229383_PM_at --- 23517 --- 0.861 + 1.08E-02 1.03E-02 
235304_PM_at --- --- --- 0.328 + 1.09E-02 4.07E-02 
228991_PM_at --- 401504 --- 0.453 + 1.10E-02 2.64E-02 
244847_PM_at --- 8476 --- 0.301 + 1.10E-02 9.29E-03 
226941_PM_at --- 6657 --- 0.695 + 1.11E-02 5.21E-03 
225227_PM_at --- 196294 --- 0.713 + 1.11E-02 4.98E-03 
238524_PM_at --- --- --- 0.305 + 1.12E-02 1.11E-02 
226399_PM_at --- 3738 --- 0.361 + 1.13E-02 2.17E-02 
228006_PM_at --- 4302 --- 0.463 + 1.13E-02 2.19E-02 
235553_PM_at --- 10446 --- 0.607 + 1.13E-02 1.53E-02 
1557375_PM_at --- 5536 --- 0.376 + 1.13E-02 9.15E-03 
240922_PM_at --- --- --- 0.306 + 1.13E-02 1.48E-02 
232999_PM_at --- 5136 --- 0.776 + 1.14E-02 1.34E-02 
236282_PM_at --- --- --- 0.335 + 1.14E-02 3.77E-02 
227273_PM_at --- 51735 /// 96459 --- 0.371 + 1.15E-02 7.76E-03 
226546_PM_at --- 3431 --- 0.274 + 1.15E-02 3.32E-02 
238115_PM_at --- 219899 --- 0.479 + 1.16E-02 2.84E-02 
233116_PM_at --- 145788 --- 0.456 + 1.17E-02 1.27E-02 
244884_PM_at --- --- --- 0.272 + 1.17E-02 2.42E-02 
1556329_PM_a_at --- 8539 --- 0.499 + 1.21E-02 4.14E-02 
226203_PM_at --- 445815 --- 0.495 + 1.23E-02 1.60E-02 
235118_PM_at --- 9581 --- 0.310 + 1.24E-02 5.47E-03 
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239278_PM_at --- --- --- 0.636 + 1.24E-02 2.63E-02 
238044_PM_at --- 10983 --- 0.271 + 1.27E-02 2.32E-03 
239425_PM_at --- 5178 --- 1.008 + 1.27E-02 1.79E-03 
227623_PM_at --- 100129250 --- 0.676 + 1.28E-02 3.95E-02 
1554007_PM_at --- 5034 --- 0.361 + 1.29E-02 2.58E-02 
229602_PM_at --- 55331 --- 0.931 + 1.29E-02 3.10E-02 
238202_PM_at --- --- --- 0.332 + 1.30E-02 1.77E-02 
226560_PM_at --- 23657 --- 0.589 + 1.30E-02 2.36E-02 
239307_PM_at --- 100134361 --- 0.267 + 1.30E-02 1.08E-02 
229861_PM_at --- 117583 --- 0.462 + 1.31E-02 4.01E-02 
236016_PM_at --- 100133130 --- 0.334 + 1.31E-02 1.98E-02 
226826_PM_at --- 23135 --- 0.575 + 1.31E-02 2.77E-02 
230794_PM_at --- 9495 --- 0.273 + 1.31E-02 2.53E-02 
226139_PM_at --- 10217 --- 0.395 + 1.33E-02 2.28E-02 
224811_PM_at --- 80144 --- 1.067 + 1.34E-02 2.14E-02 
239355_PM_at --- --- --- 0.516 + 1.40E-02 1.81E-02 
236204_PM_at --- 10490 --- 0.329 + 1.41E-02 2.82E-02 
238739_PM_at --- --- --- 0.419 + 1.43E-02 2.88E-02 
225176_PM_at --- 123228 --- 0.492 + 1.44E-02 3.78E-02 
215450_PM_at --- 58498 --- 0.497 + 1.45E-02 1.32E-02 
226756_PM_at --- 5291 --- 0.545 + 1.47E-02 2.13E-02 
226297_PM_at --- 3134 --- 0.449 + 1.51E-02 1.70E-02 
239819_PM_at --- 7483 --- 0.402 + 1.51E-02 2.56E-02 
236261_PM_at --- 7029 --- 0.573 + 1.53E-02 2.03E-02 
230305_PM_at --- 145853 --- 0.435 + 1.53E-02 4.31E-02 
229118_PM_at --- 253512 --- 0.457 + 1.53E-02 6.89E-03 
1560747_PM_at --- 7750 --- 0.334 + 1.53E-02 3.48E-02 
235556_PM_at --- 6191 --- 0.649 + 1.58E-02 1.40E-03 
233335_PM_at --- 257000 --- 0.278 + 1.60E-02 3.79E-02 
227754_PM_at --- 56945 --- 0.391 + 1.61E-02 3.40E-02 
229131_PM_at --- 79627 --- 0.694 + 1.69E-02 3.63E-02 
227929_PM_at --- 153339 --- 0.547 + 1.74E-02 1.66E-02 
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235570_PM_at --- 90011 --- 0.880 + 1.74E-02 3.44E-02 
229823_PM_at --- 222658 --- 0.571 + 1.75E-02 9.04E-03 
1569234_PM_at --- 5095 --- 0.298 + 1.77E-02 4.97E-02 
227107_PM_at --- --- --- 0.792 + 1.77E-02 3.85E-02 
1565830_PM_at --- 4152 --- 0.371 + 1.79E-02 3.08E-02 
243424_PM_at --- 255488 --- 0.268 + 1.79E-02 1.87E-02 
1555753_PM_x_at --- 6726 --- 0.313 + 1.81E-02 1.71E-02 
229828_PM_at --- 53344 --- 0.756 + 1.84E-02 1.08E-02 
236236_PM_at --- --- --- 0.567 + 1.86E-02 4.22E-02 
243134_PM_at --- --- --- 0.319 + 1.86E-02 3.94E-02 
230680_PM_at --- 730094 --- 0.516 + 1.87E-02 2.63E-02 
234881_PM_at --- 5917 --- 0.414 + 1.88E-02 1.02E-02 
238782_PM_at --- --- --- 0.281 + 1.92E-02 3.48E-03 
240892_PM_at --- --- --- 0.364 + 1.92E-02 5.27E-03 
237384_PM_x_at --- --- --- 0.868 + 1.96E-02 2.61E-02 
228390_PM_at --- 152217 --- 0.998 + 1.96E-02 1.81E-02 
225159_PM_s_at --- 221302 --- 0.371 + 2.00E-02 4.36E-02 




--- 0.395 + 2.01E-02 3.53E-02 
238133_PM_at --- --- --- 0.745 + 2.02E-02 3.73E-02 
236537_PM_at --- --- --- 0.540 + 2.02E-02 1.82E-03 
224545_PM_at --- 112495 --- 0.471 + 2.03E-02 2.41E-02 
228120_PM_at --- 387893 --- 0.511 + 2.06E-02 3.60E-02 
241114_PM_s_at --- --- --- 0.278 + 2.06E-02 3.91E-02 
237026_PM_at --- 1106 --- 0.623 + 2.07E-02 2.82E-02 
213500_PM_at --- 51780 --- 0.369 + 2.09E-02 4.00E-02 
241010_PM_x_at --- --- --- 0.372 + 2.09E-02 2.88E-02 
229687_PM_s_at --- 137392 --- 0.400 + 2.12E-02 7.40E-03 
227579_PM_at --- 60559 --- 0.915 + 2.16E-02 1.91E-02 
226468_PM_at --- 4162 --- 0.273 + 2.19E-02 1.30E-02 
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237250_PM_at --- 64710 --- 0.474 + 2.21E-02 1.11E-02 
227531_PM_at --- 11160 --- 0.335 + 2.22E-02 8.25E-03 
1556194_PM_a_at --- 4830 --- 0.736 + 2.22E-02 1.87E-02 
243974_PM_at --- --- --- 0.334 + 2.22E-02 3.55E-02 
212867_PM_at --- 3336 --- 0.503 + 2.22E-02 2.58E-03 
236402_PM_at --- --- --- 0.658 + 2.23E-02 3.80E-02 
232937_PM_at --- 730051 --- 0.386 + 2.25E-02 4.02E-02 
227200_PM_at --- 4801 --- 0.453 + 2.26E-02 1.48E-02 
239133_PM_at --- 441027 --- 0.461 + 2.27E-02 3.62E-02 
241968_PM_at --- --- --- 0.392 + 2.30E-02 3.93E-02 
213294_PM_at --- 1207 --- 0.362 + 2.31E-02 1.65E-02 
226779_PM_at --- 23172 --- 0.464 + 2.31E-02 3.88E-02 
241618_PM_at --- 10454 --- 0.299 + 2.44E-02 3.96E-02 
213686_PM_at --- 80273 --- 0.544 + 2.45E-02 3.70E-02 
232758_PM_s_at --- 56899 --- 0.380 + 2.49E-02 3.00E-02 
229359_PM_at --- 401264 --- 0.307 + 2.52E-02 3.92E-02 
229333_PM_at --- 5451 --- 0.753 + 2.53E-02 2.10E-02 
227492_PM_at --- 79184 --- 0.338 + 2.58E-02 4.36E-02 
230127_PM_at --- 5494 --- 0.621 + 2.60E-02 3.74E-02 
1555461_PM_at --- 47 --- 0.310 + 2.61E-02 4.59E-02 
213411_PM_at --- 10098 --- 0.719 + 2.62E-02 4.04E-03 
1557813_PM_at --- 10659 --- 0.593 + 2.62E-02 4.31E-02 
232081_PM_at --- 84676 --- 0.459 + 2.63E-02 2.83E-02 
226374_PM_at --- 9831 --- 0.421 + 2.63E-02 4.26E-02 
213808_PM_at --- 23312 --- 0.369 + 2.64E-02 2.88E-03 
225328_PM_at --- 2047 --- 1.031 + 2.65E-02 2.82E-02 
212812_PM_at --- 889 --- 0.878 + 2.68E-02 2.46E-02 
230042_PM_at --- 84817 --- 0.347 + 2.69E-02 2.71E-02 
1554609_PM_at --- 1933 --- 0.677 + 2.70E-02 8.15E-03 
1556153_PM_s_at --- 25813 --- 0.434 + 2.71E-02 1.68E-02 
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243856_PM_at --- --- --- 0.541 + 2.72E-02 3.91E-02 
225356_PM_at --- 163259 --- 0.393 + 2.80E-02 3.82E-02 
227095_PM_at --- 22848 --- 0.758 + 2.80E-02 2.27E-02 
229300_PM_at --- 55526 --- 0.451 + 2.83E-02 1.22E-02 
235902_PM_at --- 56946 --- 0.302 + 2.83E-02 1.63E-02 
214809_PM_at --- 114885 --- 0.345 + 2.86E-02 3.43E-02 
226345_PM_at --- 4685 --- 0.320 + 2.87E-02 3.04E-02 
222824_PM_at --- 4897 --- 0.348 + 2.89E-02 4.48E-02 
226102_PM_at --- 3398 --- 0.519 + 2.89E-02 3.26E-02 
243948_PM_at --- --- --- 0.437 + 2.90E-02 2.34E-02 
239368_PM_at --- 220108 --- 0.490 + 2.96E-02 2.17E-03 
1558102_PM_at --- 26037 --- 0.444 + 2.97E-02 3.09E-02 
1557487_PM_at --- 6397 --- 0.327 + 3.12E-02 4.57E-02 
242096_PM_at --- --- --- 0.513 + 3.15E-02 3.83E-02 
1557286_PM_at --- 8502 --- 0.288 + 3.16E-02 2.12E-02 
227772_PM_at --- 79626 --- 0.620 + 3.17E-02 2.50E-02 
235736_PM_at --- 55299 --- 0.594 + 3.18E-02 4.83E-02 
240053_PM_x_at --- 57231 --- 0.302 + 3.19E-02 3.82E-02 
243184_PM_at --- 26207 --- 0.323 + 3.32E-02 3.29E-02 
233481_PM_at --- 10802 --- 0.696 + 3.37E-02 1.53E-02 
227665_PM_at --- 55718 --- 0.346 + 3.40E-02 3.70E-03 
239710_PM_at --- --- --- 0.299 + 3.40E-02 4.24E-02 
227004_PM_at --- 10418 --- 0.602 + 3.50E-02 1.94E-02 
230785_PM_at --- 84978 --- 0.324 + 3.57E-02 2.71E-02 
232794_PM_at --- 400120 --- 0.346 + 3.66E-02 3.29E-02 
242610_PM_x_at --- --- --- 0.429 + 3.71E-02 4.56E-02 
1561242_PM_at --- 5252 --- 0.348 + 3.72E-02 3.81E-02 
244707_PM_at --- --- --- 0.367 + 3.73E-02 4.49E-02 
235434_PM_at --- 10724 --- 0.431 + 3.75E-02 4.12E-02 
239744_PM_at --- --- --- 0.788 + 3.76E-02 3.29E-02 
237509_PM_at --- --- --- 0.279 + 3.76E-02 3.15E-02 
222294_PM_s_at --- 221154 --- 0.554 + 3.78E-02 1.06E-02 
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226594_PM_at --- 3858 --- 0.580 + 3.78E-02 6.03E-03 
231078_PM_at --- 285590 --- 0.268 + 3.88E-02 1.84E-02 
239765_PM_at --- 221002 --- 0.310 + 3.89E-02 1.98E-02 
217191_PM_x_at --- 81602 --- 0.348 + 3.90E-02 9.49E-03 
226392_PM_at --- 8535 --- 0.495 + 3.94E-02 1.17E-02 
241756_PM_at --- --- --- 0.477 + 3.95E-02 4.46E-02 
230913_PM_at --- 780529 --- 0.358 + 4.05E-02 3.67E-02 
241970_PM_at --- --- --- 0.359 + 4.10E-02 4.53E-03 
229319_PM_at --- 79872 --- 0.439 + 4.12E-02 4.03E-02 
236433_PM_at --- --- --- 0.278 + 4.13E-02 4.38E-02 
234839_PM_at --- --- --- 0.522 + 4.15E-02 1.13E-02 
235302_PM_at --- --- --- 0.636 + 4.23E-02 7.24E-03 
229504_PM_at --- 10026 --- 0.643 + 4.24E-02 3.86E-02 
242384_PM_at --- --- --- 0.641 + 4.30E-02 2.12E-02 
235015_PM_at --- 8073 --- 0.759 + 4.38E-02 4.36E-02 
228724_PM_at --- 84897 --- 0.565 + 4.45E-02 2.45E-02 
226197_PM_at --- 9792 --- 0.670 + 4.51E-02 5.00E-02 
226348_PM_at --- 55972 --- 0.375 + 4.57E-02 4.06E-02 
238712_PM_at --- 253842 --- 0.695 + 4.59E-02 1.88E-02 
216565_PM_x_at --- 84641 --- 0.275 + 4.64E-02 4.09E-02 
225007_PM_at --- 6426 --- 0.313 + 4.65E-02 2.94E-02 
238719_PM_at --- --- --- 0.364 + 4.68E-02 2.99E-02 
227422_PM_at --- 79906 --- 0.400 + 4.84E-02 4.96E-02 
235782_PM_at --- 51236 --- 0.824 + 4.87E-02 4.90E-02 
242481_PM_at --- 55745 --- 0.365 + 4.87E-02 4.06E-02 
213256_PM_at membrane-associated ring finger (C3HC4) 3 7070 3-Mar 0.348 + 2.17E-03 1.55E-03 
226394_PM_at membrane-associated ring finger (C3HC4) 5 398 3-Mar 0.572 + 4.28E-03 4.19E-03 
200902_PM_at 15 kDa selenoprotein 87 3-Mar 0.394 + 6.86E-03 2.92E-02 
202653_PM_s_at membrane-associated ring finger (C3HC4) 7 3184 3-Mar 0.511 + 1.36E-02 9.51E-03 
200015_PM_s_at septin 2 137492 /// 6834 3-Mar 0.323 + 1.96E-02 1.06E-02 
230001_PM_at membrane-associated ring finger (C3HC4) 9 91750 3-Mar 0.264 + 2.63E-02 1.89E-02 
208999_PM_at septin 8 54873 3-Mar 0.592 + 2.84E-02 4.17E-02 
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214956_PM_at AP2 associated kinase 1 6839 AAK1 0.283 + 4.50E-02 4.00E-02 
231845_PM_at alanyl-tRNA synthetase 2, mitochondrial (putative) 9331 AARS2 0.398 + 2.12E-04 3.21E-03 
203505_PM_at ATP-binding cassette, sub-family A (ABC1), member 1 8573 ABCA1 0.998 + 1.15E-02 3.42E-02 
242541_PM_at ATP-binding cassette, sub-family A (ABC1), member 9 --- ABCA9 0.518 + 4.18E-02 3.02E-02 
223320_PM_s_at ATP-binding cassette, sub-family B (MDR/TAP), member 10 3839 ABCB10 0.739 + 4.69E-02 4.31E-02 
213485_PM_s_at ATP-binding cassette, sub-family C (CFTR/MRP), member 10 9146 ABCC10 0.438 + 6.70E-03 2.89E-02 
209380_PM_s_at ATP-binding cassette, sub-family C (CFTR/MRP), member 5 58533 ABCC5 0.637 + 3.32E-02 4.03E-02 
218633_PM_x_at abhydrolase domain containing 10 136227 ABHD10 0.449 + 1.92E-02 5.41E-03 
235348_PM_at abhydrolase domain containing 13 --- ABHD13 0.369 + 4.45E-03 1.19E-02 
213935_PM_at abhydrolase domain containing 5 221443 ABHD5 0.421 + 2.96E-02 4.85E-02 
225112_PM_at abl-interactor 2 141 ABI2 0.363 + 2.74E-03 2.64E-03 
200965_PM_s_at actin binding LIM protein 1 10808 ABLIM1 0.470 + 4.06E-03 6.01E-04 
202003_PM_s_at acetyl-Coenzyme A acyltransferase 2 6733 ACAA2 0.409 + 1.76E-04 5.47E-03 
49452_PM_at acetyl-Coenzyme A carboxylase beta 152485 ACACB 0.561 + 1.42E-02 1.71E-02 
219986_PM_s_at acyl-Coenzyme A dehydrogenase family, member 10 10671 ACAD10 0.354 + 3.52E-03 3.06E-02 
205412_PM_at acetyl-Coenzyme A acetyltransferase 1 10458 ACAT1 0.339 + 4.34E-03 1.38E-02 
225663_PM_at acyl-Coenzyme A binding domain containing 5 203069 ACBD5 0.314 + 3.63E-02 2.44E-02 
225317_PM_at acyl-Coenzyme A binding domain containing 6 28985 ACBD6 0.427 + 9.09E-03 1.54E-02 
227776_PM_at alkaline ceramidase 3 4325 ACER3 0.557 + 1.68E-03 1.20E-02 
201127_PM_s_at ATP citrate lyase 9324 ACLY 0.683 + 2.44E-05 1.49E-03 
241949_PM_at acyl-CoA thioesterase 6 --- ACOT6 0.337 + 2.12E-03 8.35E-03 
218795_PM_at acid phosphatase 6, lysophosphatidic 25836 ACP6 0.414 + 2.97E-02 3.21E-02 
238825_PM_at acidic repeat containing 79611 ACRC 0.339 + 6.08E-03 2.83E-03 
206465_PM_at acyl-CoA synthetase bubblegum family member 1 23275 ACSBG1 0.330 + 4.66E-02 3.30E-02 
201963_PM_at acyl-CoA synthetase long-chain family member 1 2138 ACSL1 0.644 + 2.79E-02 7.70E-03 
229725_PM_at Acyl-CoA synthetase long-chain family member 6 9879 ACSL6 0.296 + 6.21E-03 1.49E-02 
229222_PM_at acyl-CoA synthetase short-chain family member 3 81873 ACSS3 0.407 + 1.68E-02 3.08E-02 
202666_PM_s_at actin-like 6A 55863 ACTL6A 0.352 + 2.14E-02 4.29E-02 
206014_PM_at actin-like 6B 8943 ACTL6B 0.502 + 1.12E-02 2.30E-03 
203863_PM_at actinin, alpha 2 6612 ACTN2 0.715 + 1.24E-02 1.91E-02 
203862_PM_s_at actinin, alpha 2 10121 ACTN2 0.271 + 4.05E-02 2.26E-02 
218395_PM_at ARP6 actin-related protein 6 homolog (yeast) 11127 ACTR6 0.393 + 4.03E-03 1.28E-02 
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213198_PM_at activin A receptor, type IB 829 ACVR1B 0.391 + 3.36E-02 3.05E-02 
228416_PM_at activin A receptor, type IIA 59345 ACVR2A 0.653 + 3.64E-03 9.87E-03 
236126_PM_at activin A receptor, type IIB --- ACVR2B 0.689 + 2.91E-02 3.42E-02 
205260_PM_s_at acylphosphatase 1, erythrocyte (common) type 2261 ACYP1 0.481 + 2.54E-04 3.29E-03 
202603_PM_at ADAM metallopeptidase domain 10 51192 ADAM10 0.428 + 1.30E-03 6.85E-03 
213532_PM_at ADAM metallopeptidase domain 17 8671 ADAM17 0.322 + 3.40E-02 3.11E-02 
214913_PM_at ADAM metallopeptidase with thrombospondin type 1 motif, 3 55032 ADAMTS3 0.870 + 5.60E-03 2.24E-02 
235649_PM_at ADAM metallopeptidase with thrombospondin type 1 motif, 8 --- ADAMTS8 0.379 + 4.20E-04 7.13E-04 
227213_PM_at 
adenosine deaminase, tRNA-specific 2, TAD2 homolog (S. 
cerevisiae) 
56647 ADAT2 0.501 + 2.04E-03 4.93E-03 
226690_PM_at 
Adenylate cyclase activating polypeptide 1 (pituitary) receptor 
type I 
204 ADCYAP1R1 0.440 + 7.25E-04 5.59E-03 
208030_PM_s_at 255eparin255 1 (alpha) 4233 ADD1 0.298 + 2.45E-02 1.26E-02 
208848_PM_at alcohol dehydrogenase 5 (class III), chi polypeptide 9950 ADH5 0.285 + 5.69E-03 1.19E-02 
227113_PM_at alcohol dehydrogenase, iron containing, 1 23236 ADHFE1 0.514 + 4.43E-03 1.46E-02 
201346_PM_at adiponectin receptor 2 9590 ADIPOR2 0.414 + 4.08E-02 2.33E-02 
220538_PM_at adrenomedullin 2 64854 ADM2 0.296 + 3.19E-02 1.51E-02 
226426_PM_at activity-dependent neuroprotector homeobox 5994 ADNP 0.788 + 3.28E-02 2.64E-02 
203322_PM_at ADNP homeobox 2 10717 ADNP2 0.468 + 4.89E-03 1.42E-02 
220980_PM_s_at ADP-dependent glucokinase 2869 ADPGK 0.591 + 2.45E-03 2.12E-02 
228042_PM_at ADP-ribosylarginine hydrolase 90871 ADPRH 0.476 + 3.21E-02 3.40E-02 
223097_PM_at ADP-ribosylhydrolase like 2 79029 ADPRHL2 0.387 + 1.65E-02 1.14E-02 
229309_PM_at adrenergic, beta-1-, receptor 130271 ADRB1 0.796 + 4.25E-02 5.67E-03 
202144_PM_s_at adenylosuccinate lyase 22999 ADSL 0.824 + 6.16E-03 4.76E-03 
225889_PM_at AE binding protein 2 10063 AEBP2 0.495 + 1.16E-02 5.30E-03 
212221_PM_x_at arylformamidase /// iduronate 2-sulfatase 3615 AFMID /// IDS 0.266 + 1.74E-02 2.03E-02 
226561_PM_at ArfGAP with FG repeats 1 2130 AGFG1 0.486 + 4.68E-02 4.01E-02 
203566_PM_s_at amylo-1, 6-glucosidase, 4-alpha-glucanotransferase 57147 AGL 0.298 + 5.46E-03 1.48E-02 
223182_PM_s_at 1-acylglycerol-3-phosphate O-acyltransferase 3 79612 AGPAT3 0.278 + 1.80E-03 1.14E-02 
225108_PM_at alkylglycerone phosphate synthase 80143 AGPS 0.602 + 8.08E-03 3.77E-02 
238135_PM_at Angiotensin II receptor-associated protein 64750 AGTRAP 0.310 + 2.92E-03 2.22E-02 
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221008_PM_s_at alanine-glyoxylate aminotransferase 2-like 1 5509 AGXT2L1 0.599 + 1.30E-02 3.13E-02 
214766_PM_s_at AT hook containing transcription factor 1 79665 AHCTF1 0.307 + 8.19E-03 2.75E-02 
212992_PM_at AHNAK nucleoprotein 2 6861 AHNAK2 0.615 + 1.11E-02 2.44E-03 
226801_PM_s_at axin interactor, dorsalization associated 57798 AIDA 0.495 + 1.83E-02 7.26E-03 
223136_PM_at androgen-induced 1 10891 AIG1 0.309 + 8.36E-04 4.12E-04 
206513_PM_at absent in melanoma 2 83737 AIM2 0.572 + 2.14E-02 4.18E-02 
209971_PM_x_at 
aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 2 
5937 AIMP2 0.365 + 2.51E-02 1.92E-02 
205996_PM_s_at adenylate kinase 2 1983 AK2 0.333 + 2.52E-03 1.46E-02 
212174_PM_at adenylate kinase 2 22938 AK2 0.500 + 1.91E-02 4.89E-02 
225342_PM_at adenylate kinase 3-like 1 130026 AK3L1 0.519 + 1.01E-02 8.36E-03 
204348_PM_s_at adenylate kinase 3-like 1 832 AK3L1 0.271 + 1.05E-02 6.06E-03 
210517_PM_s_at A kinase (PRKA) anchor protein 12 81873 AKAP12 0.549 + 3.79E-03 9.29E-03 
227530_PM_at A kinase (PRKA) anchor protein 12 81609 AKAP12 0.899 + 1.49E-02 2.06E-02 
226694_PM_at 





0.515 + 4.34E-03 7.89E-03 
230846_PM_at A kinase (PRKA) anchor protein 5 157695 AKAP5 0.596 + 2.21E-02 2.82E-02 
205359_PM_at A kinase (PRKA) anchor protein 6 1102 AKAP6 0.505 + 1.94E-02 1.69E-02 
205771_PM_s_at A kinase (PRKA) anchor protein 7 10472 AKAP7 0.338 + 1.23E-02 4.01E-02 
210962_PM_s_at A kinase (PRKA) anchor protein (yotiao) 9 5926 AKAP9 0.821 + 6.56E-03 2.17E-03 
222459_PM_at akirin 1 23173 AKIRIN1 0.646 + 3.33E-02 3.24E-02 
204151_PM_x_at 
aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase) 
7072 AKR1C1 0.478 + 2.29E-02 2.68E-02 
209699_PM_x_at 
aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type III) 
51435 AKR1C2 0.307 + 4.89E-02 4.89E-02 
212609_PM_s_at 
V-akt murine thymoma viral oncogene homolog 3 (protein 
kinase B, gamma) 
9553 AKT3 0.339 + 4.90E-02 2.94E-03 
201952_PM_at activated leukocyte cell adhesion molecule 23522 ALCAM 0.282 + 1.42E-02 1.54E-02 
203608_PM_at aldehyde dehydrogenase 5 family, member A1 27327 ALDH5A1 0.528 + 3.55E-02 3.44E-02 
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201612_PM_at aldehyde dehydrogenase 9 family, member A1 50649 ALDH9A1 0.833 + 4.52E-02 3.68E-02 
205583_PM_s_at asparagine-linked glycosylation 13 homolog (S. cerevisiae) 120 ALG13 0.693 + 3.46E-02 3.02E-02 
218203_PM_at 
asparagine-linked glycosylation 5, dolichyl-phosphate beta-
glucosyltransferase homolog (S. cerevisiae) 
57539 ALG5 0.769 + 2.39E-03 2.48E-03 
219649_PM_at 
asparagine-linked glycosylation 6, alpha-1,3-
glucosyltransferase homolog (S. cerevisiae) 
9663 ALG6 0.485 + 1.39E-03 7.97E-03 
203545_PM_at 
asparagine-linked glycosylation 8, alpha-1,3-
glucosyltransferase homolog (S. cerevisiae) 
2810 ALG8 0.556 + 2.19E-02 3.86E-02 
228817_PM_at 
asparagine-linked glycosylation 9, alpha-1,2-
mannosyltransferase homolog (S. cerevisiae) 
23394 ALG9 0.678 + 6.96E-03 1.55E-02 
205621_PM_at alkB, alkylation repair homolog 1 (E. coli) 22887 ALKBH1 0.682 + 7.27E-03 1.99E-02 
226291_PM_at amyotrophic lateral sclerosis 2 (juvenile) 9818 ALS2 0.445 + 4.40E-02 4.78E-02 
228255_PM_at 
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 4 
254048 ALS2CR4 0.621 + 5.30E-03 9.71E-03 
209424_PM_s_at alpha-methylacyl-CoA racemase 55074 AMACR 0.341 + 1.05E-02 4.14E-02 
226421_PM_at 
Alport syndrome, mental retardation, midface hypoplasia and 
elliptocytosis chromosomal region gene 1 
7204 AMMECR1 0.552 + 4.09E-03 5.97E-03 
204976_PM_s_at 
Alport syndrome, mental retardation, midface hypoplasia and 
elliptocytosis chromosomal region gene 1 
963 AMMECR1 0.744 + 5.57E-03 2.45E-02 
223297_PM_at AMME chromosomal region gene 1-like 54819 AMMECR1L 0.950 + 4.23E-03 9.75E-03 
226258_PM_at antagonist of mitotic exit network 1 homolog (S. cerevisiae) 6239 AMN1 0.449 + 9.94E-03 6.26E-03 
208498_PM_s_at 
amylase, alpha 1A (salivary) /// amylase, alpha 1B (salivary) 
/// amylase, alpha 1C (salivary) /// amylase, alpha 2A 







0.736 + 8.26E-03 2.08E-03 
207845_PM_s_at anaphase promoting complex subunit 10 
100130175 /// 
92482 
ANAPC10 0.632 + 4.63E-03 5.50E-04 
209001_PM_s_at anaphase promoting complex subunit 13 5583 ANAPC13 0.436 + 1.05E-03 7.94E-03 
232524_PM_x_at anaphase promoting complex subunit 4 1630 ANAPC4 0.767 + 6.56E-03 6.55E-03 
226917_PM_s_at anaphase promoting complex subunit 4 --- ANAPC4 0.710 + 1.01E-02 1.46E-02 
225521_PM_at anaphase promoting complex subunit 7 6671 ANAPC7 0.671 + 1.16E-02 2.54E-02 
221825_PM_at angel homolog 2 (Drosophila) 5435 ANGEL2 0.322 + 3.14E-02 2.96E-02 
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220076_PM_at ankylosis, progressive homolog (mouse) 2591 ANKH 0.357 + 1.67E-02 4.08E-02 
208773_PM_s_at 
ankyrin repeat and KH domain containing 1 /// ANKHD1-





0.728 + 2.60E-02 2.48E-02 
214919_PM_s_at 
ANKHD1-EIF4EBP3 readthrough transcript /// eukaryotic 





0.414 + 1.08E-03 3.66E-03 
243181_PM_at ankyrin repeat and IBR domain containing 1 --- ANKIB1 0.268 + 1.02E-02 4.57E-02 
224682_PM_at ankyrin repeat and IBR domain containing 1 144363 ANKIB1 0.533 + 3.67E-02 3.95E-02 
212798_PM_s_at ankyrin repeat and MYND domain containing 2 1462 ANKMY2 0.378 + 1.36E-02 2.44E-02 
218769_PM_s_at ankyrin repeat, family A (RFXANK-like), 2 146713 ANKRA2 0.475 + 1.04E-02 7.57E-03 
223251_PM_s_at ankyrin repeat domain 10 63933 ANKRD10 0.599 + 2.30E-02 3.42E-02 
213035_PM_at ankyrin repeat domain 28 9447 ANKRD28 0.499 + 6.92E-03 1.69E-02 
223542_PM_at ankyrin repeat domain 32 55339 ANKRD32 0.740 + 7.29E-03 8.41E-03 
231118_PM_at ankyrin repeat domain 35 253039 ANKRD35 0.485 + 1.11E-03 3.22E-03 
230238_PM_at ankyrin repeat domain 43 257194 ANKRD43 0.437 + 4.49E-02 3.13E-02 
212731_PM_at ankyrin repeat domain 46 27252 ANKRD46 0.307 + 3.10E-02 4.44E-03 
219069_PM_at ankyrin repeat domain 49 6506 ANKRD49 1.170 + 5.58E-03 1.21E-02 
225731_PM_at ankyrin repeat domain 50 23527 ANKRD50 0.536 + 1.33E-02 1.11E-02 
204672_PM_s_at ankyrin repeat domain 6 23518 ANKRD6 0.702 + 3.77E-03 1.12E-02 
230972_PM_at ankyrin repeat domain 9 22871 ANKRD9 0.270 + 2.19E-02 4.20E-02 
212747_PM_at ankyrin repeat and sterile alpha motif domain containing 1A 57030 ANKS1A 0.561 + 2.55E-02 3.52E-02 
240292_PM_x_at ankyrin repeat and sterile alpha motif domain containing 1B --- ANKS1B 0.346 + 3.12E-03 5.00E-04 
218910_PM_at anoctamin 10 8996 ANO10 0.402 + 1.91E-02 1.25E-02 
236420_PM_s_at anoctamin 4 --- ANO4 0.934 + 3.65E-02 6.87E-03 
201306_PM_s_at 
acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member B 
22902 ANP32B 0.294 + 3.69E-02 2.32E-02 
221505_PM_at 
acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member E 
3741 ANP32E 0.498 + 4.82E-04 1.43E-03 
224694_PM_at anthrax toxin receptor 1 29904 ANTXR1 0.683 + 1.85E-02 1.33E-02 
228573_PM_at anthrax toxin receptor 2 7690 ANTXR2 0.361 + 3.10E-03 1.53E-03 
201012_PM_at annexin A1 821 ANXA1 0.980 + 1.76E-03 5.11E-03 
225771_PM_at adaptor-related protein complex 1, gamma 1 subunit 150622 AP1G1 0.270 + 4.78E-03 3.17E-02 
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203142_PM_s_at adaptor-related protein complex 3, beta 1 subunit 25957 AP3B1 0.350 + 1.59E-02 3.04E-02 
222517_PM_at adaptor-related protein complex 3, mu 1 subunit 167227 AP3M1 0.729 + 1.15E-02 3.94E-03 
202442_PM_at adaptor-related protein complex 3, sigma 1 subunit 10161 AP3S1 0.443 + 9.80E-03 1.97E-03 
231714_PM_s_at adaptor-related protein complex 4, beta 1 subunit 22927 AP4B1 0.439 + 7.21E-03 2.24E-02 
235647_PM_at Adaptor-related protein complex 4, sigma 1 subunit 6129 AP4S1 0.536 + 7.29E-03 1.09E-02 
215148_PM_s_at 
amyloid beta (A4) precursor protein-binding, family A, 
member 3 
55540 APBA3 0.305 + 7.84E-03 6.47E-03 
212985_PM_at 
amyloid beta (A4) precursor protein-binding, family B, 
member 2 
10538 APBB2 0.342 + 3.96E-02 4.00E-03 
203525_PM_s_at adenomatous polyposis coli 10471 APC 0.387 + 4.70E-02 3.15E-02 
225016_PM_at adenomatosis polyposis coli down-regulated 1 83999 APCDD1 0.406 + 3.75E-02 2.53E-02 
201687_PM_s_at apoptosis inhibitor 5 9777 API5 0.397 + 1.86E-02 1.42E-02 
218698_PM_at APAF1 interacting protein 165545 APIP 0.641 + 1.49E-03 4.85E-04 
213553_PM_x_at apolipoprotein C-I 5441 APOC1 0.429 + 1.78E-02 1.65E-02 
221013_PM_s_at apolipoprotein L, 2 6781 APOL2 0.378 + 1.34E-02 2.56E-02 
235433_PM_at apolipoprotein O-like --- APOOL 0.598 + 2.35E-03 8.59E-03 
202630_PM_at 
amyloid beta precursor protein (cytoplasmic tail) binding 
protein 2 
23762 APPBP2 0.556 + 2.12E-02 1.41E-02 
218158_PM_s_at 
adaptor protein, phosphotyrosine interaction, PH domain and 
leucine zipper containing 1 
285343 APPL1 0.409 + 1.13E-02 1.52E-02 
229526_PM_at aquaporin 11 199704 AQP11 0.641 + 1.11E-02 2.72E-02 
39248_PM_at aquaporin 3 (Gill blood group) 283578 AQP3 0.368 + 3.37E-02 3.70E-02 
226228_PM_at aquaporin 4 7058 AQP4 0.408 + 4.68E-03 5.62E-03 
242039_PM_at 
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 
1 
11154 ARAP1 0.303 + 8.00E-03 1.41E-02 
201097_PM_s_at ADP-ribosylation factor 4 490 ARF4 0.370 + 1.80E-02 2.06E-02 
224788_PM_at ADP-ribosylation factor 6 10818 ARF6 0.691 + 3.57E-03 2.37E-03 
202211_PM_at ADP-ribosylation factor GTPase activating protein 3 8751 ARFGAP3 0.435 + 1.52E-02 4.38E-02 
202956_PM_at 
ADP-ribosylation factor guanine nucleotide-exchange factor 
1(brefeldin A-inhibited) 
56894 ARFGEF1 0.407 + 5.84E-03 1.23E-02 
218230_PM_at ADP-ribosylation factor interacting protein 1 166929 ARFIP1 0.376 + 1.24E-02 1.81E-02 
202117_PM_at Rho GTPase activating protein 1 
386757 /// 6535 
/// 653562 
ARHGAP1 0.321 + 2.85E-02 3.98E-02 
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207606_PM_s_at Rho GTPase activating protein 12 158471 ARHGAP12 0.544 + 3.10E-02 1.98E-02 
212738_PM_at Rho GTPase activating protein 19 1318 ARHGAP19 0.323 + 1.52E-02 1.96E-02 
235635_PM_at Rho GTPase activating protein 5 6760 ARHGAP5 1.388 + 1.60E-03 4.08E-03 
217936_PM_at Rho GTPase activating protein 5 115098 ARHGAP5 0.391 + 3.41E-03 1.37E-03 
216620_PM_s_at Rho guanine nucleotide exchange factor (GEF) 10 56172 ARHGEF10 0.644 + 5.92E-03 7.21E-03 
221656_PM_s_at Rho guanine nucleotide exchange factor (GEF) 10-like 11261 ARHGEF10L 0.617 + 1.16E-02 1.04E-02 
201334_PM_s_at Rho guanine nucleotide exchange factor (GEF) 12 1432 ARHGEF12 0.553 + 2.90E-02 6.80E-03 
209435_PM_s_at Rho/Rac guanine nucleotide exchange factor (GEF) 2 10600 ARHGEF2 0.341 + 1.42E-02 3.42E-02 
209539_PM_at Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 51126 ARHGEF6 0.610 + 6.33E-03 1.30E-02 
225181_PM_at AT rich interactive domain 1B (SWI1-like) 55607 ARID1B 0.415 + 2.19E-02 6.01E-03 
218964_PM_at AT rich interactive domain 3B (BRIGHT-like) 161725 ARID3B 0.388 + 3.30E-03 1.57E-02 
230141_PM_at AT rich interactive domain 4A (RBP1-like) 340481 ARID4A 0.549 + 2.19E-02 1.96E-02 
221230_PM_s_at AT rich interactive domain 4B (RBP1-like) 9397 ARID4B 0.449 + 3.26E-02 3.11E-02 
201880_PM_at 
260eparin homolog, ubiquitin-conjugating enzyme E2 binding 
protein, 1 (Drosophila) 
1350 ARIH1 0.426 + 2.64E-02 1.79E-02 
1554245_PM_x_at 
ADP-ribosylation factor-like 17 /// ADP-ribosylation factor-like 




0.462 + 5.42E-04 2.77E-03 
223735_PM_at ADP-ribosylation factor-like 6 58480 ARL6 0.372 + 1.94E-03 9.45E-03 
235320_PM_at ADP-ribosylation factor-like 6 --- ARL6 0.395 + 2.77E-02 3.07E-03 
200761_PM_s_at ADP-ribosylation-like factor 6 interacting protein 5 8867 ARL6IP5 0.375 + 1.67E-03 4.54E-04 
217852_PM_s_at ADP-ribosylation factor-like 8B 10152 ARL8B 0.336 + 1.63E-02 1.26E-03 
229062_PM_at ADP-ribosylation factor-like 9 57695 ARL9 0.325 + 1.37E-02 4.93E-02 
203487_PM_s_at armadillo repeat containing 8 283130 ARMC8 0.634 + 5.78E-03 1.94E-02 
203404_PM_at armadillo repeat containing, X-linked 2 55737 ARMCX2 0.463 + 3.12E-02 4.11E-02 
227444_PM_at Armadillo repeat containing, X-linked 4 55777 ARMCX4 0.699 + 1.50E-02 1.83E-02 
214749_PM_s_at 
armadillo repeat containing, X-linked 6 /// similar to armadillo 




0.709 + 1.59E-03 2.78E-03 
226914_PM_at actin related protein 2/3 complex, subunit 5-like --- ARPC5L 0.760 + 6.07E-03 1.83E-02 
226915_PM_s_at actin related protein 2/3 complex, subunit 5-like 151230 ARPC5L 0.297 + 6.35E-03 2.22E-03 
220966_PM_x_at actin related protein 2/3 complex, subunit 5-like 78988 ARPC5L 0.356 + 1.62E-02 6.20E-03 
221483_PM_s_at cAMP-regulated phosphoprotein, 19kDa 204 ARPP19 0.365 + 1.18E-03 9.13E-03 
221482_PM_s_at cAMP-regulated phosphoprotein, 19kDa 2960 ARPP19 0.419 + 7.11E-03 8.65E-03 
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220359_PM_s_at cyclic AMP-regulated phosphoprotein, 21 kD 51096 ARPP-21 0.629 + 1.15E-02 2.47E-02 
231935_PM_at cyclic AMP-regulated phosphoprotein, 21 kD --- ARPP-21 0.421 + 3.22E-02 5.22E-03 
224797_PM_at arrestin domain containing 3 219854 ARRDC3 0.813 + 3.53E-03 1.86E-03 
225283_PM_at arrestin domain containing 4 125704 ARRDC4 0.329 + 1.43E-02 4.25E-02 
225280_PM_x_at arylsulfatase D 144108 ARSD 0.392 + 5.00E-03 1.79E-02 
223223_PM_at ARV1 homolog (S. cerevisiae) 51274 ARV1 0.461 + 1.51E-03 1.56E-02 
224791_PM_at ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 23476 ASAP1 0.540 + 3.01E-02 1.31E-02 
206414_PM_s_at ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 23154 ASAP2 0.466 + 2.55E-02 4.95E-02 
224524_PM_s_at 
ankyrin repeat and SOCS box-containing 3 /// G protein-





0.328 + 1.13E-02 7.51E-03 
235503_PM_at ankyrin repeat and SOCS box-containing 5 --- ASB5 0.279 + 2.04E-03 1.45E-02 
226513_PM_at ankyrin repeat and SOCS box-containing 7 521 ASB7 0.439 + 1.92E-02 7.88E-03 
226861_PM_at ankyrin repeat and SOCS box-containing 8 115123 ASB8 0.400 + 1.78E-02 1.26E-02 
1554627_PM_a_at activating signal cointegrator 1 complex subunit 1 23521 ASCC1 0.598 + 7.05E-03 1.85E-02 
209988_PM_s_at achaete-scute complex homolog 1 (Drosophila) 115106 ASCL1 0.918 + 1.96E-02 4.37E-02 
203428_PM_s_at ASF1 anti-silencing function 1 homolog A (S. cerevisiae) 84256 ASF1A 0.525 + 3.34E-02 3.26E-03 
203427_PM_at ASF1 anti-silencing function 1 homolog A (S. cerevisiae) 55738 ASF1A 0.511 + 3.83E-02 3.09E-02 
36553_PM_at acetylserotonin O-methyltransferase-like --- ASMTL 0.455 + 2.07E-03 2.19E-02 
217987_PM_at asparagine synthetase domain containing 1 84991 ASNSD1 0.458 + 2.49E-02 1.74E-02 
235514_PM_at aspartic peptidase, retroviral-like 1 30000 ASPRV1 0.267 + 6.07E-03 1.17E-02 
215407_PM_s_at astrotactin 2 51621 ASTN2 0.374 + 1.70E-02 4.27E-02 
212234_PM_at additional sex combs like 1 (Drosophila) 29889 ASXL1 0.391 + 1.38E-02 4.62E-02 
212984_PM_at activating transcription factor 2 9221 ATF2 0.725 + 5.40E-03 8.65E-03 
228830_PM_s_at activating transcription factor 7 89890 ATF7 0.391 + 2.34E-02 1.21E-02 
228829_PM_at activating transcription factor 7 528 ATF7 0.956 + 3.17E-02 2.62E-02 
204833_PM_at ATG12 autophagy related 12 homolog (S. cerevisiae) 8520 ATG12 0.302 + 4.06E-02 8.37E-03 
226684_PM_at ATG2 autophagy related 2 homolog B (S. cerevisiae) 23433 ATG2B 0.656 + 1.97E-02 2.42E-02 
213115_PM_at ATG4 autophagy related 4 homolog A (S. cerevisiae) 29855 ATG4A 0.473 + 1.64E-02 1.41E-02 
202512_PM_s_at ATG5 autophagy related 5 homolog (S. cerevisiae) 56986 ATG5 0.440 + 1.68E-02 2.06E-02 
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202511_PM_s_at ATG5 autophagy related 5 homolog (S. cerevisiae) 29071 ATG5 0.359 + 3.21E-02 1.47E-02 
224893_PM_at atlastin GTPase 3 64145 ATL3 0.745 + 1.69E-02 1.90E-02 
213238_PM_at ATPase, class V, type 10D 7415 ATP10D 0.299 + 2.68E-03 7.21E-03 
212297_PM_at ATPase type 13A3 64746 ATP13A3 0.503 + 3.96E-02 1.55E-02 
203296_PM_s_at ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 79109 ATP1A2 0.402 + 7.85E-03 1.01E-02 
212930_PM_at ATPase, Ca++ transporting, plasma membrane 1 2675 ATP2B1 0.392 + 2.93E-02 3.04E-02 
211137_PM_s_at ATPase, Ca++ transporting, type 2C, member 1 160 ATP2C1 0.304 + 6.93E-03 1.35E-02 
213366_PM_x_at 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
9459 ATP5C1 0.348 + 5.90E-03 8.25E-03 
208870_PM_x_at 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
57140 ATP5C1 0.426 + 7.30E-03 4.98E-03 
205711_PM_x_at 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
8775 ATP5C1 0.348 + 1.04E-02 6.50E-03 
211755_PM_s_at 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit B1 
51326 /// 641522 ATP5F1 0.336 + 6.35E-03 1.78E-02 
209492_PM_x_at 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit E 
51247 ATP5I 0.381 + 7.29E-03 2.00E-02 
207335_PM_x_at 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit E 
89910 ATP5I 0.340 + 8.78E-03 2.33E-02 
202325_PM_s_at 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F6 
27430 ATP5J 0.428 + 1.41E-03 7.56E-04 
202961_PM_s_at 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F2 
23621 ATP5J2 0.334 + 6.19E-03 9.34E-03 
216954_PM_x_at 
ATP synthase, H+ transporting, mitochondrial F1 complex, O 
subunit 
84064 ATP5O 0.299 + 2.02E-03 5.41E-03 
221677_PM_s_at 
ATP synthase, H+ transporting, mitochondrial F1 complex, O 




0.868 + 2.45E-03 1.99E-03 
230132_PM_at ATP5S-like 23408 ATP5SL 0.598 + 9.66E-03 5.17E-03 
201443_PM_s_at ATPase, H+ transporting, lysosomal accessory protein 2 10142 ATP6AP2 0.396 + 1.80E-02 1.53E-02 
214150_PM_x_at ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 26034 ATP6V0E1 0.403 + 6.62E-03 1.10E-02 
200096_PM_s_at ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 10150 ATP6V0E1 0.489 + 1.19E-02 1.38E-02 
226463_PM_at ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 7381 ATP6V1C1 0.333 + 1.06E-03 6.99E-03 
208898_PM_at ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 55337 ATP6V1D 0.435 + 3.75E-03 6.09E-03 
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213106_PM_at 
ATPase, aminophospholipid transporter (APLT), class I, type 
8A, member 1 
2787 ATP8A1 0.270 + 1.63E-02 2.02E-02 
226302_PM_at ATPase, class I, type 8B, member 1 357 ATP8B1 0.367 + 2.13E-02 2.20E-02 
224728_PM_at ATP synthase mitochondrial F1 complex assembly factor 1 8935 ATPAF1 0.637 + 1.01E-02 1.58E-02 
218671_PM_s_at ATPase inhibitory factor 1 115294 ATPIF1 0.564 + 3.66E-04 1.59E-03 
223338_PM_s_at ATPase inhibitory factor 1 9367 ATPIF1 0.317 + 1.09E-02 1.44E-03 
209902_PM_at ataxia telangiectasia and Rad3 related 401505 ATR 0.646 + 6.25E-03 8.06E-03 
209903_PM_s_at ataxia telangiectasia and Rad3 related 54737 ATR 0.611 + 2.29E-02 1.61E-02 
208861_PM_s_at 
alpha thalassemia/mental retardation syndrome X-linked 
(RAD54 homolog, S. cerevisiae) 
64786 ATRX 0.345 + 3.32E-03 2.17E-02 
203232_PM_s_at ataxin 1 643167 /// 9584 ATXN1 0.426 + 1.40E-02 6.36E-03 
226095_PM_s_at ataxin 1-like 5412 ATXN1L 0.564 + 1.30E-02 2.18E-02 
202622_PM_s_at ataxin 2 54758 ATXN2 0.304 + 1.62E-02 4.56E-02 
235240_PM_at ataxin 3 129642 ATXN3 0.298 + 6.43E-04 2.56E-03 
205415_PM_s_at ataxin 3 10675 ATXN3 0.418 + 4.44E-03 4.73E-03 
243259_PM_at ataxin 7 --- ATXN7 0.457 + 3.01E-02 2.96E-03 
205052_PM_at AU RNA binding protein/enoyl-Coenzyme A hydratase 7703 AUH 0.377 + 1.95E-02 3.77E-02 
222498_PM_at 5-azacytidine induced 2 4493 AZI2 0.844 + 8.96E-03 1.03E-02 
223846_PM_at 5-azacytidine induced 2 84640 AZI2 0.456 + 9.38E-03 2.83E-02 
201891_PM_s_at beta-2-microglobulin 6613 B2M 0.587 + 1.62E-02 2.12E-02 
217452_PM_s_at 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 2 
79877 B3GALT2 0.462 + 4.76E-03 1.07E-03 
227100_PM_at beta 1,3-galactosyltransferase-like 4916 B3GALTL 0.366 + 1.19E-02 2.23E-02 
235333_PM_at 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 6 
5125 B4GALT6 0.536 + 7.96E-03 6.05E-03 
218899_PM_s_at brain and acute leukemia, cytoplasmic 1540 BAALC 0.473 + 2.42E-02 1.45E-02 
221234_PM_s_at 
BTB and CNC homology 1, basic leucine zipper transcription 
factor 2 
7518 BACH2 0.832 + 1.14E-02 4.54E-03 
229720_PM_at BCL2-associated athanogene 163486 BAG1 0.806 + 2.57E-04 3.69E-03 
202387_PM_at BCL2-associated athanogene 89797 BAG1 0.291 + 8.16E-03 5.47E-03 
217911_PM_s_at BCL2-associated athanogene 3 9043 BAG3 0.404 + 7.50E-03 1.98E-02 
211946_PM_s_at BAT2 domain containing 1 7528 BAT2D1 0.474 + 4.13E-02 3.06E-02 
205965_PM_at basic leucine zipper transcription factor, ATF-like 6767 BATF 0.333 + 6.93E-03 3.97E-03 
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208445_PM_s_at bromodomain adjacent to zinc finger domain, 1B 55660 BAZ1B 0.317 + 2.88E-02 4.87E-02 
201355_PM_s_at bromodomain adjacent to zinc finger domain, 2A 658 BAZ2A 0.334 + 1.48E-02 2.21E-02 
203080_PM_s_at bromodomain adjacent to zinc finger domain, 2B 91012 BAZ2B 0.601 + 2.36E-02 1.65E-02 
211692_PM_s_at BCL2 binding component 3 83696 BBC3 0.679 + 1.32E-02 1.71E-02 
205363_PM_at 
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-
butyrobetaine hydroxylase) 1 
5126 BBOX1 0.939 + 1.51E-03 1.55E-03 
218471_PM_s_at Bardet-Biedl syndrome 1 130733 BBS1 0.669 + 7.03E-03 3.06E-02 
230697_PM_at Bardet-Biedl syndrome 5 401207 BBS5 0.503 + 1.95E-02 1.31E-02 
40093_PM_at basal cell adhesion molecule (Lutheran blood group) --- BCAM 0.288 + 2.26E-02 1.29E-02 
204032_PM_at breast cancer anti-estrogen resistance 3 5931 BCAR3 0.298 + 7.98E-03 1.93E-02 
225285_PM_at branched chain aminotransferase 1, cytosolic 643008 BCAT1 0.288 + 2.04E-02 2.45E-02 
218264_PM_at BRCA2 and CDKN1A interacting protein 148523 BCCIP 0.718 + 7.28E-04 2.90E-03 
227322_PM_s_at BRCA2 and CDKN1A interacting protein 79686 BCCIP 0.496 + 3.01E-03 1.81E-02 
210653_PM_s_at 
branched chain keto acid dehydrogenase E1, beta 
polypeptide 
1456 BCKDHB 0.346 + 4.65E-02 3.66E-02 
1559078_PM_at B-cell CLL/lymphoma 11A (zinc finger protein) 2947 BCL11A 0.507 + 1.75E-02 1.85E-02 
203685_PM_at B-cell CLL/lymphoma 2 27125 BCL2 0.774 + 1.91E-02 2.68E-02 
225606_PM_at BCL2-like 11 (apoptosis facilitator) 54556 BCL2L11 0.410 + 2.78E-02 3.23E-02 
201084_PM_s_at BCL2-associated transcription factor 1 9139 BCLAF1 0.336 + 1.31E-02 3.39E-02 
226290_PM_at 
B double prime 1, subunit of RNA polymerase III transcription 
initiation factor IIIB 
2261 BDP1 1.007 + 1.86E-02 1.04E-02 
214068_PM_at brain expressed, associated with Nedd4 6742 BEAN 0.324 + 1.22E-02 3.17E-02 
213709_PM_at basic helix-loop-helix domain containing, class B, 9 23030 BHLHB9 0.574 + 2.27E-03 1.13E-03 
206119_PM_at betaine-homocysteine methyltransferase 51382 BHMT 1.196 + 4.46E-03 2.04E-03 
213154_PM_s_at bicaudal D homolog 2 (Drosophila) 6620 BICD2 0.727 + 3.13E-02 1.41E-02 
233093_PM_s_at baculoviral IAP repeat-containing 6 --- BIRC6 0.486 + 3.52E-02 2.93E-02 
220451_PM_s_at baculoviral IAP repeat-containing 7 63931 BIRC7 0.339 + 7.04E-03 1.60E-02 
222761_PM_at basic, immunoglobulin-like variable motif containing 259217 BIVM 0.604 + 1.35E-02 8.58E-03 
225049_PM_at biogenesis of lysosomal organelles complex-1, subunit 2 2674 BLOC1S2 0.477 + 7.03E-04 1.70E-03 
203773_PM_x_at biliverdin reductase A 161497 BLVRA 0.645 + 2.93E-03 3.39E-03 
211729_PM_x_at biliverdin reductase A 23299 BLVRA 0.527 + 5.90E-03 8.59E-03 
202201_PM_at biliverdin reductase B (flavin reductase (NADPH)) 324 BLVRB 0.346 + 4.46E-02 3.01E-02 
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32088_PM_at basic leucine zipper nuclear factor 1 --- BLZF1 0.347 + 1.18E-03 7.12E-04 
59644_PM_at BMP2 inducible kinase --- BMP2K 0.278 + 3.20E-02 2.18E-02 
209590_PM_at bone morphogenetic protein 7 51313 BMP7 0.492 + 5.22E-03 1.36E-02 
213578_PM_at bone morphogenetic protein receptor, type IA 4000 BMPR1A 0.634 + 2.91E-02 1.03E-02 
229975_PM_at bone morphogenetic protein receptor, type IB 118429 BMPR1B 0.270 + 2.94E-02 4.25E-02 
201849_PM_at BCL2/adenovirus E1B 19kDa interacting protein 3 5378 BNIP3 0.349 + 1.11E-02 3.02E-02 
221478_PM_at BCL2/adenovirus E1B 19kDa interacting protein 3-like 5587 BNIP3L 0.351 + 4.11E-02 1.64E-02 
225030_PM_at biorientation of chromosomes in cell division 1 151195 BOD1 0.282 + 2.69E-03 7.51E-03 
225821_PM_s_at biorientation of chromosomes in cell division 1-like 55735 BOD1L 0.546 + 1.95E-02 1.23E-02 
209836_PM_x_at 265epa homolog 2 (E. coli) /// 265epa homolog 2B (E. coli) 84128 
BOLA2 /// 
BOLA2B 
0.554 + 3.89E-03 1.31E-02 
227291_PM_s_at 265epa homolog 3 (E. coli) 80219 BOLA3 0.527 + 3.06E-02 3.86E-02 
203502_PM_at 2,3-bisphosphoglycerate mutase 79712 BPGM 0.762 + 3.79E-03 2.99E-03 
209271_PM_at bromodomain PHD finger transcription factor 3839 BPTF 0.570 + 3.64E-02 3.74E-02 
221196_PM_x_at BRCA1/BRCA2-containing complex, subunit 3 9575 BRCC3 0.498 + 1.02E-02 2.55E-02 
229436_PM_x_at BRCA1/BRCA2-containing complex, subunit 3 651250 BRCC3 0.277 + 4.77E-02 8.25E-03 
226052_PM_at bromodomain containing 4 9167 BRD4 0.448 + 2.14E-02 2.06E-02 
226580_PM_at breast cancer metastasis-suppressor 1-like 8741 BRMS1L 0.368 + 6.93E-03 1.53E-02 
202427_PM_s_at brain protein 44 10600 BRP44 0.346 + 5.58E-03 1.75E-03 
218024_PM_at brain protein 44-like 84058 BRP44L 0.440 + 8.49E-03 7.40E-03 
225217_PM_s_at bromodomain and PHD finger containing, 3 6815 BRPF3 0.802 + 2.53E-02 2.62E-02 
231960_PM_at bromodomain and WD repeat domain containing 1 100113407 BRWD1 0.595 + 9.85E-03 1.35E-02 
209430_PM_at 
BTAF1 RNA polymerase II, B-TFIID transcription factor-
associated, 170kDa (Mot1 homolog, S. cerevisiae) 
55758 BTAF1 0.695 + 2.10E-02 1.12E-02 
224945_PM_at BTB (POZ) domain containing 7 728568 BTBD7 0.654 + 3.09E-02 1.33E-02 
214800_PM_x_at basic transcription factor 3 723790 /// 8337 BTF3 0.536 + 5.19E-03 4.86E-03 
211939_PM_x_at basic transcription factor 3 441263 BTF3 0.346 + 9.04E-03 7.23E-03 
238675_PM_x_at basic transcription factor 3-like 4 --- BTF3L4 0.474 + 9.74E-03 3.87E-02 
201236_PM_s_at BTG family, member 2 10634 BTG2 0.638 + 3.56E-02 2.41E-02 
205548_PM_s_at BTG family, member 3 79171 BTG3 0.979 + 4.15E-03 1.57E-03 
213134_PM_x_at BTG family, member 3 8544 BTG3 0.692 + 1.37E-02 1.81E-02 
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204820_PM_s_at 
butyrophilin, subfamily 3, member A2 /// butyrophilin, 




1.088 + 2.28E-02 2.12E-02 
217207_PM_s_at butyrophilin-like 3 25948 BTNL3 0.308 + 3.22E-02 3.16E-02 
224504_PM_s_at BUD13 homolog (S. cerevisiae) 10011 BUD13 0.264 + 3.14E-02 4.19E-02 
219177_PM_at brix domain containing 2 9804 BXDC2 0.287 + 1.51E-02 2.34E-02 
218462_PM_at brix domain containing 5 116835 BXDC5 0.443 + 3.53E-03 5.64E-03 
215449_PM_at 266eparin266ing266e266 receptor (peripheral)-like 1 50632 BZRPL1 0.270 + 6.65E-03 1.90E-02 
200777_PM_s_at basic leucine zipper and W2 domains 1 815 BZW1 0.307 + 3.45E-02 2.91E-02 
217809_PM_at basic leucine zipper and W2 domains 2 81555 BZW2 0.674 + 7.43E-03 6.87E-03 
229145_PM_at chromosome 10 open reading frame 104 161742 C10orf104 0.267 + 1.04E-02 3.39E-02 
224664_PM_at chromosome 10 open reading frame 104 57678 C10orf104 0.358 + 1.63E-02 4.16E-03 
242660_PM_at chromosome 10 open reading frame 112 --- C10orf112 0.268 + 1.29E-02 2.18E-02 
226892_PM_at chromosome 10 open reading frame 12 26035 C10orf12 0.567 + 1.26E-02 2.18E-02 
218331_PM_s_at chromosome 10 open reading frame 18 57722 C10orf18 0.502 + 1.15E-02 1.87E-02 
226398_PM_s_at chromosome 10 open reading frame 4 10001 C10orf4 0.475 + 3.83E-04 6.29E-04 
228155_PM_at chromosome 10 open reading frame 58 140688 C10orf58 0.362 + 1.09E-02 7.78E-04 
222617_PM_s_at chromosome 10 open reading frame 84 23116 C10orf84 0.368 + 3.69E-03 5.42E-03 
234947_PM_s_at chromosome 10 open reading frame 84 2775 C10orf84 0.263 + 4.62E-03 2.43E-02 
231530_PM_s_at chromosome 11 open reading frame 1 90342 C11orf1 0.748 + 1.66E-03 9.09E-03 
222785_PM_x_at chromosome 11 open reading frame 1 2926 C11orf1 0.515 + 1.45E-02 1.17E-02 
222807_PM_at chromosome 11 open reading frame 30 81697 C11orf30 0.398 + 7.67E-03 3.35E-02 
231045_PM_x_at chromosome 11 open reading frame 31 64145 C11orf31 0.356 + 1.07E-03 1.99E-03 
228332_PM_s_at chromosome 11 open reading frame 31 641638 C11orf31 0.444 + 8.80E-03 8.11E-03 
226383_PM_at chromosome 11 open reading frame 46 6505 C11orf46 0.485 + 4.03E-02 7.11E-03 
221637_PM_s_at chromosome 11 open reading frame 48 6367 C11orf48 0.660 + 9.74E-03 7.48E-03 
203257_PM_s_at chromosome 11 open reading frame 49 84268 C11orf49 0.314 + 2.78E-03 1.18E-02 
204218_PM_at chromosome 11 open reading frame 51 10175 C11orf51 0.309 + 1.43E-02 1.73E-03 
225811_PM_at chromosome 11 open reading frame 58 153222 C11orf58 0.424 + 1.03E-03 4.66E-04 
200084_PM_at chromosome 11 open reading frame 58 3691 C11orf58 0.401 + 3.28E-03 3.54E-03 
201784_PM_s_at chromosome 11 open reading frame 58 6934 C11orf58 0.340 + 6.22E-03 1.93E-04 
221599_PM_at chromosome 11 open reading frame 67 22878 C11orf67 1.003 + 3.85E-03 1.17E-02 
219979_PM_s_at chromosome 11 open reading frame 73 266655 C11orf73 0.871 + 5.97E-05 4.09E-04 
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230326_PM_s_at chromosome 11 open reading frame 73 --- C11orf73 0.462 + 3.81E-03 2.23E-04 
219806_PM_s_at chromosome 11 open reading frame 75 27347 C11orf75 0.579 + 2.63E-02 1.24E-02 
224759_PM_s_at chromosome 12 open reading frame 23 26122 C12orf23 0.317 + 6.96E-03 1.63E-02 
204521_PM_at chromosome 12 open reading frame 24 26054 C12orf24 0.308 + 1.38E-02 1.50E-02 
225888_PM_at chromosome 12 open reading frame 30 284098 C12orf30 0.688 + 1.58E-02 3.46E-03 
221821_PM_s_at chromosome 12 open reading frame 41 11212 C12orf41 0.660 + 1.45E-02 4.49E-03 
222767_PM_s_at chromosome 12 open reading frame 49 145389 C12orf49 0.369 + 2.79E-03 1.87E-02 
211034_PM_s_at chromosome 12 open reading frame 51 56884 C12orf51 0.496 + 3.30E-02 4.32E-02 
226943_PM_at chromosome 12 open reading frame 73 51406 C12orf73 0.283 + 5.91E-03 4.93E-03 
225105_PM_at chromosome 12 open reading frame 75 23099 C12orf75 0.968 + 1.31E-02 7.46E-03 
213346_PM_at chromosome 13 open reading frame 27 5631 C13orf27 0.697 + 2.16E-02 1.03E-02 
241672_PM_at chromosome 13 open reading frame 36 55706 C13orf36 0.524 + 2.70E-02 1.80E-02 
225578_PM_at chromosome 13 open reading frame 37 376940 C13orf37 0.268 + 3.94E-03 9.53E-03 
213246_PM_at chromosome 14 open reading frame 109 8894 C14orf109 0.482 + 1.04E-02 1.20E-03 
223060_PM_at chromosome 14 open reading frame 119 94104 C14orf119 0.290 + 8.38E-03 1.70E-02 
227158_PM_at chromosome 14 open reading frame 126 59339 C14orf126 0.807 + 4.93E-03 1.56E-02 
223239_PM_at chromosome 14 open reading frame 129 54898 C14orf129 0.978 + 1.05E-02 8.59E-03 
219563_PM_at chromosome 14 open reading frame 139 392 C14orf139 0.731 + 2.36E-02 4.02E-02 
212460_PM_at chromosome 14 open reading frame 147 55312 C14orf147 0.528 + 6.18E-03 1.67E-02 
221434_PM_s_at chromosome 14 open reading frame 156 11341 C14orf156 0.313 + 3.16E-03 6.93E-04 
217768_PM_at chromosome 14 open reading frame 166 200185 C14orf166 0.282 + 2.13E-02 4.48E-03 
225514_PM_at chromosome 14 open reading frame 21 7094 C14orf21 0.290 + 3.51E-03 7.76E-03 
243061_PM_at chromosome 14 open reading frame 23 4123 C14orf23 0.630 + 2.02E-02 4.30E-02 
238647_PM_at chromosome 14 open reading frame 28 --- C14orf28 0.441 + 2.40E-02 2.27E-02 
225980_PM_at chromosome 14 open reading frame 43 494470 C14orf43 0.529 + 4.53E-02 3.24E-02 
239933_PM_x_at chromosome 14 open reading frame 45 --- C14orf45 0.549 + 7.26E-03 1.51E-02 
215877_PM_at chromosome 14 open reading frame 56 58525 C14orf56 0.308 + 7.08E-04 3.63E-03 
218791_PM_s_at chromosome 15 open reading frame 29 64130 C15orf29 0.668 + 7.74E-03 2.14E-03 
1552310_PM_at chromosome 15 open reading frame 40 394 C15orf40 1.068 + 1.14E-03 2.49E-03 
229742_PM_at chromosome 15 open reading frame 61 154743 C15orf61 0.407 + 2.89E-02 2.81E-02 
233746_PM_x_at 





0.608 + 5.18E-03 7.63E-03 
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218680_PM_x_at 





0.410 + 7.69E-03 3.30E-02 
230721_PM_at chromosome 16 open reading frame 52 441108 C16orf52 0.619 + 3.62E-03 3.49E-03 
227351_PM_at chromosome 16 open reading frame 52 80095 C16orf52 0.452 + 3.13E-02 2.44E-02 
228373_PM_at chromosome 16 open reading frame 72 388753 C16orf72 0.392 + 1.72E-02 5.16E-04 
217957_PM_at chromosome 16 open reading frame 80 91768 C16orf80 0.437 + 4.78E-03 1.36E-03 
228452_PM_at chromosome 17 open reading frame 39 89970 C17orf39 0.335 + 3.17E-03 1.33E-02 
223401_PM_at chromosome 17 open reading frame 48 79901 C17orf48 0.395 + 7.25E-03 8.61E-04 
227668_PM_at chromosome 17 open reading frame 56 64343 C17orf56 0.287 + 1.29E-03 1.00E-02 
225966_PM_at chromosome 17 open reading frame 89 133308 C17orf89 0.327 + 1.27E-02 1.09E-02 
225808_PM_at chromosome 17 open reading frame 95 155435 C17orf95 0.583 + 1.48E-02 3.01E-02 
226406_PM_at chromosome 18 open reading frame 25 521 C18orf25 0.746 + 1.04E-02 4.65E-03 
221190_PM_s_at chromosome 18 open reading frame 8 8819 C18orf8 0.607 + 4.24E-02 2.14E-02 
231901_PM_at chromosome 19 open reading frame 52 140458 C19orf52 0.445 + 6.22E-03 1.25E-02 
218429_PM_s_at chromosome 19 open reading frame 66 7552 C19orf66 0.479 + 1.67E-02 2.08E-02 
53720_PM_at chromosome 19 open reading frame 66 --- C19orf66 0.445 + 3.42E-02 3.47E-02 
238866_PM_at chromosome 19 open reading frame 68 51477 C19orf68 0.375 + 2.98E-03 1.64E-03 
219283_PM_at C1GALT1-specific chaperone 1 8553 C1GALT1C1 0.618 + 7.88E-04 1.49E-02 
206721_PM_at chromosome 1 open reading frame 114 8450 C1orf114 0.660 + 3.85E-02 9.17E-03 
226242_PM_at chromosome 1 open reading frame 131 19 C1orf131 0.428 + 1.08E-02 2.40E-02 
228096_PM_at chromosome 1 open reading frame 151 2013 C1orf151 0.657 + 7.39E-04 3.33E-04 
224867_PM_at chromosome 1 open reading frame 151 222194 C1orf151 0.361 + 6.94E-03 3.92E-03 
213528_PM_at chromosome 1 open reading frame 156 1272 C1orf156 0.664 + 7.91E-04 2.53E-03 
224501_PM_at chromosome 1 open reading frame 170 1021 C1orf170 0.343 + 2.14E-02 2.83E-02 
230608_PM_at chromosome 1 open reading frame 182 284297 C1orf182 0.495 + 4.82E-04 7.23E-03 
229382_PM_at chromosome 1 open reading frame 183 205717 C1orf183 0.288 + 7.38E-03 2.00E-02 
221272_PM_s_at chromosome 1 open reading frame 21 4520 C1orf21 0.415 + 6.90E-03 4.28E-03 
237131_PM_at chromosome 1 open reading frame 230 5569 C1orf230 0.606 + 2.36E-02 8.91E-03 
225638_PM_at chromosome 1 open reading frame 31 4076 C1orf31 0.364 + 3.13E-02 3.94E-02 
223034_PM_s_at chromosome 1 open reading frame 43 55204 C1orf43 0.469 + 2.11E-03 4.20E-04 
219406_PM_at chromosome 1 open reading frame 50 7175 C1orf50 1.021 + 5.53E-04 2.37E-04 
62212_PM_at chromosome 1 open reading frame 50 388591 C1orf50 0.726 + 3.96E-03 9.31E-03 
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227285_PM_at chromosome 1 open reading frame 51 374354 C1orf51 0.381 + 1.09E-02 2.88E-02 
228135_PM_at chromosome 1 open reading frame 52 51274 C1orf52 0.313 + 2.08E-02 4.74E-02 
226813_PM_at chromosome 1 open reading frame 57 5286 C1orf57 0.704 + 4.03E-04 3.00E-04 
225841_PM_at chromosome 1 open reading frame 59 --- C1orf59 0.478 + 1.45E-02 2.73E-02 
205103_PM_at chromosome 1 open reading frame 61 9984 C1orf61 0.523 + 7.61E-03 8.25E-03 
229381_PM_at chromosome 1 open reading frame 64 202018 C1orf64 0.270 + 4.46E-03 3.47E-02 
228100_PM_at chromosome 1 open reading frame 88 283742 C1orf88 0.838 + 2.91E-03 1.34E-02 
203429_PM_s_at chromosome 1 open reading frame 9 8618 C1orf9 0.333 + 3.08E-02 1.30E-02 
224690_PM_at chromosome 20 open reading frame 108 1054 C20orf108 0.395 + 8.82E-03 1.88E-02 
225376_PM_at chromosome 20 open reading frame 11 163404 C20orf11 0.325 + 5.21E-03 1.27E-02 
221954_PM_at Chromosome 20 open reading frame 111 10128 C20orf111 0.384 + 2.10E-02 8.58E-03 
225224_PM_at chromosome 20 open reading frame 112 58492 C20orf112 0.419 + 2.91E-02 4.86E-02 
225313_PM_at chromosome 20 open reading frame 177 2259 C20orf177 0.877 + 4.68E-03 2.84E-02 
224915_PM_x_at chromosome 20 open reading frame 199 112574 C20orf199 0.611 + 5.54E-04 8.09E-03 
226835_PM_s_at chromosome 20 open reading frame 199 10302 C20orf199 0.557 + 5.85E-03 8.47E-03 
226227_PM_x_at chromosome 20 open reading frame 199 9652 C20orf199 0.523 + 6.66E-03 2.35E-02 
219706_PM_at chromosome 20 open reading frame 29 64844 C20orf29 0.279 + 3.56E-03 3.32E-02 
224584_PM_at chromosome 20 open reading frame 30 55691 C20orf30 0.448 + 2.19E-02 4.57E-02 
222894_PM_x_at chromosome 20 open reading frame 7 10135 C20orf7 0.610 + 1.07E-04 1.38E-03 
225499_PM_at chromosome 20 open reading frame 74 11095 C20orf74 0.318 + 5.93E-04 1.27E-03 
219004_PM_s_at chromosome 21 open reading frame 45 10302 C21orf45 0.954 + 6.39E-03 4.05E-03 
227188_PM_at chromosome 21 open reading frame 63 59343 C21orf63 0.488 + 1.25E-02 8.22E-03 
218515_PM_at chromosome 21 open reading frame 66 27115 C21orf66 0.669 + 3.31E-02 1.26E-02 
226109_PM_at chromosome 21 open reading frame 91 56255 C21orf91 0.674 + 3.94E-02 1.25E-02 
1558097_PM_at chromosome 22 open reading frame 30 9129 C22orf30 0.566 + 2.51E-02 3.97E-02 
36552_PM_at C2 calcium-dependent domain containing 3 --- C2CD3 0.741 + 2.86E-02 4.95E-02 
219329_PM_s_at chromosome 2 open reading frame 28 7411 C2orf28 0.373 + 1.95E-02 2.27E-02 
219176_PM_at chromosome 2 open reading frame 47 6282 C2orf47 0.377 + 2.46E-02 2.83E-02 
241825_PM_at chromosome 2 open reading frame 60 --- C2orf60 0.328 + 7.87E-03 2.39E-03 
235686_PM_at chromosome 2 open reading frame 60 1347 C2orf60 0.351 + 3.93E-02 3.58E-02 
225409_PM_at chromosome 2 open reading frame 64 55607 C2orf64 0.300 + 2.04E-03 1.61E-02 
238974_PM_at chromosome 2 open reading frame 69 --- C2orf69 0.485 + 2.15E-02 2.52E-02 
 270 
236909_PM_at chromosome 2 open reading frame 77 --- C2orf77 1.061 + 3.61E-03 2.92E-03 
228195_PM_at chromosome 2 open reading frame 88 414 C2orf88 0.402 + 1.99E-03 2.14E-03 
223004_PM_s_at chromosome 3 open reading frame 1 29099 C3orf1 0.342 + 1.64E-02 1.26E-02 
219288_PM_at chromosome 3 open reading frame 14 55611 C3orf14 0.402 + 6.52E-03 7.55E-03 
226688_PM_at chromosome 3 open reading frame 23 5087 C3orf23 0.448 + 2.27E-02 1.60E-02 
224523_PM_s_at chromosome 3 open reading frame 26 389203 C3orf26 0.636 + 3.14E-05 1.28E-03 
209285_PM_s_at chromosome 3 open reading frame 63 84656 C3orf63 0.371 + 8.41E-03 2.80E-02 
223204_PM_at chromosome 4 open reading frame 18 
100287515 /// 
7574 
C4orf18 0.495 + 1.38E-02 1.38E-02 
218646_PM_at chromosome 4 open reading frame 27 8562 C4orf27 0.487 + 1.42E-02 1.49E-02 
236240_PM_at chromosome 4 open reading frame 29 100131801 C4orf29 0.333 + 7.44E-04 6.18E-03 
224602_PM_at chromosome 4 open reading frame 3 54516 C4orf3 0.305 + 1.90E-02 1.30E-02 
201812_PM_s_at 
chromosome 4 open reading frame 46 /// translocase of outer 




0.273 + 3.51E-02 5.87E-03 
224876_PM_at chromosome 5 open reading frame 24 150864 C5orf24 0.575 + 1.63E-02 1.46E-02 
228594_PM_at chromosome 5 open reading frame 33 11320 C5orf33 0.308 + 1.11E-02 6.09E-03 
227267_PM_at chromosome 5 open reading frame 37 54877 C5orf37 0.912 + 3.95E-03 4.01E-03 
218674_PM_at chromosome 5 open reading frame 44 394 C5orf44 0.432 + 1.22E-03 5.53E-03 
226159_PM_at chromosome 5 open reading frame 51 10480 C5orf51 0.462 + 2.29E-02 4.64E-03 
226977_PM_at chromosome 5 open reading frame 53 5912 C5orf53 0.406 + 4.16E-02 1.10E-02 
220770_PM_s_at chromosome 5 open reading frame 54 4258 C5orf54 0.556 + 2.19E-02 7.69E-03 
230405_PM_at chromosome 5 open reading frame 56 55349 C5orf56 0.416 + 2.15E-02 2.46E-02 
223361_PM_at chromosome 6 open reading frame 115 158747 C6orf115 0.463 + 4.53E-03 4.19E-03 
213322_PM_at chromosome 6 open reading frame 130 9126 C6orf130 0.271 + 9.09E-03 1.63E-02 
236178_PM_at chromosome 6 open reading frame 162 --- C6orf162 0.327 + 6.24E-04 1.09E-03 
223576_PM_at chromosome 6 open reading frame 203 55149 C6orf203 0.350 + 1.97E-02 3.87E-03 
222638_PM_s_at chromosome 6 open reading frame 35 404672 C6orf35 0.387 + 1.28E-02 4.14E-03 
243943_PM_x_at chromosome 6 open reading frame 52 --- C6orf52 0.701 + 1.12E-02 1.77E-02 
236504_PM_x_at chromosome 6 open reading frame 52 --- C6orf52 0.568 + 3.83E-02 8.05E-03 
225419_PM_at chromosome 7 open reading frame 11 139065 C7orf11 0.716 + 5.55E-03 1.92E-03 
220231_PM_at chromosome 7 open reading frame 16 6902 C7orf16 0.593 + 7.97E-04 2.41E-03 
226386_PM_at chromosome 7 open reading frame 30 7504 C7orf30 0.448 + 3.18E-03 2.37E-03 
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226385_PM_s_at chromosome 7 open reading frame 30 2745 C7orf30 0.417 + 8.05E-03 1.37E-02 
223433_PM_at chromosome 7 open reading frame 36 51645 C7orf36 0.841 + 1.98E-03 3.57E-03 
238609_PM_at chromosome 7 open reading frame 38 --- C7orf38 0.384 + 2.04E-02 4.41E-02 
226780_PM_s_at chromosome 7 open reading frame 55 6655 C7orf55 0.415 + 6.90E-03 2.00E-02 
228149_PM_at chromosome 7 open reading frame 60 65059 C7orf60 1.106 + 7.85E-03 9.87E-03 
218507_PM_at chromosome 7 open reading frame 68 55425 C7orf68 0.356 + 2.85E-02 2.32E-02 
235509_PM_at chromosome 8 open reading frame 38 --- C8orf38 0.623 + 2.51E-03 4.47E-03 
230903_PM_s_at chromosome 8 open reading frame 42 5136 C8orf42 0.704 + 3.39E-03 5.54E-03 
236634_PM_at chromosome 8 open reading frame 48 --- C8orf48 0.269 + 1.81E-02 2.34E-02 
226165_PM_at chromosome 8 open reading frame 59 5718 C8orf59 0.491 + 2.30E-02 2.90E-03 
225702_PM_at chromosome 8 open reading frame 76 79078 C8orf76 0.371 + 5.45E-03 2.76E-03 
226027_PM_at chromosome 9 open reading frame 119 1964 C9orf119 0.454 + 1.79E-02 4.94E-02 
224879_PM_at chromosome 9 open reading frame 123 375061 C9orf123 0.539 + 1.21E-02 5.01E-03 
227443_PM_at chromosome 9 open reading frame 150 51284 C9orf150 0.670 + 5.25E-03 3.16E-03 
223522_PM_at chromosome 9 open reading frame 45 9419 C9orf45 0.515 + 2.50E-03 1.24E-03 
218992_PM_at chromosome 9 open reading frame 46 388 C9orf46 0.752 + 7.14E-03 1.09E-02 
223008_PM_s_at chromosome 9 open reading frame 5 55745 C9orf5 0.469 + 2.69E-02 3.46E-02 
218998_PM_at chromosome 9 open reading frame 6 158158 C9orf6 0.309 + 2.27E-02 2.37E-03 
220050_PM_at chromosome 9 open reading frame 9 23473 C9orf9 0.389 + 2.71E-02 2.04E-02 
219147_PM_s_at chromosome 9 open reading frame 95 161436 C9orf95 0.575 + 1.62E-02 4.12E-02 
223550_PM_s_at carbonic anhydrase X 81831 CA10 0.516 + 6.73E-03 2.92E-02 
214164_PM_x_at carbonic anhydrase XII 27324 CA12 0.326 + 6.21E-03 2.65E-02 
215867_PM_x_at carbonic anhydrase XII 1290 CA12 0.435 + 1.58E-02 1.69E-02 
225532_PM_at Cdk5 and Abl enzyme substrate 1 134701 CABLES1 0.761 + 2.02E-02 4.52E-02 
225627_PM_s_at cache domain containing 1 6314 CACHD1 0.761 + 2.30E-02 2.26E-02 
242973_PM_at calcium channel, voltage-dependent, L type, alpha 1C subunit --- CACNA1C 0.640 + 2.70E-02 4.06E-02 
1555993_PM_at calcium channel, voltage-dependent, L type, alpha 1D subunit 3725 CACNA1D 0.413 + 5.60E-03 6.63E-03 
228083_PM_at calcium channel, voltage-dependent, alpha 2/delta subunit 4 4893 CACNA2D4 0.284 + 4.98E-03 2.68E-03 
211761_PM_s_at calcyclin binding protein 285527 CACYBP 0.325 + 2.72E-02 6.46E-03 
222293_PM_at cell adhesion molecule 4 26092 CADM4 0.333 + 3.98E-04 1.46E-03 
212077_PM_at caldesmon 1 3150 CALD1 0.869 + 4.03E-03 1.83E-02 
212710_PM_at calmodulin regulated spectrin-associated protein 1 3176 CAMSAP1 0.352 + 1.03E-02 1.53E-02 
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212765_PM_at calmodulin regulated spectrin-associated protein 1-like 1 10959 CAMSAP1L1 0.389 + 2.26E-02 2.18E-02 
225693_PM_s_at calmodulin binding transcription activator 1 55589 CAMTA1 0.570 + 3.55E-03 4.82E-03 
225692_PM_at calmodulin binding transcription activator 1 79959 CAMTA1 0.682 + 8.65E-03 5.89E-03 
1555370_PM_a_at calmodulin binding transcription activator 1 6651 CAMTA1 0.422 + 2.89E-02 3.17E-02 
213268_PM_at calmodulin binding transcription activator 1 6717 CAMTA1 0.344 + 4.21E-02 3.77E-02 
213547_PM_at cullin-associated and neddylation-dissociated 2 (putative) 4233 CAND2 0.702 + 3.08E-02 1.66E-02 
238034_PM_at calnexin --- CANX 0.489 + 4.49E-02 1.83E-02 
208683_PM_at calpain 2, (m/II) large subunit 2558 CAPN2 0.510 + 3.11E-02 2.79E-02 
203356_PM_at calpain 7 55342 CAPN7 0.670 + 3.27E-03 8.24E-03 
243370_PM_at cell cycle associated protein 1 --- CAPRIN1 0.319 + 3.52E-02 3.57E-02 
236085_PM_at calcyphosine-like --- CAPSL 0.317 + 3.12E-02 2.55E-02 
208374_PM_s_at capping protein (actin filament) muscle Z-line, alpha 1 283537 CAPZA1 0.576 + 1.25E-03 9.26E-04 
1552701_PM_a_at caspase recruitment domain family, member 16 8904 /// 9054 CARD16 0.985 + 2.08E-02 3.54E-02 
224619_PM_at cancer susceptibility candidate 4 54545 CASC4 0.412 + 1.88E-03 7.65E-03 
227156_PM_at 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
7067 /// 9572 CASK 0.526 + 2.23E-02 4.37E-02 
219645_PM_at calsequestrin 1 (fast-twitch, skeletal muscle) 10444 CASQ1 0.324 + 6.86E-03 2.54E-03 
202370_PM_s_at core-binding factor, beta subunit 51422 CBFB 0.758 + 4.20E-02 4.68E-02 
225231_PM_at Cas-Br-M (murine) ecotropic retroviral transforming sequence 132946 CBL 0.539 + 6.19E-04 4.43E-03 
225234_PM_at Cas-Br-M (murine) ecotropic retroviral transforming sequence 148808 CBL 0.661 + 6.86E-03 5.10E-03 
227187_PM_at 
Cas-Br-M (murine) ecotropic retroviral transforming 
sequence-like 1 
55173 CBLL1 0.695 + 2.58E-02 3.99E-02 
220175_PM_s_at 
COBW domain containing 1 /// COBW domain containing 2 /// 
COBW domain containing 3 /// COBW domain containing 5 /// 








0.621 + 6.16E-03 1.74E-02 
201518_PM_at chromobox homolog 1 (HP1 beta homolog Drosophila ) 1022 CBX1 0.461 + 2.67E-03 1.15E-02 
234936_PM_s_at coiled-coil and C2 domain containing 2A 3416 CC2D2A 0.977 + 4.35E-03 1.63E-02 
224968_PM_at coiled-coil domain containing 104 90874 CCDC104 0.276 + 3.81E-02 1.50E-02 
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227157_PM_at coiled-coil domain containing 111 --- CCDC111 1.027 + 7.92E-03 3.09E-02 
224946_PM_s_at coiled-coil domain containing 115 201627 CCDC115 0.559 + 4.68E-03 1.45E-02 
228087_PM_at coiled-coil domain containing 126 8030 CCDC126 0.501 + 6.40E-03 5.58E-04 
217845_PM_x_at 
coiled-coil domain containing 13 /// HIG1 hypoxia inducible 






0.383 + 4.03E-03 6.24E-03 
226723_PM_at coiled-coil domain containing 23 91754 CCDC23 0.773 + 5.48E-03 6.35E-03 
209479_PM_at coiled-coil domain containing 28A 79982 CCDC28A 0.414 + 6.91E-04 2.64E-03 
226287_PM_at coiled-coil domain containing 34 2313 CCDC34 0.615 + 3.98E-03 7.25E-03 
229918_PM_at coiled-coil domain containing 40 --- CCDC40 0.391 + 3.17E-02 2.84E-02 
217814_PM_at coiled-coil domain containing 47 64951 CCDC47 0.469 + 2.39E-03 1.62E-02 
222706_PM_at coiled-coil domain containing 49 91304 CCDC49 0.624 + 1.27E-02 2.74E-02 
218628_PM_at coiled-coil domain containing 53 81627 CCDC53 0.643 + 8.80E-03 1.04E-03 
225010_PM_at coiled-coil domain containing 6 202052 CCDC6 0.416 + 6.94E-03 2.74E-02 
228122_PM_at coiled-coil domain containing 66 8540 CCDC66 0.939 + 6.55E-03 1.09E-03 
225242_PM_s_at coiled-coil domain containing 80 6299 CCDC80 1.126 + 2.63E-04 2.11E-03 
223301_PM_s_at coiled-coil domain containing 82 81563 CCDC82 0.638 + 1.71E-02 2.15E-02 
227208_PM_at coiled-coil domain containing 84 50861 CCDC84 0.585 + 1.09E-02 1.62E-02 
225045_PM_at coiled-coil domain containing 88A 94234 CCDC88A 0.441 + 2.05E-02 1.78E-03 
223663_PM_at coiled-coil domain containing 88B 51124 CCDC88B 0.336 + 2.43E-02 3.58E-02 
227228_PM_s_at coiled-coil domain containing 88C 79666 CCDC88C 0.265 + 3.50E-02 4.14E-02 
220094_PM_s_at coiled-coil domain containing 90A 10588 CCDC90A 0.761 + 1.50E-02 2.73E-02 
218288_PM_s_at coiled-coil domain containing 90B 143279 CCDC90B 0.446 + 3.57E-03 7.12E-03 
221685_PM_s_at coiled-coil domain containing 99 3621 CCDC99 0.679 + 1.33E-02 3.11E-02 
207861_PM_at chemokine (C-C motif) ligand 22 22980 CCL22 0.316 + 2.16E-02 1.98E-02 
201955_PM_at cyclin C 1385 CCNC 0.640 + 2.51E-02 5.44E-03 
213523_PM_at cyclin E1 27032 CCNE1 0.320 + 3.65E-02 4.94E-02 
228081_PM_at cyclin G2 7112 CCNG2 0.533 + 6.03E-03 5.06E-03 
202770_PM_s_at cyclin G2 54904 CCNG2 0.382 + 2.45E-02 3.06E-02 
204093_PM_at cyclin H 23478 CCNH 0.335 + 1.19E-03 6.21E-03 
220046_PM_s_at cyclin L1 22850 CCNL1 0.842 + 1.13E-02 2.02E-02 
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204645_PM_at cyclin T2 5921 CCNT2 0.429 + 3.30E-02 1.29E-02 
213743_PM_at cyclin T2 23376 CCNT2 0.680 + 4.60E-02 4.18E-02 
227280_PM_s_at cyclin Y-like 1 79596 CCNYL1 0.548 + 2.52E-02 1.64E-02 
222156_PM_x_at cell cycle progression 1 27346 CCPG1 0.312 + 3.63E-03 3.17E-02 
214152_PM_at cell cycle progression 1 689 CCPG1 0.820 + 7.18E-03 1.95E-02 
221511_PM_x_at cell cycle progression 1 7087 CCPG1 0.422 + 1.35E-02 2.67E-02 
214151_PM_s_at cell cycle progression 1 25909 CCPG1 0.453 + 1.43E-02 2.66E-02 
205271_PM_s_at cell cycle related kinase 24139 CCRK 0.322 + 2.03E-02 1.60E-02 
206587_PM_at chaperonin containing TCP1, subunit 6B (zeta 2) 8738 CCT6B 0.508 + 1.62E-02 3.04E-02 
200873_PM_s_at chaperonin containing TCP1, subunit 8 (theta) 3631 CCT8 0.352 + 1.63E-02 1.51E-02 
209583_PM_s_at CD200 molecule 56916 CD200 0.322 + 2.48E-02 1.87E-02 
203799_PM_at CD302 molecule 79856 CD302 0.309 + 1.35E-02 3.37E-02 
226016_PM_at CD47 molecule 4035 CD47 0.364 + 6.58E-03 1.16E-02 
213857_PM_s_at CD47 molecule 9527 CD47 0.519 + 2.17E-02 1.42E-02 
203416_PM_at CD53 molecule 80031 CD53 0.343 + 2.80E-02 8.86E-03 
204440_PM_at CD83 molecule 50999 CD83 0.463 + 8.37E-03 4.61E-02 
205685_PM_at CD86 molecule 4094 CD86 0.391 + 2.52E-02 3.57E-02 
233647_PM_s_at cytidine and dCMP deaminase domain containing 1 --- CDADC1 0.642 + 4.42E-03 2.66E-03 
223527_PM_s_at cytidine and dCMP deaminase domain containing 1 64224 CDADC1 0.548 + 4.44E-03 6.20E-03 
221556_PM_at CDC14 cell division cycle 14 homolog B (S. cerevisiae) 7539 CDC14B 0.441 + 3.77E-02 2.91E-02 
202717_PM_s_at cell division cycle 16 homolog (S. cerevisiae) 2122 CDC16 0.435 + 3.33E-03 6.20E-03 
209659_PM_s_at cell division cycle 16 homolog (S. cerevisiae) 57579 CDC16 0.648 + 9.89E-03 5.58E-03 
210559_PM_s_at cell division cycle 2, G1 to S and G2 to M 59271 CDC2 0.306 + 3.67E-03 1.37E-02 
225422_PM_at cell division cycle 26 homolog (S. cerevisiae) 57448 CDC26 0.769 + 1.15E-04 9.23E-04 
217880_PM_at cell division cycle 27 homolog (S. cerevisiae) 27154 CDC27 0.619 + 2.54E-03 1.92E-03 
212899_PM_at cell division cycle 2-like 6 (CDK8-like) 8540 CDC2L6 0.363 + 4.14E-02 1.24E-02 
214230_PM_at cell division cycle 42 (GTP binding protein, 25kDa) 4665 CDC42 0.806 + 4.82E-03 7.39E-03 
240735_PM_at CDC42 binding protein kinase alpha (DMPK-like) --- CDC42BPA 0.264 + 1.88E-02 2.76E-02 
209286_PM_at CDC42 effector protein (Rho GTPase binding) 3 56994 CDC42EP3 0.432 + 1.40E-02 3.73E-02 
224709_PM_s_at CDC42 small effector 2 54534 CDC42SE2 0.329 + 1.99E-02 7.31E-03 
204510_PM_at cell division cycle 7 homolog (S. cerevisiae) 51567 CDC7 0.823 + 2.16E-02 3.62E-02 
234932_PM_s_at CUB domain containing protein 1 9475 CDCP1 0.278 + 3.24E-03 1.09E-02 
 275 
201938_PM_at cyclin-dependent kinase 2 associated protein 1 1200 CDK2AP1 0.293 + 3.68E-02 2.03E-02 
204995_PM_at cyclin-dependent kinase 5, regulatory subunit 1 (p35) 6653 CDK5R1 0.347 + 3.50E-02 9.24E-03 
233540_PM_s_at CDK5 regulatory subunit associated protein 2 26005 CDK5RAP2 0.796 + 6.61E-04 1.23E-02 
224847_PM_at cyclin-dependent kinase 6 129531 CDK6 0.401 + 2.53E-04 8.41E-04 
211297_PM_s_at cyclin-dependent kinase 7 7569 CDK7 0.616 + 6.14E-04 2.02E-03 
1553113_PM_s_at cyclin-dependent kinase 8 9139 CDK8 0.357 + 4.43E-02 3.58E-02 
204831_PM_at cyclin-dependent kinase 8 4891 CDK8 0.458 + 4.57E-02 2.84E-02 
1555758_PM_a_at cyclin-dependent kinase inhibitor 3 5686 CDKN3 0.721 + 1.83E-03 4.25E-03 
209714_PM_s_at cyclin-dependent kinase inhibitor 3 96459 CDKN3 0.760 + 2.35E-03 7.85E-04 
204154_PM_at cysteine dioxygenase, type I 1736 CDO1 0.535 + 2.85E-02 2.42E-02 
212010_PM_s_at CDV3 homolog (mouse) 2058 CDV3 0.495 + 9.81E-03 1.18E-02 
203098_PM_at chromodomain protein, Y-like 51692 CDYL 0.589 + 1.07E-02 1.29E-02 
225527_PM_at CCAAT/enhancer binding protein (C/EBP), gamma 84466 CEBPG 0.379 + 6.62E-03 1.06E-02 
226610_PM_at centromere protein V 6535 CENPV 0.548 + 9.46E-03 2.93E-03 
226449_PM_at centrosomal protein 120kDa 1452 CEP120 0.305 + 1.68E-02 3.43E-02 
213165_PM_at centrosomal protein 350kDa 5467 CEP350 0.420 + 2.92E-02 2.08E-02 
203493_PM_s_at centrosomal protein 57kDa 9627 CEP57 0.848 + 1.09E-02 1.87E-02 
224150_PM_s_at centrosomal protein 70kDa 150274 CEP70 0.315 + 1.96E-02 7.35E-03 
52285_PM_f_at centrosomal protein 76kDa --- CEP76 0.720 + 1.97E-02 2.79E-02 
219375_PM_at choline/ethanolamine phosphotransferase 1 950 CEPT1 0.296 + 3.14E-02 2.83E-02 
209662_PM_at centrin, EF-hand protein, 3 (CDC31 homolog, yeast) 51250 CETN3 0.668 + 3.10E-03 6.45E-03 
203166_PM_at craniofacial development protein 1 6217 CFDP1 0.275 + 3.97E-02 4.37E-02 
224352_PM_s_at cofilin 2 (muscle) 116151 CFL2 0.655 + 6.38E-03 2.56E-03 
224663_PM_s_at cofilin 2 (muscle) 136647 CFL2 0.400 + 1.09E-02 2.62E-03 
209939_PM_x_at CASP8 and FADD-like apoptosis regulator 57492 CFLAR 0.436 + 6.91E-03 2.08E-02 
205387_PM_s_at 
chorionic gonadotropin, beta polypeptide /// chorionic 
gonadotropin, beta polypeptide 5 
8505 CGB /// CGB5 0.268 + 2.98E-02 8.07E-03 
224599_PM_at CGG triplet repeat binding protein 1 9218 CGGBP1 0.312 + 2.71E-02 2.96E-02 
235117_PM_at ChaC, cation transport regulator homolog 2 (E. coli) --- CHAC2 0.424 + 4.29E-03 2.17E-03 
217972_PM_at coiled-coil-helix-coiled-coil-helix domain containing 3 25879 CHCHD3 0.382 + 4.38E-03 4.75E-03 
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229595_PM_at coiled-coil-helix-coiled-coil-helix domain containing 4 55628 CHCHD4 0.444 + 1.78E-02 1.15E-02 
235791_PM_x_at chromodomain helicase DNA binding protein 1 51526 CHD1 0.353 + 3.34E-02 1.96E-02 
1556988_PM_s_at chromodomain helicase DNA binding protein 1-like 2202 CHD1L 0.877 + 6.29E-03 1.42E-02 
226830_PM_x_at Chromodomain helicase DNA binding protein 2 23302 CHD2 0.402 + 6.95E-03 6.46E-03 
225951_PM_s_at Chromodomain helicase DNA binding protein 2 --- CHD2 0.422 + 4.28E-02 2.27E-02 
213965_PM_s_at chromodomain helicase DNA binding protein 5 11037 CHD5 0.271 + 3.01E-02 3.77E-02 
225031_PM_at chromodomain helicase DNA binding protein 6 55432 CHD6 0.695 + 4.28E-03 1.14E-02 
225026_PM_at chromodomain helicase DNA binding protein 6 134359 CHD6 0.496 + 3.23E-02 2.26E-02 
212616_PM_at chromodomain helicase DNA binding protein 9 10247 CHD9 0.377 + 4.47E-03 4.36E-03 
229954_PM_at choline dehydrogenase --- CHDH 0.915 + 1.37E-02 1.38E-02 
228345_PM_at cysteine-rich hydrophobic domain 1 51714 CHIC1 0.663 + 6.16E-03 2.12E-02 
204193_PM_at choline kinase beta 56681 CHKB 0.309 + 1.12E-02 1.58E-02 
218085_PM_at chromatin modifying protein 5 64420 CHMP5 0.691 + 3.05E-03 3.88E-03 
219356_PM_s_at chromatin modifying protein 5 80777 CHMP5 0.338 + 4.16E-03 1.93E-02 
221675_PM_s_at choline phosphotransferase 1 3431 CHPT1 0.419 + 1.50E-02 1.15E-02 
230364_PM_at choline phosphotransferase 1 440957 CHPT1 0.467 + 4.23E-02 3.43E-02 
209763_PM_at chordin-like 1 79038 CHRDL1 0.599 + 1.96E-02 3.64E-02 
203044_PM_at chondroitin sulfate synthase 1 1073 CHSY1 0.417 + 4.78E-02 4.50E-02 
226736_PM_at 276eparin276i domain containing 1 253782 CHURC1 0.515 + 7.34E-03 5.97E-03 
205008_PM_s_at calcium and integrin binding family member 2 9839 CIB2 0.601 + 8.15E-03 1.34E-02 
221058_PM_s_at chemokine-like factor 2245 CKLF 0.320 + 2.83E-03 2.05E-02 
219161_PM_s_at chemokine-like factor 5885 CKLF 0.430 + 1.22E-02 3.31E-02 
223451_PM_s_at chemokine-like factor 51320 CKLF 0.383 + 1.46E-02 2.36E-02 
201897_PM_s_at CDC28 protein kinase regulatory subunit 1B 3015 CKS1B 0.725 + 7.11E-03 2.79E-03 
212309_PM_at cytoplasmic linker associated protein 2 2962 CLASP2 0.307 + 8.38E-03 8.87E-03 
226274_PM_at chloride channel 5 9706 CLCN5 0.557 + 2.77E-03 1.72E-03 
203950_PM_s_at chloride channel 6 9403 CLCN6 0.290 + 5.51E-03 1.07E-02 
205328_PM_at claudin 10 7347 CLDN10 0.401 + 3.46E-02 4.90E-02 
201769_PM_at clathrin interactor 1 113251 CLINT1 0.474 + 1.37E-02 1.88E-03 
209143_PM_s_at chloride channel, nucleotide-sensitive, 1A 9946 CLNS1A 0.297 + 4.97E-03 2.54E-03 
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204370_PM_at 
CLP1, cleavage and polyadenylation factor I subunit, homolog 
(S. cerevisiae) 
6251 CLP1 0.369 + 5.26E-03 1.45E-02 
227522_PM_at carboxymethylenebutenolidase homolog (Pseudomonas) 9334 CMBL 0.361 + 2.47E-03 1.72E-02 
228283_PM_at COX assembly mitochondrial protein homolog (S. cerevisiae) 55161 CMC1 0.633 + 1.04E-02 1.08E-02 
217870_PM_s_at cytidine monophosphate (UMP-CMP) kinase 1, cytosolic 151613 CMPK1 0.566 + 4.31E-02 3.95E-02 
226702_PM_at cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 25957 CMPK2 0.324 + 2.42E-02 4.60E-02 
224998_PM_at CKLF-like MARVEL transmembrane domain containing 4 221710 CMTM4 0.415 + 3.68E-03 7.83E-04 
227731_PM_at CCHC-type zinc finger, nucleic acid binding protein 80267 CNBP 0.534 + 1.33E-02 2.39E-02 
201653_PM_at cornichon homolog (Drosophila) 1457 CNIH 0.442 + 1.25E-03 1.31E-03 
228306_PM_at cornichon homolog 4 (Drosophila) 253461 CNIH4 0.518 + 1.01E-03 5.14E-04 
228437_PM_at cornichon homolog 4 (Drosophila) 4040 CNIH4 0.467 + 5.24E-03 1.39E-02 
218728_PM_s_at cornichon homolog 4 (Drosophila) 25942 CNIH4 0.397 + 6.67E-03 5.57E-03 
223993_PM_s_at cornichon homolog 4 (Drosophila) 85025 CNIH4 0.291 + 2.82E-02 1.47E-02 
218900_PM_at cyclin M4 26051 CNNM4 0.435 + 3.12E-02 3.92E-02 
217798_PM_at CCR4-NOT transcription complex, subunit 2 55066 CNOT2 0.488 + 1.68E-02 1.81E-02 
222476_PM_at CCR4-NOT transcription complex, subunit 6 8939 CNOT6 0.608 + 1.74E-03 7.79E-03 
227119_PM_at CCR4-NOT transcription complex, subunit 6-like 4661 CNOT6L 0.703 + 1.18E-03 4.38E-03 
225053_PM_at CCR4-NOT transcription complex, subunit 7 54790 CNOT7 0.363 + 2.29E-02 2.95E-03 
213436_PM_at cannabinoid receptor 1 (brain) 6760 CNR1 0.429 + 1.98E-02 2.94E-02 
227202_PM_at Contactin 1 9525 CNTN1 0.537 + 9.48E-03 9.88E-04 
207195_PM_at contactin 6 4297 CNTN6 0.366 + 5.02E-03 1.21E-02 
232388_PM_at contactin associated protein-like 4 374920 CNTNAP4 0.468 + 2.63E-02 9.34E-03 
223450_PM_s_at component of oligomeric golgi complex 3 55197 COG3 0.498 + 1.54E-03 2.70E-03 
212189_PM_s_at component of oligomeric golgi complex 4 5824 COG4 0.603 + 5.62E-05 2.04E-03 
227089_PM_at component of oligomeric golgi complex 5 8502 COG5 0.318 + 9.29E-03 3.24E-02 
219575_PM_s_at 
component of oligomeric golgi complex 8 /// peptide 
deformylase (mitochondrial) 
10221 COG8 /// PDF 0.352 + 2.09E-02 1.51E-02 
204345_PM_at collagen, type XVI, alpha 1 1362 COL16A1 0.534 + 2.21E-02 3.41E-02 
202312_PM_s_at collagen, type I, alpha 1 8554 COL1A1 0.316 + 9.35E-03 1.21E-02 
211980_PM_at collagen, type IV, alpha 1 4144 COL4A1 0.581 + 9.47E-03 3.35E-02 
226277_PM_at 
collagen, type IV, alpha 3 (Goodpasture antigen) binding 
protein 
2483 COL4A3BP 0.338 + 1.05E-02 1.61E-02 
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221729_PM_at collagen, type V, alpha 2 51100 COL5A2 0.791 + 2.78E-02 2.19E-02 
221730_PM_at collagen, type V, alpha 2 7326 COL5A2 0.313 + 4.11E-02 1.84E-02 
226024_PM_at copper metabolism (Murr1) domain containing 1 10527 COMMD1 0.549 + 2.44E-03 1.77E-03 
222637_PM_at COMM domain containing 10 4750 COMMD10 0.462 + 1.36E-02 7.71E-03 
218048_PM_at COMM domain containing 3 54149 COMMD3 0.569 + 5.87E-03 1.31E-02 
225312_PM_at COMM domain containing 6 84630 COMMD6 0.378 + 3.46E-02 2.10E-02 
218351_PM_at COMM domain containing 8 151354 COMMD8 0.764 + 1.86E-03 2.05E-03 
218072_PM_at COMM domain containing 9 361 COMMD9 0.598 + 5.11E-04 1.17E-03 
201359_PM_at coatomer protein complex, subunit beta 1 983 COPB1 0.499 + 1.10E-02 1.17E-02 
201358_PM_s_at coatomer protein complex, subunit beta 1 5987 COPB1 0.441 + 1.50E-02 3.73E-02 
201098_PM_at coatomer protein complex, subunit beta 2 (beta prime) 11321 COPB2 0.408 + 2.75E-02 3.30E-02 
213486_PM_at COPG2 imprinted transcript 1 (non-protein coding) 1006 COPG2IT1 0.343 + 4.77E-02 4.44E-02 
209838_PM_at 
COP9 constitutive photomorphogenic homolog subunit 2 
(Arabidopsis) 
3146 COPS2 0.354 + 1.90E-02 2.54E-02 
202467_PM_s_at 
COP9 constitutive photomorphogenic homolog subunit 2 
(Arabidopsis) 
51072 /// 84661 COPS2 0.290 + 2.02E-02 5.26E-04 
202078_PM_at 
COP9 constitutive photomorphogenic homolog subunit 3 
(Arabidopsis) 
79017 COPS3 0.277 + 4.74E-03 2.75E-02 
218042_PM_at 
COP9 constitutive photomorphogenic homolog subunit 4 
(Arabidopsis) 
91748 COPS4 0.470 + 8.67E-03 4.72E-03 
202141_PM_s_at 
COP9 constitutive photomorphogenic homolog subunit 8 
(Arabidopsis) 
9378 COPS8 0.316 + 1.47E-02 2.20E-02 
219561_PM_at coatomer protein complex, subunit zeta 2 6400 COPZ2 0.277 + 3.37E-02 4.46E-02 
219397_PM_at coenzyme Q10 homolog B (S. cerevisiae) 5903 COQ10B 0.531 + 4.51E-03 1.36E-03 
223515_PM_s_at coenzyme Q3 homolog, methyltransferase (S. cerevisiae) 55284 COQ3 0.395 + 2.37E-02 1.14E-02 
223114_PM_at coenzyme Q5 homolog, methyltransferase (S. cerevisiae) 54069 COQ5 0.330 + 2.90E-02 2.77E-02 
223191_PM_at 
COX16 cytochrome c oxidase assembly homolog (S. 
cerevisiae) 
79728 COX16 0.439 + 6.81E-03 8.76E-03 
1558346_PM_at 
COX17 cytochrome c oxidase assembly homolog (S. 
cerevisiae) 
1454 COX17 0.798 + 4.41E-02 3.96E-02 
203663_PM_s_at cytochrome c oxidase subunit Va 26269 COX5A 0.348 + 2.89E-02 2.26E-02 
202343_PM_x_at cytochrome c oxidase subunit Vb 10580 COX5B 0.315 + 3.26E-02 2.28E-02 
201441_PM_at cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) 9948 COX6B1 0.297 + 1.65E-02 1.78E-02 
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201754_PM_at cytochrome c oxidase subunit Vic 23513 COX6C 0.423 + 2.36E-03 1.49E-03 
201597_PM_at cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 2581 COX7A2 0.760 + 3.84E-04 1.58E-03 
217249_PM_x_at cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 54675 COX7A2 0.457 + 3.07E-02 9.48E-03 
201256_PM_at cytochrome c oxidase subunit VIIa polypeptide 2 like 9378 COX7A2L 0.413 + 3.92E-05 2.62E-04 
202110_PM_at cytochrome c oxidase subunit VIIb 5364 COX7B 0.432 + 1.03E-03 7.96E-04 
217491_PM_x_at cytochrome c oxidase subunit VIIc 6730 COX7C 0.297 + 1.64E-02 2.17E-03 
213846_PM_at cytochrome c oxidase subunit VIIc 6942 COX7C 0.277 + 4.77E-02 1.04E-04 
204662_PM_at CP110 protein 25804 CP110 0.347 + 4.80E-02 7.20E-03 
201941_PM_at carboxypeptidase D 10979 CPD 0.634 + 1.92E-02 6.71E-03 
226939_PM_at cytoplasmic polyadenylation element binding protein 2 6657 CPEB2 0.641 + 2.91E-02 3.01E-03 
202119_PM_s_at copine III 
100294451 /// 
2990 /// 91316 
CPNE3 0.832 + 7.93E-03 1.76E-02 
228365_PM_at copine VIII 55824 CPNE8 0.673 + 8.70E-03 2.63E-02 
225082_PM_at cleavage and polyadenylation specific factor 3, 73kDa 127933 CPSF3 0.303 + 4.52E-03 8.72E-03 
217866_PM_at cleavage and polyadenylation specific factor 7, 59kDa 85476 CPSF7 0.424 + 3.08E-03 3.80E-03 
203633_PM_at carnitine palmitoyltransferase 1A (liver) 10260 CPT1A 0.331 + 2.69E-04 3.09E-03 
209833_PM_at 
CASP2 and RIPK1 domain containing adaptor with death 
domain 
219771 CRADD 0.324 + 1.81E-02 4.66E-02 
222533_PM_at cereblon 23119 CRBN 0.326 + 1.21E-02 2.13E-02 
225572_PM_at cAMP responsive element binding protein 1 386618 CREB1 0.454 + 3.42E-02 2.61E-03 
228177_PM_at CREB binding protein 867 CREBBP 0.645 + 2.38E-02 4.04E-02 
201990_PM_s_at cAMP responsive element binding protein-like 2 813 CREBL2 0.314 + 9.58E-03 4.33E-02 
225594_PM_at CREB/ATF bZIP transcription factor 641372 CREBZF 0.840 + 5.42E-03 1.22E-02 
202979_PM_s_at CREB/ATF bZIP transcription factor 25821 CREBZF 0.647 + 1.52E-02 2.60E-02 
228092_PM_at cAMP responsive element modulator 55274 CREM 0.480 + 1.16E-02 1.52E-02 
218643_PM_s_at cysteine-rich PDZ-binding protein 57697 CRIPT 0.507 + 1.10E-02 4.58E-03 
222702_PM_x_at cysteine-rich PDZ-binding protein 28996 CRIPT 0.441 + 2.24E-02 4.34E-02 
212180_PM_at v-crk sarcoma virus CT10 oncogene homolog (avian)-like 1209 CRKL 0.428 + 7.25E-03 7.41E-03 
223978_PM_s_at cardiolipin synthase 1 65977 CRLS1 0.444 + 1.68E-03 5.39E-03 
218648_PM_at CREB regulated transcription coactivator 3 79152 CRTC3 0.648 + 2.18E-02 2.32E-02 
209674_PM_at cryptochrome 1 (photolyase-like) 56853 CRY1 0.645 + 3.16E-02 6.00E-03 
206778_PM_at 279eparin279ing, beta B2 224 CRYBB2 0.295 + 5.15E-03 1.44E-03 
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205489_PM_at 280eparin280ing, mu 2110 CRYM 0.406 + 4.87E-03 9.48E-03 
226151_PM_x_at 280eparin280ing, zeta (quinone reductase)-like 1 9354 CRYZL1 0.661 + 7.29E-03 2.33E-03 
219767_PM_s_at 280eparin280ing, zeta (quinone reductase)-like 1 2200 CRYZL1 0.528 + 1.96E-02 1.69E-02 
201111_PM_at CSE1 chromosome segregation 1-like (yeast) 8613 CSE1L 0.451 + 1.87E-02 1.28E-02 
240228_PM_at CUB and Sushi multiple domains 3 --- CSMD3 0.756 + 2.00E-02 2.78E-02 
208865_PM_at casein kinase 1, alpha 1 60492 CSNK1A1 0.335 + 8.35E-03 6.41E-03 
227767_PM_at casein kinase 1, gamma 3 51805 CSNK1G3 0.731 + 9.63E-03 7.96E-03 
224922_PM_at casein kinase 2, alpha prime polypeptide 79066 CSNK2A2 0.368 + 4.83E-02 3.96E-02 
227105_PM_at centrosome and spindle pole associated protein 1 --- CSPP1 0.274 + 2.98E-02 2.55E-02 
221260_PM_s_at cysteine-serine-rich nuclear protein 2 2176 CSRNP2 0.422 + 3.20E-02 6.51E-03 
207030_PM_s_at cysteine and glycine-rich protein 2 1209 CSRP2 0.465 + 6.84E-03 2.24E-02 
229666_PM_s_at cleavage stimulation factor, 3’ pre-RNA, subunit 3, 77kDa 158586 CSTF3 0.522 + 1.88E-03 6.45E-03 
201218_PM_at C-terminal binding protein 2 26135 CTBP2 0.304 + 8.43E-03 6.06E-03 
201220_PM_x_at C-terminal binding protein 2 11100 CTBP2 0.594 + 9.98E-03 2.20E-02 
202521_PM_at CCCTC-binding factor (zinc finger protein) 51611 CTCF 0.407 + 4.32E-02 1.51E-02 
203445_PM_s_at 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 2 
55812 CTDSP2 0.352 + 4.16E-02 1.45E-02 
223270_PM_at 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase like 2 
29951 CTDSPL2 0.725 + 1.91E-02 3.54E-02 
202468_PM_s_at catenin (cadherin-associated protein), alpha-like 1 56947 CTNNAL1 0.464 + 4.52E-03 5.92E-03 
209618_PM_at 
catenin (cadherin-associated protein), delta 2 (neural 
plakophilin-related arm-repeat protein) 
84255 CTNND2 0.443 + 4.69E-02 3.75E-02 
222819_PM_at CTP synthase II 730092 CTPS2 0.524 + 9.63E-03 3.11E-02 
202060_PM_at 
Ctr9, Paf1/RNA polymerase II complex component, homolog 
(S. cerevisiae) 
23499 CTR9 0.654 + 2.07E-02 7.14E-03 
214377_PM_s_at chymotrypsin-like 7328 CTRL 0.281 + 2.99E-02 2.87E-02 
201487_PM_at cathepsin C 5528 CTSC 0.356 + 8.10E-03 1.92E-02 
202087_PM_s_at cathepsin L1 
163131 /// 
284323 
CTSL1 0.601 + 4.85E-03 1.42E-02 
232136_PM_s_at cortactin binding protein 2 344405 CTTNBP2 0.425 + 4.65E-02 1.40E-02 
226410_PM_at cytosolic thiouridylase subunit 2 homolog (S. pombe) 57343 CTU2 0.292 + 7.40E-03 1.72E-02 
201370_PM_s_at cullin 3 2976 CUL3 0.645 + 7.46E-03 7.60E-05 
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201424_PM_s_at cullin 4A 8522 CUL4A 0.357 + 6.20E-03 5.08E-03 
203531_PM_at cullin 5 775 CUL5 0.405 + 2.27E-03 1.54E-02 
223067_PM_at 
CWC15 spliceosome-associated protein homolog (S. 
cerevisiae) 
54463 CWC15 0.330 + 3.54E-02 3.06E-02 
232087_PM_at chromosome X open reading frame 23 --- Cxorf23 0.728 + 9.26E-03 1.61E-02 
225216_PM_at Chromosome X open reading frame 39 96459 Cxorf39 0.715 + 9.34E-03 3.19E-03 
214112_PM_s_at 
chromosome X open reading frame 40A /// chromosome X 




0.298 + 6.04E-04 2.60E-03 
219355_PM_at chromosome X open reading frame 57 223 Cxorf57 0.466 + 1.74E-02 4.53E-02 
215726_PM_s_at cytochrome b5 type A (microsomal) 81603 CYB5A 0.490 + 2.28E-04 5.96E-03 
207843_PM_x_at cytochrome b5 type A (microsomal) 6670 CYB5A 0.329 + 1.11E-03 1.67E-02 
201634_PM_s_at cytochrome b5 type B (outer mitochondrial membrane) 23236 CYB5B 0.557 + 2.55E-02 8.80E-03 
224735_PM_at cytochrome b, ascorbate dependent 3 57182 CYBASC3 0.457 + 6.18E-03 1.03E-02 
222453_PM_at cytochrome b reductase 1 5781 CYBRD1 0.538 + 1.80E-02 4.39E-02 
229415_PM_at cytochrome c, somatic 113263 CYCS 0.384 + 3.45E-03 2.14E-02 
208923_PM_at cytoplasmic FMR1 interacting protein 1 56943 CYFIP1 0.908 + 1.39E-02 8.24E-03 
213295_PM_at cylindromatosis (turban tumor syndrome) 6307 CYLD 0.601 + 8.55E-03 2.82E-03 
39582_PM_at cylindromatosis (turban tumor syndrome) --- CYLD 0.315 + 1.94E-02 3.92E-02 
219825_PM_at cytochrome P450, family 26, subfamily B, polypeptide 1 9053 CYP26B1 0.296 + 1.12E-02 3.00E-02 
202314_PM_at cytochrome P450, family 51, subfamily A, polypeptide 1 27249 CYP51A1 0.305 + 9.39E-03 1.61E-02 
220813_PM_at cysteinyl leukotriene receptor 2 23288 CYSLTR2 0.331 + 1.53E-02 3.35E-02 
201278_PM_at 
disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila) 
361 DAB2 1.143 + 2.26E-02 3.94E-02 
228915_PM_at dachshund homolog 1 (Drosophila) 23248 DACH1 0.779 + 3.61E-02 4.84E-02 
200046_PM_at defender against cell death 1 8317 DAD1 0.384 + 7.96E-03 2.37E-02 
205417_PM_s_at dystroglycan 1 (dystrophin-associated glycoprotein 1) 9472 DAG1 0.282 + 1.08E-02 3.56E-02 
211070_PM_x_at 
diazepam binding inhibitor (GABA receptor modulator, acyl-
Coenzyme A binding protein) 
860 DBI 0.303 + 3.47E-02 2.62E-02 
225676_PM_s_at DDB1 and CUL4 associated factor 13 4862 DCAF13 0.543 + 1.12E-02 1.36E-02 
217908_PM_s_at DDB1 and CUL4 associated factor 6 84923 DCAF6 0.522 + 2.58E-02 3.36E-02 
224522_PM_s_at dephospho-CoA kinase domain containing 26258 DCAKD 0.401 + 4.38E-03 1.91E-02 
239446_PM_x_at discoidin, CUB and LCCL domain containing 2 90133 DCBLD2 0.300 + 1.78E-02 2.42E-02 
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238914_PM_at deleted in colorectal carcinoma --- DCC 0.715 + 4.31E-02 1.75E-02 
229800_PM_at Doublecortin-like kinase 1 256714 DCLK1 0.483 + 7.56E-03 2.26E-02 
209804_PM_at DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae) 8545 DCLRE1A 0.305 + 8.69E-04 5.60E-03 
209335_PM_at decorin 84861 DCN 0.293 + 8.73E-03 1.12E-02 
225443_PM_at DCP1 decapping enzyme homolog A (S. cerevisiae) 51523 DCP1A 0.753 + 2.65E-02 1.75E-02 
212919_PM_at DCP2 decapping enzyme homolog (S. cerevisiae) 9734 DCP2 0.788 + 8.75E-03 1.86E-02 
203261_PM_at dynactin 6 10914 DCTN6 0.472 + 6.32E-04 1.36E-03 
218583_PM_s_at 
DCN1, defective in cullin neddylation 1, domain containing 1 
(S. cerevisiae) 
57453 DCUN1D1 0.628 + 1.03E-02 2.69E-03 
212855_PM_at 
DCN1, defective in cullin neddylation 1, domain containing 4 
(S. cerevisiae) 
10046 DCUN1D4 0.264 + 4.05E-03 3.40E-03 
223151_PM_at 
DCN1, defective in cullin neddylation 1, domain containing 5 
(S. cerevisiae) 
57415 DCUN1D5 0.787 + 8.13E-04 1.37E-04 
204850_PM_s_at doublecortin 4646 DCX 0.384 + 2.27E-02 4.73E-02 
209094_PM_at dimethylarginine dimethylaminohydrolase 1 10390 DDAH1 0.378 + 5.78E-03 2.18E-02 
225971_PM_at DDHD domain containing 1 26207 DDHD1 0.383 + 1.35E-02 3.57E-03 
208718_PM_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 51727 DDX17 0.274 + 3.07E-02 3.40E-02 
224654_PM_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 151636 DDX21 0.777 + 1.46E-02 2.89E-02 
228039_PM_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 64432 DDX46 0.500 + 1.93E-02 1.02E-02 
225549_PM_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 93953 DDX6 0.429 + 4.38E-06 9.29E-05 
202447_PM_at 2,4-dienoyl CoA reductase 1, mitochondrial 54778 DECR1 0.439 + 2.07E-03 1.08E-02 
228032_PM_s_at DENN/MADD domain containing 1B 57606 DENND1B 0.364 + 4.14E-02 4.81E-02 
230769_PM_at DENN/MADD domain containing 2C 57495 DENND2C 0.371 + 8.26E-03 1.52E-02 
1554352_PM_s_at DENN/MADD domain containing 4A 8661 DENND4A 0.382 + 1.15E-02 2.26E-02 
226867_PM_at DENN/MADD domain containing 4C 57403 DENND4C 0.683 + 2.76E-02 3.35E-02 
212561_PM_at DENN/MADD domain containing 5A 9057 DENND5A 0.452 + 2.15E-02 1.59E-02 
214027_PM_x_at desmin /// family with sequence similarity 48, member A 3836 
DES /// 
FAM48A 
0.283 + 3.34E-02 3.65E-02 
219641_PM_at de-etiolated homolog 1 (Arabidopsis) 6256 DET1 0.392 + 2.45E-02 7.19E-03 
221887_PM_s_at deafness, autosomal recessive 31 8837 DFNB31 0.296 + 9.53E-03 2.84E-02 
208072_PM_s_at diacylglycerol kinase, delta 130kDa 6472 DGKD 0.406 + 1.70E-02 3.97E-02 
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239093_PM_at dihydrodipicolinate synthase-like, mitochondrial --- DHDPSL 0.291 + 3.99E-02 2.63E-02 
202534_PM_x_at dihydrofolate reductase 51322 DHFR 0.591 + 5.46E-03 1.19E-03 
210788_PM_s_at dehydrogenase/reductase (SDR family) member 7 91942 DHRS7 0.509 + 3.60E-02 1.83E-02 
227094_PM_at dehydrogenase E1 and transketolase domain containing 1 9508 DHTKD1 0.385 + 7.78E-04 1.59E-03 
239772_PM_x_at DEAH (Asp-Glu-Ala-His) box polypeptide 30 --- DHX30 0.417 + 1.39E-03 3.87E-03 
218277_PM_s_at DEAH (Asp-Glu-Ala-His) box polypeptide 40 55553 DHX40 0.392 + 2.97E-02 1.69E-02 
212888_PM_at dicer 1, ribonuclease type III 2218 DICER1 0.534 + 3.07E-02 2.29E-03 
217106_PM_x_at DIM1 dimethyladenosine transferase 1-like (S. cerevisiae) 55646 DIMT1L 0.348 + 8.90E-03 6.18E-03 
204405_PM_x_at DIM1 dimethyladenosine transferase 1-like (S. cerevisiae) 9337 DIMT1L 0.295 + 3.56E-02 4.34E-02 
224872_PM_at DIP2 disco-interacting protein 2 homolog B (Drosophila) 54708 DIP2B 0.408 + 4.28E-02 9.52E-03 
201479_PM_at dyskeratosis 283eparin283in 1, dyskerin 4849 DKC1 0.424 + 1.36E-02 3.42E-03 
213149_PM_at dihydrolipoamide S-acetyltransferase 10393 DLAT 0.289 + 3.76E-02 2.32E-02 
202515_PM_at discs, large homolog 1 (Drosophila) 51374 DLG1 0.489 + 4.24E-02 8.96E-03 
201681_PM_s_at discs, large homolog 5 (Drosophila) 57509 DLG5 0.654 + 4.06E-03 7.61E-03 
235527_PM_at 
discs, large (Drosophila) homolog-associated protein 1 /// 
hypothetical protein LOC284214 
100132832 /// 
100289811 /// 
441259 /// 5379 
/// 5380 /// 5383 
/// 5387 /// 5395 
DLGAP1 /// 
LOC284214 
0.480 + 2.42E-02 7.00E-04 
242138_PM_at distal-less homeobox 1 --- DLX1 0.512 + 3.91E-02 3.80E-02 
230882_PM_at DLX6 antisense RNA (non-protein coding) 280636 DLX6AS 0.354 + 2.28E-02 3.53E-02 
203881_PM_s_at dystrophin 23196 DMD 0.572 + 4.56E-03 9.66E-04 
212820_PM_at Dmx-like 2 4092 DMXL2 0.344 + 9.15E-03 2.14E-02 
220125_PM_at dynein, axonemal, intermediate chain 1 10106 DNAI1 0.413 + 1.67E-02 1.98E-03 
226994_PM_at DnaJ (Hsp40) homolog, subfamily A, member 2 5733 DNAJA2 0.743 + 5.64E-04 3.21E-03 
203810_PM_at DnaJ (Hsp40) homolog, subfamily B, member 4 6727 DNAJB4 0.642 + 3.68E-03 4.86E-03 
218976_PM_at DnaJ (Hsp40) homolog, subfamily C, member 12 114792 DNAJC12 0.843 + 1.64E-03 4.38E-03 
225359_PM_at DnaJ (Hsp40) homolog, subfamily C, member 19 167359 DNAJC19 0.455 + 4.09E-02 2.18E-02 
238337_PM_s_at DnaJ (Hsp40) homolog, subfamily C, member 21 11128 DNAJC21 0.614 + 2.91E-02 1.38E-03 
213853_PM_at DnaJ (Hsp40) homolog, subfamily C, member 24 259230 DNAJC24 0.941 + 2.54E-03 9.44E-04 
227859_PM_at DnaJ (Hsp40) homolog, subfamily C, member 27 1979 DNAJC27 0.356 + 2.15E-02 2.07E-02 
225284_PM_at DnaJ (Hsp40) homolog, subfamily C, member 3 573 DNAJC3 0.292 + 3.69E-02 2.81E-02 
 284 
204720_PM_s_at DnaJ (Hsp40) homolog, subfamily C, member 6 5335 DNAJC6 0.391 + 9.72E-03 5.20E-03 
212491_PM_s_at DnaJ (Hsp40) homolog, subfamily C, member 8 477 DNAJC8 0.566 + 1.11E-02 4.53E-02 
213088_PM_s_at DnaJ (Hsp40) homolog, subfamily C, member 9 1021 DNAJC9 0.456 + 1.47E-02 3.07E-02 
226309_PM_at dynein, axonemal, light chain 1 26747 DNAL1 0.547 + 9.13E-03 1.12E-02 
227081_PM_at dynein, axonemal, light intermediate chain 1 23504 DNALI1 0.316 + 4.16E-03 2.08E-02 
226154_PM_at dynamin 1-like 25800 DNM1L 0.346 + 1.48E-02 8.49E-03 
209839_PM_at dynamin 3 55749 DNM3 0.311 + 2.42E-02 1.73E-02 
213482_PM_at dedicator of cytokinesis 3 6323 DOCK3 0.431 + 3.89E-02 2.95E-02 
225384_PM_at dedicator of cytokinesis 7 57505 DOCK7 0.932 + 4.58E-03 3.60E-03 
223553_PM_s_at docking protein 3 64776 DOK3 0.911 + 2.97E-03 4.56E-03 
231980_PM_at docking protein 6 --- DOK6 0.331 + 7.07E-03 5.26E-03 
213271_PM_s_at dopey family member 1 65018 DOPEY1 0.411 + 3.45E-02 3.51E-02 
40612_PM_at dopey family member 1 339500 DOPEY1 0.272 + 4.42E-02 1.33E-02 
236442_PM_at D4, zinc and double PHD fingers, family 3 --- DPF3 0.695 + 2.08E-03 3.43E-03 
238532_PM_at D4, zinc and double PHD fingers, family 3 5692 DPF3 1.048 + 6.54E-03 7.91E-03 
202673_PM_at 
dolichyl-phosphate mannosyltransferase polypeptide 1, 
catalytic subunit 
8675 DPM1 0.470 + 2.27E-03 3.01E-04 
228598_PM_at dipeptidyl-peptidase 10 4131 DPP10 0.678 + 2.56E-02 1.82E-02 
230158_PM_at dpy-19-like 2 (C. elegans) 22990 DPY19L2 0.353 + 1.98E-02 3.56E-02 
213391_PM_at dpy-19-like 4 (C. elegans) 49855 DPY19L4 0.387 + 1.93E-02 3.30E-02 
224129_PM_s_at dpy-30 homolog (C. elegans) 7546 DPY30 0.399 + 6.72E-03 1.34E-02 
219065_PM_s_at dpy-30 homolog (C. elegans) /// mediator of cell motility 1 284119 
DPY30 /// 
MEMO1 
0.611 + 1.06E-02 6.19E-03 
236055_PM_at DEAQ box RNA-dependent ATPase 1 --- DQX1 0.284 + 1.75E-02 2.22E-02 
209187_PM_at 
down-regulator of transcription 1, TBP-binding (negative 
cofactor 2) 
79444 DR1 0.385 + 1.14E-02 2.25E-03 
206032_PM_at desmocollin 3 1312 DSC3 0.341 + 1.77E-02 3.12E-02 
232059_PM_at Down syndrome cell adhesion molecule like 1 646113 DSCAML1 0.571 + 4.46E-02 4.81E-02 
203635_PM_at Down syndrome critical region gene 3 81554 DSCR3 0.328 + 2.14E-02 3.01E-02 
215016_PM_x_at dystonin 29097 DST 0.429 + 2.33E-02 2.05E-02 
212254_PM_s_at dystonin 9821 DST 0.469 + 2.48E-02 1.18E-02 
205741_PM_s_at dystrobrevin, alpha 9754 DTNA 0.451 + 1.00E-02 7.08E-03 
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244142_PM_at dystrobrevin, alpha --- DTNA 0.368 + 4.52E-02 2.37E-02 
219291_PM_at DTW domain containing 1 23365 DTWD1 0.371 + 7.61E-03 2.51E-03 
225415_PM_at deltex 3-like (Drosophila) 256643 DTX3L 0.501 + 1.97E-03 8.47E-03 
202703_PM_at 
dual specificity phosphatase 11 (RNA/RNP complex 1-
interacting) 
3134 DUSP11 0.687 + 4.91E-03 1.33E-02 
218576_PM_s_at dual specificity phosphatase 12 57711 DUSP12 0.585 + 1.90E-04 6.38E-05 
203367_PM_at dual specificity phosphatase 14 55624 DUSP14 0.504 + 5.48E-03 2.89E-02 
229211_PM_at dual specificity phosphatase 28 85460 DUSP28 0.299 + 1.23E-02 2.24E-03 
216473_PM_x_at 
double homeobox, 4 /// double homeobox, 4-like /// double 








0.541 + 1.43E-03 2.12E-03 
203230_PM_at 285eparin285in, dsh homolog 1 (Drosophila) 11217 /// 445815 DVL1 0.313 + 1.58E-02 1.87E-02 
239733_PM_at DPY30 domain containing 2 284112 DYDC2 0.598 + 1.79E-02 3.11E-02 
219469_PM_at dynein, cytoplasmic 2, heavy chain 1 664 DYNC2H1 0.568 + 2.41E-02 4.20E-02 
203763_PM_at dynein, cytoplasmic 2, light intermediate chain 1 1131 DYNC2LI1 0.691 + 2.03E-02 1.31E-02 
200703_PM_at dynein, light chain, LC8-type 1 1452 DYNLL1 0.351 + 7.48E-03 6.31E-03 
238116_PM_at dynein, light chain, roadblock-type 2 --- DYNLRB2 0.790 + 8.88E-03 4.03E-03 
201999_PM_s_at dynein, light chain, Tctex-type 1 6046 DYNLT1 0.562 + 4.33E-03 1.07E-02 
203303_PM_at dynein, light chain, Tctex-type 3 51501 DYNLT3 0.298 + 1.77E-02 1.21E-02 
209033_PM_s_at 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1A 
79675 DYRK1A 0.454 + 9.14E-03 1.27E-02 
226952_PM_at ELL associated factor 1 120526 EAF1 0.312 + 7.51E-03 2.85E-02 
204274_PM_at estrogen receptor binding site associated, antigen, 9 3930 EBAG9 0.429 + 7.15E-03 1.63E-02 
201323_PM_at EBNA1 binding protein 2 1998 EBNA1BP2 0.461 + 1.05E-02 1.95E-02 
202735_PM_at emopamil binding protein (sterol isomerase) 51231 EBP 0.465 + 4.40E-03 2.08E-02 
218552_PM_at enoyl Coenzyme A hydratase domain containing 2 1128 ECHDC2 0.690 + 8.77E-03 8.50E-03 
219298_PM_at enoyl Coenzyme A hydratase domain containing 3 10625 ECHDC3 0.330 + 7.62E-03 3.55E-02 
206101_PM_at extracellular matrix protein 2, female organ and adipocyte 9908 ECM2 0.835 + 2.70E-02 2.41E-02 
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specific 
218225_PM_at ECSIT homolog (Drosophila) 132789 ECSIT 0.315 + 1.53E-03 1.07E-02 
225885_PM_at early endosome antigen 1 --- EEA1 0.769 + 1.03E-02 1.27E-02 
209572_PM_s_at embryonic ectoderm development 83549 EED 0.583 + 1.07E-03 8.79E-05 
1557120_PM_at Eukaryotic translation elongation factor 1 alpha 1 5445 EEF1A1 0.285 + 3.30E-03 1.71E-04 
200705_PM_s_at eukaryotic translation elongation factor 1 beta 2 598 EEF1B2 0.319 + 1.37E-02 1.93E-03 
214394_PM_x_at 
eukaryotic translation elongation factor 1 delta (guanine 
nucleotide exchange protein) 
3609 EEF1D 0.398 + 2.12E-02 1.06E-02 
204905_PM_s_at eukaryotic translation elongation factor 1 epsilon 1 6416 EEF1E1 0.481 + 6.11E-04 3.61E-03 
225546_PM_at eukaryotic elongation factor-2 kinase 8715 EEF2K 0.342 + 2.92E-03 2.94E-03 
225545_PM_at eukaryotic elongation factor-2 kinase 125488 EEF2K 0.355 + 6.64E-03 2.95E-02 
1558301_PM_a_at EF-hand calcium binding domain 5 1595 EFCAB5 0.286 + 1.35E-02 2.17E-02 
201843_PM_s_at EGF-containing fibulin-like extracellular matrix protein 1 65220 EFEMP1 0.279 + 5.71E-03 1.58E-02 
201842_PM_s_at EGF-containing fibulin-like extracellular matrix protein 1 9045 EFEMP1 0.392 + 3.32E-02 4.89E-02 
212410_PM_at EF-hand domain family, member A1 4683 EFHA1 0.526 + 1.19E-03 5.22E-03 
217992_PM_s_at EF-hand domain family, member D2 123606 EFHD2 0.421 + 6.33E-03 1.36E-03 
202023_PM_at ephrin-A1 667 EFNA1 0.290 + 4.85E-02 2.03E-02 
212149_PM_at EFR3 homolog A (S. cerevisiae) 1977 EFR3A 0.617 + 7.81E-03 8.68E-04 
209826_PM_at 
EGF-like-domain, multiple 8 /// palmitoyl-protein thioesterase 
2 
27248 EGFL8 /// PPT2 0.467 + 4.90E-03 9.04E-03 
219232_PM_s_at egl nine homolog 3 (C. elegans) 7803 EGLN3 0.298 + 5.73E-03 1.22E-02 
212653_PM_s_at EH domain binding protein 1 1185 EHBP1 0.356 + 2.89E-02 4.74E-02 
225461_PM_at euchromatic histone-lysine N-methyltransferase 1 26190 EHMT1 0.308 + 4.63E-02 4.08E-02 
208669_PM_s_at EP300 interacting inhibitor of differentiation 1 9149 EID1 0.332 + 9.70E-03 1.11E-03 
201018_PM_at eukaryotic translation initiation factor 1A, X-linked 23191 EIF1AX 0.373 + 1.50E-02 3.46E-02 
201738_PM_at eukaryotic translation initiation factor 1B 23327 EIF1B 0.370 + 3.61E-02 7.15E-03 
223015_PM_at eukaryotic translation initiation factor 2A, 65kDa 25996 EIF2A 0.332 + 4.20E-02 8.93E-03 
217736_PM_s_at eukaryotic translation initiation factor 2-alpha kinase 1 116228 EIF2AK1 0.556 + 1.56E-02 3.19E-02 
201142_PM_at 
eukaryotic translation initiation factor 2, subunit 1 alpha, 
35kDa 
2887 EIF2S1 0.481 + 2.88E-04 1.85E-04 
208726_PM_s_at eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa 9531 EIF2S2 0.371 + 7.00E-03 3.61E-03 
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200597_PM_at eukaryotic translation initiation factor 3, subunit A 5281 EIF3A 0.413 + 2.58E-03 9.93E-03 
201592_PM_at eukaryotic translation initiation factor 3, subunit H 7321 EIF3H 0.540 + 1.02E-03 2.66E-03 
208985_PM_s_at eukaryotic translation initiation factor 3, subunit J 51409 EIF3J 0.377 + 2.04E-02 1.01E-02 
217719_PM_at eukaryotic translation initiation factor 3, subunit L 339287 EIF3L 0.421 + 2.86E-02 2.60E-02 
202231_PM_at eukaryotic translation initiation factor 3, subunit M 2002 /// 652030 EIF3M 0.582 + 2.66E-05 3.54E-04 
202232_PM_s_at eukaryotic translation initiation factor 3, subunit M 9568 EIF3M 0.624 + 6.80E-03 1.55E-03 
201303_PM_at eukaryotic translation initiation factor 4A, isoform 3 274 EIF4A3 0.383 + 2.34E-02 2.83E-02 
201437_PM_s_at eukaryotic translation initiation factor 4E 6624 EIF4E 0.667 + 1.16E-03 2.75E-03 
201436_PM_at eukaryotic translation initiation factor 4E 2969 EIF4E 0.888 + 2.51E-03 5.61E-03 
213571_PM_s_at eukaryotic translation initiation factor 4E family member 2 23190 EIF4E2 0.371 + 9.23E-03 2.81E-02 
225941_PM_at eukaryotic translation initiation factor 4E family member 3 63947 /// 728656 EIF4E3 0.617 + 2.77E-03 5.88E-03 
225939_PM_at eukaryotic translation initiation factor 4E family member 3 6638 EIF4E3 0.587 + 6.08E-03 1.10E-02 
224653_PM_at eukaryotic translation initiation factor 4E binding protein 2 4155 EIF4EBP2 0.417 + 2.04E-02 1.80E-02 
208706_PM_s_at eukaryotic translation initiation factor 5 10927 EIF5 0.342 + 3.38E-02 1.01E-02 
201726_PM_at 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R) 
204851 ELAVL1 0.635 + 1.88E-02 2.39E-02 
244660_PM_at 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R) 
--- ELAVL1 0.704 + 2.31E-02 4.47E-02 
210361_PM_s_at E74-like factor 2 (ets domain transcription factor) 55814 ELF2 0.393 + 1.32E-04 2.39E-04 
203822_PM_s_at E74-like factor 2 (ets domain transcription factor) 8661 ELF2 0.498 + 2.64E-02 4.67E-02 
229581_PM_at 
extracellular leucine-rich repeat and fibronectin type III 
domain containing 1 
4093 ELFN1 0.284 + 3.61E-02 2.83E-02 
55692_PM_at engulfment and cell motility 2 --- ELMO2 0.400 + 3.81E-02 1.19E-02 
208788_PM_at 
ELOVL family member 5, elongation of long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3-like, yeast) 
9978 ELOVL5 0.384 + 3.60E-02 1.63E-02 
227180_PM_at 
ELOVL family member 7, elongation of long chain fatty acids 
(yeast) 
51304 ELOVL7 0.735 + 7.81E-03 1.13E-02 
234464_PM_s_at essential meiotic endonuclease 1 homolog 1 (S. pombe) 51231 EME1 0.349 + 1.90E-04 1.18E-03 
233894_PM_x_at EMI domain containing 2 --- EMID2 0.291 + 2.32E-02 2.32E-02 
225079_PM_at epithelial membrane protein 2 5494 EMP2 0.493 + 4.15E-03 2.95E-02 
221950_PM_at empty spiracles homeobox 2 51552 EMX2 0.573 + 9.26E-04 6.60E-03 
232531_PM_at EMX2 opposite strand (non-protein coding) 7707 EMX2OS 0.716 + 4.05E-03 1.89E-02 
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228310_PM_at enabled homolog (Drosophila) 161424 ENAH 0.355 + 4.24E-02 3.90E-02 
217956_PM_s_at enolase-phosphatase 1 6542 ENOPH1 0.598 + 5.76E-03 1.38E-02 
204844_PM_at glutamyl aminopeptidase (aminopeptidase A) 2744 ENPEP 0.318 + 5.90E-04 7.90E-04 
227803_PM_at 
ectonucleotide pyrophosphatase/phosphodiesterase 5 
(putative function) 
84319 ENPP5 0.426 + 8.03E-03 1.27E-02 
221486_PM_at endosulfine alpha 1825 ENSA 0.359 + 1.55E-03 6.11E-03 
204076_PM_at ectonucleoside triphosphate diphosphohydrolase 4 55611 ENTPD4 0.351 + 7.73E-03 1.27E-03 
218482_PM_at enhancer of yellow 2 homolog (Drosophila) 131474 ENY2 0.699 + 1.70E-03 6.18E-03 
226776_PM_at enhancer of yellow 2 homolog (Drosophila) 6272 ENY2 0.263 + 2.19E-03 3.30E-03 
225051_PM_at 
erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-
linked) 
9204 EPB41 0.667 + 6.89E-03 1.36E-02 
225855_PM_at erythrocyte membrane protein band 4.1 like 5 388403 EPB41L5 0.641 + 3.18E-03 1.34E-02 
225417_PM_at enhancer of polycomb homolog 1 (Drosophila) 115399 EPC1 0.584 + 7.16E-04 1.53E-03 
225838_PM_at enhancer of polycomb homolog 2 (Drosophila) --- EPC2 0.434 + 2.13E-02 1.22E-02 
230425_PM_at EPH receptor B1 658 EPHB1 0.936 + 6.32E-03 1.44E-02 
204600_PM_at EPH receptor B3 8204 EPHB3 0.367 + 9.64E-03 2.11E-02 
227847_PM_at EPM2A (laforin) interacting protein 1 3998 EPM2AIP1 0.474 + 2.04E-02 3.28E-02 
200843_PM_s_at glutamyl-prolyl-tRNA synthetase 7881 EPRS 0.471 + 1.69E-02 2.88E-02 
217941_PM_s_at erbb2 interacting protein 95681 ERBB2IP 0.409 + 1.84E-03 2.67E-06 
222473_PM_s_at erbb2 interacting protein 10228 ERBB2IP 0.330 + 1.93E-03 1.02E-03 
214053_PM_at 
v-erb-a erythroblastic leukemia viral oncogene homolog 4 
(avian) 
23512 /// 440423 ERBB4 0.617 + 1.77E-02 1.67E-02 
228131_PM_at 
excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (includes overlapping antisense 
sequence) 
54764 ERCC1 0.360 + 6.05E-03 1.40E-02 
218135_PM_at ERGIC and golgi 2 84153 ERGIC2 0.461 + 1.35E-02 2.05E-02 
226416_PM_at exoribonuclease 1 4185 ERI1 0.495 + 1.36E-02 1.60E-02 
213365_PM_at exoribonuclease 2 54861 ERI2 0.759 + 2.94E-03 8.27E-03 
227017_PM_at glutamate-rich 1 10690 ERICH1 0.367 + 1.02E-02 7.40E-03 
224628_PM_at endoplasmic reticulum lectin 1 22834 ERLEC1 0.313 + 3.35E-02 3.47E-02 
221543_PM_s_at ER lipid raft associated 2 781 ERLIN2 0.949 + 7.71E-03 5.13E-03 
218342_PM_s_at endoplasmic reticulum metallopeptidase 1 152100 ERMP1 0.359 + 2.27E-02 3.71E-02 
208959_PM_s_at endoplasmic reticulum protein 44 51306 ERP44 0.609 + 4.95E-04 8.48E-04 
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226866_PM_at establishment of cohesion 1 homolog 1 (S. cerevisiae) 23211 ESCO1 0.739 + 4.68E-03 6.40E-03 
209009_PM_at esterase D/formylglutathione hydrolase 10352 ESD 0.406 + 1.96E-03 1.16E-02 
215096_PM_s_at esterase D/formylglutathione hydrolase 56521 ESD 0.508 + 1.46E-02 1.06E-02 
201931_PM_at electron-transfer-flavoprotein, alpha polypeptide 113251 ETFA 0.410 + 5.83E-03 8.44E-03 
33494_PM_at electron-transferring-flavoprotein dehydrogenase --- ETFDH 0.829 + 7.94E-03 1.60E-02 
205530_PM_at electron-transferring-flavoprotein dehydrogenase 942 ETFDH 0.345 + 2.13E-02 3.56E-02 
225290_PM_at ethanolamine kinase 1 55036 ETNK1 0.513 + 3.44E-02 1.11E-02 
224833_PM_at v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 140467 ETS1 0.850 + 5.77E-03 9.67E-03 
226259_PM_at exocyst complex component 6 11080 EXOC6 0.575 + 1.70E-02 9.25E-03 
227916_PM_x_at exosome component 3 201595 EXOSC3 0.407 + 3.45E-02 3.53E-02 
215136_PM_s_at exosome component 8 54433 EXOSC8 0.599 + 5.09E-03 1.84E-02 
205061_PM_s_at exosome component 9 22911 EXOSC9 0.454 + 4.73E-03 3.58E-03 
214608_PM_s_at eyes absent homolog 1 (Drosophila) 8303 EYA1 0.617 + 1.88E-03 1.28E-02 
226170_PM_at eyes absent homolog 3 (Drosophila) 5906 EYA3 0.360 + 1.58E-02 9.13E-03 
203358_PM_s_at enhancer of zeste homolog 2 (Drosophila) 404734 /// 54882 EZH2 0.293 + 2.30E-02 3.33E-02 
223000_PM_s_at F11 receptor 23609 F11R 0.580 + 7.70E-03 8.12E-03 
205756_PM_s_at coagulation factor VIII, procoagulant component 4915 F8 0.572 + 3.18E-02 1.43E-02 
202345_PM_s_at fatty acid binding protein 5 (psoriasis-associated) 4718 FABP5 0.631 + 1.91E-03 5.51E-03 
205030_PM_at fatty acid binding protein 7, brain 6905 FABP7 0.532 + 1.46E-03 5.58E-03 
220643_PM_s_at Fas apoptotic inhibitory molecule 5134 FAIM 0.368 + 2.61E-02 3.98E-02 
225208_PM_s_at family with sequence similarity 103, member A1 152137 FAM103A1 0.735 + 2.32E-03 1.07E-03 
225210_PM_s_at family with sequence similarity 103, member A1 113510 FAM103A1 0.742 + 5.94E-03 3.43E-03 
225319_PM_s_at family with sequence similarity 104, member A 112936 FAM104A 0.960 + 6.15E-03 2.33E-02 
218248_PM_at family with sequence similarity 111, member A 51123 FAM111A 0.304 + 2.32E-03 7.15E-03 
222682_PM_s_at family with sequence similarity 114, member A2 402055 FAM114A2 0.402 + 9.92E-03 1.19E-02 
218588_PM_s_at family with sequence similarity 114, member A2 83992 FAM114A2 0.763 + 3.86E-02 1.77E-02 
226965_PM_at family with sequence similarity 116, member A 317662 FAM116A 0.344 + 9.40E-04 2.22E-03 
226431_PM_at family with sequence similarity 117, member B 10284 FAM117B 0.644 + 3.45E-03 7.80E-03 
229512_PM_at family with sequence similarity 120C --- FAM120C 0.745 + 4.13E-02 4.04E-02 
222673_PM_x_at family with sequence similarity 122B 657 FAM122B 0.590 + 8.55E-03 1.97E-02 
225361_PM_x_at family with sequence similarity 122B 6687 FAM122B 0.574 + 3.09E-02 4.86E-02 
230067_PM_at Family with sequence similarity 124A 54557 FAM124A 0.613 + 3.97E-02 3.79E-02 
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227239_PM_at family with sequence similarity 126, member A 51318 FAM126A 0.589 + 1.62E-02 4.33E-02 
231131_PM_at family with sequence similarity 133, member A 84340 FAM133A 0.569 + 2.15E-02 3.02E-02 
226332_PM_at family with sequence similarity 133, member B 1605 FAM133B 0.544 + 3.46E-03 8.05E-03 
218532_PM_s_at family with sequence similarity 134, member B 83700 FAM134B 0.444 + 1.25E-03 2.24E-03 
223497_PM_at family with sequence similarity 135, member A 51397 FAM135A 0.647 + 1.11E-02 3.05E-03 
217047_PM_s_at family with sequence similarity 13, member A 5150 FAM13A 0.490 + 3.57E-02 2.51E-02 
218518_PM_at family with sequence similarity 13, member B 118672 FAM13B 0.456 + 4.04E-02 1.66E-02 
213896_PM_x_at family with sequence similarity 149, member B1 1737 FAM149B1 0.344 + 2.65E-03 1.89E-02 
241808_PM_at family with sequence similarity 164, member A --- FAM164A 0.337 + 1.23E-02 4.96E-03 
226614_PM_s_at family with sequence similarity 167, member A 361 FAM167A 0.415 + 2.51E-02 2.99E-02 
36612_PM_at family with sequence similarity 168, member A --- FAM168A 0.416 + 1.49E-02 2.45E-02 
212017_PM_at family with sequence similarity 168, member B 2058 FAM168B 0.283 + 2.17E-02 5.63E-03 
227370_PM_at family with sequence similarity 171, member B 149986 FAM171B 0.287 + 1.79E-02 1.11E-03 
226521_PM_s_at family with sequence similarity 175, member A 1501 FAM175A 0.278 + 3.62E-02 4.60E-02 
212837_PM_at family with sequence similarity 175, member B 7091 FAM175B 0.519 + 4.00E-02 1.32E-02 
227029_PM_at family with sequence similarity 177, member A1 8992 FAM177A1 0.618 + 9.24E-03 3.25E-03 
203482_PM_at family with sequence similarity 178, member A 22854 FAM178A 0.538 + 8.73E-03 8.38E-03 
213304_PM_at family with sequence similarity 179, member B 30851 FAM179B 0.310 + 1.07E-02 5.00E-03 
231430_PM_at family with sequence similarity 181, member B 57718 FAM181B 0.401 + 1.50E-02 1.19E-02 
1558523_PM_at family with sequence similarity 184, member A 4147 FAM184A 0.593 + 1.36E-02 1.17E-02 
218446_PM_s_at family with sequence similarity 18, member B 84324 FAM18B 0.449 + 9.81E-03 2.15E-02 
241399_PM_at 
family with sequence similarity 19 (chemokine (C-C motif)-
like), member A2 
26091 FAM19A2 0.509 + 1.03E-02 3.19E-02 
202916_PM_s_at family with sequence similarity 20, member B 5522 FAM20B 0.301 + 1.03E-02 1.91E-02 
234414_PM_at 
family with sequence similarity 22, member A /// family with 
sequence similarity 22, member B /// family with sequence 







0.635 + 2.39E-03 1.47E-02 
234695_PM_x_at family with sequence similarity 22, member B --- FAM22B 0.368 + 5.05E-03 2.52E-02 
224824_PM_at family with sequence similarity 36, member A 57589 FAM36A 0.581 + 5.60E-03 7.40E-03 
240062_PM_at family with sequence similarity 3, member C 283713 FAM3C 0.344 + 1.51E-02 1.81E-02 
226330_PM_s_at family with sequence similarity 48, member A 5203 FAM48A 0.784 + 2.15E-02 3.55E-03 
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230276_PM_at family with sequence similarity 49, member A 80205 FAM49A 0.300 + 3.51E-02 1.56E-02 
218023_PM_s_at family with sequence similarity 53, member C 57669 FAM53C 0.363 + 1.00E-02 1.54E-02 
217562_PM_at family with sequence similarity 5, member C 80829 FAM5C 0.680 + 1.72E-02 1.24E-02 
220147_PM_s_at family with sequence similarity 60, member A 27095 FAM60A 0.759 + 2.51E-02 3.16E-02 
213689_PM_x_at family with sequence similarity 69, member A 51592 FAM69A 0.394 + 2.02E-02 4.71E-03 
216044_PM_x_at family with sequence similarity 69, member A 80204 FAM69A 0.329 + 2.50E-02 1.43E-02 
229645_PM_at family with sequence similarity 69, member C 114787 FAM69C 0.276 + 2.05E-02 2.24E-02 
225834_PM_at 
family with sequence similarity 72, member A /// family with 
sequence similarity 72, member B /// family with sequence 





0.434 + 1.56E-02 1.80E-02 
235125_PM_x_at family with sequence similarity 73, member A 8301 FAM73A 0.550 + 2.08E-04 1.38E-03 
228604_PM_at family with sequence similarity 76, member A 342371 FAM76A 0.653 + 5.63E-03 1.39E-02 
226753_PM_at family with sequence similarity 76, member B 3987 FAM76B 0.749 + 1.06E-02 1.74E-02 
225864_PM_at family with sequence similarity 84, member B --- FAM84B 0.708 + 2.72E-02 2.01E-03 
226448_PM_at family with sequence similarity 89, member A 128 FAM89A 0.506 + 6.88E-03 1.93E-02 
203420_PM_at family with sequence similarity 8, member A1 55593 FAM8A1 0.440 + 1.01E-02 8.84E-03 
228011_PM_at family with sequence similarity 92, member A1 382 FAM92A1 0.456 + 1.92E-03 8.24E-03 
235391_PM_at family with sequence similarity 92, member A1 284244 FAM92A1 0.309 + 3.72E-02 3.79E-03 
224779_PM_s_at family with sequence similarity 96, member A 80821 FAM96A 0.540 + 1.87E-02 2.30E-02 
225086_PM_at Family with sequence similarity 98, member B 90390 FAM98B 0.466 + 3.76E-03 2.12E-02 
205189_PM_s_at Fanconi anemia, complementation group C 4329 FANCC 0.310 + 4.54E-02 4.05E-02 
234733_PM_s_at Fanconi anemia, complementation group M --- FANCM 0.531 + 4.49E-02 3.52E-02 
227996_PM_at 
FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 
(chondrocyte-derived) 
647087 FARP1 0.870 + 1.63E-02 8.23E-03 
204282_PM_s_at phenylalanyl-tRNA synthetase 2, mitochondrial 201725 /// 54543 FARS2 0.486 + 3.49E-04 4.47E-03 
219002_PM_at FAST kinase domains 1 9652 FASTKD1 0.315 + 2.44E-02 3.37E-02 
201579_PM_at FAT tumor suppressor homolog 1 (Drosophila) 5682 FAT1 0.422 + 4.08E-02 2.41E-02 
225258_PM_at filamin binding LIM protein 1 2043 FBLIM1 0.282 + 1.94E-03 1.72E-02 
202766_PM_s_at fibrillin 1 56997 FBN1 0.910 + 7.86E-03 1.34E-02 
222119_PM_s_at F-box protein 11 23360 FBXO11 0.427 + 1.53E-02 2.50E-02 
231472_PM_at F-box protein 15 730200 FBXO15 0.452 + 3.23E-02 2.26E-02 
214891_PM_at F-box protein 21 55596 FBXO21 0.298 + 4.69E-02 4.31E-02 
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225736_PM_at F-box protein 22 157753 FBXO22 0.542 + 1.07E-03 2.45E-03 
225737_PM_s_at F-box protein 22 122773 FBXO22 0.432 + 2.21E-02 3.85E-02 
202271_PM_at F-box protein 28 7763 FBXO28 0.742 + 2.11E-02 2.77E-02 
218432_PM_at F-box protein 3 92482 FBXO3 0.310 + 3.66E-02 3.72E-02 
226541_PM_at F-box protein 30 23169 FBXO30 0.323 + 1.64E-03 1.25E-02 
227521_PM_at F-box protein 33 103910 FBXO33 0.769 + 4.70E-03 1.66E-03 
224369_PM_s_at F-box protein 38 401397 FBXO38 0.574 + 2.02E-02 2.53E-02 
47773_PM_at F-box protein 42 --- FBXO42 0.346 + 3.82E-02 2.70E-02 
223240_PM_at F-box protein 8 80235 FBXO8 0.294 + 1.16E-02 1.84E-02 
1554806_PM_a_at F-box protein 8 5660 FBXO8 0.668 + 3.06E-02 2.94E-02 
212987_PM_at F-box protein 9 51412 FBXO9 0.416 + 1.96E-02 2.39E-02 
235195_PM_at F-box and WD repeat domain containing 2 7779 FBXW2 0.691 + 2.37E-02 4.93E-02 
214511_PM_x_at Fc fragment of IgG, high affinity Ib, receptor (CD64) 28972 FCGR1B 0.278 + 2.47E-02 7.36E-03 
210889_PM_s_at Fc fragment of IgG, low affinity Iib, receptor (CD32) 151126 FCGR2B 0.266 + 1.98E-03 1.81E-03 
228220_PM_at FCH domain only 2 --- FCHO2 0.649 + 1.11E-02 1.34E-02 
203115_PM_at ferrochelatase (protoporphyria) 57231 FECH 0.411 + 3.94E-03 2.32E-02 
212367_PM_at fem-1 homolog b (C. elegans) 2764 FEM1B 0.273 + 1.76E-02 1.66E-02 
233353_PM_at fer-1-like 5 (C. elegans) 1994 FER1L5 0.377 + 1.01E-02 2.64E-02 
1553906_PM_s_at FYVE, RhoGEF and PH domain containing 2 152503 FGD2 1.006 + 2.38E-03 1.24E-02 
230231_PM_at fibroblast growth factor 14 257000 FGF14 0.845 + 5.37E-03 1.11E-02 
204379_PM_s_at fibroblast growth factor receptor 3 57862 FGFR3 0.415 + 1.85E-02 3.16E-02 
201540_PM_at four and a half LIM domains 1 11309 FHL1 0.323 + 4.17E-02 3.11E-02 
202949_PM_s_at four and a half LIM domains 2 56996 FHL2 0.353 + 2.47E-03 2.03E-02 
218980_PM_at formin homology 2 domain containing 3 79842 FHOD3 0.345 + 4.48E-02 7.25E-03 
226769_PM_at fin bud initiation factor homolog (zebrafish) 23294 FIBIN 0.353 + 1.55E-02 1.89E-02 
203656_PM_at FIG4 homolog (S. cerevisiae) 55353 FIG4 0.485 + 3.97E-02 4.38E-02 
218003_PM_s_at FK506 binding protein 3, 25kDa 221895 FKBP3 0.414 + 1.35E-03 1.07E-03 
224840_PM_at FK506 binding protein 5 4084 FKBP5 0.576 + 3.69E-03 2.92E-02 
224002_PM_s_at FK506 binding protein 7 81571 FKBP7 0.471 + 2.91E-03 2.61E-03 
205283_PM_at fukutin 1917 FKTN 0.590 + 2.12E-02 4.42E-02 
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204236_PM_at Friend leukemia virus integration 1 9878 FLI1 0.340 + 8.81E-04 3.98E-03 
229623_PM_at Hypothetical LOC441027 162073 FLJ12993 0.745 + 3.38E-02 1.08E-02 
1553292_PM_s_at uncharacterized serine/threonine-protein kinase SgK494 5825 FLJ25006 0.426 + 3.03E-02 8.71E-03 
243309_PM_at hypothetical LOC145788 --- FLJ27352 0.608 + 2.39E-02 1.34E-02 
1553446_PM_at hypothetical protein FLJ37396 30819 FLJ37396 0.295 + 6.73E-03 2.22E-02 
227298_PM_at hypothetical gene supported by AK095117 79078 FLJ37798 0.368 + 1.05E-02 4.71E-02 
229914_PM_at FLJ38717 protein 153572 FLJ38717 0.519 + 1.61E-02 3.66E-02 
227717_PM_at FLJ41603 protein 79794 FLJ41603 0.279 + 1.38E-02 2.18E-02 
229014_PM_at hypothetical LOC441094 64376 FLJ42709 0.605 + 2.62E-03 2.07E-03 
236360_PM_at hypothetical LOC440556 --- FLJ42875 0.265 + 1.37E-02 3.95E-03 
236902_PM_at hypothetical LOC646113 23143 FLJ43390 0.676 + 1.82E-02 1.81E-02 
229246_PM_at hypothetical LOC645460 10294 FLJ44342 0.597 + 1.77E-03 1.34E-03 
226419_PM_s_at hypothetical LOC645460 2260 FLJ44342 0.640 + 6.80E-03 7.12E-03 
230404_PM_at glutaredoxin-like protein YDR286C homolog 401261 FLJ44606 0.501 + 1.44E-03 7.00E-03 
204359_PM_at fibronectin leucine rich transmembrane protein 2 2180 FLRT2 0.420 + 4.29E-02 3.10E-02 
226498_PM_at 
fms-related tyrosine kinase 1 (vascular endothelial growth 
factor/vascular permeability factor receptor) 
9044 FLT1 0.606 + 5.29E-03 3.09E-03 
222033_PM_s_at 
fms-related tyrosine kinase 1 (vascular endothelial growth 
factor/vascular permeability factor receptor) 
4502 FLT1 0.922 + 6.31E-03 1.56E-02 
206674_PM_at fms-related tyrosine kinase 3 361 FLT3 0.354 + 3.47E-02 3.90E-02 
223618_PM_at formin 2 54926 FMN2 0.376 + 1.16E-02 2.30E-02 
1555471_PM_a_at formin 2 7078 FMN2 0.439 + 1.73E-02 2.65E-02 
215245_PM_x_at fragile X mental retardation 1 54968 FMR1 0.933 + 7.19E-04 2.29E-03 
203689_PM_s_at fragile X mental retardation 1 253559 FMR1 0.558 + 6.06E-03 3.07E-02 
211719_PM_x_at fibronectin 1 57605 FN1 0.991 + 1.26E-02 1.56E-02 
216442_PM_x_at fibronectin 1 80757 FN1 0.928 + 1.65E-02 2.98E-02 
215017_PM_s_at formin binding protein 1-like 56925 FNBP1L 0.752 + 1.42E-02 2.88E-03 
212232_PM_at formin binding protein 4 8099 FNBP4 0.846 + 2.31E-02 9.23E-03 
225032_PM_at fibronectin type III domain containing 3B 56647 FNDC3B 0.785 + 1.28E-03 1.20E-02 
228768_PM_at folliculin interacting protein 1 84376 FNIP1 0.581 + 2.00E-02 2.98E-02 
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219112_PM_at 
folliculin interacting protein 1 /// Rap guanine nucleotide 




0.447 + 2.24E-02 1.92E-02 
206015_PM_s_at forkhead box J3 8237 FOXJ3 0.304 + 9.57E-03 3.85E-02 
226711_PM_at forkhead box N2 115207 FOXN2 0.558 + 1.11E-02 6.72E-03 
202724_PM_s_at forkhead box O1 25861 FOXO1 0.407 + 3.57E-02 3.10E-02 
224891_PM_at forkhead box O3 84085 FOXO3 0.477 + 3.48E-03 5.42E-03 
221333_PM_at forkhead box P3 9912 FOXP3 0.430 + 3.17E-04 6.37E-03 
227475_PM_at forkhead box Q1 619426 FOXQ1 0.425 + 1.25E-02 2.77E-02 
226145_PM_s_at Fraser syndrome 1 1362 FRAS1 0.742 + 2.36E-02 2.04E-02 
219889_PM_at frequently rearranged in advanced T-cell lymphomas 22836 FRAT1 0.374 + 9.54E-03 7.93E-03 
204145_PM_at FSHD region gene 1 1340 FRG1 0.372 + 1.61E-02 3.56E-02 
225163_PM_at FERM domain containing 4A 280636 FRMD4A 0.613 + 1.37E-02 2.17E-02 
230831_PM_at FERM domain containing 5 285987 FRMD5 0.758 + 3.90E-02 1.78E-03 
225464_PM_at FERM domain containing 6 28962 FRMD6 0.541 + 3.78E-03 8.38E-03 
225481_PM_at FERM domain containing 6 137392 FRMD6 0.601 + 1.01E-02 1.75E-02 
226045_PM_at fibroblast growth factor receptor substrate 2 8125 FRS2 0.783 + 2.53E-02 1.19E-02 
212548_PM_s_at FRY-like 687 FRYL 0.395 + 3.36E-02 6.21E-03 
203697_PM_at frizzled-related protein 30818 FRZB 0.508 + 2.02E-02 3.45E-02 
230904_PM_at fibronectin type III and SPRY domain containing 1-like 137970 FSD1L 0.730 + 1.01E-02 6.83E-03 
232010_PM_at follistatin-like 5 283401 FSTL5 0.837 + 9.40E-03 2.45E-02 
214211_PM_at ferritin, heavy polypeptide 1 81931 FTH1 0.466 + 4.46E-03 2.17E-02 
205324_PM_s_at FtsJ homolog 1 (E. coli) 3422 FTSJ1 0.399 + 6.31E-03 9.25E-03 
212847_PM_at Far upstream element (FUSE) binding protein 1 10518 FUBP1 0.536 + 3.61E-02 2.24E-02 
212824_PM_at far upstream element (FUSE) binding protein 3 9140 FUBP3 0.514 + 6.02E-03 9.86E-03 
235346_PM_at FUN14 domain containing 1 --- FUNDC1 0.932 + 3.29E-04 2.69E-03 
223042_PM_s_at FUN14 domain containing 2 80135 FUNDC2 0.339 + 1.02E-02 1.11E-02 
225348_PM_at FUS interacting protein (serine/arginine-rich) 1 9120 FUSIP1 0.620 + 3.43E-02 1.94E-02 
214046_PM_at fucosyltransferase 9 (alpha (1,3) fucosyltransferase) 83941 FUT9 0.686 + 4.24E-03 7.79E-04 
205674_PM_x_at FXYD domain containing ion transport regulator 2 11163 /// 440672 FXYD2 0.318 + 9.88E-04 4.18E-03 
224325_PM_at frizzled homolog 8 (Drosophila) 80829 FZD8 0.646 + 3.96E-03 6.87E-03 
208841_PM_s_at GTPase activating protein (SH3 domain) binding protein 2 27236 G3BP2 0.422 + 2.07E-02 1.70E-02 
44654_PM_at glucose 6 phosphatase, catalytic, 3 --- G6PC3 0.360 + 1.56E-02 2.69E-02 
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229114_PM_at GRB2-associated binding protein 1 154791 GAB1 0.750 + 3.74E-02 9.67E-03 
227690_PM_at gamma-aminobutyric acid (GABA) A receptor, beta 3 51201 GABRB3 0.406 + 3.00E-02 8.31E-03 
1568612_PM_at gamma-aminobutyric acid (GABA) A receptor, gamma 2 4712 GABRG2 0.280 + 2.29E-02 1.49E-02 
238123_PM_at gamma-aminobutyric acid (GABA) receptor, theta 158947 GABRQ 0.438 + 1.43E-02 1.03E-02 
207574_PM_s_at growth arrest and DNA-damage-inducible, beta 23041 GADD45B 0.497 + 2.86E-02 1.65E-02 
203397_PM_s_at 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) 
29989 /// 29991 GALNT3 0.347 + 8.56E-03 1.41E-02 
219110_PM_at GAR1 ribonucleoprotein homolog (yeast) 378938 GAR1 0.336 + 1.36E-02 2.90E-02 
213049_PM_at GTPase activating Rap/RanGAP domain-like 1 1415 GARNL1 0.517 + 4.02E-02 1.08E-02 
223604_PM_at GTPase activating Rap/RanGAP domain-like 3 79896 GARNL3 0.441 + 6.59E-03 8.14E-03 
213280_PM_at GTPase activating Rap/RanGAP domain-like 4 23576 GARNL4 0.311 + 1.87E-02 2.35E-02 
31874_PM_at growth arrest-specific 2 like 1 --- GAS2L1 0.587 + 8.70E-03 2.18E-02 
209729_PM_at growth arrest-specific 2 like 1 51661 GAS2L1 0.308 + 2.22E-02 6.31E-03 
228238_PM_at growth arrest-specific 5 (non-protein coding) 493753 GAS5 0.711 + 1.03E-03 9.25E-03 
224841_PM_x_at growth arrest-specific 5 (non-protein coding) 57679 GAS5 0.278 + 3.14E-02 1.02E-02 
213018_PM_at GATA zinc finger domain containing 1 9211 GATAD1 0.663 + 1.48E-02 2.91E-02 
203178_PM_at 
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
57223 GATM 0.447 + 3.73E-02 1.31E-02 
201816_PM_s_at glioblastoma amplified sequence 8622 GBAS 0.428 + 1.26E-02 1.66E-02 
202748_PM_at guanylate binding protein 2, interferon-inducible 26010 GBP2 0.284 + 4.37E-03 1.55E-03 
202832_PM_at GRIP and coiled-coil domain containing 2 51300 GCC2 0.499 + 1.75E-02 1.74E-02 
203925_PM_at glutamate-cysteine ligase, modifier subunit 6434 GCLM 0.375 + 2.43E-02 1.20E-02 
212139_PM_at GCN1 general control of amino-acid synthesis 1-like 1 (yeast) 156 GCN1L1 0.523 + 5.36E-03 1.08E-02 
226269_PM_at ganglioside-induced differentiation-associated protein 1 5728 GDAP1 0.380 + 1.95E-02 1.60E-02 
219473_PM_at ganglioside induced differentiation associated protein 2 5552 GDAP2 0.327 + 1.75E-03 2.01E-02 
226234_PM_at growth differentiation factor 11 3720 GDF11 0.620 + 1.05E-02 2.23E-02 
221314_PM_at growth differentiation factor 9 53340 GDF9 0.692 + 5.30E-03 1.00E-02 
225712_PM_at gem (nuclear organelle) associated protein 5 11057 GEMIN5 0.342 + 2.22E-02 3.40E-02 
225153_PM_at G elongation factor, mitochondrial 1 96459 GFM1 0.563 + 7.40E-03 1.23E-03 
227027_PM_at glutamine-fructose-6-phosphate transaminase 1 11010 GFPT1 0.509 + 7.71E-03 7.98E-03 
227550_PM_at GDNF family receptor alpha 1 253943 GFRA1 0.340 + 1.16E-02 4.08E-02 
215380_PM_s_at gamma-glutamyl cyclotransferase 55592 GGCT 0.357 + 3.52E-02 1.05E-02 
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214005_PM_at gamma-glutamyl carboxylase 5880 GGCX 0.386 + 2.21E-03 3.14E-05 
203560_PM_at 
gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
29780 GGH 0.881 + 3.68E-03 3.03E-03 
218079_PM_s_at gametogenetin binding protein 2 196394 GGNBP2 0.442 + 1.69E-02 1.34E-02 
202321_PM_at geranylgeranyl diphosphate synthase 1 6945 GGPS1 0.624 + 2.74E-02 3.02E-02 
209248_PM_at growth hormone inducible transmembrane protein 55681 GHITM 0.496 + 2.14E-02 3.88E-02 
206102_PM_at GINS complex subunit 1 (Psf1 homolog) 7070 GINS1 0.717 + 6.65E-03 1.70E-02 
204982_PM_at G protein-coupled receptor kinase interacting ArfGAP 2 23480 GIT2 0.594 + 6.81E-03 5.47E-03 
225558_PM_at G protein-coupled receptor kinase interacting ArfGAP 2 326625 GIT2 0.526 + 2.62E-02 1.37E-02 
231771_PM_at gap junction protein, beta 6, 30kDa 57458 GJB6 0.531 + 2.02E-03 2.06E-02 
234192_PM_s_at G kinase anchoring protein 1 --- GKAP1 0.288 + 4.00E-03 4.17E-03 
225706_PM_at glucocorticoid induced transcript 1 27092 GLCCI1 0.648 + 1.38E-02 5.70E-03 
227525_PM_at glucocorticoid induced transcript 1 51271 GLCCI1 0.450 + 3.17E-02 1.98E-02 
213552_PM_at glucuronic acid epimerase 644 GLCE 0.600 + 3.26E-02 2.43E-02 
227376_PM_at GLI family zinc finger 3 80345 GLI3 0.565 + 3.04E-02 3.96E-02 
214085_PM_x_at GLI pathogenesis-related 1 9236 GLIPR1 0.636 + 1.51E-02 3.25E-02 
225602_PM_at GLI pathogenesis-related 2 25831 GLIPR2 0.435 + 2.56E-03 2.64E-02 
229435_PM_at GLIS family zinc finger 3 29078 GLIS3 0.695 + 3.35E-04 1.59E-03 
207153_PM_s_at glomulin, FKBP associated protein 23215 GLMN 0.436 + 9.42E-03 3.99E-04 
200681_PM_at glyoxalase I 5582 GLO1 0.264 + 1.51E-02 4.61E-02 
244680_PM_at glycine receptor, beta --- GLRB 0.285 + 4.12E-02 1.14E-02 
206662_PM_at glutaredoxin (thioltransferase) 9353 GLRX 0.428 + 4.13E-03 1.44E-02 
219933_PM_at glutaredoxin 2 3800 GLRX2 0.342 + 1.74E-02 2.94E-02 
209080_PM_x_at glutaredoxin 3 11201 GLRX3 0.400 + 1.42E-02 3.35E-02 
221932_PM_s_at glutaredoxin 5 3082 GLRX5 0.533 + 7.27E-03 1.57E-02 
221510_PM_s_at glutaminase 3759 GLS 0.525 + 3.02E-02 2.24E-02 
218146_PM_at glycosyltransferase 8 domain containing 1 7994 GLT8D1 0.469 + 2.44E-02 3.63E-02 
212414_PM_s_at glyoxylate reductase 1 homolog (Arabidopsis) /// septin 6 7525 
GLYR1 /// 
SEPT6 
0.551 + 6.88E-03 1.10E-02 
235233_PM_s_at glucocorticoid modulatory element binding protein 1 27229 GMEB1 0.691 + 2.07E-02 4.89E-02 
202544_PM_at glia maturation factor, beta 7812 GMFB 0.444 + 4.13E-03 1.21E-03 
218350_PM_s_at geminin, DNA replication inhibitor 84458 GMNN 0.603 + 6.50E-03 9.09E-03 
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214431_PM_at guanine 297eparin297ing297e synthetase 51125 GMPS 0.591 + 3.41E-02 2.52E-02 
227539_PM_at guanine nucleotide binding protein (G protein), alpha 13 28971 GNA13 0.378 + 3.03E-02 3.25E-02 
224761_PM_at guanine nucleotide binding protein (G protein), alpha 13 114990 GNA13 0.387 + 3.18E-02 3.77E-02 
201180_PM_s_at 
guanine nucleotide binding protein (G protein), alpha inhibiting 
activity polypeptide 3 
58497 GNAI3 0.677 + 3.06E-02 2.15E-02 
214157_PM_at GNAS complex locus 54874 GNAS 0.329 + 2.49E-02 3.10E-02 
225710_PM_at 
guanine nucleotide binding protein (G protein), beta 
polypeptide 4 
79874 GNB4 0.546 + 9.00E-03 1.13E-02 
224964_PM_s_at guanine nucleotide binding protein (G protein), gamma 2 157697 GNG2 0.450 + 5.34E-03 1.40E-02 
207157_PM_s_at guanine nucleotide binding protein (G protein), gamma 5 23215 GNG5 0.505 + 3.05E-02 2.15E-02 
201948_PM_at guanine nucleotide binding protein-like 2 (nucleolar) 3845 GNL2 0.418 + 2.05E-02 1.14E-02 
217850_PM_at guanine nucleotide binding protein-like 3 (nucleolar) 55239 GNL3 0.350 + 5.69E-03 2.57E-03 
202382_PM_s_at glucosamine-6-phosphate deaminase 1 55288 GNPDA1 0.558 + 1.61E-03 1.09E-02 
227022_PM_at glucosamine-6-phosphate deaminase 2 146227 GNPDA2 0.484 + 3.52E-02 9.86E-03 
225853_PM_at glucosamine-phosphate N-acetyltransferase 1 --- GNPNAT1 0.265 + 2.90E-02 1.98E-02 
212334_PM_at glucosamine (N-acetyl)-6-sulfatase 1176 GNS 0.551 + 1.68E-02 3.61E-02 
219876_PM_s_at golgi autoantigen, golgin subfamily a, 2-like 1 6662 GOLGA2L1 0.294 + 8.04E-04 1.80E-03 
201567_PM_s_at golgi autoantigen, golgin subfamily a, 4 27113 GOLGA4 0.921 + 9.85E-03 7.17E-03 
218241_PM_at golgi autoantigen, golgin subfamily a, 5 79848 GOLGA5 0.478 + 4.44E-02 4.23E-02 
217819_PM_at golgi autoantigen, golgin subfamily a, 7 112942 GOLGA7 0.460 + 3.18E-02 1.29E-02 
218361_PM_at golgi phosphoprotein 3-like 389114 GOLPH3L 0.531 + 2.49E-03 2.74E-03 
222552_PM_at golgi transport 1 homolog B (S. cerevisiae) 112464 GOLT1B 0.680 + 1.12E-02 4.08E-03 
213020_PM_at golgi SNAP receptor complex member 1 8853 GOSR1 0.338 + 3.05E-02 4.90E-02 
200708_PM_at 
glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate 
aminotransferase 2) 
2571 GOT2 0.342 + 4.49E-02 4.44E-02 
212485_PM_at G patch domain containing 8 1819 GPATCH8 0.371 + 7.19E-04 4.24E-03 
224648_PM_at GC-rich promoter binding protein 1 90780 GPBP1 0.453 + 4.22E-02 2.36E-02 
217877_PM_s_at GC-rich promoter binding protein 1-like 1 22808 GPBP1L1 0.482 + 1.77E-02 1.25E-02 
225447_PM_at glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 200312 GPD2 0.321 + 1.28E-02 2.11E-02 
203776_PM_at G patch domain and KOW motifs 10419 GPKOW 0.351 + 1.11E-02 6.03E-03 
209313_PM_at GPN-loop GTPase 1 221037 GPN1 0.350 + 3.90E-03 1.32E-02 
65718_PM_at G protein-coupled receptor 124 --- GPR124 0.498 + 1.07E-02 8.73E-03 
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1556039_PM_s_at G protein-coupled receptor 173 6240 GPR173 0.622 + 7.82E-03 1.26E-03 
228949_PM_at G protein-coupled receptor 177 84312 GPR177 0.653 + 1.91E-02 1.29E-02 
207183_PM_at G protein-coupled receptor 19 23199 GPR19 0.672 + 7.32E-03 1.56E-02 
221288_PM_at G protein-coupled receptor 22 5203 GPR22 0.576 + 3.69E-02 5.30E-03 
214586_PM_at 
G protein-coupled receptor 37 (endothelin receptor type B-
like) 
79180 GPR37 0.619 + 4.10E-03 6.10E-03 
229055_PM_at G protein-coupled receptor 68 6745 GPR68 0.287 + 2.05E-02 4.28E-02 
225463_PM_x_at 
G protein-coupled receptor 89A /// G protein-coupled receptor 





0.420 + 1.72E-02 1.06E-02 
223582_PM_at G protein-coupled receptor 98 56952 GPR98 0.584 + 4.31E-03 1.08E-02 
225511_PM_at G protein-coupled receptor, family C, group 5, member B 64805 GPRC5B 0.367 + 3.06E-03 2.66E-03 
227975_PM_at G protein regulated inducer of neurite outgrowth 1 10238 GPRIN1 0.295 + 3.27E-02 3.15E-02 
204265_PM_s_at G-protein signaling modulator 3 (AGS3-like, C. elegans) 9685 GPSM3 0.376 + 5.33E-03 1.33E-02 
209409_PM_at growth factor receptor-bound protein 10 23609 GRB10 0.494 + 3.35E-02 3.44E-02 
206204_PM_at growth factor receptor-bound protein 14 10539 GRB14 1.010 + 1.33E-02 4.10E-02 
205862_PM_at GREB1 protein 1528 GREB1 0.520 + 3.02E-02 1.57E-02 
214864_PM_s_at glyoxylate reductase/hydroxypyruvate reductase 55325 GRHPR 0.423 + 1.47E-04 5.96E-04 
230593_PM_at glutamate receptor, ionotropic, 298eparin 3 --- GRIK3 0.380 + 3.43E-02 4.18E-02 
233220_PM_at glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 25791 GRIN3A 0.856 + 2.55E-02 2.66E-02 
235957_PM_at glutamate receptor interacting protein 1 53832 GRIP1 0.595 + 2.58E-02 3.22E-02 
204396_PM_s_at G protein-coupled receptor kinase 5 8899 GRK5 0.765 + 4.16E-03 7.13E-03 
207299_PM_s_at glutamate receptor, metabotropic 1 92140 GRM1 0.582 + 2.32E-03 4.04E-03 
241049_PM_at glutamate receptor, metabotropic 7 --- GRM7 0.357 + 1.91E-02 3.14E-02 
206326_PM_at gastrin-releasing peptide 8473 GRP 0.641 + 2.14E-02 1.79E-02 
212434_PM_at GrpE-like 1, mitochondrial (E. coli) 4594 GRPEL1 0.362 + 1.39E-02 6.75E-03 
226881_PM_at GrpE-like 2, mitochondrial (E. coli) 5094 GRPEL2 0.715 + 1.63E-02 1.90E-03 
215030_PM_at G-rich RNA sequence binding factor 1 57763 GRSF1 0.474 + 5.46E-03 1.82E-02 
226183_PM_at glycogen synthase kinase 3 beta 6782 GSK3B 0.430 + 1.20E-02 7.84E-03 
201415_PM_at glutathione synthetase 9743 GSS 0.352 + 1.07E-02 4.51E-02 
235405_PM_at glutathione S-transferase alpha 4 6136 GSTA4 0.457 + 1.35E-02 4.22E-02 
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202554_PM_s_at glutathione S-transferase mu 3 (brain) 57018 GSTM3 0.441 + 4.08E-03 2.30E-02 
205752_PM_s_at glutathione S-transferase mu 5 3760 GSTM5 0.657 + 4.33E-02 3.46E-02 
225433_PM_at General transcription factor IIA, 1, 19/37kDa 11198 GTF2A1 0.514 + 1.68E-02 2.98E-02 
202678_PM_at general transcription factor IIA, 2, 12kDa 55275 GTF2A2 0.631 + 1.59E-03 1.57E-03 
208066_PM_s_at general transcription factor IIB 2017 GTF2B 0.468 + 1.47E-03 1.68E-03 
205930_PM_at general transcription factor IIE, polypeptide 1, alpha 56kDa 7430 GTF2E1 0.635 + 3.11E-02 4.91E-02 
202451_PM_at general transcription factor IIH, polypeptide 1, 62kDa 80150 GTF2H1 0.512 + 1.83E-02 1.22E-02 
213357_PM_at general transcription factor IIH, polypeptide 5 81542 GTF2H5 0.794 + 1.58E-03 9.37E-04 
201338_PM_x_at general transcription factor IIIA 8829 GTF3A 0.631 + 3.30E-03 2.15E-03 
215091_PM_s_at general transcription factor IIIA 10620 GTF3A 0.425 + 2.33E-02 4.77E-03 
225083_PM_at general transcription factor IIIC, polypeptide 6, alpha 35kDa 90390 GTF3C6 0.364 + 3.31E-02 4.24E-02 
221050_PM_s_at GTP binding protein 2 3131 GTPBP2 0.471 + 1.97E-02 2.86E-03 
207003_PM_at guanylate cyclase activator 2A (guanylin) 8487 GUCA2A 0.282 + 1.41E-04 4.07E-03 
203817_PM_at guanylate cyclase 1, soluble, beta 3 3550 GUCY1B3 0.467 + 2.37E-02 1.47E-03 
202605_PM_at glucuronidase, beta 55704 GUSB 0.631 + 1.52E-03 2.66E-03 
215816_PM_at 
glucuronidase, beta /// similar to hCG1820960 /// 






0.337 + 2.74E-02 3.17E-02 
211275_PM_s_at glycogenin 1 137682 GYG1 0.397 + 3.22E-02 4.16E-02 
207168_PM_s_at H2A histone family, member Y 3320 H2AFY 0.294 + 2.11E-02 5.50E-03 
213911_PM_s_at H2A histone family, member Z 5094 H2AFZ 0.284 + 1.78E-04 1.69E-04 
200853_PM_at H2A histone family, member Z 10634 H2AFZ 0.494 + 4.53E-03 4.17E-03 
216875_PM_x_at B1 for mucin 81603 HAB1 0.332 + 9.31E-03 9.44E-03 
233919_PM_s_at hyaluronan binding protein 4 --- HABP4 0.404 + 8.37E-03 2.63E-02 
223541_PM_at hyaluronan synthase 3 54841 HAS3 0.670 + 1.37E-02 3.13E-02 
203138_PM_at histone acetyltransferase 1 
51463 /// 653519 
/// 728932 
HAT1 0.562 + 1.34E-02 3.50E-03 
225297_PM_at HAUS augmin-like complex, subunit 1 1153 HAUS1 0.386 + 1.19E-02 2.99E-03 
222685_PM_at HAUS augmin-like complex, subunit 6 --- HAUS6 0.332 + 2.86E-02 7.37E-03 
201145_PM_at HCLS1 associated protein X-1 23600 HAX1 0.336 + 1.54E-02 5.59E-03 
209314_PM_s_at HBS1-like (S. cerevisiae) 89941 HBS1L 0.539 + 3.48E-02 1.01E-02 
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202299_PM_s_at hepatitis B virus x interacting protein 5464 HBXIP 0.530 + 3.39E-03 3.81E-03 
203745_PM_at holocytochrome c synthase (cytochrome c heme-lyase) 10085 HCCS 0.363 + 3.87E-03 2.96E-02 
202474_PM_s_at host cell factor C1 (VP16-accessory protein) 54981 HCFC1 0.497 + 1.01E-02 3.54E-02 
241710_PM_at hCG1645220 --- hCG_1645220 0.591 + 6.25E-03 3.12E-02 
200833_PM_s_at 
RAP1B, member of RAS oncogene family pseudogene /// 




0.379 + 1.73E-02 9.78E-03 
225577_PM_at HLA complex group 18 157378 HCG18 0.287 + 1.27E-02 3.55E-02 
208018_PM_s_at hemopoietic cell kinase 3297 HCK 0.269 + 3.47E-03 2.29E-02 
201833_PM_at histone deacetylase 2 341 HDAC2 0.289 + 3.78E-02 3.56E-02 
205659_PM_at histone deacetylase 9 9331 HDAC9 0.574 + 2.90E-02 8.14E-03 
203259_PM_s_at HD domain containing 2 126969 HDDC2 0.608 + 5.89E-03 7.40E-03 
227008_PM_at HD domain containing 3 10418 HDDC3 0.289 + 5.87E-04 8.94E-04 
223155_PM_at haloacid dehalogenase-like hydrolase domain containing 2 79746 HDHD2 0.434 + 4.58E-02 1.30E-02 
1553646_PM_at highly divergent homeobox 6487 HDX 0.510 + 1.41E-02 1.02E-02 
218991_PM_at HEAT repeat containing 6 221472 HEATR6 0.358 + 4.33E-02 2.23E-02 
218603_PM_at headcase homolog (Drosophila) 85445 HECA 0.618 + 2.83E-02 2.91E-03 
227568_PM_at HECT domain containing 2 5911 HECTD2 0.775 + 9.23E-03 4.39E-03 
228736_PM_at helicase, POLQ-like 5478 HELQ 0.592 + 2.22E-03 7.83E-03 
225910_PM_at helicase with zinc finger 728052 HELZ 0.599 + 6.36E-03 1.20E-02 
218620_PM_s_at HemK methyltransferase family member 1 26297 HEMK1 0.305 + 2.65E-02 3.56E-02 
218306_PM_s_at 
hect (homologous to the E6-AP (UBE3A) carboxyl terminus) 
domain and RCC1 (CHC1)-like domain (RLD) 1 
91419 HERC1 0.543 + 4.57E-02 4.37E-02 
222751_PM_at HERPUD family member 2 339105 HERPUD2 0.353 + 3.05E-02 3.18E-02 
219743_PM_at hairy/enhancer-of-split related with YRPW motif 2 9452 HEY2 1.063 + 3.55E-02 4.04E-02 
210755_PM_at hepatocyte growth factor (hepapoietin A; scatter factor) 1903 HGF 0.337 + 1.90E-03 1.04E-03 
219687_PM_at hedgehog acyltransferase 10473 HHAT 0.430 + 1.65E-07 1.24E-04 
223073_PM_at hippocampus abundant transcript-like 1 79023 HIATL1 0.552 + 2.18E-02 2.75E-02 
224812_PM_at 3-hydroxyisobutyrate dehydrogenase 145567 HIBADH 0.388 + 3.64E-02 4.29E-02 
203711_PM_s_at 3-hydroxyisobutyryl-Coenzyme A hydrolase 64399 HIBCH 0.449 + 4.77E-02 3.72E-02 
212964_PM_at hypermethylated in cancer 2 9450 HIC2 0.809 + 2.61E-02 2.03E-02 
206495_PM_s_at histone H4 transcription factor 83737 HINFP 0.273 + 3.94E-03 1.98E-02 
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226364_PM_at Huntingtin interacting protein 1 9837 HIP1 0.310 + 1.69E-02 1.04E-02 
212293_PM_at homeodomain interacting protein kinase 1 27258 HIPK1 0.469 + 2.49E-03 6.20E-03 
217427_PM_s_at 
HIR histone cell cycle regulation defective homolog A (S. 
cerevisiae) 
9117 HIRA 0.521 + 1.33E-02 2.96E-02 
204578_PM_at histidine acid phosphatase domain containing 2A 9474 HISPPD2A 0.401 + 7.76E-04 5.42E-03 




0.282 + 7.22E-03 2.64E-02 
204512_PM_at 
human immunodeficiency virus type I enhancer binding 
protein 1 
4694 HIVEP1 0.795 + 1.51E-02 2.16E-02 
204754_PM_at hepatic leukemia factor 10928 HLF 0.325 + 9.08E-03 4.42E-03 
218152_PM_at high-mobility group 20A 57187 HMG20A 0.300 + 5.00E-03 2.21E-02 
224731_PM_at high-mobility group box 1 51776 HMGB1 0.307 + 1.67E-02 1.89E-02 
203744_PM_at high-mobility group box 3 22950 HMGB3 0.618 + 1.48E-02 2.51E-02 
202540_PM_s_at 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 5101 HMGCR 0.880 + 1.22E-02 4.45E-02 
221750_PM_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 1810 HMGCS1 0.369 + 1.29E-02 2.58E-02 
200943_PM_at high-mobility group nucleosome binding domain 1 334 HMGN1 0.405 + 1.37E-02 1.16E-02 
209377_PM_s_at high mobility group nucleosomal binding domain 3 51495 HMGN3 0.447 + 3.71E-03 2.62E-03 
202579_PM_x_at high mobility group nucleosomal binding domain 4 55671 HMGN4 0.542 + 1.21E-02 1.79E-02 
204112_PM_s_at histamine N-methyltransferase 1315 HNMT 0.548 + 1.04E-02 3.82E-02 
244131_PM_at heterogeneous nuclear ribonucleoprotein A2/B1 --- HNRNPA2B1 0.350 + 1.37E-02 1.87E-02 
211929_PM_at heterogeneous nuclear ribonucleoprotein A3 2566 HNRNPA3 0.333 + 4.21E-02 1.84E-02 
221480_PM_at 
heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa) 
2902 HNRNPD 0.344 + 1.54E-02 2.74E-02 
208990_PM_s_at heterogeneous nuclear ribonucleoprotein H3 (2H9) 51074 HNRNPH3 0.441 + 5.15E-03 4.27E-03 
232004_PM_at heterogeneous nuclear ribonucleoprotein R --- HNRNPR 0.657 + 3.51E-02 1.70E-02 
235603_PM_at 
heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A) 
8028 HNRNPU 0.310 + 6.45E-03 1.06E-02 
225385_PM_s_at heterogeneous nuclear ribonucleoprotein L-like 27143 HNRPLL 0.538 + 1.97E-02 1.49E-02 
219976_PM_at hook homolog 1 (Drosophila) 10428 HOOK1 0.674 + 7.82E-03 3.85E-02 
225792_PM_at hook homolog 1 (Drosophila) 3340 HOOK1 0.377 + 3.22E-02 9.36E-03 
 302 
226395_PM_at hook homolog 3 (Drosophila) 9394 HOOK3 0.482 + 6.53E-03 6.76E-03 
211597_PM_s_at HOP homeobox 9786 HOPX 0.391 + 2.24E-04 3.64E-03 
202854_PM_at hypoxanthine phosphoribosyltransferase 1 51742 HPRT1 0.272 + 3.88E-03 6.24E-03 
227139_PM_s_at Hermansky-Pudlak syndrome 3 140885 HPS3 0.490 + 2.16E-02 3.20E-02 
203790_PM_s_at heat-responsive protein 12 5411 HRSP12 0.349 + 3.18E-02 4.28E-02 
203284_PM_s_at 302eparin sulfate 2-O-sulfotransferase 1 7068 HS2ST1 0.725 + 1.38E-02 1.52E-02 
230030_PM_at 302eparin sulfate 6-O-sulfotransferase 2 57537 HS6ST2 0.555 + 4.98E-02 2.94E-02 
200941_PM_at heat shock factor binding protein 1 7086 HSBP1 0.331 + 2.63E-02 2.29E-02 
223647_PM_x_at HscB iron-sulfur cluster co-chaperone homolog (E. coli) 51503 HSCB 0.319 + 2.05E-02 3.50E-02 
205404_PM_at hydroxysteroid (11-beta) dehydrogenase 1 25950 HSD11B1 0.300 + 4.61E-02 1.91E-02 
219113_PM_x_at hydroxysteroid (17-beta) dehydrogenase 14 374900 HSD17B14 0.386 + 7.35E-04 4.53E-03 
228713_PM_s_at hydroxysteroid (17-beta) dehydrogenase 14 5205 HSD17B14 0.269 + 2.29E-02 2.62E-02 
201413_PM_at hydroxysteroid (17-beta) dehydrogenase 4 56681 HSD17B4 0.642 + 4.36E-03 1.59E-02 
209513_PM_s_at hydroxysteroid dehydrogenase like 2 8907 HSDL2 0.314 + 6.62E-03 1.77E-03 
209657_PM_s_at heat shock transcription factor 2 57129 HSF2 0.652 + 1.20E-02 1.78E-02 
214434_PM_at heat shock 70kDa protein 12A 79811 HSPA12A 0.618 + 4.58E-02 2.36E-02 
229172_PM_at heat shock 70kD protein 12B 26148 HSPA12B 0.581 + 3.45E-02 3.98E-02 
202557_PM_at heat shock protein 70kDa family, member 13 56891 HSPA13 0.576 + 6.44E-03 1.72E-02 
219212_PM_at heat shock 70kDa protein 14 22919 HSPA14 0.635 + 1.43E-02 1.11E-02 
210189_PM_at heat shock 70kDa protein 1-like 94241 HSPA1L 0.352 + 1.25E-02 1.57E-02 
203960_PM_s_at heat shock protein family B (small), member 11 3895 HSPB11 1.357 + 2.52E-03 1.25E-02 
215691_PM_x_at heat shock protein family B (small), member 11 81873 HSPB11 0.873 + 5.15E-03 1.30E-02 
226188_PM_at galectin-related protein 10513 HSPC159 0.657 + 1.45E-02 5.48E-03 
205133_PM_s_at heat shock 10kDa protein 1 (chaperonin 10) 1645 HSPE1 0.353 + 1.80E-02 7.68E-03 
209448_PM_at HIV-1 Tat interactive protein 2, 30kDa 10827 HTATIP2 0.432 + 7.67E-03 2.11E-02 
202602_PM_s_at HIV-1 Tat specific factor 1 29968 HTATSF1 0.327 + 8.90E-03 5.99E-04 
207307_PM_at 5-hydroxytryptamine (serotonin) receptor 2C 23028 HTR2C 1.139 + 5.86E-03 2.64E-02 
236281_PM_x_at 
5-hydroxytryptamine (serotonin) receptor 7 (adenylate 
cyclase-coupled) 
--- HTR7 0.410 + 1.21E-02 4.27E-02 
232984_PM_at hydrocephalus inducing homolog (mouse) 140732 HYDIN 0.473 + 1.51E-02 4.05E-02 
227687_PM_at hydrolethalus syndrome 1 54801 HYLS1 0.663 + 7.41E-03 2.56E-03 
230454_PM_at islet cell autoantigen 1,69kDa-like 116442 ICA1L 0.346 + 1.49E-02 4.51E-02 
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201566_PM_x_at 
inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein 
9568 ID2 0.478 + 1.85E-02 4.63E-03 
209292_PM_at 
Inhibitor of DNA binding 4, dominant negative helix-loop-helix 
protein 
54908 ID4 0.361 + 1.90E-02 5.58E-03 
203327_PM_at insulin-degrading enzyme 80863 IDE 0.783 + 1.94E-02 3.60E-02 
208881_PM_x_at isopentenyl-diphosphate delta isomerase 1 64431 IDI1 0.364 + 5.83E-03 1.43E-02 
204615_PM_x_at isopentenyl-diphosphate delta isomerase 1 2990 IDI1 0.549 + 1.34E-02 1.91E-02 
223071_PM_at immediate early response 3 interacting protein 1 60561 IER3IP1 0.400 + 3.28E-03 5.74E-03 
203153_PM_at interferon-induced protein with tetratricopeptide repeats 1 84897 IFIT1 0.712 + 9.59E-04 2.84E-04 
203595_PM_s_at interferon-induced protein with tetratricopeptide repeats 5 9522 IFIT5 0.272 + 1.52E-02 1.56E-02 
210312_PM_s_at intraflagellar transport 20 homolog (Chlamydomonas) 84678 IFT20 0.354 + 2.67E-02 2.90E-03 
218709_PM_s_at intraflagellar transport 52 homolog (Chlamydomonas) 80167 IFT52 0.601 + 1.71E-02 1.24E-02 
218100_PM_s_at intraflagellar transport 57 homolog (Chlamydomonas) 219541 IFT57 0.541 + 5.05E-03 2.19E-04 
202105_PM_at immunoglobulin (CD79A) binding protein 1 11332 IGBP1 0.426 + 5.72E-03 2.99E-02 
227870_PM_at immunoglobulin superfamily, DCC subclass, member 4 54467 IGDCC4 1.149 + 5.61E-03 9.81E-03 
209540_PM_at insulin-like growth factor 1 (somatomedin C) 65991 IGF1 0.550 + 6.15E-03 1.14E-02 
230670_PM_at immunoglobulin superfamily, member 10 81553 IGSF10 0.495 + 2.57E-02 4.66E-02 
200066_PM_at IK cytokine, down-regulator of HLA II 4291 IK 0.312 + 1.20E-02 1.15E-02 
209341_PM_s_at 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta 
25932 IKBKB 0.612 + 3.70E-02 1.24E-02 
231929_PM_at IKAROS family zinc finger 2 (Helios) 4089 IKZF2 1.073 + 1.20E-02 1.50E-02 
226680_PM_at IKAROS family zinc finger 5 (Pegasus) 151162 /// 4249 IKZF5 0.450 + 1.01E-02 1.89E-02 
201887_PM_at interleukin 13 receptor, alpha 1 961 IL13RA1 0.352 + 3.71E-02 1.12E-02 
227401_PM_at interleukin 17D 23493 IL17D 0.335 + 4.31E-02 2.67E-02 
224156_PM_x_at interleukin 17 receptor B 114900 IL17RB 1.402 + 4.89E-03 7.03E-03 
219255_PM_x_at interleukin 17 receptor B 6224 IL17RB 0.866 + 1.58E-02 3.49E-02 
224361_PM_s_at interleukin 17 receptor B 84168 IL17RB 0.341 + 4.86E-02 3.56E-02 
222828_PM_at interleukin 20 receptor, alpha 8711 IL20RA 0.277 + 1.32E-03 5.19E-03 
207952_PM_at interleukin 5 (colony-stimulating factor, eosinophil) 6907 IL5 0.372 + 3.42E-02 1.07E-02 
217804_PM_s_at interleukin enhancer binding factor 3, 90kDa 441951 ILF3 0.352 + 5.47E-03 6.39E-03 
229025_PM_s_at 
IMP1 inner mitochondrial membrane peptidase-like (S. 
cerevisiae) 
117 IMMP1L 0.441 + 3.65E-03 1.25E-03 
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230556_PM_at 
IMP1 inner mitochondrial membrane peptidase-like (S. 
cerevisiae) 
55101 IMMP1L 0.656 + 1.28E-02 3.29E-02 
224743_PM_at inositol monophosphatase domain containing 1 124512 IMPAD1 0.410 + 9.07E-03 8.40E-03 
201892_PM_s_at IMP (inosine monophosphate) dehydrogenase 2 23543 IMPDH2 0.407 + 1.40E-03 7.80E-03 
208415_PM_x_at inhibitor of growth family, member 1 222658 ING1 0.417 + 1.69E-02 1.60E-02 
231863_PM_at inhibitor of growth family, member 3 --- ING3 0.977 + 5.62E-03 3.10E-02 
242293_PM_at inhibitor of growth family, member 3 --- ING3 0.370 + 4.44E-02 4.71E-02 
228287_PM_at inhibitor of growth family, member 5 144438 ING5 0.472 + 1.10E-02 1.93E-02 
205376_PM_at inositol polyphosphate-4-phosphatase, type II, 105kDa 2173 INPP4B 0.368 + 9.76E-03 3.39E-02 
218616_PM_at integrator complex subunit 12 9468 INTS12 0.598 + 1.33E-02 3.21E-03 
222239_PM_s_at integrator complex subunit 6 2799 INTS6 0.554 + 2.53E-02 7.77E-03 
218905_PM_at integrator complex subunit 8 27147 INTS8 0.751 + 1.66E-02 3.01E-03 
214735_PM_at interaction protein for cytohesin exchange factors 1 51118 IPCEF1 0.764 + 1.24E-02 3.57E-03 
211952_PM_at importin 5 754 IPO5 0.266 + 2.17E-02 2.98E-02 
200994_PM_at importin 7 5693 IPO7 0.346 + 3.48E-02 4.93E-02 
211707_PM_s_at IQ motif containing B1 127933 IQCB1 0.373 + 4.54E-03 2.68E-03 
204202_PM_at IQ motif containing E 2803 IQCE 0.437 + 2.66E-02 2.53E-02 
213392_PM_at IQ motif containing K 6683 IQCK 0.515 + 8.85E-03 3.64E-02 
201587_PM_s_at interleukin-1 receptor-associated kinase 1 515 IRAK1 0.678 + 4.28E-03 2.03E-02 
224571_PM_at interferon regulatory factor 2 binding protein 2 93380 IRF2BP2 0.496 + 2.88E-03 7.25E-03 
228462_PM_at 304eparin304 homeobox 2 27161 IRX2 0.266 + 1.59E-02 2.83E-02 
209274_PM_s_at iron-sulfur cluster assembly 1 homolog (S. cerevisiae) 8555 ISCA1 0.392 + 1.75E-03 1.66E-03 
209075_PM_s_at iron-sulfur cluster scaffold homolog (E. coli) 79683 ISCU 0.406 + 7.02E-05 2.93E-04 
205483_PM_s_at ISG15 ubiquitin-like modifier 11104 ISG15 0.370 + 1.67E-02 3.13E-02 
229324_PM_x_at inositol-3-phosphate synthase 1 100132815 ISYNA1 0.267 + 9.47E-03 1.80E-02 
226295_PM_at integrin alpha FG-GAP repeat containing 2 6461 ITFG2 0.364 + 3.42E-02 3.01E-02 
206493_PM_at 
integrin, alpha 2b (platelet glycoprotein Iib of Iib/IIIa complex, 
antigen CD41) 
1407 ITGA2B 0.397 + 5.83E-03 1.34E-02 
202351_PM_at 
integrin, alpha V (vitronectin receptor, alpha polypeptide, 
antigen CD51) 
51295 ITGAV 0.346 + 1.56E-02 1.22E-02 
211945_PM_s_at 
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen 
CD29 includes MDF2, MSK12) 
1603 ITGB1 0.481 + 1.96E-02 7.83E-03 
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203336_PM_s_at integrin beta 1 binding protein 1 10777 ITGB1BP1 0.429 + 3.51E-02 4.38E-02 
226189_PM_at integrin, beta 8 5440 ITGB8 0.513 + 3.24E-02 9.65E-03 
202746_PM_at integral membrane protein 2A 29127 ITM2A 0.459 + 2.04E-03 5.16E-03 
202661_PM_at inositol 1,4,5-triphosphate receptor, type 2 51176 ITPR2 0.347 + 1.32E-02 2.75E-02 
227792_PM_at inositol 1,4,5-triphosphate receptor interacting protein-like 2 378938 ITPRIPL2 0.368 + 2.43E-04 5.45E-03 
225311_PM_at isovaleryl Coenzyme A dehydrogenase 283417 IVD 0.427 + 2.90E-03 1.42E-02 
201363_PM_s_at influenza virus NS1A binding protein 6303 IVNS1ABP 0.672 + 1.03E-02 1.75E-03 
201362_PM_at influenza virus NS1A binding protein 30000 IVNS1ABP 0.754 + 4.01E-02 8.89E-03 
216268_PM_s_at jagged 1 (Alagille syndrome) 79047 JAG1 0.548 + 1.82E-02 2.23E-02 
203297_PM_s_at jumonji, AT rich interactive domain 2 641649 JARID2 0.871 + 1.69E-03 4.61E-03 
203298_PM_s_at jumonji, AT rich interactive domain 2 54542 JARID2 0.460 + 3.15E-02 4.89E-02 
221778_PM_at 
jumonji C domain containing histone demethylase 1 homolog 
D (S. cerevisiae) 
9554 JHDM1D 0.975 + 2.08E-03 1.20E-03 
221763_PM_at jumonji domain containing 1C 23208 JMJD1C 0.656 + 3.99E-02 4.28E-02 
226352_PM_at junction mediating and regulatory protein, p53 cofactor 10499 JMY 0.503 + 2.71E-02 2.11E-02 
229139_PM_at junctophilin 1 57456 JPH1 0.780 + 2.90E-03 1.62E-02 
1568605_PM_at jerky homolog (mouse) 8481 JRK 0.314 + 2.60E-02 4.78E-02 
205206_PM_at Kallmann syndrome 1 sequence 4763 KAL1 0.499 + 2.48E-02 1.78E-02 
221068_PM_at KN motif and ankyrin repeat domains 2 89795 KANK2 0.439 + 9.28E-03 3.49E-02 
200840_PM_at lysyl-tRNA synthetase 81550 KARS 0.402 + 7.88E-03 1.12E-02 
203845_PM_at K(lysine) acetyltransferase 2B 4924 KAT2B 0.754 + 2.36E-02 7.26E-03 
205526_PM_s_at katanin p60 (ATPase-containing) subunit A 1 57147 KATNA1 0.427 + 8.35E-03 1.43E-02 
203162_PM_s_at katanin p80 (WD repeat containing) subunit B 1 317649 KATNB1 0.863 + 7.36E-03 4.01E-03 
226479_PM_at kelch repeat and BTB (POZ) domain containing 6 10602 KBTBD6 0.598 + 1.04E-02 1.45E-02 
222471_PM_s_at potassium channel modulatory factor 1 57037 KCMF1 0.875 + 1.10E-02 1.17E-02 
230849_PM_at 
potassium voltage-gated channel, shaker-related subfamily, 
member 1 (episodic ataxia with myokymia) 
83856 KCNA1 0.462 + 2.89E-02 4.57E-02 
206762_PM_at 
potassium voltage-gated channel, shaker-related subfamily, 
member 5 
6327 KCNA5 0.380 + 1.60E-04 3.51E-03 
206765_PM_at potassium inwardly-rectifying channel, subfamily J, member 2 6328 KCNJ2 0.573 + 4.08E-02 1.65E-02 
220629_PM_at KCNQ1 downstream neighbor 7988 KCNQ1DN 0.431 + 4.19E-04 2.22E-03 
244455_PM_at potassium channel, subfamily T, member 2 --- KCNT2 0.701 + 2.33E-03 1.95E-03 
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226245_PM_at potassium channel tetramerisation domain containing 1 8065 KCTD1 0.426 + 4.59E-02 3.08E-02 
226518_PM_at potassium channel tetramerisation domain containing 10 655 KCTD10 0.398 + 9.60E-03 3.09E-02 
212192_PM_at potassium channel tetramerisation domain containing 12 1182 KCTD12 0.574 + 2.67E-02 5.17E-03 
222668_PM_at potassium channel tetramerisation domain containing 15 1795 KCTD15 0.511 + 1.10E-02 4.30E-02 
228299_PM_at potassium channel tetramerisation domain containing 20 57186 KCTD20 0.937 + 4.08E-03 5.62E-03 
240512_PM_x_at potassium channel tetramerisation domain containing 4 80349 KCTD4 0.691 + 1.61E-02 2.19E-02 
239787_PM_at potassium channel tetramerisation domain containing 4 --- KCTD4 0.441 + 2.32E-02 1.33E-02 
225128_PM_at KDEL (Lys-Asp-Glu-Leu) containing 2 115548 KDELC2 0.395 + 1.98E-03 9.47E-03 
212348_PM_s_at lysine (K)-specific demethylase 1 22877 KDM1 0.343 + 3.97E-02 9.19E-03 
226215_PM_s_at lysine (K)-specific demethylase 2B 4938 KDM2B 0.613 + 2.57E-03 7.54E-03 
212689_PM_s_at lysine (K)-specific demethylase 3A 7016 KDM3A 0.605 + 4.78E-02 2.30E-02 
210878_PM_s_at lysine (K)-specific demethylase 3B 203523 KDM3B 0.489 + 1.94E-02 3.74E-03 
211202_PM_s_at lysine (K)-specific demethylase 5B 7227 KDM5B 0.415 + 1.62E-02 1.66E-02 
203991_PM_s_at lysine (K)-specific demethylase 6A 7533 KDM6A 0.963 + 3.11E-02 2.91E-02 
229850_PM_at 3-ketodihydrosphingosine reductase 5592 KDSR 0.706 + 4.32E-02 2.49E-03 
204371_PM_s_at KH-type splicing regulatory protein 6993 KHSRP 0.283 + 2.54E-02 1.69E-02 
212395_PM_s_at KIAA0090 11073 KIAA0090 0.622 + 2.90E-03 1.14E-02 
212056_PM_at KIAA0182 4074 KIAA0182 0.493 + 1.67E-02 2.96E-02 
206017_PM_at KIAA0319 404734 /// 54882 KIAA0319 0.541 + 3.30E-03 2.56E-02 
212355_PM_at KIAA0323 3156 KIAA0323 0.784 + 2.95E-02 3.18E-02 
214356_PM_s_at KIAA0368 51109 KIAA0368 0.913 + 2.57E-02 1.84E-02 
204546_PM_at KIAA0513 10237 KIAA0513 0.501 + 8.00E-04 2.85E-03 
212946_PM_at KIAA0564 2949 KIAA0564 0.449 + 2.75E-02 2.76E-02 
37232_PM_at KIAA0586 --- KIAA0586 0.265 + 2.77E-02 5.10E-03 
212314_PM_at KIAA0746 protein 865 KIAA0746 0.431 + 2.43E-02 2.76E-02 
212633_PM_at KIAA0776 10946 KIAA0776 0.643 + 1.47E-02 1.47E-02 
204568_PM_at KIAA0831 10844 KIAA0831 0.422 + 7.20E-03 2.51E-03 
227465_PM_at KIAA0892 55539 KIAA0892 0.387 + 2.93E-02 1.62E-02 
207305_PM_s_at KIAA1012 55187 KIAA1012 0.371 + 4.68E-02 3.56E-02 
226816_PM_s_at KIAA1143 55023 KIAA1143 1.204 + 2.03E-04 4.54E-05 
227231_PM_at KIAA1211 10166 KIAA1211 0.296 + 1.13E-02 4.62E-02 
230765_PM_at KIAA1239 730094 KIAA1239 0.802 + 1.17E-02 2.47E-02 
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231887_PM_s_at KIAA1274 --- KIAA1274 0.287 + 1.66E-02 2.73E-02 
232358_PM_at KIAA1328 130752 KIAA1328 0.273 + 3.58E-02 1.53E-02 
226221_PM_at KIAA1432 6147 KIAA1432 0.633 + 2.88E-02 3.74E-02 
225506_PM_at KIAA1468 123263 KIAA1468 0.321 + 1.57E-03 1.12E-02 
52837_PM_at KIAA1644 --- KIAA1644 0.268 + 3.00E-04 5.68E-03 
229891_PM_x_at KIAA1704 29097 KIAA1704 0.908 + 3.77E-03 8.55E-03 
225623_PM_at KIAA1737 10350 KIAA1737 0.269 + 1.07E-02 3.60E-02 
218503_PM_at KIAA1797 5255 KIAA1797 0.463 + 2.42E-02 4.07E-02 
238828_PM_at KIAA1919 --- KIAA1919 0.293 + 1.56E-03 8.66E-04 
227433_PM_at KIAA2018 11092 KIAA2018 0.707 + 1.63E-02 3.14E-02 
225878_PM_at kinesin family member 1B 57709 KIF1B 0.864 + 1.04E-02 1.43E-02 
228680_PM_at kinesin family member 3A 84693 KIF3A 0.420 + 3.82E-03 3.32E-03 
231319_PM_x_at kinesin family member 9 57162 KIF9 0.790 + 6.12E-03 4.27E-03 
228429_PM_x_at kinesin family member 9 171024 KIF9 0.733 + 7.23E-03 2.01E-02 
209661_PM_at kinesin family member C3 84250 KIFC3 0.328 + 1.46E-02 2.53E-02 
216428_PM_x_at killer cell immunoglobulin-like receptor, three domains, X1 51555 KIR3DX1 0.281 + 1.58E-02 1.96E-02 
227261_PM_at Kruppel-like factor 12 59338 KLF12 0.928 + 2.92E-03 8.10E-03 
225133_PM_at Kruppel-like factor 3 (basic) 5828 KLF3 0.539 + 1.51E-02 1.01E-02 
203543_PM_s_at Kruppel-like factor 9 10554 KLF9 0.681 + 7.72E-03 4.15E-03 
1552733_PM_at kelch domain containing 1 113451 KLHDC1 0.328 + 1.93E-02 2.83E-02 
217906_PM_at kelch domain containing 2 57181 KLHDC2 0.282 + 1.89E-02 1.76E-02 
221219_PM_s_at kelch domain containing 4 8851 KLHDC4 0.283 + 3.36E-02 4.26E-02 
225961_PM_at kelch domain containing 5 --- KLHDC5 0.589 + 1.43E-03 2.70E-03 
227875_PM_at kelch-like 13 (Drosophila) --- KLHL13 0.567 + 3.52E-02 1.00E-03 
226370_PM_at kelch-like 15 (Drosophila) 1399 KLHL15 0.783 + 1.94E-02 2.76E-03 
212882_PM_at kelch-like 18 (Drosophila) 5157 KLHL18 0.565 + 6.98E-03 9.29E-03 
204176_PM_at kelch-like 20 (Drosophila) 10951 KLHL20 0.743 + 3.48E-03 1.57E-03 
204177_PM_s_at kelch-like 20 (Drosophila) 2926 KLHL20 0.517 + 1.44E-02 8.43E-03 
203068_PM_at kelch-like 21 (Drosophila) 4257 KLHL21 0.296 + 3.08E-02 1.94E-02 
213610_PM_s_at kelch-like 23 (Drosophila) 6383 KLHL23 0.400 + 2.30E-02 2.44E-02 
219354_PM_at kelch-like 26 (Drosophila) 2195 KLHL26 0.333 + 1.15E-02 3.25E-02 
228328_PM_at kelch-like 28 (Drosophila) 51434 KLHL28 0.651 + 5.44E-03 9.06E-04 
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1553765_PM_a_at kelch-like 32 (Drosophila) 55218 KLHL32 0.297 + 1.75E-02 7.55E-03 
226001_PM_at kelch-like 5 (Drosophila) 7453 KLHL5 0.437 + 1.01E-02 3.49E-03 
242648_PM_at kelch-like 8 (Drosophila) --- KLHL8 0.541 + 5.63E-03 1.61E-02 
213233_PM_s_at kelch-like 9 (Drosophila) 8073 KLHL9 0.289 + 4.36E-03 6.52E-03 
234495_PM_at kallikrein-related peptidase 15 --- KLK15 0.354 + 1.16E-02 1.13E-02 
1553955_PM_at KLRAQ motif containing 1 5136 KLRAQ1 0.629 + 2.26E-02 1.35E-02 
202057_PM_at karyopherin alpha 1 (importin alpha 5) 26986 KPNA1 0.726 + 9.60E-03 6.25E-03 
202056_PM_at karyopherin alpha 1 (importin alpha 5) 6257 KPNA1 0.541 + 1.36E-02 1.61E-02 
221502_PM_at karyopherin alpha 3 (importin alpha 4) 7074 KPNA3 0.393 + 4.29E-02 3.57E-02 
225268_PM_at karyopherin alpha 4 (importin alpha 3) 283209 KPNA4 0.531 + 8.04E-03 1.62E-03 
229317_PM_at karyopherin alpha 5 (importin alpha 6) 114134 KPNA5 0.535 + 1.90E-02 3.93E-02 
204009_PM_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 5886 KRAS 0.424 + 3.31E-03 7.51E-03 
227250_PM_at kringle containing transmembrane protein 1 55656 KREMEN1 0.298 + 1.08E-02 1.98E-02 
216713_PM_at KRIT1, ankyrin repeat containing 84274 KRIT1 0.641 + 7.61E-03 7.73E-03 
213287_PM_s_at keratin 10 9039 KRT10 0.559 + 2.78E-04 1.60E-03 
210633_PM_x_at keratin 10 4644 KRT10 0.410 + 4.75E-03 9.43E-03 
224885_PM_s_at keratinocyte associated protein 2 84142 KRTCAP2 0.557 + 3.00E-04 5.81E-04 
200915_PM_x_at kinectin 1 (kinesin receptor) 8763 KTN1 0.455 + 4.88E-02 3.59E-02 
217388_PM_s_at kynureninase (L-kynurenine hydrolase) 79102 KYNU 1.136 + 6.18E-03 1.49E-02 
229393_PM_at l(3)mbt-like 3 (Drosophila) 9926 L3MBTL3 0.469 + 1.66E-02 4.16E-02 
226354_PM_at lactamase, beta 8976 LACTB 0.551 + 2.39E-02 1.31E-02 
222714_PM_s_at lactamase, beta 2 2066 LACTB2 0.361 + 2.48E-02 1.91E-02 
203726_PM_s_at laminin, alpha 3 7327 LAMA3 1.068 + 5.91E-04 1.33E-02 
202202_PM_s_at laminin, alpha 4 84268 LAMA4 0.367 + 3.29E-02 4.08E-02 
226671_PM_at lysosomal-associated membrane protein 2 --- LAMP2 0.428 + 4.91E-02 3.35E-02 
202020_PM_s_at LanC lantibiotic synthetase component C-like 1 (bacterial) 9024 LANCL1 0.330 + 2.02E-02 1.60E-02 
217933_PM_s_at leucine aminopeptidase 3 2820 LAP3 0.530 + 2.76E-02 1.93E-02 
212714_PM_at La ribonucleoprotein domain family, member 4 8460 LARP4 0.337 + 5.84E-03 4.87E-02 
214155_PM_s_at La ribonucleoprotein domain family, member 4 8801 LARP4 0.614 + 1.62E-02 3.22E-02 
212785_PM_s_at La ribonucleoprotein domain family, member 7 3096 LARP7 0.425 + 3.82E-02 2.77E-02 
200618_PM_at LIM and SH3 protein 1 24140 LASP1 0.438 + 7.10E-03 2.37E-02 
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224951_PM_at LAG1 homolog, ceramide synthase 5 222166 LASS5 0.318 + 2.29E-03 3.41E-03 
212446_PM_s_at LAG1 homolog, ceramide synthase 6 2235 LASS6 0.489 + 2.87E-02 2.24E-02 
209881_PM_s_at 
linker for activation of T cells /// spinster homolog 1 
(Drosophila) 
57606 LAT /// SPNS1 0.282 + 1.84E-03 1.73E-03 
227013_PM_at LATS, large tumor suppressor, homolog 2 (Drosophila) 6421 LATS2 1.074 + 1.63E-02 4.68E-02 
213261_PM_at lupus brain antigen 1 7905 LBA1 0.270 + 1.45E-02 3.15E-02 
201795_PM_at lamin B receptor 6137 LBR 0.304 + 4.04E-02 2.75E-02 
226996_PM_at lysocardiolipin acyltransferase 1 51099 LCLAT1 0.813 + 5.80E-03 1.37E-02 
204012_PM_s_at leucine carboxyl methyltransferase 2 5886 LCMT2 0.334 + 3.10E-03 6.28E-03 
228454_PM_at ligand dependent nuclear receptor corepressor 284702 LCOR 0.619 + 3.57E-02 3.98E-02 
232293_PM_at ligand dependent nuclear receptor corepressor-like 51693 LCORL 0.428 + 6.46E-03 1.13E-02 
240592_PM_at ligand dependent nuclear receptor corepressor-like 153346 LCORL 0.579 + 1.93E-02 3.22E-02 
200650_PM_s_at lactate dehydrogenase A 5789 LDHA 0.270 + 1.36E-02 8.32E-03 
213564_PM_x_at lactate dehydrogenase B 10955 LDHB 0.308 + 2.80E-02 2.91E-02 
201030_PM_x_at lactate dehydrogenase B 22992 LDHB 0.427 + 2.83E-02 1.83E-02 
223228_PM_at leucine zipper, down-regulated in cancer 1-like 55317 LDOC1L 0.511 + 1.61E-02 2.89E-02 
221558_PM_s_at lymphoid enhancer-binding factor 1 5454 LEF1 0.465 + 2.20E-02 4.56E-02 
202594_PM_at leptin receptor overlapping transcript-like 1 55179 LEPROTL1 0.407 + 1.21E-02 2.38E-02 
220158_PM_at lectin, galactoside-binding, soluble, 14 24149 LGALS14 0.492 + 1.34E-03 7.15E-03 
206349_PM_at leucine-rich, glioma inactivated 1 2063 LGI1 0.323 + 8.05E-03 3.60E-02 
219699_PM_at leucine-rich repeat LGI family, member 2 23484 LGI2 0.325 + 1.74E-03 1.43E-03 
218253_PM_s_at ligatin 201973 LGTN 0.579 + 1.96E-03 4.66E-03 
225575_PM_at leukemia inhibitory factor receptor alpha 8925 LIFR 0.788 + 2.48E-02 6.75E-03 
212327_PM_at LIM and calponin homology domains 1 7994 LIMCH1 0.303 + 2.88E-02 8.27E-03 
222762_PM_x_at LIM domains containing 1 5898 LIMD1 0.424 + 1.12E-02 4.02E-03 
212687_PM_at LIM and senescent cell antigen-like domains 1 10810 LIMS1 0.529 + 5.93E-03 6.00E-03 
213526_PM_s_at lin-37 homolog (C. elegans) 10765 LIN37 0.797 + 5.56E-03 2.68E-03 
228583_PM_at lin-52 homolog (C. elegans) 1106 LIN52 0.709 + 2.01E-02 2.05E-02 
241957_PM_x_at lin-7 homolog B (C. elegans) --- LIN7B 0.526 + 3.17E-04 1.94E-03 
205571_PM_at lipoyltransferase 1 8976 LIPT1 0.878 + 4.57E-02 1.65E-02 
224629_PM_at lectin, mannose-binding, 1 91947 LMAN1 0.620 + 1.92E-02 2.69E-02 
212089_PM_at lamin A/C 9276 LMNA 0.385 + 2.13E-02 4.85E-03 
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204249_PM_s_at LIM domain only 2 (rhombotin-like 1) 5756 LMO2 0.445 + 2.13E-02 3.42E-02 
1565936_PM_a_at LIM domain only 3 (rhombotin-like 2) 9776 LMO3 0.290 + 8.52E-03 2.58E-02 
231062_PM_at Hypothetical protein LOC100129122 729082 LOC100129122 0.327 + 3.10E-04 8.44E-04 
221979_PM_at similar to hCG1811779 23673 LOC100129250 0.655 + 4.66E-03 1.06E-02 
78383_PM_at similar to hCG1811779 23201 LOC100129250 0.340 + 1.03E-02 8.38E-03 
213220_PM_at 






0.525 + 1.24E-04 2.11E-04 
208738_PM_x_at 
similar to SMT3 suppressor of mif two 3 homolog 2 /// similar 
to SMT3 suppressor of mif two 3 homolog 2 pseudogene /// 
SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae) /// 




/// SUMO2 /// 
SUMO4 
0.308 + 1.07E-03 4.04E-03 
227074_PM_at hypothetical protein LOC100131564 91754 LOC100131564 0.391 + 1.74E-02 3.91E-02 
226006_PM_at similar to hCG2036585 2806 LOC100131801 0.336 + 3.80E-02 9.25E-03 
227234_PM_at Hypothetical protein LOC100132815 79768 LOC100132815 0.299 + 8.56E-03 5.68E-03 
223766_PM_at PRO1102 26269 LOC100133130 0.264 + 1.55E-02 4.40E-02 
229930_PM_at similar to hCG1811002 64065 LOC100134361 0.785 + 6.77E-04 1.22E-02 
214676_PM_x_at 
similar to Mucin-3A precursor (Intestinal mucin-3A) /// mucin 




0.281 + 1.41E-02 1.81E-02 
219595_PM_at 





0.630 + 7.65E-03 3.22E-02 
210111_PM_s_at PNAS-119 26263 LOC100287552 0.526 + 8.54E-03 4.93E-03 
200834_PM_s_at similar to ribosomal protein S21 /// ribosomal protein S21 5980 
LOC100291837 
/// RPS21 
0.265 + 1.26E-02 3.34E-02 
230374_PM_at hypothetical protein LOC100294358 2531 LOC100294358 0.485 + 3.52E-03 1.09E-02 
225493_PM_at hypothetical LOC144438 29942 LOC144438 0.408 + 2.43E-02 2.59E-02 
1557430_PM_at hypothetical protein LOC147670 4700 LOC147670 0.576 + 1.76E-03 4.71E-03 
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1553797_PM_a_at hypothetical LOC150622 1495 LOC150622 0.300 + 1.36E-02 4.83E-03 
1553796_PM_at hypothetical LOC150622 4916 LOC150622 0.420 + 2.16E-02 3.33E-02 
212098_PM_at 





0.473 + 5.20E-03 1.98E-02 
225657_PM_at hypothetical LOC152217 1837 LOC152217 0.538 + 4.49E-03 1.93E-02 
232181_PM_at hypothetical protein LOC153346 55879 LOC153346 0.796 + 8.37E-03 2.35E-02 
230692_PM_at hypothetical protein LOC157503 56994 LOC157503 0.860 + 1.65E-03 3.94E-03 
228051_PM_at Hypothetical protein LOC202451 25923 LOC202451 0.667 + 5.14E-03 7.04E-03 
213510_PM_x_at TL132 protein 6904 LOC220594 0.444 + 2.68E-02 2.35E-02 
227124_PM_at hypothetical protein LOC221710 5782 LOC221710 0.319 + 3.47E-02 1.07E-02 
231828_PM_at hypothetical LOC253039 84100 LOC253039 0.640 + 5.28E-05 1.21E-03 
228894_PM_at hypothetical protein LOC253842 140460 LOC253842 0.364 + 1.69E-02 1.75E-02 
229734_PM_at hypothetical LOC283174 901 LOC283174 0.555 + 3.16E-02 4.28E-02 
230783_PM_at hypothetical protein LOC283713 7707 LOC283713 0.857 + 3.92E-03 1.17E-02 
230353_PM_at hypothetical protein LOC284112 --- LOC284112 0.412 + 2.88E-02 3.43E-02 
214162_PM_at hypothetical protein LOC284244 2098 LOC284244 0.471 + 4.88E-02 3.94E-02 
230228_PM_at hypothetical LOC284297 55924 LOC284297 0.278 + 3.77E-02 4.73E-04 
1560934_PM_at hypothetical protein LOC284669 287 LOC284669 0.408 + 9.22E-03 2.49E-02 
242852_PM_at hypothetical protein LOC285147 --- LOC285147 0.315 + 1.38E-02 1.41E-02 
227270_PM_at hypothetical protein LOC285550 55751 LOC285550 0.436 + 3.98E-03 2.34E-02 
236321_PM_at hypothetical protein LOC285550 --- LOC285550 0.572 + 4.28E-03 1.16E-02 
226236_PM_at hypothetical LOC388789 10019 LOC388789 0.483 + 1.82E-02 4.15E-02 
225014_PM_at hypothetical protein LOC389203 134637 LOC389203 0.480 + 2.74E-03 9.61E-04 
236640_PM_at Hypothetical gene supported by BX647608 --- LOC399959 0.435 + 7.82E-03 4.64E-04 
225381_PM_at hypothetical LOC399959 27092 LOC399959 0.765 + 1.39E-02 2.53E-03 
227887_PM_at hypothetical LOC400236 116151 LOC400236 0.294 + 1.15E-02 3.70E-03 
224723_PM_x_at hypothetical LOC401397 113174 LOC401397 0.747 + 3.36E-04 1.05E-03 
226635_PM_at Hypothetical gene supported by AK091718 4899 LOC401504 0.293 + 3.09E-02 3.42E-02 
1558345_PM_a_at hypothetical gene supported by NM_194304 522 LOC439911 0.718 + 3.46E-03 1.17E-02 
238207_PM_at similar to CG32736-PA 7024 LOC440957 0.763 + 3.02E-03 9.03E-04 
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229826_PM_at similar to CG32736-PA 114825 LOC440957 0.551 + 8.64E-03 9.02E-03 
229740_PM_at hypothetical protein LOC643008 --- LOC643008 0.420 + 2.47E-02 3.62E-02 
230388_PM_s_at hypothetical protein LOC644246 --- LOC644246 0.338 + 2.33E-02 2.49E-02 
213754_PM_s_at 
similar to poly(A) binding protein interacting protein 1 /// 




0.421 + 4.99E-02 1.45E-02 
230902_PM_at Hypothetical LOC645323 23566 LOC645323 0.410 + 3.33E-03 2.78E-02 
230272_PM_at hypothetical LOC645323 392617 LOC645323 0.414 + 1.33E-02 9.61E-03 
244268_PM_x_at p21-activated kinase 2 pseudogene --- LOC646214 0.467 + 1.57E-02 3.59E-02 
227567_PM_at hypothetical LOC651250 --- LOC651250 0.333 + 2.98E-03 6.18E-05 
201240_PM_s_at 
signal peptidase complex subunit 2 homolog pseudogene /// 




0.353 + 1.31E-02 2.03E-02 
238152_PM_at hypothetical protein LOC65998 --- LOC65998 0.318 + 3.65E-02 1.26E-02 
214129_PM_at 
similar to phosphodiesterase 4D interacting protein isoform 2 




0.463 + 2.91E-02 4.34E-02 
1558796_PM_a_at Similar to hCG2031213 1719 LOC728052 0.730 + 4.85E-03 2.41E-03 
1558795_PM_at Similar to hCG2031213 1400 LOC728052 0.576 + 4.87E-03 7.76E-03 
218380_PM_at 





0.344 + 2.66E-03 6.83E-03 
242070_PM_at hypothetical protein LOC728485 --- LOC728485 0.447 + 1.31E-02 3.17E-02 
229429_PM_x_at hypothetical LOC728855 --- LOC728855 0.442 + 6.85E-03 2.31E-02 
225225_PM_at Hypothetical protein LOC729082 441094 LOC729082 0.492 + 2.59E-04 6.40E-03 
233249_PM_at Hypothetical LOC730200 347744 LOC730200 0.292 + 1.87E-04 1.39E-03 
231027_PM_at Hypothetical LOC730631 220382 LOC730631 0.509 + 1.49E-04 2.55E-03 
231354_PM_at hypothetical LOC780529 --- LOC780529 0.289 + 6.53E-03 2.99E-02 
220849_PM_at hypothetical LOC79999 4335 LOC79999 0.275 + 3.42E-03 3.89E-03 
233566_PM_at hypothetical LOC84856 85352 LOC84856 0.329 + 1.84E-03 3.35E-03 
231192_PM_at lysophosphatidic acid receptor 3 10236 LPAR3 0.508 + 2.46E-02 1.95E-02 
218589_PM_at lysophosphatidic acid receptor 6 57536 LPAR6 0.485 + 3.78E-02 4.31E-02 
227476_PM_at lysophosphatidylglycerol acyltransferase 1 79788 LPGAT1 0.468 + 3.85E-02 1.92E-02 
206953_PM_s_at latrophilin 2 8407 LPHN2 0.501 + 4.02E-02 1.33E-02 
202460_PM_s_at lipin 2 51002 LPIN2 0.545 + 8.27E-03 5.66E-03 
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216250_PM_s_at leupaxin 55269 LPXN 0.293 + 3.44E-02 2.56E-02 
226795_PM_at 
leucine-rich repeats and calponin homology (CH) domain 
containing 1 
323 LRCH1 0.620 + 4.84E-02 3.35E-02 
227688_PM_at 
leucine-rich repeats and calponin homology (CH) domain 
containing 2 
55014 LRCH2 0.552 + 2.55E-02 4.36E-02 
228119_PM_at 
leucine-rich repeats and calponin homology (CH) domain 
containing 3 
7402 LRCH3 0.353 + 3.63E-03 1.19E-02 
225060_PM_at low density lipoprotein receptor-related protein 11 2562 LRP11 0.474 + 4.05E-02 2.10E-02 
219631_PM_at low density lipoprotein-related protein 12 3423 LRP12 0.329 + 2.80E-02 3.27E-02 
212850_PM_s_at low density lipoprotein receptor-related protein 4 5557 LRP4 0.597 + 1.42E-02 1.57E-02 
225745_PM_at low density lipoprotein receptor-related protein 6 6854 LRP6 0.849 + 1.20E-02 5.59E-03 
205282_PM_at 
low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor 
4644 LRP8 0.359 + 2.31E-02 7.91E-03 
211615_PM_s_at leucine-rich PPR-motif containing 10826 LRPPRC 0.339 + 1.88E-03 7.70E-03 
219573_PM_at leucine rich repeat containing 16A 5504 LRRC16A 0.445 + 1.38E-02 1.60E-02 
205381_PM_at leucine rich repeat containing 17 973 LRRC17 0.874 + 3.46E-03 1.58E-02 
229085_PM_at leucine rich repeat containing 3B 91612 LRRC3B 0.680 + 4.38E-03 1.97E-02 
208140_PM_s_at leucine rich repeat containing 48 4926 LRRC48 0.388 + 1.18E-02 1.33E-02 
219338_PM_s_at leucine rich repeat containing 49 1075 LRRC49 0.453 + 2.64E-02 2.57E-02 
232554_PM_at leucine rich repeat containing 56 94030 LRRC56 0.415 + 1.77E-04 1.70E-03 
212976_PM_at leucine rich repeat containing 8 family, member B 5781 LRRC8B 0.660 + 4.85E-02 2.52E-02 
229584_PM_at leucine-rich repeat kinase 2 201562 LRRK2 0.803 + 2.81E-03 9.78E-03 
202209_PM_at 
LSM3 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
6627 LSM3 0.738 + 7.42E-03 7.90E-04 
202737_PM_s_at 
LSM4 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
4666 /// 83955 LSM4 0.293 + 3.98E-02 4.52E-02 
211747_PM_s_at 
LSM5 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
84146 LSM5 0.757 + 5.35E-04 2.27E-03 
219119_PM_at 
LSM8 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
9147 LSM8 0.581 + 8.28E-03 5.66E-03 
215633_PM_x_at leukocyte specific transcript 1 29954 LST1 0.381 + 1.95E-02 1.18E-02 
207339_PM_s_at lymphotoxin beta (TNF superfamily, member 3) 26092 LTB 0.374 + 7.12E-03 3.67E-02 
223295_PM_s_at LUC7-like (S. cerevisiae) 83482 LUC7L 0.446 + 4.54E-02 1.30E-02 
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226758_PM_at LUC7-like 2 (S. cerevisiae) 157922 LUC7L2 0.668 + 3.11E-03 6.09E-03 
218729_PM_at latexin 83657 LXN 0.763 + 4.83E-02 3.10E-02 
205859_PM_at lymphocyte antigen 86 1741 LY86 0.808 + 2.82E-02 7.86E-03 
223414_PM_s_at Ly1 antibody reactive homolog (mouse) 79647 LYAR 0.496 + 8.97E-03 3.63E-02 
227764_PM_at LY6/PLAUR domain containing 6 10724 LYPD6 0.423 + 2.26E-02 3.72E-02 
212449_PM_s_at lysophospholipase I 8546 LYPLA1 0.308 + 2.24E-02 1.59E-03 
230174_PM_at lysophospholipase-like 1 153 LYPLAL1 0.598 + 5.27E-03 8.77E-03 
203897_PM_at LYR motif containing 1 3015 LYRM1 0.438 + 2.60E-02 1.29E-02 
225469_PM_at LYR motif containing 5 139341 LYRM5 0.436 + 9.43E-03 1.15E-02 
228841_PM_at Lyrm7 homolog (mouse) 57224 LYRM7 0.640 + 5.01E-03 4.97E-03 
232283_PM_at LysM, putative peptidoglycan-binding, domain containing 1 84959 LYSMD1 0.282 + 4.59E-03 3.11E-02 
226748_PM_at LysM, putative peptidoglycan-binding, domain containing 2 8723 LYSMD2 0.286 + 8.01E-03 2.71E-02 
228954_PM_at LysM, putative peptidoglycan-binding, domain containing 4 160418 LYSMD4 0.379 + 1.19E-02 1.44E-02 
218437_PM_s_at leucine zipper transcription factor-like 1 64282 LZTFL1 0.536 + 4.25E-02 1.88E-02 
214894_PM_x_at microtubule-actin crosslinking factor 1 29923 MACF1 0.472 + 2.69E-02 4.17E-02 
208634_PM_s_at microtubule-actin crosslinking factor 1 3995 MACF1 0.399 + 2.84E-02 2.85E-02 
215222_PM_x_at microtubule-actin crosslinking factor 1 79139 MACF1 0.519 + 4.51E-02 3.30E-02 
209348_PM_s_at 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
196743 MAF 0.866 + 1.88E-02 9.50E-03 
206363_PM_at 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
11311 MAF 0.774 + 2.73E-02 2.64E-02 
1559256_PM_at 
membrane associated guanylate kinase, WW and PDZ 
domain containing 1 
4140 MAGI1 0.500 + 2.06E-02 2.58E-02 
225465_PM_at 
membrane associated guanylate kinase, WW and PDZ 
domain containing 1 
130589 MAGI1 0.322 + 2.06E-02 3.13E-03 
209737_PM_at 
membrane associated guanylate kinase, WW and PDZ 
domain containing 2 
79966 MAGI2 0.462 + 1.76E-02 8.08E-03 
226770_PM_at 
membrane associated guanylate kinase, WW and PDZ 
domain containing 3 
23304 MAGI3 0.563 + 4.51E-02 2.35E-02 
218969_PM_at 
mitochondria-associated protein involved in granulocyte-
macrophage colony-stimulating factor signal transduction 
196500 Magmas 0.400 + 1.04E-02 1.34E-02 
210093_PM_s_at mago-nashi homolog, proliferation-associated (Drosophila) 91452 MAGOH 0.657 + 3.35E-04 4.54E-03 
210092_PM_at mago-nashi homolog, proliferation-associated (Drosophila) 10018 MAGOH 0.479 + 3.57E-03 2.69E-02 
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224899_PM_s_at magnesium transporter 1 134492 MAGT1 0.562 + 4.14E-02 2.65E-02 
202360_PM_at mastermind-like 1 (Drosophila) 63901 MAML1 0.403 + 2.64E-02 5.57E-03 
205088_PM_at mastermind-like domain containing 1 3845 MAMLD1 0.675 + 4.17E-02 6.55E-03 
226538_PM_at mannosidase, alpha, class 2A, member 1 23169 MAN2A1 0.759 + 1.54E-02 5.01E-03 
238230_PM_x_at mannosidase, alpha, class 2C, member 1 --- MAN2C1 0.281 + 1.97E-02 1.63E-02 
224689_PM_at mannosidase, beta A, lysosomal-like 4289 MANBAL 0.318 + 8.91E-03 4.35E-02 
222805_PM_at mannosidase, endo-alpha 222642 MANEA 0.498 + 1.48E-02 3.33E-02 
212741_PM_at monoamine oxidase A 10465 MAOA 0.363 + 3.36E-03 1.14E-02 
204389_PM_at monoamine oxidase A 9592 MAOA 0.555 + 2.63E-02 1.37E-02 
204041_PM_at monoamine oxidase B 5226 MAOB 0.277 + 1.42E-02 2.41E-02 
203266_PM_s_at mitogen-activated protein kinase kinase 4 11016 MAP2K4 0.399 + 3.76E-02 2.35E-02 
226556_PM_at mitogen-activated protein kinase kinase kinase 13 5781 MAP3K13 0.365 + 1.49E-03 9.86E-03 
227131_PM_at mitogen-activated protein kinase kinase kinase 3 539 MAP3K3 0.534 + 3.21E-03 6.00E-04 
216199_PM_s_at mitogen-activated protein kinase kinase kinase 4 58508 MAP3K4 0.663 + 4.78E-03 2.24E-03 
204089_PM_x_at mitogen-activated protein kinase kinase kinase 4 23608 MAP3K4 0.705 + 1.20E-02 6.49E-03 
203837_PM_at mitogen-activated protein kinase kinase kinase 5 6418 MAP3K5 0.438 + 3.39E-02 1.78E-02 
233679_PM_at 
Mitogen-activated protein kinase kinase kinase 7 interacting 
protein 1 
--- MAP3K7IP1 0.480 + 9.65E-03 4.63E-02 
213927_PM_at mitogen-activated protein kinase kinase kinase 9 1540 MAP3K9 0.718 + 2.10E-02 8.31E-03 
212566_PM_at microtubule-associated protein 4 9057 MAP4 0.323 + 3.91E-02 2.21E-02 
218311_PM_at mitogen-activated protein kinase kinase kinase kinase 3 284695 MAP4K3 0.431 + 2.79E-02 3.26E-02 
222548_PM_s_at mitogen-activated protein kinase kinase kinase kinase 4 23515 MAP4K4 0.409 + 1.92E-02 2.14E-02 
203552_PM_at mitogen-activated protein kinase kinase kinase kinase 5 10298 MAP4K5 0.563 + 1.22E-02 7.97E-03 
221713_PM_s_at MAP6 domain containing 1 23071 MAP6D1 0.318 + 3.29E-03 4.33E-03 
202890_PM_at microtubule-associated protein 7 55692 MAP7 0.523 + 1.43E-02 4.90E-02 
228262_PM_at MAP7 domain containing 2 9223 MAP7D2 0.435 + 1.93E-02 4.13E-02 
228423_PM_at microtubule-associated protein 9 25929 MAP9 0.287 + 3.91E-02 7.81E-03 
207121_PM_s_at mitogen-activated protein kinase 6 27101 MAPK6 0.439 + 2.37E-02 1.97E-03 
229664_PM_at mitogen-activated protein kinase 8 10160 MAPK8 0.703 + 1.52E-02 8.76E-03 
217971_PM_at MAPK scaffold protein 1 57659 MAPKSP1 0.500 + 3.36E-03 5.96E-04 
200712_PM_s_at microtubule-associated protein, RP/EB family, member 1 2554 MAPRE1 0.326 + 6.43E-03 2.59E-02 
200713_PM_s_at microtubule-associated protein, RP/EB family, member 1 4062 MAPRE1 0.455 + 3.29E-02 2.54E-02 
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225897_PM_at myristoylated alanine-rich protein kinase C substrate 79632 MARCKS 0.660 + 7.46E-03 6.07E-04 
202569_PM_s_at MAP/microtubule affinity-regulating kinase 3 
150472 /// 
220869 /// 
445571 /// 55871 
/// 644019 /// 
728013 
MARK3 0.541 + 5.89E-03 8.41E-03 
213671_PM_s_at methionyl-tRNA synthetase 5962 MARS 0.338 + 1.32E-03 4.34E-03 
239148_PM_at MARVEL domain containing 3 --- MARVELD3 0.303 + 1.70E-03 7.28E-03 
215903_PM_s_at microtubule associated serine/threonine kinase 2 84851 MAST2 0.366 + 5.19E-03 4.58E-03 
217993_PM_s_at methionine adenosyltransferase II, beta 3842 MAT2B 0.333 + 9.81E-03 2.82E-02 
202350_PM_s_at matrilin 2 65083 MATN2 0.599 + 7.62E-03 9.47E-03 
228798_PM_x_at 
MYC-associated zinc finger protein (purine-binding 
transcription factor) 
645460 MAZ 0.319 + 1.52E-02 4.78E-02 
203353_PM_s_at methyl-CpG binding domain protein 1 11276 MBD1 0.398 + 2.55E-02 2.52E-02 
202484_PM_s_at methyl-CpG binding domain protein 2 51192 MBD2 0.685 + 4.30E-02 2.22E-02 
214047_PM_s_at methyl-CpG binding domain protein 4 4603 MBD4 0.590 + 1.43E-02 1.25E-02 
209580_PM_s_at methyl-CpG binding domain protein 4 387521 /// 7335 MBD4 0.594 + 1.93E-02 1.20E-02 
220195_PM_at methyl-CpG binding domain protein 5 9797 MBD5 0.361 + 3.05E-03 1.54E-02 
227833_PM_s_at methyl-CpG binding domain protein 6 401152 MBD6 0.511 + 3.65E-05 8.84E-04 
218411_PM_s_at MAP3K12 binding inhibitory protein 1 51171 MBIP 0.363 + 1.64E-02 4.28E-02 
201153_PM_s_at muscleblind-like (Drosophila) 10553 MBNL1 0.777 + 3.95E-03 5.20E-03 
203640_PM_at muscleblind-like 2 (Drosophila) 79918 MBNL2 0.303 + 3.85E-02 3.10E-04 
213288_PM_at membrane bound O-acyltransferase domain containing 2 9100 MBOAT2 0.695 + 5.06E-03 6.62E-03 
225407_PM_at myelin basic protein 53944 MBP 0.571 + 1.56E-02 2.49E-02 
226797_PM_at mbt domain containing 1 26268 MBTD1 0.592 + 3.23E-02 6.93E-03 
209087_PM_x_at melanoma cell adhesion molecule 55086 MCAM 0.444 + 1.36E-04 4.30E-03 
226225_PM_at mutated in colorectal cancers 9910 MCC 0.890 + 2.05E-02 2.25E-03 
218440_PM_at methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 8111 MCCC1 0.306 + 6.74E-03 2.63E-02 
209623_PM_at methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 83787 MCCC2 0.738 + 2.29E-02 3.49E-02 
226238_PM_at methylmalonyl CoA epimerase 25842 MCEE 0.695 + 4.73E-03 1.05E-02 
208017_PM_s_at MCF.2 cell line derived transforming sequence 905 MCF2 0.489 + 2.28E-02 3.58E-02 
212245_PM_at multiple coagulation factor deficiency 2 214 MCFD2 0.311 + 2.70E-02 3.25E-02 
200797_PM_s_at myeloid cell leukemia sequence 1 (BCL2-related) 4595 MCL1 0.455 + 2.56E-02 1.99E-02 
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212269_PM_s_at 
minichromosome maintenance complex component 3 
associated protein 
3476 MCM3AP 0.287 + 1.80E-02 1.06E-02 
222036_PM_s_at minichromosome maintenance complex component 4 25963 MCM4 0.426 + 3.86E-03 1.51E-02 
230235_PM_at malignant T cell amplified sequence 1 54205 MCTS1 0.589 + 2.34E-03 6.25E-03 
218163_PM_at malignant T cell amplified sequence 1 91404 MCTS1 0.365 + 3.60E-02 4.14E-02 
203062_PM_s_at mediator of DNA-damage checkpoint 1 60592 MDC1 0.395 + 2.30E-03 1.33E-03 
238721_PM_at malate dehydrogenase 1B, NAD (soluble) --- MDH1B 0.546 + 3.00E-02 2.49E-02 
225740_PM_x_at Mdm4 p53 binding protein homolog (mouse) 94032 MDM4 0.539 + 9.21E-03 1.16E-02 
218061_PM_at male-enhanced antigen 1 84132 MEA1 0.275 + 3.88E-03 3.81E-03 
226420_PM_at MDS1 and EVI1 complex locus 1268 MECOM 0.399 + 9.13E-03 5.94E-03 
201987_PM_at mediator complex subunit 13 23032 MED13 0.647 + 6.41E-03 1.98E-03 
209362_PM_at mediator complex subunit 21 23677 MED21 0.657 + 1.72E-03 3.18E-03 
227787_PM_s_at mediator complex subunit 30 64231 MED30 0.565 + 2.51E-03 5.53E-04 
227786_PM_at mediator complex subunit 30 64343 MED30 0.506 + 3.07E-03 4.67E-03 
222867_PM_s_at mediator complex subunit 31 171392 MED31 0.692 + 3.14E-03 1.35E-03 
207078_PM_at mediator complex subunit 6 5048 MED6 0.280 + 8.71E-03 1.52E-02 
204350_PM_s_at mediator complex subunit 7 892 MED7 0.467 + 5.43E-03 5.76E-03 
212535_PM_at myocyte enhancer factor 2A 687 MEF2A 0.421 + 3.53E-02 3.98E-02 
236517_PM_at multiple EGF-like-domains 10 4124 MEGF10 0.338 + 3.31E-02 3.90E-02 
224675_PM_at mesoderm development candidate 2 135293 MESDC2 0.693 + 1.22E-02 1.42E-02 
212673_PM_at methionyl aminopeptidase 1 7403 METAP1 0.658 + 1.68E-02 3.69E-02 
226744_PM_at methyltransferase 10 domain containing 10000 METT10D 0.354 + 8.74E-04 4.57E-03 
238773_PM_at methyltransferase 5 domain containing 1 --- METT5D1 0.404 + 1.35E-02 7.91E-03 
223368_PM_s_at methyltransferase like 11A 5128 METTL11A 0.359 + 2.84E-02 3.73E-02 
212407_PM_at methyltransferase like 13 10427 METTL13 0.520 + 1.23E-02 4.88E-02 
222447_PM_at methyltransferase like 9 10240 METTL9 0.619 + 9.75E-03 4.93E-03 
213123_PM_at microfibrillar-associated protein 3 7691 MFAP3 0.401 + 4.01E-03 1.73E-03 




9520 MFNG 0.314 + 1.09E-02 1.05E-02 
229254_PM_at major facilitator superfamily domain containing 4 2673 MFSD4 0.409 + 2.96E-02 4.27E-02 




acetylglucosaminyltransferase, isozyme A 
5870 MGAT4A 0.367 + 1.90E-02 3.04E-02 
238445_PM_x_at 
mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase, isozyme B 
152485 MGAT5B 0.353 + 6.79E-03 7.65E-03 
228235_PM_at hypothetical protein MGC16121 54994 MGC16121 0.514 + 4.34E-04 1.44E-03 
230864_PM_at serine/threonine-protein kinase NIM1 --- MGC42105 0.434 + 1.47E-02 8.61E-03 
200899_PM_s_at meningioma expressed antigen 5 (hyaluronidase) 1981 MGEA5 0.415 + 1.86E-02 4.09E-02 
224918_PM_x_at microsomal glutathione S-transferase 1 374969 MGST1 0.443 + 2.21E-02 1.89E-04 
204168_PM_at microsomal glutathione S-transferase 2 5547 MGST2 0.503 + 2.22E-02 4.29E-03 
203637_PM_s_at midline 1 (Opitz/BBB syndrome) 85406 MID1 1.016 + 8.27E-03 3.01E-02 
203636_PM_at midline 1 (Opitz/BBB syndrome) 1499 MID1 0.461 + 8.36E-03 1.69E-02 
228961_PM_at mesoderm induction early response 1, family member 3 83648 MIER3 0.580 + 3.59E-03 3.64E-04 
223411_PM_at MIF4G domain containing 79647 MIF4GD 0.310 + 4.44E-06 1.71E-04 
221559_PM_s_at 
MIS12, MIND kinetochore complex component, homolog (S. 
pombe) 
4974 MIS12 0.439 + 8.95E-04 3.22E-03 
226329_PM_s_at 
MIT, microtubule interacting and transport, domain containing 
1 
6565 MITD1 0.283 + 7.90E-04 2.30E-03 
225526_PM_at muskelin 1, intracellular mediator containing kelch motifs 121601 MKLN1 0.317 + 9.36E-03 8.87E-04 
201285_PM_at makorin ring finger protein 1 20 MKRN1 0.341 + 3.34E-02 3.20E-02 
218071_PM_s_at makorin ring finger protein 2 441951 MKRN2 0.476 + 1.32E-02 1.52E-02 
204784_PM_s_at myeloid leukemia factor 1 25843 MLF1 0.606 + 1.71E-03 6.22E-03 
217216_PM_x_at mutL homolog 3 (E. coli) 84437 MLH3 0.465 + 1.50E-02 3.44E-02 
226981_PM_at 
Myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila) 
4293 MLL 0.509 + 6.28E-03 7.61E-03 
222415_PM_at myeloid/lymphoid or mixed-lineage leukemia 3 285527 MLL3 0.547 + 1.39E-02 1.11E-02 
226100_PM_at 
myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax 
homolog, Drosophila) 
2273 MLL5 0.746 + 2.77E-02 8.70E-03 
211071_PM_s_at 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 11 
91392 MLLT11 0.308 + 9.10E-03 4.98E-02 
224784_PM_at 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 6 
23328 MLLT6 0.379 + 2.40E-03 1.16E-02 
217910_PM_x_at MAX-like protein X 54842 MLX 0.581 + 1.06E-02 1.82E-02 
238975_PM_at methylmalonic aciduria (cobalamin deficiency) cblB type --- MMAB 0.503 + 2.18E-02 4.33E-02 
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217883_PM_at 
methylmalonic aciduria (cobalamin deficiency) cblD type, with 
homocystinuria 
3840 MMADHC 0.349 + 9.46E-03 6.28E-03 
225125_PM_at membrane magnesium transporter 1 404217 MMGT1 0.297 + 4.09E-02 4.52E-02 
223614_PM_at matrix metallopeptidase 16 (membrane-inserted) 50848 MMP16 0.713 + 8.05E-04 8.82E-04 
203565_PM_s_at 
319epari a trois homolog 1, cyclin H assembly factor 
(Xenopus laevis) 
23770 MNAT1 0.422 + 2.08E-03 3.26E-03 
204206_PM_at MAX binding protein 9989 MNT 0.411 + 2.39E-02 4.77E-02 
201298_PM_s_at MOB1, Mps One Binder kinase activator-like 1B (yeast) 10396 MOBKL1B 0.529 + 1.32E-02 1.16E-02 
214812_PM_s_at MOB1, Mps One Binder kinase activator-like 1B (yeast) 8491 MOBKL1B 0.495 + 2.09E-02 1.71E-02 
219265_PM_at MOB1, Mps One Binder kinase activator-like 2B (yeast) 6235 MOBKL2B 0.692 + 3.53E-02 2.68E-02 
202919_PM_at MOB1, Mps One Binder kinase activator-like 3 (yeast) 84059 MOBKL3 0.352 + 1.47E-02 1.25E-02 
212754_PM_s_at MON2 homolog (S. cerevisiae) 10667 MON2 0.550 + 5.10E-03 2.13E-03 
213000_PM_at MORC family CW-type zinc finger 3 4356 MORC3 0.323 + 7.59E-03 6.56E-03 
219852_PM_s_at MORN repeat containing 1 4927 MORN1 0.568 + 1.11E-03 2.56E-03 
226790_PM_at MORN repeat containing 2 4673 MORN2 0.634 + 7.95E-03 2.97E-03 
218865_PM_at MOCO sulphurase C-terminal domain containing 1 85004 MOSC1 0.425 + 3.66E-02 1.28E-02 
218853_PM_s_at motile sperm domain containing 1 91120 MOSPD1 0.724 + 1.58E-03 5.03E-03 
203740_PM_at M-phase phosphoprotein 6 
221178 /// 
338872 
MPHOSPH6 0.409 + 2.00E-02 4.85E-02 
206186_PM_at 
membrane protein, palmitoylated 3 (MAGUK p55 subfamily 
member 3) 
2098 MPP3 0.512 + 9.75E-03 1.57E-02 
213924_PM_at Metallophosphoesterase 1 23108 MPPE1 0.496 + 1.53E-02 3.71E-02 
227226_PM_at melanocortin 2 receptor accessory protein 2 55347 MRAP2 0.695 + 2.74E-02 4.95E-02 
225185_PM_at muscle RAS oncogene homolog 9378 MRAS 0.471 + 9.25E-03 9.99E-03 
204386_PM_s_at mitochondrial ribosomal protein 63 8533 MRP63 0.449 + 2.69E-03 4.47E-03 
223154_PM_at mitochondrial ribosomal protein L1 55145 MRPL1 0.583 + 1.69E-03 3.59E-03 
218049_PM_s_at mitochondrial ribosomal protein L13 146198 MRPL13 0.956 + 1.05E-03 3.88E-03 
217980_PM_s_at mitochondrial ribosomal protein L16 113263 MRPL16 0.614 + 1.14E-02 3.32E-03 
222216_PM_s_at mitochondrial ribosomal protein L17 23168 MRPL17 0.433 + 8.29E-03 1.23E-02 
217907_PM_at mitochondrial ribosomal protein L18 3712 MRPL18 0.333 + 2.82E-02 6.42E-03 
203465_PM_at mitochondrial ribosomal protein L19 132864 MRPL19 0.311 + 1.34E-03 1.67E-03 
218339_PM_at mitochondrial ribosomal protein L22 26090 MRPL22 0.396 + 3.97E-03 1.83E-03 
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225260_PM_s_at mitochondrial ribosomal protein L32 146713 MRPL32 0.377 + 1.74E-02 5.39E-03 
203781_PM_at mitochondrial ribosomal protein L33 4297 MRPL33 0.580 + 2.04E-02 2.62E-02 
225255_PM_at mitochondrial ribosomal protein L35 5529 MRPL35 0.582 + 1.14E-02 3.08E-02 
218890_PM_x_at mitochondrial ribosomal protein L35 360 MRPL35 0.511 + 1.44E-02 4.96E-02 
203152_PM_at mitochondrial ribosomal protein L40 26263 MRPL40 0.511 + 1.23E-02 2.61E-02 
222466_PM_s_at mitochondrial ribosomal protein L42 7334 MRPL42 0.317 + 1.34E-02 1.26E-03 
219244_PM_s_at mitochondrial ribosomal protein L46 6745 MRPL46 0.473 + 1.52E-02 2.39E-02 
223480_PM_s_at mitochondrial ribosomal protein L47 63877 MRPL47 0.544 + 2.42E-03 3.19E-03 
218281_PM_at mitochondrial ribosomal protein L48 9590 MRPL48 0.460 + 4.09E-03 6.20E-03 
225580_PM_at mitochondrial ribosomal protein L50 138199 MRPL50 1.024 + 7.74E-04 2.37E-03 
223086_PM_x_at mitochondrial ribosomal protein L51 51575 MRPL51 0.409 + 1.19E-02 1.16E-03 
226241_PM_s_at mitochondrial ribosomal protein L52 25852 MRPL52 0.547 + 1.02E-02 2.23E-03 
218106_PM_s_at mitochondrial ribosomal protein S10 84460 MRPS10 0.550 + 5.14E-03 2.25E-02 
203800_PM_s_at mitochondrial ribosomal protein S14 11315 MRPS14 0.333 + 1.43E-02 3.45E-02 
226296_PM_s_at mitochondrial ribosomal protein S15 2342 MRPS15 0.406 + 9.14E-04 6.72E-04 
228019_PM_s_at mitochondrial ribosomal protein S18C 50807 MRPS18C 0.533 + 3.56E-03 4.49E-03 
222997_PM_s_at mitochondrial ribosomal protein S21 55505 MRPS21 0.385 + 1.40E-03 2.42E-04 
226257_PM_x_at mitochondrial ribosomal protein S22 22909 MRPS22 0.450 + 4.76E-03 1.36E-02 
219220_PM_x_at mitochondrial ribosomal protein S22 22919 MRPS22 0.420 + 8.29E-03 2.71E-02 
223448_PM_x_at mitochondrial ribosomal protein S22 55745 MRPS22 0.482 + 8.57E-03 3.30E-02 
228059_PM_x_at mitochondrial ribosomal protein S22 1459 MRPS22 0.490 + 1.24E-02 2.72E-02 
223156_PM_at mitochondrial ribosomal protein S23 26232 MRPS23 0.540 + 2.42E-03 6.41E-03 
224948_PM_at mitochondrial ribosomal protein S24 492311 MRPS24 0.411 + 3.56E-03 2.02E-03 
224873_PM_s_at mitochondrial ribosomal protein S25 128637 MRPS25 0.402 + 2.22E-04 2.04E-05 
212603_PM_at mitochondrial ribosomal protein S31 3052 MRPS31 0.409 + 2.73E-02 1.11E-02 
218654_PM_s_at mitochondrial ribosomal protein S33 157869 MRPS33 0.329 + 2.11E-02 2.47E-02 
224302_PM_s_at mitochondrial ribosomal protein S36 199692 MRPS36 0.427 + 1.98E-02 1.09E-02 
225126_PM_at mitochondrial ribosome recycling factor 286205 MRRF 0.396 + 1.89E-02 3.99E-02 
228542_PM_at 
MRS2 magnesium homeostasis factor homolog (S. 
cerevisiae) 
84912 MRS2 0.373 + 1.20E-03 6.50E-03 
226047_PM_at murine retrovirus integration site 1 homolog 1965 MRVI1 0.870 + 7.39E-03 1.66E-02 
223922_PM_x_at membrane-spanning 4-domains, subfamily A, member 6A 54822 MS4A6A 0.281 + 3.28E-02 2.51E-02 
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243010_PM_at musashi homolog 2 (Drosophila) --- MSI2 1.388 + 6.60E-03 2.63E-02 
224765_PM_at male-specific lethal 1 homolog (Drosophila) 57542 MSL1 0.334 + 3.06E-02 1.18E-02 
212859_PM_x_at metallothionein 1E 6443 MT1E 0.604 + 6.24E-03 2.95E-02 
212185_PM_x_at metallothionein 2A 5706 MT2A 0.366 + 2.55E-02 3.26E-02 
216862_PM_s_at mature T-cell proliferation 1 neighbor 55031 MTCP1NB 0.544 + 1.16E-02 4.53E-02 
210212_PM_x_at mature T-cell proliferation 1 neighbor 5562 MTCP1NB 0.591 + 1.79E-02 2.56E-02 
212248_PM_at metadherin 10449 MTDH 0.337 + 2.60E-03 1.95E-03 
225346_PM_at MTERF domain containing 3 129880 MTERFD3 0.687 + 4.85E-02 3.43E-02 
209705_PM_at metal response element binding transcription factor 2 81847 MTF2 0.711 + 1.37E-02 1.61E-02 




441457 /// 54754 
/// 728118 /// 
729262 
MTHFS 0.478 + 1.45E-02 4.24E-02 
203095_PM_at mitochondrial translational initiation factor 2 25870 MTIF2 0.409 + 3.38E-02 3.07E-02 
36920_PM_at myotubularin 1 --- MTM1 0.459 + 2.48E-02 4.76E-02 
204101_PM_at myotubularin 1 2971 MTM1 0.365 + 3.75E-02 2.53E-02 
225232_PM_at myotubularin related protein 12 2549 MTMR12 0.459 + 2.35E-03 2.67E-04 
203678_PM_at myotubularin related protein 15 26493 MTMR15 0.280 + 6.44E-03 1.94E-02 
203212_PM_s_at myotubularin related protein 2 56945 MTMR2 0.455 + 1.95E-02 3.89E-02 
226956_PM_at myotubularin related protein 3 81688 MTMR3 0.421 + 3.28E-02 2.23E-02 
214429_PM_at myotubularin related protein 6 57092 MTMR6 0.471 + 2.61E-02 1.05E-02 
224430_PM_s_at 
mitochondrial translation optimization 1 homolog (S. 
cerevisiae) 
10672 MTO1 0.329 + 4.43E-03 7.83E-03 
222794_PM_x_at mitochondrial poly(A) polymerase 199731 MTPAP 0.503 + 1.97E-02 1.88E-02 
203774_PM_at 5-methyltetrahydrofolate-homocysteine methyltransferase 1131 MTR 0.326 + 1.68E-02 4.95E-02 
225206_PM_s_at mitochondrial translational release factor 1-like 126328 MTRF1L 0.506 + 1.99E-02 3.16E-02 
210386_PM_s_at metaxin 1 2122 MTX1 0.545 + 3.74E-04 7.83E-03 
203517_PM_at metaxin 2 114788 MTX2 0.873 + 6.80E-03 1.36E-02 
226528_PM_at metaxin 3 1070 MTX3 0.641 + 1.04E-02 2.52E-02 
222531_PM_s_at MU-2/AP1M2 domain containing, death-inducing 23078 MUDENG 0.589 + 1.49E-03 9.60E-03 
218139_PM_s_at MU-2/AP1M2 domain containing, death-inducing 83892 MUDENG 0.611 + 6.36E-03 3.15E-03 
232156_PM_at MU-2/AP1M2 domain containing, death-inducing --- MUDENG 0.704 + 2.34E-02 2.09E-02 
236004_PM_at MU-2/AP1M2 domain containing, death-inducing 51128 MUDENG 0.351 + 2.37E-02 4.17E-02 
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202959_PM_at methylmalonyl Coenzyme A mutase 10910 MUT 0.349 + 1.45E-02 6.68E-03 
207727_PM_s_at mutY homolog (E. coli) 490 MUTYH 0.479 + 5.85E-04 6.75E-03 
226275_PM_at MAX dimerization protein 1 51634 MXD1 0.573 + 1.15E-02 5.31E-03 
235836_PM_at matrix-remodelling associated 7 --- MXRA7 0.330 + 1.65E-02 2.60E-02 
213906_PM_at v-myb myeloblastosis viral oncogene homolog (avian)-like 1 23405 MYBL1 0.552 + 1.83E-02 4.27E-02 
203360_PM_s_at c-myc binding protein 84867 MYCBP 0.479 + 3.51E-03 4.98E-03 
209757_PM_s_at 
v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) 
81545 MYCN 0.853 + 9.13E-03 6.02E-03 
226845_PM_s_at myeloma overexpressed 2 10154 MYEOV2 0.319 + 3.22E-02 1.02E-02 
221474_PM_at myosin, light chain 12B, regulatory 1040 MYL12B 0.363 + 1.81E-03 1.20E-04 
212082_PM_s_at myosin, light chain 6, alkali, smooth muscle and non-muscle 6599 MYL6 0.328 + 4.02E-03 1.62E-02 
219942_PM_at myosin, light chain 7, regulatory 3434 MYL7 0.327 + 1.54E-02 2.97E-02 
224823_PM_at myosin light chain kinase 29094 MYLK 0.391 + 1.59E-02 3.58E-02 
227761_PM_at myosin VA (heavy chain 12, myoxin) 83548 MYO5A 0.285 + 2.93E-02 4.50E-03 
203216_PM_s_at myosin VI 80325 MYO6 0.740 + 2.97E-02 1.07E-02 
214156_PM_at myosin VIIA and Rab interacting protein 23014 MYRIP 0.731 + 1.02E-02 2.56E-03 
221820_PM_s_at MYST histone acetyltransferase 1 4094 MYST1 0.515 + 2.88E-02 1.31E-02 
226547_PM_at MYST histone acetyltransferase (monocytic leukemia) 3 10152 MYST3 0.452 + 7.80E-03 1.89E-02 
213375_PM_s_at NEDD4 binding protein 2-like 1 23355 N4BP2L1 0.305 + 4.10E-02 3.90E-02 
209272_PM_at NGFI-A binding protein 1 (EGR1 binding protein 1) 81611 NAB1 0.683 + 1.23E-02 2.09E-02 
222018_PM_at 
nascent polypeptide-associated complex alpha subunit /// 





0.725 + 6.13E-03 8.79E-03 
202268_PM_s_at NEDD8 activating enzyme E1 subunit 1 27102 NAE1 0.318 + 1.92E-02 1.37E-02 
1555041_PM_a_at N-acetylgalactosaminidase, alpha- 7317 NAGA 0.307 + 7.03E-03 3.03E-02 
228608_PM_at sodium leak channel, non-selective --- NALCN 0.539 + 2.78E-03 7.36E-03 
217738_PM_at nicotinamide phosphoribosyltransferase 80315 NAMPT 0.621 + 1.93E-02 1.18E-02 
217739_PM_s_at nicotinamide phosphoribosyltransferase 80315 NAMPT 0.496 + 2.49E-02 1.91E-02 
218189_PM_s_at N-acetylneuraminic acid synthase 4774 NANS 0.499 + 7.43E-04 5.35E-03 
1556121_PM_at nucleosome assembly protein 1-like 1 2273 NAP1L1 0.553 + 1.37E-02 7.07E-03 
212967_PM_x_at nucleosome assembly protein 1-like 1 9687 NAP1L1 0.349 + 1.50E-02 1.56E-02 
226998_PM_at NMDA receptor regulated 1 4916 NARG1 1.096 + 5.35E-04 6.01E-03 
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219378_PM_at NMDA receptor regulated 1-like 9512 NARG1L 0.474 + 1.60E-02 2.86E-02 
200027_PM_at asparaginyl-tRNA synthetase 4128 NARS 0.343 + 3.58E-02 3.49E-02 
242918_PM_at Nuclear autoantigenic sperm protein (histone-binding) --- NASP 0.872 + 1.27E-02 1.22E-02 
225679_PM_at N-acetyltransferase 12 (GCN5-related, putative) 4059 NAT12 0.465 + 7.62E-03 3.09E-03 
223040_PM_at N-acetyltransferase 5 (GCN5-related, putative) 54585 NAT5 0.375 + 2.40E-03 1.39E-02 
204382_PM_at N-acetyltransferase 9 (GCN5-related, putative) 3836 NAT9 0.301 + 8.13E-04 3.55E-03 
218330_PM_s_at neuron navigator 2 163175 NAV2 0.598 + 1.65E-02 3.09E-02 
204823_PM_at neuron navigator 3 9425 NAV3 0.418 + 2.03E-02 4.22E-02 
202907_PM_s_at nibrin 56934 NBN 0.524 + 9.79E-03 3.09E-02 
201521_PM_s_at nuclear cap binding protein subunit 2, 20kDa 334 NCBP2 0.706 + 3.50E-03 1.65E-02 
207738_PM_s_at NCK-associated protein 1 127544 NCKAP1 0.269 + 1.57E-02 2.97E-03 
209106_PM_at nuclear receptor coactivator 1 7564 NCOA1 0.395 + 8.14E-03 3.45E-02 
209061_PM_at nuclear receptor coactivator 3 80196 NCOA3 0.307 + 1.41E-02 2.05E-02 
210774_PM_s_at nuclear receptor coactivator 4 389362 NCOA4 0.368 + 4.33E-02 3.42E-02 
225344_PM_at nuclear receptor coactivator 7 196294 NCOA7 0.406 + 4.97E-03 1.32E-03 
232910_PM_at non-protein coding RNA 81 200014 NCRNA00081 0.455 + 1.15E-03 8.65E-03 
228993_PM_s_at non-protein coding RNA 81 84132 NCRNA00081 0.949 + 1.37E-03 2.68E-03 
203245_PM_s_at non-protein coding RNA 94 116154 NCRNA00094 0.354 + 9.67E-03 8.47E-03 
237291_PM_at non-protein coding RNA 117 --- NCRNA00117 0.994 + 1.38E-03 4.61E-03 
225786_PM_at non-protein coding RNA 201 --- NCRNA00201 0.845 + 2.46E-02 3.24E-02 
222423_PM_at Nedd4 family interacting protein 1 23012 NDFIP1 0.317 + 1.93E-02 2.92E-02 
224801_PM_at Nedd4 family interacting protein 2 54887 NDFIP2 0.753 + 2.71E-02 5.87E-03 
206022_PM_at Norrie disease (pseudoglioma) 7514 NDP 0.432 + 1.84E-02 5.46E-03 
202607_PM_at N-deacetylase/N-sulfotransferase (323eparin glucosaminyl) 1 54715 NDST1 0.327 + 9.91E-03 1.11E-02 
1554010_PM_at N-deacetylase/N-sulfotransferase (323eparin glucosaminyl) 1 7030 NDST1 0.362 + 2.27E-02 4.72E-02 
202298_PM_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 
7.5kDa 
5859 NDUFA1 0.316 + 8.37E-03 1.93E-02 
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228690_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 
14.7kDa 
401548 NDUFA11 0.417 + 1.26E-02 4.78E-02 
223244_PM_s_at NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 64376 NDUFA12 0.543 + 7.14E-04 5.58E-03 
201304_PM_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 
13kDa 
1032 NDUFA5 0.487 + 1.23E-02 1.08E-02 
202001_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa 
404734 /// 8637 NDUFA6 0.421 + 8.02E-03 8.77E-03 
218160_PM_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 
19kDa 
57544 NDUFA8 0.320 + 4.60E-03 3.49E-03 
204125_PM_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 1 
6173 NDUFAF1 0.536 + 2.82E-03 4.12E-03 
228355_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 2 
58487 NDUFAF2 0.885 + 1.66E-03 1.10E-02 
227559_PM_at 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
assembly factor 4 
100128062 NDUFAF4 0.576 + 8.00E-03 7.90E-03 
206790_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 
7kDa 
8558 NDUFB1 0.408 + 1.52E-03 1.95E-04 
218320_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 
17.3kDa 
219844 NDUFB11 0.264 + 1.08E-02 1.84E-02 
218200_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 
8kDa 
134266 NDUFB2 0.278 + 1.75E-02 1.15E-03 
203613_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 
17kDa 
23576 NDUFB6 0.346 + 5.63E-03 2.36E-02 
201227_PM_s_at 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 
19kDa 
1033 NDUFB8 0.568 + 2.52E-03 2.48E-03 
218101_PM_s_at 
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 
2, 14.5kDa 
64960 NDUFC2 0.339 + 2.06E-03 6.12E-04 
232169_PM_x_at 
NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
114786 NDUFS8 0.433 + 3.31E-02 3.39E-02 
226616_PM_s_at NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa 283450 NDUFV3 0.544 + 8.06E-03 2.56E-02 
241782_PM_at nebulette 55384 NEBL 0.321 + 2.97E-02 4.60E-02 
203962_PM_s_at nebulette 473 NEBL 0.280 + 3.44E-02 4.96E-02 
229461_PM_x_at neuronal growth regulator 1 51585 NEGR1 0.411 + 2.81E-03 2.01E-03 
213331_PM_s_at NIMA (never in mitosis gene a)-related kinase 1 3551 NEK1 0.600 + 2.80E-02 2.33E-02 
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204634_PM_at NIMA (never in mitosis gene a)-related kinase 4 7456 NEK4 0.392 + 8.18E-03 3.15E-02 
212530_PM_at NIMA (never in mitosis gene a)-related kinase 7 80208 NEK7 0.894 + 1.49E-02 3.18E-03 
212299_PM_at NIMA (never in mitosis gene a)- related kinase 9 1329 NEK9 0.479 + 2.08E-02 2.05E-02 
226806_PM_s_at nuclear factor I/A 6738 NFIA 0.461 + 1.41E-02 3.39E-02 
218946_PM_at NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae) 54965 NFU1 0.529 + 2.42E-03 1.59E-03 
218128_PM_at nuclear transcription factor Y, beta 5163 NFYB 0.311 + 1.27E-02 1.18E-02 
220742_PM_s_at N-glycanase 1 51103 NGLY1 0.455 + 2.99E-02 2.50E-02 
219353_PM_at NHL repeat containing 2 1845 NHLRC2 0.473 + 1.90E-02 1.63E-02 
228933_PM_at 
Nance-Horan syndrome (congenital cataracts and dental 
anomalies) 
--- NHS 0.832 + 2.77E-02 3.42E-02 
226490_PM_at NHS-like 1 9412 NHSL1 0.493 + 1.74E-03 8.04E-03 
225752_PM_at non imprinted in Prader-Willi/Angelman syndrome 1 285754 NIPA1 0.511 + 3.81E-02 3.32E-02 
219438_PM_at Na+/K+ transporting ATPase interacting 1 7251 NKAIN1 0.287 + 6.98E-04 2.50E-03 
242002_PM_at Na+/K+ transporting ATPase interacting 2 --- NKAIN2 0.419 + 4.40E-02 1.17E-02 
223439_PM_at NFKB activating protein 11124 NKAP 0.673 + 5.77E-03 6.79E-03 
205004_PM_at NFKB repressing factor 5867 NKRF 0.475 + 3.48E-02 9.53E-03 
231361_PM_at neuroligin 1 29945 NLGN1 0.673 + 7.14E-03 1.79E-02 
201577_PM_at non-metastatic cells 1, protein (NM23A) expressed in 2335 NME1 0.292 + 3.24E-02 9.63E-03 
206197_PM_at 
non-metastatic cells 5, protein expressed in (nucleoside-
diphosphate kinase) 
7327 NME5 0.443 + 1.17E-02 1.62E-02 
219553_PM_at 
non-metastatic cells 7, protein expressed in (nucleoside-
diphosphate kinase) 
3836 NME7 0.792 + 1.02E-03 2.16E-03 
203964_PM_at N-myc (and STAT) interactor 27230 NMI 0.465 + 2.57E-02 1.79E-02 
228090_PM_at nicotinamide nucleotide adenylyltransferase 3 84181 NMNAT3 0.333 + 1.83E-02 3.39E-02 
205006_PM_s_at N-myristoyltransferase 2 25972 NMT2 0.412 + 6.23E-03 1.09E-02 
218889_PM_at nucleolar complex associated 3 homolog (S. cerevisiae) 1874 NOC3L 0.716 + 4.30E-03 4.21E-03 
221970_PM_s_at nucleolar protein 11 130074 NOL11 0.506 + 3.03E-02 2.58E-02 
59625_PM_at nucleolar protein 3 (apoptosis repressor with CARD domain) --- NOL3 0.270 + 9.42E-03 4.13E-02 
238605_PM_at nucleolar protein 4 64783 NOL4 0.672 + 1.75E-02 1.70E-02 
218199_PM_s_at nucleolar protein family 6 (RNA-associated) 55667 NOL6 0.292 + 1.70E-02 1.93E-02 
213838_PM_at nucleolar protein 7, 27kDa 4038 NOL7 0.550 + 1.49E-02 5.18E-03 
202882_PM_x_at nucleolar protein 7, 27kDa 55193 NOL7 0.279 + 2.69E-02 1.07E-02 
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217962_PM_at NOP10 ribonucleoprotein homolog (yeast) 57685 NOP10 0.307 + 2.02E-02 9.25E-03 
200875_PM_s_at NOP56 ribonucleoprotein homolog (yeast) 1827 NOP56 0.266 + 1.03E-02 4.64E-02 
223096_PM_at NOP58 ribonucleoprotein homolog (yeast) 54680 NOP58 0.464 + 6.95E-04 3.82E-03 
39549_PM_at neuronal PAS domain protein 2 --- NPAS2 0.466 + 4.68E-02 1.92E-02 
229281_PM_at neuronal PAS domain protein 3 --- NPAS3 0.729 + 1.09E-03 7.58E-04 
209798_PM_at nuclear protein, ataxia-telangiectasia locus 83999 NPAT 0.855 + 2.77E-02 3.74E-02 
200701_PM_at Niemann-Pick disease, type C2 6595 NPC2 0.534 + 2.05E-02 2.04E-02 
201455_PM_s_at aminopeptidase puromycin sensitive 10636 NPEPPS 0.326 + 4.36E-02 4.86E-02 
221923_PM_s_at nucleophosmin (nucleolar phosphoprotein B23, numatrin) 28954 NPM1 0.751 + 1.30E-02 1.63E-02 
206801_PM_at natriuretic peptide precursor B 11237 NPPB 0.293 + 1.18E-02 2.18E-02 
201468_PM_s_at NAD(P)H dehydrogenase, quinone 1 1622 NQO1 0.548 + 1.43E-03 1.05E-02 
217476_PM_at 
nuclear receptor subfamily 1, group D, member 1 /// thyroid 
hormone receptor, alpha (erythroblastic leukemia viral (v-erb-




0.389 + 8.35E-03 1.04E-02 
207443_PM_at nuclear receptor subfamily 2, group E, member 1 1654 NR2E1 0.903 + 1.79E-02 1.58E-02 
209262_PM_s_at nuclear receptor subfamily 2, group F, member 6 2029 NR2F6 0.306 + 2.55E-03 2.16E-02 
226499_PM_at NOTCH-regulated ankyrin repeat protein 10418 NRARP 0.439 + 8.81E-03 2.21E-02 
224985_PM_at neuroblastoma RAS viral (v-ras) oncogene homolog 403341 NRAS 0.864 + 3.35E-03 2.27E-04 
208241_PM_at neuregulin 1 8833 NRG1 0.302 + 2.89E-03 3.20E-02 
228699_PM_at Neuropilin 2 4076 NRP2 0.277 + 6.49E-04 1.50E-03 
228547_PM_at neurexin 1 8411 NRXN1 0.279 + 5.16E-03 1.29E-02 
215093_PM_at NAD(P) dependent steroid dehydrogenase-like 51025 NSDHL 0.281 + 2.28E-03 5.50E-03 
203269_PM_at 
neutral sphingomyelinase (N-Smase) activation associated 
factor 
116135 NSMAF 0.533 + 2.25E-02 1.42E-02 
211376_PM_s_at non-SMC element 4 homolog A (S. cerevisiae) 317649 NSMCE4A 0.530 + 1.17E-02 1.60E-02 
219067_PM_s_at non-SMC element 4 homolog A (S. cerevisiae) 6506 NSMCE4A 0.645 + 1.85E-02 2.81E-02 
236247_PM_at NOL1/NOP2/Sun domain family, member 4 --- NSUN4 0.284 + 4.54E-03 8.39E-03 
209155_PM_s_at 5’-nucleotidase, cytosolic II 387893 NT5C2 0.324 + 5.72E-03 1.13E-02 
213061_PM_s_at N-terminal asparagine amidase 4879 NTAN1 0.300 + 4.06E-04 3.10E-03 
223315_PM_at netrin 4 54583 NTN4 0.729 + 1.19E-02 1.54E-02 
236088_PM_at netrin G1 5576 NTNG1 0.563 + 2.49E-02 5.03E-03 
213960_PM_at neurotrophic tyrosine kinase, receptor, type 3 124152 NTRK3 0.452 + 2.09E-02 2.12E-02 
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203675_PM_at nucleobindin 2 57541 NUCB2 0.943 + 5.11E-04 2.46E-03 
226642_PM_s_at NudC domain containing 2 9475 NUDCD2 0.699 + 2.09E-02 2.89E-03 
219347_PM_at nudix (nucleoside diphosphate linked moiety X)-type motif 15 7247 NUDT15 0.338 + 3.12E-02 4.10E-02 
212181_PM_s_at 
nudix (nucleoside diphosphate linked moiety X)-type motif 4 /// 





0.327 + 4.63E-02 4.39E-02 
223100_PM_s_at nudix (nucleoside diphosphate linked moiety X)-type motif 5 27344 NUDT5 0.623 + 1.26E-02 9.46E-04 
218375_PM_at nudix (nucleoside diphosphate linked moiety X)-type motif 9 133686 NUDT9 0.531 + 4.88E-03 2.13E-03 
205136_PM_s_at 
nuclear fragile X mental retardation protein interacting protein 
1 
23099 NUFIP1 0.439 + 1.76E-02 4.36E-02 
224938_PM_at 
nuclear fragile X mental retardation protein interacting protein 
2 
64853 NUFIP2 0.553 + 2.02E-03 1.25E-02 
218768_PM_at nucleoporin 107kDa 386618 NUP107 0.738 + 4.32E-03 2.78E-02 
212247_PM_at nucleoporin 205kDa 23077 NUP205 0.779 + 2.00E-02 3.94E-02 
218622_PM_at nucleoporin 37kDa 60684 NUP37 0.847 + 5.05E-04 2.78E-03 
202900_PM_s_at nucleoporin 88kDa 117177 NUP88 0.683 + 2.11E-02 2.42E-02 
204435_PM_at nucleoporin like 1 8522 NUPL1 1.009 + 6.26E-03 5.25E-03 
232377_PM_at neurexophilin 1 91749 NXPH1 0.570 + 3.56E-02 7.32E-03 
218708_PM_at NTF2-like export factor 1 57150 NXT1 0.393 + 4.20E-03 1.00E-02 
202869_PM_at 2’,5’-oligoadenylate synthetase 1, 40/46kDa 55904 OAS1 0.595 + 5.31E-03 1.00E-02 
234841_PM_x_at odorant binding protein 2A /// odorant binding protein 2B 9295 
OBP2A /// 
OBP2B 
0.267 + 2.32E-02 1.09E-02 
233860_PM_s_at odorant binding protein 2A /// odorant binding protein 2B --- 
OBP2A /// 
OBP2B 
0.292 + 2.91E-02 1.54E-02 
205728_PM_at odz, odd Oz/ten-m homolog 1(Drosophila) 9522 ODZ1 1.092 + 1.08E-02 3.34E-02 
203569_PM_s_at oral-facial-digital syndrome 1 56834 OFD1 0.594 + 8.34E-03 1.87E-02 
221090_PM_s_at 
2-oxoglutarate and iron-dependent oxygenase domain 
containing 1 
51367 OGFOD1 0.317 + 1.22E-03 5.87E-03 
225106_PM_s_at 
2-oxoglutarate and iron-dependent oxygenase domain 
containing 1 
51023 OGFOD1 0.336 + 1.01E-02 4.40E-02 
211512_PM_s_at opioid growth factor receptor 1745 OGFR 0.401 + 2.35E-03 1.30E-02 
226810_PM_at opioid growth factor receptor-like 1 196441 OGFRL1 0.624 + 2.68E-03 6.27E-03 
209240_PM_at 
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl 
140803 OGT 0.265 + 2.35E-03 7.68E-03 
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transferase) 
219293_PM_s_at Obg-like ATPase 1 11176 OLA1 0.326 + 7.37E-03 2.76E-03 
207093_PM_s_at oligodendrocyte myelin glycoprotein 377 OMG 0.462 + 2.64E-02 1.63E-02 
212213_PM_x_at optic atrophy 1 (autosomal dominant) 51663 OPA1 0.312 + 1.36E-02 4.77E-02 
203351_PM_s_at origin recognition complex, subunit 4-like (yeast) 131408 ORC4L 0.264 + 4.06E-03 4.93E-03 
204957_PM_at origin recognition complex, subunit 5-like (yeast) 26292 ORC5L 0.703 + 1.67E-02 1.81E-02 
227548_PM_at ORM1-like 1 (S. cerevisiae) 7503 ORMDL1 0.435 + 1.51E-02 1.53E-03 
200714_PM_x_at osteosarcoma amplified 9, endoplasmic reticulum lectin 5451 OS9 0.272 + 1.35E-02 1.32E-02 
218304_PM_s_at oxysterol binding protein-like 11 146705 OSBPL11 0.545 + 2.90E-02 4.31E-02 
212585_PM_at oxysterol binding protein-like 8 9377 OSBPL8 0.643 + 1.59E-02 5.58E-03 
218047_PM_at oxysterol binding protein-like 9 23468 OSBPL9 0.340 + 1.80E-02 5.58E-03 
235198_PM_at osteopetrosis associated transmembrane protein 1 23503 OSTM1 0.520 + 1.03E-02 1.19E-02 
235197_PM_s_at osteopetrosis associated transmembrane protein 1 --- OSTM1 0.271 + 1.21E-02 3.48E-02 
226140_PM_s_at OTU domain containing 1 10412 OTUD1 0.474 + 3.81E-02 3.96E-02 
203480_PM_s_at OTU domain containing 4 5080 OTUD4 0.421 + 1.77E-02 1.20E-02 
222553_PM_x_at oxidation resistance 1 9479 OXR1 0.459 + 1.81E-02 1.91E-03 
235885_PM_at purinergic receptor P2Y, G-protein coupled, 12 54883 P2RY12 0.978 + 2.80E-02 2.44E-02 
202733_PM_at prolyl 4-hydroxylase, alpha polypeptide II 51150 P4HA2 0.507 + 2.07E-03 2.20E-02 
218957_PM_s_at proteasomal ATPase-associated factor 1 163051 PAAF1 0.315 + 4.82E-02 2.49E-02 
214204_PM_at PARK2 co-regulated 29966 PACRG 0.875 + 5.55E-05 1.72E-03 
227354_PM_at 
phosphoprotein associated with glycosphingolipid 
microdomains 1 
844 PAG1 0.521 + 6.50E-03 6.50E-03 
208051_PM_s_at poly(A) binding protein interacting protein 1 23215 PAIP1 0.422 + 1.73E-02 2.60E-02 
222984_PM_at poly(A) binding protein interacting protein 2 23469 PAIP2 0.413 + 1.16E-03 3.95E-03 
230100_PM_x_at p21 protein (Cdc42/Rac)-activated kinase 1 90624 PAK1 0.314 + 4.87E-02 4.88E-02 
208878_PM_s_at p21 protein (Cdc42/Rac)-activated kinase 2 55055 PAK2 0.295 + 7.99E-03 2.66E-03 
210721_PM_s_at p21 protein (Cdc42/Rac)-activated kinase 7 
100293328 /// 
90736 
PAK7 0.721 + 7.00E-04 2.68E-03 
219530_PM_at partner and localizer of BRCA2 3799 PALB2 0.341 + 4.89E-02 4.74E-02 
200897_PM_s_at 328eparin, cytoskeletal associated protein 5915 PALLD 0.966 + 6.07E-03 1.21E-02 
218736_PM_s_at palmdelphin 8110 PALMD 0.359 + 4.92E-02 3.51E-02 
225563_PM_at PAN3 poly(A) specific ribonuclease subunit homolog (S. 80127 PAN3 0.569 + 8.91E-03 1.17E-02 
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cerevisiae) 
218809_PM_at pantothenate kinase 2 155054 PANK2 0.428 + 8.28E-03 1.43E-04 
221941_PM_at polyamine oxidase (exo-N4-amino) 3709 PAOX 0.417 + 4.58E-02 3.11E-02 
231397_PM_at phosphatidic acid phosphatase type 2 196047 PAP2D 0.731 + 2.26E-02 1.55E-02 
229043_PM_at PAP associated domain containing 5 3344 PAPD5 0.816 + 1.75E-02 1.90E-03 
228569_PM_at poly(A) polymerase alpha 9931 PAPOLA 0.618 + 1.50E-02 1.51E-03 
222273_PM_at poly(A) polymerase gamma 5962 PAPOLG 0.924 + 3.87E-03 6.15E-03 
213372_PM_at progestin and adipoQ receptor family member III 3479 PAQR3 0.709 + 2.76E-02 8.77E-03 
227626_PM_at progestin and adipoQ receptor family member VIII 6925 PAQR8 0.331 + 2.70E-02 1.45E-02 
228411_PM_at par-3 partitioning defective 3 homolog B (C. elegans) 84933 PARD3B 0.512 + 2.47E-02 2.40E-02 
205060_PM_at poly (ADP-ribose) glycohydrolase 10618 PARG 0.302 + 2.72E-02 9.66E-03 
200006_PM_at Parkinson disease (autosomal recessive, early onset) 7 4005 PARK7 0.341 + 5.33E-03 2.65E-03 
214086_PM_s_at poly (ADP-ribose) polymerase 2 771 PARP2 0.460 + 2.06E-02 6.86E-03 
215773_PM_x_at poly (ADP-ribose) polymerase 2 81892 PARP2 0.490 + 2.42E-02 2.10E-02 
219033_PM_at poly (ADP-ribose) polymerase family, member 8 56776 PARP8 0.904 + 6.32E-03 1.77E-02 
217890_PM_s_at parvin, alpha 55841 PARVA 0.577 + 4.81E-02 2.43E-02 
206802_PM_at paired box 5 57144 PAX5 0.286 + 2.06E-02 1.27E-02 
235795_PM_at paired box 6 51333 PAX6 0.665 + 8.92E-04 2.77E-03 
219543_PM_at phenazine biosynthesis-like protein domain containing 23013 PBLD 0.270 + 9.66E-03 2.80E-02 
223238_PM_s_at polybromo 1 80724 PBRM1 0.752 + 2.09E-03 2.92E-03 
212148_PM_at pre-B-cell leukemia homeobox 1 2937 PBX1 0.450 + 5.09E-03 4.30E-02 
214177_PM_s_at pre-B-cell leukemia homeobox interacting protein 1 9546 PBXIP1 0.351 + 2.47E-02 7.62E-04 
213264_PM_at poly(rC) binding protein 2 7150 PCBP2 0.365 + 7.25E-03 2.31E-02 
203860_PM_at propionyl Coenzyme A carboxylase, alpha polypeptide 11014 PCCA 0.559 + 8.44E-03 2.89E-02 
228863_PM_at protocadherin 17 80012 PCDH17 0.716 + 7.15E-03 4.98E-03 
227622_PM_at 
PCF11, cleavage and polyadenylation factor subunit, homolog 
(S. cerevisiae) 
5165 PCF11 0.398 + 1.36E-02 1.48E-02 
203792_PM_x_at polycomb group ring finger 2 5286 PCGF2 0.360 + 1.16E-02 3.71E-02 
226326_PM_at polycomb group ring finger 5 6038 PCGF5 0.561 + 4.33E-02 1.81E-02 
201202_PM_at proliferating cell nuclear antigen 8881 PCNA 0.412 + 5.33E-03 1.11E-02 
217816_PM_s_at PEST proteolytic signal containing nuclear protein 54331 PCNP 0.384 + 3.10E-03 2.13E-03 
203660_PM_s_at pericentrin 3632 PCNT 0.480 + 1.13E-02 1.01E-02 
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229287_PM_at pecanex homolog (Drosophila) 100131564 PCNX 0.533 + 1.38E-02 1.30E-02 
205549_PM_at Purkinje cell protein 4 8448 PCP4 0.599 + 2.80E-02 9.79E-04 
213652_PM_at Proprotein convertase subtilisin/kexin type 5 23122 PCSK5 0.779 + 7.48E-03 1.74E-02 
221918_PM_at PCTAIRE protein kinase 2 100272147 PCTK2 0.364 + 4.05E-02 2.48E-02 
218953_PM_s_at prenylcysteine oxidase 1 like 84984 PCYOX1L 0.345 + 5.42E-03 1.40E-02 
232553_PM_at phosphate cytidylyltransferase 1, choline, beta 23043 PCYT1B 0.362 + 9.32E-03 3.58E-02 
210907_PM_s_at programmed cell death 10 79184 PDCD10 0.690 + 2.82E-03 3.17E-03 
204025_PM_s_at programmed cell death 2 9774 PDCD2 0.756 + 2.15E-03 2.04E-03 
224467_PM_s_at programmed cell death 2-like 11112 PDCD2L 0.436 + 4.97E-03 1.96E-03 
231213_PM_at phosphodiesterase 1A, calmodulin-dependent 57695 PDE1A 0.735 + 1.39E-02 2.57E-02 
204491_PM_at 
phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 
dunce homolog, Drosophila) 
3910 PDE4D 0.459 + 2.29E-02 1.29E-02 
213388_PM_at phosphodiesterase 4D interacting protein 9655 PDE4DIP 0.490 + 2.40E-02 4.02E-02 
214099_PM_s_at phosphodiesterase 4D interacting protein 1314 PDE4DIP 0.585 + 2.67E-02 2.25E-02 
227088_PM_at phosphodiesterase 5A, cGMP-specific 55233 PDE5A 0.307 + 5.91E-03 3.62E-02 
223358_PM_s_at phosphodiesterase 7A 90806 PDE7A 0.313 + 1.55E-02 4.20E-02 
230109_PM_at phosphodiesterase 7B 2043 PDE7B 0.271 + 5.26E-03 2.13E-02 
212522_PM_at phosphodiesterase 8A 9801 PDE8A 0.307 + 2.90E-02 8.62E-03 
218718_PM_at platelet derived growth factor C 129881 PDGFC 0.519 + 7.16E-03 2.47E-02 
203131_PM_at platelet-derived growth factor receptor, alpha polypeptide 170622 PDGFRA 0.572 + 1.50E-02 1.19E-02 
205226_PM_at platelet-derived growth factor receptor-like 7188 PDGFRL 0.310 + 4.70E-03 8.43E-03 
211023_PM_at pyruvate dehydrogenase (lipoamide) beta 22807 PDHB 0.380 + 4.36E-03 1.02E-02 
203067_PM_at pyruvate dehydrogenase complex, component X 4638 PDHX 0.570 + 2.94E-02 4.51E-02 
208638_PM_at protein disulfide isomerase family A, member 6 23369 PDIA6 0.313 + 3.30E-02 4.87E-02 
226452_PM_at pyruvate dehydrogenase kinase, isozyme 1 5062 PDK1 0.325 + 1.36E-02 8.46E-03 
224904_PM_at pyruvate dehydrogenase phosphatase regulatory subunit 6198 PDPR 0.304 + 4.96E-03 7.77E-03 
212140_PM_at 
PDS5, regulator of cohesion maintenance, homolog A (S. 
cerevisiae) 
5500 PDS5A 0.588 + 3.04E-02 2.21E-02 
204742_PM_s_at 
PDS5, regulator of cohesion maintenance, homolog B (S. 
cerevisiae) 
10907 PDS5B 0.432 + 1.08E-02 1.12E-02 
220865_PM_s_at prenyl (decaprenyl) diphosphate synthase, subunit 1 25906 PDSS1 0.844 + 7.61E-03 7.99E-03 
219307_PM_at prenyl (decaprenyl) diphosphate synthase, subunit 2 6659 PDSS2 0.434 + 1.05E-03 6.91E-03 
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220595_PM_at PDZ domain containing ring finger 4 8504 PDZRN4 0.426 + 2.69E-02 3.38E-02 
208982_PM_at platelet/endothelial cell adhesion molecule 57117 PECAM1 0.473 + 9.31E-03 2.98E-02 
209242_PM_at paternally expressed 3 29919 PEG3 0.439 + 2.30E-03 5.71E-04 
232304_PM_at Pellino homolog 1 (Drosophila) 91408 PELI1 0.808 + 3.14E-02 2.40E-02 
218472_PM_s_at pelota homolog (Drosophila) 64710 PELO 0.349 + 2.70E-02 4.30E-02 
205251_PM_at period homolog 2 (Drosophila) 9857 PER2 0.458 + 2.47E-02 2.33E-02 
222392_PM_x_at PERP, TP53 apoptosis effector 64795 PERP 0.642 + 1.82E-02 3.37E-02 
228541_PM_x_at PERP, TP53 apoptosis effector 84912 PERP 0.294 + 4.52E-02 4.54E-02 
201707_PM_at peroxisomal biogenesis factor 19 6595 PEX19 0.488 + 9.74E-03 2.26E-02 
203970_PM_s_at peroxisomal biogenesis factor 3 5538 PEX3 0.436 + 1.87E-02 2.70E-02 
205362_PM_s_at prefoldin subunit 4 10329 PFDN4 0.300 + 2.81E-03 1.31E-02 
205361_PM_s_at prefoldin subunit 4 11326 PFDN4 0.518 + 1.52E-02 4.25E-03 
242048_PM_at prefoldin subunit 6 --- PFDN6 0.275 + 2.01E-02 3.66E-02 
226733_PM_at 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 10116 PFKFB2 0.721 + 1.32E-02 1.17E-02 
239725_PM_at post-GPI attachment to proteins 1 --- PGAP1 0.467 + 3.00E-03 2.28E-03 
220576_PM_at post-GPI attachment to proteins 1 2730 PGAP1 0.414 + 1.24E-02 3.19E-02 
200738_PM_s_at phosphoglycerate kinase 1 4050 PGK1 0.273 + 5.00E-02 4.28E-02 
225367_PM_at phosphoglucomutase 2 58512 PGM2 0.472 + 4.59E-03 2.52E-02 
229256_PM_at phosphoglucomutase 2-like 1 23161 PGM2L1 0.446 + 5.72E-03 6.63E-03 
210041_PM_s_at phosphoglucomutase 3 122786 PGM3 0.467 + 8.78E-03 2.93E-03 
227949_PM_at phosphatase and actin regulator 3 7528 PHACTR3 0.444 + 1.98E-02 1.18E-02 
225958_PM_at polyhomeotic homolog 1 (Drosophila) --- PHC1 0.559 + 2.89E-02 4.57E-02 
226508_PM_at polyhomeotic homolog 3 (Drosophila) 201254 PHC3 0.666 + 4.43E-03 1.46E-03 
225048_PM_at PHD finger protein 10 254170 PHF10 0.508 + 1.65E-02 1.64E-03 
221816_PM_s_at PHD finger protein 11 5495 PHF11 0.462 + 1.83E-02 1.08E-02 
225816_PM_at PHD finger protein 17 374408 PHF17 0.502 + 1.26E-02 1.01E-02 
217954_PM_s_at PHD finger protein 3 84295 PHF3 0.420 + 1.53E-02 1.16E-02 
225501_PM_at PHD finger protein 6 129450 PHF6 0.386 + 4.88E-02 3.33E-02 
213074_PM_at pleckstrin homology domain interacting protein 9283 PHIP 0.604 + 2.03E-02 4.98E-03 
229876_PM_at phosphorylase kinase, alpha 1 (muscle) 92 PHKA1 0.935 + 3.32E-03 4.28E-03 
213407_PM_at PH domain and leucine rich repeat protein phosphatase 2 6404 PHLPP2 0.635 + 9.59E-03 2.08E-02 
230434_PM_at phosphatase, orphan 2 258010 PHOSPHO2 0.775 + 2.22E-03 2.10E-03 
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217863_PM_at protein inhibitor of activated STAT, 1 143888 PIAS1 0.515 + 1.20E-02 1.08E-02 
213239_PM_at progesterone immunomodulatory binding factor 1 23741 PIBF1 0.358 + 2.53E-03 1.00E-02 
212511_PM_at phosphatidylinositol binding clathrin assembly protein 25842 PICALM 1.083 + 2.69E-02 2.67E-02 
205452_PM_at phosphatidylinositol glycan anchor biosynthesis, class B 10234 PIGB 0.802 + 1.55E-03 4.10E-03 
202846_PM_s_at phosphatidylinositol glycan anchor biosynthesis, class C 55591 PIGC 0.696 + 5.76E-03 1.05E-02 
205077_PM_s_at phosphatidylinositol glycan anchor biosynthesis, class F 10479 PIGF 0.696 + 9.42E-04 4.42E-04 
209707_PM_at phosphatidylinositol glycan anchor biosynthesis, class K 51520 PIGK 0.558 + 1.19E-02 1.40E-02 
227639_PM_at phosphatidylinositol glycan anchor biosynthesis, class K 51187 PIGK 0.739 + 2.01E-02 1.13E-02 
1558292_PM_s_at phosphatidylinositol glycan anchor biosynthesis, class W 9637 PIGW 0.638 + 2.33E-04 2.40E-04 
1552291_PM_at phosphatidylinositol glycan anchor biosynthesis, class X 3716 PIGX 0.424 + 3.38E-02 3.76E-02 
224660_PM_at phosphatidylinositol glycan anchor biosynthesis, class Y 80314 PIGY 0.335 + 2.29E-02 4.05E-02 
220041_PM_at phosphatidylinositol glycan anchor biosynthesis, class Z 6990 PIGZ 0.327 + 9.43E-03 3.97E-02 
213070_PM_at phosphoinositide-3-kinase, class 2, alpha polypeptide 2980 PIK3C2A 0.709 + 6.43E-03 8.23E-03 
212688_PM_at phosphoinositide-3-kinase, catalytic, beta polypeptide 4900 PIK3CB 0.573 + 3.22E-02 3.63E-02 
203879_PM_at phosphoinositide-3-kinase, catalytic, delta polypeptide 813 PIK3CD 0.570 + 9.62E-03 1.98E-02 
212740_PM_at phosphoinositide-3-kinase, regulatory subunit 4 8732 PIK3R4 0.322 + 4.74E-02 2.86E-02 
214224_PM_s_at 
protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 
4 (parvulin) 
55966 PIN4 0.603 + 5.02E-03 8.19E-03 
204571_PM_x_at 
protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 
4 (parvulin) 
10982 PIN4 0.543 + 1.07E-02 2.84E-02 
207469_PM_s_at pirin (iron-binding nuclear protein) 23029 PIR 0.359 + 2.29E-02 3.01E-02 
202522_PM_at phosphatidylinositol transfer protein, beta 51389 PITPNB 0.500 + 2.76E-02 1.02E-02 
229414_PM_at phosphatidylinositol transfer protein, cytoplasmic 1 134147 PITPNC1 0.784 + 2.68E-03 1.34E-02 
214868_PM_at piwi-like 1 (Drosophila) 79887 PIWIL1 0.300 + 4.49E-03 1.06E-02 
226864_PM_at Protein kinase (cAMP-dependent, catalytic) inhibitor alpha 23033 PKIA 0.545 + 2.26E-02 1.28E-02 
223551_PM_at protein kinase (cAMP-dependent, catalytic) inhibitor beta 7468 PKIB 0.576 + 8.31E-03 2.49E-02 
214874_PM_at plakophilin 4 79735 PKP4 0.767 + 1.04E-02 1.41E-02 
224751_PM_at PL-5283 protein 79960 PL-5283 0.557 + 1.29E-02 2.08E-02 
224752_PM_at PL-5283 protein 259282 PL-5283 0.431 + 4.39E-02 2.49E-02 
215870_PM_s_at phospholipase A2, group V 54737 PLA2G5 0.458 + 3.20E-02 9.81E-03 
244374_PM_at placenta-specific 2 (non-protein coding) --- PLAC2 0.318 + 3.48E-03 2.29E-03 
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229385_PM_s_at placenta-specific 2 (non-protein coding) 85439 PLAC2 0.329 + 2.08E-02 4.73E-02 
205372_PM_at pleiomorphic adenoma gene 1 9949 PLAG1 0.274 + 2.63E-02 1.06E-02 
201860_PM_s_at plasminogen activator, tissue 10605 /// 645139 PLAT 0.499 + 2.81E-02 1.13E-02 
218454_PM_at phospholipase B domain containing 1 118491 PLBD1 0.889 + 2.67E-02 3.51E-02 
202789_PM_at phospholipase C, gamma 1 159090 PLCG1 0.341 + 4.51E-04 6.39E-03 
204613_PM_at phospholipase C, gamma 2 (phosphatidylinositol-specific) 27336 PLCG2 0.407 + 3.60E-02 3.82E-02 
214745_PM_at phospholipase C, eta 1 51082 PLCH1 0.672 + 1.73E-02 6.25E-04 
213309_PM_at phospholipase C-like 2 23299 PLCL2 0.689 + 2.28E-02 7.77E-03 
224892_PM_at pallidin homolog (mouse) 147184 PLDN 0.486 + 1.81E-02 1.58E-02 
223370_PM_at 
pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 3 
4869 PLEKHA3 0.570 + 2.45E-03 9.19E-03 
220952_PM_s_at pleckstrin homology domain containing, family A member 5 23768 PLEKHA5 0.569 + 1.85E-02 1.32E-02 
201410_PM_at 
pleckstrin homology domain containing, family B (evectins) 
member 2 
2902 PLEKHB2 0.410 + 1.32E-02 1.98E-02 
218640_PM_s_at 
pleckstrin homology domain containing, family F (with FYVE 
domain) member 2 
146956 PLEKHF2 0.351 + 2.87E-03 1.83E-02 
227148_PM_at 
pleckstrin homology domain containing, family H (with MyTH4 
domain) member 2 
50628 PLEKHH2 0.297 + 1.02E-02 1.52E-02 
200827_PM_at procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 118 PLOD1 0.311 + 3.27E-03 8.47E-03 
213241_PM_at plexin C1 51433 PLXNC1 1.041 + 3.12E-02 1.87E-02 
225421_PM_at peptidase M20 domain containing 2 140700 PM20D2 0.438 + 8.95E-03 2.76E-02 
201682_PM_at peptidase (mitochondrial processing) beta 23543 PMPCB 0.353 + 3.85E-02 4.58E-02 
213677_PM_s_at PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 9522 PMS1 1.093 + 2.55E-03 2.08E-03 
216039_PM_at postmeiotic segregation increased 2-like 5-like  83444 PMS2L5 0.713 + 2.56E-02 9.42E-03 
212037_PM_at pinin, desmosome associated protein 23022 PNN 0.492 + 2.70E-02 1.77E-02 
1567214_PM_a_at pinin, desmosome associated protein 26019 PNN 0.304 + 3.29E-02 1.02E-02 
225291_PM_at polyribonucleotide nucleotidyltransferase 1 90161 PNPT1 0.694 + 2.46E-02 2.51E-02 
209578_PM_s_at protein O-fucosyltransferase 2 56894 POFUT2 0.420 + 5.48E-03 2.04E-02 
214226_PM_at polyserase 3 771 POL3S 0.378 + 3.24E-02 3.34E-02 
204835_PM_at polymerase (DNA directed), alpha 1, catalytic subunit 9830 POLA1 0.340 + 4.16E-03 2.16E-03 
203616_PM_at polymerase (DNA directed), beta 253982 POLB 0.563 + 5.92E-04 1.65E-03 
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217806_PM_s_at polymerase (DNA-directed), delta interacting protein 2 221037 POLDIP2 0.300 + 2.87E-02 3.04E-02 
203366_PM_at polymerase (DNA directed), gamma 55959 POLG 0.306 + 5.47E-03 8.44E-03 
219317_PM_at polymerase (DNA directed) iota 7265 POLI 0.602 + 4.57E-02 2.17E-02 
218258_PM_at polymerase (RNA) I polypeptide D, 16kDa 112609 POLR1D 0.713 + 1.21E-03 2.43E-03 
231041_PM_at polymerase (RNA) I polypeptide E, 53kDa 3767 POLR1E 0.277 + 4.56E-02 2.77E-02 
201803_PM_at polymerase (RNA) II (DNA directed) polypeptide B, 140kDa 6125 POLR2B 0.353 + 3.58E-02 1.15E-02 
1555837_PM_s_at polymerase (RNA) II (DNA directed) polypeptide B, 140kDa 3295 POLR2B 0.301 + 4.60E-02 4.74E-02 
214263_PM_x_at polymerase (RNA) II (DNA directed) polypeptide C, 33kDa 49855 POLR2C 0.533 + 1.63E-02 7.24E-03 
209511_PM_at polymerase (RNA) II (DNA directed) polypeptide F 9406 POLR2F 0.359 + 5.04E-03 1.89E-02 
202306_PM_at polymerase (RNA) II (DNA directed) polypeptide G 51566 POLR2G 0.496 + 8.01E-03 1.68E-03 
202635_PM_s_at polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa 2661 POLR2K 0.377 + 1.98E-03 5.43E-03 
202634_PM_at polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa 84991 POLR2K 0.507 + 1.88E-02 2.71E-02 
211730_PM_s_at polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa 11329 POLR2L 0.274 + 4.29E-02 4.30E-02 
227872_PM_at polymerase (RNA) III (DNA directed) polypeptide A, 155kDa 54467 POLR3A 0.265 + 3.07E-02 1.88E-02 
209382_PM_at polymerase (RNA) III (DNA directed) polypeptide C (62kD) 58508 POLR3C 0.635 + 4.53E-02 4.76E-02 
222490_PM_at polymerase (RNA) III (DNA directed) polypeptide E (80kD) 23076 POLR3E 0.633 + 2.70E-02 3.11E-02 
223269_PM_at 
polymerase (RNA) III (DNA directed) polypeptide G (32kD)-
like 
79924 POLR3GL 0.356 + 1.56E-02 3.94E-02 
202466_PM_at polymerase (DNA directed) sigma 29803 POLS 0.481 + 1.21E-02 3.97E-03 
217769_PM_s_at proteasome maturation protein 10413 POMP 0.543 + 1.39E-03 2.71E-03 
220632_PM_s_at protein-O-mannosyltransferase 2 9836 POMT2 0.420 + 2.73E-03 1.80E-02 
201876_PM_at paraoxonase 2 6535 PON2 0.647 + 1.78E-03 5.89E-03 
202868_PM_s_at 
processing of precursor 4, ribonuclease P/MRP subunit (S. 
cerevisiae) 
55904 POP4 0.417 + 2.96E-02 1.13E-02 
204839_PM_at 
processing of precursor 5, ribonuclease P/MRP subunit (S. 
cerevisiae) 
64976 POP5 0.587 + 7.13E-03 6.40E-03 
227254_PM_at POU class 2 homeobox 1 64418 POU2F1 0.495 + 3.62E-02 3.43E-02 
242455_PM_at POU class 3 homeobox 2 --- POU3F2 0.433 + 3.23E-02 1.28E-02 
217848_PM_s_at pyrophosphatase (inorganic) 1 387882 PPA1 0.459 + 3.37E-03 3.75E-03 
220741_PM_s_at pyrophosphatase (inorganic) 2 4199 PPA2 0.619 + 1.08E-03 5.37E-03 
208044_PM_s_at peroxisome proliferator-activated receptor delta 8930 PPARD 0.546 + 1.14E-03 1.29E-03 
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37152_PM_at peroxisome proliferator-activated receptor delta --- PPARD 0.667 + 7.34E-03 1.37E-02 
219195_PM_at 
peroxisome proliferator-activated receptor gamma, coactivator 
1 alpha 
10577 PPARGC1A 0.523 + 2.08E-02 2.34E-02 
235833_PM_at Phosphoribosyl pyrophosphate amidotransferase 64895 PPAT 0.306 + 5.21E-03 1.21E-02 
218341_PM_at phosphopantothenoylcysteine synthetase 29796 PPCS 0.339 + 6.04E-03 1.64E-02 
202066_PM_at 
protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 1 
84271 PPFIA1 0.434 + 3.64E-02 3.81E-02 
226336_PM_at peptidylprolyl isomerase A (cyclophilin A) 5502 PPIA 0.323 + 8.48E-03 2.63E-02 
204228_PM_at peptidylprolyl isomerase H (cyclophilin H) 9097 PPIH 0.540 + 2.43E-03 8.79E-03 
222500_PM_at peptidylprolyl isomerase (cyclophilin)-like 1 10484 PPIL1 0.410 + 1.39E-02 1.91E-02 
224364_PM_s_at peptidylprolyl isomerase (cyclophilin)-like 3 27327 PPIL3 0.561 + 3.05E-03 5.18E-03 
227728_PM_at 
protein phosphatase 1A (formerly 2C), magnesium-
dependent, alpha isoform 
51241 PPM1A 0.653 + 6.78E-03 3.31E-03 
229027_PM_at 
protein phosphatase 1A (formerly 2C), magnesium-
dependent, alpha isoform 
129607 PPM1A 0.427 + 1.60E-02 4.51E-02 
213225_PM_at 
protein phosphatase 1B (formerly 2C), magnesium-
dependent, beta isoform 
9545 PPM1B 0.762 + 2.97E-02 4.42E-02 
209296_PM_at 
protein phosphatase 1B (formerly 2C), magnesium-
dependent, beta isoform 
3157 PPM1B 0.421 + 3.50E-02 7.46E-04 
37384_PM_at protein phosphatase 1F (PP2C domain containing) --- PPM1F 0.362 + 9.74E-03 1.51E-02 
201408_PM_at protein phosphatase 1, catalytic subunit, beta isoform 8031 PPP1CB 0.385 + 4.86E-03 1.97E-02 
201407_PM_s_at protein phosphatase 1, catalytic subunit, beta isoform 10395 PPP1CB 0.436 + 6.78E-03 3.41E-03 
201603_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 12A 10580 PPP1R12A 0.333 + 4.36E-02 2.68E-02 
41577_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 16B 387978 PPP1R16B 0.433 + 4.07E-02 1.38E-02 
235129_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 1A --- PPP1R1A 0.273 + 3.13E-02 3.29E-02 
202165_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 2 387522 /// 7335 PPP1R2 0.349 + 1.05E-02 1.68E-02 
204554_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 3D 9318 PPP1R3D 0.270 + 4.41E-02 1.86E-02 
228494_PM_at protein phosphatase 1, regulatory (inhibitor) subunit 9A 6558 PPP1R9A 0.471 + 3.16E-03 3.07E-03 
202883_PM_s_at 
protein phosphatase 2 (formerly 2A), regulatory subunit A, 
beta isoform 
55967 PPP2R1B 0.610 + 5.51E-04 2.02E-03 
222351_PM_at 
protein phosphatase 2 (formerly 2A), regulatory subunit A, 
beta isoform 
9522 PPP2R1B 0.282 + 3.00E-02 4.09E-02 
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218852_PM_at 
protein phosphatase 2 (formerly 2A), regulatory subunit B’’, 
gamma 
139231 PPP2R3C 0.650 + 5.44E-03 2.20E-03 
202187_PM_s_at protein phosphatase 2, regulatory subunit B’, alpha isoform 80036 PPP2R5A 0.480 + 4.28E-02 1.51E-02 
201594_PM_s_at protein phosphatase 4, regulatory subunit 1 8514 PPP4R1 0.623 + 2.17E-02 8.02E-03 
233002_PM_at protein phosphatase 4, regulatory subunit 4 124540 PPP4R4 0.995 + 3.26E-02 2.10E-02 
225429_PM_at protein phosphatase 6, catalytic subunit 116443 PPP6C 0.345 + 3.65E-02 2.91E-02 
212371_PM_at PPPDE peptidase domain containing 1 23484 PPPDE1 0.583 + 3.27E-02 3.65E-02 
200975_PM_at palmitoyl-protein thioesterase 1 7341 PPT1 0.345 + 4.27E-02 1.47E-02 
213483_PM_at peptidylprolyl isomerase domain and WD repeat containing 1 4580 PPWD1 0.414 + 2.81E-03 9.46E-03 
201494_PM_at prolylcarboxypeptidase (angiotensinase C) 8573 PRCP 0.273 + 3.06E-02 4.39E-02 
203057_PM_s_at PR domain containing 2, with ZNF domain 220002 PRDM2 0.427 + 3.49E-02 1.75E-02 
218329_PM_at PR domain containing 4 59084 PRDM4 0.370 + 6.42E-03 2.82E-02 
201923_PM_at peroxiredoxin 4 727927 /// 9659 PRDX4 0.499 + 5.79E-03 6.16E-03 
228224_PM_at proline/arginine-rich end leucine-rich repeat protein 10772 PRELP 0.385 + 9.70E-03 2.39E-02 
218233_PM_s_at 
prickle homolog 4 (Drosophila) /// translocase of outer 




0.282 + 2.32E-02 2.03E-02 
205053_PM_at primase, DNA, polypeptide 1 (49kDa) 1998 PRIM1 0.447 + 9.21E-03 3.37E-02 
225985_PM_at protein kinase, AMP-activated, alpha 1 catalytic subunit 8724 PRKAA1 0.320 + 1.20E-02 4.81E-02 
225011_PM_at Protein kinase, cAMP-dependent, regulatory, type II, alpha 338657 PRKAR2A 0.647 + 4.19E-04 1.19E-03 
203680_PM_at protein kinase, cAMP-dependent, regulatory, type II, beta 23261 PRKAR2B 0.435 + 2.02E-02 1.23E-02 
213010_PM_at protein kinase C, delta binding protein 8382 PRKCDBP 0.275 + 5.47E-03 2.28E-02 
218764_PM_at protein kinase C, eta 83659 PRKCH 0.418 + 2.18E-02 1.23E-02 
205880_PM_at protein kinase D1 8527 PRKD1 0.749 + 1.55E-02 1.97E-02 
228396_PM_at protein kinase, cGMP-dependent, type I 339745 PRKG1 1.395 + 2.95E-03 4.16E-03 
209323_PM_at 
protein-kinase, interferon-inducible double stranded RNA 
dependent inhibitor, repressor of (P58 repressor) 
196403 PRKRIR 0.843 + 7.78E-03 8.00E-03 
1564520_PM_s_at protein arginine methyltransferase 5 1855 PRMT5 0.277 + 1.78E-02 2.95E-02 
207808_PM_s_at protein S (alpha) 7337 PROS1 0.416 + 2.11E-02 1.63E-02 
209384_PM_at proline synthetase co-transcribed homolog (bacterial) 28977 PROSC 0.744 + 7.32E-04 5.18E-03 
202251_PM_at PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae) 1350 PRPF3 0.683 + 8.03E-03 9.32E-03 
202127_PM_at PRP4 pre-mRNA processing factor 4 homolog B (yeast) 604 PRPF4B 0.504 + 3.54E-03 4.53E-03 
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202126_PM_at PRP4 pre-mRNA processing factor 4 homolog B (yeast) 2710 PRPF4B 0.517 + 2.34E-02 9.28E-03 
209440_PM_at phosphoribosyl pyrophosphate synthetase 1 30001 PRPS1 0.285 + 3.15E-02 1.20E-02 
220014_PM_at proline rich 16 8439 PRR16 0.946 + 1.69E-02 1.36E-02 
224643_PM_at proline-rich coiled-coil 1 131118 PRRC1 0.396 + 9.82E-03 1.67E-02 
222803_PM_at phosphoribosyl transferase domain containing 1 51710 PRTFDC1 0.319 + 3.36E-02 1.31E-02 
212805_PM_at prune homolog 2 (Drosophila) 9738 PRUNE2 0.383 + 1.21E-02 1.69E-02 
211746_PM_x_at proteasome (prosome, macropain) subunit, alpha type, 1 64478 PSMA1 0.348 + 1.36E-02 3.35E-02 
201317_PM_s_at proteasome (prosome, macropain) subunit, alpha type, 2 814 PSMA2 0.321 + 1.77E-02 1.23E-02 
201316_PM_at proteasome (prosome, macropain) subunit, alpha type, 2 47 PSMA2 0.341 + 3.50E-02 1.57E-02 
201532_PM_at proteasome (prosome, macropain) subunit, alpha type, 3 5265 PSMA3 0.302 + 3.11E-02 4.18E-02 
201274_PM_at proteasome (prosome, macropain) subunit, alpha type, 5 5238 PSMA5 0.525 + 2.85E-03 5.54E-03 
208805_PM_at proteasome (prosome, macropain) subunit, alpha type, 6 26225 PSMA6 0.274 + 3.10E-03 3.63E-03 
214288_PM_s_at proteasome (prosome, macropain) subunit, beta type, 1 64499 /// 7177 PSMB1 0.554 + 2.25E-04 5.84E-05 
202244_PM_at proteasome (prosome, macropain) subunit, beta type, 4 23390 PSMB4 0.495 + 4.89E-04 2.53E-03 
208799_PM_at proteasome (prosome, macropain) subunit, beta type, 5 10431 PSMB5 0.451 + 2.05E-03 1.01E-02 
204279_PM_at 
proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) 
9559 PSMB9 0.385 + 7.36E-03 1.71E-02 
201068_PM_s_at proteasome (prosome, macropain) 26S subunit, ATPase, 2 11170 PSMC2 0.407 + 2.70E-04 6.12E-04 
201699_PM_at proteasome (prosome, macropain) 26S subunit, ATPase, 6 8613 PSMC6 0.364 + 3.40E-03 2.07E-03 
219485_PM_s_at 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
10 
55186 PSMD10 0.395 + 7.88E-03 1.84E-02 
202353_PM_s_at 




PSMD12 0.673 + 6.75E-03 8.58E-03 
212296_PM_at 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
14 
10542 PSMD14 0.439 + 4.37E-04 5.24E-04 
200882_PM_s_at 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
4 
1993 PSMD4 0.462 + 1.25E-03 7.85E-03 
203447_PM_at 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 
5 
113178 PSMD5 0.624 + 6.50E-04 1.60E-03 
200814_PM_at 
proteasome (prosome, macropain) activator subunit 1 (PA28 
alpha) 
3382 PSME1 0.581 + 1.11E-02 2.58E-02 
212222_PM_at proteasome (prosome, macropain) activator subunit 4 7528 PSME4 0.763 + 1.49E-02 1.41E-02 
218467_PM_at proteasome (prosome, macropain) assembly chaperone 2 64067 PSMG2 0.449 + 2.03E-02 8.42E-03 
228217_PM_s_at proteasome (prosome, macropain) assembly chaperone 4 55500 PSMG4 0.624 + 9.50E-03 9.55E-03 
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218371_PM_s_at paraspeckle component 1 129831 PSPC1 0.295 + 7.59E-03 4.02E-02 
230129_PM_at phosphoseryl-tRNA kinase 7473 PSTK 0.566 + 1.29E-03 4.57E-03 
226110_PM_at protein prenyltransferase alpha subunit repeat containing 1 4082 PTAR1 0.414 + 2.10E-02 3.19E-02 
209815_PM_at patched homolog 1 (Drosophila) 57533 PTCH1 0.750 + 1.29E-02 3.58E-02 
225363_PM_at phosphatase and tensin homolog 148741 PTEN 0.382 + 3.61E-03 3.56E-03 
213933_PM_at prostaglandin E receptor 3 (subtype EP3) 23228 PTGER3 0.275 + 2.62E-02 4.26E-02 
207388_PM_s_at prostaglandin E synthase 9522 PTGES 0.284 + 3.17E-02 4.05E-02 
200733_PM_s_at protein tyrosine phosphatase type IVA, member 1 6660 PTP4A1 0.407 + 8.69E-03 2.46E-02 
200732_PM_s_at protein tyrosine phosphatase type IVA, member 1 10529 PTP4A1 0.464 + 1.55E-02 6.68E-03 
208617_PM_s_at protein tyrosine phosphatase type IVA, member 2 56928 PTP4A2 0.421 + 4.26E-03 1.57E-02 
208615_PM_s_at protein tyrosine phosphatase type IVA, member 2 744 PTP4A2 0.303 + 2.62E-02 4.04E-02 
219654_PM_at 
protein tyrosine phosphatase-like (proline instead of catalytic 
arginine), member A 
3054 PTPLA 0.348 + 1.23E-03 6.62E-03 
223808_PM_s_at protein tyrosine phosphatase, mitochondrial 1 84265 PTPMT1 0.417 + 2.30E-04 4.51E-04 
212610_PM_at protein tyrosine phosphatase, non-receptor type 11 23635 PTPN11 0.311 + 1.99E-02 2.20E-02 
202006_PM_at protein tyrosine phosphatase, non-receptor type 12 8539 PTPN12 0.664 + 2.16E-02 2.17E-02 
204201_PM_s_at 
protein tyrosine phosphatase, non-receptor type 13 (APO-
1/CD95 (Fas)-associated phosphatase) 
6624 PTPN13 0.495 + 1.02E-03 1.37E-02 
213136_PM_at protein tyrosine phosphatase, non-receptor type 2 4616 PTPN2 1.061 + 1.91E-03 1.81E-04 
207238_PM_s_at protein tyrosine phosphatase, receptor type, C 25839 PTPRC 0.284 + 4.63E-02 4.41E-02 
203329_PM_at protein tyrosine phosphatase, receptor type, M 10804 PTPRM 0.531 + 1.76E-02 4.10E-02 
204469_PM_at protein tyrosine phosphatase, receptor-type, Z polypeptide 1 8897 PTPRZ1 0.418 + 7.75E-03 8.82E-03 
218732_PM_at peptidyl-tRNA hydrolase 2 55074 PTRH2 0.461 + 6.81E-03 1.10E-02 
209694_PM_at 6-pyruvoyltetrahydropterin synthase 84100 PTS 0.616 + 4.12E-03 4.60E-03 
203554_PM_x_at pituitary tumor-transforming 1 816 PTTG1 0.424 + 5.63E-05 3.66E-05 
200677_PM_at pituitary tumor-transforming 1 interacting protein 8187 PTTG1IP 0.374 + 3.82E-02 2.01E-02 
201166_PM_s_at pumilio homolog 1 (Drosophila) 6119 PUM1 0.295 + 2.24E-02 2.69E-02 
216221_PM_s_at pumilio homolog 2 (Drosophila) 51185 PUM2 0.580 + 2.84E-02 2.71E-02 
225120_PM_at purine-rich element binding protein B 90693 PURB 0.353 + 1.36E-02 1.25E-03 
235634_PM_at purine-rich element binding protein G 55547 PURG 0.315 + 3.15E-02 3.02E-02 
221025_PM_x_at pseudouridylate synthase 7 homolog (S. cerevisiae)-like 9771 PUS7L 0.386 + 1.58E-03 2.66E-03 
201607_PM_at PWP1 homolog (S. cerevisiae) 23522 PWP1 0.269 + 3.59E-02 1.79E-02 
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226720_PM_at PWWP domain containing 2A 23192 PWWP2A 0.662 + 2.81E-03 1.47E-02 
228336_PM_at PWWP domain containing 2A 1656 PWWP2A 0.907 + 3.22E-02 3.04E-02 
228225_PM_at peroxisomal membrane protein 3, 35kDa 5728 PXMP3 0.280 + 3.20E-02 4.94E-02 
217846_PM_at glutaminyl-tRNA synthetase 9135 QARS 0.330 + 1.03E-02 2.55E-02 
1556205_PM_at Quinoid dihydropteridine reductase 3654 QDPR 0.267 + 1.51E-02 2.98E-02 
212265_PM_at quaking homolog, KH domain RNA binding (mouse) 25800 QKI 0.360 + 1.83E-02 1.82E-03 
226265_PM_at glutamine and serine rich 1 88 QSER1 0.699 + 1.28E-02 3.86E-02 
35156_PM_at R3H domain and coiled-coil containing 1 --- R3HCC1 0.368 + 1.80E-04 1.32E-03 
202754_PM_at R3H domain containing 1 26512 R3HDM1 0.423 + 3.71E-02 2.14E-02 
200864_PM_s_at RAB11A, member RAS oncogene family 9478 RAB11A 0.427 + 4.17E-02 2.51E-02 
225177_PM_at RAB11 family interacting protein 1 (class I) 57619 RAB11FIP1 0.282 + 1.69E-02 4.66E-02 
203884_PM_s_at RAB11 family interacting protein 2 (class I) 9689 RAB11FIP2 0.730 + 1.62E-02 2.22E-02 
223336_PM_s_at RAB18, member RAS oncogene family 1290 RAB18 0.348 + 4.75E-02 4.05E-02 
213440_PM_at RAB1A, member RAS oncogene family 6772 RAB1A 0.440 + 6.75E-03 8.27E-03 
226268_PM_at RAB21, member RAS oncogene family 88 RAB21 0.354 + 4.75E-02 3.90E-02 
213405_PM_at RAB22A, member RAS oncogene family 5889 RAB22A 0.453 + 1.09E-02 1.53E-02 
225074_PM_at RAB2B, member RAS oncogene family 56849 RAB2B 0.556 + 1.84E-03 4.10E-03 
221014_PM_s_at RAB33B, member RAS oncogene family 2049 RAB33B 0.334 + 1.39E-02 4.28E-02 
230075_PM_at RAB39B, member RAS oncogene family 4150 RAB39B 0.726 + 1.39E-02 1.45E-02 
202372_PM_at RAB3 GTPase activating protein subunit 2 (non-catalytic) 54539 RAB3GAP2 0.854 + 3.00E-02 8.32E-03 
231399_PM_at RAB3A interacting protein (rabin3) --- RAB3IP 0.624 + 2.82E-02 2.16E-02 
223471_PM_at RAB3A interacting protein (rabin3) 55236 RAB3IP 0.396 + 2.85E-02 2.02E-02 
226633_PM_at RAB8B, member RAS oncogene family 27332 RAB8B 0.404 + 1.06E-02 1.41E-02 
221808_PM_at RAB9A, member RAS oncogene family 23272 RAB9A 0.457 + 3.10E-03 7.11E-03 
222918_PM_at RAB9B, member RAS oncogene family 10492 RAB9B 0.508 + 4.24E-03 7.18E-03 
225092_PM_at rabaptin, RAB GTPase binding effector protein 1 4086 RABEP1 0.348 + 1.15E-02 5.50E-04 
74694_PM_s_at rabaptin, RAB GTPase binding effector protein 2 --- RABEP2 0.585 + 1.09E-02 1.30E-03 
203150_PM_at Rab9 effector protein with kelch motifs 414777 RABEPK 0.611 + 3.65E-03 1.35E-02 
213313_PM_at RAB GTPase activating protein 1 9126 RABGAP1 0.358 + 3.06E-02 4.01E-02 
203020_PM_at RAB GTPase activating protein 1-like 80333 RABGAP1L 0.341 + 3.09E-02 3.11E-02 
209181_PM_s_at Rab geranylgeranyltransferase, beta subunit 56996 RABGGTB 0.606 + 2.24E-04 1.21E-03 
213970_PM_at RAB, member of RAS oncogene family-like 3 10799 RABL3 0.593 + 1.74E-03 2.20E-02 
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226089_PM_at RAB, member of RAS oncogene family-like 3 9868 RABL3 0.493 + 3.39E-02 4.56E-02 
213603_PM_s_at 
ras-related C3 botulinum toxin substrate 2 (rho family, small 
GTP binding protein Rac2) 
23516 RAC2 0.273 + 5.19E-03 9.20E-03 
222077_PM_s_at Rac GTPase activating protein 1 23389 RACGAP1 0.301 + 1.26E-02 2.51E-02 
228535_PM_at RAD1 homolog (S. pombe) 157638 RAD1 0.632 + 5.27E-03 1.51E-02 
207405_PM_s_at RAD17 homolog (S. pombe) 200734 RAD17 0.512 + 6.76E-03 8.08E-03 
201046_PM_s_at RAD23 homolog A (S. cerevisiae) 10735 RAD23A 0.383 + 2.95E-03 2.00E-02 
209849_PM_s_at RAD51 homolog C (S. cerevisiae) 92912 RAD51C 0.404 + 1.81E-02 4.19E-02 
224880_PM_at v-ral simian leukemia viral oncogene homolog A (ras related) 153241 RALA 0.457 + 1.07E-02 8.23E-03 
204199_PM_at Ral GEF with PH domain and SH3 binding motif 1 3916 RALGPS1 0.574 + 1.69E-02 1.82E-02 
201712_PM_s_at RAN binding protein 2 8888 RANBP2 0.483 + 1.43E-02 3.09E-03 
201713_PM_s_at RAN binding protein 2 23175 RANBP2 0.269 + 2.30E-02 2.14E-02 
202640_PM_s_at RAN binding protein 3 30819 RANBP3 0.352 + 2.17E-02 2.60E-02 
218526_PM_s_at RAN guanine nucleotide release factor 201456 RANGRF 0.565 + 1.44E-03 1.55E-02 
202362_PM_at RAP1A, member of RAS oncogene family 54704 RAP1A 0.653 + 5.61E-03 2.09E-03 
213923_PM_at RAP2B, member of RAS oncogene family 57209 RAP2B 0.506 + 6.50E-03 7.57E-03 
218668_PM_s_at RAP2C, member of RAS oncogene family 25999 RAP2C 0.884 + 1.28E-02 1.90E-02 
218669_PM_at RAP2C, member of RAS oncogene family 83852 RAP2C 0.616 + 1.75E-02 2.98E-02 
203097_PM_s_at Rap guanine nucleotide exchange factor (GEF) 2 2035 RAPGEF2 0.330 + 2.00E-02 3.80E-02 
230078_PM_at Rap guanine nucleotide exchange factor (GEF) 6 11016 RAPGEF6 0.417 + 2.27E-02 3.06E-02 
225189_PM_s_at 
Ras association (RalGDS/AF-6) and pleckstrin homology 
domains 1 
255758 RAPH1 0.294 + 3.10E-02 6.06E-03 
201330_PM_at arginyl-tRNA synthetase 5298 RARS 0.265 + 2.30E-02 3.05E-02 
202677_PM_at RAS p21 protein activator (GTPase activating protein) 1 29980 /// 539 RASA1 0.707 + 1.33E-02 1.30E-02 
210621_PM_s_at RAS p21 protein activator (GTPase activating protein) 1 94101 RASA1 0.392 + 2.04E-02 4.28E-02 
1553986_PM_at RAS and EF-hand domain containing 11325 RASEF 0.299 + 6.94E-03 6.81E-04 
230563_PM_at RasGEF domain family, member 1A 54542 RASGEF1A 0.369 + 1.74E-02 2.90E-02 
205801_PM_s_at RAS guanyl releasing protein 3 (calcium and DAG-regulated) 2186 RASGRP3 0.433 + 9.14E-03 1.33E-02 
225946_PM_at 
Ras association (RalGDS/AF-6) domain family (N-terminal) 
member 8 
--- RASSF8 0.725 + 1.62E-02 1.82E-02 
203132_PM_at retinoblastoma 1 135112 RB1 0.724 + 3.68E-02 3.27E-02 
202034_PM_x_at RB1-inducible coiled-coil 1 598 RB1CC1 0.905 + 3.24E-02 3.96E-03 
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225396_PM_at retinoblastoma binding protein 4 90580 RBBP4 0.567 + 1.85E-02 1.64E-02 
212781_PM_at retinoblastoma binding protein 6 29966 RBBP6 0.460 + 1.38E-02 5.94E-03 
232044_PM_at retinoblastoma binding protein 6 144404 RBBP6 0.462 + 2.01E-02 4.33E-02 
201092_PM_at retinoblastoma binding protein 7 488 RBBP7 0.488 + 7.96E-03 7.09E-03 
203344_PM_s_at retinoblastoma binding protein 8 56987 RBBP8 0.737 + 5.56E-03 7.07E-03 
57540_PM_at ribokinase --- RBKS 0.409 + 2.46E-02 2.22E-02 
212168_PM_at RNA binding motif protein 12 6844 RBM12 0.764 + 2.00E-02 1.13E-02 
228455_PM_at RNA binding motif protein 15 51361 RBM15 0.404 + 1.36E-03 9.30E-03 
219286_PM_s_at RNA binding motif protein 15 7832 RBM15 0.819 + 2.68E-02 1.92E-02 
1555762_PM_s_at RNA binding motif protein 15 5683 RBM15 0.818 + 3.46E-02 2.21E-02 
221309_PM_at RNA binding motif protein 17 9037 RBM17 0.334 + 1.05E-02 4.40E-02 
224780_PM_at RNA binding motif protein 17 2549 RBM17 0.429 + 1.80E-02 1.40E-02 
226732_PM_at RNA binding motif protein 33 23351 RBM33 0.282 + 1.67E-02 5.63E-03 
1554095_PM_at RNA binding motif protein 33 5879 RBM33 0.334 + 4.05E-02 2.15E-02 
212591_PM_at RNA binding motif protein 34 2332 RBM34 0.459 + 1.39E-02 3.04E-02 
228578_PM_at RNA binding motif protein 45 11228 RBM45 0.639 + 3.56E-03 2.54E-03 
242516_PM_x_at RNA binding motif protein 46 --- RBM46 0.270 + 2.02E-02 3.79E-02 
222443_PM_s_at RNA binding motif protein 8A 23347 RBM8A 0.486 + 9.36E-04 1.08E-03 
213852_PM_at RNA binding motif protein 8A 22934 RBM8A 0.623 + 1.44E-02 3.77E-02 
225269_PM_s_at RNA binding motif, single stranded interacting protein 1 8239 RBMS1 0.761 + 9.05E-03 1.09E-02 
204098_PM_at RNA binding motif protein, X-linked 2 10969 RBMX2 0.430 + 2.17E-02 4.34E-02 
211974_PM_x_at 
recombination signal binding protein for immunoglobulin 
kappa J region 
6612 RBPJ 0.299 + 2.67E-02 4.96E-02 
218117_PM_at ring-box 1 257218 RBX1 0.430 + 1.47E-02 3.92E-02 
225893_PM_at ring finger and CCCH-type zinc finger domains 1 64857 RC3H1 0.521 + 3.01E-02 4.03E-02 
225813_PM_at ring finger and CCCH-type zinc finger domains 2 10097 RC3H2 0.532 + 1.53E-02 2.53E-02 
208370_PM_s_at regulator of calcineurin 1 29 RCAN1 0.497 + 2.19E-02 9.84E-03 
204759_PM_at 
regulator of chromosome condensation (RCC1) and BTB 
(POZ) domain containing protein 2 
3251 RCBTB2 0.281 + 7.49E-03 3.89E-02 
222605_PM_at REST corepressor 3 26175 RCOR3 0.578 + 2.18E-02 3.37E-02 
217776_PM_at retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 10413 RDH11 0.282 + 1.22E-02 6.11E-03 
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222203_PM_s_at retinol dehydrogenase 14 (all-trans/9-cis/11-cis) 10213 RDH14 0.351 + 4.29E-03 4.33E-03 
212397_PM_at radixin 10682 RDX 0.756 + 2.94E-03 3.50E-03 
244739_PM_at radixin --- RDX 0.765 + 4.40E-02 3.21E-02 
212918_PM_at RecQ protein-like (DNA helicase Q1-like) 10950 RECQL 0.408 + 1.02E-02 2.58E-02 
204365_PM_s_at receptor accessory protein 1 523 REEP1 0.362 + 3.25E-02 4.39E-02 
226430_PM_at RELT-like 1 5455 RELL1 0.775 + 1.55E-02 1.10E-02 
210300_PM_at RAS (RAD and GEM)-like GTP-binding 1 401466 REM1 0.333 + 8.89E-04 3.55E-03 
219041_PM_s_at replication initiator 1 4673 REPIN1 0.663 + 1.43E-02 1.90E-02 
224366_PM_s_at RALBP1 associated Eps domain containing 1 90231 REPS1 0.395 + 2.01E-02 2.85E-02 
227425_PM_at RALBP1 associated Eps domain containing 2 10023 REPS2 0.671 + 2.40E-03 2.90E-03 
200940_PM_s_at arginine-glutamic acid dipeptide (RE) repeats 6046 RERE 0.397 + 4.32E-02 3.27E-02 
244745_PM_at RAS-like, estrogen-regulated, growth inhibitor --- RERG 0.309 + 6.84E-03 1.48E-02 
208070_PM_s_at REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 10038 REV3L 0.744 + 9.52E-03 1.20E-02 
218194_PM_at REX2, RNA exonuclease 2 homolog (S. cerevisiae) 114799 REXO2 0.620 + 8.54E-03 6.36E-03 
203224_PM_at riboflavin kinase 4731 RFK 0.341 + 6.42E-03 1.51E-02 
223673_PM_at regulatory factor X, 4 (influences HLA class II expression) 54936 RFX4 1.468 + 8.38E-03 1.10E-02 
202963_PM_at regulatory factor X, 5 (influences HLA class II expression) 53938 RFX5 0.713 + 3.68E-02 3.04E-02 
222630_PM_at regulatory factor X, 7 22941 RFX7 0.382 + 3.25E-02 3.30E-02 
210751_PM_s_at regucalcin (senescence marker protein-30) 221785 RGN 0.348 + 3.59E-03 8.51E-03 
220334_PM_at regulator of G-protein signaling 17 26275 RGS17 0.383 + 2.05E-02 1.11E-02 
210138_PM_at regulator of G-protein signaling 20 113802 RGS20 0.472 + 4.94E-03 1.44E-02 
225202_PM_at Rho-related BTB domain containing 3 414918 RHOBTB3 0.487 + 1.80E-03 1.08E-02 
212120_PM_at ras homolog gene family, member Q 6451 RHOQ 0.667 + 9.23E-03 1.17E-02 
212122_PM_at ras homolog gene family, member Q 5683 RHOQ 0.717 + 1.88E-02 4.08E-02 
218323_PM_at ras homolog gene family, member T1 643836 RHOT1 0.388 + 2.08E-02 6.05E-03 
223168_PM_at ras homolog gene family, member U 55270 RHOU 0.634 + 2.63E-02 2.19E-03 
205414_PM_s_at Rho-type GTPase-activating protein RICH2 9071 RICH2 0.412 + 1.97E-03 4.79E-03 
226207_PM_at Rab interacting lysosomal protein-like 1 6921 RILPL1 0.311 + 4.20E-02 1.24E-02 
214811_PM_at RIMS binding protein 2 8925 RIMBP2 0.456 + 3.83E-02 2.14E-02 
226164_PM_x_at Ribosomal modification protein rimK-like family member B 1277 RIMKLB 0.521 + 1.12E-02 2.51E-02 
209684_PM_at Ras and Rab interactor 2 9406 RIN2 0.511 + 2.82E-02 2.88E-02 
218598_PM_at RAD50 interactor 1 30010 RINT1 0.383 + 2.23E-02 2.33E-02 
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209545_PM_s_at receptor-interacting serine-threonine kinase 2 83930 RIPK2 0.883 + 2.04E-02 2.71E-02 
236771_PM_at ripply2 homolog (zebrafish) 51631 RIPPLY2 0.344 + 1.12E-02 2.26E-02 
204243_PM_at rearranged L-myc fusion 5514 RLF 0.623 + 1.78E-02 1.91E-02 
225416_PM_at ring finger protein, LIM domain interacting 388695 RLIM 0.553 + 9.29E-03 1.80E-02 
213397_PM_x_at ribonuclease, Rnase A family, 4 4613 RNASE4 0.366 + 6.19E-03 2.47E-02 
205158_PM_at ribonuclease, Rnase A family, 4 1376 RNASE4 0.602 + 2.36E-02 2.79E-02 
213566_PM_at ribonuclease, Rnase A family, k6 1975 RNASE6 1.392 + 1.27E-02 1.16E-02 
226453_PM_at ribonuclease H2, subunit C 5175 RNASEH2C 0.316 + 1.76E-02 2.05E-03 
218761_PM_at ring finger protein 111 146177 RNF111 0.611 + 1.72E-02 6.77E-03 
219263_PM_at ring finger protein 128 1964 RNF128 0.373 + 1.36E-02 1.30E-02 
204040_PM_at ring finger protein 144A 378 RNF144A 0.671 + 2.28E-02 1.19E-02 
239012_PM_at Ring finger protein 144B 26207 RNF144B 0.277 + 1.24E-02 1.11E-02 
223886_PM_s_at ring finger protein 146 79780 RNF146 0.319 + 3.22E-02 1.69E-02 
226739_PM_at ring finger protein 169 140609 RNF169 0.841 + 2.67E-03 4.48E-03 
223085_PM_at ring finger protein 19A 51121 RNF19A 0.985 + 5.70E-03 1.15E-03 
36564_PM_at ring finger protein 19B --- RNF19B 0.935 + 7.91E-03 4.79E-02 
213038_PM_at ring finger protein 19B 51276 RNF19B 0.453 + 1.35E-02 3.35E-02 
222683_PM_at ring finger protein 20 10924 RNF20 0.687 + 1.40E-02 2.09E-02 
244591_PM_x_at Ring finger protein 207 22836 RNF207 0.385 + 2.16E-02 1.01E-02 
227065_PM_at ring finger protein 216 9898 RNF216 0.348 + 3.60E-03 2.18E-03 
219303_PM_at ring finger protein 219 9898 RNF219 0.470 + 5.12E-04 4.70E-03 
219035_PM_s_at ring finger protein 34 23241 RNF34 0.414 + 8.62E-03 1.14E-02 
218528_PM_s_at ring finger protein 38 83700 RNF38 0.426 + 4.46E-02 1.70E-02 
203160_PM_s_at ring finger protein 8 221955 RNF8 0.317 + 2.60E-02 9.13E-03 
221908_PM_at ring finger protein, transmembrane 2 51560 RNFT2 0.592 + 2.48E-02 2.76E-02 
204208_PM_at RNA guanylyltransferase and 5’-phosphatase 11137 RNGTT 0.285 + 3.78E-02 3.85E-02 
218301_PM_at arginyl aminopeptidase (aminopeptidase B)-like 1 57570 RNPEPL1 0.357 + 5.90E-03 2.33E-02 
202762_PM_at Rho-associated, coiled-coil containing protein kinase 2 55291 ROCK2 0.438 + 1.29E-02 3.01E-03 
224617_PM_at ROD1 regulator of differentiation 1 (S. pombe) 83640 ROD1 0.667 + 1.19E-02 2.92E-02 
226682_PM_at RAR-related orphan receptor A 552889 RORA 0.543 + 1.48E-02 7.06E-03 
219732_PM_at plasticity related gene 3 8446 RP11-35N6.1 0.724 + 2.31E-03 9.43E-03 
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224835_PM_at hypothetical protein KIAA1434 54332 RP5-1022P6.2 0.527 + 1.56E-02 2.49E-02 
227035_PM_x_at retinitis pigmentosa 9 pseudogene 998 RP9P 0.264 + 1.00E-02 1.72E-02 
236675_PM_at replication protein A1, 70kDa --- RPA1 0.341 + 9.99E-03 2.11E-03 
209507_PM_at replication protein A3, 14kDa 54460 RPA3 0.613 + 8.21E-04 1.51E-03 
228183_PM_s_at RPA interacting protein 51560 RPAIN 0.415 + 1.60E-02 2.87E-02 
216961_PM_s_at RPA interacting protein 79365 RPAIN 0.340 + 1.66E-02 8.17E-03 
222893_PM_s_at RNA polymerase II associated protein 2 2892 RPAP2 0.272 + 1.06E-02 4.07E-02 
212973_PM_at ribose 5-phosphate isomerase A 6545 RPIA 0.595 + 9.77E-03 2.11E-02 
200036_PM_s_at ribosomal protein L10a 8536 RPL10A 0.299 + 1.67E-02 1.41E-02 
200088_PM_x_at ribosomal protein L12 10150 RPL12 0.334 + 6.94E-03 4.85E-03 
214271_PM_x_at ribosomal protein L12 2917 RPL12 0.331 + 2.05E-02 6.27E-03 
212933_PM_x_at ribosomal protein L13 1837 RPL13 0.315 + 3.25E-02 3.90E-02 
200715_PM_x_at ribosomal protein L13a 4707 RPL13A 0.477 + 5.22E-03 3.92E-03 
213588_PM_x_at ribosomal protein L14 23633 RPL14 0.401 + 2.00E-03 1.36E-03 
200074_PM_s_at ribosomal protein L14 5001 RPL14 0.398 + 6.79E-03 1.08E-02 
214335_PM_at ribosomal protein L18 5291 RPL18 0.534 + 1.41E-02 1.18E-02 
225541_PM_at ribosomal protein L22-like 1 54885 RPL22L1 1.157 + 9.59E-04 4.19E-03 
203012_PM_x_at ribosomal protein L23a 
100302652 /// 
10936 /// 51130 
RPL23A 0.270 + 3.07E-03 2.20E-03 
200013_PM_at ribosomal protein L24 5698 RPL24 0.325 + 3.19E-02 2.44E-02 
222229_PM_x_at ribosomal protein L26 23231 RPL26 0.327 + 2.45E-02 8.26E-03 
218830_PM_at ribosomal protein L26-like 1 165215 RPL26L1 0.484 + 5.52E-03 1.54E-02 
200025_PM_s_at ribosomal protein L27 9443 RPL27 0.334 + 1.48E-02 2.10E-03 
200062_PM_s_at ribosomal protein L30 5336 RPL30 0.264 + 1.27E-02 1.19E-02 
201406_PM_at ribosomal protein L36a 4067 RPL36A 0.389 + 4.99E-03 1.88E-03 
217256_PM_x_at ribosomal protein L36a 84661 RPL36A 0.465 + 9.78E-03 7.00E-03 
207585_PM_s_at ribosomal protein L36a-like 23304 RPL36AL 0.417 + 1.51E-02 1.06E-02 
213080_PM_x_at ribosomal protein L5 5597 RPL5 0.352 + 2.04E-03 2.86E-03 
217092_PM_x_at ribosomal protein L7 53349 RPL7 0.366 + 8.12E-04 3.69E-03 
224738_PM_x_at ribosomal protein L7-like 1 164 RPL7L1 0.688 + 2.39E-02 2.82E-02 
213427_PM_at ribonuclease P/MRP 40kDa subunit 57862 RPP40 1.016 + 2.64E-03 1.50E-03 
 345 
222559_PM_s_at regulation of nuclear pre-mRNA domain containing 1A 56987 RPRD1A 0.398 + 3.49E-03 4.01E-03 
225953_PM_at regulation of nuclear pre-mRNA domain containing 1A 284669 RPRD1A 0.546 + 6.16E-03 1.70E-03 
226527_PM_at regulation of nuclear pre-mRNA domain containing 2 83604 RPRD2 0.412 + 2.71E-02 2.55E-02 
226131_PM_s_at ribosomal protein S16 9913 RPS16 0.375 + 1.69E-03 4.35E-03 
200949_PM_x_at ribosomal protein S20 54499 RPS20 0.354 + 3.86E-02 3.93E-02 
214097_PM_at ribosomal protein S21 23451 RPS21 0.409 + 1.93E-02 3.46E-02 
217753_PM_s_at ribosomal protein S26 57606 RPS26 0.441 + 1.59E-03 4.92E-03 
218007_PM_s_at ribosomal protein S27-like 113402 RPS27L 0.658 + 1.81E-03 9.63E-04 
201094_PM_at ribosomal protein S29 6713 RPS29 0.297 + 3.08E-02 4.11E-02 
216342_PM_x_at ribosomal protein S4, X-linked 29117 RPS4X 0.493 + 5.12E-03 1.72E-03 
213347_PM_x_at ribosomal protein S4, X-linked 333 RPS4X 0.400 + 1.02E-02 6.97E-03 
204171_PM_at ribosomal protein S6 kinase, 70kDa, polypeptide 1 10146 RPS6KB1 0.592 + 1.32E-02 1.08E-02 
226660_PM_at ribosomal protein S6 kinase, 70kDa, polypeptide 1 56112 RPS6KB1 0.523 + 2.55E-02 3.21E-02 
218909_PM_at ribosomal protein S6 kinase, 52kDa, polypeptide 1 64080 RPS6KC1 0.519 + 1.96E-02 2.45E-02 
213941_PM_x_at ribosomal protein S7 10413 RPS7 0.367 + 1.12E-02 7.60E-03 
213179_PM_at RCD1 required for cell differentiation1 homolog (S. pombe) 5594 RQCD1 0.466 + 2.33E-03 1.73E-02 
1554080_PM_at RCD1 required for cell differentiation1 homolog (S. pombe) 253959 RQCD1 0.821 + 4.64E-03 4.91E-03 
222514_PM_at Ras-related GTP binding C 5965 RRAGC 0.381 + 2.07E-02 2.35E-02 
212589_PM_at related RAS viral (r-ras) oncogene homolog 2 5577 RRAS2 1.162 + 4.88E-03 1.02E-02 
203704_PM_s_at ras responsive element binding protein 1 57488 RREB1 0.362 + 2.06E-02 2.64E-02 
219037_PM_at ribosomal RNA processing 15 homolog (S. cerevisiae) 23235 RRP15 0.404 + 1.94E-03 7.21E-04 
212846_PM_at ribosomal RNA processing 1 homolog B (S. cerevisiae) 8406 RRP1B 0.509 + 3.10E-03 8.75E-03 
222791_PM_at round spermatid basic protein 1 440434 RSBN1 0.884 + 7.62E-03 1.02E-02 
213694_PM_at round spermatid basic protein 1 10434 RSBN1 0.517 + 1.29E-02 1.84E-02 
226387_PM_at round spermatid basic protein 1-like 57821 RSBN1L 0.476 + 2.26E-02 4.92E-02 
213750_PM_at ribosomal L1 domain containing 1 3842 RSL1D1 0.441 + 1.59E-02 2.91E-02 
222465_PM_at ribosomal L24 domain containing 1 84986 RSL24D1 0.500 + 2.91E-04 4.27E-03 
225773_PM_at ring finger and SPRY domain containing 1 150622 RSPRY1 0.782 + 4.71E-03 4.27E-03 
201980_PM_s_at Ras suppressor protein 1 2734 RSU1 0.305 + 1.09E-02 3.50E-02 
212301_PM_at 
Rtf1, Paf1/RNA polymerase II complex component, homolog 
(S. cerevisiae) 
2171 RTF1 0.286 + 2.55E-02 1.15E-02 
232231_PM_at runt-related transcription factor 2 7284 RUNX2 0.872 + 9.73E-03 1.75E-02 
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201459_PM_at RuvB-like 2 (E. coli) 3551 RUVBL2 0.599 + 2.34E-02 1.61E-02 
219598_PM_s_at RWD domain containing 1 5436 RWDD1 0.591 + 1.04E-02 1.05E-02 
205087_PM_at RWD domain containing 3 9111 RWDD3 0.918 + 2.48E-02 1.84E-02 
202449_PM_s_at retinoid X receptor, alpha 55012 RXRA 0.292 + 3.44E-02 3.16E-02 
200660_PM_at S100 calcium binding protein A11 2157 S100A11 0.365 + 2.59E-03 1.39E-03 
228176_PM_at sphingosine-1-phosphate receptor 3 867 S1PR3 0.282 + 4.07E-03 1.84E-02 
225614_PM_at serum amyloid A-like 1 166863 SAAL1 0.722 + 9.39E-03 2.73E-02 
202797_PM_at SAC1 suppressor of actin mutations 1-like (yeast) 51000 SACM1L 0.427 + 4.41E-02 2.94E-02 
229273_PM_at sal-like 1 (Drosophila) 80110 SALL1 0.736 + 4.09E-02 1.76E-03 
229402_PM_at sterile alpha motif domain containing 13 26040 SAMD13 0.438 + 4.93E-03 1.25E-02 
212845_PM_at sterile alpha motif domain containing 4A 9521 SAMD4A 0.432 + 4.02E-02 7.59E-03 
201569_PM_s_at 
sorting and assembly machinery component 50 homolog (S. 
cerevisiae) 
474343 /// 54466 SAMM50 0.383 + 1.48E-02 1.16E-02 
208741_PM_at Sin3A-associated protein, 18kDa 55914 SAP18 0.548 + 1.10E-03 1.01E-03 
204900_PM_x_at Sin3A-associated protein, 30kDa 7572 SAP30 0.621 + 1.96E-02 3.36E-02 
222831_PM_at SAP30-like 7290 SAP30L 0.670 + 9.64E-03 1.37E-02 
222467_PM_s_at SAPS domain family, member 3 23271 SAPS3 0.510 + 8.74E-03 2.81E-03 
201542_PM_at SAR1 homolog A (S. cerevisiae) 1432 SAR1A 0.444 + 4.08E-02 3.59E-02 
223512_PM_at SAR1 homolog B (S. cerevisiae) 729515 SAR1B 0.711 + 6.12E-03 1.83E-02 
218254_PM_s_at SAR1 homolog B (S. cerevisiae) 84557 SAR1B 0.511 + 1.05E-02 7.59E-03 
229069_PM_at SAP domain containing ribonucleoprotein 155435 SARNP 0.491 + 1.37E-03 4.56E-03 
226022_PM_at SAM and SH3 domain containing 1 7009 SASH1 0.450 + 9.99E-03 2.69E-02 
210592_PM_s_at spermidine/spermine N1-acetyltransferase 1 57120 SAT1 0.639 + 1.10E-03 1.85E-03 
203455_PM_s_at spermidine/spermine N1-acetyltransferase 1 2941 SAT1 0.549 + 7.03E-03 2.01E-03 
226169_PM_at SET binding factor 2 9794 SBF2 0.666 + 3.05E-02 3.75E-02 
209146_PM_at sterol-C4-methyl oxidase-like 51361 SC4MOL 0.412 + 8.61E-03 4.81E-02 
228174_PM_at suppressor of cancer cell invasion 729082 SCAI 0.681 + 2.27E-03 4.86E-03 
212416_PM_at secretory carrier membrane protein 1 7525 SCAMP1 0.264 + 1.57E-02 1.86E-02 
212425_PM_at secretory carrier membrane protein 1 10565 SCAMP1 0.619 + 1.94E-02 9.88E-03 
216399_PM_s_at S-phase cyclin A-associated protein in the ER 10000 SCAPER 0.574 + 1.28E-02 2.57E-02 
209741_PM_x_at S-phase cyclin A-associated protein in the ER 79048 SCAPER 0.574 + 3.20E-02 4.04E-02 
201826_PM_s_at saccharopine dehydrogenase (putative) 509 SCCPDH 0.384 + 1.79E-02 6.11E-03 
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215548_PM_s_at sec1 family domain containing 1 115290 /// 54938 SCFD1 0.502 + 7.94E-03 1.38E-02 
203889_PM_at secretogranin V (7B2 protein) 4170 SCG5 0.417 + 1.95E-02 2.56E-02 
206147_PM_x_at sex comb on midleg-like 2 (Drosophila) 5447 SCML2 0.482 + 4.59E-02 3.27E-02 
210383_PM_at sodium channel, voltage-gated, type I, alpha subunit 118924 SCN1A 0.428 + 3.83E-03 2.87E-04 
229057_PM_at sodium channel, voltage-gated, type II, alpha subunit 114825 SCN2A 0.296 + 1.53E-02 5.48E-04 
210432_PM_s_at sodium channel, voltage-gated, type III, alpha subunit 128637 SCN3A 0.570 + 7.07E-03 2.39E-02 
224786_PM_at short coiled-coil protein 375757 SCOC 0.284 + 1.23E-04 4.68E-04 
218217_PM_at serine carboxypeptidase 1 55599 SCPEP1 0.463 + 1.52E-02 7.66E-03 
205475_PM_at stimulator of chondrogenesis 1 11021 SCRG1 0.586 + 2.25E-02 4.37E-02 
212556_PM_at scribbled homolog (Drosophila) 11183 SCRIB 0.366 + 7.12E-03 2.80E-02 
205607_PM_s_at SCY1-like 3 (S. cerevisiae) 7704 SCYL3 0.501 + 3.89E-03 5.47E-03 
41329_PM_at SCY1-like 3 (S. cerevisiae) --- SCYL3 0.562 + 2.56E-02 1.71E-02 
200958_PM_s_at syndecan binding protein (syntenin) 10521 SDCBP 0.395 + 3.07E-02 1.50E-02 
223337_PM_at serologically defined colon cancer antigen 10 54915 SDCCAG10 0.397 + 1.80E-02 3.61E-03 
227785_PM_at serologically defined colon cancer antigen 8 55504 SDCCAG8 0.534 + 1.29E-02 1.95E-02 
202026_PM_at 
succinate dehydrogenase complex, subunit D, integral 
membrane protein 
9369 SDHD 0.357 + 9.25E-03 6.97E-03 
201290_PM_at SEC11 homolog A (S. cerevisiae) 8601 SEC11A 0.537 + 1.31E-02 1.08E-02 
209206_PM_at SEC22 vesicle trafficking protein homolog B (S. cerevisiae) 23780 SEC22B 0.438 + 5.12E-03 8.54E-03 
225460_PM_at SEC22 vesicle trafficking protein homolog C (S. cerevisiae) 127933 SEC22C 0.349 + 3.20E-02 4.16E-03 
212887_PM_at Sec23 homolog A (S. cerevisiae) 97 SEC23A 0.432 + 6.54E-03 7.14E-03 
209175_PM_at SEC23 interacting protein 26575 SEC23IP 0.292 + 9.10E-04 3.43E-03 
212900_PM_at SEC24 family, member A (S. cerevisiae) 9488 SEC24A 0.450 + 3.34E-02 4.82E-02 
202798_PM_at SEC24 family, member B (S. cerevisiae) 56658 SEC24B 0.435 + 3.71E-02 1.81E-02 
200945_PM_s_at SEC31 homolog A (S. cerevisiae) 1983 SEC31A 0.538 + 2.10E-02 9.61E-03 
209889_PM_at SEC31 homolog B (S. cerevisiae) 84317 SEC31B 0.295 + 6.53E-03 3.99E-02 
203133_PM_at Sec61 beta subunit 159090 SEC61B 0.298 + 6.48E-04 2.25E-03 
203484_PM_at Sec61 gamma subunit 3363 SEC61G 0.638 + 7.79E-03 9.60E-03 
229969_PM_at SEC63 homolog (S. cerevisiae) 65986 SEC63 0.381 + 2.13E-04 1.67E-04 
218265_PM_at SECIS binding protein 2 388962 SECISBP2 0.722 + 2.70E-03 1.80E-03 
221931_PM_s_at SEH1-like (S. cerevisiae) 6854 SEH1L 0.507 + 9.58E-03 2.18E-02 
202061_PM_s_at sel-1 suppressor of lin-12-like (C. elegans) 1827 SEL1L 0.606 + 3.76E-03 5.23E-03 
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223070_PM_at selenoprotein K 55870 SELK 0.485 + 9.23E-04 3.56E-03 
209879_PM_at selectin P ligand 2289 SELPLG 0.383 + 2.79E-03 4.64E-03 
223209_PM_s_at selenoprotein S 9200 SELS 0.373 + 1.08E-02 2.68E-02 
225561_PM_at selenoprotein T 80055 SELT 0.439 + 2.00E-02 1.91E-02 
219259_PM_at 
sema domain, immunoglobulin domain (Ig), transmembrane 
domain I and short cytoplasmic domain, (348eparin348ing) 4A 
10628 SEMA4A 0.360 + 2.02E-02 2.84E-03 
226492_PM_at 
sema domain, transmembrane domain I, and cytoplasmic 
domain, (348eparin348ing) 6D 
10623 SEMA6D 0.562 + 3.29E-02 2.08E-02 
202318_PM_s_at SUMO1/sentrin specific peptidase 6 55827 SENP6 0.528 + 3.35E-02 6.25E-03 
228398_PM_at SUMO/sentrin specific peptidase family member 8 122830 SENP8 0.618 + 1.21E-02 3.09E-02 
232983_PM_s_at secretion regulating guanine nucleotide exchange factor 340895 SERGEF 0.303 + 2.53E-02 9.44E-03 
221472_PM_at serine incorporator 3 10570 SERINC3 0.333 + 2.87E-02 3.61E-02 
200969_PM_at stress-associated endoplasmic reticulum protein 1 10211 SERP1 0.569 + 2.62E-02 7.61E-03 
228044_PM_at 
stress-associated endoplasmic reticulum protein family 
member 2 
154807 SERP2 0.315 + 1.41E-02 7.34E-03 
211429_PM_s_at 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
196074 SERPINA1 0.493 + 1.02E-02 1.47E-02 
202657_PM_s_at SERTA domain containing 2 56288 SERTAD2 0.547 + 4.11E-02 2.83E-02 
218346_PM_s_at sestrin 1 55740 SESN1 0.498 + 2.48E-02 1.29E-02 
227041_PM_at SEC14 and spectrin domains 1 6141 SESTD1 0.650 + 1.04E-02 1.32E-02 
200631_PM_s_at SET nuclear oncogene 5305 SET 0.308 + 3.96E-05 8.04E-04 
227478_PM_at SET binding protein 1 83448 SETBP1 0.622 + 6.65E-03 9.94E-03 
212493_PM_s_at SET domain containing 2 5797 SETD2 0.669 + 7.44E-03 7.04E-03 
1554555_PM_a_at SET domain containing 6 7323 SETD6 0.352 + 2.64E-02 9.63E-03 
224928_PM_at SET domain containing (lysine methyltransferase) 7 143684 SETD7 0.431 + 4.63E-02 3.12E-02 
238684_PM_at SET domain, bifurcated 2 --- SETDB2 0.778 + 6.77E-03 3.75E-02 
235339_PM_at SET domain, bifurcated 2 --- SETDB2 0.799 + 2.46E-02 4.32E-02 
227516_PM_at splicing factor 3a, subunit 1, 120kDa 10955 SF3A1 0.713 + 2.73E-02 3.12E-02 
203818_PM_s_at splicing factor 3a, subunit 3, 60kDa 10944 SF3A3 0.411 + 1.01E-02 2.58E-02 
223416_PM_at splicing factor 3B, 14 kDa subunit 57472 SF3B14 0.479 + 7.31E-03 4.94E-03 
33322_PM_i_at stratifin 400931 SFN 0.606 + 1.15E-03 1.30E-03 
 349 
33323_PM_r_at stratifin --- SFN 0.727 + 5.87E-03 1.28E-02 
214016_PM_s_at 
splicing factor proline/glutamine-rich (polypyrimidine tract 
binding protein associated) 
7626 SFPQ 0.446 + 7.89E-03 1.77E-02 
207468_PM_s_at secreted frizzled-related protein 5 4205 SFRP5 0.282 + 3.15E-02 3.25E-02 
227164_PM_at splicing factor, arginine/serine-rich 1 10135 SFRS1 0.422 + 2.01E-02 3.60E-02 
200685_PM_at splicing factor, arginine/serine-rich 11 9908 SFRS11 0.743 + 4.33E-03 9.61E-03 
200686_PM_s_at splicing factor, arginine/serine-rich 11 4137 SFRS11 0.431 + 4.11E-02 2.87E-02 
212179_PM_at splicing factor, arginine/serine-rich 18 1347 SFRS18 0.358 + 2.22E-02 3.43E-02 
208804_PM_s_at splicing factor, arginine/serine-rich 6 51290 SFRS6 0.531 + 1.12E-02 4.89E-03 
201129_PM_at splicing factor, arginine/serine-rich 7, 35kDa 2887 SFRS7 0.424 + 3.06E-03 1.15E-03 
225849_PM_s_at SFT2 domain containing 1 5860 SFT2D1 0.382 + 3.45E-03 2.01E-02 
227560_PM_at sideroflexin 2 80853 SFXN2 0.378 + 6.51E-03 2.23E-02 
204688_PM_at sarcoglycan, epsilon 27338 SGCE 0.666 + 3.50E-03 5.81E-03 
223672_PM_at SH3-domain GRB2-like (endophilin) interacting protein 1 51602 SGIP1 0.295 + 2.00E-02 2.94E-02 
227627_PM_at serum/glucocorticoid regulated kinase family, member 3 64065 SGK3 0.546 + 4.66E-03 2.31E-03 
212989_PM_at sphingomyelin synthase 1 10389 SGMS1 0.586 + 4.56E-02 3.51E-03 
227038_PM_at sphingomyelin synthase 2 3727 SGMS2 0.497 + 1.43E-02 5.15E-03 
228745_PM_at 
small glutamine-rich tetratricopeptide repeat (TPR)-
containing, beta 
80311 SGTB 0.566 + 1.46E-03 3.91E-04 
203320_PM_at SH2B adaptor protein 3 117177 SH2B3 0.678 + 2.65E-02 2.72E-02 
201312_PM_s_at SH3 domain binding glutamic acid-rich protein like 7750 SH3BGRL 0.516 + 2.49E-03 1.41E-03 
222258_PM_s_at SH3-domain binding protein 4 51029 SH3BP4 0.794 + 2.32E-02 1.29E-02 
209090_PM_s_at SH3-domain GRB2-like endophilin B1 51510 SH3GLB1 0.672 + 1.65E-02 1.58E-02 
224817_PM_at SH3 and PX domains 2A 2932 SH3PXD2A 0.324 + 2.53E-02 4.40E-02 
231823_PM_s_at SH3 and PX domains 2B 26137 SH3PXD2B 0.298 + 6.01E-03 2.74E-02 
213307_PM_at SH3 and multiple ankyrin repeat domains 2 5876 SHANK2 0.417 + 2.27E-02 2.83E-02 
243681_PM_at SH3 and multiple ankyrin repeat domains 2 --- SHANK2 0.723 + 2.87E-02 1.23E-02 
204656_PM_at Src homology 2 domain containing adaptor protein B 558 SHB 0.470 + 1.27E-02 5.15E-03 
202276_PM_at split hand/foot malformation (ectrodactyly) type 1 6231 SHFM1 0.275 + 4.07E-03 5.31E-03 
224954_PM_at serine hydroxymethyltransferase 1 (soluble) 374659 SHMT1 0.471 + 3.89E-03 1.79E-02 
214095_PM_at serine hydroxymethyltransferase 2 (mitochondrial) 57326 SHMT2 0.582 + 1.16E-03 4.47E-03 
226366_PM_at SNF2 histone linker PHD RING helicase 7693 SHPRH 1.113 + 3.56E-03 2.56E-03 
 350 
204967_PM_at shroom family member 2 9823 SHROOM2 0.263 + 3.83E-02 3.70E-02 
228400_PM_at shroom family member 3 23261 SHROOM3 0.328 + 1.08E-02 3.63E-02 
1556056_PM_at salt-inducible kinase 2 5684 SIK2 0.490 + 1.06E-02 1.43E-02 
228026_PM_at suppressor of IKBKE 1 60674 SIKE1 0.849 + 7.18E-03 5.46E-03 
238005_PM_s_at SIN3 homolog A, transcription regulator (yeast) --- SIN3A 0.445 + 3.99E-02 3.25E-02 
211114_PM_x_at survival of motor neuron protein interacting protein 1 81602 SIP1 0.332 + 3.19E-03 2.15E-03 
205063_PM_at survival of motor neuron protein interacting protein 1 5293 SIP1 0.464 + 4.11E-03 1.85E-02 
210779_PM_x_at survival of motor neuron protein interacting protein 1 51733 SIP1 0.393 + 5.18E-03 7.87E-03 
211115_PM_x_at survival of motor neuron protein interacting protein 1 10169 /// 25764 SIP1 0.549 + 7.17E-03 7.59E-03 
218878_PM_s_at 
sirtuin (silent mating type information regulation 2 homolog) 1 
(S. cerevisiae) 
5467 SIRT1 0.973 + 7.23E-03 7.23E-03 
222248_PM_s_at 
sirtuin (silent mating type information regulation 2 homolog) 4 
(S. cerevisiae) 
10608 SIRT4 0.309 + 1.67E-02 2.57E-02 
229112_PM_at 
sirtuin (silent mating type information regulation 2 homolog) 5 
(S. cerevisiae) 
--- SIRT5 0.329 + 1.94E-02 2.57E-02 
225684_PM_at spindle and kinetochore associated complex subunit 2 32 SKA2 0.635 + 3.39E-02 1.41E-02 
225639_PM_at src kinase associated phosphoprotein 2 22941 SKAP2 0.918 + 1.46E-03 1.13E-02 
227447_PM_at superkiller viralicidic activity 2-like 2 (S. cerevisiae) 57118 SKIV2L2 0.770 + 3.70E-03 1.23E-04 
203625_PM_x_at S-phase kinase-associated protein 2 (p45) 54462 SKP2 0.562 + 3.76E-02 4.50E-02 
224844_PM_at SLAIN motif family, member 2 22847 SLAIN2 0.652 + 1.12E-02 3.47E-03 
1553770_PM_a_at SLAM family member 9 5431 SLAMF9 0.281 + 6.02E-03 1.70E-02 
203124_PM_s_at 
solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2 
92399 SLC11A2 0.539 + 3.80E-02 4.22E-02 
225835_PM_at 
solute carrier family 12 (sodium/potassium/chloride 
transporters), member 2 
85302 SLC12A2 0.520 + 3.79E-02 7.15E-03 
220371_PM_s_at 
solute carrier family 12 (potassium/chloride transporters), 
member 9 
3149 SLC12A9 0.431 + 3.17E-03 7.33E-03 
228844_PM_at 
solute carrier family 13 (sodium-dependent citrate 
transporter), member 5 
2321 SLC13A5 0.305 + 1.30E-02 3.72E-02 
205316_PM_at solute carrier family 15 (H+/peptide transporter), member 2 5303 SLC15A2 0.600 + 1.46E-03 3.48E-03 
230748_PM_at 
solute carrier family 16, member 6 (monocarboxylic acid 
transporter 7) 
2899 SLC16A6 0.663 + 1.24E-03 1.58E-02 
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223441_PM_at solute carrier family 17 (anion/sugar transporter), member 5 26985 SLC17A5 0.322 + 1.20E-02 9.15E-03 
220551_PM_at 
solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 6 
22841 SLC17A6 0.517 + 9.32E-04 2.26E-03 
244377_PM_at 
Solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
--- SLC1A4 0.532 + 8.95E-04 6.58E-04 
205074_PM_at 
solute carrier family 22 (organic cation/carnitine transporter), 
member 5 
57149 SLC22A5 0.316 + 2.04E-02 1.90E-02 
204587_PM_at 
solute carrier family 25 (mitochondrial carrier, brain), member 
14 
1455 SLC25A14 0.432 + 1.45E-02 1.67E-02 
218653_PM_at 
solute carrier family 25 (mitochondrial carrier; ornithine 
transporter) member 15 
494143 SLC25A15 0.313 + 2.10E-02 2.23E-02 
235747_PM_at 
Solute carrier family 25 (mitochondrial carrier; Graves disease 
autoantigen), member 16 
--- SLC25A16 0.447 + 4.64E-03 3.06E-02 
223192_PM_at solute carrier family 25, member 28 79572 SLC25A28 0.467 + 1.00E-02 3.92E-03 
226782_PM_at solute carrier family 25, member 30 10802 SLC25A30 0.364 + 1.21E-03 4.65E-04 
221020_PM_s_at solute carrier family 25, member 32 6787 SLC25A32 0.487 + 2.39E-02 5.46E-03 
223296_PM_at solute carrier family 25, member 33 55239 SLC25A33 0.426 + 8.29E-03 2.78E-02 
201919_PM_at solute carrier family 25, member 36 2934 SLC25A36 0.497 + 1.57E-02 2.19E-02 
226179_PM_at solute carrier family 25, member 37 573 SLC25A37 0.472 + 3.03E-02 3.06E-02 
236436_PM_at solute carrier family 25, member 45 --- SLC25A45 0.608 + 1.75E-02 3.85E-02 
219344_PM_at solute carrier family 29 (nucleoside transporters), member 3 7247 SLC29A3 0.264 + 2.61E-02 4.09E-02 
227176_PM_at 
solute carrier family 2 (facilitated glucose transporter), 
member 13 
51065 SLC2A13 0.430 + 1.71E-02 4.03E-02 
221751_PM_at 
Solute carrier family 2 (facilitated glucose transporter), 
member 3 pseudogene 1 
84617 SLC2A3P1 0.456 + 3.92E-03 1.99E-02 
212907_PM_at Solute carrier family 30 (zinc transporter), member 1 64771 SLC30A1 0.459 + 7.54E-03 8.95E-03 
226601_PM_at solute carrier family 30 (zinc transporter), member 7 54499 SLC30A7 0.267 + 2.57E-02 2.49E-02 
204204_PM_at solute carrier family 31 (copper transporters), member 2 8667 SLC31A2 0.754 + 5.90E-03 3.08E-02 
203164_PM_at solute carrier family 33 (acetyl-CoA transporter), member 1 123016 SLC33A1 0.794 + 1.39E-02 2.75E-03 
203306_PM_s_at 
solute carrier family 35 (CMP-sialic acid transporter), member 
A1 
26140 SLC35A1 0.445 + 2.19E-02 1.06E-02 
218519_PM_at solute carrier family 35, member A5 132204 SLC35A5 0.495 + 4.14E-02 3.75E-02 
202433_PM_at solute carrier family 35, member B1 56922 SLC35B1 0.294 + 5.73E-03 4.73E-04 
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222691_PM_at solute carrier family 35, member B3 54665 SLC35B3 0.268 + 7.75E-03 1.86E-02 
225882_PM_at solute carrier family 35, member B4 100133991 SLC35B4 0.552 + 3.51E-03 3.63E-03 
209712_PM_at 
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), member D1 
29097 SLC35D1 0.355 + 3.47E-02 4.59E-02 
223304_PM_at 
solute carrier family 37 (glycerol-3-phosphate transporter), 
member 3 
2845 SLC37A3 0.567 + 1.11E-02 1.51E-02 
214830_PM_at solute carrier family 38, member 6 11108 SLC38A6 0.485 + 2.20E-02 3.00E-02 
225295_PM_at solute carrier family 39 (zinc transporter), member 10 254263 SLC39A10 0.337 + 2.22E-02 1.90E-02 
227046_PM_at solute carrier family 39 (metal ion transporter), member 11 4131 SLC39A11 0.337 + 9.13E-03 3.79E-02 
212110_PM_at solute carrier family 39 (zinc transporter), member 14 9775 SLC39A14 0.380 + 1.50E-02 1.18E-03 
202088_PM_at solute carrier family 39 (zinc transporter), member 6 7940 SLC39A6 0.508 + 3.54E-02 3.70E-02 
222445_PM_at solute carrier family 39 (zinc transporter), member 9 22800 SLC39A9 0.606 + 1.44E-02 2.50E-02 
223044_PM_at solute carrier family 40 (iron-regulated transporter), member 1 28978 SLC40A1 0.579 + 2.13E-02 3.83E-02 
228221_PM_at solute carrier family 44, member 3 283578 SLC44A3 0.856 + 1.09E-02 2.30E-02 
214719_PM_at solute carrier family 46, member 3 4702 SLC46A3 1.020 + 4.13E-02 4.22E-03 
1558201_PM_s_at 
solute carrier family 4 (anion exchanger), member 1, adaptor 
protein 
10421 SLC4A1AP 0.325 + 1.08E-02 1.06E-02 
234291_PM_s_at solute carrier family 6 (proline IMINO transporter), member 20 --- SLC6A20 0.282 + 5.71E-03 6.59E-03 
209921_PM_at 
solute carrier family 7, (cationic amino acid transporter, y+ 
system) member 11 
56927 SLC7A11 0.452 + 3.91E-02 4.80E-02 
1556641_PM_at 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 14 
10944 SLC7A14 0.399 + 1.76E-02 4.02E-02 
225516_PM_at 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 2 
387338 SLC7A2 0.384 + 1.06E-02 1.63E-02 
203578_PM_s_at 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 6 
54976 SLC7A6 0.338 + 7.96E-03 8.29E-04 
203580_PM_s_at 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 6 
63916 SLC7A6 0.611 + 2.80E-02 3.34E-02 
238546_PM_at solute carrier family 8 (sodium/calcium exchanger), member 1 --- SLC8A1 0.322 + 3.37E-02 3.73E-02 
235518_PM_at solute carrier family 8 (sodium/calcium exchanger), member 1 89919 SLC8A1 0.389 + 4.11E-02 4.35E-02 
203909_PM_at 
solute carrier family 9 (sodium/hydrogen exchanger), member 
6 
10694 SLC9A6 0.358 + 4.09E-02 3.88E-02 
217828_PM_at SAFB-like, transcription modulator 147495 SLTM 0.350 + 3.87E-02 3.78E-02 
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227798_PM_at SMAD family member 1 80321 SMAD1 0.595 + 1.58E-02 2.68E-02 
203077_PM_s_at SMAD family member 2 81555 SMAD2 0.615 + 7.62E-03 1.21E-02 
226563_PM_at SMAD family member 2 7881 SMAD2 0.660 + 8.42E-03 1.12E-02 
235725_PM_at SMAD family member 4 
100130383 /// 
152206 /// 25994 
SMAD4 0.704 + 2.24E-03 4.04E-03 
225223_PM_at SMAD family member 5 79971 SMAD5 0.537 + 1.33E-02 1.03E-02 
204790_PM_at SMAD family member 7 8445 SMAD7 0.713 + 1.81E-02 3.12E-02 
227719_PM_at SMAD family member 9 51209 SMAD9 0.583 + 6.67E-03 4.42E-03 
217707_PM_x_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 2 
64756 SMARCA2 0.699 + 2.17E-02 1.09E-02 
206542_PM_s_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 2 
91851 SMARCA2 0.298 + 2.30E-02 2.44E-02 
213251_PM_at 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 5 
60481 SMARCA5 0.385 + 3.81E-02 1.75E-03 
223197_PM_s_at 
SWI/SNF-related, matrix-associated actin-dependent 
regulator of chromatin, subfamily a, containing DEAD/H box 1 
51226 SMARCAD1 0.649 + 3.52E-02 7.71E-03 
213253_PM_at structural maintenance of chromosomes 2 9908 SMC2 0.278 + 1.86E-02 2.75E-02 
209259_PM_s_at structural maintenance of chromosomes 3 54332 SMC3 0.620 + 1.10E-02 2.09E-02 
218781_PM_at structural maintenance of chromosomes 6 10529 SMC6 0.426 + 9.57E-03 3.53E-02 
212577_PM_at 
structural maintenance of chromosomes flexible hinge domain 
containing 1 
10311 SMCHD1 0.425 + 2.77E-03 1.51E-02 
212569_PM_at 
structural maintenance of chromosomes flexible hinge domain 
containing 1 
9694 SMCHD1 0.289 + 4.87E-02 4.37E-02 
222270_PM_at SMEK homolog 2, suppressor of mek1 (Dictyostelium) 6925 SMEK2 0.664 + 9.41E-05 2.76E-04 
1568627_PM_at SMEK homolog 2, suppressor of mek1 (Dictyostelium) 5423 SMEK2 0.277 + 6.25E-03 9.74E-03 
233759_PM_s_at SMEK homolog 2, suppressor of mek1 (Dictyostelium) --- SMEK2 0.550 + 7.09E-03 2.54E-03 
226230_PM_at SMEK homolog 2, suppressor of mek1 (Dictyostelium) 9693 SMEK2 0.662 + 1.14E-02 2.55E-02 
200071_PM_at survival motor neuron domain containing 1 1641 SMNDC1 0.491 + 2.25E-02 1.96E-02 
213624_PM_at sphingomyelin phosphodiesterase, acid-like 3A 23165 SMPDL3A 0.508 + 4.53E-03 1.71E-02 
227489_PM_at SMAD specific E3 ubiquitin protein ligase 2 25959 SMURF2 0.591 + 1.45E-02 2.27E-02 
219480_PM_at snail homolog 1 (Drosophila) 25820 SNAI1 0.270 + 1.18E-02 2.94E-02 
213203_PM_at small nuclear RNA activating complex, polypeptide 5, 19kDa 9031 SNAPC5 0.331 + 4.23E-03 1.46E-02 
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1554093_PM_a_at small nuclear RNA activating complex, polypeptide 5, 19kDa 26268 SNAPC5 0.400 + 1.80E-02 4.69E-02 
237833_PM_s_at synuclein, alpha interacting protein --- SNCAIP 0.308 + 2.39E-03 1.09E-02 
226149_PM_at small nucleolar RNA host gene 11 (non-protein coding) 9969 SNHG11 0.365 + 2.12E-02 1.45E-02 
225547_PM_at small nucleolar RNA host gene 6 (non-protein coding) 122525 SNHG6 0.402 + 8.93E-03 1.89E-02 
1554759_PM_at SNAP25-interacting protein 6633 SNIP 0.293 + 1.24E-02 4.24E-03 
218032_PM_at stannin 55197 SNN 0.504 + 1.00E-02 1.21E-02 
209481_PM_at SNF related kinase 79133 SNRK 0.431 + 2.69E-02 7.11E-03 
212438_PM_at small nuclear ribonucleoprotein 27kDa (U4/U6.U5) 58487 SNRNP27 0.452 + 8.61E-03 6.79E-03 
212440_PM_at small nuclear ribonucleoprotein 27kDa (U4/U6.U5) 9903 SNRNP27 0.305 + 1.56E-02 1.06E-02 
216977_PM_x_at small nuclear ribonucleoprotein polypeptide A’ 55829 SNRPA1 0.625 + 8.57E-03 1.39E-02 
202690_PM_s_at small nuclear ribonucleoprotein D1 polypeptide 16kDa 84148 SNRPD1 0.585 + 2.12E-03 2.82E-04 
200826_PM_at small nuclear ribonucleoprotein D2 polypeptide 16.5kDa 10735 SNRPD2 0.572 + 6.22E-03 8.92E-03 
203316_PM_s_at small nuclear ribonucleoprotein polypeptide E 116988 SNRPE 0.572 + 1.39E-03 9.15E-04 
203832_PM_at small nuclear ribonucleoprotein polypeptide F 808 SNRPF 0.389 + 3.31E-04 2.77E-03 
205644_PM_s_at small nuclear ribonucleoprotein polypeptide G 2043 SNRPG 0.563 + 2.97E-03 4.39E-04 
1559546_PM_s_at small nuclear ribonucleoprotein polypeptide N 9874 SNRPN 0.657 + 1.12E-02 6.23E-03 
226591_PM_at small nuclear ribonucleoprotein polypeptide N 2904 SNRPN 0.356 + 4.42E-02 2.62E-02 
201575_PM_at SNW domain containing 1 6319 SNW1 0.515 + 1.43E-02 1.46E-02 
213364_PM_s_at sorting nexin 1 25901 SNX1 0.628 + 3.71E-02 3.66E-02 
218404_PM_at sorting nexin 10 254778 SNX10 0.518 + 1.40E-02 4.53E-03 
227031_PM_at sorting nexin 13 7503 SNX13 0.644 + 4.76E-02 4.57E-02 
230759_PM_at Sorting nexin 14 55000 SNX14 0.283 + 6.77E-03 4.61E-03 
225101_PM_s_at sorting nexin 14 153396 SNX14 0.535 + 9.02E-03 1.75E-02 
226683_PM_at sorting nexin 18 23433 SNX18 0.672 + 8.21E-03 1.06E-02 
221498_PM_at sorting nexin family member 27 635 SNX27 0.476 + 3.00E-02 2.74E-03 
200067_PM_x_at sorting nexin 3 10384 /// 11118 SNX3 0.520 + 1.59E-02 5.48E-03 
213545_PM_x_at sorting nexin 3 25778 SNX3 0.359 + 2.29E-02 4.49E-03 
226249_PM_at sorting nexin family member 30 9724 SNX30 0.364 + 7.58E-03 1.38E-03 
212652_PM_s_at sorting nexin 4 6447 SNX4 0.444 + 3.84E-02 2.88E-02 
222410_PM_s_at sorting nexin 6 27351 SNX6 0.275 + 2.85E-02 9.56E-03 
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205573_PM_s_at sorting nexin 7 7381 SNX7 0.827 + 2.50E-03 7.31E-03 
209648_PM_x_at suppressor of cytokine signaling 5 28989 SOCS5 0.553 + 1.60E-02 1.13E-02 
200642_PM_at superoxide dismutase 1, soluble 6637 SOD1 0.343 + 8.68E-03 3.79E-03 
214988_PM_s_at SON DNA binding protein 29107 SON 0.343 + 1.22E-02 6.78E-03 
218087_PM_s_at sorbin and SH3 domain containing 1 10087 SORBS1 0.449 + 4.06E-02 7.12E-03 
228720_PM_at sortilin-related VPS10 domain containing receptor 2 83544 SORCS2 0.287 + 1.52E-02 2.23E-02 
215522_PM_at sortilin-related VPS10 domain containing receptor 3 57338 SORCS3 0.473 + 4.68E-02 5.70E-04 
212780_PM_at son of sevenless homolog 1 (Drosophila) 5144 SOS1 0.666 + 4.68E-02 1.19E-02 
212870_PM_at son of sevenless homolog 2 (Drosophila) 1678 SOS2 0.689 + 1.51E-02 1.44E-02 
204915_PM_s_at SRY (sex determining region Y)-box 11 9270 SOX11 0.527 + 1.47E-02 1.44E-02 
217040_PM_x_at SRY (sex determining region Y)-box 15 10283 SOX15 0.572 + 8.29E-04 3.71E-03 
228038_PM_at SRY (sex determining region Y)-box 2 57609 SOX2 0.469 + 1.59E-02 1.73E-03 
201417_PM_at SRY (sex determining region Y)-box 4 4850 SOX4 0.902 + 3.49E-04 1.10E-03 
201416_PM_at SRY (sex determining region Y)-box 4 5802 SOX4 0.669 + 1.67E-02 2.28E-02 
227498_PM_at SRY (sex determining region Y)-box 6 60468 SOX6 0.873 + 2.35E-02 6.86E-03 
202864_PM_s_at SP100 nuclear antigen 56987 SP100 0.349 + 7.70E-04 1.10E-03 
208012_PM_x_at SP110 nuclear body protein 10772 SP110 0.558 + 3.89E-03 3.48E-03 
209762_PM_x_at SP110 nuclear body protein 51534 SP110 0.556 + 3.33E-02 2.71E-02 
213168_PM_at Sp3 transcription factor 81553 SP3 0.626 + 1.53E-02 8.22E-03 
236265_PM_at Sp4 transcription factor 57494 SP4 0.544 + 3.55E-02 3.35E-03 
205406_PM_s_at sperm autoantigenic protein 17 1174 SPA17 0.529 + 6.42E-03 2.20E-02 
240898_PM_at sperm associated antigen 16 --- SPAG16 0.567 + 2.24E-06 1.73E-05 
225339_PM_at sperm associated antigen 9 493911 SPAG9 0.448 + 2.23E-02 1.05E-02 
209748_PM_at spastin 55540 SPAST 0.514 + 7.71E-03 2.90E-03 
218933_PM_at spermatogenesis associated 5-like 1 25960 SPATA5L1 0.364 + 2.82E-02 2.02E-02 
234929_PM_s_at spermatogenesis associated 7 8874 SPATA7 0.465 + 1.29E-02 3.01E-02 
222154_PM_s_at spermatogenesis associated, serine-rich 2-like 27346 SPATS2L 0.519 + 1.87E-02 1.70E-02 
217927_PM_at signal peptidase complex subunit 1 homolog (S. cerevisiae) 5928 SPCS1 0.385 + 1.92E-03 5.44E-04 
221844_PM_x_at signal peptidase complex subunit 3 homolog (S. cerevisiae) 9863 SPCS3 0.374 + 1.91E-02 2.18E-03 
203513_PM_at spastic paraplegia 11 (autosomal recessive) 10447 SPG11 0.886 + 3.32E-02 4.34E-02 
211704_PM_s_at 






0.555 + 2.54E-02 1.94E-02 
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213994_PM_s_at spondin 1, extracellular matrix protein 55957 SPON1 0.527 + 1.64E-02 1.45E-02 
213993_PM_at spondin 1, extracellular matrix protein 89845 SPON1 0.987 + 2.85E-02 1.89E-02 
225658_PM_at speckle-type POZ protein-like 5962 SPOPL 0.497 + 3.12E-02 3.44E-03 
226837_PM_at 356epari-related, EVH1 domain containing 1 55958 SPRED1 0.605 + 3.05E-02 1.96E-03 
229594_PM_at SPT2, Suppressor of Ty, domain containing 1 (S. cerevisiae) 130574 SPTY2D1 0.413 + 4.33E-02 4.46E-02 
209218_PM_at squalene epoxidase 54676 SQLE 0.405 + 1.64E-02 4.55E-02 
224864_PM_at steroid receptor RNA activator 1 115416 SRA1 0.327 + 1.60E-02 2.38E-02 
201859_PM_at serglycin 55660 SRGN 0.789 + 1.25E-02 8.31E-03 
208921_PM_s_at sorcin 53918 SRI 0.315 + 4.61E-03 4.35E-03 
200007_PM_at 
signal recognition particle 14kDa (homologous Alu RNA 
binding protein) 
63940 SRP14 0.423 + 1.82E-03 1.85E-03 
205335_PM_s_at signal recognition particle 19kDa 905 SRP19 0.363 + 6.35E-03 3.38E-04 
224607_PM_s_at signal recognition particle 68kDa 83640 SRP68 0.333 + 4.24E-02 1.84E-02 
208801_PM_at signal recognition particle 72kDa 56683 SRP72 0.588 + 1.21E-02 2.40E-03 
201273_PM_s_at signal recognition particle 9kDa 4133 SRP9 0.680 + 4.26E-04 1.07E-03 
204955_PM_at sushi-repeat-containing protein, X-linked 2146 SRPX 1.103 + 7.52E-03 2.52E-02 
213608_PM_s_at SRR1 domain containing 8289 SRRD 0.379 + 8.84E-04 9.62E-03 
218283_PM_at 
synovial sarcoma translocation gene on chromosome 18-like 
2 
118980 SS18L2 0.511 + 3.72E-03 7.81E-03 
214060_PM_at single-stranded DNA binding protein 1 1674 /// 55578 SSBP1 0.266 + 3.89E-03 2.20E-03 
202591_PM_s_at single-stranded DNA binding protein 1 1600 SSBP1 0.501 + 5.81E-03 1.80E-02 
203787_PM_at single-stranded DNA binding protein 2 54884 SSBP2 0.433 + 3.66E-02 8.07E-03 
202506_PM_at sperm specific antigen 2 64218 SSFA2 0.486 + 4.69E-02 2.05E-02 
226932_PM_at sarcospan (Kras oncogene-associated gene) 9204 SSPN 0.881 + 1.79E-02 2.03E-02 
200891_PM_s_at signal sequence receptor, alpha 9372 SSR1 0.514 + 4.23E-02 1.88E-02 
223051_PM_at 
SSU72 RNA polymerase II CTD phosphatase homolog (S. 
cerevisiae) 
7227 SSU72 0.364 + 2.85E-03 8.69E-03 
208666_PM_s_at 
suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 
interacting protein) 
27030 ST13 0.499 + 2.97E-02 6.43E-03 
204542_PM_at 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2 
25874 ST6GALNAC2 0.291 + 3.74E-02 4.96E-02 
207871_PM_s_at suppression of tumorigenicity 7 6843 ST7 0.644 + 1.59E-02 3.76E-02 
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230262_PM_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 54954 ST8SIA3 0.418 + 3.37E-02 2.37E-02 
202294_PM_at stromal antigen 1 28969 STAG1 0.402 + 2.10E-02 1.16E-02 
209022_PM_at stromal antigen 2 51205 STAG2 0.645 + 2.36E-02 1.97E-03 
203544_PM_s_at 
signal transducing adaptor molecule (SH3 domain and ITAM 
motif) 1 
2810 STAM 0.467 + 2.42E-02 8.65E-03 
223065_PM_s_at STARD3 N-terminal like 29110 STARD3NL 0.582 + 8.65E-04 2.83E-03 
206868_PM_at StAR-related lipid transfer (START) domain containing 8 9229 STARD8 0.306 + 4.85E-02 3.93E-02 
209969_PM_s_at signal transducer and activator of transcription 1, 91kDa 5937 STAT1 0.648 + 8.70E-03 8.65E-03 
204597_PM_x_at stanniocalcin 1 6742 STC1 0.409 + 1.12E-02 1.32E-02 
225649_PM_s_at serine/threonine kinase 35 127254 STK35 0.701 + 1.19E-02 1.60E-02 
202951_PM_at serine/threonine kinase 38 56134  STK38 0.427 + 2.61E-03 3.45E-03 
212572_PM_at serine/threonine kinase 38 like 1783 STK38L 0.503 + 3.13E-02 4.17E-02 
202786_PM_at serine threonine kinase 39 (STE20/SPS1 homolog, yeast) 152006 STK39 0.544 + 3.58E-02 6.57E-03 
213413_PM_at 357eparin 1 545 STON1 0.307 + 4.48E-02 1.70E-02 
227461_PM_at 357eparin 2 80055 STON2 0.913 + 3.40E-03 1.44E-02 
229378_PM_at storkhead box 1 55824 STOX1 0.317 + 3.87E-04 7.32E-04 
209478_PM_at stimulated by retinoic acid 13 homolog (mouse) 56474 STRA13 0.298 + 1.18E-03 4.82E-03 
223266_PM_at STE20-related kinase adaptor beta 56660 STRADB 0.779 + 2.11E-02 1.55E-02 
233251_PM_at Spermatid perinuclear RNA binding protein --- STRBP 0.567 + 1.45E-05 3.28E-04 
233252_PM_s_at spermatid perinuclear RNA binding protein 646214 STRBP 0.347 + 2.64E-02 6.62E-03 
1561306_PM_s_at stereocilin 274 STRC 0.521 + 7.55E-03 2.10E-02 
204496_PM_at striatin, calmodulin binding protein 3 26286 STRN3 0.619 + 3.39E-02 4.31E-02 
224700_PM_at 
STT3, subunit of the oligosaccharyltransferase complex, 
homolog B (S. cerevisiae) 
203547 STT3B 0.469 + 1.74E-02 1.33E-02 
212111_PM_at syntaxin 12 4698 STX12 0.472 + 3.08E-02 3.96E-02 
221500_PM_s_at syntaxin 16 3423 STX16 0.277 + 3.43E-02 3.89E-02 
212799_PM_at syntaxin 6 9252 STX6 0.530 + 6.18E-03 3.29E-02 
228853_PM_at serine/threonine/tyrosine interacting protein 441478 STYX 0.704 + 5.59E-03 5.28E-03 
224586_PM_x_at SUB1 homolog (S. cerevisiae) 757 SUB1 0.356 + 4.14E-03 1.42E-02 
202930_PM_s_at succinate-CoA ligase, ADP-forming, beta subunit 84251 SUCLA2 0.353 + 3.66E-02 2.23E-02 
212459_PM_x_at succinate-CoA ligase, GDP-forming, beta subunit 2628 SUCLG2 0.710 + 1.15E-02 1.60E-02 
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214835_PM_s_at succinate-CoA ligase, GDP-forming, beta subunit 54906 SUCLG2 0.713 + 1.94E-02 3.29E-02 
215772_PM_x_at succinate-CoA ligase, GDP-forming, beta subunit 83460 SUCLG2 0.501 + 2.05E-02 2.43E-02 
224309_PM_s_at SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) 84808 SUGT1 0.348 + 2.44E-03 8.38E-04 
223330_PM_s_at SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) 440738 SUGT1 0.520 + 6.55E-03 7.64E-03 
212354_PM_at sulfatase 1 23760 SULF1 0.987 + 6.32E-03 1.07E-02 
225002_PM_s_at sulfatase modifying factor 2 57690 SUMF2 0.265 + 2.93E-04 1.52E-03 
211069_PM_s_at SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) 23064 SUMO1 0.421 + 2.02E-03 2.81E-03 
208761_PM_s_at SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) 51660 SUMO1 0.381 + 7.72E-03 5.95E-03 
213881_PM_x_at SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae) 10396 SUMO2 0.265 + 3.03E-03 1.55E-02 
200740_PM_s_at SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae) 5884 SUMO3 0.292 + 2.25E-02 1.05E-02 
201838_PM_s_at suppressor of Ty 7 (S. cerevisiae)-like 3945 SUPT7L 0.315 + 8.06E-03 2.40E-02 
204295_PM_at 





0.377 + 7.95E-03 3.34E-03 
226264_PM_at sushi domain containing 1 4217 SUSD1 0.407 + 5.48E-03 1.62E-02 
218619_PM_s_at suppressor of variegation 3-9 homolog 1 (Drosophila) 57038 SUV39H1 0.311 + 1.13E-02 3.46E-02 
222566_PM_at suppressor of variegation 4-20 homolog 1 (Drosophila) 23234 SUV420H1 0.545 + 3.15E-02 4.03E-02 
222759_PM_at suppressor of variegation 4-20 homolog 1 (Drosophila) 23392 SUV420H1 0.453 + 3.69E-02 3.41E-02 
230006_PM_s_at small VCP/p97-interacting protein 5629 SVIP 0.376 + 7.83E-03 6.85E-03 
230005_PM_at small VCP/p97-interacting protein 259232 SVIP 0.651 + 2.25E-02 2.95E-02 
217833_PM_at synaptotagmin binding, cytoplasmic RNA interacting protein 84181 SYNCRIP 0.813 + 1.12E-03 2.26E-03 
209025_PM_s_at synaptotagmin binding, cytoplasmic RNA interacting protein 26750 SYNCRIP 0.577 + 3.02E-02 4.62E-02 
225721_PM_at synaptopodin 2 123207 SYNPO2 0.387 + 1.24E-02 1.98E-02 
243313_PM_at synaptopodin 2-like --- SYNPO2L 0.325 + 1.59E-02 2.80E-02 
230303_PM_at synaptoporin 414918 SYNPR 0.357 + 1.07E-02 1.72E-02 
232387_PM_at synergin, gamma 55161 SYNRG 0.297 + 7.15E-03 3.21E-03 
64418_PM_at synergin, gamma --- SYNRG 0.416 + 1.83E-02 2.49E-02 
201260_PM_s_at synaptophysin-like 1 9379 SYPL1 0.263 + 2.79E-02 5.65E-03 
226086_PM_at synaptotagmin XIII 1728 SYT13 0.431 + 6.52E-03 2.18E-02 
1554797_PM_at synaptotagmin XVI 10768 SYT16 0.369 + 3.85E-02 4.44E-02 
223529_PM_at synaptotagmin IV 51095 SYT4 0.448 + 1.36E-02 2.33E-02 
202289_PM_s_at transforming, acidic coiled-coil containing protein 2 51646 TACC2 0.693 + 2.66E-02 3.56E-02 
 359 
213090_PM_s_at 
TAF4 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 135kDa 
11146 TAF4 0.762 + 2.63E-02 2.37E-02 
210053_PM_at 
TAF5 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 100kDa 
129787 TAF5 0.972 + 2.50E-02 2.12E-02 
203893_PM_at 
TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa 
3735 TAF9 0.598 + 2.26E-03 2.07E-03 
202168_PM_at 
TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa 
7146 /// 7148 TAF9 0.516 + 2.88E-03 4.66E-03 
226523_PM_at transgelin 1174 TAGLN 0.290 + 1.67E-02 2.30E-02 
206283_PM_s_at T-cell acute lymphocytic leukemia 1 10548 TAL1 0.331 + 9.86E-03 6.84E-03 
227407_PM_at transmembrane anterior posterior transformation 1 9113 TAPT1 0.550 + 1.64E-02 1.09E-02 
219443_PM_at taspase, threonine aspartase, 1 9690 TASP1 0.522 + 1.35E-02 8.59E-03 
223231_PM_at TatD Dnase domain containing 1 55088 TATDN1 0.514 + 1.27E-02 4.87E-03 
203648_PM_at TatD Dnase domain containing 2 10659 TATDN2 0.406 + 1.45E-02 4.20E-02 
209154_PM_at Tax1 (human T-cell leukemia virus type I) binding protein 3 11282 TAX1BP3 1.136 + 1.19E-03 1.83E-03 
224622_PM_at TBC1 domain family, member 14 51318 TBC1D14 0.468 + 1.97E-02 1.23E-02 
218268_PM_at TBC1 domain family, member 15 53342 TBC1D15 0.540 + 4.89E-03 7.56E-04 
226409_PM_at TBC1 domain family, member 20 3765 TBC1D20 0.550 + 1.83E-03 3.88E-03 
225121_PM_at TBC1 domain family, member 23 1390 TBC1D23 0.495 + 5.00E-03 4.22E-03 
213912_PM_at TBC1 domain family, member 30 23261 TBC1D30 0.800 + 1.23E-02 5.46E-03 
223461_PM_at TBC1 domain family, member 7 65244 TBC1D7 0.435 + 3.74E-02 4.60E-02 
238067_PM_at TBC1 domain family, member 8B (with GRAM domain) 165215 TBC1D8B 0.298 + 8.19E-04 2.06E-04 
212956_PM_at TBC1 domain family, member 9 (with GRAM domain) 7220 TBC1D9 0.450 + 7.21E-03 5.82E-03 
203667_PM_at tubulin folding cofactor A 399979 TBCA 0.451 + 2.23E-04 1.85E-03 
211052_PM_s_at tubulin folding cofactor D 94015 TBCD 0.264 + 2.86E-02 1.56E-02 
203714_PM_s_at tubulin folding cofactor E 400073 TBCE 0.567 + 5.81E-04 2.99E-03 
227395_PM_at Tubulin folding cofactor E-like 55203 TBCEL 0.494 + 1.78E-02 4.55E-02 
218520_PM_at TANK-binding kinase 1 122416 TBK1 0.640 + 2.11E-02 1.73E-02 
213400_PM_s_at 359eparin359ing (beta)-like 1X-linked 9937 TBL1X 0.405 + 7.80E-03 2.20E-02 
226318_PM_at transforming growth factor beta regulator 1 9865 TBRG1 0.322 + 9.22E-04 8.71E-03 
225819_PM_at transforming growth factor beta regulator 1 80725 TBRG1 0.374 + 8.06E-03 5.04E-03 
207555_PM_s_at thromboxane A2 receptor 23301 TBXA2R 0.295 + 1.07E-03 5.05E-04 
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227705_PM_at transcription elongation factor A (SII)-like 7 8994 TCEAL7 0.405 + 2.25E-02 1.24E-02 
224819_PM_at transcription elongation factor A (SII)-like 8 29767 TCEAL8 0.464 + 4.71E-04 4.78E-05 
202824_PM_s_at 
transcription elongation factor B (SIII), polypeptide 1 (15kDa, 
elongin C) 
7812 TCEB1 0.376 + 1.30E-02 9.55E-03 
202823_PM_at 
transcription elongation factor B (SIII), polypeptide 1 (15kDa, 
elongin C) 
26289 TCEB1 0.357 + 4.22E-02 3.81E-02 
202396_PM_at transcription elongation regulator 1 79717 TCERG1 0.577 + 1.17E-02 6.71E-03 
208986_PM_at transcription factor 12 80006 TCF12 0.607 + 2.13E-02 1.03E-02 
207306_PM_at transcription factor 15 (basic helix-loop-helix) 22998 TCF15 0.319 + 1.70E-02 7.33E-05 
212761_PM_at transcription factor 7-like 2 (T-cell specific, HMG-box) 26151 TCF7L2 0.645 + 3.64E-02 9.77E-03 
228606_PM_at Tctex1 domain containing 2 375743 TCTEX1D2 0.525 + 8.79E-03 4.03E-03 
203743_PM_s_at thymine-DNA glycosylase 10097 TDG 0.526 + 1.29E-02 2.26E-03 
208089_PM_s_at tudor domain containing 3 9659 TDRD3 0.501 + 3.03E-02 2.33E-02 
236904_PM_x_at tectorin alpha 84284 TECTA 0.487 + 3.32E-03 1.45E-02 
239216_PM_at tektin 1 23305 TEKT1 0.286 + 2.26E-02 4.23E-02 
204106_PM_at testis-specific kinase 1 8507 TESK1 0.339 + 3.23E-04 4.29E-03 
227624_PM_at tet oncogene family member 2 2321 TET2 0.753 + 2.26E-02 6.20E-03 
228075_PM_x_at transcription factor B1, mitochondrial 57532 TFB1M 0.622 + 1.11E-03 1.51E-02 
227637_PM_at Transcription factor CP2 80762 TFCP2 0.452 + 3.01E-02 1.44E-02 
226157_PM_at Transcription factor Dp-2 (E2F dimerization partner 2) 7716 TFDP2 0.325 + 2.70E-02 3.05E-02 
212457_PM_at transcription factor binding to IGHM enhancer 3 7019 TFE3 0.377 + 5.00E-03 2.14E-03 
224793_PM_s_at transforming growth factor, beta receptor 1 84134 TGFBR1 0.686 + 1.30E-02 2.98E-03 
219292_PM_at THAP domain containing, apoptosis associated protein 1 79602 THAP1 0.436 + 2.25E-02 1.66E-02 
212910_PM_at THAP domain containing 11 9636 THAP11 0.514 + 4.27E-03 8.93E-04 
203083_PM_at thrombospondin 2 4774 THBS2 0.806 + 7.10E-03 1.37E-02 
222931_PM_s_at threonine synthase-like 1 (S. cerevisiae) 996 THNSL1 0.449 + 3.78E-02 4.31E-03 
204064_PM_at THO complex 1 653566 /// 9789 THOC1 0.436 + 3.51E-02 3.11E-02 
226628_PM_at THO complex 2 2902 THOC2 0.272 + 4.15E-03 4.36E-03 
226626_PM_at THO complex 2 1432 THOC2 0.639 + 1.86E-02 8.09E-03 
218334_PM_at THO complex 7 homolog (Drosophila) 51010 THOC7 0.451 + 1.67E-02 5.51E-03 
229657_PM_at 
thyroid hormone receptor, beta (erythroblastic leukemia viral 
(v-erb-a) oncogene homolog 2, avian) 
79692 THRB 0.770 + 1.03E-02 6.87E-04 
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229159_PM_at Thrombospondin, type I, domain containing 7A 150678 THSD7A 0.491 + 4.10E-02 3.46E-02 
201448_PM_at TIA1 cytotoxic granule-associated RNA binding protein 3308 TIA1 0.805 + 8.85E-03 1.52E-02 
201447_PM_at TIA1 cytotoxic granule-associated RNA binding protein 373 TIA1 0.618 + 3.87E-02 1.26E-02 
228234_PM_at 






0.383 + 1.61E-02 4.61E-02 
229758_PM_at tigger transposable element derived 5 84848 TIGD5 0.273 + 3.77E-02 3.23E-02 
215171_PM_s_at 
translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
57107 TIMM17A 0.619 + 1.01E-02 1.09E-02 
219184_PM_x_at 
translocase of inner mitochondrial membrane 22 homolog 
(yeast) 
6711 TIMM22 0.291 + 1.05E-02 2.12E-02 
218118_PM_s_at 
translocase of inner mitochondrial membrane 23 homolog 
(yeast) 
147339 TIMM23 0.404 + 8.95E-03 2.64E-02 
225535_PM_s_at 
translocase of inner mitochondrial membrane 23 homolog 
(yeast) 
284485 TIMM23 0.294 + 1.57E-02 1.88E-03 
205217_PM_at 
translocase of inner mitochondrial membrane 8 homolog A 
(yeast) 
205 TIMM8A 0.500 + 4.51E-03 1.02E-02 
219058_PM_x_at tubulointerstitial nephritis antigen-like 1 415056 TINAGL1 0.300 + 9.84E-04 3.99E-03 
201922_PM_at TGF beta-inducible nuclear protein 1 541578 /// 91966 TINP1 0.355 + 2.82E-03 1.32E-03 
212665_PM_at TCDD-inducible poly(ADP-ribose) polymerase 10529 TIPARP 0.692 + 8.88E-03 7.48E-03 
204872_PM_at 
361eparin361ing-like enhancer of split 4 (E(sp1) homolog, 
Drosophila) 
4849 TLE4 0.648 + 1.88E-02 2.38E-03 
202606_PM_s_at tousled-like kinase 1 54816 TLK1 0.572 + 1.51E-02 3.02E-02 
228627_PM_at tousled-like kinase 2 285636 TLK2 0.378 + 4.73E-03 2.38E-02 
212997_PM_s_at tousled-like kinase 2 6861 TLK2 0.353 + 9.69E-03 1.73E-03 
236132_PM_at talin 1 63939 TLN1 0.290 + 1.56E-02 1.29E-02 
220146_PM_at toll-like receptor 7 9702 TLR7 0.413 + 1.63E-02 2.42E-02 
213883_PM_s_at TM2 domain containing 1 4238 TM2D1 1.105 + 2.27E-03 1.41E-03 
211703_PM_s_at TM2 domain containing 1 114112 TM2D1 0.315 + 2.48E-02 2.35E-02 
224413_PM_s_at TM2 domain containing 2 647087 TM2D2 0.280 + 1.97E-03 9.93E-03 
209150_PM_s_at transmembrane 9 superfamily member 1 27019 TM9SF1 0.301 + 1.74E-02 9.13E-03 
235146_PM_at transmembrane and coiled-coil domain family 3 8880 TMCC3 0.543 + 2.53E-02 2.64E-02 
208716_PM_s_at transmembrane and coiled-coil domains 1 79869 TMCO1 0.348 + 1.69E-03 2.63E-03 
210768_PM_x_at transmembrane and coiled-coil domains 1 84281 TMCO1 0.417 + 2.56E-02 1.42E-02 
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202194_PM_at transmembrane emp24 protein transport domain containing 5 8028 TMED5 0.575 + 2.38E-02 1.65E-02 
209404_PM_s_at transmembrane emp24 protein transport domain containing 7 55914 TMED7 0.306 + 1.71E-02 4.49E-03 
225343_PM_at transmembrane emp24 protein transport domain containing 8 146434 TMED8 0.442 + 1.77E-02 7.78E-03 
205122_PM_at 
transmembrane protein with EGF-like and two follistatin-like 
domains 1 
2309 TMEFF1 0.555 + 4.07E-02 1.62E-03 
219230_PM_at transmembrane protein 100 6500 TMEM100 0.610 + 1.95E-03 1.70E-04 
201764_PM_at transmembrane protein 106C 10042 TMEM106C 0.397 + 7.15E-04 1.10E-03 
239824_PM_s_at transmembrane protein 107 --- TMEM107 0.298 + 2.26E-02 1.82E-02 
223334_PM_at transmembrane protein 126A 79929 TMEM126A 0.426 + 4.48E-03 1.02E-03 
221622_PM_s_at transmembrane protein 126B 23495 TMEM126B 0.620 + 8.02E-04 8.04E-05 
218477_PM_at transmembrane protein 14A 84456 TMEM14A 0.517 + 3.24E-05 4.24E-04 
227861_PM_at transmembrane protein 161B 9188 TMEM161B 0.518 + 2.13E-02 1.06E-02 
226276_PM_at transmembrane protein 167A 4534 TMEM167A 0.674 + 1.96E-03 3.52E-03 
224702_PM_at transmembrane protein 167A 1385 TMEM167A 0.316 + 4.17E-02 2.57E-02 
218962_PM_s_at transmembrane protein 168 6853 TMEM168 0.896 + 1.08E-02 2.27E-02 
235798_PM_at transmembrane protein 170B 4173 TMEM170B 0.686 + 3.37E-03 2.53E-04 
229302_PM_at transmembrane protein 178 246175 TMEM178 0.308 + 3.06E-02 1.77E-02 
225489_PM_at transmembrane protein 18 139322 TMEM18 0.515 + 9.49E-03 4.70E-02 
219074_PM_at transmembrane protein 184C 253143 TMEM184C 0.357 + 2.86E-03 1.48E-02 
204340_PM_at transmembrane protein 187 10549 TMEM187 0.453 + 5.17E-04 1.05E-03 
235812_PM_at transmembrane protein 188 57223 TMEM188 0.425 + 1.33E-04 3.00E-03 
223186_PM_at 
transmembrane protein 189 /// ubiquitin-conjugating enzyme 




0.501 + 1.57E-02 1.51E-02 
229126_PM_at transmembrane protein 19 5989 TMEM19 1.010 + 4.99E-04 3.08E-04 
223305_PM_at transmembrane protein 216 2850 TMEM216 0.830 + 2.27E-03 3.65E-03 
226073_PM_at transmembrane protein 218 26118 TMEM218 0.590 + 5.36E-03 1.34E-02 
219569_PM_s_at transmembrane protein 22 8895 TMEM22 0.460 + 3.23E-02 5.74E-04 
222391_PM_at transmembrane protein 30A 9728 TMEM30A 0.325 + 2.26E-03 3.69E-03 
225492_PM_at transmembrane protein 33 57118 TMEM33 0.401 + 2.76E-03 7.83E-03 
212622_PM_at transmembrane protein 41B 9936 TMEM41B 0.565 + 1.21E-02 5.06E-03 
209656_PM_s_at transmembrane protein 47 53349 TMEM47 0.433 + 9.78E-03 2.13E-02 
234672_PM_s_at transmembrane protein 48 --- TMEM48 0.582 + 3.45E-02 3.87E-02 
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204808_PM_s_at transmembrane protein 5 29994 TMEM5 0.461 + 2.20E-02 3.59E-02 
225182_PM_at transmembrane protein 50B 5810 TMEM50B 0.325 + 2.42E-02 5.60E-03 
200620_PM_at transmembrane protein 59 1082 /// 93659 TMEM59 0.346 + 9.53E-05 6.79E-04 
223396_PM_at transmembrane protein 60 55334 TMEM60 0.527 + 1.55E-03 2.12E-03 
241342_PM_at transmembrane protein 65 55342 TMEM65 0.441 + 1.29E-03 1.10E-02 
219449_PM_s_at transmembrane protein 70 51097 TMEM70 0.440 + 5.43E-03 8.49E-04 
1552520_PM_at transmembrane protein 74 5905 TMEM74 0.693 + 1.54E-02 1.55E-02 
229957_PM_at transmembrane protein 91 --- TMEM91 0.283 + 4.37E-03 4.23E-02 
221255_PM_s_at transmembrane protein 93 10090 TMEM93 0.331 + 4.17E-02 4.88E-02 
212282_PM_at transmembrane protein 97 645 TMEM97 0.715 + 7.48E-03 4.81E-02 
212281_PM_s_at transmembrane protein 97 8899 TMEM97 0.895 + 7.82E-03 2.75E-02 
226565_PM_at transmembrane protein 99 100287552 TMEM99 0.351 + 6.59E-04 4.80E-04 
227685_PM_at TATA element modulatory factor 1 9935 TMF1 0.415 + 3.21E-02 1.31E-02 
226186_PM_at tropomodulin 2 (neuronal) 3340 TMOD2 0.415 + 3.94E-03 1.08E-02 
224944_PM_at thymopoietin 8082 TMPO 0.319 + 3.58E-02 2.25E-03 
214051_PM_at thymosin beta 15B 26038 TMSB15B 0.583 + 9.15E-03 1.77E-02 
226604_PM_at transmembrane and tetratricopeptide repeat containing 3 2902 TMTC3 0.392 + 2.87E-02 2.66E-02 
225666_PM_at transmembrane and tetratricopeptide repeat containing 4 9647 TMTC4 0.345 + 2.06E-02 1.14E-02 
209476_PM_at thioredoxin-related transmembrane protein 1 9462 TMX1 0.420 + 1.19E-02 6.16E-03 
225302_PM_at thioredoxin-related transmembrane protein 3 23413 TMX3 0.603 + 4.69E-03 1.29E-02 
201581_PM_at thioredoxin-related transmembrane protein 4 23658 TMX4 0.336 + 8.73E-03 1.58E-02 
223583_PM_at tumor necrosis factor, alpha-induced protein 8-like 2 51003 TNFAIP8L2 0.264 + 1.67E-02 3.49E-02 
207641_PM_at tumor necrosis factor receptor superfamily, member 13B 23405 TNFRSF13B 0.363 + 9.04E-03 2.17E-02 
210314_PM_x_at tumor necrosis factor (ligand) superfamily, member 13 128061 TNFSF13 0.613 + 1.55E-02 4.12E-02 
207426_PM_s_at tumor necrosis factor (ligand) superfamily, member 4 23032 TNFSF4 0.454 + 4.66E-02 4.80E-02 
239288_PM_at TRAF2 and NCK interacting kinase --- TNIK 0.731 + 1.72E-02 3.68E-02 
217149_PM_x_at tyrosine kinase, non-receptor, 1 93183 TNK1 0.388 + 3.48E-03 6.46E-04 
218228_PM_s_at 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 2 
283635 TNKS2 0.305 + 2.25E-02 7.13E-03 
225765_PM_at transportin 1 284339 TNPO1 0.453 + 9.49E-03 2.45E-02 
212635_PM_at transportin 1 22924 TNPO1 0.490 + 1.92E-02 3.65E-02 
215844_PM_at transportin 2 80143 TNPO2 0.296 + 4.66E-02 4.68E-02 
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224704_PM_at trinucleotide repeat containing 6A 3977 TNRC6A 0.591 + 2.37E-03 3.34E-03 
217853_PM_at tensin 3 128866 TNS3 0.591 + 7.50E-03 1.32E-02 
200662_PM_s_at 
translocase of outer mitochondrial membrane 20 homolog 
(yeast) 
9465 TOMM20 0.282 + 5.30E-03 5.75E-03 
226059_PM_at 
translocase of outer mitochondrial membrane 40 homolog 
(yeast)-like 
26118 TOMM40L 0.507 + 4.64E-02 1.18E-02 
225036_PM_at 
translocase of outer mitochondrial membrane 5 homolog 
(yeast) 
2737 TOMM5 0.465 + 4.04E-03 7.84E-03 
201519_PM_at 
translocase of outer mitochondrial membrane 70 homolog A 
(S. cerevisiae) 
8202 TOMM70A 0.290 + 1.35E-02 7.32E-03 
211987_PM_at topoisomerase (DNA) II beta 180kDa 5351 TOP2B 0.415 + 1.97E-02 2.46E-02 
202633_PM_at topoisomerase (DNA) II binding protein 1 81926 TOPBP1 0.624 + 3.64E-02 1.62E-02 
204071_PM_s_at topoisomerase I binding, arginine/serine-rich 481 TOPORS 0.572 + 9.49E-03 1.48E-02 
212408_PM_at torsin A interacting protein 1 9648 TOR1AIP1 0.449 + 1.83E-02 2.21E-02 
215108_PM_x_at TOX high mobility group box family member 3 51018 TOX3 0.804 + 2.66E-02 2.46E-02 
225912_PM_at tumor protein p53 inducible nuclear protein 1 728052 TP53INP1 0.774 + 1.82E-02 1.18E-02 
201690_PM_s_at tumor protein D52 4976 TPD52 0.270 + 1.38E-03 7.88E-04 
203786_PM_s_at tumor protein D52-like 1 55885 TPD52L1 0.489 + 1.76E-02 3.95E-02 
224164_PM_at tropomyosin 3 54414 TPM3 0.383 + 8.20E-04 9.38E-04 
230104_PM_s_at tubulin polymerization promoting protein 27253 TPPP 0.368 + 3.34E-02 1.51E-02 
219030_PM_at TP53RK binding protein 83851 TPRKB 0.991 + 7.16E-03 2.18E-02 
217023_PM_x_at tryptase alpha/beta 1 /// tryptase beta 2 84275 
TPSAB1 /// 
TPSB2 
0.299 + 5.70E-03 2.01E-02 
204140_PM_at tyrosylprotein sulfotransferase 1 1977 TPST1 0.324 + 3.43E-02 4.29E-02 
200893_PM_at transformer 2 beta homolog (Drosophila) 
276 /// 277 /// 
278 /// 279 /// 
280 
TRA2B 0.341 + 5.84E-03 8.08E-03 
1729_PM_at TNFRSF1A-associated via death domain 5783 TRADD 0.352 + 6.53E-03 6.68E-04 
204352_PM_at TNF receptor-associated factor 5 10193 TRAF5 0.507 + 3.29E-03 1.51E-02 
238628_PM_s_at trafficking protein particle complex 2-like 199870 TRAPPC2L 0.296 + 4.35E-02 3.12E-02 
203512_PM_at trafficking protein particle complex 3 84314 TRAPPC3 0.421 + 2.08E-03 1.34E-02 
202241_PM_at tribbles homolog 1 (Drosophila) 2752 TRIB1 0.327 + 4.66E-02 8.46E-03 
205151_PM_s_at TLR4 interactor with leucine rich repeats 11102 TRIL 0.673 + 2.70E-03 7.63E-03 
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202702_PM_at tripartite motif-containing 26 
23420 /// 283820 
/// 408050 
TRIM26 0.281 + 3.58E-02 1.69E-02 
212435_PM_at tripartite motif-containing 33 58487 TRIM33 0.578 + 3.31E-02 1.68E-02 
222732_PM_at tripartite motif-containing 39 25924 TRIM39 0.582 + 6.66E-03 2.49E-02 
217760_PM_at tripartite motif-containing 44 134553 TRIM44 0.397 + 4.25E-02 4.15E-02 
221897_PM_at tripartite motif-containing 52 6430 TRIM52 0.424 + 9.60E-03 1.76E-02 
236972_PM_at tripartite motif-containing 63 --- TRIM63 0.853 + 1.04E-02 1.66E-02 
221012_PM_s_at tripartite motif-containing 8 22863 TRIM8 0.479 + 2.81E-02 1.73E-02 
218877_PM_s_at tRNA methyltransferase 11 homolog (S. cerevisiae) 2801 TRMT11 0.451 + 1.34E-04 1.00E-04 
227653_PM_at TRM5 tRNA methyltransferase 5 homolog (S. cerevisiae) 56888 TRMT5 0.575 + 8.22E-03 1.21E-02 
221229_PM_s_at tRNA methyltransferase 61 homolog B (S. cerevisiae) 55922 TRMT61B 0.515 + 3.38E-02 2.13E-02 
222754_PM_at tRNA nucleotidyl transferase, CCA-adding, 1 3691 TRNT1 0.329 + 1.39E-02 3.73E-02 
213027_PM_at TROVE domain family, member 2 5128 TROVE2 0.673 + 3.01E-02 4.88E-02 
205803_PM_s_at 
transient receptor potential cation channel, subfamily C, 
member 1 
2915 TRPC1 0.340 + 1.49E-02 2.12E-02 
221102_PM_s_at 
transient receptor potential cation channel, subfamily M, 
member 6 
27107 TRPM6 0.294 + 8.38E-03 3.74E-02 
223324_PM_s_at 
transient receptor potential cation channel, subfamily M, 
member 7 
2744 TRPM7 0.383 + 2.01E-02 4.45E-02 
218502_PM_s_at trichorhinophalangeal syndrome I 2562 TRPS1 0.516 + 2.12E-03 1.00E-02 
223109_PM_at TruB pseudouridine (psi) synthase homolog 2 (E. coli) 55848 TRUB2 0.564 + 1.27E-03 9.46E-05 
208763_PM_s_at TSC22 domain family, member 3 51138 TSC22D3 0.338 + 9.32E-03 8.31E-04 
201758_PM_at tumor susceptibility gene 101 4134 TSG101 0.548 + 1.29E-02 2.27E-02 
223282_PM_at teashirt zinc finger homeobox 1 83452 TSHZ1 0.651 + 1.45E-03 5.16E-03 
223393_PM_s_at teashirt zinc finger homeobox 3 55629 TSHZ3 0.807 + 1.21E-02 2.41E-02 
201515_PM_s_at translin 7337 TSN 0.285 + 8.01E-03 9.08E-03 
201513_PM_at translin 1612 TSN 0.411 + 1.38E-02 5.98E-04 
203983_PM_at translin-associated factor X 3728 TSNAX 0.481 + 2.16E-02 1.70E-02 
203227_PM_s_at tetraspanin 31 84866 TSPAN31 0.454 + 7.01E-03 1.77E-02 
209108_PM_at tetraspanin 6 29922 TSPAN6 0.374 + 4.89E-02 3.58E-02 
213122_PM_at TSPY-like 5 10085 TSPYL5 0.493 + 4.72E-03 1.79E-02 
230191_PM_at tau tubulin kinase 1 3841 TTBK1 0.465 + 2.56E-02 2.38E-02 
201434_PM_at tetratricopeptide repeat domain 1 2213 TTC1 0.580 + 1.24E-03 1.24E-03 
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225180_PM_at tetratricopeptide repeat domain 14 55153 TTC14 0.361 + 1.97E-02 1.34E-02 
229169_PM_at tetratricopeptide repeat domain 18 140461 TTC18 0.315 + 9.73E-03 2.63E-02 
229170_PM_s_at tetratricopeptide repeat domain 18 --- TTC18 0.278 + 4.09E-02 1.33E-02 
203584_PM_at tetratricopeptide repeat domain 35 56990 TTC35 0.532 + 5.74E-03 7.73E-03 
203049_PM_s_at tetratricopeptide repeat domain 37 63905 TTC37 0.564 + 9.52E-03 8.66E-03 
238480_PM_at tetratricopeptide repeat domain 39C 440574 TTC39C 0.694 + 2.57E-04 3.47E-03 
226152_PM_at tetratricopeptide repeat domain 7B 22906 TTC7B 0.619 + 3.00E-02 4.10E-02 
226120_PM_at tetratricopeptide repeat domain 8 5903 TTC8 0.513 + 1.64E-02 1.48E-02 
224896_PM_s_at tubulin tyrosine ligase 9213 TTL 0.685 + 2.51E-02 5.82E-03 
202266_PM_at TRAF and TNF receptor associated protein 166 TTRAP 0.497 + 1.80E-03 3.98E-03 
209191_PM_at tubulin, beta 6 57718 TUBB6 0.484 + 3.72E-02 4.12E-02 
203690_PM_at tubulin, gamma complex associated protein 3 29761 TUBGCP3 0.520 + 2.62E-02 1.24E-02 
213266_PM_at Tubulin, gamma complex associated protein 4 23062 TUBGCP4 0.607 + 9.85E-03 2.20E-02 
238190_PM_at Tu translation elongation factor, mitochondrial --- TUFM 0.305 + 2.47E-02 3.78E-02 
201745_PM_at twinfilin, actin-binding protein, homolog 1 (Drosophila) 23522 TWF1 0.700 + 1.61E-02 1.71E-02 
226784_PM_at TWIST neighbor 137886 TWISTNB 0.471 + 2.55E-02 4.58E-02 
208864_PM_s_at thioredoxin 51642 TXN 0.272 + 2.06E-02 1.56E-02 
226747_PM_at thioredoxin domain containing 16 440026 TXNDC16 0.847 + 7.77E-03 6.92E-03 
224511_PM_s_at thioredoxin domain containing 17 440574 TXNDC17 0.564 + 2.84E-03 5.57E-03 
228743_PM_at thioredoxin domain containing 17 --- TXNDC17 0.344 + 2.49E-02 4.15E-02 
202836_PM_s_at thioredoxin-like 4A 83939 TXNL4A 0.469 + 1.21E-03 3.87E-03 
201266_PM_at thioredoxin reductase 1 9568 TXNRD1 0.402 + 2.21E-02 5.84E-03 
59631_PM_at thioredoxin reductase 3 --- TXNRD3 0.473 + 7.25E-03 8.88E-03 
223279_PM_s_at 
uveal autoantigen with coiled-coil domains and ankyrin 
repeats 
64388 UACA 0.752 + 3.37E-02 3.86E-02 
201177_PM_s_at ubiquitin-like modifier activating enzyme 2 8726 UBA2 0.520 + 9.60E-03 2.59E-03 
209115_PM_at ubiquitin-like modifier activating enzyme 3 80723 UBA3 0.454 + 3.36E-03 3.24E-03 
222602_PM_at ubiquitin-like modifier activating enzyme 6 10464 UBA6 0.272 + 2.02E-03 6.34E-03 
222601_PM_at ubiquitin-like modifier activating enzyme 6 57205 UBA6 0.446 + 7.57E-03 4.37E-02 
46270_PM_at ubiquitin associated protein 1 --- UBAP1 0.430 + 2.39E-02 1.18E-02 
221490_PM_at ubiquitin associated protein 1 8745 UBAP1 0.526 + 2.55E-02 1.69E-02 
214695_PM_at ubiquitin associated protein 2-like 10363 UBAP2L 0.362 + 3.31E-03 2.59E-02 
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201377_PM_at ubiquitin associated protein 2-like 594 UBAP2L 0.760 + 4.34E-02 4.68E-02 
238462_PM_at ubiquitin associated and SH3 domain containing, B --- UBASH3B 0.660 + 9.51E-03 1.31E-02 
202334_PM_s_at ubiquitin-conjugating enzyme E2B (RAD6 homolog) 51510 UBE2B 0.363 + 3.53E-02 4.19E-02 
227790_PM_at ubiquitin-conjugating enzyme E2C binding protein 84066 UBE2CBP 0.345 + 3.52E-02 3.13E-02 
211764_PM_s_at ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) 11240 UBE2D1 0.411 + 2.40E-02 2.21E-02 
201344_PM_at ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 7422 UBE2D2 0.696 + 3.08E-03 5.27E-03 
209141_PM_at ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast) 54886 UBE2G1 0.338 + 2.10E-02 2.02E-03 
1557053_PM_s_at ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) 51663 UBE2G2 0.394 + 6.64E-03 3.51E-02 
209042_PM_s_at ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast) 79668 UBE2G2 0.552 + 4.64E-02 4.29E-02 
222421_PM_at ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 23258 UBE2H 0.607 + 2.79E-02 2.57E-02 
212751_PM_at ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast) 9166 UBE2N 0.281 + 2.10E-02 2.36E-03 
224747_PM_at ubiquitin-conjugating enzyme E2Q family member 2 10944 UBE2Q2 0.513 + 1.39E-02 2.78E-02 
223229_PM_at ubiquitin-conjugating enzyme E2T (putative) 56603 UBE2T 0.408 + 4.19E-02 3.28E-02 
209096_PM_at ubiquitin-conjugating enzyme E2 variant 2 10000 UBE2V2 0.483 + 5.35E-04 8.64E-04 
222656_PM_at ubiquitin-conjugating enzyme E2W (putative) 23035 UBE2W 0.360 + 1.03E-02 5.21E-04 
222657_PM_s_at ubiquitin-conjugating enzyme E2W (putative) 7474 UBE2W 0.571 + 1.13E-02 1.72E-02 
213128_PM_s_at ubiquitin protein ligase E3A 7292 UBE3A 0.477 + 3.93E-03 1.39E-02 
211285_PM_s_at ubiquitin protein ligase E3A 3192 UBE3A 0.401 + 2.44E-02 4.53E-02 
212403_PM_at ubiquitin protein ligase E3B 22908 UBE3B 0.451 + 4.88E-03 3.28E-03 
201817_PM_at ubiquitin protein ligase E3C 1508 UBE3C 0.285 + 7.23E-03 1.12E-02 
202038_PM_at ubiquitination factor E4A (UFD2 homolog, yeast) 23348 UBE4A 0.648 + 2.02E-03 2.91E-03 
201535_PM_at ubiquitin-like 3 11054 UBL3 0.531 + 3.82E-02 2.30E-02 
207253_PM_s_at ubinuclein 1 23014 UBN1 0.351 + 1.69E-02 4.29E-02 
225444_PM_at ubinuclein 2 56977 UBN2 0.714 + 7.27E-03 1.27E-02 
224513_PM_s_at ubiquilin 4 5898 UBQLN4 0.623 + 5.12E-03 2.74E-04 
226921_PM_at ubiquitin protein ligase E3 component n-recognin 1 388650 UBR1 0.757 + 6.45E-03 1.68E-03 
212760_PM_at ubiquitin protein ligase E3 component n-recognin 2 8570 UBR2 0.379 + 1.82E-03 1.84E-02 
230029_PM_x_at ubiquitin protein ligase E3 component n-recognin 3 (putative) 254778 UBR3 0.412 + 3.57E-02 2.28E-02 
208883_PM_at ubiquitin protein ligase E3 component n-recognin 5 51562 UBR5 0.811 + 2.42E-02 2.87E-02 
208882_PM_s_at ubiquitin protein ligase E3 component n-recognin 5 29887 UBR5 0.786 + 2.99E-02 2.88E-02 
212934_PM_at UBX domain protein 2B 55658 UBXN2B 0.271 + 7.66E-03 1.61E-02 
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204616_PM_at 
ubiquitin carboxyl-terminal esterase L3 (ubiquitin 
thiolesterase) 
6311 UCHL3 0.432 + 7.52E-03 9.74E-03 
228142_PM_at ubiquinol-cytochrome c reductase complex (7.2 kD) 80223 UCRC 0.265 + 7.21E-03 3.22E-02 
218449_PM_at UFM1-specific peptidase 2 125150 UFSP2 0.348 + 1.59E-02 2.99E-02 
231968_PM_at UDP-glucose glycoprotein glucosyltransferase 1 93 UGGT1 0.448 + 6.65E-03 4.58E-02 
226135_PM_at UHRF1 binding protein 1 7528 UHRF1BP1 0.490 + 8.15E-03 3.87E-03 
213118_PM_at UHRF1 binding protein 1-like 3358 UHRF1BP1L 0.553 + 2.92E-04 4.58E-04 
204063_PM_s_at unc-51-like kinase 2 (C. elegans) 2773 ULK2 0.550 + 2.58E-02 3.07E-02 
202893_PM_at unc-13 homolog B (C. elegans) 51192 UNC13B 0.323 + 3.36E-02 3.03E-02 
203583_PM_at unc-50 homolog (C. elegans) 56990 UNC50 0.353 + 3.92E-03 1.63E-02 
231325_PM_at unc-5 homolog D (C. elegans) 202181 UNC5D 0.475 + 3.82E-02 2.20E-02 
243523_PM_at LMNE6487 --- UNQ6487 0.409 + 2.11E-02 4.11E-02 
228219_PM_s_at ureidopropionase, beta --- UPB1 0.359 + 2.38E-02 9.99E-03 
203519_PM_s_at UPF2 regulator of nonsense transcripts homolog (yeast) 60412 UPF2 0.353 + 1.44E-02 3.52E-02 
218757_PM_s_at UPF3 regulator of nonsense transcripts homolog B (yeast) 221786 UPF3B 0.389 + 1.34E-02 2.11E-02 
205849_PM_s_at ubiquinol-cytochrome c reductase binding protein 6915 UQCRB 0.335 + 5.55E-04 1.98E-03 
209066_PM_x_at ubiquinol-cytochrome c reductase binding protein 64129 UQCRB 0.300 + 1.60E-02 4.10E-02 
244293_PM_at ubiquinol-cytochrome c reductase binding protein --- UQCRB 0.539 + 2.02E-02 1.56E-02 
212600_PM_s_at ubiquinol-cytochrome c reductase core protein II 6996 UQCRC2 0.325 + 2.47E-02 2.08E-02 
202233_PM_s_at ubiquinol-cytochrome c reductase hinge protein 7416 UQCRH 0.366 + 1.20E-02 3.57E-03 
218386_PM_x_at ubiquitin specific peptidase 16 440823 USP16 0.678 + 5.14E-03 1.88E-03 
228822_PM_s_at ubiquitin specific peptidase 16 55500 USP16 0.765 + 7.96E-03 6.83E-03 
226357_PM_at ubiquitin specific peptidase 19 9856 USP19 0.643 + 2.83E-03 4.55E-03 
223167_PM_s_at ubiquitin specific peptidase 25 55315 USP25 0.643 + 1.65E-02 1.64E-02 
220419_PM_s_at ubiquitin specific peptidase 25 3727 USP25 0.347 + 2.46E-02 1.35E-02 
212513_PM_s_at ubiquitin specific peptidase 33 1000 USP33 0.427 + 3.49E-02 1.23E-02 
212066_PM_s_at ubiquitin specific peptidase 34 8407 USP34 0.521 + 1.25E-02 2.99E-02 
232033_PM_at ubiquitin specific peptidase 37 --- USP37 0.446 + 1.37E-03 5.26E-03 
226730_PM_s_at ubiquitin specific peptidase 37 286451 USP37 0.475 + 1.60E-02 1.36E-02 
223288_PM_at ubiquitin specific peptidase 38 81034 USP38 0.432 + 1.54E-02 3.08E-02 
226669_PM_at ubiquitin specific peptidase 42 677 USP42 0.560 + 3.86E-02 2.59E-02 
238057_PM_at ubiquitin specific peptidase 45 --- USP45 0.279 + 4.80E-03 6.23E-03 
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203870_PM_at ubiquitin specific peptidase 46 2782 USP46 0.476 + 3.15E-02 1.41E-02 
223117_PM_s_at ubiquitin specific peptidase 47 54780 USP47 0.435 + 1.03E-02 3.10E-02 
229501_PM_s_at ubiquitin specific peptidase 8 --- USP8 0.714 + 3.09E-02 2.93E-02 
201099_PM_at ubiquitin specific peptidase 9, X-linked 10767 USP9X 0.813 + 2.51E-02 2.32E-02 
229573_PM_at ubiquitin specific peptidase 9, X-linked 5814 USP9X 0.528 + 3.34E-02 2.88E-02 
205139_PM_s_at uronyl-2-sulfotransferase 1120 UST 0.411 + 1.83E-03 1.35E-02 
218235_PM_s_at UTP11-like, U3 small nucleolar ribonucleoprotein, (yeast) 54476 UTP11L 0.377 + 3.62E-02 3.57E-02 
203614_PM_at 
UTP14, U3 small nucleolar ribonucleoprotein, homolog C 
(yeast) 
89886 UTP14C 0.286 + 1.28E-02 4.81E-02 
203721_PM_s_at 




27316 /// 494115 
UTP18 0.665 + 3.96E-02 3.21E-02 
225093_PM_at utrophin 114785 UTRN 0.517 + 3.98E-02 4.95E-02 
218495_PM_at ubiquitously-expressed transcript 9589 UXT 0.423 + 1.87E-02 9.97E-03 
213326_PM_at vesicle-associated membrane protein 1 (synaptobrevin 1) 81689 VAMP1 0.647 + 2.74E-02 1.02E-02 
213480_PM_at vesicle-associated membrane protein 4 4116 VAMP4 0.869 + 7.82E-03 6.02E-03 
202829_PM_s_at vesicle-associated membrane protein 7 51523 VAMP7 0.742 + 3.36E-02 1.03E-02 
225198_PM_at 
VAMP (vesicle-associated membrane protein)-associated 
protein A, 33kDa 
7637 VAPA 0.341 + 1.53E-02 4.67E-02 
226200_PM_at valyl-tRNA synthetase 2, mitochondrial (putative) 3709 VARS2 0.487 + 1.51E-02 4.57E-02 
225867_PM_at vasorin --- VASN 0.390 + 4.91E-03 1.17E-02 
201472_PM_at von Hippel-Lindau binding protein 1 4771 VBP1 0.367 + 1.60E-03 3.06E-03 
204619_PM_s_at versican 5440 VCAN 0.847 + 1.75E-02 4.91E-03 
200931_PM_s_at vinculin 824 VCL 0.574 + 7.45E-03 9.90E-03 
1556228_PM_a_at 
valosin containing protein (p97)/p47 complex interacting 
protein 1 
4659 VCPIP1 0.337 + 8.17E-03 2.84E-02 
210512_PM_s_at vascular endothelial growth factor A 729967 VEGFA 0.497 + 2.39E-02 1.89E-02 
202172_PM_at vascular endothelial zinc finger 1 2335 VEZF1 0.429 + 4.04E-02 2.43E-02 
223090_PM_x_at vezatin, adherens junctions transmembrane protein 64318 VEZT 0.585 + 2.49E-02 4.00E-02 
223675_PM_s_at vezatin, adherens junctions transmembrane protein 81563 VEZT 0.670 + 3.09E-02 3.95E-02 
224881_PM_at vitamin K epoxide reductase complex, subunit 1-like 1 84186 VKORC1L1 0.457 + 6.04E-03 8.92E-03 
225556_PM_at VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) 205327 VMA21 0.505 + 7.83E-03 2.03E-02 
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208091_PM_s_at vesicular, overexpressed in cancer, prosurvival protein 1 23062 VOPP1 0.384 + 2.73E-03 3.95E-03 
235023_PM_at Vacuolar protein sorting 13 homolog C (S. cerevisiae) 8073 VPS13C 0.471 + 1.76E-04 6.15E-03 
201807_PM_at vacuolar protein sorting 26 homolog A (S. pombe) 23043 VPS26A 0.354 + 3.96E-02 2.50E-02 
222478_PM_at vacuolar protein sorting 36 homolog (S. cerevisiae) 23034 VPS36 0.581 + 2.23E-02 2.97E-02 
209268_PM_at vacuolar protein sorting 45 homolog (S. cerevisiae) 8675 VPS45 0.429 + 5.64E-03 6.67E-03 
218171_PM_at vacuolar protein sorting 4 homolog B (S. cerevisiae) 260425 VPS4B 0.407 + 3.42E-02 1.42E-02 
218423_PM_x_at vacuolar protein sorting 54 homolog (S. cerevisiae) 79796 VPS54 0.756 + 9.97E-03 5.34E-03 
233656_PM_s_at vacuolar protein sorting 54 homolog (S. cerevisiae) --- VPS54 0.750 + 2.44E-02 1.46E-02 
209553_PM_at vacuolar protein sorting 8 homolog (S. cerevisiae) 112398 VPS8 0.277 + 4.85E-02 2.56E-02 
203856_PM_at vaccinia related kinase 1 9295 VRK1 0.330 + 1.25E-02 1.77E-02 
1566701_PM_at vaccinia related kinase 3 10651 VRK3 0.288 + 1.33E-02 2.58E-02 
204787_PM_at V-set and immunoglobulin domain containing 4 8803 VSIG4 0.366 + 1.71E-04 1.36E-03 
223022_PM_s_at Vps20-associated 1 homolog (S. cerevisiae) 80145 VTA1 0.407 + 1.79E-02 4.00E-02 
224437_PM_s_at Vps20-associated 1 homolog (S. cerevisiae) 283991 VTA1 0.266 + 2.46E-02 9.86E-03 
225926_PM_at 
vesicle transport through interaction with t-SNAREs homolog 
1B (yeast) 
--- VTI1B 0.448 + 1.11E-02 1.20E-02 
238864_PM_at von Willebrand factor A domain containing 3A --- VWA3A 0.318 + 7.12E-03 2.12E-02 
218766_PM_s_at tryptophanyl tRNA synthetase 2, mitochondrial 131566 WARS2 0.393 + 4.16E-03 1.51E-02 
205400_PM_at Wiskott-Aldrich syndrome (eczema-thrombocytopenia) 5393 WAS 0.311 + 3.56E-02 3.57E-02 
204042_PM_at WAS protein family, member 3 6432 WASF3 0.433 + 1.01E-02 8.23E-03 
217975_PM_at WW domain binding protein 5 348235 WBP5 0.581 + 4.13E-03 1.20E-02 
212606_PM_at WD repeat and FYVE domain containing 3 51626 WDFY3 0.429 + 4.93E-02 3.29E-02 
220917_PM_s_at WD repeat domain 19 9849 WDR19 0.456 + 8.25E-03 2.53E-02 
227541_PM_at WD repeat domain 20 55160 WDR20 0.674 + 1.44E-02 3.19E-02 
222763_PM_s_at WD repeat domain 33 2210 WDR33 0.542 + 7.70E-03 1.58E-02 
226889_PM_at WD repeat domain 35 8724 WDR35 0.764 + 1.30E-02 5.86E-03 
218055_PM_s_at WD repeat domain 41 81846 WDR41 0.454 + 6.65E-03 1.09E-02 
203855_PM_at WD repeat domain 47 7332 WDR47 0.538 + 8.77E-03 2.31E-03 
56919_PM_at WD repeat domain 48 --- WDR48 0.315 + 2.96E-02 3.98E-02 
225898_PM_at WD repeat domain 54 441461 WDR54 0.283 + 5.49E-03 3.00E-04 
235850_PM_at WD repeat domain 5B 55754 WDR5B 1.031 + 6.14E-03 1.56E-02 
217734_PM_s_at WD repeat domain 6 90843 WDR6 0.348 + 3.95E-02 4.06E-02 
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232075_PM_at WD repeat domain 61 7007 WDR61 0.380 + 3.51E-02 1.45E-02 
215218_PM_s_at WD repeat domain 62 54839 WDR62 0.306 + 5.42E-03 9.76E-03 
224721_PM_at WD repeat domain 75 90313 WDR75 0.463 + 1.98E-03 3.13E-03 
222777_PM_s_at Wolf-Hirschhorn syndrome candidate 1 2901 WHSC1 0.303 + 6.43E-03 6.90E-03 
229103_PM_at wingless-type MMTV integration site family, member 3 254225 WNT3 0.334 + 2.14E-02 4.00E-02 
213425_PM_at wingless-type MMTV integration site family, member 5A 659 WNT5A 0.462 + 5.53E-03 5.48E-03 
230643_PM_at wingless-type MMTV integration site family, member 9A 51046 WNT9A 0.680 + 5.49E-04 7.24E-04 
213155_PM_at WSC domain containing 1 23177 WSCD1 0.378 + 3.62E-02 2.73E-02 
229630_PM_s_at Wilms tumor 1 associated protein 400236 WTAP 0.420 + 1.81E-02 2.65E-02 
219520_PM_s_at WWC family member 3 1389 WWC3 0.470 + 1.31E-02 1.09E-02 
204022_PM_at WW domain containing E3 ubiquitin protein ligase 2 5701 WWP2 0.533 + 3.92E-02 1.32E-02 
214567_PM_s_at chemokine (C motif) ligand 1 /// chemokine (C motif) ligand 2 54927 XCL1 /// XCL2 0.422 + 6.23E-03 1.34E-02 
214218_PM_s_at X (inactive)-specific transcript (non-protein coding) 10038 XIST 0.377 + 4.15E-03 5.86E-03 
221728_PM_x_at X (inactive)-specific transcript (non-protein coding) 23705 XIST 0.471 + 9.16E-03 9.13E-03 
206698_PM_at X-linked Kx blood group (McLeod syndrome) 8500 XK 0.870 + 1.74E-02 3.74E-02 
228820_PM_at X-prolyl aminopeptidase (aminopeptidase P) 3, putative 768211 XPNPEP3 0.869 + 7.75E-03 2.10E-02 
208775_PM_at exportin 1 (CRM1 homolog, yeast) 56654 XPO1 0.435 + 3.45E-02 3.64E-02 
222649_PM_at exportin 4 126208 XPO4 0.353 + 2.48E-02 2.93E-02 
226615_PM_at xenotropic and polytropic retrovirus receptor 373 XPR1 0.590 + 2.14E-03 1.15E-02 
205071_PM_x_at 
X-ray repair complementing defective repair in Chinese 
hamster cells 4 
1613 XRCC4 0.480 + 2.39E-02 3.67E-02 
227678_PM_at XRCC6 binding protein 1 51026 XRCC6BP1 1.103 + 1.55E-03 1.25E-03 
225814_PM_at 5’-3’ exoribonuclease 1 --- XRN1 0.997 + 1.84E-02 3.08E-02 
224894_PM_at Yes-associated protein 1, 65kDa 148867 YAP1 0.891 + 6.82E-03 6.83E-03 
224895_PM_at Yes-associated protein 1, 65kDa 201161 YAP1 0.338 + 1.48E-02 1.29E-02 
202932_PM_at v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 55591 YES1 0.843 + 4.50E-03 1.12E-02 
202933_PM_s_at v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 114971 YES1 0.729 + 6.82E-03 2.65E-03 
224934_PM_at Yip1 domain family, member 5 54799 YIPF5 0.691 + 9.33E-03 1.01E-02 
224949_PM_at Yip1 domain family, member 5 80155 YIPF5 0.285 + 1.89E-02 1.74E-02 
212343_PM_at Yip1 domain family, member 6 9474 YIPF6 0.529 + 2.23E-02 2.09E-02 
227309_PM_at YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) 6615 YOD1 0.718 + 1.99E-03 4.22E-03 
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1556420_PM_s_at yippee-like 2 (Drosophila) 7163 YPEL2 0.664 + 2.45E-02 2.64E-02 
217783_PM_s_at yippee-like 5 (Drosophila) 150465 YPEL5 0.516 + 9.83E-03 7.36E-03 
221741_PM_s_at YTH domain family, member 1 2824 YTHDF1 0.450 + 4.72E-02 3.62E-02 
221749_PM_at YTH domain family, member 3 11196 YTHDF3 0.492 + 8.13E-03 1.93E-03 
224711_PM_at YY1 transcription factor 57630 YY1 0.354 + 4.06E-02 4.99E-02 
200047_PM_s_at YY1 transcription factor 9677 YY1 0.373 + 4.92E-02 3.38E-02 
225665_PM_at sterile alpha motif and leucine zipper containing kinase AZK 4534 ZAK 1.120 + 5.93E-03 2.18E-03 
218263_PM_s_at zinc finger, BED-type containing 5 440193 ZBED5 0.712 + 1.51E-02 1.21E-02 
236105_PM_at zinc finger and BTB domain containing 10 139231 ZBTB10 0.367 + 6.25E-03 1.68E-02 
228562_PM_at zinc finger and BTB domain containing 10 4082 ZBTB10 0.738 + 3.17E-02 7.06E-03 
204847_PM_at zinc finger and BTB domain containing 11 8898 ZBTB11 0.649 + 1.84E-02 8.45E-04 
1553858_PM_at zinc finger and BTB domain containing 3 8675 ZBTB3 0.559 + 2.65E-02 2.08E-02 
226255_PM_at zinc finger and BTB domain containing 33 1374 ZBTB33 0.643 + 6.62E-03 1.78E-02 
227111_PM_at zinc finger and BTB domain containing 34 22986 ZBTB34 0.685 + 9.54E-03 2.60E-03 
225512_PM_at zinc finger and BTB domain containing 38 23426 ZBTB38 0.480 + 2.63E-02 1.38E-02 
225629_PM_s_at zinc finger and BTB domain containing 4 79933 ZBTB4 0.463 + 1.61E-02 8.86E-03 
227991_PM_x_at zinc finger and BTB domain containing 43 54928 ZBTB43 0.398 + 4.28E-02 4.86E-02 
227329_PM_at zinc finger and BTB domain containing 46 55604 ZBTB46 0.454 + 2.00E-03 1.13E-03 
229234_PM_at zinc finger CCCH-type containing 12B 197131 ZC3H12B 0.763 + 1.44E-02 3.92E-02 
213063_PM_at zinc finger CCCH-type containing 14 5079 ZC3H14 0.298 + 1.64E-02 3.45E-02 
201595_PM_s_at zinc finger CCCH-type containing 15 10152 ZC3H15 0.347 + 6.41E-03 7.26E-04 
213390_PM_at zinc finger CCCH-type containing 4 5805 ZC3H4 0.365 + 1.89E-02 1.72E-02 
241372_PM_at zinc finger CCCH-type containing 6 --- ZC3H6 0.478 + 2.79E-02 2.71E-02 
221193_PM_s_at zinc finger, CCHC domain containing 10 6664 ZCCHC10 0.523 + 1.38E-02 2.20E-02 
223107_PM_s_at zinc finger, CCHC domain containing 17 63897 ZCCHC17 0.381 + 2.05E-02 1.32E-02 
219062_PM_s_at zinc finger, CCHC domain containing 2 25831 ZCCHC2 0.661 + 3.26E-02 2.22E-02 
236155_PM_at Zinc finger, CCHC domain containing 6 205 ZCCHC6 0.361 + 3.38E-02 2.69E-02 
226496_PM_at zinc finger, CCHC domain containing 7 51014 ZCCHC7 0.431 + 8.07E-03 1.41E-02 
218478_PM_s_at zinc finger, CCHC domain containing 8 169792 ZCCHC8 0.326 + 1.64E-02 3.14E-02 
225538_PM_at zinc finger, CCHC domain containing 9 821 ZCCHC9 0.433 + 2.54E-02 4.13E-02 
228749_PM_at zinc finger, DBF-type containing 2 115416 ZDBF2 0.524 + 3.03E-02 2.92E-02 
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222731_PM_at zinc finger, DHHC-type containing 2 440434 ZDHHC2 0.292 + 2.16E-02 3.92E-03 
229240_PM_at Zinc finger, DHHC-type containing 21 85403 ZDHHC21 0.498 + 4.34E-03 5.08E-03 
212764_PM_at zinc finger E-box binding homeobox 1 10959 ZEB1 0.620 + 4.31E-03 1.22E-02 
203603_PM_s_at zinc finger E-box binding homeobox 2 149986 ZEB2 0.808 + 1.45E-02 3.26E-03 
221613_PM_s_at zinc finger, AN1-type domain 6 6425 ZFAND6 0.397 + 3.28E-03 1.65E-02 
213065_PM_at zinc finger, C3H1-type containing 2977 ZFC3H1 0.561 + 3.39E-02 1.99E-02 
211962_PM_s_at zinc finger protein 36, C3H type-like 1 2739 ZFP36L1 0.440 + 1.67E-02 2.68E-02 
207068_PM_at zinc finger protein 37 homolog (mouse) 11054 ZFP37 0.382 + 3.91E-02 9.99E-03 
227796_PM_at zinc finger protein 62 homolog (mouse) 84278 ZFP62 0.994 + 1.57E-02 1.60E-02 
226124_PM_at zinc finger protein 90 homolog (mouse) 9813 ZFP90 0.410 + 9.32E-03 7.57E-03 
224636_PM_at zinc finger protein 91 homolog (mouse) 84320 ZFP91 0.379 + 1.05E-02 1.00E-02 
237463_PM_at Zinc finger protein, multitype 1 --- ZFPM1 0.450 + 4.89E-03 1.16E-02 
201857_PM_at zinc finger RNA binding protein 5164 ZFR 0.302 + 3.55E-02 3.79E-02 
214678_PM_x_at zinc finger protein, X-linked 79893 ZFX 0.378 + 1.81E-02 3.05E-02 
223387_PM_at zinc finger, FYVE domain containing 1 25926 ZFYVE1 0.446 + 4.31E-02 4.83E-02 
226581_PM_at zinc finger, FYVE domain containing 20 2002 ZFYVE20 0.529 + 8.81E-03 1.03E-02 
231765_PM_at zinc finger, FYVE domain containing 20 374986 ZFYVE20 0.275 + 3.92E-02 3.57E-02 
224445_PM_s_at zinc finger, FYVE domain containing 21 57561 ZFYVE21 0.529 + 2.88E-03 3.47E-03 
213073_PM_at zinc finger, FYVE domain containing 26 1466 ZFYVE26 0.335 + 7.14E-03 1.90E-02 
223642_PM_at Zic family member 2 (odd-paired homolog, Drosophila) 29101 ZIC2 0.816 + 8.54E-03 9.26E-03 
226344_PM_at zinc finger, matrin type 1 79868 ZMAT1 0.904 + 1.10E-02 8.95E-03 
212124_PM_at zinc finger, MIZ-type containing 1 7322 ZMIZ1 0.577 + 1.83E-02 2.29E-02 
202778_PM_s_at zinc finger, MYM-type 2 84146 ZMYM2 0.482 + 3.61E-02 1.65E-02 
202051_PM_s_at zinc finger, MYM-type 4 116986 ZMYM4 0.557 + 2.75E-02 3.03E-02 
213698_PM_at zinc finger, MYM-type 6 7030 ZMYM6 0.989 + 3.18E-03 1.47E-02 
227595_PM_at zinc finger, MYM-type 6 7702 ZMYM6 1.085 + 1.28E-02 2.66E-02 
226015_PM_at zinc finger protein 12 10097 ZNF12 0.306 + 4.98E-02 3.45E-02 
225916_PM_at zinc finger protein 131 9223 ZNF131 0.511 + 3.04E-02 2.36E-02 
206182_PM_at zinc finger protein 134 9360 ZNF134 0.490 + 2.01E-02 4.59E-02 
221873_PM_at zinc finger protein 143 9318 ZNF143 0.736 + 3.22E-02 1.26E-02 
230821_PM_at zinc finger protein 148 3736 ZNF148 1.059 + 2.28E-03 7.65E-04 
238711_PM_s_at zinc finger protein 148 63929 ZNF148 0.433 + 7.84E-03 6.62E-03 
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239024_PM_at zinc finger protein 148 --- ZNF148 0.484 + 2.54E-02 1.91E-02 
219548_PM_at zinc finger protein 16 9202 ZNF16 0.443 + 2.96E-02 2.57E-02 
207417_PM_s_at zinc finger protein 177 22826 ZNF177 0.611 + 2.26E-02 4.98E-02 
235810_PM_at zinc finger protein 182 6154 ZNF182 0.368 + 3.51E-02 1.94E-02 
205437_PM_at zinc finger protein 211 5324 ZNF211 0.702 + 1.06E-02 2.28E-02 
203985_PM_at zinc finger protein 212 1964 /// 280661 ZNF212 0.360 + 1.03E-03 4.67E-03 
203739_PM_at zinc finger protein 217 23077 ZNF217 0.385 + 1.26E-02 4.12E-02 
218005_PM_at zinc finger protein 22 (KOX 15) 54464 ZNF22 0.395 + 1.03E-02 1.42E-02 
206261_PM_at zinc finger protein 239 23558 ZNF239 0.278 + 1.26E-02 2.62E-02 
213269_PM_at zinc finger protein 248 25847 ZNF248 0.484 + 2.75E-03 3.70E-03 
228920_PM_at zinc finger protein 260 345778 ZNF260 0.459 + 4.10E-03 2.75E-02 
203707_PM_at zinc finger protein 263 23196 ZNF263 0.469 + 9.11E-03 2.44E-02 
221213_PM_s_at zinc finger protein 280D 9815 ZNF280D 0.805 + 1.13E-02 8.48E-03 
228785_PM_at Zinc finger protein 281 90459 ZNF281 0.650 + 1.56E-02 2.28E-03 
225539_PM_at zinc finger protein 295 85015 ZNF295 0.700 + 3.37E-02 4.55E-02 
207753_PM_at zinc finger protein 304 115201 ZNF304 0.426 + 2.26E-02 4.64E-02 
236551_PM_at zinc finger protein 311 --- ZNF311 0.730 + 9.29E-03 1.65E-02 
203521_PM_s_at zinc finger protein 318 116985 ZNF318 0.454 + 2.07E-02 1.82E-02 
227980_PM_at zinc finger protein 322A 285855 ZNF322A 0.735 + 9.55E-03 1.65E-03 
227680_PM_at zinc finger protein 326 79718 ZNF326 0.371 + 3.43E-03 1.86E-03 
229019_PM_at zinc finger protein 385B 55102 ZNF385B 0.543 + 3.94E-02 4.59E-02 
227768_PM_at zinc finger protein 407 79930 ZNF407 0.377 + 2.33E-03 1.95E-02 
209944_PM_at zinc finger protein 410 4090 ZNF410 0.731 + 8.82E-03 6.05E-04 
202010_PM_s_at zinc finger protein 410 6651 ZNF410 0.371 + 1.56E-02 2.27E-02 
218707_PM_at zinc finger protein 444 133690 ZNF444 0.412 + 1.80E-02 4.86E-02 
228968_PM_at zinc finger protein 449 57187 ZNF449 0.560 + 3.53E-02 4.60E-02 
222028_PM_at zinc finger protein 45 1399 ZNF45 0.387 + 3.16E-02 2.92E-02 
212557_PM_at zinc finger protein 451 8836 ZNF451 0.308 + 9.66E-03 3.21E-02 
228138_PM_at zinc finger protein 498 --- ZNF498 0.265 + 6.47E-03 4.02E-04 
226327_PM_at zinc finger protein 507 3730 ZNF507 0.502 + 3.04E-03 5.61E-03 
204291_PM_at zinc finger protein 518A 2631 ZNF518A 0.648 + 3.79E-02 3.56E-02 
226909_PM_at zinc finger protein 518B 6039 ZNF518B 0.605 + 8.48E-04 1.03E-03 
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226676_PM_at zinc finger protein 521 58517 ZNF521 1.020 + 4.04E-03 7.28E-03 
226677_PM_at zinc finger protein 521 5411 ZNF521 0.804 + 1.33E-02 3.75E-02 
231940_PM_at zinc finger protein 529 8034 ZNF529 0.407 + 3.94E-03 1.66E-02 
238316_PM_at zinc finger protein 567 --- ZNF567 0.486 + 1.78E-02 4.27E-02 
1568900_PM_a_at zinc finger protein 568 51704 ZNF568 0.562 + 3.37E-03 2.57E-03 
206648_PM_at zinc finger protein 571 25956 ZNF571 0.361 + 5.68E-03 7.98E-03 
218762_PM_at zinc finger protein 574 112817 ZNF574 0.628 + 7.21E-03 7.91E-03 
227674_PM_at zinc finger protein 585A 64121 ZNF585A 0.424 + 5.76E-03 8.10E-04 
227507_PM_at zinc finger protein 592 50943 ZNF592 0.691 + 4.59E-02 3.51E-02 
219635_PM_at zinc finger protein 606 10444 ZNF606 0.456 + 8.11E-03 3.77E-02 
227045_PM_at zinc finger protein 614 9107 ZNF614 0.455 + 4.15E-02 3.68E-02 
225152_PM_at zinc finger protein 622 253260 ZNF622 0.585 + 1.48E-03 4.39E-03 
206188_PM_at zinc finger protein 623 10938 ZNF623 0.322 + 4.22E-03 9.10E-03 
224492_PM_s_at zinc finger protein 627 56261 ZNF627 0.505 + 1.56E-03 5.48E-03 
213775_PM_x_at zinc finger protein 638 6934 ZNF638 0.458 + 2.75E-02 3.33E-03 
211257_PM_x_at zinc finger protein 638 4287 ZNF638 0.378 + 4.32E-02 4.21E-02 
222580_PM_at zinc finger protein 644 23074 ZNF644 0.806 + 2.13E-02 8.13E-03 
225266_PM_at zinc finger protein 652 282679 ZNF652 0.534 + 7.65E-03 3.56E-03 
228538_PM_at zinc finger protein 662 23095 ZNF662 0.314 + 4.98E-02 2.52E-02 
236635_PM_at zinc finger protein 667 --- ZNF667 0.723 + 2.02E-02 1.80E-02 
242923_PM_at zinc finger protein 678 --- ZNF678 0.290 + 3.17E-02 2.11E-02 
242915_PM_at zinc finger protein 682 --- ZNF682 1.329 + 3.72E-04 2.00E-03 
227080_PM_at zinc finger protein 697 --- ZNF697 0.613 + 1.58E-03 1.13E-03 
227132_PM_at zinc finger protein 706 7091 ZNF706 0.351 + 1.70E-02 5.39E-03 
1553247_PM_a_at zinc finger protein 709 9181 ZNF709 0.682 + 3.03E-03 7.82E-03 
228988_PM_at zinc finger protein 711 51762 ZNF711 0.719 + 1.32E-02 9.45E-03 
213659_PM_at zinc finger protein 75D 23065 ZNF75D 0.453 + 1.50E-02 3.56E-02 
229000_PM_at zinc finger protein 77 25925 ZNF77 0.369 + 5.02E-03 2.02E-02 
221968_PM_s_at Zinc finger protein 771 7155 ZNF771 0.277 + 2.84E-02 4.65E-02 
213402_PM_at zinc finger protein 787 26052 ZNF787 0.279 + 7.71E-03 4.40E-03 
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235398_PM_at zinc finger protein 805 4926 ZNF805 0.622 + 2.34E-02 3.09E-02 
242564_PM_at Zinc finger protein 814 79670 ZNF814 0.792 + 2.63E-02 4.30E-02 
243618_PM_s_at Zinc finger protein 827 --- ZNF827 0.819 + 1.98E-03 2.80E-03 
243617_PM_at Zinc finger protein 827 4842 ZNF827 0.859 + 2.64E-03 7.90E-04 
228046_PM_at Zinc finger protein 827 2309 ZNF827 0.730 + 1.58E-02 1.99E-02 
228630_PM_at zinc finger protein 84 2140 ZNF84 0.454 + 1.43E-02 1.34E-02 
218932_PM_at zinc finger, HIT type 6 64748 ZNHIT6 0.383 + 2.83E-03 1.80E-02 
223716_PM_s_at zinc finger, RAN-binding domain containing 2 51649 ZRANB2 0.430 + 1.55E-02 4.68E-03 
213876_PM_x_at 
zinc finger (CCCH type), RNA-binding motif and 
serine/arginine rich 2 
123803 ZRSR2 0.473 + 2.46E-03 8.27E-03 
219676_PM_at zinc finger and SCAN domain containing 16 10664 ZSCAN16 0.321 + 3.79E-03 1.20E-02 
229119_PM_s_at zinc finger, SWIM-type containing 7 221830 ZSWIM7 0.588 + 1.83E-02 3.99E-02 
228330_PM_at zinc finger with UFM1-specific peptidase domain 29904 ZUFSP 0.378 + 6.90E-03 2.54E-02 
228005_PM_at zinc finger, X-linked, duplicated B --- ZXDB 0.476 + 2.34E-02 3.67E-02 






Supplementary Table 10. Transcripts correlated (r>0.60 and r <-0.60) with mean total activity in the caudate nucleus. Transcripts are identified by their 
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mean total activity in both caudate replicates (R1c and R2c).  Positive correlations are indicated in red text and negative correlation is denoted by blue. 
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215063_PM_x_at leucine rich repeat containing 40 LRRC40 55631 -0.943 -0.799 
218742_PM_at nuclear prelamin A recognition factor-like NARFL 64428 -0.942 -0.688 
234913_PM_at 
testis-specific transcript, Y-linked 4 (non-protein 
coding) /// testis-specific transcript, Y-linked 4B (non-







201384_PM_s_at neighbor of BRCA1 gene 1 NBR1 4077 -0.875 -0.937 
232547_PM_at SRC kinase signaling inhibitor 1 SRCIN1 80725 -0.865 -0.792 
232566_PM_at nucleolar protein family 6 (RNA-associated) NOL6 65083 -0.811 -0.662 
243724_PM_at --- --- --- -0.805 -0.898 
243719_PM_at 







215645_PM_at folliculin FLCN 201163 -0.791 -0.661 
221404_PM_at interleukin 1 family, member 6 (epsilon) IL1F6 27179 -0.768 -0.857 
224532_PM_at ubiquitin specific peptidase 26 USP26 83844 -0.756 -0.684 
224211_PM_at forkhead box P3 FOXP3 50943 -0.743 -0.766 
227811_PM_at FYVE, RhoGEF and PH domain containing 3 FGD3 89846 -0.742 -0.774 
213905_PM_x_at biglycan BGN 633 -0.730 -0.666 
221849_PM_s_at DDB1 and CUL4 associated factor 15 DCAF15 90379 -0.726 -0.699 
236222_PM_at chromosome 3 open reading frame 15 C3orf15 89876 -0.708 -0.788 
214715_PM_x_at zinc finger protein 160 ZNF160 90338 -0.707 -0.644 
 378 
1560754_PM_at 
CKLF-like MARVEL transmembrane domain containing 
7 
CMTM7 112616 -0.699 -0.830 
224388_PM_s_at collagen, type XXV, alpha 1 COL25A1 84570 -0.698 -0.793 
214778_PM_at multiple EGF-like-domains 8 MEGF8 1954 -0.680 -0.731 
242824_PM_at --- --- --- -0.677 -0.622 
203904_PM_x_at CD82 molecule CD82 3732 -0.677 -0.724 
1556292_PM_s_at POM121 membrane glycoprotein-like 12 (rat) POM121L12 285877 -0.675 -0.776 
241020_PM_at --- --- --- -0.675 -0.623 
241924_PM_at --- --- --- -0.675 -0.774 
243971_PM_x_at hypothetical LOC731789 LOC731789 731789 -0.670 -0.776 
204189_PM_at retinoic acid receptor, gamma RARG 5916 -0.668 -0.668 
221283_PM_at runt-related transcription factor 2 RUNX2 860 -0.665 -0.811 
1557008_PM_at hypothetical protein LOC340107 LOC340107 340107 -0.664 -0.656 
1555135_PM_at --- --- --- -0.662 -0.817 
229471_PM_s_at --- --- --- -0.658 -0.712 
219144_PM_at dual specificity phosphatase 26 (putative) DUSP26 78986 -0.653 -0.761 
209245_PM_s_at kinesin family member 1C KIF1C 10749 -0.652 -0.608 
216216_PM_at slit homolog 3 (Drosophila) SLIT3 6586 -0.648 -0.814 
210413_PM_x_at 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 4 
SERPINB4 6318 -0.644 -0.674 
1553560_PM_at vomeronasal 1 receptor 4 VN1R4 317703 -0.640 -0.816 
222319_PM_at --- --- --- -0.639 -0.642 
1553328_PM_a_at 
solute carrier family 18 (vesicular monoamine), 
member 2 
SLC18A2 6571 -0.631 -0.764 
239495_PM_at --- --- --- -0.627 -0.657 
230641_PM_at --- --- --- -0.621 -0.821 
244830_PM_at Ras interacting protein 1 RASIP1 54922 -0.620 -0.657 
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1559911_PM_at --- --- --- -0.616 -0.735 
205425_PM_at huntingtin interacting protein 1 HIP1 3092 -0.614 -0.771 
1559166_PM_at --- --- --- -0.613 -0.720 
1557347_PM_at microcephalin 1 MCPH1 79648 0.615 0.768 
236728_PM_at leucyl/cystinyl aminopeptidase LNPEP 4012 0.616 0.624 
236143_PM_at --- --- --- 0.618 0.645 
1565900_PM_at Methyltransferase 5 domain containing 1 METT5D1 196074 0.621 0.600 
224941_PM_at pregnancy-associated plasma protein A, pappalysin 1 PAPPA 5069 0.625 0.646 
203461_PM_at chromodomain helicase DNA binding protein 2 CHD2 1106 0.648 0.827 
229101_PM_at interleukin 17 receptor A IL17RA 23765 0.650 0.860 
235890_PM_at 379eparin379ing (beta)-like 1 X-linked receptor 1 TBL1XR1 79718 0.660 0.872 
216447_PM_at --- --- --- 0.661 0.698 
208092_PM_s_at family with sequence similarity 49, member A FAM49A 81553 0.676 0.761 
228393_PM_s_at zinc finger protein 302 ZNF302 55900 0.676 0.878 
224296_PM_x_at --- --- --- 0.677 0.661 
244142_PM_at dystrobrevin, alpha DTNA 1837 0.678 0.660 
236542_PM_at --- --- --- 0.698 0.704 
232462_PM_s_at non-protein coding RNA 181 NCRNA00181 503538 0.708 0.610 
233358_PM_at --- --- --- 0.710 0.605 
228685_PM_at interleukin 17 receptor A IL17RA 23765 0.732 0.777 
215894_PM_at prostaglandin D2 receptor (DP) PTGDR 5729 0.744 0.646 
236524_PM_at --- --- --- 0.751 0.746 
243368_PM_at --- --- --- 0.765 0.698 
216209_PM_at 
hypothetical gene supported by AK057632; AL137270; 
BC057846 
LOC400084 400084 0.778 0.644 
237392_PM_at hypothetical protein LOC283480 LOC283480 283480 0.782 0.691 
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202965_PM_s_at calpain 6 CAPN6 827 0.790 0.713 
1558885_PM_at --- --- --- 0.791 0.744 
241490_PM_s_at piggyBac transposable element derived 2 PGBD2 267002 0.792 0.796 
205205_PM_at v-rel reticuloendotheliosis viral oncogene homolog B RELB 5971 0.797 0.788 
230064_PM_at --- --- --- 0.802 0.908 
1556162_PM_at immunoglobulin superfamily, member 3 IGSF3 3321 0.811 0.702 
215053_PM_at Snf2-related CREBBP activator protein SRCAP 10847 0.816 0.905 
214744_PM_s_at ribosomal protein L23 RPL23 9349 0.825 0.716 
216755_PM_at oxysterol binding protein-like 10 OSBPL10 114884 0.827 0.777 
233142_PM_at --- --- --- 0.833 0.721 
237745_PM_at hypothetical LOC641467 LOC641467 641467 0.845 0.661 
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neural precursor cell expressed, developmentally down-
regulated 9 
NEDD9 4739 -0.964 -0.768 
230865_PM_at Lix1 homolog (chicken) LIX1 167410 -0.951 -0.826 
222458_PM_s_at akirin 1 AKIRIN1 79647 -0.945 -0.674 
239186_PM_at hypothetical protein MGC39372 MGC39372 221756 -0.945 -0.794 
233557_PM_s_at MON1 homolog B (yeast) MON1B 22879 -0.933 -0.614 
244072_PM_at --- --- --- -0.913 -0.701 
233848_PM_x_at zinc finger protein 221 ZNF221 7638 -0.903 -0.607 
225327_PM_at KIAA1370 KIAA1370 56204 -0.885 -0.837 
210131_PM_x_at 
succinate dehydrogenase complex, subunit C, integral 
membrane protein, 15kDa 
SDHC 6391 -0.876 -0.733 
1556619_PM_at shisa homolog 9 (Xenopus laevis) SHISA9 729993 -0.869 -0.665 
1555198_PM_x_at chromosome 21 open reading frame 58 C21orf58 54058 -0.864 -0.657 
211385_PM_x_at 
sulfotransferase family, cytosolic, 1A, phenol-preferring, 
member 2 
SULT1A2 6799 -0.855 -0.880 
221569_PM_at Abelson helper integration site 1 AHI1 54806 -0.849 -0.797 
230294_PM_at --- --- --- -0.847 -0.922 
205546_PM_s_at tyrosine kinase 2 TYK2 7297 -0.830 -0.637 
244703_PM_x_at importin 9 IPO9 55705 -0.826 -0.757 
207906_PM_at interleukin 3 (colony-stimulating factor, multiple) IL3 3562 -0.825 -0.614 
229966_PM_at Ewing sarcoma breakpoint region 1 EWSR1 2130 -0.819 -0.946 
1552585_PM_s_at general transcription factor IIA, 1-like GTF2A1L 11036 -0.803 -0.680 
226870_PM_at catechol-O-methyltransferase domain containing 1 COMTD1 118881 -0.803 -0.645 
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242088_PM_at kelch-like 24 (Drosophila) KLHL24 54800 -0.798 -0.834 
1568686_PM_at ATPase, class I, type 8B, member 5, pseudogene ATP8B5P 158381 -0.796 -0.738 
233376_PM_at --- --- --- -0.794 -0.657 
216985_PM_s_at syntaxin 3 STX3 6809 -0.792 -0.779 
237715_PM_at AT-hook transcription factor AKNA 80709 -0.789 -0.774 
221251_PM_x_at INO80 complex subunit B INO80B 83444 -0.782 -0.836 
209295_PM_at tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 8795 -0.777 -0.627 
205308_PM_at family with sequence similarity 164, member A FAM164A 51101 -0.775 -0.606 
238340_PM_at DDB1 and CUL4 associated factor 8 DCAF8 50717 -0.774 -0.713 
216488_PM_s_at ATPase, class VI, type 11A ATP11A 23250 -0.773 -0.726 
219470_PM_x_at cyclin J CCNJ 54619 -0.771 -0.634 
224519_PM_at similar to hCG1993567 LOC100132167 100132167 -0.770 -0.873 
52005_PM_at widely interspaced zinc finger motifs WIZ 58525 -0.761 -0.666 
212619_PM_at transmembrane protein 194A TMEM194A 23306 -0.761 -0.711 
1561204_PM_at --- --- --- -0.752 -0.623 
1556395_PM_at --- --- --- -0.747 -0.743 
203715_PM_at tubulin folding cofactor E TBCE 6905 -0.747 -0.650 
1557944_PM_s_at catenin (cadherin-associated protein), delta 1 CTNND1 1500 -0.742 -0.684 
231230_PM_at potassium channel, subfamily K, member 10 KCNK10 54207 -0.740 -0.680 
218886_PM_at PAK1 interacting protein 1 PAK1IP1 55003 -0.740 -0.633 
235622_PM_at --- --- --- -0.736 -0.712 
237981_PM_at cardiomyopathy associated 5 CMYA5 202333 -0.734 -0.607 
215025_PM_at neurotrophic tyrosine kinase, receptor, type 3 NTRK3 4916 -0.731 -0.644 
214765_PM_s_at N-acylethanolamine acid amidase NAAA 27163 -0.719 -0.843 
226243_PM_at chromosome 2 open reading frame 79 C2orf79 391356 -0.716 -0.669 
235641_PM_at Tribbles homolog 1 (Drosophila) TRIB1 10221 -0.714 -0.669 
226403_PM_at transmembrane channel-like 4 TMC4 147798 -0.709 -0.715 
207546_PM_at ATPase, H+/K+ exchanging, beta polypeptide ATP4B 496 -0.707 -0.761 
231274_PM_s_at --- --- --- -0.701 -0.803 
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243686_PM_at --- --- --- -0.695 -0.864 
1562866_PM_at --- --- --- -0.691 -0.839 
225695_PM_at chromosome 2 open reading frame 18 C2orf18 54978 -0.686 -0.743 
203056_PM_s_at PR domain containing 2, with ZNF domain PRDM2 7799 -0.680 -0.650 
202736_PM_s_at 
LSM4 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
LSM4 25804 -0.679 -0.804 
218159_PM_at DDRGK domain containing 1 DDRGK1 65992 -0.679 -0.731 
225009_PM_at CKLF-like MARVEL transmembrane domain containing 4 CMTM4 146223 -0.671 -0.696 
240024_PM_at SEC14-like 2 (S. cerevisiae) SEC14L2 23541 -0.671 -0.923 
224868_PM_at zinc finger, DHHC-type containing 5 ZDHHC5 25921 -0.666 -0.613 
205424_PM_at TBK1 binding protein 1 TBKBP1 9755 -0.665 -0.889 
217438_PM_at --- --- --- -0.664 -0.625 
214336_PM_s_at coatomer protein complex, subunit alpha COPA 1314 -0.662 -0.665 
241481_PM_at Family with sequence similarity 81, member A FAM81A 145773 -0.661 -0.679 
204490_PM_s_at CD44 molecule (Indian blood group) CD44 960 -0.661 -0.667 
234370_PM_at V-set and immunoglobulin domain containing 1 VSIG1 340547 -0.660 -0.629 
228884_PM_at leucine rich repeat containing 27 LRRC27 80313 -0.660 -0.880 
210813_PM_s_at 
X-ray repair complementing defective repair in Chinese 
hamster cells 4 
XRCC4 7518 -0.653 -0.872 
202761_PM_s_at spectrin repeat containing, nuclear envelope 2 SYNE2 23224 -0.642 -0.762 
219369_PM_s_at OTU domain, ubiquitin aldehyde binding 2 OTUB2 78990 -0.641 -0.725 
1555495_PM_a_at 
CWC27 spliceosome-associated protein homolog (S. 
cerevisiae) 
CWC27 10283 -0.641 -0.621 
228124_PM_at abhydrolase domain containing 12 ABHD12 26090 -0.641 -0.665 
1557812_PM_a_at --- --- --- -0.641 -0.742 
214569_PM_at interferon, alpha 5 IFNA5 3442 -0.639 -0.792 
227845_PM_s_at Src homology 2 domain containing transforming protein D SHD 56961 -0.639 -0.804 
238221_PM_at --- --- --- -0.639 -0.611 
215595_PM_x_at --- --- --- -0.637 -0.659 
218808_PM_at DALR anticodon binding domain containing 3 DALRD3 55152 -0.636 -0.708 
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206980_PM_s_at fms-related tyrosine kinase 3 ligand FLT3LG 2323 -0.636 -0.805 
244378_PM_at Chromosome 12 open reading frame 51 C12orf51 283450 -0.634 -0.812 
55093_PM_at chondroitin polymerizing factor 2 CHPF2 54480 -0.626 -0.689 
214911_PM_s_at bromodomain containing 2 BRD2 6046 -0.625 -0.838 
238047_PM_at Rho GTPase activating protein 36 ARHGAP36 158763 -0.625 -0.617 
211891_PM_s_at Rho guanine nucleotide exchange factor (GEF) 4 ARHGEF4 50649 -0.622 -0.617 
206845_PM_s_at ring finger protein 40 RNF40 9810 -0.618 -0.605 
214196_PM_s_at tripeptidyl peptidase I TPP1 1200 -0.617 -0.841 
231385_PM_at developmental pluripotency associated 3 DPPA3 359787 -0.617 -0.791 
228275_PM_at --- --- --- -0.617 -0.785 
244644_PM_at family with sequence similarity 9, member C FAM9C 171484 -0.614 -0.883 
204545_PM_at peroxisomal biogenesis factor 6 PEX6 5190 -0.610 -0.857 
227093_PM_at Ubiquitin specific peptidase 36 USP36 57602 -0.604 -0.612 
239409_PM_at --- --- --- -0.604 -0.620 
202990_PM_at phosphorylase, glycogen, liver PYGL 5836 -0.602 -0.782 
1555113_PM_at par-3 partitioning defective 3 homolog B (C. elegans) PARD3B 117583 0.605 0.752 
1562633_PM_at 
rhabdomyosarcoma 2 associated transcript (non-protein 
coding) 
RMST 196475 0.605 0.643 
1561137_PM_s_at glycophorin E (MNS blood group) GYPE 2996 0.607 0.760 
1557116_PM_at apolipoprotein L, 6 APOL6 80830 0.609 0.818 
228421_PM_s_at EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 2202 0.612 0.857 
216766_PM_at --- --- --- 0.615 0.845 
215580_PM_at 
minichromosome maintenance complex component 3 
associated protein 
MCM3AP 8888 0.618 0.727 
1555492_PM_a_at bestrophin 3 BEST3 144453 0.619 0.716 
230892_PM_at --- --- --- 0.623 0.684 
210807_PM_s_at 
solute carrier family 16, member 7 (monocarboxylic acid 
transporter 2) 
SLC16A7 9194 0.623 0.706 
240090_PM_at --- --- --- 0.626 0.883 
210530_PM_s_at nuclear receptor subfamily 2, group C, member 1 NR2C1 7181 0.626 0.796 
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203627_PM_at insulin-like growth factor 1 receptor IGF1R 3480 0.628 0.725 
200940_PM_s_at arginine-glutamic acid dipeptide (RE) repeats RERE 473 0.629 0.609 
1554029_PM_a_at tetratricopeptide repeat domain 37 TTC37 9652 0.631 0.731 
1559891_PM_at high mobility group AT-hook 2 HMGA2 8091 0.636 0.862 
1558430_PM_at --- --- --- 0.636 0.957 
219457_PM_s_at Ras and Rab interactor 3 RIN3 79890 0.639 0.693 
240098_PM_at RAP1 interacting factor homolog (yeast) RIF1 55183 0.641 0.655 
1561224_PM_at --- --- --- 0.642 0.665 
233610_PM_at hypothetical LOC645355 LOC645355 645355 0.645 0.906 
1552672_PM_a_at immunoglobulin superfamily, member 3 IGSF3 3321 0.647 0.822 
207208_PM_at RNA binding motif protein, X-linked-like 2 RBMXL2 27288 0.649 0.711 
215742_PM_at --- --- --- 0.657 0.668 
1553517_PM_at Fer3-like (Drosophila) FERD3L 222894 0.659 0.946 
237690_PM_at G protein-coupled receptor 115 GPR115 221393 0.660 0.754 
222100_PM_at Cytochrome P450, family 2, subfamily E, polypeptide 1 CYP2E1 1571 0.660 0.766 
1555185_PM_x_at telomeric repeat binding factor 2 TERF2 7014 0.665 0.766 
209720_PM_s_at serpin peptidase inhibitor, clade B (ovalbumin), member 3 SERPINB3 6317 0.666 0.674 
219701_PM_at tropomodulin 2 (neuronal) TMOD2 29767 0.668 0.709 
236821_PM_at --- --- --- 0.669 0.899 
204302_PM_s_at KIAA0427 KIAA0427 9811 0.672 0.793 
1559042_PM_at 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 
6, 17kDa 
NDUFB6 4712 0.674 0.659 
203469_PM_s_at cyclin-dependent kinase 10 CDK10 8558 0.675 0.651 
237392_PM_at hypothetical protein LOC283480 LOC283480 283480 0.675 0.807 
232133_PM_at 
ADAM metallopeptidase with thrombospondin type 1 
motif, 10 
ADAMTS10 81794 0.675 0.630 
1560812_PM_at --- --- --- 0.683 0.880 
241669_PM_x_at protein kinase D2 PRKD2 25865 0.684 0.807 
221160_PM_s_at calcium binding protein 5 CABP5 56344 0.685 0.742 
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220635_PM_at psoriasis susceptibility 1 candidate 2 PSORS1C2 170680 0.685 0.879 
1569345_PM_at --- --- --- 0.689 0.968 
220451_PM_s_at baculoviral IAP repeat-containing 7 BIRC7 79444 0.689 0.763 
211480_PM_s_at 
solute carrier organic anion transporter family, member 
1A2 
SLCO1A2 6579 0.689 0.729 
215029_PM_at --- --- --- 0.691 0.731 
1558546_PM_at deoxyribonuclease I DNASE1 1773 0.692 0.844 
217152_PM_at --- --- --- 0.693 0.618 
1569878_PM_at cyclin Y-like 2 CCNYL2 414194 0.698 0.778 
237431_PM_at Ubiquitin specific peptidase 32 USP32 84669 0.698 0.783 
239542_PM_at inositol 1,4,5-triphosphate receptor, type 3 ITPR3 3710 0.699 0.651 
1552311_PM_a_at retina and anterior neural fold homeobox 2 RAX2 84839 0.703 0.801 
1553560_PM_at vomeronasal 1 receptor 4 VN1R4 317703 0.708 0.767 
1556971_PM_a_at Hypothetical protein LOC100289312 LOC100289312 100289312 0.710 0.695 
218389_PM_s_at anterior pharynx defective 1 homolog A (C. elegans) APH1A 51107 0.711 0.762 
1557056_PM_at chromosome 5 open reading frame 47 C5orf47 133491 0.713 0.862 
232442_PM_at breast cancer anti-estrogen resistance 1 BCAR1 9564 0.717 0.904 
213907_PM_at Eukaryotic translation elongation factor 1 epsilon 1 EEF1E1 9521 0.718 0.695 
1555100_PM_at aprataxin and PNKP like factor APLF 200558 0.720 0.887 
231942_PM_at --- --- --- 0.721 0.738 
236676_PM_at --- --- --- 0.722 0.703 
229085_PM_at leucine rich repeat containing 3B LRRC3B 116135 0.726 0.826 
203722_PM_at aldehyde dehydrogenase 4 family, member A1 ALDH4A1 8659 0.728 0.903 
223839_PM_s_at stearoyl-CoA desaturase (delta-9-desaturase) SCD 6319 0.728 0.683 
216879_PM_at Hr44 antigen HR44 27251 0.730 0.716 
1554222_PM_at hypothetical LOC284365 MGC45922 284365 0.731 0.679 
223153_PM_x_at transmembrane and ubiquitin-like domain containing 1 TMUB1 83590 0.731 0.872 
229920_PM_at --- --- --- 0.735 0.878 
219765_PM_at zinc finger protein 329 ZNF329 79673 0.736 0.631 
 387 
225497_PM_at arginyltransferase 1 ATE1 11101 0.737 0.637 
222030_PM_at SIVA1, apoptosis-inducing factor SIVA1 10572 0.738 0.644 
1568745_PM_at hCG1654703 LOC646268 646268 0.740 0.601 
1560818_PM_at Hypothetical protein LOC100288701 LOC100288701 100288701 0.740 0.895 
244151_PM_at hypothetical LOC285733 LOC285733 285733 0.740 0.692 
239049_PM_at --- --- --- 0.741 0.706 
226635_PM_at Hypothetical gene supported by AK091718 LOC401504 401504 0.741 0.893 
239111_PM_at PR domain containing 8 PRDM8 56978 0.741 0.829 
1552459_PM_a_at methyl-CpG binding domain protein 3-like 1 MBD3L1 85509 0.745 0.640 
218783_PM_at integrator complex subunit 7 INTS7 25896 0.748 0.693 
233531_PM_at solute carrier family 46 (folate transporter), member 1 SLC46A1 113235 0.749 0.717 
1553321_PM_a_at sulfotransferase family, cytosolic, 1C, member 4 SULT1C4 27233 0.751 0.706 
205044_PM_at gamma-aminobutyric acid (GABA) A receptor, pi GABRP 2568 0.751 0.719 
1559237_PM_a_at --- --- --- 0.751 0.681 
228157_PM_at zinc finger protein 207 ZNF207 7756 0.751 0.775 
238104_PM_at --- --- --- 0.754 0.866 
220360_PM_at THAP domain containing 9 THAP9 79725 0.755 0.603 
233644_PM_at katanin p60 subunit A-like 2 KATNAL2 83473 0.755 0.762 
239792_PM_at --- --- --- 0.757 0.804 
214155_PM_s_at La ribonucleoprotein domain family, member 4 LARP4 113251 0.757 0.791 
224356_PM_x_at membrane-spanning 4-domains, subfamily A, member 6A MS4A6A 64231 0.760 0.789 
226231_PM_at --- --- --- 0.762 0.807 
236152_PM_at P antigen family, member 5 (prostate associated) PAGE5 90737 0.763 0.835 
208726_PM_s_at 
eukaryotic translation initiation factor 2, subunit 2 beta, 
38kDa 
EIF2S2 8894 0.764 0.699 
220653_PM_at zinc finger, imprinted 2 ZIM2 23619 0.766 0.680 
1569780_PM_at --- --- --- 0.767 0.970 
212321_PM_at sphingosine-1-phosphate lyase 1 SGPL1 8879 0.768 0.923 
227044_PM_at --- --- --- 0.772 0.920 
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231871_PM_at G protein-coupled receptor 180 GPR180 160897 0.772 0.852 
226850_PM_at sulfatase modifying factor 1 SUMF1 285362 0.773 0.728 
1554739_PM_at intracisternal A particle-promoted polypeptide IPP 3652 0.778 0.638 
1557480_PM_a_at dysferlin interacting protein 1 DYSFIP1 116729 0.781 0.869 
238703_PM_at 









carboxylase (ATP-hydrolysing)) ligase) 
HLCS 3141 0.782 0.698 
237369_PM_at --- --- --- 0.785 0.777 
221864_PM_at ORAI calcium release-activated calcium modulator 3 ORAI3 93129 0.789 0.601 
218690_PM_at PDZ and LIM domain 4 PDLIM4 8572 0.790 0.674 
218300_PM_at chromosome 16 open reading frame 53 C16orf53 79447 0.791 0.819 
1557775_PM_a_at --- --- --- 0.793 0.736 
202440_PM_s_at suppression of tumorigenicity 5 ST5 6764 0.793 0.736 
236683_PM_at --- --- --- 0.798 0.941 
225409_PM_at chromosome 2 open reading frame 64 C2orf64 493753 0.799 0.823 
233707_PM_at --- --- --- 0.799 0.677 
239023_PM_at --- --- --- 0.800 0.838 
235811_PM_at --- --- --- 0.801 0.767 
1554831_PM_x_at 
amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 11 
ALS2CR11 151254 0.802 0.938 
206705_PM_at tubby like protein 1 TULP1 7287 0.804 0.858 
219508_PM_at glucosaminyl (N-acetyl) transferase 3, mucin type GCNT3 9245 0.804 0.836 
235943_PM_at --- --- --- 0.806 0.712 
230758_PM_at gem (nuclear organelle) associated protein 8 GEMIN8 54960 0.808 0.704 
1557683_PM_at --- --- --- 0.810 0.885 
220322_PM_at interleukin 1 family, member 9 IL1F9 56300 0.813 0.853 
220652_PM_at kinesin family member 24 KIF24 347240 0.816 0.864 
229059_PM_at 
chromosome 9 open reading frame 109 /// chromosome 9 







239790_PM_s_at --- --- --- 0.818 0.856 
1560012_PM_at --- --- --- 0.819 0.793 
239086_PM_at --- --- --- 0.821 0.784 
208902_PM_s_at ribosomal protein S28 RPS28 6234 0.821 0.710 
233031_PM_at zinc finger E-box binding homeobox 2 ZEB2 9839 0.824 0.858 
233267_PM_at Selenium binding protein 1 SELENBP1 8991 0.825 0.740 
219746_PM_at D4, zinc and double PHD fingers, family 3 DPF3 8110 0.832 0.902 
223861_PM_at HORMA domain containing 1 HORMAD1 84072 0.833 0.676 
213759_PM_at --- --- --- 0.840 0.657 
1553612_PM_at zinc finger protein 354B ZNF354B 117608 0.844 0.747 
1562330_PM_s_at CUB and Sushi multiple domains 1 CSMD1 64478 0.845 0.845 
207965_PM_at neurogenin 3 NEUROG3 50674 0.848 0.853 
243966_PM_at --- --- --- 0.850 0.738 
1555516_PM_at forkhead box P2 FOXP2 93986 0.850 0.733 
210718_PM_s_at 
ADP-ribosylation factor-like 17A /// similar to ADP-







transcription elongation factor B (SIII), polypeptide 3 
(110kDa, elongin A) 
TCEB3 6924 0.857 0.685 
237306_PM_at zinc finger protein 829 ZNF829 374899 0.857 0.878 
215274_PM_at 
solute carrier family 12 (sodium/chloride transporters), 
member 3 
SLC12A3 6559 0.859 0.761 
231712_PM_at --- --- --- 0.860 0.802 
1553992_PM_s_at neighbor of BRCA1 gene 2 (non-protein coding) NBR2 10230 0.861 0.796 
206314_PM_at zinc finger protein 167 ZNF167 55888 0.862 0.915 
242155_PM_x_at ring finger and FYVE-like domain containing 1 RFFL 117584 0.869 0.807 
219697_PM_at 389eparin sulfate (glucosamine) 3-O-sulfotransferase 2 HS3ST2 9956 0.869 0.819 
213120_PM_at UHRF1 binding protein 1-like UHRF1BP1L 23074 0.869 0.719 
242189_PM_at --- --- --- 0.870 0.653 
1563868_PM_a_at chromosome 9 open reading frame 79 C9orf79 286234 0.871 0.690 
244864_PM_at --- --- --- 0.872 0.752 
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239286_PM_at cadherin 11, type 2, OB-cadherin (osteoblast) CDH11 1009 0.874 0.751 
201487_PM_at cathepsin C CTSC 1075 0.877 0.811 
233133_PM_at --- --- --- 0.879 0.714 
1561148_PM_at --- --- --- 0.883 0.708 
240093_PM_x_at --- --- --- 0.901 0.741 
212972_PM_x_at 
amyloid beta (A4) precursor protein-binding, family B, 
member 2 
APBB2 323 0.902 0.920 
206007_PM_at proteoglycan 4 PRG4 10216 0.915 0.734 
202068_PM_s_at low density lipoprotein receptor LDLR 3949 0.917 0.836 
235890_PM_at 390eparin390ing (beta)-like 1 X-linked receptor 1 TBL1XR1 79718 0.919 0.642 
241994_PM_at xanthine dehydrogenase XDH 7498 0.922 0.772 
234692_PM_at --- --- --- 0.923 0.842 
1561061_PM_at --- --- --- 0.925 0.882 
219455_PM_at chromosome 7 open reading frame 63 C7orf63 79846 0.926 0.834 
210946_PM_at phosphatidic acid phosphatase type 2A PPAP2A 8611 0.927 0.646 
228905_PM_at pericentriolar material 1 PCM1 5108 0.930 0.692 
240168_PM_at exportin 7 XPO7 23039 0.931 0.662 
1554895_PM_a_at rhomboid, veinlet-like 2 (Drosophila) RHBDL2 54933 0.949 0.659 






Supplementary Table 12. Transcripts correlated (r>0.60 and r <-0.60) with mean total activity, percent loss [
11
C]DTBZ binding potential (PET), and 
percent loss tyrosine hydroxylase levels (TH) in the caudate nucleus. Transcripts are identified by their Affymetrix Probe Set ID, Gene Title, Gene Symbol, 
Entrez Gene ID number. The last six columns denote Pearson correlation between gene expression mean total activity, gene expression and percent loss 
[
11
C]DTBZ binding, and gene expression and percent loss TH in both caudate replicates (R1c and R2c). Positive correlations are indicated in red text and 
negative correlation is denoted by blue text. 
 
SUPPLEMENTARY TABLE 12. Transcripts correlated (r > 0.60 or r < -0.60) with mean total activity, PET, and TH in the caudate.   


















leucine rich repeat 
containing 40 
LRRC40 55631 -0.943 -0.799 -0.652 -0.615 -0.622 -0.655 
232566_PM_at 
nucleolar protein family 6 
(RNA-associated) 
NOL6 65083 -0.811 -0.662 -0.791 -0.882 -0.781 -0.806 
215645_PM_at folliculin FLCN 201163 -0.791 -0.661 -0.661 -0.823 -0.716 -0.824 
214778_PM_at multiple EGF-like-domains 8 MEGF8 1954 -0.680 -0.731 -0.735 -0.897 -0.639 -0.891 
242824_PM_at --- --- --- -0.677 -0.622 -0.857 -0.652 -0.860 -0.650 
204189_PM_at 
retinoic acid receptor, 
gamma 
RARG 5916 -0.668 -0.668 -0.901 -0.829 -0.894 -0.827 
1553328_PM_a_at 
solute carrier family 18 
(vesicular monoamine), 
member 2 
SLC18A2 6571 -0.631 -0.764 -0.712 -0.708 -0.675 -0.622 
230641_PM_at --- --- --- -0.621 -0.821 -0.744 -0.894 -0.794 -0.881 
236143_PM_at --- --- --- 0.618 0.645 0.740 0.813 0.678 0.729 
224941_PM_at 
pregnancy-associated 
plasma protein A, 
pappalysin 1 
PAPPA 5069 0.625 0.646 0.890 0.710 0.902 0.653 
235890_PM_at 
transducin (beta)-like 1 X-
linked receptor 1 
TBL1XR1 79718 0.660 0.872 0.813 0.611 0.783 0.621 
208092_PM_s_at 
family with sequence 
similarity 49, member A 
FAM49A 81553 0.676 0.761 0.723 0.771 0.758 0.824 
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228393_PM_s_at zinc finger protein 302 ZNF302 55900 0.676 0.878 0.707 0.687 0.749 0.716 
233358_PM_at --- --- --- 0.710 0.605 0.955 0.782 0.943 0.715 
241490_PM_s_at 
piggyBac transposable 
element derived 2 
PGBD2 267002 0.792 0.796 0.818 0.671 0.881 0.630 
230064_PM_at --- --- --- 0.802 0.908 0.833 0.828 0.843 0.795 
214744_PM_s_at ribosomal protein L23 RPL23 9349 0.825 0.716 0.888 0.671 0.858 0.699 
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Supplementary Table 13. Transcripts correlated (r>0.60 and r <-0.60) with mean total activity, percent loss [
11
C]DTBZ binding potential (PET), and 
percent loss tyrosine hydroxylase levels (TH) in the putamen. Transcripts are identified by their Affymetrix Probe Set ID, Gene Title, Gene Symbol, Entrez 
Gene ID number. The last six columns denote Pearson correlation between gene expression mean total activity, gene expression and percent loss [
11
C]DTBZ 
binding, and gene expression and percent loss TH  in both putamen replicates (R1p and R2p). Positive correlations are indicated in red text and negative 
correlation is denoted by blue text. 
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neural precursor cell 
expressed, developmentally 
down-regulated 9 
NEDD9 4739 -0.964 -0.768 -0.894 -0.706 -0.857 -0.835 
230865_PM_at Lix1 homolog (chicken) LIX1 167410 -0.951 -0.826 -0.719 -0.645 -0.732 -0.685 
244072_PM_at --- --- --- -0.913 -0.701 -0.756 -0.616 -0.808 -0.670 
233848_PM_x_at zinc finger protein 221 ZNF221 7638 -0.903 -0.607 -0.924 -0.911 -0.870 -0.864 
1555198_PM_x_at 
chromosome 21 open 
reading frame 58 




preferring, member 2 
SULT1A2 6799 -0.855 -0.880 -0.783 -0.776 -0.671 -0.712 
244703_PM_x_at importin 9 IPO9 55705 -0.826 -0.757 -0.752 -0.743 -0.752 -0.665 
207906_PM_at 
interleukin 3 (colony-
stimulating factor, multiple) 
IL3 3562 -0.825 -0.614 -0.715 -0.735 -0.634 -0.748 
229966_PM_at 
Ewing sarcoma breakpoint 
region 1 
EWSR1 2130 -0.819 -0.946 -0.927 -0.833 -0.894 -0.748 
1552585_PM_s_at 
general transcription factor 
IIA, 1-like 
GTF2A1L 11036 -0.803 -0.680 -0.806 -0.809 -0.833 -0.714 
1568686_PM_at 
ATPase, class I, type 8B, 
member 5, pseudogene 
ATP8B5P 158381 -0.796 -0.738 -0.665 -0.691 -0.747 -0.704 
216985_PM_s_at syntaxin 3 STX3 6809 -0.792 -0.779 -0.636 -0.839 -0.698 -0.826 
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1556395_PM_at --- --- --- -0.747 -0.743 -0.755 -0.977 -0.721 -0.927 








TMC4 147798 -0.709 -0.715 -0.702 -0.724 -0.725 -0.725 
1562866_PM_at --- --- --- -0.691 -0.839 -0.857 -0.979 -0.920 -0.937 
202736_PM_s_at 
LSM4 homolog, U6 small 
nuclear RNA associated (S. 
cerevisiae) 
LSM4 25804 -0.679 -0.804 -0.714 -0.678 -0.685 -0.732 
204490_PM_s_at 
CD44 molecule (Indian 
blood group) 
CD44 960 -0.661 -0.667 -0.804 -0.907 -0.844 -0.884 
214569_PM_at interferon, alpha 5 IFNA5 3442 -0.639 -0.792 -0.659 -0.774 -0.693 -0.833 
206980_PM_s_at 
fms-related tyrosine kinase 
3 ligand 
FLT3LG 2323 -0.636 -0.805 -0.710 -0.669 -0.630 -0.705 
244378_PM_at 
Chromosome 12 open 
reading frame 51 
C12orf51 283450 -0.634 -0.812 -0.845 -0.866 -0.859 -0.838 
214911_PM_s_at bromodomain containing 2 BRD2 6046 -0.625 -0.838 -0.616 -0.673 -0.664 -0.681 




PEX6 5190 -0.610 -0.857 -0.777 -0.701 -0.737 -0.658 
1557116_PM_at apolipoprotein L, 6 APOL6 80830 0.609 0.818 0.616 0.725 0.678 0.810 
210530_PM_s_at 
nuclear receptor subfamily 
2, group C, member 1 
NR2C1 7181 0.626 0.796 0.795 0.826 0.811 0.734 
203627_PM_at 
insulin-like growth factor 1 
receptor 




TTC37 9652 0.631 0.731 0.686 0.729 0.765 0.796 
1558430_PM_at --- --- --- 0.636 0.957 0.685 0.908 0.605 0.891 
219457_PM_s_at Ras and Rab interactor 3 RIN3 79890 0.639 0.693 0.663 0.732 0.686 0.733 
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240098_PM_at 
RAP1 interacting factor 
homolog (yeast) 
RIF1 55183 0.641 0.655 0.689 0.805 0.684 0.903 
1561224_PM_at --- --- --- 0.642 0.665 0.647 0.863 0.635 0.762 
1553517_PM_at Fer3-like (Drosophila) FERD3L 222894 0.659 0.946 0.813 0.873 0.886 0.883 
1555185_PM_x_at 
telomeric repeat binding 
factor 2 
TERF2 7014 0.665 0.766 0.639 0.782 0.604 0.684 
209720_PM_s_at 
serpin peptidase inhibitor, 
clade B (ovalbumin), 
member 3 
SERPINB3 6317 0.666 0.674 0.743 0.649 0.675 0.677 
1560812_PM_at --- --- --- 0.683 0.880 0.737 0.816 0.858 0.856 
221160_PM_s_at calcium binding protein 5 CABP5 56344 0.685 0.742 0.751 0.679 0.845 0.724 
239542_PM_at 
inositol 1,4,5-triphosphate 
receptor, type 3 
ITPR3 3710 0.699 0.651 0.643 0.712 0.622 0.746 
1553560_PM_at vomeronasal 1 receptor 4 VN1R4 317703 0.708 0.767 0.785 0.978 0.709 0.961 
232442_PM_at 
breast cancer anti-estrogen 
resistance 1 





TMUB1 83590 0.731 0.872 0.774 0.827 0.722 0.860 




LOC100288701 1E+08 0.740 0.895 0.799 0.792 0.877 0.798 
226635_PM_at 
Hypothetical gene supported 
by AK091718 
LOC401504 401504 0.741 0.893 0.847 0.789 0.850 0.803 
1552459_PM_a_at 
methyl-CpG binding domain 
protein 3-like 1 
MBD3L1 85509 0.745 0.640 0.708 0.627 0.821 0.760 
1553321_PM_a_at 
sulfotransferase family, 
cytosolic, 1C, member 4 
SULT1C4 27233 0.751 0.706 0.706 0.605 0.836 0.660 
1559237_PM_a_at --- --- --- 0.751 0.681 0.688 0.864 0.798 0.938 
228157_PM_at zinc finger protein 207 ZNF207 7756 0.751 0.775 0.789 0.848 0.691 0.865 
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238104_PM_at --- --- --- 0.754 0.866 0.875 0.735 0.779 0.669 
239792_PM_at --- --- --- 0.757 0.804 0.804 0.742 0.873 0.850 
224356_PM_x_at 
membrane-spanning 4-
domains, subfamily A, 
member 6A 
MS4A6A 64231 0.760 0.789 0.662 0.699 0.671 0.753 
236152_PM_at 
P antigen family, member 5 
(prostate associated) 
PAGE5 90737 0.763 0.835 0.832 0.774 0.776 0.803 




SGPL1 8879 0.768 0.923 0.835 0.832 0.692 0.740 
226850_PM_at sulfatase modifying factor 1 SUMF1 285362 0.773 0.728 0.804 0.931 0.772 0.905 
237369_PM_at --- --- --- 0.785 0.777 0.621 0.635 0.639 0.663 
221864_PM_at 
ORAI calcium release-
activated calcium modulator 
3 
ORAI3 93129 0.789 0.601 0.651 0.766 0.750 0.825 
218690_PM_at PDZ and LIM domain 4 PDLIM4 8572 0.790 0.674 0.664 0.730 0.657 0.847 
218300_PM_at 
chromosome 16 open 
reading frame 53 
C16orf53 79447 0.791 0.819 0.666 0.611 0.749 0.623 




ST5 6764 0.793 0.736 0.713 0.937 0.812 0.944 
236683_PM_at --- --- --- 0.798 0.941 0.709 0.697 0.805 0.744 
239023_PM_at --- --- --- 0.800 0.838 0.776 0.773 0.876 0.847 
1554831_PM_x_at 
amyotrophic lateral sclerosis 
2 (juvenile) chromosome 
region, candidate 11 
ALS2CR11 151254 0.802 0.938 0.895 0.708 0.964 0.720 
235943_PM_at --- --- --- 0.806 0.712 0.815 0.755 0.835 0.660 
1557683_PM_at --- --- --- 0.810 0.885 0.739 0.843 0.851 0.837 
 397 
229059_PM_at 
chromosome 9 open reading 
frame 109 /// chromosome 9 





0.817 0.753 0.707 0.660 0.776 0.743 
239790_PM_s_at --- --- --- 0.818 0.856 0.731 0.913 0.692 0.894 
208902_PM_s_at ribosomal protein S28 RPS28 6234 0.821 0.710 0.742 0.757 0.800 0.847 
233031_PM_at 
zinc finger E-box binding 
homeobox 2 
ZEB2 9839 0.824 0.858 0.697 0.666 0.771 0.677 
219746_PM_at 
D4, zinc and double PHD 
fingers, family 3 
DPF3 8110 0.832 0.902 0.617 0.885 0.669 0.853 
1553612_PM_at zinc finger protein 354B ZNF354B 117608 0.844 0.747 0.833 0.712 0.765 0.765 
1562330_PM_s_at 
CUB and Sushi multiple 
domains 1 
CSMD1 64478 0.845 0.845 0.673 0.722 0.742 0.744 
207965_PM_at neurogenin 3 NEUROG3 50674 0.848 0.853 0.822 0.751 0.897 0.804 
210718_PM_s_at 
ADP-ribosylation factor-like 
17A /// similar to ADP-





0.855 0.781 0.836 0.712 0.883 0.797 
237306_PM_at zinc finger protein 829 ZNF829 374899 0.857 0.878 0.762 0.778 0.852 0.857 
215274_PM_at 
solute carrier family 12 
(sodium/chloride 
transporters), member 3 
SLC12A3 6559 0.859 0.761 0.749 0.736 0.738 0.836 
1553992_PM_s_at 
neighbor of BRCA1 gene 2 
(non-protein coding) 
NBR2 10230 0.861 0.796 0.611 0.791 0.690 0.862 
242155_PM_x_at 
ring finger and FYVE-like 
domain containing 1 





HS3ST2 9956 0.869 0.819 0.720 0.720 0.721 0.831 
 398 
213120_PM_at 
UHRF1 binding protein 1-
like 
UHRF1BP1L 23074 0.869 0.719 0.798 0.661 0.766 0.680 
1563868_PM_a_at 
chromosome 9 open reading 
frame 79 
C9orf79 286234 0.871 0.690 0.661 0.767 0.651 0.793 
244864_PM_at --- --- --- 0.872 0.752 0.730 0.692 0.735 0.795 
239286_PM_at 
cadherin 11, type 2, OB-
cadherin (osteoblast) 
CDH11 1009 0.874 0.751 0.851 0.636 0.799 0.667 
212972_PM_x_at 
amyloid beta (A4) precursor 
protein-binding, family B, 
member 2 
APBB2 323 0.902 0.920 0.915 0.785 0.938 0.717 
202068_PM_s_at 
low density lipoprotein 
receptor 
LDLR 3949 0.917 0.836 0.821 0.646 0.815 0.752 
219455_PM_at 
chromosome 7 open reading 
frame 63 
C7orf63 79846 0.926 0.834 0.859 0.788 0.853 0.891 
210946_PM_at 
phosphatidic acid 
phosphatase type 2A 
PPAP2A 8611 0.927 0.646 0.944 0.870 0.886 0.904 
228905_PM_at pericentriolar material 1 PCM1 5108 0.930 0.692 0.754 0.652 0.822 0.734 
240309_PM_at --- --- --- 0.966 0.718 0.916 0.743 0.909 0.712 
 399 
Supplementary Table 14. Transcripts associated with the lesioned hemisphere. Transcripts are identified by their Affymetrix Probe Set ID, Gene Title, Gene 
Symbol, and Entrez Gene ID number. Transcripts are differentially expressed between the lesioned and nonlesioned hemispheres with p< 0.05 for a paired t-test 
and an average log ratio (ALR) > 0.3785 indicated a 30% change in expression. Positive ALRs are indicated in red text and negative ALRs are denoted by blue 
text. 
 
SUPPLEMENTARY TABLE 14. Transcripts associated with the lesioned hemisphere. 
Probe Set ID Gene Title Gene Symbol Entrez Gene t-test ALR 
203263_PM_s_at Cdc42 guanine nucleotide exchange factor (GEF) 9 ARHGEF9 23229 0.016 -0.73 
219935_PM_at ADAM metallopeptidase with thrombospondin type 1 motif, 5 ADAMTS5 11096 0.041 -0.68 
229824_PM_at --- --- --- 0.005 -0.65 
226084_PM_at microtubule-associated protein 1B MAP1B 4131 0.023 -0.64 
226232_PM_at growth differentiation factor 11 GDF11 10220 0.047 -0.57 
221646_PM_s_at zinc finger, DHHC-type containing 11 ZDHHC11 79844 0.009 -0.57 
232224_PM_at 
mannan-binding lectin serine peptidase 1 (C4/C2 activating 
component of Ra-reactive factor) 
MASP1 5648 0.016 -0.55 
206513_PM_at absent in melanoma 2 AIM2 9447 0.017 -0.55 
211383_PM_s_at WD repeat domain 37 WDR37 22884 0.004 -0.53 
204388_PM_s_at monoamine oxidase A MAOA 4128 0.033 -0.5 
201821_PM_s_at 
translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
TIMM17A 10440 0.025 -0.5 
201899_PM_s_at ubiquitin-conjugating enzyme E2A (RAD6 homolog) UBE2A 7319 0.016 -0.5 
232176_PM_at SLIT and NTRK-like family, member 6 SLITRK6 84189 0.03 -0.49 
213762_PM_x_at RNA binding motif protein, X-linked RBMX 27316 0.025 -0.48 
235905_PM_at --- --- --- 0.016 -0.48 
219810_PM_at 
valosin containing protein (p97)/p47 complex interacting 
protein 1 
VCPIP1 80124 0.048 -0.47 
244040_PM_at --- --- --- 0.043 -0.47 
233422_PM_at --- --- --- 0.036 -0.46 
232347_PM_x_at --- --- --- 0.016 -0.45 
238604_PM_at --- --- --- 0.038 -0.45 
232653_PM_at --- --- --- 0.021 -0.45 
233268_PM_s_at churchill domain containing 1 CHURC1 91612 0.041 -0.45 
227217_PM_at WNK lysine deficient protein kinase 2 WNK2 65268 0.012 -0.44 
 400 
225317_PM_at acyl-CoA binding domain containing 6 ACBD6 84320 0.047 -0.44 
239036_PM_at --- --- --- 0.024 -0.43 
208942_PM_s_at SEC62 homolog (S. cerevisiae) SEC62 7095 0.022 -0.43 
218457_PM_s_at DNA (cytosine-5-)-methyltransferase 3 alpha DNMT3A 1788 0.006 -0.43 
203580_PM_s_at 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 6 
SLC7A6 9057 0.033 -0.43 
205592_PM_at 
solute carrier family 4, anion exchanger, member 1 
(erythrocyte membrane protein band 3, Diego blood group) 
SLC4A1 6521 0 -0.43 
1561192_PM_at --- --- --- 0.002 -0.43 
213259_PM_s_at sterile alpha and TIR motif containing 1 SARM1 23098 0.026 -0.43 
232220_PM_at S100 calcium binding protein A7A S100A7A 338324 0.042 -0.42 
208345_PM_s_at POU class 3 homeobox 1 POU3F1 5453 0.005 -0.42 
226923_PM_at sec1 family domain containing 2 SCFD2 152579 0.031 -0.42 
219566_PM_at 
pleckstrin homology domain containing, family F (with FYVE 
domain) member 1 
PLEKHF1 79156 0.044 -0.41 
216042_PM_at tumor necrosis factor receptor superfamily, member 25 TNFRSF25 8718 0.022 -0.41 
225830_PM_at PDZ domain containing 8 PDZD8 118987 0.022 -0.41 
233407_PM_at --- --- --- 0.021 -0.4 
1568639_PM_a_at --- --- --- 0.032 -0.4 
214040_PM_s_at gelsolin GSN 2934 0.001 -0.4 
243033_PM_at Twinfilin, actin-binding protein, homolog 1 (Drosophila) TWF1 5756 0.047 -0.4 
222977_PM_at surfeit 4 SURF4 6836 0.024 -0.4 
235603_PM_at 
heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A) 
HNRNPU 3192 0.014 -0.39 
1562381_PM_at hypothetical LOC285830 LOC285830 285830 0.036 -0.39 
1554572_PM_a_at suppressor of variegation 3-9 homolog 2 (Drosophila) SUV39H2 79723 0.039 -0.39 
236772_PM_s_at --- --- --- 0.047 -0.39 
238104_PM_at --- --- --- 0.015 -0.38 
201669_PM_s_at myristoylated alanine-rich protein kinase C substrate MARCKS 4082 0.036 -0.38 
240799_PM_at solute carrier family 35, member F4 SLC35F4 341880 0.046 -0.38 
204290_PM_s_at aldehyde dehydrogenase 6 family, member A1 ALDH6A1 4329 0.021 -0.38 
226347_PM_at --- --- --- 0.041 -0.38 
 401 
244334_PM_at translocation associated membrane protein 1-like 1 TRAM1L1 133022 0.011 -0.38 
206645_PM_s_at nuclear receptor subfamily 0, group B, member 1 NR0B1 190 0.01 -0.38 
215779_PM_s_at histone cluster 1, H2bg HIST1H2BG 8339 0.038 -0.37 
204758_PM_s_at C2CD2-like C2CD2L 9854 0.03 -0.36 
215282_PM_at anaphase promoting complex subunit 13 ANAPC13 25847 0.041 -0.36 
234070_PM_at --- --- --- 0.049 -0.36 
217570_PM_x_at --- --- --- 0.012 -0.36 
1557185_PM_at two pore segment channel 1 TPCN1 53373 0.049 -0.36 
241218_PM_at --- --- --- 0.045 -0.36 
216921_PM_s_at keratin 35 KRT35 3886 0.049 -0.36 
1556771_PM_a_at hypothetical LOC415056 LOC415056 415056 0.015 -0.35 
235497_PM_at hypothetical LOC643837 LOC643837 643837 0.019 -0.35 
234424_PM_at --- --- --- 0.038 -0.35 
1569996_PM_at ankyrin repeat domain 26 pseudogene LOC100101938 100101938 0.05 -0.35 
238334_PM_at Shadow of prion protein homolog (zebrafish) SPRN 503542 0.038 -0.35 
209605_PM_at thiosulfate sulfurtransferase (rhodanese) TST 7263 0.026 -0.35 
217296_PM_at 
Killer cell immunoglobulin-like receptor, two domains, long 
cytoplasmic tail, 1 
KIR2DL1 3802 0.009 -0.35 
234074_PM_at --- --- --- 0.009 -0.35 
1560352_PM_at --- --- --- 0.024 -0.35 
244457_PM_at --- --- --- 0.046 -0.35 
205434_PM_s_at AP2 associated kinase 1 AAK1 22848 0.003 -0.35 
233952_PM_s_at zinc finger protein 295 ZNF295 49854 0.046 -0.35 
1559369_PM_at chromosome 5 open reading frame 44 C5orf44 80006 0.021 -0.34 
237945_PM_at --- --- --- 0.021 -0.34 
225303_PM_at kin of IRRE like (Drosophila) KIRREL 55243 0.024 -0.34 
238184_PM_at --- --- --- 0.029 -0.34 
220482_PM_s_at secretion regulating guanine nucleotide exchange factor SERGEF 26297 0.02 -0.34 
1565544_PM_at ring finger protein 141 RNF141 50862 0.021 -0.34 
1555037_PM_a_at isocitrate dehydrogenase 1 (NADP+), soluble IDH1 3417 0.026 -0.34 
1555734_PM_x_at adaptor-related protein complex 1, sigma 3 subunit AP1S3 130340 0.045 -0.34 
218729_PM_at latexin LXN 56925 0.018 -0.33 
 402 
213196_PM_at zinc finger protein 629 ZNF629 23361 0.024 -0.33 
202384_PM_s_at Treacher Collins-Franceschetti syndrome 1 TCOF1 6949 0.001 -0.33 
1557275_PM_a_at TLC domain containing 2 TLCD2 727910 0.04 -0.33 
224954_PM_at serine hydroxymethyltransferase 1 (soluble) SHMT1 6470 0.039 -0.33 
1553523_PM_at NLR family, pyrin domain containing 14 NLRP14 338323 0.017 -0.33 
220731_PM_s_at NECAP endocytosis associated 2 NECAP2 55707 0.038 -0.33 
210568_PM_s_at RecQ protein-like (DNA helicase Q1-like) RECQL 5965 0.002 -0.33 
206521_PM_s_at general transcription factor IIA, 1, 19/37kDa GTF2A1 2957 0.038 -0.32 
234869_PM_at --- --- --- 0.038 -0.32 
220573_PM_at kallikrein-related peptidase 14 KLK14 43847 0.014 -0.32 
1557780_PM_at --- --- --- 0.015 -0.32 
244763_PM_at mitochondrial translational release factor 1 MTRF1 9617 0.04 -0.32 
228454_PM_at ligand dependent nuclear receptor corepressor LCOR 84458 0.047 -0.32 
202665_PM_s_at WAS/WASL interacting protein family, member 1 WIPF1 7456 0.015 -0.32 
210620_PM_s_at general transcription factor IIIC, polypeptide 2, beta 110kDa GTF3C2 2976 0.015 -0.32 
1553405_PM_a_at CUB and Sushi multiple domains 1 CSMD1 64478 0.034 -0.32 
217095_PM_x_at natural cytotoxicity triggering receptor 1 NCR1 9437 0.049 -0.32 
200656_PM_s_at prolyl 4-hydroxylase, beta polypeptide P4HB 5034 0.021 -0.32 
205809_PM_s_at Wiskott-Aldrich syndrome-like WASL 8976 0.008 -0.31 
209902_PM_at ataxia telangiectasia and Rad3 related ATR 545 0.041 -0.31 
206091_PM_at matrilin 3 MATN3 4148 0.043 -0.31 
207823_PM_s_at allograft inflammatory factor 1 AIF1 199 0.001 -0.31 
225943_PM_at neurolysin (metallopeptidase M3 family) NLN 57486 0.047 -0.31 
227941_PM_at hypothetical protein LOC339803 LOC339803 339803 0.048 -0.31 
1553067_PM_a_at gonadotropin-releasing hormone (type 2) receptor 2 GNRHR2 114814 0.033 -0.31 
1570402_PM_at kinesin light chain 3 KLC3 147700 0.016 -0.31 
241866_PM_at 
solute carrier family 16, member 7 (monocarboxylic acid 
transporter 2) 
SLC16A7 9194 0.009 -0.31 
225331_PM_at coiled-coil domain containing 50 CCDC50 152137 0.017 -0.31 
208815_PM_x_at heat shock 70kDa protein 4 HSPA4 3308 0.027 -0.31 
215351_PM_at RNA terminal phosphate cyclase domain 1 RTCD1 8634 0.03 -0.31 
206900_PM_x_at zinc finger protein 253 ZNF253 56242 0.032 -0.31 
 403 
226298_PM_at RUN domain containing 1 RUNDC1 146923 0.037 -0.31 
222130_PM_s_at FtsJ homolog 2 (E. coli) FTSJ2 29960 0.01 -0.31 
226572_PM_at suppressor of cytokine signaling 7 SOCS7 30837 0.021 -0.31 
1558602_PM_a_at hypothetical LOC285194 LOC285194 285194 0.043 -0.31 
1561853_PM_a_at interleukin 23 receptor IL23R 149233 0.049 -0.31 
224029_PM_x_at sodium channel, voltage-gated, type XI, alpha subunit SCN11A 11280 0.024 -0.3 
243591_PM_at --- --- --- 0.03 -0.3 
227765_PM_at --- --- --- 0.012 -0.3 
231831_PM_at 
COX19 cytochrome c oxidase assembly homolog (S. 
cerevisiae) 
COX19 90639 0.038 -0.3 
1564165_PM_at PRKR interacting protein 1 (IL11 inducible) PRKRIP1 79706 0.026 -0.3 
226787_PM_at zinc finger protein 18 ZNF18 7566 0.034 -0.3 
201310_PM_s_at chromosome 5 open reading frame 13 C5orf13 9315 0.04 -0.3 
221342_PM_at chromosome 6 open reading frame 25 C6orf25 80739 0.049 -0.3 
214316_PM_x_at --- --- --- 0.014 -0.3 
223531_PM_x_at 
G protein-coupled receptor 89A /// G protein-coupled receptor 








241163_PM_at --- --- --- 0.049 -0.3 
1552803_PM_a_at stathmin 1 STMN1 3925 0.003 -0.3 
240274_PM_at --- --- --- 0.001 -0.3 
227270_PM_at family with sequence similarity 200, member B FAM200B 285550 0.007 -0.3 
209038_PM_s_at EH-domain containing 1 EHD1 10938 0.008 -0.3 
223714_PM_at zinc finger protein 256 ZNF256 10172 0.019 -0.3 
1562947_PM_x_at --- --- --- 0.027 -0.3 






244372_PM_at --- --- --- 0.045 -0.3 
1566487_PM_at --- --- --- 0.014 -0.29 
234129_PM_at Rho guanine nucleotide exchange factor (GEF) 12 ARHGEF12 23365 0.031 -0.29 
1561451_PM_a_at --- --- --- 0.032 -0.29 
233401_PM_at --- --- --- 0.038 -0.29 
 404 
238372_PM_s_at --- --- --- 0.007 -0.29 
209751_PM_s_at 
trafficking protein particle complex 2 /// trafficking protein 






232790_PM_at --- --- --- 0.044 -0.29 
230381_PM_at chromosome 1 open reading frame 186 C1orf186 440712 0.031 -0.29 
234260_PM_at --- --- --- 0.044 -0.29 
230861_PM_at Hypothetical LOC26082 DKFZP434L187 26082 0.013 -0.29 
215985_PM_at Non-protein coding RNA 171 NCRNA00171 80862 0.045 -0.29 
211442_PM_x_at cytochrome P450, family 3, subfamily A, polypeptide 43 CYP3A43 64816 0.046 -0.29 
243434_PM_at --- --- --- 0.013 -0.29 
206962_PM_x_at --- --- --- 0.016 -0.29 
243331_PM_at --- --- --- 0.025 -0.29 
1564112_PM_at Family with sequence similarity 71, member A FAM71A 149647 0.03 -0.29 
1561542_PM_at --- --- --- 0.02 -0.29 
244669_PM_at 
small nucleolar RNA host gene 5 (non-protein coding) /// 
small nucleolar RNA, C/D box 50A /// small nucleolar RNA, 














206736_PM_x_at cholinergic receptor, nicotinic, alpha 4 CHRNA4 1137 0.046 -0.29 
233524_PM_at chromosome 9 open reading frame 44 C9orf44 158314 0.033 -0.28 
202523_PM_s_at 
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 2 
SPOCK2 9806 0.015 -0.28 
215678_PM_at --- --- --- 0.046 -0.28 
222501_PM_s_at replication initiator 1 REPIN1 29803 0.008 -0.28 
201011_PM_at ribophorin I RPN1 6184 0.021 -0.28 
225533_PM_at PHD finger protein 19 PHF19 26147 0.027 -0.28 
221528_PM_s_at engulfment and cell motility 2 ELMO2 63916 0.032 -0.28 
1553859_PM_at tryptophan hydroxylase 1 TPH1 7166 0.003 -0.28 
219095_PM_at 








1561016_PM_at --- --- --- 0.034 -0.28 
 405 
220251_PM_at chromosome 1 open reading frame 107 C1orf107 27042 0.038 -0.28 
232934_PM_at --- --- --- 0.044 -0.28 
221034_PM_s_at testis expressed 13B TEX13B 56156 0.007 -0.28 
204332_PM_s_at aspartylglucosaminidase AGA 175 0.047 -0.28 
1553482_PM_at chromosome 15 open reading frame 32 C15orf32 145858 0.006 -0.28 
229364_PM_at --- --- --- 0.02 -0.28 
233965_PM_at hypothetical protein LOC255480 LOC255480 255480 0.029 -0.28 
1560979_PM_a_at --- --- --- 0.049 -0.28 
231375_PM_at Hypothetical protein LOC202181 LOC202181 202181 0.02 -0.28 
205466_PM_s_at heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 9957 0.035 -0.28 
220818_PM_s_at 
transient receptor potential cation channel, subfamily C, 
member 4 
TRPC4 7223 0.013 -0.27 
201108_PM_s_at thrombospondin 1 THBS1 7057 0.023 -0.27 
209545_PM_s_at receptor-interacting serine-threonine kinase 2 RIPK2 8767 0.023 -0.27 
238058_PM_at hypothetical LOC150381 LOC150381 150381 0.023 -0.27 
210433_PM_at protein O-fucosyltransferase 1 POFUT1 23509 0.009 -0.27 
220494_PM_s_at --- --- --- 0.018 -0.27 
237814_PM_at --- --- --- 0.029 -0.27 
226725_PM_at --- --- --- 0.009 -0.27 
204357_PM_s_at LIM domain kinase 1 LIMK1 3984 0.048 -0.27 
244367_PM_at --- --- --- 0.022 -0.27 
223005_PM_s_at chromosome 9 open reading frame 5 C9orf5 23731 0.038 -0.27 
213695_PM_at paraoxonase 3 PON3 5446 0.044 -0.27 
1559249_PM_at ataxin 1 ATXN1 6310 0.029 -0.27 
207274_PM_at cholinergic receptor, nicotinic, epsilon CHRNE 1145 0.017 -0.27 
232062_PM_at adenylate cyclase 1 (brain) ADCY1 107 0.02 -0.27 
222057_PM_at nucleolar protein 12 NOL12 79159 0.017 -0.27 
244414_PM_at --- --- --- 0.045 -0.27 
225847_PM_at neutral cholesterol ester hydrolase 1 NCEH1 57552 0.001 -0.27 
242391_PM_at --- --- --- 0.046 -0.27 
1553672_PM_at enabled homolog (Drosophila) ENAH 55740 0.012 -0.26 
214742_PM_at 5-azacytidine induced 1 AZI1 22994 0.021 -0.26 
 406 
1558670_PM_at --- --- --- 0.028 -0.26 
38157_PM_at dom-3 homolog Z (C. elegans) DOM3Z 1797 0 0.264 
240253_PM_at --- --- --- 0.014 0.264 
1562245_PM_a_at Zinc finger protein 578 ZNF578 147660 0.027 0.265 
203668_PM_at mannosidase, alpha, class 2C, member 1 MAN2C1 4123 0.047 0.265 
1555613_PM_a_at zeta-chain (TCR) associated protein kinase 70kDa ZAP70 7535 0.021 0.266 
203393_PM_at hairy and enhancer of split 1, (Drosophila) HES1 3280 0.024 0.266 
220927_PM_s_at heparanase 2 HPSE2 60495 0.029 0.266 
232592_PM_at --- --- --- 0.01 0.267 
220279_PM_at tripartite motif-containing 17 TRIM17 51127 0.014 0.267 
232958_PM_at --- --- --- 0.035 0.267 
240327_PM_at --- --- --- 0.005 0.268 
207643_PM_s_at tumor necrosis factor receptor superfamily, member 1A TNFRSF1A 7132 0.014 0.269 
224608_PM_s_at vacuolar protein sorting 25 homolog (S. cerevisiae) VPS25 84313 0.049 0.269 
235715_PM_at shadow of prion protein pseudogene FLJ44653 399833 0.036 0.27 
236453_PM_at --- --- --- 0.005 0.271 
219187_PM_at FK506 binding protein like FKBPL 63943 0.009 0.271 
210871_PM_x_at synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 117178 0.041 0.271 
223406_PM_x_at family with sequence similarity 192, member A FAM192A 80011 0.021 0.272 
211367_PM_s_at 
caspase 1, apoptosis-related cysteine peptidase (interleukin 
1, beta, convertase) 
CASP1 834 0.039 0.272 
1556865_PM_at --- --- --- 0.003 0.273 
231545_PM_at --- --- --- 0.003 0.273 
204716_PM_at coiled-coil domain containing 6 CCDC6 8030 0.005 0.273 
234475_PM_x_at Cholecystokinin B receptor CCKBR 887 0.025 0.273 
1555509_PM_a_at solute carrier family 25, member 41 SLC25A41 284427 0.002 0.275 
210336_PM_x_at myeloid zinc finger 1 MZF1 7593 0.012 0.276 
201638_PM_s_at cleavage and polyadenylation specific factor 1, 160kDa CPSF1 29894 0.021 0.277 
236716_PM_at --- --- --- 0.037 0.278 
241970_PM_at --- --- --- 0.002 0.279 
212272_PM_at lipin 1 LPIN1 23175 0.003 0.279 
209508_PM_x_at CASP8 and FADD-like apoptosis regulator CFLAR 8837 0.017 0.282 
 407 
222336_PM_at chromosome 4 open reading frame 34 C4orf34 201895 0.024 0.282 
220694_PM_at ASAP1 intronic transcript 1 (non-protein coding) ASAP1IT1 29065 0.028 0.283 
41660_PM_at 
cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo 
homolog, Drosophila) 
CELSR1 9620 0.003 0.284 
213676_PM_at transmembrane protein 151B TMEM151B 441151 0.013 0.284 
234209_PM_at --- --- --- 0.017 0.285 
1566881_PM_at --- --- --- 0.025 0.285 
211990_PM_at major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 3113 0.041 0.285 
1561132_PM_at DEAH (Asp-Glu-Ala-His) box polypeptide 35 DHX35 60625 0.026 0.286 
233599_PM_at hCG2003663 LOC728061 728061 0.039 0.286 
237541_PM_at --- --- --- 0.001 0.287 
225226_PM_at family with sequence similarity 40, member A FAM40A 85369 0.031 0.287 
241658_PM_at --- --- --- 0.049 0.287 
223632_PM_s_at brevican BCAN 63827 0.045 0.288 
236240_PM_at chromosome 4 open reading frame 29 C4orf29 80167 0 0.289 
1556354_PM_s_at ral guanine nucleotide dissociation stimulator-like 3 RGL3 57139 0.014 0.289 
AFFX-BioC-5_at --- --- --- 0.015 0.289 
234294_PM_x_at GATA zinc finger domain containing 2A GATAD2A 54815 0.029 0.289 
231900_PM_at Zinc finger, DHHC-type containing 18 ZDHHC18 84243 0.012 0.29 
238950_PM_at --- --- --- 0.028 0.29 
241187_PM_at --- --- --- 0.039 0.29 
1553107_PM_s_at chromosome 5 open reading frame 24 C5orf24 134553 0.003 0.291 
1554849_PM_at torsin family 1, member A (torsin A) TOR1A 1861 0.005 0.291 
201767_PM_s_at elaC homolog 2 (E. coli) ELAC2 60528 0.048 0.291 
241318_PM_at --- --- --- 0.019 0.292 
227435_PM_at KIAA2018 KIAA2018 205717 0.024 0.292 
1562863_PM_at --- --- --- 0.008 0.293 
200822_PM_x_at triosephosphate isomerase 1 TPI1 7167 0.034 0.293 
1563783_PM_a_at zinc finger protein 333 ZNF333 84449 0.035 0.294 
1557131_PM_at hypothetical protein LOC254100 LOC254100 254100 0.046 0.294 
1557260_PM_a_at zinc finger protein 382 ZNF382 84911 0.009 0.295 
241161_PM_at --- --- --- 0.009 0.295 
 408 
211982_PM_x_at exportin 6 XPO6 23214 0.025 0.295 
1560274_PM_at Wilms tumor 1 associated protein WTAP 9589 0.032 0.295 
1563584_PM_at family with sequence similarity 38, member B FAM38B 63895 0.047 0.295 
213746_PM_s_at filamin A, alpha FLNA 2316 0.017 0.298 
211030_PM_s_at 
solute carrier family 6 (neurotransmitter transporter, taurine), 
member 6 
SLC6A6 6533 0.048 0.298 
218699_PM_at RAB7, member RAS oncogene family-like 1 RAB7L1 8934 0.015 0.299 
214643_PM_x_at bridging integrator 1 BIN1 274 0.022 0.299 
225995_PM_x_at 
WAS protein family homolog 1 /// WAS protein family 






239368_PM_at --- --- --- 0.04 0.3 
1565689_PM_at --- --- --- 0.006 0.302 
209021_PM_x_at KIAA0652 KIAA0652 9776 0.012 0.302 
226655_PM_at syntaxin 17 STX17 55014 0 0.303 
212892_PM_at zinc finger protein 282 ZNF282 8427 0.044 0.303 
227451_PM_s_at Coiled-coil domain containing 90A CCDC90A 63933 0.049 0.303 
242057_PM_at --- --- --- 0.015 0.305 
218185_PM_s_at armadillo repeat containing 1 ARMC1 55156 0.015 0.306 
1558858_PM_at --- --- --- 0.014 0.307 
1558666_PM_at --- --- --- 0.032 0.309 
205698_PM_s_at mitogen-activated protein kinase kinase 6 MAP2K6 5608 0.031 0.311 
237239_PM_at --- --- --- 0.037 0.311 
1552344_PM_s_at CCR4-NOT transcription complex, subunit 7 CNOT7 29883 0.043 0.311 
220641_PM_at NADPH oxidase, EF-hand calcium binding domain 5 NOX5 79400 0.004 0.313 
1563369_PM_at non-protein coding RNA 173 NCRNA00173 100287569 0.008 0.313 
241547_PM_at --- --- --- 0.011 0.314 
244586_PM_x_at --- --- --- 0.003 0.315 
236380_PM_at --- --- --- 0.037 0.315 
229074_PM_at EH-domain containing 4 EHD4 30844 0.012 0.316 
1556846_PM_at --- --- --- 0.027 0.316 
236540_PM_at --- --- --- 0.032 0.316 
217230_PM_at ezrin EZR 7430 0.04 0.316 
 409 
221670_PM_s_at LIM homeobox 3 LHX3 8022 0.019 0.318 
224234_PM_at --- --- --- 0.025 0.318 
242519_PM_at coiled-coil domain containing 152 CCDC152 100129792 0.017 0.319 
240207_PM_at --- --- --- 0.029 0.32 
1559535_PM_s_at --- --- --- 0.038 0.321 
238961_PM_s_at Fibronectin type III domain containing 3A FNDC3A 22862 0.012 0.322 
225192_PM_at chromosome 10 open reading frame 46 C10orf46 143384 0.042 0.324 
243418_PM_at --- --- --- 0.049 0.324 
219451_PM_at methionine sulfoxide reductase B2 MSRB2 22921 0.01 0.325 
225296_PM_at zinc finger protein 317 ZNF317 57693 0.035 0.325 
1563894_PM_at hypothetical LOC441178 LOC441178 441178 0.046 0.325 
206169_PM_x_at zinc finger CCCH-type containing 7B ZC3H7B 23264 0.029 0.326 
204421_PM_s_at fibroblast growth factor 2 (basic) FGF2 2247 0.035 0.326 
234088_PM_at --- --- --- 0.017 0.328 
221893_PM_s_at aarF domain containing kinase 2 ADCK2 90956 0.009 0.329 
213642_PM_at --- --- --- 0.043 0.329 
220031_PM_at OTU domain containing 7B OTUD7B 56957 0.037 0.33 
203287_PM_at ladinin 1 LAD1 3898 0.016 0.331 
202887_PM_s_at DNA-damage-inducible transcript 4 DDIT4 54541 0.018 0.331 
204658_PM_at transformer 2 alpha homolog (Drosophila) TRA2A 29896 0.025 0.333 
204272_PM_at lectin, galactoside-binding, soluble, 4 LGALS4 3960 0.012 0.336 
227872_PM_at polymerase (RNA) III (DNA directed) polypeptide A, 155kDa POLR3A 11128 0.014 0.336 
206959_PM_s_at UPF3 regulator of nonsense transcripts homolog A (yeast) UPF3A 65110 0.017 0.336 
237721_PM_s_at ankyrin repeat and SOCS box-containing 4 ASB4 51666 0.036 0.337 
241662_PM_x_at --- --- --- 0.004 0.339 
217580_PM_x_at --- --- --- 0.012 0.339 
1569091_PM_at --- --- --- 0.047 0.339 
1569034_PM_a_at hypothetical gene supported by BC040724 LOC440864 440864 0.042 0.34 
217843_PM_s_at mediator complex subunit 4 MED4 29079 0.043 0.34 






244030_PM_at serine/threonine/tyrosine interacting protein STYX 6815 0.016 0.342 
 410 
239318_PM_at family with sequence similarity 118, member B FAM118B 79607 0.032 0.342 
1557966_PM_x_at MTERF domain containing 2 MTERFD2 130916 0.04 0.342 
222252_PM_x_at ubiquilin 4 UBQLN4 56893 0.017 0.343 
213213_PM_at death inducer-obliterator 1 DIDO1 11083 0.042 0.343 
1563916_PM_at hypothetical protein LOC283089 LOC283089 283089 0.037 0.345 
243178_PM_at --- --- --- 0.041 0.346 
223739_PM_at peptidyl arginine deiminase, type I PADI1 29943 0.046 0.347 
229995_PM_at syncollin SYCN 342898 0.04 0.348 
1559490_PM_at 
leucine-rich repeats and calponin homology (CH) domain 
containing 3 
LRCH3 84859 0.038 0.351 
227587_PM_at KRI1 homolog (S. cerevisiae) KRI1 65095 0.049 0.352 
235086_PM_at thrombospondin 1 THBS1 7057 0.033 0.356 
203090_PM_at stromal cell-derived factor 2 SDF2 6388 0.015 0.357 
213526_PM_s_at lin-37 homolog (C. elegans) LIN37 55957 0.022 0.357 
239967_PM_at --- --- --- 0.045 0.357 
207418_PM_s_at D-aspartate oxidase DDO 8528 0.035 0.358 
208185_PM_x_at --- --- --- 0.019 0.361 
229988_PM_at --- --- --- 0.025 0.361 
220934_PM_s_at transmembrane protein 223 TMEM223 79064 0.029 0.365 
1561216_PM_at --- --- --- 0.019 0.366 
223765_PM_s_at kelch repeat and BTB (POZ) domain containing 4 KBTBD4 55709 0.046 0.368 
209856_PM_x_at abl-interactor 2 ABI2 10152 0.011 0.377 
209238_PM_at syntaxin 3 STX3 6809 0.036 0.38 
218038_PM_at ATP5S-like ATP5SL 55101 0.03 0.381 
203766_PM_s_at leiomodin 1 (smooth muscle) LMOD1 25802 0.028 0.383 
236550_PM_s_at zinc finger protein 311 ZNF311 282890 0.04 0.383 
1567622_PM_at Actin binding LIM protein family, member 2 ABLIM2 84448 0.046 0.383 
202385_PM_s_at Treacher Collins-Franceschetti syndrome 1 TCOF1 6949 0.039 0.386 
237954_PM_x_at Protein SOLO FLJ10357 55701 0.006 0.388 
209964_PM_s_at ataxin 7 ATXN7 6314 0.005 0.391 
235340_PM_at glucosidase, alpha; neutral C GANC 2595 0.02 0.393 
203509_PM_at sortilin-related receptor, L(DLR class) A repeats-containing SORL1 6653 0.032 0.398 
 411 
219905_PM_at 
erythroblast membrane-associated protein (Scianna blood 
group) 
ERMAP 114625 0.038 0.401 
242537_PM_at --- --- --- 0.021 0.404 
236397_PM_at --- --- --- 0.024 0.405 
209565_PM_at ring finger protein 113A RNF113A 7737 0.014 0.406 
225671_PM_at spinster homolog 2 (Drosophila) SPNS2 124976 0.044 0.414 
229776_PM_at solute carrier organic anion transporter family, member 3A1 SLCO3A1 28232 0.042 0.415 
202246_PM_s_at cyclin-dependent kinase 4 CDK4 1019 0.043 0.42 
228874_PM_at Pleckstrin homology-like domain, family B, member 3 PHLDB3 653583 0.013 0.422 
228158_PM_at lymphocyte-specific protein 1 pseudogene LOC645166 645166 0.029 0.425 
229514_PM_at chromosome 14 open reading frame 118 C14orf118 55668 0.038 0.426 
43511_PM_s_at --- --- --- 0.023 0.432 
213748_PM_at tripartite motif-containing 66 TRIM66 9866 0.04 0.433 
243787_PM_at --- --- --- 0.042 0.433 
91682_PM_at --- --- --- 0.004 0.434 
228620_PM_at --- --- --- 0.006 0.437 
210720_PM_s_at N-terminal EF-hand calcium binding protein 3 NECAB3 63941 0.032 0.442 
235292_PM_at hypothetical protein LOC643977 FLJ32255 643977 0.031 0.444 
235480_PM_at TGF-beta activated kinase 1/MAP3K7 binding protein 1 TAB1 10454 0.046 0.445 
204261_PM_s_at presenilin 2 (Alzheimer disease 4) PSEN2 5664 0.028 0.455 
205645_PM_at RALBP1 associated Eps domain containing 2 REPS2 9185 0.046 0.455 
200696_PM_s_at gelsolin GSN 2934 0.04 0.475 
1554621_PM_at diacylglycerol kinase, epsilon 64kDa DGKE 8526 0.025 0.476 
1555554_PM_at breast cancer and salivary gland expression gene BASE 317716 0.045 0.483 
1554112_PM_a_at unc-51-like kinase 2 (C. elegans) ULK2 9706 0.027 0.484 
214487_PM_s_at 
RAP2A, member of RAS oncogene family /// RAP2B, 
member of RAS oncogene family 
RAP2A /// 
RAP2B 
5911 /// 5912 0.004 0.506 
233230_PM_s_at SLAIN motif family, member 2 SLAIN2 57606 0.006 0.509 
213622_PM_at collagen, type IX, alpha 2 COL9A2 1298 0.031 0.549 
226734_PM_at eukaryotic translation initiation factor 4E family member 2 EIF4E2 9470 0.04 0.567 
215700_PM_x_at copine VI (neuronal) CPNE6 9362 0.031 0.573 
240947_PM_at anoctamin 6 ANO6 196527 0.026 0.633 
 412 
201823_PM_s_at ring finger protein 14 RNF14 9604 0.042 0.725 
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